EA046368B1 - FUNGICIDAL COMPOSITIONS - Google Patents

Description

The present invention relates to new fungicidal compositions, to their use in agriculture or plant production for the control of diseases caused by phytopathogens, especially phytopathogenic fungi, and to methods for controlling diseases of useful plants.

WO 2010/012793, WO 2017/207362 and WO 2019/105933 describe thiazole derivatives as pesticides.

While many fungicidal compounds and compositions belonging to various distinct chemical classes have been/continue to be developed for use as fungicides in crops of beneficial plants, crop tolerance and activity against certain phytopathogenic fungi do not always meet the needs of agricultural practices in many relationships. Therefore, there is a constant need to find new compounds and compositions characterized by superior biological properties for use in controlling or preventing plant infestation by phytopathogenic fungi. For example, compounds with higher biological activity, a preferred spectrum of activity, an increased safety profile, improved physicochemical properties, and increased biodegradability. Or in other words, compositions having a broader spectrum of activity, improved crop tolerance, synergistic interactions or potentiating properties, or compositions that exhibit a faster onset of action or that have longer residual activity, or that provide reduced application rates and/or reduced Application rates for compounds and compositions required to effectively control a plant pathogen, thereby providing preferred practices for persistence management, reducing environmental impact, and reducing operator exposure.

The use of compositions containing mixtures of different fungicidal compounds having different mechanisms of action may meet some of these needs (eg, by combining fungicides with different activity spectra).

According to the present invention, there is provided a fungicidal composition containing a mixture of components (A) and (B) as active ingredients, wherein component (A) is a compound of formula (I)

R ²

F H1\r

N where

Y represents C-F or C-H;

X represents N;

R ¹ represents ^-^-alkyl, ^-^-alkoxy, C ₁ -C ₄ -haloalkyl or HC(O)NH-;

R ² represents C1- _C8- alkyl, ^-C^cycloalkyl, _C3 - _C8 -cycloalkyl- _C1 - _C2 -alkyl (where the cycloalkyl groups are optionally substituted by 1-3 groups represented by ^R3 ), phenyl, phenyl-Q^alkyl (where the phenyl rings are optionally substituted with 1-3 groups represented by R ³ ) or a 5-12 membered non-aromatic spirocyclic carbobi- or carbotricyclyl ring system;

R ³ represents QQ-alkyl, ^-^-alogenalkyl or C ₃ -C ₆ -cycloalkyl-C ₁ -C ₂ -alkyl;

or a salt or N-oxide thereof and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, pyraclostrobin, picoxystrobin, cumoxystrobin, methyltetraprole, cyproconazole, tebuconazole, difenoconazole, hexaconazole, propiconazole, fenhexamide, prothioconazole, mefentrifluconazole , prochloraz, fenpropidine, fenpropimorpha, fluxapyroxad, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, bixafen, pentiopyrad, inpirfluxam, isofetamide, pyrapropone, fluindapyr, fenpicoxamide, florylpicoxamide, acibenzolar^-methyl a, trinexepak-ethyl, fosetyl-aluminum, chlorothalonil , mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifen, folpet, ipflufenoquin, quinofumeline, tebufloquin, tolprocarb, tricyclazole, pyroquilone, cyflufenamide, metrafenone, No-[2-chloro-4-(2- fluorophenoxy )-5-methylphenyl]-M-ethyl-Mmethylformamidine (this compound can be prepared using the methods described in WO 2016/202742); N-[4-(2-bromophenoxy)-5-chloro-2-methylphenyl]-M-ethyl-M-methylformamidine (this compound can be prepared using the methods described in WO 2016/202688); N(1-benzyl-1,3dimethylbutyl)-8-fluoroquinoline-3-carboxamide, N(1-benzyl-3,3,3-trifluoro-1-methylpropyl)-8-fluoroquinoline-3-carboxamide, N(1- benzyl-3-chloro-1-methylbut-3-enyl)-8-fluoroquinoline-3-carboxamide (these compounds can be prepared using the methods described in WO 2017/153380); 1-(6,7- 1 046368 dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl1- (7-methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline, 1-(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,6trifluoro-3,3 -dimethylisoquinoline (these compounds can be obtained using the methods described in WO 2017/025510); 1-(4,5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 1 -(4,5-dimethylbenzimidazol-1-yl)-4,4-difluoro-3, 3-dimethylisoquinoline, 6-chloro-4,4-difluoro-3,3-dimethyl1-(4-methylbenzimidazol-1-yl)isoquinoline (these compounds can be prepared using the methods described in WO 2016/156085); I-[5-bromo-2-methyl-6-(1-methyl-2-propoxyethoxy)-3-pyridyl|-ethyl-N-methylformamidine, N'-[5-chloro-2-methyl-6-( 1 -methyl-2-propoxyethoxy)-3-pyridyl] -Ν-μήλ-Νmethylformamidine, N'-[5-bromo-2-methyl-6-(1-methyl-2-propoxyethoxy)-3-pyridyl]-N- isopropyl-Nmethylformamidine (these compounds can be prepared using the methods described in WO 2015/155075); N-isopropyl-N'-[5-methoxy-2-methyl-4-(2,2,2-trifluoro-1-hydroxy-1-phenylethyl)phenyl]-Nmethylformamidine (this compound can be prepared using the methods described in WO 2018/228896); N-methoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropanecarboxamide, N,2-dimethoxy-N-[[4-[5- (trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, N-ethyl-2-methyl-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazole -3-yl]phenyl]methyl]propanamide, 1-methoxy-3methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1, 3-dimethoxy-1-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 3-ethyl-1-methoxy-1-[[4-[5 -(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, ethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl] methyl]pyrazole-4-carboxylate, N,N-dimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]-1,2,4-triazol- 3-amine (these compounds can be prepared using the methods described in WO 2017/055473, WO 2017/055469, WO 2017/093348 and WO 2017/118689); methyl-(2)-3methoxy-2-[2-methyl-5-[3 -(trifluoromethyl)pyrazol-1-yl]phenoxy]prop-2-enoate, methyl-(2)-3-methoxy-2-[ 2methyl-5-(3-propylpyrazol-1-yl)phenoxy]prop-2-enoate, methyl-(2)-2-[5-(3-isopropylpyrazol-1-yl)-2methylphenoxy]-3-methoxyprop-2 -enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-(4-propyltriazol-2-yl)phenoxy]prop-2-enoate, methyl-(2)-3-methoxy-2 -[2-methyl-5-[4-(trifluoromethyl)triazol-2-yl]phenoxy]prop-2enoate (these compounds can be prepared using the methods described in WO 2020/079111); methyl (2)-2-(5-cyclohexyl-2-methylphenoxy)-3-methoxyprop-2-enoate, methyl (2)-2-(5-cyclopentyl-2methylphenoxy)-3-methoxyprop-2-enoate, methyl (2)-2-[5-(4-cyclohexylthiazol-2-yl)-2-methylphenoxy]-3methoxyprop-2-enoate, methyl (2)-2-[5-[4-(ethoxymethyl)thiazole -2-yl]-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-2-[5-(4-bromothiazol-2-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate , methyl-(2)-3methoxy-2-[2-methyl-5-[5-(trifluoromethyl)thiazol-2-yl]phenoxy]prop-2-enoate, TAEGRO® (i.e. Bacillus amyloliquefaciens strain FZB24) , Timorex Gold™ (a plant extract containing tea tree oil) and methylpicoxamide.

Generally, the weight ratio of component (A) to component (B) may preferably be 100:1 to 1:100, 50:1 to 1:50, 20:1 to 1:40, 15:1 to 1 :30, 12:1 to 1:25, 10:1 to 1:20, 5:1 to 1:15, 3:1 to 1:10 or 2:1 to 1:5.

Additionally, the present invention provides a method for controlling or preventing phytopathogenic diseases of useful plants or their propagation material, especially those caused by phytopathogenic fungi, which includes applying a fungicidal composition according to the present invention to useful plants, their habitat or their propagation material.

The benefits provided by certain fungicidal mixture compositions of the present invention may also include, inter alia, preferential levels of biological activity for protecting plants against diseases caused by fungi, or superior properties for use as agrochemical active ingredients (e.g., higher biological activity, preferred spectrum of activity, improved safety profile, improved physicochemical properties or increased biodegradability).

The presence of one or more possible asymmetric carbon atoms in a compound of formula (I) means that the compounds may occur in optically isomeric forms, i.e. enantiomeric or diastereomeric forms. Atropoisomers can also arise as a result of limited rotation around a single bond. Formula (I) is intended to include all such possible isomeric forms and mixtures thereof. The present invention includes all such possible isomeric forms of the compound of formula (I) and mixtures thereof. Likewise, formula (I) is intended to include all possible tautomers. The present invention includes all possible tautomeric forms of the compound of formula (I). In each case, the compounds of formula (I) according to the present invention are in free form, in oxidized form in the form of an N-oxide or in the form of a salt, for example, in the form of an agronomically useful salt. N-oxides are oxidized forms of tertiary amines or oxidized forms of nitrogen-containing heteroaromatic compounds. They are described, for example, in the book Heterocyclic N-oxides by A. Albini and S. Pietra, CRC Press, Boca Raton 1991.

Preferred groups and meanings for substituents in the compounds of formula (I) in any combination thereof are as follows.

- 2 046368

Y represents C-F or C-H. In one set of embodiments, Y is C-F. In another set of embodiments, Y is C-H.

X represents N.

R ¹ represents CpC^alkyl, C _g C ₄ -alkoxy, C ₁ -C ₄ -alogenalkyl or HC(O)NH-. Preferably R ¹ represents CpC3-alkyl or HC(O)NH-. More preferably, R ¹ is methyl.

R ² represents C1-C8 alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkyl-C1-C2 alkyl (where the cycloalkyl groups are optionally substituted by 1-3 groups represented by R ³ ), phenyl, phenyl-C1-C ₂ alkyl (where the phenyl rings are optionally substituted with 1-3 groups represented by R ³ ) or a 5-12 membered non-aromatic spirocyclic carbobi- or carbotricyclyl ring system. Preferably R ² is C1-C6 alkyl, C3-C6 cycloalkyl, C3-C6 cycloalkyl-C1-C2 alkyl (where the cycloalkyl groups are optionally substituted with 1 or 2 groups represented by R ³ ), phenyl, phenyl-C1- C ₂ -alkyl (where the phenyl rings are optionally substituted with 1 or 2 groups represented by R ³ ) or a 5-12 membered non-aromatic spirocyclic carbobi- or carbotricyclyl ring system. More preferably, R ² is n-butyl, isobutyl, n-pentyl, isopentyl, 2,2dimethylpropyl, n-hexyl, 1-(cyclopropylmethyl)cyclopropylmethyl, cyclobutyl, 2,2dimethylcyclobutyl, 1-methylcyclopentyl, benzyl, 1-phenylethyl, 3 ,5-bis(trifluoromethyl)phenylmethyl, spiro[3.3]heptanyl, spiro[3.4]octanyl or spiro[cyclobutan-1,2'-indanyl] and most preferably 1-(cyclopropylmethyl)cyclopropylmethyl, cyclobutyl, 2,2-dimethylcyclobutyl, spiro[3.3]heptan-3-yl, spiro[3.4]octan-3-yl or spiro[cyclobutan-1,2'-indan]-1-yl.

R ³ represents C ₁ -C ₃ -alkyl, C ₁ -C ₃ -haloalkyl or C ₃ -C ₆ -cycloalkyl-C ₁ -C ₂ -alkyl. Preferably R ³ is methyl, trifluoromethyl or cyclopropylmethyl.

Preferably, component (A) is a compound selected from

2-[cyano-(5-fluoro-3-pyridyl)amino]-N-cy clobutyl-5-methylthiazol-4carboxamide (compound X.01);

2-[cyano-(2,6-difluoro-4-pyridyl)amino]-M-cyclobutyl-5-methylthiazol-4carboxamide (compound X.02);

2-(M-cyano-3,5-difluoroanilino)-M-(2,2-dimethylcyclobutyl)-5-methylthiazol-4carboxamide (compound X.OZ);

2-[cyano-(5-fluoro-3-pyridyl)amino]-M-(2,2-dimethylcyclobutyl)-5-methylthiazol-4carboxamide (compound X.04);

2-[cyano-(2,6-difluoro-4-pyridyl)amino]-M-(2,2-dimethylcyclobutyl)-5methylthiazol-4-carboxamide (compound X.05);

2-[cyano-(2,6-difluoro-4-pyridyl)amino]-M-(2,2-dimethylcyclobutyl)-5formamidothiazole-4-carboxamide (compound X.06);

2-[cyano-(2,6-difluoro-4-pyridyl)amino]-5-methyl-N-spiro[3.4]octan-3-yl-thiazol4-carboxamide (compound X.07);

2-[cyano-(2,6-difluoro-4-pyridyl)amino]-5-methyl-M-spiro[cyclobutan-2,2'indan]-1-yl-thiazol-4-carboxamide (compound X.08 );

2-[cyano-(2,6-difluoro-4-pyridyl)amino]-5-methyl-M-spiro[3.3]heptan-3-ylthiazol-4-carboxamide (compound X.09);

2-[cyano-(2,6-difluoro-4-pyridyl)amino]-M-[[1(cyclopropylmethyl)cyclopropyl]methyl]-5-methylthiazol-4-carboxamide (compound xy);

- 3 046368

2-(M-cyano-3,5-difluoroanilino)-5-methyl-M-(1-methylcyclopentyl)thiazole-4carboxamide (compound X. 11);

2-[cyano-(2,6-difluoro-4-pyridyl)amino]-5-methyl-X-(1-methylcyclopentyl)thiazole4-carboxamide (compound X.12);

2-[cyano-(5-fluoro-3-pyridyl)amino]-M-hexyl-5-methylthiazol-4-carboxamide (compound X. 13);

2-[cyano-(2,6-difluoro-4-pyridyl)amino]-M-hexyl-5-methylthiazol-4-carboxamide (compound X. 14);

2-[cyano-(2,6-difluoro-4-pyridyl)amino]-M-isobutyl-5-methylthiazol-4carboxamide (compound X. 15);

2-[cyano-(2,6-difluoro-4-pyridyl)amino]-5-methyl-M-(1-phenylethyl)thiazole-4carboxamide (compound X. 16);

2-[cyano-(5-fluoro-3-pyridyl)amino]-M-(2,2-dimethylpropyl)-5-methylthiazol-4carboxamide (compound X. 17);

2-[cyano-(2,6-difluoro-4-pyridyl)amino]-M-(2,2-dimethylpropyl)-5-methylthiazol-4carboxamide (compound X.18);

2-[cyano-(5-fluoro-3-pyridyl)amino]-5-methyl-M-pentylthiazole-4-carboxamide (compound X. 19);

2-[cyano-(2,6-difluoro-4-pyridyl)amino]-5-methyl-M-pentylthiazole-4-carboxamide (compound X.20);

2-[cyano-(5-fluoro-3-pyridyl)amino]-M-isopentyl-5-methylthiazol-4-carboxamide (compound X.21);

X-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-[cyano-(2,6-difluoro-4-pyridyl)amino]5-methylthiazol-4-carboxamide (compound X.22);

X-benzyl-2-[cyano-(2,6-difluoro-4-pyridyl)amino]-5-methylthiazol-4-carboxamide (compound X.23) and M-butyl-2-[cyano-(2,6 -difluoro-4-pyridyl)amino]-5-methylthiazole-4carboxamide (compound X.24).

More preferably, component (A) is a compound selected from 2-[cyano-(5-fluoro-3-pyridyl)amino]-M-cyclobutyl-5-methylthiazole-4carboxamide (compound X.01);

2-[cyano-(2,6-difluoro-4-pyridyl)amino]-PM-cyclobutyl-5-methylthiazol-4carboxamide (compound X.02);

- 4 046368

2-(T\G-cyano-3,5-difluoroanilino)-M-(2,2-dimethylcyclobutyl)-5-methylthiazol-4carboxamide (compound X.OZ);

2-[cyano-(5-fluoro-3-pyridyl)amino]-M-(2,2-dimethylcyclobutyl)-5-methylthiazol-4carboxamide (compound X.04);

2-[cyano-(2,6-difluoro-4-pyridyl)amino]-M-(2,2-dimethylcyclobutyl)-5methylthiazol-4-carboxamide (compound X.05);

2-[cyano-(2,6-difluoro-4-pyridyl)amino]-5-methyl-N-spiro[3.4]octan-3-yl-thiazol4-carboxamide (compound X.07);

2-[cyano-(2,6-difluoro-4-pyridyl)amino]-5-methyl-N-spiro[3.3]heptan-3-yl-thiazol4-carboxamide (compound X.09);

2-(X-cyano-3,5-difluoroanilino)-5-methyl-X-(1-methylcyclopentyl)thiazole-4carboxamide (compound X.11);

2-[cyano-(2,6-difluoro-4-pyridyl)amino]-5-methyl-M-(1-methylcyclopentyl)thiazole4-carboxamide (compound X. 12);

X.14, X.15, X.16, X.17, X.18, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-M-hexyl-5methylthiazol-4-carboxamide (compound X.14);

2-[cyano-(2,6-difluoro-4-pyridyl)amino]-M-isobutyl-5-methylthiazol-4carboxamide (compound X.15);

2-[cyano-(2,6-difluoro-4-pyridyl)amino]-5-methyl-M-(1-phenylethyl)thiazole-4carboxamide (compound X.16);

2-[cyano-(5-fluoro-3-pyridyl)amino]-M-(2,2-dimethylpropyl)-5-methylthiazol-4carboxamide (compound X.17);

2-[cyano-(2,6-difluoro-4-pyridyl)amino]-M-(2,2-dimethylpropyl)-5-methylthiazol-4carboxamide (compound X. 18) and

T\G-butyl-2-[cyano-(2,6-difluoro-4-pyridyl)amino]-5-methylthiazol-4-carboxamide (compound X.24).

Even more preferably, component (A) is a compound selected from 2-[cyano-(5-fluoro-3-pyridyl)amino]-M-cyclobutyl-5-methylthiazole-4carboxamide (compound X.01);

2-[cyano-(2,6-difluoro-4-pyridyl)amino]-M-cyclobutyl-5-methylthiazol-4carboxamide (compound X.02);

2-(T\G-cyano-3,5-difluoroanilino)-M-(2,2-dimethylcyclobutyl)-5-methylthiazol-4carboxamide (compound X.OZ);

- 5 046368

2-[cyano-(5-fluoro-3-pyridyl)amino]-C-(2,2-dimethylcyclobutyl)-5-methylthiazol-4·carboxamide (compound X.04);

2-[cyano-(2,6-difluoro-4-pyridyl)amino]-X-(2,2-dimethylcyclobutyl)-5methylthiazol-4-carboxamide (compound X.05);

2-[cyano-(2,6-difluoro-4-pyridyl)amino]-5-methyl-X-spiro[3.4]octan-3-yl-thiazol4-carboxamide (compound X.07);

2-[cyano-(2,6-difluoro-4-pyridyl)amino]-5-methyl-X-spiro[3.3]heptan-3-yl-thiazol4-carboxamide (compound X.09);

2-(H-cyano-3,5-difluoroanilino)-5-methyl-H-(1-methylcyclopentyl)thiazole-4carboxamide (compound X. 11);

2-[cyano-(2,6-difluoro-4-pyridyl)amino]-5-methyl-X-(1-methylcyclopentyl)thiazole4-carboxamide (compound X.12);

X.14, X.15, X.16, X.17, X.18, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-K-hexyl-5 methylthiazole-4-carboxamide (X.14 connection) and

2-[cyano-(2,6-difluoro-4-pyridyl)amino]-X-(2,2-dimethylpropyl)-5-methylthiazol-4carboxamide (compound X.18).

Table X

- 6 046368

- 7 046368

X.08 i YjAd · L ΪΙ II 7—ch ₃ I ' N 2-[Cyano-(2,6-difluoro-4pyridyl)amino]-5-methyl-Nspiro[cyclobutane-2,2'-indan]-1-ylthiazol-4-carboxamide X.09 C) l\^ 1 VN 1 / ^H N'ZX N--\ L jl JI CH ₃ IN 2-[Cyano-(2,6-difluoro-4pyridyl)amino]-5-methyl-Nspiro[3.3] heptan-3-yl-thiazol-4carboxamide X.10 1 ΐίΐ T$-^ II N 2-[Cyano-(2,6-difluoro-4pyridyl)amino]-CG-[[1(cyclopropylmethyl)cyclopropyl]methyl]-5-methylthiazol-4carboxamide X.ll X.12 X.13 X.14 X.15 FV?^ ³ GAL»—, ιϊι N FV^ ^CH3 II 2 II /^ch ₃ F^Xz^N^S ill N —CH ₃ I У» uJA IN --CH ₃ AA ill N CH ₃ O. /- -X f A n ^CH 3 1 1 h A Γν-сн Il Ji /— ill N 2-(X-Cyano-3,5-difluoroanilino)-5methyl-CG-(1methylcyclopentyl)thiazol-4carboxamide 2-[Cyano-(2,6-difluoro-4pyridyl)amino]-5-methyl-M-(1 methylcyclopentyl)thiazole-4carboxamide 2-[Cyano-(5-fluoro-3 pyridyl)amino]-M-hexyl-5methylthiazol-4-carboxamide 2-[Cyano-(2,6-difluoro-4pyridyl)amino]-M-hexyl-5methylthiazol-4-carboxamide 2-[Cyano-(2,6-difluoro-4pyridyl)amino]-N-isobutyl-5 methylthiazol-4-carboxamide

- 8 046368

- 9 046368

Preferably, component (B) is a compound selected from the group consisting of isazoxystrobin, trifloxystrobin, pyraclostrobin, picoxystrobin, cumoxystrobin, methyltetraprole, cyproconazole, tebuconazole, difenoconazole, hexaconazole, propiconazole, fenhexamide, prothioconazole, mefentrifluconazole, prochloraz , fenpropidine, fenpropimorph, fluxapyroxade, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, bixafen, pentiopyrad, inpirfluxam, isofetamide, pyrapropone, fluindapyr, fenpicoxamide, florylpicoxamide, acibenzolar^-methyl, trinexepak-ethyl, fosetyl-aluminum, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam , fludioxonil, cyprodinil, metalaxyl-M, aminopyrifen, folpet, ipflufenoquin, quinofumeline, tebufloquin, tolprocarb, tricyclazole, pyroquilone, cyflufenamide, metrafenone, N-[2-chloro-4-(2-fluorophenoxy)-5-methylphenyl]^- ethyl^methylformamidine, N-[4-(2-bromophenoxy)-5-chloro-2-methylphenyl]-^ethyl-^methylformamidine, N-(1benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro-1-methylpropyl)8-fluoroquinoline-3-carboxamide, N(1-benzyl-3-chloro-1-methylbut-3-enyl)-8-fluoroquinoline- 3-carboxamide, 1 -(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4difluoro-3,3-dimethyl- 1 -(7-methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline, 1 -(6,7-dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,6-trifluoro-3 ,3-dimethylisoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4 -difluoro-3,3-dimethylisoquinoline, 6-chloro-4,4-difluoro-3,3-dimethyl-1 -(4-methylbenzimidazol-1 -yl)isoquinoline, N'-[5-bromo-2-methyl- 6-(1 methyl-2-propoxyethoxy)-3-pyridyl]-Nethyl-^methylformamidine, N-[5-chloro-2-methyl-6-(1-methyl-2propoxyethoxy)-3-pyridyl]-Nethyl -N-methylformamidine, N-[5-bromo-2-methyl-6-(1-methyl-2-propoxyethoxy)-3-pyridyl-N-isopropyl-N-methylformamidine, N-isopropyl-N-[5-methoxy-2-methyl -4-(2,2,2trifluoro-1-hydroxy-1-phenylethyl)phenyl]-N-methylformamidine, N-methoxy-N - [[4-[5-(trifluoromethyl)1,2,4-oxadiazole-3 -yl]phenyl]methyl]cyclopropanecarboxamide, H2-dimethoxy-N[[4-[5-(trifluoromethyl)1,2,4-oxadiazol-3 -yl]phenyl]methyl]propanamide, N-ethyl-2 -methyl- N -[[4-[5 -(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl )-1,2,4-oxadiazol-3yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl ] methyl]urea, 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, ethyl-1-[[ 4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrazole-4-carboxylate, H^dimethyl1-[[4-[5-(trifluoromethyl)-1,2, 4-oxadiazol-3-yl]phenyl]methyl]-1,2,4-triazol-3-amine, methyl-^)-3-methoxy-2-[2-methyl-5-[3-(trifluoromethyl)pyrazole -1-yl]phenoxy]prop-2-enoate, methyl-^)-3-methoxy-2-[2methyl-5-(3-propylpyrazol-1-yl)phenoxy]prop-2-enoate, methyl-^) -2-[5-(3-isopropylpyrazol-1-yl)-2methylphenoxy]-3-methoxyprop-2-enoate, methyl-^)-3-methoxy-2-[2-methyl-5-(4-propyltriazol- 2-yl)phenoxy]prop-2-enoate, methyl-^)-3-methoxy-2-[2-methyl-5-[4-(trifluoromethyl)triazol-2-yl]phenoxy]prop-2- 10 046368 enoate, methyl-^)-2-(5-cyclohexyl-2-methylphenoxy)-3-methoxyprop-2-enoate, methyl-(2)-2-(5-cyclopentyl-2-methylphenoxy)-3-methoxyprop-2 -enoate, methyl-^)-2-[5-(4-cyclohexylthiazol-2-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-2-[5-[4- (ethoxymethyl)thiazol-2-yl]-2-methylphenoxy]-3 methoxyprop-2-enoate, methyl-(2)-2-[5-(4-bromothiazol-2-yl)-2-methylphenoxy]-3- methoxyprop-2-enoate, methyl (2)-3-methoxy-2-[2-methyl-5-[5-(trifluoromethyl)thiazol-2-yl]phenoxy]prop-2-enoate, TAEGRO® (i.e. e. strain FZB24 Bacillus amyloliquefaciens), Timorex Gold™ (a plant extract containing tea tree oil) and methylpicoxamide.

More preferably, component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxad, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapyr, fenpicoxamide, florylpicoxamide, acibenzolar^-methyl, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifen, folpet, ipflufenoquin, quinofumeline, tricycle azole, pyroquilone, cyflufenamide, metrafenone, no. -[2-chloro-4-(2-fluorophenoxy)-5-methylphenyl]-N-ethyl-Nmethylformamidine, N-[4-(2-bromophenoxy)-5-chloro-2-methylphenyl]-N-ethyl-N -methylformamidine, N-(1-benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro-1-methylpropyl)8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3-chloro-1-methylbut-3-enyl)-8-fluoroquinolin-3-carboxamide, 1 -(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)- 4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro3,3-dimethyl-1-(7-methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline, 1-(6, 7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,6-trifluoro-3,3-dimethylisoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4,5 -trifluoro-3,3dimethylisoquinoline, 1 -(4,5-dimethylbenzimidazol-1 -yl)-4,4-difluoro-3,3-dimethylisoquinoline, 6-chloro4,4-difluoro-3,3-dimethyl-1-( 4-methylbenzimidazol-1-yl)isoquinoline, N-[5-bromo-2-methyl-6-(1-methyl-2propoxyethoxy)-3-pyridyl]-N-ethyl-N-methylformamidine, N-[5-chloro -2-methyl-6-(1-methyl-2-propoxyethoxy)-3-pyridyl]-N-ethyl-N-methylformamidine, N-[5-bromo-2-methyl-6-(1-methyl-2- propoxyethoxy)-3pyridyl]-H-isopropyl-N-methylformamidine, N-isopropyl-H'-[5-methoxy-2-methyl-4-(2,2,2-trifluoro-1hydroxy-1-phenylethyl)phenyl]-N -methylformamidine, N-methoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropanecarboxamide, K2-dimethoxy-H-[[4-[5- (trifluoromethyl)-1.2.4oxadiazol-3-yl]phenyl]methyl]propanamide, Nethyl-2-methyl-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol3-yl]phenyl] methyl]propanamide, 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1 -[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl) -1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, ethyl-1[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrazole -4-carboxylate, KH-dimethyl-1-[[4[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]-1,2,4-triazol-3-amine, methyl-^)-3-methoxy-2-[2methyl-5-[3-(trifluoromethyl)pyrazol-1-yl]phenoxy]prop-2-enoate, methyl-^)-3-methoxy-2-[2- methyl 5-(3propylpyrazol-1-yl)phenoxy]prop-2-enoate, methyl-^)-2-[5-(3-isopropylpyrazol-1-yl)-2-methylphenoxy]-3-methoxyprop-2- enoate, methyl-^)-3-methoxy-2-[2-methyl-5-(4-propyltriazol-2-yl)phenoxy]prop-2enoate, methyl-^)-3-methoxy-2-[2-methyl -5-[4-(trifluoromethyl)triazol-2-yl]phenoxy]prop-2-enoate, methyl^)-2-(5-cyclohexyl-2-methylphenoxy)-3-methoxyprop-2-enoate, methyl-^ )-2-(5-cyclopentyl-2-methylphenoxy)-3-methoxyprop-2-enoate, methyl-^)-2-[5-(4-cyclohexylthiazol-2-yl)-2-methylphenoxy]-3-methoxyprop -2-enoate, methyl-^)-2-[5-[4-(ethoxymethyl)thiazol-2-yl]-2-methylphenoxy]-3-methoxyprop-2enoate, methyl-^)-2-[5-( 4-bromothiazol-2-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate and methyl-^)-3 methoxy-2-[2-methyl-5-[5-(trifluoromethyl)thiazol-2-yl ]phenoxy]prop-2-enoate.

Even more preferably, component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxad, fluopyram, isopyrazam, sedaxane, benzovindiflupyr , pidiflumetofen, isoflucipram , isofetamide, pyrapropone, fluindapyr, fenpicoxamide, florilpicoxamide, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifene, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone , №(1-benzyl1,3-dimethylbutyl )-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro-1-methylpropyl)-8-fluoroquinoline-3-carboxamide, 1-(6,7-dimethylpyrazolo[1,5 -a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl-1-(7-methylpyrazolo[1,5-a]pyridine -3-yl)isoquinoline, 1-(4,5dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline and 1-(4,5-dimethylbenzimidazol-1yl)-4,4-difluoro -3,3-dimethylisoquinoline.

In one set of embodiments, component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxad, fluopyram, isopyrazam, sedaxane, benzovindif lupira, pidiflumetofen , bixafen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florylpicoxamide, methylpicoxamide, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, flu

- 11 046368 dioxonil, cyprodinil, metalaxyl-M, aminopyrifen, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, acibenzolar-methyl, cyflufenamide, metrafenone, fluazinam, fosetylaluminum, N-(1-benzyl-1,3-dimethylbutyl)- 8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro1-methylpropyl)-8-fluoroquinoline-3-carboxamide, 1-(6,7-dimethylpyrazolo[1,5-a]pyridine -3-yl)-4,4,5trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl-1-(7-methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline , 1-(4,5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4-difluoro-3 ,3-dimethylisoquinoline, TAEGRO® and Timorex Gold™.

In a particularly preferred set of embodiments, component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxad, fluopyram, isopyrazam, sedaxane, benzovin diflupyra, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapyr, fenpicoxamide, florylpicoxamide, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifene, folpet, ipflufenoquin, quinofu melina, tricyclazole, pyroquilone, N-(1-benzyl - 1,3-dimethylbutyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3 trifluoro-1-methylpropyl)-8-fluoroquinoline-3-carboxamide, 1 -(6,7- dimethylpyrazolo[1,5-a]pyridin-3-yl)4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl-1-(7-methylpyrazolo[1,5 -a]pyridin-3yl)isoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 1-(4,5dimethylbenzimidazol-1-yl)-4 ,4-difluoro-3,3-dimethylisoquinoline, N'-[5-bromo-2-methyl-6-(1-methyl-2propoxyethoxy)-3-pyridyl]-N-ethyl-N-methylformamidine, N-isopropyl- N'-[5-methoxy-2-methyl-4-(2,2,2trifluoro-1-hydroxy-1-phenylethyl)phenyl]-N-methylformamidine, TAEGRO®, Timorex GoldTM, acibenzolar^-methyl, cyflufenamide, metrafenone , fosetyl-aluminium, methyl-picoxamide, methyl-(2)-3methoxy-2-[2-methyl-5-[3 -(trifluoromethyl)pyrazol-1-yl]phenoxy]prop-2-enoate, methyl-(2)- 3-methoxy-2-[2methyl-5-(3-propylpyrazol-1-yl)phenoxy]prop-2-enoate, methyl-(2)-2-(5-cyclohexyl-2-methylphenoxy)-3methoxyprop-2- enoate, methyl (2)-2-(5-cyclopentyl-2-methylphenoxy)-3-methoxyprop-2-enoate, methyl(2)-2-[5-(3-isopropylpyrazol-1-yl)-2- methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-3-methoxy-2-[2methyl-5-(4-propyltriazol-2-yl)phenoxy]prop-2-enoate, methyl-(2) -3-methoxy-2-[2-methyl-5-[4-(trifluoromethyl)triazol-2-yl]phenoxy]prop-2-enoate, N-methoxy-N-[[4-[5-(trifluoromethyl) -1,2,4-oxadiazol-3yl]phenyl]methyl]cyclopropanecarboxamide, N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl] propanamide, N-ethyl-2-methyl-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, 1-methoxy-3-methyl-1 -[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 3-ethyl-1methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] methyl]urea and ethyl 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrazole-4-carboxylate.

The compounds constituting component (B) are listed herein and above under the so-called ISO common name or other common name used in individual cases or under a brand name. The compounds representing component (B) are known and commercially available and/or can be prepared using procedures known in the art and/or procedures described in the literature.

In a preferred composition according to the present invention, component (A) is Compound No. X.01, 2-[cyano-(5-fluoro-3-pyridyl)amino]-N-cyclobutyl-5-methylthiazol-4carboxamide, or a salt thereof , enantiomer, tautomer or N-oxide, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxade, fluopyram, isopyrase ma, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapyr, fenpicoxamide, florylpicoxamide, acibenzolar-methyl, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M, ami nopyrifen, folpet, ipflufenoquin, quinofumeline, tricyclazole , pyroquilone, cyflufenamide, metrafenone, N'-[2-chloro-4-(2-fluorophenoxy)-5methylphenyl]-N-ethyl-N-methylformamidine, N'-[4-(2-bromophenoxy)-5-chloro- 2-methylphenyl]-Ν-μήλ-Νmethylformamidine, N-(1-benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3trifluoro-1-methylpropyl) -8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3-chloro-1-methylbut-3-enyl)-8-fluoroquinoline-3-carboxamide, 1 -(6,7-dimethylpyrazolo[1,5-a] pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl-1 -(7-methylpyrazolo[1,5-a]pyridin-3 - yl)isoquinoline, 1-(6,7dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,6-trifluoro-3,3-dimethylisoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl )-4,4,5-trifluoro-3,3-dimethylisoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4-difluoro-3,3dimethylisoquinoline, 6-chloro-4,4-difluoro- 3,3-dimethyl-1-(4-methylbenzimidazol-1-yl)isoquinoline, N'-[5bromo-2-methyl-6-(1-methyl-2-propoxyethoxy)-3-pyridyl]-N-ethyl- N-methylformamidine, N'-[5-chloro-2methyl-6 -(1-methyl-2-propoxyethoxy)-3-pyridyl]-N-ethyl-N-methylformamidine, N'-[5-bromo-2-methyl -6 -(1methyl-2-propoxyethoxy)-3-pyridyl]-N-isopropyl-N-methylformamidine, N-isopropyl-N'-[5-methoxy-2methyl-4-(2,2,2-trifluoro-1 -hydroxy-1-phenylethyl)phenyl]-N-methylformamidine, N-methoxy-N-[[4-[5

- 12 046368 (trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropanecarboxamide, N,2-guMeTOKCu-N-[[4-[5(trifluoromethyl)-1,2,4-oxadiazole -3-yl]phenyl]methyl]propanamide, N-ethyl-2-methyl-H-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1.2.4oxadiazol-3-yl]phenyl]methyl]urea, 1.3-dimethoxy-1-[[4-[5-(trifluoromethyl )-1.2.4-oxadiazol-3yl]phenyl]methyl]urea, 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl ]methyl]urea, ethyl 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrazole-4-carboxylate, H.H-dimethyl-1- [[4-[5-(tri(()tormethyl)-1.2.4-oxadiazol-3-yl|(()enyl|methyl|-1.2.4-triazol-3amine, methyl-(Z)-3-methoxy -2-[2-methyl-5-[3-(trifluoromethyl)pyrazol-1-yl]phenoxy]prop-2-enoate, methyl(Z)-3-methoxy-2-[2-methyl-5-(3 -propylpyrazol-1-yl)phenoxy]prop-2-enoate, methyl-^)-2-[5-(3-isopropylpyrazol-1-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl- ^)-3-methoxy-2-[2-methyl-5-(4-propyltriazol-2-yl)phenoxy]prop-2-enoate, methyl-^)-3-methoxy-2-[2-methyl-5 -[4-(trifluoromethyl)triazol-2yl]phenoxy]prop-2-enoate, methyl-(Z)-2-(5-cyclohexyl-2-methylphenoxy)-3-methoxyprop-2-enoate. methyl (Z)-2-(5-cyclopentyl-2-methylphenoxy)-3-methoxyprop-2-enoate, methyl-^)-2-[5-(4-cyclohexylthiazol-2-yl)-2-methylphenoxy] -3-methoxyprop-2-enoate, methyl-^)-2-[5-[4-(ethoxymethyl)thiazol-2-yl]-2methylphenoxy]-3-methoxyprop-2-enoate, methyl-^)-2- [5-(4-bromothiazol-2-yl)-2-methylphenoxy|-3-methoxyprop-2-enoate. methyl-^)-3-methoxy-2-[2-methyl-5-[5-(trifluoromethyl)thiazol-2-yl]phenoxy|prop-2enoate. Bixafen. fosetyl aluminum. TAEGRO®. Timorex Gold™ and methylpicoxamide. where the weight ratio of component (A) and component (B) is from 15:1 to 1:30.

In another preferred composition according to the present invention, component (A) is Compound No. X.02. 2-[cyano-(2.6-difluoro-4-pyridyl)amino]-N-cyclobutyl-5methylthiazol-4-carboxamide. or its salt. enantiomer. tautomer or N-oxide. and component (B) is a compound. selected from a group. consisting of azoxystrobin. tri(loxystrobin. methyltetraprol. di(enoconazole. hexaconazole. propiconazole. prothioconazole. me(entri(luconazole. (enpropidine. (enpropimor(a.) (luxapyroxade. (luopyram. isopyrazam. sedaxane. benzovindi(lupyra. pidi(lumeto(ene) iso(lucipram. iso(etamide. pyrapropone. (luindapir. (enpicoxamide. florylpicoxamide. acibenzolar^-methyl. chlorothalonil. mancozeb. mandipropamide. oxathiapiproline. fluazinam. fludioxonil. cyprodinil. metalaxyl-M. aminopyrifene. folpeta. ipflufenoquina. quin ofumelin, tricyclazole pyroquilone cyflufenamide metrafenone H'-[2-chloro-4-(2fluorophenoxy)-5-methylphenyl]-N-ethyl-N-methylformamidine I-[4-(2-bromophenoxy)-5-chloro-2methylphenyl | -N-ethyl-N-methylformamidine. N-(1-benzyl-1.3-dimethylbutyl)-8-fluoroquinoline-3-carboxamide. N-(1-benzyl-3.3.3-trifluoro-1-methylpropyl)-8- fluoroquinoline-3-carboxamide N-(1-benzyl-3 chloro-1-methylbut-3-enyl)-8-fluoroquinoline-3-carboxamide 1 -(6.7-dimethylpyrazolo[1.5-a|pyridin-3-yl) 4.4.5-trifluoro-3.3-dimethylisoquinoline. 4.4-difluoro-3.3-dimethyl-1-(7-methylpyrazolo[1.5-a]pyridin-3yl)isoquinoline. 1 -(6.7-dimethylpyrazolo[1.5-a|pyridin-3-yl)-4.4.6-trifluoro-3.3-dimethylisoquinoline. 1 (4.5-dimethylbenzimidazol-1-yl)-4.4.5-trifluoro-3.3-dimethylisoquinoline. 1-(4.5-dimethylbenzimidazol-1yl)-4.4-difluoro-3.3-dimethylisoquinoline. 6-chloro-4.4-difluoro-3.3-dimethyl-1-(4-methylbenzimidazol-1 yl)isoquinoline. N'-[5-bromo-2-methyl-6-(1-methyl-2-propoxyethoxy)-3-pyridyl]-N-ethyl-N-methylformamidine. N'-[5-chloro-2-methyl-6-(1-methyl-2-propoxyethoxy)-3-pyridyl]-N-ethyl-N-methylformamidine. N'-[5-bromo-2-methyl-6-(1-methyl-2-propoxyethoxy)-3-pyridyl]-N-isopropyl-N-methylformamidine. Nisopropyl-N'-[5-methoxy-2-methyl-4-(2.2.2-trifluoro-1-hydroxy-1-phenylethyl)phenyl]-N-methylformamidine. N-methoxy-N-[[4-[5-(trifluoromethyl)-1.2.4-oxadiazol-3-yl]phenyl]methyl]cyclopropanecarboxamide. N.2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1.2.4-oxadiazol-3-yl]phenyl]methyl]propanamide. Nethyl-2-methyl-N-[[4-[5-(trifluoromethyl)-1.2.4-oxadiazol-3-yl| phenyl|methyl| propanamide. 1-methoxy-3 methyl-1-[[4-[5-(trifluoromethyl)-1.2.4-oxadiazol-3-yl]phenyl]methyl]urea. 1.3-dimethoxy-1-[[4-[5(Ίrifluoromethyl)-1.2.4-oxadiazol-3-yl]phenyl]methyl]urea. 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1.2.4-oxadiazol-3-yl]phenyl]methyl]urea. ethyl 1-[[4-[5-(trifluoromethyl)-1.2.4-oxadiazol-3yl]phenyl]methyl]pyrazole-4-carboxylate. KH-dimethyl-1-[[4-[5-(trifluoromethyl)-1.2.4-oxadiazol-.3yl]phenyl]methyl]-1.2.4-triazol-3-amine. methyl-^)-3-methoxy-2-[2-methyl-5-[3-(trifluoromethyl)pyrazol-1yl]phenoxy]prop-2-enoate. methyl-^)-3-methoxy-2-[2-methyl-5-(3-propylpyrazol-1-yl)phenoxy|prop-2enoate. methyl-(®)-2-[5-(3 -isopropylpyrazol-1 -yl)-2-methylphenoxy| -3-methoxyprop-2-enoate. methyl (®)3-methoxy-2-[2-methyl-5-(4-propyltriazol-2-yl)phenoxy|prop-2-enoate. methyl-^)-3-methoxy-2-[2-methyl5-[4-(trifluoromethyl)triazol-2-yl]phenoxy]prop-2-enoate. methyl-^)-2-(5-cyclohexyl-2-methylphenoxy)3-methoxyprop-2-enoate. methyl-^)-2-(5-cyclopentyl-2-methylphenoxy)-3-methoxyprop-2-enoate. methyl(Z)-2-[5-(4-cyclohexyl-2-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate. methyl (®)-2-[5-[4-(ethoxymethyl)thiazol-2-yl]-2-methylphenoxy]-3-methoxyprop-2-enoate. methyl-^)-2-[5-(4-bromothiazol-2-yl)-2methylphenoxy|-3-methoxyprop-2-enoate. methyl-^)-3-methoxy-2-[2-methyl-5-[5-(trifluoromethyl)thiazol-2yl|phenoxy|prop-2-enoate. Bixafen. fosetyl aluminum. TAEGRO®. Timorex Gold™ and methylpicoxamide. where the weight ratio of component (A) and component (B) is from 15:1 to 1:30.

In another preferred composition according to the present invention, component (A) is Compound No. X.03. 2-(Ncyano-3.5-difluoroanilino)-H-(2.2-dimethylcyclobutyl)-5methylthiazol-4-carboxamide. or its salt. enantiomer. tautomer or N-oxide. and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mephentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxad, fluopyram, isopyrazam, c edaxan, benzovindiflupyr, pidiflumetofen , isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florylpicoxamide, acibenzolar^-methyl, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifen, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, cyflufenamide, metrafenone, N'-[2-χλορ-4-(2fluorophenoxy)-5-methylphenyl]-N-ethyl-N-methylformamidine, I-[4-(2-bromophenoxy)-5-chloro-2methylphenyl]-N-ethyl -N-methylformamidine, N-(1-benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro-1-methylpropyl)-8-fluoroquinoline -3-carboxamide, N-(1-benzyl-3chloro-1-methylbut-3-enyl)-8-fluoroquinoline-3-carboxamide, 1-(6,7-dimethylpyrazolo[1,5-a]pyridine-3 -yl)4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl-1-(7-methylpyrazolo[1,5-a]pyridin-3yl)isoquinoline, 1 - (6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,6-trifluoro-3,3-dimethylisoquinoline, 1 (4,5-dimethylbenzimidazol-1-yl)-4,4 ,5-trifluoro-3,3-dimethylisoquinoline, 1-(4,5-dimethylbenzimidazol-1yl)-4,4-difluoro-3,3-dimethylisoquinoline, 6-chloro-4,4-difluoro-3,3-dimethyl -1 -(4-methylbenzimidazol-1 yl)isoquinoline, N-[5-bromo-2-methyl-6-(1-methyl-2-propoxyethoxy)-3-pyridyl]-Nethyl-Nmethylformamidine, N-[ 5-chloro-2-methyl-6-(1-methyl-2-propoxyethoxy)-3-pyridyl]-Nethyl-Nmethylformamidine, N-[5-bromo-2-methyl-6-(1-methyl-2 -propoxyethoxy)-3-pyridyl]-Nisopropyl-Nmethylformamidine, Nisopropyl-H'-[5-methoxy-2-methyl-4-(2,2,2-trifluoro-1-hydroxy-1-phenylethyl)phenyl] -H-methylformamidine, N-methoxy-H-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropanecarboxamide, N-2-dimethoxy-H-[[4- [5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, Nethyl-2-methyl-H-[[4-[5-(trifluoromethyl)-1,2,4- oxadiazol-3-yl]phenyl]methyl]propanamide, 1-methoxy-3 methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 3-ethyl-1-methoxy-1-[[4- [5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, ethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl] phenyl]methyl]pyrazol-4-carboxylate, ^Ndimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]-1,2,4-triazol- 3-amine, methyl-(2)-3-methoxy-2-[2-methyl-5-[3-(trifluoromethyl)pyrazol-1yl]phenoxy]prop-2-enoate, methyl (2)-3-methoxy -2-[2-methyl-5-(3-propylpyrazol-1-yl)phenoxy]prop-2enoate, methyl-(2)-2-[5-(3-isopropylpyrazol-1-yl)-2-methylphenoxy] -3-methoxyprop-2-enoate, methyl-(2)3-methoxy-2-[2-methyl-5-(4-propyltriazol-2-yl)phenoxy]prop-2-enoate, methyl-(2)- 3-methoxy-2-[2-methyl5-[4-(trifluoromethyl)triazol-2-yl]phenoxy]prop-2-enoate, methyl (2)-2-(5-cyclohexyl-2-methylphenoxy)3- methoxyprop-2-enoate, methyl (2)-2-(5-cyclopentyl-2-methylphenoxy)-3-methoxyprop-2-enoate, methyl(2)-2-[5-(4-cyclohexylthiazol-2-yl) )-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-2-[5-[4-(ethoxymethyl)thiazol-2-yl]-2-methylphenoxy]-3-methoxyprop-2- enoate, methyl (2)-2-[5-(4-bromothiazol-2-yl)-2methylphenoxy]-3-methoxyprop-2-enoate, methyl (2)-3-methoxy-2-[2-methyl -5-[5-(trifluoromethyl)thiazol-2yl]phenoxy]prop-2-enoate, sbixaphene, fosetyl aluminum, TAEGRO®, Timorex Gold™ and methylpicoxamide, wherein the weight ratio of component (A) to component (B) is from 15:1 to 1:30.

In another preferred composition according to the present invention, component (A) is Compound No. X.04, 2-[cyano-(5-fluoro-3-pyridyl)amino]-N-(2,2dimethylcyclobutyl)-5-methylthiazol- 4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph , fluxapyroxad, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florylpicoxamide, acibenzolar^-methyl, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fl udioxonil, cyprodinil, metalaxyl-M, aminopyrifene, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, cyflufenamide, metrafenone, N-[2-chloro-4-(2-fluorophenoxy)-5-methylphenyl]-N-ethyl-N-methylformamidine, N'-[4-(2bromophenoxy )-5-chloro-2-methylphenyl]-N-ethyl-N-methylformamidine, N-(1-benzyl-1,3-dimethylbutyl)-8fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3, 3-trifluoro-1-methylpropyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3-chloro-1-methylbut-3-enyl)-8-fluoroquinoline-3-carboxamide, 1 -(6, 7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl-1-(7methylpyrazolo[1, 5-a]pyridin-3-yl)isoquinoline, 1-(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,6trifluoro-3,3-dimethylisoquinoline, 1 -(4 ,5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4-difluoro-3,3-dimethylisoquinoline, 6-chloro-4,4difluoro-3,3-dimethyl-1-(4-methylbenzimidazol-1 -yl)isoquinoline, I-N-bromo-3-methyl-bH 1 -methyl-2-propoxyethoxy)-3-pyridyl ]-N-ethyl-N-methylformamidine, N'-[5-chloro-2-methyl-6-(1-methyl-2-nropoxyethoxy)3-pyridyl]-N-ethyl-N-methylformamidine, N'-[ 5-bromo-2-methyl-6-(1-methyl-2-npropoxyethoxy)-3-pyridyl]-N-isopropyl-N-methylformamidine, N-isonropyl-N'-[5-methoxy-2-methyl-4 -(2,2,2-trifluoro-1-hydroxy-1-phenylethyl)phenyl]-N-methylformamidine, N-methoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol- 3yl]phenyl]methyl]cyclopropanecarboxamide, N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]propanamide, N-ethyl-2-methyl -N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]me

- 14 046368 til]propanamide, 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3- dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 3-ethyl-1methoxy-1-[[4-[5-(trifluoromethyl )-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, ethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl ]pyrazole-4-carboxylate, KH-dimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]-1,2,4-triazol-3 -amine, methyl-(2)-3-methoxy-2-[2-methyl-5-[3 (trifluoromethyl)pyrazol-1-yl]phenoxy]prop-2-enoate, methyl-(2)-3-methoxy -2-[2-methyl-5-(3-propylpyrazol-1-yl)phenoxy]prop-2-enoate, methyl-(2)-2-[5-(3-isopropylpyrazol-1-yl)-2- methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-(4-propylriazol-2-yl)phenoxy|prop-2-enoate. methyl (2)-3-methoxy-2-[2-methyl-5-[4-(trifluoromethyl)triazol-2-yl]phenoxy]prop-2-enoate, methyl (2)-2-(5cyclohexyl- 2-methylphenoxy)-3-methoxyprop-2-enoate, methyl-(2)-2-(5-cyclopentyl-2-methylphenoxy)-3methoxyprop-2-enoate, methyl-(2)-2-[5-(4 -cyclohexylthiazol-2-yl)-2-methylphenoxy]-3-methoxyprop-2enoate, methyl-(2)-2-[5-[4-(ethoxymethyl)thiazol-2-yl]-2-methylphenoxy]-3- methoxyprop-2-enoate, methyl(2)-2-[5-(4-bromothiazol-2-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl (2)-3-methoxy-2 -[2-methyl5-[5-(trifluoromethyl)thiazol-2-yl]phenoxy]prop-2-enoate, bixaphen, fosetyl aluminum, TAEGRO®, Timorex Gold™ and methylpicoxamide, where the weight ratio of component (A) and component (B) is from 15:1 to 1:30.

In another preferred composition according to the present invention, component (A) is Compound No. X.05, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-H-(2,2dimethylcyclobutyl)-5- methylthiazole-4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine , fenpropimorph, fluxapyroxad, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapyr, fenpicoxamide, florylpicoxamide, acibenzolar^-methyl, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifene, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, cyflufenamide, metrafenone, N-[2-chloro-4-(2-fluorophenoxy)-5-methylphenyl]-N-ethyl-N-methylformamidine, N'-[4- (2bromophenoxy)-5-chloro-2-methylphenyl]-N-ethyl-N-methylformamidine, N-(1-benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3, 3,3-trifluoro-1-methylpropyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3-chloro-1-methylbut-3-enyl)-8-fluoroquinoline-3-carboxamide, 1 -( 6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl-1-(7methylpyrazolo[ 1,5-a]pyridin-3-yl)isoquinoline, 1-(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,6trifluoro-3,3-dimethylisoquinoline, 1- (4,5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4-difluoro-3,3- dimethylisoquinoline, 6-chloro-4,4-difluoro3,3-dimethyl-1 -(4 -methylbenzimidazol-1 -yl)isoquinoline, N'-[5-bromo-2-methyl-6-( 1 -methyl-2 - propoxyethoxy)-3-pyridyl]-N-ethyl-N-methylformamidine, N-[5-chloro-2-methyl-6-(1-methyl-2-propoxyethoxy)-3pyridyl]-N-ethyl-N-methylformamidine, Na-[5-bromo-2-methyl-6-(1-methyl-2-propoxyethoxy)-3-pyridyl]Ni-isopropyl-N-methylformamidine, Na-isopropyl-H'-[5-methoxy-2-methyl-4 -(2,2,2-trifluoro-1-hydroxy-1phenylethyl)phenyl]-N-methylformamidine, N-methoxy-H-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl ]phenyl]methyl]cyclopropanecarboxamide, N2-dimethoxy-H-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]propanamide, Nethyl-2-methyl-H- [[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)- 1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl ]methyl]urea, 3-ethyl-1methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, ethyl-1-[[4- [5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrazole-4-carboxylate, KH-dimethyl-1-[[4-[5-(trifluoromethyl)-1,2, 4-oxadiazol-3-yl]phenyl]methyl]-1,2,4-triazol-3-amine, methyl-(2)-3-methoxy-2-[2-methyl-5-[3 (trifluoromethyl)pyrazole -1 -yl]phenoxy]prop-2-enoate, methyl (2)-3 -methoxy-2-[2-methyl-5-(3 -propylpyrazol-1 -yl)phenoxy]prop-2-enoate, methyl -(2)-2-[5-(3-isopropylpyrazol-1-yl)-2-methylphenoxy]-3 methoxyprop-2-enoate, methyl (2)-3-methoxy-2-[2-methyl-5 -(4-propyltriazol-2-yl)phenoxy]prop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-[4-(trifluoromethyl)triazol-2-yl]phenoxy ]prop-2-enoate, methyl-(2)-2(5-cyclohexyl-2-methylphenoxy)-3-methoxyprop-2-enoate, methyl-(2)-2-(5-cyclopentyl-2-methylphenoxy)- 3-methoxyprop-2-enoate, methyl-(2)-2-[5-(4-cyclohexylthiazol-2-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-2- [5-[4-(ethoxymethyl)thiazol-2-yl]-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-2-[5-(4-bromothiazol-2-yl)- 2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-3-methoxy-2-[2methyl-5-[5-(trifluoromethyl)thiazol-2-yl]phenoxy]prop-2-enoate, bixafen, fosetyl aluminum, TAEGRO®, Timorex Gold™, and methylpicoxamide, where the weight ratio of component (A) to component (B) is from 15:1 to 1:30.

In another preferred composition according to the present invention, component (A) is Compound No. X.06, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-H-(2,2dimethylcyclobutyl)-5- formamidothiazole-4-carboxamide, or a salt, enantiomer, tautomer or Noxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole , fenpropidine, fenpropimorph, fluxapyroxad, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florylpicoxamide, acibenzolar^-methyl, chlorothalonil, mancozeb, mandipropamide, oxa tiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl- M, aminopyrifene, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, cyflufenamide, metrafenone, N-[2-chloro-4-(2-fluorophenoxy)-5-methylphenyl]-N-ethyl-N-methylformamidine, N'-[ 4-(2bromophenoxy)-5-chloro-2-methylphenyl]-Nethyl-Nmethylformamidine, N-(1-benzyl-1,3-dimethylbutyl)-8fluoroquinoline-3-carboxamide, N-(1-benzyl-3, 3,3-trifluoro-1-methylpropyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3-chloro-1-methylbut-3-enyl)-8-fluoroquinoline-3-carboxamide, 1 -( 6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl-1-(7methylpyrazolo[ 1,5-a]pyridin-3-yl)isoquinoline, 1-(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,6trifluoro-3,3-dimethylisoquinoline, 1- (4,5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4-difluoro-3,3- dimethylisoquinoline, 6-chloro-4,4-difluoro3,3-dimethyl-1 -(4 -methylbenzimidazol-1 -yl)isoquinoline, N'-[5-bromo-2-methyl-6-( 1 -methyl-2 - propoxyethoxy)-3-pyridyl]-N-ethyl-N-methylformamidine, N-[5-chloro-2-methyl-6-(1-methyl-2-propoxyethoxy)-3pyridyl]-N-ethyl-N-methylformamidine, Na-[5-bromo-2-methyl-6-(1-methyl-2-propoxyethoxy)-3-pyridyl]Ni-isopropyl-N-methylformamidine, Na-isopropyl-N'-[5-methoxy-2-methyl-4 -(2,2,2-trifluoro-1-hydroxy-1phenylethyl)phenyl]-N-methylformamidine, N-methoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl ]methyl]cyclopropanecarboxamide, N2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]propanamide, Nethyl-2-methyl-N-[[ 4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1, 2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl ]urea, 3-ethyl-1methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, ethyl-1-[[4-[5 -(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrazole-4-carboxylate, KH-dimethyl-1-||4-|5-(trifluoromethyl)-1,2,4- oxadiazol-3-yl]phenyl]methyl]-1,2,4-triazol-3-amine, methyl-(2)-3-methoxy-2-[2-methyl-5-[3 (trifluoromethyl)pyrazol-1 -yl]phenoxy]prop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-(3-propylpyrazol-1-yl)phenoxy]prop-2-enoate, methyl-( 2)-2-[5-(3-isopropylpyrazol-1-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5- (4-propyltriazol-2-yl)phenoxy]prop-2-enoate, methyl (2)-3-methoxy-2-[2-methyl-5-[4-(trifluoromethyl)triazol-2-yl]phenoxy] prop-2-enoate, methyl (2)-2-(5-cyclohexyl-2-methylphenoxy)-3-methoxyprop-2-enoate, methyl (2)-2-(5-cyclopentyl-2-methylphenoxy)-3methoxyprop- 2-enoate, methyl-(2)-2-[5-(4-cyclohexylthiazol-2-yl)-2-methylphenoxy]-3-methoxyprop-2enoate, methyl-(2)-2-[5-[4- (ethoxymethyl)thiazol-2-yl]-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl(2)-2-[5-(4-bromothiazol-2-yl)-2-methylphenoxy]-3- methoxyprop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl5-[5-(trifluoromethyl)thiazol-2-yl]phenoxy]prop-2-enoate, bixafen, fosetyl aluminum, TAEGRO ®, Timorex Gold™ and methylpicoxamide, wherein the weight ratio of component (A) to component (B) is from 15:1 to 1:30.

In another preferred composition according to the present invention, component (A) is Compound No. X.07, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-5-methyl-Nspiro[3.4]octane- 3-yl-thiazol-4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole , mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxade, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapyr, fenpicoxamide, florylpicoxamide, acibenzolar^-methyl, chlorothalonil, mancose ba, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifene, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, cyflufenamide, metrafenone, N-[2-chloro-4-(2-fluorophenoxy)-5-methylphenyl]-N-ethyl-N-methylformamidine, N- [4-(2-bromophenoxy)-5chloro-2-methylphenyl]-N-ethyl-N-methylformamidine, N-(1-benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3 carboxamide, N-(1 - benzyl-3,3,3-trifluoro-1-methylpropyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl3-chloro-1-methylbut-3-enyl)-8-fluoroquinoline-3-carboxamide, 1 -(6,7-dimethylpyrazolo[1,5-a]pyridin-3 yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl-1 -(7 -methylpyrazolo[1,5-a]pyridin3-yl)isoquinoline, 1-(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,6-trifluoro-3,3-dimethylisoquinoline , 1-(4,5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 1-(4,5-dimethylbenzimidazol1 -yl)-4,4-difluoro-3,3 -dimethylisoquinoline, 6-chloro-4,4-difluoro-3,3-dimethyl-1-(4-methylbenzimidazol-1yl)isoquinoline, N'-[5 -bromo-2-methyl-6-( 1 -methyl-2 -propoxyethoxy)-3-pyridyl]-N-ethyl-Nmethylformamidine, N'-[5-chloro-2-methyl-6-(1-methyl-2-npropoxyethoxy)-3-pyridyl]-N-ethyl-Nmethylformamidine, N'-[5-bromo-2-methyl-6-(1-methyl-2-npropoxyethoxy)-3-pyridyl]-N-isopropyl-Nmethylformamidine, N-isonropyl-N'-[5-methoxy-2-methyl -4-(2,2,2-trifluoro-1-hydroxy-1phenylethyl)phenyl]-M-methylformamidine, N-methoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol- 3yl]phenyl]methyl]cyclopropanecarboxamide, N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3

- 16 046368 yl]phenyl]methyl]propanamide, No. ethyl-2-methyl-H-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, 1 -methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4- [5-(1fluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 3-ethyl-1methoxy-1-[[4-[5-(1fluoromethyl)-1,2,4- oxadiazol-3-yl]phenyl]methyl]urea, ethyl 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrazole-4-carboxylate, KN -dimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]-1,2,4-triazol-3-amine, methyl-(2) -.3-methoxy-2-[2-methyl-5-[3 (trifluoromethyl)pyrazol-1-yl]phenoxy]prop-2-enoate, methyl (2)-3-methoxy-2-[2-methyl -5-(3-propylpyrazol-1-yl)phenoxy]prop-2-enoate, methyl (2)-2-[5-(3-isopropylpyrazol-1-yl)-2-methylphenoxy]-3-methoxyprop- 2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-(4-propyltriazol-2-yl)phenoxy|prop-2-enoate. methyl (2)-3-methoxy-2-[2-methyl-5-[4-(trifluoromethyl)triazol-2-yl]phenoxy]prop-2-enoate, methyl (2)-2-(5cyclohexyl- 2-methylphenoxy)-3-methoxyprop-2-enoate, methyl-(2)-2-(5-cyclopentyl-2-methylphenoxy)-3methoxyprop-2-enoate, methyl-(2)-2-[5-(4 -cyclohexylthiazol-2-yl)-2-methylphenoxy|-3-methoxyprop-2enoate, methyl-(2)-2-[5-[4-(ethoxymethyl)thiazol-2-yl]-2-methylphenoxy]-3- methoxyprop-2-enoate, methyl(2)-2-[5-(4-bromothiazol-2-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl (2)-3-methoxy-2 -[2-methyl5-[5-(trifluoromethyl)thiazol-2-yl]phenoxy]prop-2-enoate, bixaphen, fosetyl aluminum, TAEGRO®, Timorex Gold™ and methylpicoxamide, where the weight ratio of component (A) and component (B) is from 15:1 to 1:30.

In another preferred composition according to the present invention, component (A) is Compound No. X.08, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-5-methyl-Spiro[cyclobutane-2, 2'-indan]-1-yl-thiazol-4-carboxamide, or a salt, enantiomer, tautomer or Noxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole , propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxad, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapyr, fenpicoxamide, florylpicoxamide, acibenzolar^ -methyl, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifen, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, cyflufenamide, metrafenone, N-[2-chloro-4-(2-fluorophenoxy)-5-methylphenyl]-N-ethyl-N- methylformamidine, N'-[4-(2bromophenoxy)-5-chloro-2-methylphenyl]-N-ethyl-N-methylformamidine, N-(1-benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3-carboxamide, N -(1-benzyl-3,3,3-trifluoro-1-methylpropyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3-chloro-1-methylbut-3-enyl)-8-fluoroquinoline -3-carboxamide, 1 -(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3 -dimethyl-1-(7methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline, 1-(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,6trifluoro- 3,3-dimethylisoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4, 4-difluoro-3,3-dimethylisoquinoline, 6-chloro-4,4-difluoro3,3-dimethyl-1 -(4 -methylbenzimidazol-1 -yl)isoquinoline, N'-[5-bromo-2-methyl-6 -(1-methyl-2-propoxyethoxy)-3-pyridyl]-N-ethyl-N-methylformamidine, N-[5-chloro-2-methyl-6-(1-methyl-2-propoxyethoxy)-3pyridyl]- N-ethyl-N-methylformamidine, N-[5-bromo-2-methyl-6-(1-methyl-2-propoxyethoxy)-3-pyridyl]N-isopropyl-N-methylformamidine, N-isopropyl-H'-[5 -methoxy-2-methyl-4-(2,2,2-trifluoro-1-hydroxy-1phenylethyl)phenyl]-N-methylformamidine, Nmethoxy-H-[[4-[5-(trifluoromethyl)-1,2 ,4-oxadiazol-3yl]phenyl]methyl]cyclopropanecarboxamide, ^2-dimethoxy-H-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]propanamide, Nethyl- 2-methyl-H-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, 1-methoxy-3-methyl-1-[[4-[ 5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazole -3-yl]phenyl]methyl]urea, 3-ethyl-1methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, ethyl- 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrazole-4-carboxylate, KH-dimethyl-1-[[4-[5-(trifluoromethyl )-1,2,4-oxadiazol-3-yl]phenyl]methyl]-1,2,4-triazol-3-amine, methyl-(2)-3-methoxy-2-[2-methyl-5- [3 (trifluoromethyl)pyrazol-1-yl]phenoxy]prop-2-enoate, methyl (2)-3-methoxy-2-[2-methyl-5-(3-propylpyrazol-1-yl)phenoxy]prop -2-enoate, methyl-(2)-2-[5-(3-isopropylpyrazol-1-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-3-methoxy-2 -[2-methyl-5-(4-propyltriazol-2-yl)phenoxy]prop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-[4-(trifluoromethyl) triazol-2-yl]phenoxy]prop-2-enoate, methyl (2)-2-(5cyclohexyl-2-methylphenoxy)-3-methoxyprop-2-enoate, methyl (2)-2-(5-cyclopentyl) -2-methylphenoxy)-3methoxyprop-2-enoate, methyl-(2)-2-[5-(4-cyclohexylthiazol-2-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)- 2-[5-[4-(ethoxymethyl)thiazol-2-yl]-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl(2)-2-[5-(4-bromothiazol-2-yl) -2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl5-[5-(trifluoromethyl)thiazol-2-yl]phenoxy]prop-2-enoate , bixafen, fosetyl aluminum, TAEGRO®, Timorex Gold™ and methylpicoxamide, where the weight ratio of component (A) to component (B) is from 15:1 to 1:30.

In another preferred composition according to the present invention, component (A) is Compound No. X.09, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-5-methyl-Nspiro[3.3]heptane- 3-yl-thiazol-4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole , propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxad, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapyr, fenpicoxamide, florylpicoxamide, acibenzolar^ -methyl, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifen, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, cyflufenamide, metrafenone, N-[2-chloro-4-(2-fluorophenoxy)-5-methylphenyl]-N-ethyl-N- methylformamidine, H'-[4-(2-bromophenoxy)-5chloro-2-methylphenyl]-N-ethyl-H-methylformamidine, N-(1-benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3 carboxamide, N-(1-benzyl-3,3,3-trifluoro-1-methylpropyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl3-chloro-1-methylbut-3-enyl)-8-fluoroquinoline- 3-carboxamide, 1-(6,7-dimethylpyrazolo[1,5-a]pyridin-3 yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl -1-(7-methylpyrazolo[1,5-a]pyridin3-yl)isoquinoline, 1-(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,6-trifluoro- 3,3-dimethylisoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 1-(4,5-dimethylbenzimidazol1 -yl)-4,4- difluoro-3,3-dimethylisoquinoline, 6-chloro-4,4-difluoro-3,3-dimethyl-1-(4-methylbenzimidazol-1yl)isoquinoline, N'-[5-bromo-2-methyl-6-( 1 -methyl-2-propoxyethoxy)-3-pyridyl]-N-ethyl-Nmethylformamidine, N'-[5-chloro-2-methyl-6-(1-methyl-2-npropoxyethoxy)-3-pyridyl]-N -ethyl-Nmethylformamidine, N'-[5-bromo-2-methyl-6-(1-methyl-2-nropoxyethoxy)-3-pyridyl]-N-isopropyl-Nmethylformamidine, N-isonropyl-N'-[5- methoxy-2-methyl-4-(2,2,2-trifluoro-1 -hydroxy-1 phenylethyl)phenyl]-M-methylformamidine, N-methoxy-N-[[4-[5-(trifluoromethyl)-1, 2,4-oxadiazol-3yl]phenyl]methyl]cyclopropanecarboxamide, N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]propanamide, N -ethyl-2-methyl-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, 1-methoxy-3-methyl-1-[[ 4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2, 4-oxadiazol-3-yl]phenyl]methyl]urea, 3-ethyl-1methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea , ethyl 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrazole-4-carboxylate, N,N-dimethyl-1-[[4- [5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]-1,2,4-triazol-3-amine, methyl-(2)-3-methoxy-2-[2 -methyl-5-[3 (trifluoromethyl)pyrazol-1-yl]phenoxy]prop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-(3-propylpyrazol-1 - yl)phenoxy]prop-2-enoate, methyl-(2)-2-[5-(3-isopropylpyrazol-1-yl)-2-methylphenoxy]-3 methoxyprop-2-enoate, methyl-(2)-3 -methoxy-2-[2-methyl-5-(4-propyltriazol-2-yl)phenoxy]prop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-[4 -(trifluoromethyl)triazol-2-yl]phenoxy]prop-2-enoate, methyl-(2)-2(5-cyclohexyl-2-methylphenoxy)-3-methoxyprop-2-enoate, methyl-(2)-2 -(5-cyclopentyl-2-methylphenoxy)-3-methoxyprop-2-enoate, methyl-(2)-2-[5-(4-cyclohexylthiazol-2-yl)-2-methylphenoxy]-3-methoxyprop-2 -enoate, methyl-(2)-2-[5-[4-(ethoxymethyl)thiazol-2-yl]-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-2-[5 -(4-bromothiazol-2-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-3-methoxy-2-[2methyl-5-[5-(trifluoromethyl)thiazol-2 -yl]phenoxy]prop-2-enoate, bixafen, fosetyl aluminum, TAEGRO®, Timorex Gold™ and methylpicoxamide, where the weight ratio of component (A) to component (B) is from 15:1 to 1:30.

In another preferred composition according to the present invention, component (A) is Compound No. X.10, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-M-[[1(cyclopropylmethyl)cyclopropyl] methyl]-5-methylthiazole-4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxad, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapyr, fenpicoxamide, florylpicoxamide, acibenzolar-methyl, chlorothalone ila, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil , metalaxyl-M, aminopyrifene, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, cyflufenamide, metrafenone, N'-[2-chloro-4-(2-fluorophenoxy)-5-methylphenyl]-N-ethyl-N-methylformamidine, N'-[4-(2bromophenoxy)-5-chloro-2-methylphenyl]-N-ethyl-N-methylformamidine, N-(1-benzyl-1,3-dimethylbutyl)-8fluoroquinoline-3-carboxamide, N-( 1-benzyl-3,3,3-trifluoro-1-methylpropyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3-chloro-1-methylbut-3-enyl)-8-fluoroquinoline-3 -carboxamide, 1 -(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl -1-(7methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline, 1-(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,6trifluoro-3, 3-dimethylisoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4- difluoro-3,3-dimethylisoquinoline, 6-chloro-4,4-difluoro3,3-dimethyl-1-(4-methylbenzimidazol-1 -yl)isoquinoline, N'-[5-bromo-2-methyl-6-( 1 -methyl-2-propoxyethoxy)-3-pyridyl]-N-ethyl-N-methylformamidine, N'-[5-chloro-2-methyl-6-(1-methyl-2-propoxyethoxy)-3pyridyl]-N -ethyl-N-methylformamidine, N'-[5-bromo-2-methyl-6-(1-methyl-2-propoxyethoxy)-3-pyridyl]N-isopropyl-N-methylformamidine, N-isopropyl-N'- [5-methoxy-2-methyl-4-(2,2,2-Ίrifluoro-1-hydroxy-1phenylethyl)phenyl]-M-methylformamidine, N-methoxy-N-[[4-[5-(trifluoromethyl)- 1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropanecarboxamide, N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3

- 18 046368 yl]phenyl]methyl]propanamide, No. ethyl-2-methyl-H-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, 1 -methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4- [5-(1fluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 3-ethyl-1methoxy-1-[[4-[5-(1fluoromethyl)-1,2,4- oxadiazol-3-yl]phenyl]methyl]urea, ethyl 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrazole-4-carboxylate, KN -dimethyl-1-[[4-[5-(tri(|)tormethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]-1,2,4-triazol-3-amine, methyl -(2)-.3-methoxy-2-[2-methyl-5-[3 (trifluoromethyl)pyrazol-1-yl]phenoxy]prop-2-enoate, methyl-(2)-3-methoxy-2- [2-methyl-5-(3-propylpyrazol-1-yl)phenoxy]prop-2-enoate, methyl-(2)-2-[5-(3-isopropylpyrazol-1-yl)-2-methylphenoxy]- 3-methoxyprop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-(4-propyltriazol-2-yl)phenoxy|prop-2-enoate. methyl (2)-3-methoxy-2-[2-methyl-5-[4-(trifluoromethyl)triazol-2-yl]phenoxy]prop-2-enoate, methyl (2)-2-(5cyclohexyl- 2-methylphenoxy)-3-methoxyprop-2-enoate, methyl-(2)-2-(5-cyclopentyl-2-methylphenoxy)-3methoxyprop-2-enoate, methyl-(2)-2-[5-(4 -cyclohexylthiazol-2-yl)-2-methylphenoxy|-3-methoxyprop-2enoate, methyl-(2)-2-[5-[4-(ethoxymethyl)thiazol-2-yl]-2-methylphenoxy]-3- methoxyprop-2-enoate, methyl(2)-2-[5-(4-bromothiazol-2-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl (2)-3-methoxy-2 -[2-methyl5-[5-(trifluoromethyl)thiazol-2-yl]phenoxy]prop-2-enoate, bixaphen, fosetyl aluminum, TAEGRO®, Timorex Gold™ and methylpicoxamide, where the weight ratio of component (A) and component (B) is from 15:1 to 1:30.

In another preferred composition according to the present invention, component (A) is Compound No. X.11, 2-(Ncyano-3,5-difluoroanilino)-5-methyl-H-(1methylcyclopentyl)thiazole-4-carboxamide, or its salt, enantiomer, tautomer or N-oxide, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxade, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapyr, fenpicoxamide, florylpicoxamide, acibenzolar-methyl, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl -M, aminopyrifene, folpet, ipflufenoquin, quinofumeline , tricyclazole, pyroquilone, cyflufenamide, metrafenone, N'-[2chloro-4-(2-fluorophenoxy)-5-methylphenyl]-N-ethyl-N-methylformamidine, N-[4-(2-bromophenoxy)-5-chloro -2methylphenyl]-N-ethyl-N-methylformamidine, N-(1-benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3 carboxamide, N-(1-benzyl-3,3,3-trifluoro-1- methylpropyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl3-chloro-1-methylbut-3-enyl)-8-fluoroquinoline-3-carboxamide, 1-(6,7-dimethylpyrazolo[1,5- a]pyridin-3 yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl-1-(7-methylpyrazolo[1,5-a]pyridin3 -yl )isoquinoline, 1 -(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,6-trifluoro-3,3-dimethylisoquinoline, 1-(4,5-dimethylbenzimidazol-1- yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 1-(4,5-dimethylbenzimidazol1 -yl)-4,4-difluoro-3,3-dimethylisoquinoline, 6-chloro-4,4-difluoro -3,3-dimethyl-1-(4-methylbenzimidazol-1yl)isoquinoline, N'-[5-bromo-2-methyl-6-(1-methyl-2-propoxyethoxy)-3-pyridyl]-N-ethyl -Nmethylformamidine, N'-[5-chloro-2-methyl-6-(1-methyl-2-propoxyethoxy)-3-pyridyl]-N-ethyl-Nmethylformamidine, N'-[5-bromo-2-methyl- 6-(1-methyl-2-propoxyethoxy)-3-pyridyl]-N-isopropyl-Nmethylformamidine, N-isopropyl-N'-[5-methoxy-2-methyl-4-(2,2,2-trifluoro- 1-hydroxy-1phenylethyl)phenyl]-N-methylformamidine, N-methoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]cyclopropanecarboxamide, N,2- dimethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]propanamide, N-ethyl-2-methyl-N-[[4-[5-(trifluoromethyl )-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3 -yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 3-ethyl- 1methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, ethyl-1-[[4-[5-(trifluoromethyl)-1, 2,4-oxadiazol-3-yl]phenyl]methyl]pyrazole-4-carboxylate, N,N-dimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl ]phenyl]methyl]-1,2,4-triazol-3-amine, methyl-(2)-3-methoxy-2-[2-methyl-5-[3 (trifluoromethyl)pyrazol-1-yl]phenoxy] prop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-(3-propylpyrazol-1-yl)phenoxy]prop-2-enoate, methyl-(2)-2- [5-(3-isopropylpyrazol-1-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-(4-propyltriazol- 2-yl)phenoxy]prop-2-enoate, methyl (2)-3-methoxy-2-[2-methyl-5-[4-(trifluoromethyl)triazol-2-yl]phenoxy]prop-2-enoate , methyl (2)-2-(5cyclohexyl-2-methylphenoxy)-3-methoxyprop-2-enoate, methyl (2)-2-(5-cyclopentyl-2-methylphenoxy)-3methoxyprop-2-enoate, methyl -(2)-2-[5-(4-cyclohexylthiazol-2-yl)-2-methylphenoxy]-3-methoxyprop-2enoate, methyl-(2)-2-[5-[4-(ethoxymethyl)thiazol- 2-yl]-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl(2)-2-[5-(4-bromothiazol-2-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate , methyl-(2)-3-methoxy-2-[2-methyl5-[5-(trifluoromethyl)thiazol-2-yl]phenoxy]prop-2-enoate, bixafen, fosetyl aluminum, TAEGRO®, Timorex Gold™ and methylpicoxamide, wherein the weight ratio of component (A) to component (B) is from 15:1 to 1:30.

In another preferred composition according to the present invention, component (A) is Compound No. X.12, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-5-methyl-H-(1methylcyclopentyl)thiazole -4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component

- 19 046368 (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxad, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapyr, fenpicoxamide, florylpicoxamide, acibenzolar^-methyl, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifen, folpet, ipflufenoquin, quinofumeline, tricycle azole, pyroquilone, cyflufenamide, metrafenone, N '-[2chloro-4-(2-fluorophenoxy)-5-methylphenyl]-N-ethyl-N-methylformamidine, N-[4-(2-bromophenoxy)-5-chloro-2methylphenyl]-N-ethyl-N-methylformamidine, N-(1-benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro-1-methylpropyl)-8-fluoroquinoline-3-carboxamide, N -(1-benzyl3-chloro-1-methylbut-3-enyl)-8-fluoroquinoline-3-carboxamide, 1 -(6,7-dimethylpyrazolo[1,5-a]pyridin-3 yl)-4,4, 5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl-1-(7-methylpyrazolo[1,5-a]pyridin3-yl)isoquinoline, 1-(6,7-dimethylpyrazolo[ 1,5-a]pyridin-3-yl)-4,4,6-trifluoro-3,3-dimethylisoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3 ,3-dimethylisoquinoline, 1-(4,5-dimethylbenzimidazol1 -yl)-4,4-difluoro-3,3-dimethylisoquinoline, 6-chloro-4,4-difluoro-3,3-dimethyl-1-(4- methylbenzimidazol-1yl)isoquinoline, N'-[5-bromo-2-methyl-6-(1-methyl-2-propoxyethoxy)-3-pyridyl]-N-ethyl-Nmethylformamidine, N'-[5-chloro-2 -methyl-6-(1-methyl-2-nropoxyethoxy)-3-pyridyl]-N-ethyl-Nmethylformamidine, N'-[5-bromo-2-methyl-6-(1-methyl-2-nropoxyethoxy)- 3-pyridyl]-N-isopropyl-Nmethylformamidine, N-isonropyl-N'-[5-methoxy-2-methyl-4-(2,2,2-trifluoro-1-hydroxy-1phenylethyl)phenyl]-I-methylformamidine , N-methoxy-N-[[4-[5-(Ίriforomethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]cyclopropanecarboxamide, N,2-dimethoxy-N-[[4-[5-( trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]propanamide, N-ethyl-2-methyl-N-[[4-[5-(Ίriforomethyl)-1,2,4-oxadiazol-3- yl]phenyl]methyl]propanamide, 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1.3 -dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 3-ethyl-1 methoxy-1-[[4-[5- (trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, ethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl ]methyl]pyrazol-4-carboxylate, N,N-dimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]-1,2,4 -triazol-3-amine, methyl-(2)-3-methoxy-2-[2-methyl-5-[3 (trifluoromethyl)pyrazol-1-yl]phenoxy]prop-2-enoate, methyl-(2) -3-methoxy-2-[2-methyl-5-(3-propylpyrazol-1-yl)phenoxy]prop-2-enoate, methyl-(2)-2-[5-(3-isopropylpyrazol-1-yl) )-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-(4-propyltriazol-2-yl)phenoxy]prop-2-enoate , methyl (2)-3-methoxy-2-[2-methyl-5-[4-(trifluoromethyl)triazol-2-yl]phenoxy]prop-2-enoate, methyl (2)-2-(5cyclohexyl -2-methylphenoxy)-3-methoxyprop-2-enoate, methyl-(2)-2-(5-cyclopentyl-2-methylphenoxy)-3methoxyprop-2-enoate, methyl-(2)-2-[5-( 4-cyclohexylthiazol-2-yl)-2-methylphenoxy]-3-methoxyprop-2enoate, methyl (2)-2-[5-[4-(ethoxymethyl)thiazol-2-yl]-2-methylphenoxy]-3 -methoxyprop-2-enoate, methyl(2)-2-[5-(4-bromothiazol-2-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-3-methoxy- 2-[2-methyl5-[5-(trifluoromethyl)thiazol-2-yl]phenoxy]prop-2-enoate, bixaphen, fosetyl aluminum, TAEGRO®, Timorex Gold™ and methylpicoxamide, where the weight ratio of component (A) and component (B) is from 15:1 to 1:30.

In another preferred composition according to the present invention, component (A) is Compound No. X.13, 2-[cyano-(5-fluoro-3-pyridyl)amino]-H-hexyl-5-methylthiazol-4carboxamide, or a salt, enantiomer, tautomer or N-oxide, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxade, fluopyram, isopyrase ma ... aminopyrifene, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, cyflufenamide, metrafenone, N'-[2-chloro-4-(2-fluorophenoxy)-5methylphenyl]-N-ethyl-N-methylformamidine, N'-[4-(2-bromophenoxy)-5-chloro -2-methylphenyl]-N-ethyl-Nmethylformamidine, N-(1-benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3trifluoro-1-methylpropyl )-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3-chloro-1-methylbut-3-enyl)-8-fluoroquinoline-3-carboxamide, 1-(6,7-dimethylpyrazolo[1,5-a ]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl-1 -(7-methylpyrazolo[1,5-a]pyridin-3 -yl)isoquinoline, 1-(6,7dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,6-trifluoro-3,3-dimethylisoquinoline, 1-(4,5-dimethylbenzimidazol-1- yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4-difluoro-3,3dimethylisoquinoline, 6-chloro-4,4-difluoro -3,3-dimethyl-1-(4-methylbenzimidazol-1-yl)isoquinoline, N'-[5bromo-2-methyl-6-(1-methyl-2-propoxyethoxy)-3-pyridyl]-N-ethyl -N-methylformamidine, N-[5-chloro-2methyl-6-(1-methyl-2-nropoxyethoxy)-3-pyridyl]-N-ethyl-N-methylformamidine, N'-[5-bromo-2-methyl -6-(1methyl-2-propoxyethoxy)-3-pyridyl]-N-isopropyl-N-methylformamidine, N-isopropyl-N'-[5-methoxy-2methyl-4-(2,2,2-Ίriforo-1 -hydroxy-1-phenylethyl)phenyl]-N-methylformamidine, N-methoxy-N-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropanecarboxamide, N, 2-dimethoxy-N-[[4-[5

- 20 046368 (trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, No. ethyl-2-methyl-H-[[4-[5-(trifluoromethyl)-1,2,4 -oxadiazol-3-yl]phenyl]methyl]propanamide, 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]urea, 3-ethyl-1-methoxy-1-[[4-[ 5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, ethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl ]phenyl]methyl]pyrazole-4-carboxylate, H,H-dimethyl-1-[[4-[5-(tri(|)tormethyl)-1,2,4-oxadiazol-3-yl|(|)enyl |methyl|-1,2,4-triazol-3-amine, methyl-(2)-3-methoxy-2-[2-methyl-5-[3-(trifluoromethyl)pyrazol-1-yl]phenoxy]prop -2-enoate, methyl-(2)-3methoxy-2-[2-methyl-5-(3-propylpyrazol-1-yl)phenoxy]prop-2-enoate, methyl-(2)-2-[5- (3-isopropylpyrazol-1-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-.3-methoxy-2-[2-methyl-5-(4-propyltriazol-2- yl)phenoxy]prop-2-enoate, methyl (2)-3-methoxy-2-[2-methyl-5-[4-(trifluoromethyl)triazol-2-yl|phenoxy]prop-2-enoate, methyl -(2)-2-(5-cyclohexyl-2-methylphenoxy)-3-methoxyprop-2-enoate, methyl (2)2-(5-cyclopentyl-2-methylphenoxy)-3-methoxyprop-2-enoate, methyl (2)-2-[5-(4-cyclohexylthiazol-2-yl)2-methylphenoxy]-3-methoxyprop-2-enoate, methyl (2)-2-[5-[4-(ethoxymethyl) thiazol-2-yl]-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-2-[5-(4-bromothiazol-2-yl)-2-methylphenoxy]-3-methoxyprop- 2enoate, methyl (2)-3-methoxy-2-[2-methyl-5-[5-(trifluoromethyl)thiazol-2-yl]phenoxy]prop-2-enoate, bixaphen, fosetyl aluminum, TAEGRO®, Timorex Gold™ and methylpicoxamide, wherein the weight ratio of component (A) to component (B) is from 15:1 to 1:30.

In another preferred composition according to the present invention, component (A) is Compound No. X.14, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-H-hexyl-5methylthiazol-4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxade, fluopyram , isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florylpicoxamide, acibenzolar^-methyl, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metal xyla-M, aminopyrifene, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, cyflufenamide, metrafenone, H'-[2-chloro-4-(2fluorophenoxy)-5-methylphenyl]-N-ethyl-N-methylformamidine, I-[4-(2-bromophenoxy)-5- chloro-2methylphenyl]-N-ethyl-N-methylformamidine, N-(1-benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro- 1 -methylpropyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3 chloro-1-methylbut-3-enyl)-8-fluoroquinoline-3-carboxamide, 1 -(6,7-dimethylpyrazolo [1 ,5-a]pyridin-3-yl)4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl-1-(7-methylpyrazolo[1,5-a] pyridin-3yl)isoquinoline, 1 -(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,6-trifluoro-3,3-dimethylisoquinoline, 1 (4,5-dimethylbenzimidazol- 1-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 1-(4,5-dimethylbenzimidazol-1yl)-4,4-difluoro-3,3-dimethylisoquinoline, 6-chloro-4,4 -difluoro-3,3-dimethyl-1 -(4-methylbenzimidazol-1 yl)isoquinoline, N'-[5-bromo-2-methyl-6-(1-methyl-2-propoxyethoxy)-3-pyridyl]- N-ethyl-N-methylformamidine, N'-[5-chloro-2-methyl-6-(1-methyl-2-propoxyethoxy)-3-pyridyl]-N-ethyl-N-methylformamidine, N'-[5 -bromo-2-methyl-6-(1-methyl-2-propoxyethoxy)-3-pyridyl]-N-isopropyl-N-methylformamidine, Nisopropyl-N'-[5-methoxy-2-methyl-4-(2 ,2,2-trifluoro-1-hydroxy-1-phenylethyl)phenyl]-N-methylformamidine, N-methoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl ]phenyl]methyl]cyclopropanecarboxamide, N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, Nethyl-2-methyl- N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, 1-methoxy-3 methyl-1-[[4-[5-(trifluoromethyl) -1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl ]methyl]urea, 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, ethyl-1-[[ 4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]pyrazole-4-carboxylate, N,N-dimethyl-1-[[4-[5-(trifluoromethyl)-1, 2,4-oxadiazol-3yl]phenyl]methyl]-1,2,4-triazol-3-amine, methyl-(2)-3-methoxy-2-[2-methyl-5-[3-(trifluoromethyl) pyrazol-1yl]phenoxy]prop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-(3-propylpyrazol-1-yl)phenoxy]prop-2-enoate, methyl-(2 )-2-[5-(3-isopropylpyrazol-1-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)3-methoxy-2-[2-methyl-5-(4 -propyltriazol-2-yl)phenoxy]prop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl5-[4-(trifluoromethyl)triazol-2-yl]phenoxy]prop-2- enoate, methyl (2)-2-(5-cyclohexyl-2-methylphenoxy)3-methoxyprop-2-enoate, methyl (2)-2-(5-cyclopentyl-2-methylphenoxy)-3-methoxyprop-2 -enoate, methyl(2)-2-[5-(4-cyclohexylthiazol-2-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-2-[5-[4- (ethoxymethyl)thiazol-2-yl]-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl (2)-2-[5-(4-bromothiazol-2-yl)-2methylphenoxy]-3-methoxyprop -2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-[5-(trifluoromethyl)thiazol-2yl|phenoxy|prop-2-enoate, bixaphen, fosetyl aluminum, TAEGRO® , Timorex Gold™ and methylpicoxamide, wherein the weight ratio of component (A) to component (B) is from 15:1 to 1:30.

In another preferred composition according to the present invention, component (A) is Compound No. X.15, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-H-isobutyl-5methylthiazol-4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyl tetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph , fluxapyroxad, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florylpicoxamide, acibenzolar^-methyl, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fl udioxonil, cyprodinil, metalaxyl-M, aminopyrifene, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, cyflufenamide, metrafenone, N'-[2-χλορ-4-(2fluorophenoxy)-5-methylphenyl]-N-ethyl-N-methylformamidine, I-[4-(2-bromophenoxy )-5-chloro-2methylphenyl]-N-ethyl-N-methylformamidine, N-(1-benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3, 3-trifluoro-1-methylpropyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3chloro-1-methylbut-3-enyl)-8-fluoroquinoline-3-carboxamide, 1 -(6,7 -dimethylpyrazolo[1,5-a]pyridin-3-yl)4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl-1-(7-methylpyrazolo[1, 5-a]pyridin-3yl)isoquinoline, 1 -(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,6-trifluoro-3,3-dimethylisoquinoline, 1 (4, 5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 1-(4,5-dimethylbenzimidazol-1yl)-4,4-difluoro-3,3-dimethylisoquinoline, 6-chloro -4,4-difluoro-3,3-dimethyl-1-(4-methylbenzimidazol-1 yl)isoquinoline, N-[5-bromo-2-methyl-6-(1-methyl-2-propoxyethoxy)-3- pyridyl]-Nethyl-Nmethylformamidine, N-[5-chloro-2-methyl-6-(1-methyl-2-propoxyethoxy)-3-pyridyl]-Nethyl-Nmethylformamidine, N-[5-bromo- 2-methyl-6-(1-methyl-2-propoxyethoxy)-3-pyridyl]-Nisopropyl-Nmethylformamidine, Nisopropyl-H'-[5-methoxy-2-methyl-4-(2,2,2- trifluoro-1-hydroxy-1-phenylethyl)phenyl]-N-methylformamidine, N-methoxy-H-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropanecarboxamide , N2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, Nethyl-2-methyl-H-[[4-[ 5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, 1-methoxy-3 methyl-1-[[4-[5-(trifluoromethyl)-1,2,4- oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 3- ethyl 1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, ethyl 1-[[4-[5-(trifluoromethyl )-1,2,4-oxadiazol-3yl]phenyl]methyl]pyrazol-4-carboxylate, ^Ndimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl ]methyl]-1,2,4-triazol-3-amine, methyl-(2)-3-methoxy-2-[2-methyl-5-[3-(trifluoromethyl)pyrazol-1yl]phenoxy]prop-2 -enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-(3-propylpyrazol-1-yl)phenoxy]prop-2enoate, methyl-(2)-2-[5-(3 -isopropylpyrazol-1-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)3-methoxy-2-[2-methyl-5-(4-propyltriazol-2-yl)phenoxy] prop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl5-[4-(trifluoromethyl)triazol-2-yl]phenoxy]prop-2-enoate, methyl-(2)-2 -(5-cyclohexyl-2-methylphenoxy)3-methoxyprop-2-enoate, methyl (2)-2-(5-cyclopentyl-2-methylphenoxy)-3-methoxyprop-2-enoate, methyl(2)-2 -[5-(4-cyclohexylthiazol-2-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-2-[5-[4-(ethoxymethyl)thiazol-2-yl] -2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-2-[5-(4-bromothiazol-2-yl)-2methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2 )-3-methoxy-2-[2-methyl-5-[5-(trifluoromethyl)thiazol-2yl]phenoxy]prop-2-enoate, bixaphen, fosetyl aluminum, TAEGRO®, Timorex Gold™ and methylpicoxamide, where wt. the ratio of component (A) and component (B) is from 15:1 to 1:30.

In another preferred composition according to the present invention, component (A) is Compound No. X.16, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-5-methyl-N-(1phenylethyl)thiazole -4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxad, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapyr, fenpicoxamide, florylpicoxamide, acibenzolar^-methyl, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, flu azinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifene , folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, cyflufenamide, metrafenone, N'-[2chloro-4-(2-fluorophenoxy)-5-methylphenyl]-N-ethyl-N-methylformamidine, N-[4-(2- bromophenoxy)-5-chloro-2methylphenyl]-N-ethyl-N-methylformamidine, N-(1-benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3 ,3-trifluoro-1-methylpropyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3chloro-1-methylbut-3-enyl)-8-fluoroquinoline-3-carboxamide, 1 -(6, 7-dimethylpyrazolo[1,5-a]pyridin-3-yl)4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl-1-(7-methylpyrazolo[1 ,5-a]pyridin-3yl)isoquinoline, 1 -(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,6-trifluoro-3,3-dimethylisoquinoline, 1 (4 ,5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 1-(4,5-dimethylbenzimidazol-1yl)-4,4-difluoro-3,3-dimethylisoquinoline, 6- chloro-4,4-difluoro-3,3-dimethyl-1 -(4-methylbenzimidazol-1 yl)isoquinoline, N'-[5-bromo-2-methyl-6-(1-methyl-2-propoxyethoxy)- 3-pyridyl]-N-ethyl-N-methylformamidine, N'-[5-chloro-2-methyl-6-(1-methyl-2-npropoxyethoxy)-3-pyridyl]-N-ethyl-N-methylformamidine, N'-[5-bromo-2-methyl-6-(1-methyl-2-nropoxyethoxy)-3-pyridyl]-N-isopropyl-N-methylformamidine, Nisopropyl-N'-[5-methoxy-2-methyl -4-(2,2,2-trifluoro-1-hydroxy-1-phenylethyl)phenyl]-N-methylformamidine, N-methoxy-N-[[4-[5-(Ίrifluoromethyl)-1,2,4- Oxadiazol-3-yl]phenyl]methyl]cyclopropanecarboxamide, N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, Nethyl -2-methyl-H-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, 1-methoxy-3 methyl-1-[[4-[ 5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5- 22 046368 (trifluoromethyl)-1,2,4 -oxadiazol-3-yl]phenyl]methyl]urea, 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl] urea, ethyl 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]pyrazole-4-carboxylate, KH-dimethyl-1-[[4-[5- (tri(|)tormethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]-1,2,4-triazol-3-amine, methyl-(2)-3-methoxy-2-[2- methyl 5-[3-(trifluoromethyl)pyrazol-1yl]phenoxy]prop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-(3-propylpyrazol-1-yl) phenoxy|prop-2-enoate, methyl-(2)-2-[5-(3-isopropylpyrazol-1-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)3-methoxy-2 -[2-methyl-5-(4-propyltriazol-2-yl)phenoxy]prop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl5-[4-(trifluoromethyl)triazol- 2-yl]phenoxy]prop-2-enoate, methyl (2)-2-(5-cyclohexyl-2-methylphenoxy)3-methoxyprop-2-enoate, methyl (2)-2-(5-cyclopentyl- 2-methylphenoxy)-3-methoxyprop-2-enoate, methyl(2)-2-[5-(4-cyclohexylthiazol-2-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2 )-2-[5-[4(ethoxymethyl)thiazol-2-yl]-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl (2)-2-[5-(4-bromothiazol-2yl) -2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-[5-(trifluoromethyl)thiazol-2-yl]phenoxy]prop-2 -enoate, bixafen, fosetyl aluminum, TAEGRO®, Timorex Gold™ and methylpicoxamide, where the weight ratio of component (A) to component (B) is from 15:1 to 1:30.

In another preferred composition according to the present invention, component (A) is Compound No. X.17, 2-[cyano-(5-fluoro-3-pyridyl)amino]-H-(2,2-dimethylpropyl)-5methylthiazol- 4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph , fluxapyroxad, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florylpicoxamide, acibenzolar^-methyl, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fl udioxonil, cyprodinil, metalaxyl-M, aminopyrifene, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, cyflufenamide, metrafenone, H'-[2-chloro-4-(2fluorophenoxy)-5-methylphenyl]-H-ethyl-N-methylformamidine, I-[4-(2-bromophenoxy )-5-chloro-2methylphenyl]-N-ethyl-N-methylformamidine, N-(1-benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3, 3-trifluoro-1-methylpropyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3chloro-1-methylbut-3-enyl)-8-fluoroquinoline-3-carboxamide, 1 -(6,7 -dimethylpyrazolo[1,5-a]pyridin-3-yl)4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl-1-(7-methylpyrazolo[1, 5-a]pyridin-3yl)isoquinoline, 1 -(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,6-trifluoro-3,3-dimethylisoquinoline, 1 (4, 5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 1-(4,5-dimethylbenzimidazol-1yl)-4,4-difluoro-3,3-dimethylisoquinoline, 6-chloro -4,4-difluoro-3,3-dimethyl-1 -(4-methylbenzimidazol-1 yl)isoquinoline, N'-[5-bromo-2-methyl-6-(1-methyl-2-propoxyethoxy)-3 -pyridyl]-N-ethyl-N-methylformamidine, N'-[5-chloro-2-methyl-6-(1-methyl-2-propoxyethoxy)-3-pyridyl]-N-ethyl-N-methylformamidine, N '-[5-bromo-2-methyl-6-(1-methyl-2-propoxyethoxy)-3-pyridyl]-N-isopropyl-N-methylformamidine, Nisopropyl-N'-[5-methoxy-2-methyl- 4-(2,2,2-trifluoro-1-hydroxy-1-phenylethyl)phenyl]-N-methylformamidine, N-methoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazole -3-yl]phenyl]methyl]cyclopropanecarboxamide, N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, Nethyl- 2-methyl-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, 1-methoxy-3 methyl-1-[[4-[5 -(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3 -yl]phenyl]methyl]urea, 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, ethyl- 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]pyrazole-4-carboxylate, N,N-dimethyl-1-[[4-[5-(trifluoromethyl )-1,2,4-oxadiazol-3yl]phenyl]methyl]-1,2,4-triazol-3-amine, methyl-(2)-3-methoxy-2-[2-methyl-5-[3 -(trifluoromethyl)pyrazol-1yl]phenoxy]prop-2-enoate, methyl (2)-3-methoxy-2-[2-methyl-5-(3-propylpyrazol-1-yl)phenoxy]prop-2-enoate, methyl-(2)-2-[5-(3-isopropylpyrazol-1-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)3-methoxy-2-[2-methyl- 5-(4-propyltriazol-2-yl)phenoxy]prop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl5-[4-(trifluoromethyl)triazol-2-yl]phenoxy] prop-2-enoate, methyl (2)-2-(5-cyclohexyl-2-methylphenoxy)3-methoxyprop-2-enoate, methyl (2)-2-(5-cyclopentyl-2-methylphenoxy)-3 -methoxyprop-2-enoate, methyl(2)-2-[5-(4-cyclohexylthiazol-2-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-2-[5 -[4-(ethoxymethyl)thiazol-2-yl]-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-2-[5-(4-bromothiazol-2-yl)-2methylphenoxy] -3-methoxyprop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-[5-(trifluoromethyl)thiazol-2yl]phenoxy]prop-2-enoate, bixafen, fosetyl- aluminum, TAEGRO®, Timorex Gold™ and methylpicoxamide, where the weight ratio of component (A) to component (B) is from 15:1 to 1:30.

In another preferred composition according to the present invention, component (A) is Compound No. X.18, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-H-(2,2dimethylpropyl)-5- methylthiazole-4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine , fenpropimorph, fluxapyroxad, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapyr, fenpicoxamide, florylpicoxamide, acibenzolar^-methyl, chlorothalonil, mancozeb, mandiprop amide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifene, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, cyflufenamide, metrafenone, N-[2-chloro-4-(2-fluorophenoxy)-5-methylphenyl]-N-ethyl-N-methylformamidine, N' -[4-(2bromophenoxy)-5-chloro-2-methylphenyl]-N-ethyl-N-methylformamidine, N-(1-benzyl-1,3-dimethylbutyl)-8fluoroquinoline-3-carboxamide, N-(1 - benzyl-3,3,3-trifluoro-1-methylpropyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3-chloro-1-methylbut-3-enyl)-8-fluoroquinoline-3-carboxamide , 1 -(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl-1 -(7methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline, 1-(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,6trifluoro-3,3- dimethylisoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4-difluoro- 3,3-dimethylisoquinoline, 6-chloro-4,4difluoro-3,3-dimethyl-1-(4-methylbenzimidazol-1 -yl)isoquinoline, N'-[5-bromo-2-methyl-6-( 1 - methyl-2-propoxyethoxy)-3-pyridyl]-N-ethyl-N-methylformamidine, N'-[5-chloro-2-methyl-6-(1-methyl-2-propoxyethoxy)3-pyridyl]-N- ethyl-N-methylformamidine, N'-[5-bromo-2-methyl-6-(1-methyl-2-propoxyethoxy)-3-pyridyl]-N-isopropyl-N-methylformamidine, N-isopropyl-N'- [5-methoxy-2-methyl-4-(2,2,2-trifluoro-1-hydroxy-1-phenylethyl)phenyl]-I-methylformamidine, N-methoxy-N-[[4-[5-(trifluoromethyl )-1,2,4-oxadiazol-3yl]phenyl]methyl]cyclopropanecarboxamide, N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl ]propanamide, N-ethyl-2-methyl-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, 1-methoxy-3-methyl- 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)- 1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 3-ethyl-1methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl ]methyl]urea, ethyl 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrazole-4-carboxylate, N,N-dimethyl-1- [[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]-1,2,4-triazol-3-amine, methyl-(2)-3-methoxy- 2-[2-methyl-5-[3 (trifluoromethyl)pyrazol-1 -yl]phenoxy]prop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-(3 - propylpyrazol-1 -yl)phenoxy]prop-2-enoate, methyl-(2)-2-[5-(3-isopropylpyrazol-1-yl)-2-methylphenoxy]-3 methoxyprop-2-enoate, methyl-( 2)-3-methoxy-2-[2-methyl-5-(4-propyltriazol-2-yl)phenoxy]prop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl- 5-[4-(trifluoromethyl)triazol-2-yl]phenoxy]prop-2-enoate, methyl-(2)-2(5-cyclohexyl-2-methylphenoxy)-3-methoxyprop-2-enoate, methyl-( 2)-2-(5-cyclopentyl-2-methylphenoxy)-3-methoxyprop-2-enoate, methyl (2)-2-[5-(4-cyclohexylthiazol-2-yl)-2-methylphenoxy]-3 -methoxyprop-2-enoate, methyl-(2)-2-[5-[4-(ethoxymethyl)thiazol-2-yl]-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)- 2-[5-(4-bromothiazol-2-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-3-methoxy-2-[2methyl-5-[5-(trifluoromethyl )thiazol-2-yl]phenoxy]prop-2-enoate, bixafen, fosetyl aluminum, TAEGRO®, Timorex Gold™ and methylpicoxamide, where the weight ratio of component (A) to component (B) is from 15:1 to 1: thirty.

In another preferred composition according to the present invention, component (A) is Compound No. X.19, 2-[cyano-(5-fluoro-3-pyridyl)amino]-5-methyl-N-pentylthiazol-4carboxamide, or a salt, enantiomer, tautomer or N-oxide, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxade, fluopyram, isopyrase ma ... aminopyrifene, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, cyflufenamide, metrafenone, N'-[2-chloro-4-(2-fluorophenoxy)-5methylphenyl]-N-ethyl-N-methylformamidine, N'-[4-(2-bromophenoxy)-5-chloro -2-methylphenyl]-N-ethyl-Nmethylformamidine, N-(1-benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3trifluoro-1-methylpropyl )-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3-chloro-1-methylbut-3-enyl)-8-fluoroquinoline-3-carboxamide, 1 -(6,7-dimethylpyrazolo[1,5-a ]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl-1 -(7-methylpyrazolo[1,5-a]pyridin-3 -yl)isoquinoline, 1-(6,7dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,6-trifluoro-3,3-dimethylisoquinoline, 1-(4,5-dimethylbenzimidazol-1- yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4-difluoro3,3-dimethylisoquinoline, 6-chloro-4,4-difluoro -3,3-dimethyl-1-(4-methylbenzimidazol-1-yl)isoquinoline, N'[5-bromo-2-methyl-6-(1-methyl-2-propoxyethoxy)-3-pyridyl]-N- ethyl-N-methylformamidine, N-[5-chloro-2methyl-6-(1-methyl-2-propoxyethoxy)-3-pyridyl]-N-ethyl-N-methylformamidine, N'-[5-bromo-2- methyl-6-(1methyl-2-propoxyethoxy)-3-pyridyl]-N-isopropyl-N-methylformamidine, N-isopropyl-N'-[5-methoxy-2methyl-4-(2,2,2-Ίriforo- 1-Hydroxy-1-phenylethyl)phenyl]-N-methylformamidine, N-methoxy-N-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropanecarboxamide, N ,2-dimethoxy-N-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, N-ethyl-2-methyl-N-[[4-[ 5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)1,2,4- oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol3-yl]phenyl]methyl]urea, 3-ethyl -1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]me

- 24 046368 til]urea, ethyl 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrazole-4-carboxylate, H,H-dimethyl- 1-[[4-[5-(tri(|)tormethyl)-1,2,4-oxadiazol-3-yl|(|)enyl|methyl|-1,2,4-triazol-3-amine, methyl -(2)-3-methoxy-2-[2-methyl-5-[3-(trifluoromethyl)pyrazol-1-yl]phenoxy]prop-2-enoate, methyl-(2)-3methoxy-2-[2 -methyl-5-(3-propylpyrazol-1-yl)phenoxy]prop-2-enoate, methyl-(2)-2-[5-(3-isopropylpyrazol-1-yl)-2-methylphenoxy]-3- methoxyprop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-(4-propyltriazol-2-yl)phenoxy]prop-2-enoate, methyl-(2)-3- methoxy-2-[2-methyl-5-[4-(trifluoromethyl)triazol-2yl]phenoxy]prop-2-enoate, methyl-(2)-2-(5-cyclohexyl-2-methylphenoxy)-3-methoxyprop -2-enoate, methyl-(2)-2-(5-cyclopentyl-2-methylphenoxy)-3-methoxyprop-2-enoate, methyl-(2)-2-[5-(4-cyclohexylthiazol-2-yl) )-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-2-[5-[4-(ethoxymethyl)thiazol-2-yl]-2methylphenoxy]-3-methoxyprop-2-enoate, methyl (2)-2-[5-(4-bromothiazol-2-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl (2)-3-methoxy-2-[2-methyl -5-[5-(trifluoromethyl)thiazol-2-yl]phenoxy]prop-2enoate, bixaphen, fosetyl aluminum, TAEGRO®, Timorex Gold™ and methylpicoxamide, wherein the weight ratio of component (A) to component (B) is from 15:1 to 1:30.

In another preferred composition according to the present invention, component (A) is Compound No. X.20, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-5-methyl-Npentylthiazol-4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxade, fluopyram , isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florylpicoxamide, acibenzolar^-methyl, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metal xyla-M, aminopyrifene, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, cyflufenamide, metrafenone, I-[2-chloro4-(2-fluorophenoxy)-5-methylphenyl]-N-ethyl-N-methylformamidine, I-[4-(2-bromophenoxy)-5-chloro -2methylphenyl]-N-ethyl-N-methylformamidine, N-(1-benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro-1 -methylpropyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3-chloro-1-methylbut-3-enyl)-8-fluoroquinoline-3-carboxamide, 1-(6,7-dimethylpyrazolo [1, 5-a]pyridin-3-yl)4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl-1-(7-methylpyrazolo[1,5-a]pyridine -3yl)isoquinoline, 1 -(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,6-trifluoro-3,3-dimethylisoquinoline, 1 (4,5-dimethylbenzimidazol-1 -yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 1-(4,5-dimethylbenzimidazol-1yl)-4,4-difluoro-3,3-dimethylisoquinoline, 6-chloro-4,4- difluoro-3,3-dimethyl-1-(4-methylbenzimidazol-1 yl)isoquinoline, N'-[5-bromo-2-methyl-6-(1-methyl-2-propoxyethoxy)-3-pyridyl]-N -ethyl-N-methylformamidine, N'-[5-chloro-2-methyl-6-(1-methyl-2-propoxyethoxy)-3-pyridyl]-N-ethyl-N-methylformamidine, N'-[5- bromo-2-methyl-6-(1-methyl-2-propoxyethoxy)-3-pyridyl]-N-isopropyl-N-methylformamidine, Nisopropyl-N'-[5-methoxy-2-methyl-4-(2, 2,2-trifluoro-1-hydroxy-1-phenylethyl)phenyl]-N-methylformamidine, N-methoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl] phenyl]methyl]cyclopropanecarboxamide, N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, Nethyl-2-methyl-N -[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, 1 -methoxy-3 methyl-1-[[4-[5-(trifluoromethyl)- 1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] methyl]urea, 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, ethyl-1-[[4 -[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]pyrazole-4-carboxylate, N,N-dimethyl-1-[[4-[5-(trifluoromethyl)-1,2 ,4-oxadiazol-3yl]phenyl]methyl]-1,2,4-triazol-3-amine, methyl-(2)-3-methoxy-2-[2-methyl-5-[3-(trifluoromethyl)pyrazole -1yl]phenoxy]prop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-(3-propylpyrazol-1-yl)phenoxy]prop-2enoate, methyl-(2) -2-[5-(3-isopropylpyrazol-1-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)3-methoxy-2-[2-methyl-5-(4- propyltriazol-2-yl)phenoxy]prop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl5-[4-(trifluoromethyl)triazol-2-yl]phenoxy]prop-2-enoate , methyl (2)-2-(5-cyclohexyl-2-methylphenoxy)3-methoxyprop-2-enoate, methyl (2)-2-(5-cyclopentyl-2-methylphenoxy)-3-methoxyprop-2- enoate, methyl(2)-2-[5-(4-cyclohexylthiazol-2-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-2-[5-[4-( ethoxymethyl)thiazol-2-yl]-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-2-[5-(4-bromothiazol-2-yl)-2methylphenoxy]-3-methoxyprop- 2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-[5-(trifluoromethyl)thiazol-2yl|phenoxy|prop-2-enoate, bixaphen, fosetyl aluminum, TAEGRO®, Timorex Gold™ and methylpicoxamide, wherein the weight ratio of component (A) to component (B) is from 15:1 to 1:30.

In another preferred composition according to the present invention, component (A) is Compound No. X.21, 2-[cyano-(5-fluoro-3-pyridyl)amino]-H-isopentyl-5methylthiazol-4-carboxamide, or a salt, enantiomer, tautomer or N-oxide, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxade, fluopyram, isopyrase ma , sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapyr, fenpicoxamide, florylpicoxamide, acibenzolar^-methyl, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifene, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, cyflufenamide, metrafenone, N'-[2-x.tor-4-(2fluorophenoxy)-5-methylphenyl]-N-ethyl-N-methylformamidine, N-[4-(2-bromophenoxy )-5-chloro-2methylphenyl]-N-ethyl-N-methylformamidine, N-(1-benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3, 3-trifluoro-1-methylpropyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3chloro-1-methylbut-3-enyl)-8-fluoroquinoline-3-carboxamide, 1 -(6,7 -dimethylpyrazolo[1,5-a]pyridin-3-yl)4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl-1-(7-methylpyrazolo[1, 5-a]pyridin-3yl)isoquinoline, 1 -(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,6-trifluoro-3,3-dimethylisoquinoline, 1 (4, 5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 1-(4,5-dimethylbenzimidazol-1yl)-4,4-difluoro-3,3-dimethylisoquinoline, 6-chloro -4,4-difluoro-3,3-dimethyl-1 -(4-methylbenzimidazol-1 yl)isoquinoline, H'-[5-bromo-2-methyl-6-(1-methyl-2-propoxyethoxy)-3 -pyridyl]-N-ethyl-N-methylformamidine, H'-[5-chloro-2-methyl-6-(1-methyl-2-propoxyethoxy)-3-pyridyl]-N-ethyl-N-methylformamidine, H '-[5-bromo-2-methyl-6-(1-methyl-2-propoxyethoxy)-3-pyridyl]-H-isopropyl-N-methylformamidine, Nisopropyl-H'-[5-methoxy-2-methyl- 4-(2,2,2-trifluoro-1-hydroxy-1-phenylethyl)phenyl]-N-methylformamidine, N-methoxy-H-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazole -3-yl]phenyl]methyl]cyclopropanecarboxamide, H,2-dimethoxy-H-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, Nethyl- 2-methyl-H-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, 1-methoxy-3 methyl-1-[[4-[5 -(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3 -yl]phenyl]methyl]urea, 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, ethyl- 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]pyrazole-4-carboxylate, N,N-dimethyl-1-[[4-[5-(trifluoromethyl )-1,2,4-oxadiazol-3yl]phenyl]methyl]-1,2,4-triazol-3-amine, methyl-(2)-3-methoxy-2-[2-methyl-5-[3 -(trifluoromethyl)pyrazol-1yl]phenoxy]prop-2-enoate, methyl (2)-3-methoxy-2-[2-methyl-5-(3-propylpyrazol-1-yl)phenoxy]prop-2-enoate, methyl-(2)-2-[5-(3-isopropylpyrazol-1-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)3-methoxy-2-[2-methyl- 5-(4-propyltriazol-2-yl)phenoxy]prop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl5-[4-(trifluoromethyl)triazol-2-yl]phenoxy] prop-2-enoate, methyl (2)-2-(5-cyclohexyl-2-methylphenoxy)3-methoxyprop-2-enoate, methyl (2)-2-(5-cyclopentyl-2-methylphenoxy)-3 -methoxyprop-2-enoate, methyl(2)-2-[5-(4-cyclohexylthiazol-2-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-2-[5 -[4-(ethoxymethyl)thiazol-2-yl]-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-2-[5-(4-bromothiazol-2-yl)-2methylphenoxy] -3-methoxyprop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-[5-(trifluoromethyl)thiazol-2yl]phenoxy]prop-2-enoate, bixafen, fosetyl- aluminum, TAEGRO®, Timorex Gold™ and methylpicoxamide, where the weight ratio of component (A) to component (B) is from 15:1 to 1:30.

In another preferred composition according to the present invention, component (A) is Compound No. X.22, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-[cyano-(2,6-difluoro4- pyridyl)amino]-5-methylthiazol-4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxad, fluopyram, isopyrazam, sedaxane, benzovindiflupir, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florylpicoxamide, acibenzolar^-methyl a, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxonil , cyprodinil, metalaxyl-M, aminopyrifen, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, cyflufenamide, metrafenone, N'-[2-chloro-4-(2-fluorophenoxy)-5-methylphenyl]-N-ethyl-N- methylformamidine, N'-[4-(2bromophenoxy)-5-chloro-2-methylphenyl]-N-ethyl-N-methylformamidine, N-(1-benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3-carboxamide, N -(1-benzyl-3,3,3-trifluoro-1-methylpropyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3-chloro-1-methylbut-3-enyl)-8-fluoroquinoline -3-carboxamide, 1 -(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3 -dimethyl-1-(7methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline, 1-(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,6trifluoro- 3,3-dimethylisoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4, 4-difluoro-3,3-dimethylisoquinoline, 6-chloro-4,4-difluoro3,3-dimethyl-1 -(4 -methylbenzimidazol-1 -yl)isoquinoline, N'-[5 -bromo-2-methyl-6 -(1-methyl-2-propoxyethoxy)-3-pyridyl]-N-ethyl-N-methylformamidine, N'-[5-chloro-2-methyl-6-(1-methyl-2-propoxyethoxy)-3pyridyl] -N-ethyl-N-methylformamidine, N'-[5-bromo-2-methyl-6-(1-methyl-2-propoxyethoxy)-3-pyridyl]N-isopropyl-N-methylformamidine, N-isopropyl-N '-[5-methoxy-2-methyl-4-(2,2,2-Ίriforo-1-hydroxy-1phenylethyl)phenyl]-N-methylformamidine, N-methoxy-N-[[4-[5-(trifluoromethyl )-1,2,4-oxadiazol-3yl]phenyl]methyl]cyclopropanecarboxamide, N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl ]propanamide, N-ethyl-2-methyl-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, 1-methoxy-3-methyl- 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)- 1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 3-ethyl-1methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl ]methyl]urea, ethyl 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrazole-4-carboxylate, N,N-dimethyl-1- [[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]-1,2,4-triazol-3-amine, methyl-(2)-3-methoxy- 2-[2-methyl-5-[3

- 26 046368 (trifluoromethyl)pyrazol-1-yl]phenoxy]prop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-(3-propylpyrazol-1-yl)phenoxy] prop-2-enoate, methyl-(2)-2-[5-(3-isopropylpyrazol-1-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-3-methoxy- 2-[2-methyl-5-(4-propyltriazol-2-yl)phenoxy|prop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-[4-(1fluoromethyl )triazol-2-yl]phenoxy]prop-2-enoate, methyl-(2)-2-(5cyclohexyl-2-methylphenoxy)-3-methoxyprop-2-enoate, methyl-(2)-2-(5- cyclopentyl-2-methylphenoxy)-3methoxyprop-2-enoate, methyl-(2)-2-[5-(4-cyclohexylthiazol-2-yl)-2-methylphenoxy|-3-methoxyprop-2-enoate, methyl-(2) -2-[5-[4-(ethoxymethyl)thiazol-2-yl|-2-methyl(|)enoxy|-3-methoxyprop-2-enoate. methyl(2)-2-[5-(4-bromothiazol-2-yl)-2-methyl(|)enoxy|-3-methoxyprop-2-enoate. methyl (2)-3-methoxy-2-[2-methyl5-[5-(trifluoromethyl)thiazol-2-yl]phenoxy]prop-2-enoate, bixafen, fosetyl aluminum, TAEGRO®, Timorex Gold™ and methylpicoxamide, where the weight ratio of component (A) and component (B) is from 15:1 to 1:30.

In another preferred composition according to the present invention, component (A) is Compound No. X.23, N-benzyl-2-[cyano-(2,6-difluoro-4-pyridyl)amino]-5methylthiazol-4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxade, fluopyram , isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florylpicoxamide, acibenzolar^-methyl, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metal xyla-M, aminopyrifene, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, cyflufenamide, metrafenone, N'-[2-chloro-4-(2fluorophenoxy)-5-methylphenyl]-N-ethyl-N-methylformamidine, N'-[4-(2-bromophenoxy)-5 -chloro-2methylphenyl| -N-ethyl-N-methylformamidine, N-(1-benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro-1-methylpropyl) -8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3chloro-1-methylbut-3-enyl)-8-fluoroquinoline-3-carboxamide, 1-(6,7-dimethylpyrazolo[1,5-a |pyridin-3-yl)4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl-1-(7-methylpyrazolo[1,5-a]pyridin-3yl) isoquinoline, 1 -(6,7-dimethylpyrazolo[1,5-a|pyridin-3-yl)-4,4,6-trifluoro-3,3-dimethylisoquinoline, 1 (4,5-dimethylbenzimidazol-1-yl) -4,4,5-trifluoro-3,3-dimethylisoquinoline, 1-(4,5-dimethylbenzimidazol-1yl)-4,4-difluoro-3,3-dimethylisoquinoline, 6-chloro-4,4-difluoro-3 ,3-dimethyl-1 -(4-methylbenzimidazol-1 yl)isoquinoline, N'-[5-bromo-2-methyl-6-(1-methyl-2-propoxyethoxy)-3-pyridyl]-N-ethyl- N-methylformamidine, N'-[5-chloro-2-methyl-6-(1-methyl-2-propoxyethoxy)-3-pyridyl]-Nethyl-N-methylformamidine, N'-[5-bromo-2- methyl-6-(1-methyl-2-npropoxyethoxy)-3-pyridyl]-N-isonropyl-N-methylformamidine, Nisopropyl-N'-[5-methoxy-2-methyl-4-(2,2,2- trifluoro-1-hydroxy-1-phenylethyl)phenyl]-N-methylformamidine, N-methoxy-N-[[4-[5-(Ίriforomethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl] cyclopropanecarboxamide, N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]npropanamide, Nethyl-2-methyl-N-[[4 -[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl| phenyl|methyl| propanamide, 1-methoxy-3 methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[ 4-[5(Ίrifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2 ,4-oxadiazol-3-yl]phenyl]methyl]urea, ethyl 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]pyrazole-4-carboxylate, N,N-dimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]-1,2,4-triazol-3-amine, methyl-(2 )-3-methoxy-2-[2-methyl-5-[3-(trifluoromethyl)pyrazol-1it|phenoxy|prop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl- 5-(3-propylpyrazol-1-yl)phenoxy|prop-2enoate, methyl-(2)-2-[5-(3-isopropylpyrazol-1-yl)-2-methylphenoxy| -3-methoxyprop-2-enoate, methyl-(2)3-methoxy-2-[2-methyl-5-(4-propyltriazol-2-yl)phenoxy]prop-2-enoate, methyl-(2)- 3-methoxy-2-[2-methyl5-[4-(trifluoromethyl)triazol-2-yl]phenoxy]prop-2-enoate, methyl (2)-2-(5-cyclohexyl-2-methylphenoxy)3- methoxyprop-2-enoate, methyl (2)-2-(5-cyclopentyl-2-methylphenoxy)-3-methoxyprop-2-enoate, methyl(2)-2-[5-(4-cyclohexylthiazol-2-yl) )-2-methylphenoxy|-3-methoxyprop-2-enoate, methyl-(2)-2-[5-[4(ethoxymethyl)thiazol-2-yl]-2-methylphenoxy]-3-methoxyprop-2-enoate , methyl-(2)-2-[5-(4-bromothiazol-2yl)-2-methylphenoxy|-3-methoxyprop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl- 5-[5-(trifluoromethyl)thiazol-2-yl]phenoxy]prop-2-enoate, bixaphen, fosetyl aluminum, TAEGRO®, Timorex Gold™ and methylpicoxamide, wherein the weight ratio of component (A) to component (B) is from 15:1 to 1:30.

In another preferred composition according to the present invention, component (A) is Compound No. X.24, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-[cyano-(2,6-difluoro4- pyridyl)amino|-5-methylthiazol-4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxad, fluopyram, isopyrazam, sedaxane, benzovindiflupir, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florylpicoxamide, acibenzolar^-methyl a, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxonil , cyprodinil, metalaxyl-M, aminopyrifen, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, cyflufenamide, met-27 046368 raphenone, I-[2-chloro-4-(2-(|)tor(|)enoxy)-5 -methyl(|)enyl|-N-ethyl-N-methyl(|yurmamidine, N'-[4-(2bromophenoxy)-5-chloro-2-methylphenyl]-N-ethyl-N-methylformamidine. N-(1-benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro-1-methylpropyl)-8-fluoroquinoline-3-carboxamide, N- (1-benzyl-3-chloro-1-methylbut-3-enyl)-8-fluoroquinoline-3-carboxamide, 1 -(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4, 4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl-1-(7methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline, 1-(6,7- dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,6trifluoro-3,3-dimethylisoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3 ,3-dimethylisoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4-difluoro-3,3-dimethylisoquinoline, 6-chloro-4,4-difluoro3,3-dimethyl-1-(4- methylbenzimidazol-1-yl)isoquinoline, H'-[5-bromo-2-methyl-6-(1-methyl-2-propoxyethoxy)-3-pyridyl]-N-ethyl-N-methylformamidine, H'-[5 -chloro-2-methyl-6-(1-methyl-2-propoxyethoxy)-3-pyridyl]-N-ethyl-N-methylformamidine, H'-[5-bromo-2-methyl-6-(1-methyl -2-propoxyethoxy)-3-pyridyl]-Nisopropyl-N-methylformamidine, N-isopropyl-H'-[5-methoxy-2-methyl-4-(2,2,2-trifluoro-1-hydroxy-1phenylethyl) phenyl]-N-methylformamidine, H-methoxy-H-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropanecarboxamide, H,2-dimethoxy-H- [[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]propanamide, N-ethyl-2-methyl-H-[[4-[5-(trifluoromethyl)-1, 2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl ]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 3-ethyl-1methoxy-1- [[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, ethyl-1-[[4-[5-(trifluoromethyl)-1,2,4- oxadiazol-3-yl]phenyl]methyl]pyrazol-4-carboxylate, H,H-dimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl ]-1,2,4-triazol-3-amine, methyl-(2)-3-methoxy-2-[2-methyl-5-[3 (trifluoromethyl)pyrazol-1-yl]phenoxy]prop-2- enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-(3-propylpyrazol-1-yl)phenoxy]prop-2-enoate, methyl-(2)-2-[5-( 3-isopropylpyrazol-1-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl (2)-3-methoxy-2-[2-methyl-5-(4-propyltriazol-2-yl) phenoxy]prop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-[4-(trifluoromethyl)triazol-2-yl]phenoxy]prop-2-enoate, methyl-( 2)-2-(5cyclohexyl-2-methylphenoxy)-3-methoxyprop-2-enoate, methyl-(2)-2-(5-cyclopentyl-2-methylphenoxy)-3methoxyprop-2-enoate, methyl-(2) -2-[5-(4-cyclohexylthiazol-2-yl)-2-methylphenoxy]-3-methoxyprop-2enoate, methyl-(2)-2-[5-[4-(ethoxymethyl)thiazol-2-yl] -2-methylphenoxy]-3-methoxyprop-2-enoate, methyl(2)-2-[5-(4-bromothiazol-2-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-( 2)-3-methoxy-2-[2-methyl5-[5-(trifluoromethyl)thiazol-2-yl]phenoxy]prop-2-enoate, bixaphen, fosetyl aluminum, TAEGRO®, Timorex Gold™ and methylpicoxamide, where the weight ratio of component (A) and component (B) is from 15:1 to 1:30.

In another preferred composition according to the present invention, component (A) is Compound No. X.01, 2-[cyano-(5-fluoro-3-pyridyl)amino]-H-cyclobutyl-5methylthiazol-4-carboxamide, or salt, enantiomer, tautomer or H-oxide, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxade, fluopyram, isopyrase ma , sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapyr, fenpicoxamide, florylpicoxamide, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifene, folpet a, ipflufenoquin, quinofumelin, tricyclazole, pyroquilone, H -(1-benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro-1-methylpropyl)-8-fluoroquinoline-3-carboxamide, 1-( 6,7-dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl-1 -(7 methylpyrazolo[1 ,5-a]pyridin-3-yl)isoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3,3dimethylisoquinoline and 1-(4,5-dimethylbenzimidazol-1- yl)-4,4-difluoro-3,3-dimethylisoquinoline, where the weight ratio of component (A) and component (B) is from 15:1 to 1:30.

In another preferred composition according to the present invention, component (A) is Compound No. X.02, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-H-cyclobutyl-5methylthiazol-4-carboxamide, or a salt, enantiomer, tautomer or H-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxade, fluopyram , isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florylpicoxamide, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrif ena, folpeta, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone , H-(1-benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro-1-methylpropyl)-8-fluoroquinoline-3-carboxamide, 1 -(6,7-dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl-1 -(7 methylpyrazolo [1,5-a]pyridin-3-yl)isoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3,3dimethylisoquinoline and 1-(4,5-dimethylbenzimidazol- 1-yl)-4,4-difluoro-3,3-dimethylisoquinoline, where the weight ratio of component (A) and component (B) is from 15:1 to 1:30.

- 28 046368

In another preferred composition according to the present invention, component (A) is Compound No. X.03, 2-(Ncyano-3,5-difluoroanilino)-N-(2,2-dimethylcyclobutyl)-5methylthiazole-4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxade, fluopyram , isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florylpicoxamide, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrif ena, folpeta, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone , N-(1-benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro-1-methylpropyl)-8-fluoroquinoline-3-carboxamide, 1- (6,7-dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl-1 -(7 methylpyrazolo[ 1,5-a]pyridin-3-yl)isoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3,3dimethylisoquinoline and 1-(4,5-dimethylbenzimidazol-1 -yl)-4,4-difluoro-3,3-dimethylisoquinoline, where the weight ratio of component (A) and component (B) is from 15:1 to 1:30.

In another preferred composition according to the present invention, component (A) is Compound No. X.04, 2-[cyano-(5-fluoro-3-pyridyl)amino]-N-(2,2dimethylcyclobutyl)-5-methylthiazol- 4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph , fluxapiroxad, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florylpicoxamide, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil , metalaxyl-M, aminopyrifene, folpet, ipflufenoquin, quinofumeline , tricyclazole, pyroquilone, N-(1-benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro-1-methylpropyl)-8-fluoroquinoline-3 - carboxamide, 1 -(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro3,3-dimethyl-1 - (7-methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline, 1 -(4,5-dimethylbenzimidazol-1 -yl)4,4,5-trifluoro-3,3-dimethylisoquinoline and 1 -(4 ,5-dimethylbenzimidazol-1-yl)-4,4-difluoro-3,3dimethylisoquinoline, where the weight ratio of component (A) to component (B) is from 15:1 to 1:30.

In another preferred composition according to the present invention, component (A) is Compound No. X.05, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-N-(2,2dimethylcyclobutyl)-5- methylthiazole-4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine , fenpropimorpha, fluxapyroxad, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florylpicoxamide, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxon yl, cyprodinil, metalaxyl-M, aminopyrifene, folpet, ipflufenoquin , quinofumeline, tricyclazole, pyroquilone, N-(1-benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro-1-methylpropyl)-8-fluoroquinoline- 3-carboxamide, 1-(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro3,3-dimethyl- 1-(7-methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)4,4,5-trifluoro-3,3-dimethylisoquinoline and 1- (4,5-dimethylbenzimidazol-1-yl)-4,4-difluoro-3,3-dimethylisoquinoline, where the weight ratio of component (A) to component (B) is from 15:1 to 1:30.

In another preferred composition according to the present invention, component (A) is Compound No. X.06, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-N-(2,2dimethylcyclobutyl)-5- formamidothiazole-4-carboxamide, or a salt, enantiomer, tautomer or Noxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph , fluxapiroxad, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florilpicoxamide, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil , metalaxyl-M, aminopyrifene, folpet, ipflufenoquin, quinofumeline , tricyclazole, pyroquilone, N-(1-benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro-1-methylpropyl)-8-fluoroquinoline-3 - carboxamide, 1 -(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro3,3-dimethyl-1 - (7-methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)4,4,5-trifluoro-3,3-dimethylisoquinoline and 1-(4 ,5-dimethylbenzimidazol-1-yl)-4,4-difluoro-3,3-dimethylisoquinoline, where the weight ratio of component (A) to component (B) is from 15:1 to 1:30.

In another preferred composition according to the present invention, component (A)

- 29 046368 is compound No. X.07, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-5-methyl-Nspiro[3.4]octan-3-ylthiazol-4-carboxamide, or its a salt, enantiomer, tautomer or N-oxide, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxade, fluopyram, isopyrase ma , sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapyr, fenpicoxamide, florylpicoxamide, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifene, folpet a, ipflufenoquin, quinofumelin, tricyclazole, pyroquilone, no. (1-benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro-1-methylpropyl)-8-fluoroquinoline-3-carboxamide, 1-(6 ,7dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl1-(7-methylpyrazolo[1,5 -a]pyridin-3-yl)isoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro3,3-dimethylisoquinoline and 1-(4,5-dimethylbenzimidazol-1-yl) -4,4-difluoro-3,3-dimethylisoquinoline, where the weight ratio of component (A) and component (B) is from 15:1 to 1:30.

In another preferred composition according to the present invention, component (A) is Compound No. X.08, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-5-methyl-Spiro[cyclobutane-2, 2'-indan]-1-yl-thiazol-4-carboxamide, or a salt, enantiomer, tautomer or Noxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole , propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxad, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florylpicoxamide, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl -M, aminopyrifene, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, N-(1-benzyl-1,3-dimethylbutyl)-8fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro-1 -methylpropyl)-8-fluoroquinoline-3-carboxamide, 1 -(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4, 4-difluoro3,3-dimethyl-1-(7-methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline, 1 -(4,5-dimethylbenzimidazol-1-yl)4,4,5-trifluoro- 3,3-dimethylisoquinoline and 1-(4,5-dimethylbenzimidazol-1-yl)-4,4-difluoro-3,3-dimethylisoquinoline, where the weight ratio of component (A) to component (B) is from 15:1 to 1:30.

In another preferred composition according to the present invention, component (A) is Compound No. X.09, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-5-methyl-Nspiro[3.3]heptane- 3-yl-thiazol-4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole , mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxad, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florilpicoxamide, chlorothalonil, mancozeb, mandipropamide, o xathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifene , folpeta, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, N-(1-benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3carboxamide, N-(1-benzyl-3,3,3-trifluoro-1-methylpropyl)- 8-fluoroquinolin-3-carboxamide, 1-(6,7dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3, 3-dimethyl1-(7-methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro3,3-dimethylisoquinoline and 1 -(4,5-dimethylbenzimidazol-1-yl)-4,4-difluoro-3,3-dimethylisoquinoline, where the weight ratio of component (A) to component (B) is from 15:1 to 1:30.

In another preferred composition according to the present invention, component (A) is Compound No. X.10, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-N-[[1(cyclopropylmethyl)cyclopropyl] methyl]-5-methylthiazole-4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxad, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florylpicoxamide, chlorothalonil, mancozeb, mandipro pamida, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifene, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, N-(1-benzyl-1,3-dimethylbutyl)-8fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro-1-methylpropyl) -8-fluoroquinolin-3-carboxamide, 1 -(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4difluoro-3 ,3-dimethyl-1-(7-methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline, 1-(4,5-dimethylbenzimidazol1 -yl)-4,4,5-trifluoro-3,3- dimethylisoquinoline and 1 -(4,5-dimethylbenzimidazol-1 -yl)-4,4-difluoro-3,3 dimethylisoquinoline, where the weight ratio of component (A) to component (B) is from 15:1 to 1:30.

In another preferred composition according to the present invention, component (A) is Compound No. X.11, 2-(Ncyano-3,5-difluoroanalino)-5-methyl-N-(1

- 30 046368 methylcyclopentyl)thiazole-4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxad, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florylpicoxamide, chlorothalonil, mancozeb, mandipro pamida, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifene, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, N-(1-benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3carboxamide, N-(1-benzyl-3,3,3-trifluoro-1-methylpropyl) -8-fluoroquinoline-3-carboxamide, 1-(6,7dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3 ,3-dimethyl1-(7-methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro3,3-dimethylisoquinoline and 1-(4,5-dimethylbenzimidazol-1-yl)-4,4-difluoro-3,3-dimethylisoquinoline, where the weight ratio of component (A) to component (B) is from 15:1 to 1:30.

In another preferred composition according to the present invention, component (A) is Compound No. X.12, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-5-methyl-N-(1methylcyclopentyl)thiazole -4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxad, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florylpicoxamide, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifene, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, N-(1-benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3carboxamide, N-(1-benzyl-3,3,3-trifluoro-1-methylpropyl)-8-fluoroquinoline-3 -carboxamide, 1 -(6,7 dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl1- (7-methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro3,3-dimethylisoquinoline and 1-(4, 5-dimethylbenzimidazol-1-yl)-4,4-difluoro-3,3-dimethylisoquinoline, where the weight ratio of component (A) to component (B) is from 15:1 to 1:30.

In another preferred composition according to the present invention, component (A) is Compound No. X.13, 2-[cyano-(5-fluoro-3-pyridyl)amino]-N-hexyl-5-methylthiazol-4carboxamide, or a salt, enantiomer, tautomer or N-oxide, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxade, fluopyram, isopyrase ma , sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapyr, fenpicoxamide, florylpicoxamide, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifene, folpet a, ipflufenoquin, quinofumelin, tricyclazole, pyroquilone, N -(1-benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3 trifluoro-1-methylpropyl)-8-fluoroquinoline-3-carboxamide, 1 - (6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl-1-(7- methylpyrazolo[1,5-a]pyridin-3yl)isoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline and 1-(4,5dimethylbenzimidazol-1 -yl)-4,4-difluoro-3,3-dimethylisoquinoline, where the weight ratio of component (A) and component (B) is from 15:1 to 1:30.

In another preferred composition according to the present invention, component (A) is Compound No. X.14, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-N-hexyl-5methylthiazol-4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxade, fluopyram , isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florylpicoxamide, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrif ena, folpeta, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone , N-(1-benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro-1-methylpropyl)-8-fluoroquinoline-3-carboxamide, 1- (6,7-dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl-1 -(7 methylpyrazolo[ 1,5-a]pyridin-3-yl)isoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3,3dimethylisoquinoline and 1-(4,5-dimethylbenzimidazol-1 -yl)-4,4-difluoro-3,3-dimethylisoquinoline, where the weight ratio of component (A) and component (B) is from 15:1 to 1:30.

In another preferred composition according to the present invention, component (A) is Compound No. X.15, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-N-isobutyl-5methylthiazol-4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyl tetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph , fluxapiroxad, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florilpicoxamide, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil , metalaxyl-M, aminopyrifene, folpet, ipflufenoquin, quinofumeline , tricyclazole, pyroquilone, N-(1-benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro-1-methylpropyl)-8-fluoroquinoline-3 - carboxamide, 1-(6,7-dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl-1 - (7 methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3,3dimethylisoquinoline and 1-(4,5 -dimethylbenzimidazol-1-yl)-4,4-difluoro-3,3-dimethylisoquinoline, where the weight ratio of component (A) and component (B) is from 15:1 to 1:30.

In another preferred composition according to the present invention, component (A) is Compound No. X.16, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-5-methyl-N-(1phenylethyl)thiazole -4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxad, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florylpicoxamide, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifene, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, N-(1-benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro-1-methylpropyl)-8-fluoroquinoline -3-carboxamide, 1 -(6,7-dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl -1-(7 methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3,3dimethylisoquinoline and 1-( 4,5-dimethylbenzimidazol-1-yl)-4,4-difluoro-3,3-dimethylisoquinoline, where the weight ratio of component (A) to component (B) is from 15:1 to 1:30.

In another preferred composition according to the present invention, component (A) is Compound No. X.17, 2-[cyano-(5-fluoro-3-pyridyl)amino]-N-(2,2-dimethylpropyl)-5methylthiazol- 4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxad, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florilpicoxamide, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, meta laxila-M, aminopyrifene, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, N-(1-benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro-1-methylpropyl)-8-fluoroquinoline-3-carboxamide , 1-(6,7-dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl-1 -( 7 methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3,3dimethylisoquinoline and 1-(4,5- dimethylbenzimidazol-1-yl)-4,4-difluoro-3,3-dimethylisoquinoline, where the weight ratio of component (A) and component (B) is from 15:1 to 1:30.

In another preferred composition according to the present invention, component (A) is Compound No. X.18, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-N-(2,2dimethylpropyl)-5- methylthiazole-4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine , fenpropimorpha, fluxapyroxad, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florylpicoxamide, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxon yl, cyprodinil, metalaxyl-M, aminopyrifene, folpet, ipflufenoquin , quinofumeline, tricyclazole, pyroquilone, N-(1-benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro-1-methylpropyl)-8-fluoroquinoline- 3-carboxamide, 1 -(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro3,3-dimethyl- 1-(7-methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)4,4,5-trifluoro-3,3-dimethylisoquinoline and 1- (4,5-dimethylbenzimidazol-1-yl)-4,4-difluoro-3,3-dimethylisoquinoline, where the weight ratio of component (A) to component (B) is from 15:1 to 1:30.

In another preferred composition according to the present invention, component (A) is Compound No. X.19, 2-[cyano-(5-fluoro-3-pyridyl)amino]-5-methyl-N-pentylthiazol-4carboxamide, or salt, enantiomer, tautomer or N-oxide, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxade, fluopyram, isopyrase ma , sedaxane, benzovindiflupyr, pidiflu

- 32 046368 metofen, isoflucipram, isofetamide, pyrapropone, fluindapyr, fenpicoxamide, florylpicoxamide, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifen, folpet, ipflufen quinoquine, quinofumeline, tricyclazole, pyroquilone, N-( 1-benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3 trifluoro-1-methylpropyl)-8-fluoroquinoline-3-carboxamide, 1 -(6 ,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl-1-(7-methylpyrazolo[ 1,5-a]pyridin-3yl)isoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline and 1-(4,5dimethylbenzimidazol-1-yl) )-4,4-difluoro-3,3-dimethylisoquinoline, where the weight ratio of component (A) and component (B) is from 15:1 to 1:30.

In another preferred composition according to the present invention, component (A) is Compound No. X.20, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-5-methyl-pentylthiazol-4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxade, fluopyram , isopyrazam, sedaxane, benzovindiflupir, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florylpicoxamide, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrif ena, folpeta, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone , N-(1-benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro-1-methylpropyl)-8-fluoroquinoline-3-carboxamide, 1- (6,7-dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl-1 -(7 methylpyrazolo[ 1,5-a]pyridin-3-yl)isoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3,3dimethylisoquinoline and 1-(4,5-dimethylbenzimidazol-1 -yl)-4,4-difluoro-3,3-dimethylisoquinoline, where the weight ratio of component (A) and component (B) is from 15:1 to 1:30.

In another preferred composition according to the present invention, component (A) is Compound No. X.21, 2-[cyano-(5-fluoro-3-pyridyl)amino]-N-isopentyl-5methylthiazol-4-carboxamide, or a salt, enantiomer, tautomer or N-oxide, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxade, fluopyram, isopyrase ma , sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapyr, fenpicoxamide, florylpicoxamide, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifene, folpet a, ipflufenoquin, quinofumelin, tricyclazole, pyroquilone, no. (1-benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3-carboxamide, N-(1benzyl-3,3,3-trifluoro-1-methylpropyl)-8-fluoroquinoline-3-carboxamide, 1-(6 ,7-dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl-1 -(7 methylpyrazolo[1, 5-a]pyridin-3-yl)isoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3,3dimethylisoquinoline and 1-(4,5-dimethylbenzimidazol-1-yl) )-4,4-difluoro-3,3-dimethylisoquinoline, where the weight ratio of component (A) and component (B) is from 15:1 to 1:30.

In another preferred composition according to the present invention, component (A) is Compound No. X.22, No. [[3,5-bis(trifluoromethyl)phenyl]methyl]-2-[cyano-(2,6-difluoro4-pyridyl )amino]-5-methylthiazol-4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole , prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxad, fluopyram, isopyrazam, sedaxane, benzovindiflupir, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florilpicoxamide, chlorothalonil, mancozeb, man dipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M , aminopyrifene, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, N-(1-benzyl-1,3-dimethylbutyl)-8fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro-1-methylpropyl )-8-fluoroquinolin-3-carboxamide, 1 -(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4difluoro- 3,3-dimethyl-1-(7-methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline, 1-(4,5-dimethylbenzimidazol1 -yl)-4,4,5-trifluoro-3,3 -dimethylisoquinoline and 1 -(4,5-dimethylbenzimidazol-1 -yl)-4,4-difluoro-3,3 dimethylisoquinoline, where the weight ratio of component (A) to component (B) is from 15:1 to 1:30.

In another preferred composition according to the present invention, component (A) is Compound No. X.23, N-benzyl-2-[cyano-(2,6-difluoro-4-pyridyl)amino]-5methylthiazol-4-carboxamide, or its salt, enantiomer, tautomer or N-oxide, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxade, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide,

- 33 046368 florylpicoxamide, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifen, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, N(1-benzyl-1,3-dimethylbutyl )-8- fluoroquinoline-3-carboxamide, N-(1benzyl-3,3,3-trifluoro-1-methylpropyl)-8-fluoroquinoline-3-carboxamide, 1-(6,7-dimethylpyrazolo[1,5a]pyridin-3-yl )-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl-1 -(7 methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline, 1- (4,5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3,3dimethylisoquinoline and 1-(4,5-dimethylbenzimidazol-1-yl)-4,4-difluoro-3,3-dimethylisoquinoline, where the weight ratio of component (A) and component (B) is from 15:1 to 1:30.

In another preferred composition according to the present invention, component (A) is Compound No. X.24, No. [[3,5-bis(trifluoromethyl)phenyl]methyl]-2-[cyano-(2,6-difluoro4-pyridyl )amino]-5-methylthiazol-4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole , prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxad, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florylpicoxamide, chlorothalonil, mancozeb, man dipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M , aminopyrifene, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, N-(1-benzyl-1,3-dimethylbutyl)-8fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro-1-methylpropyl )-8-fluoroquinolin-3-carboxamide, 1 -(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4difluoro- 3,3-dimethyl-1-(7-methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline, 1-(4,5-dimethylbenzimidazol1 -yl)-4,4,5-trifluoro-3,3 -dimethylisoquinoline and 1 -(4,5-dimethylbenzimidazol-1 -yl)-4,4-difluoro-3,3dimethylisoquinoline, where the weight ratio of component (A) and component (B) is from 15:1 to 1:30.

In a preferred composition according to the present invention, component (A) is Compound No. X.01, 2-[cyano-(5-fluoro-3-pyridyl)amino]-N-cyclobutyl-5-methylthiazol-4carboxamide or a salt thereof, enantiomer, tautomer or N-oxide, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxad, fluopyram, isopyrazam, sedaxana , benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapyr, fenpicoxamide, florylpicoxamide, acibenzolar^-methyl, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifene , folpeta, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, cyflufenamide, metrafenone, N-[2-chloro-4-(2-fluorophenoxy)-5methylphenyl]-N-ethyl-N-methylformamidine, I-|4-(2-bromophenoxy)-5-chloro-2-methylphenyl ] -N-ethyl-Nmethylformamidine, N-(1-benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3trifluoro-1-methylpropyl)-8- fluoroquinoline-3-carboxamide, N-(1-benzyl-3-chloro-1-methylbut-3-enyl)-8fluoroquinoline-3-carboxamide, 1 -(6,7-dimethylpyrazolo[1,5-a]pyridine-3 -yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl-1-(7-methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline , 1-(6,7dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,6-trifluoro-3,3-dimethylisoquinoline, 1 -(4,5-dimethylbenzimidazol-1-yl)-4 ,4,5-trifluoro-3,3-dimethylisoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4-difluoro-3,3dimethylisoquinoline, 6-chloro-4,4-difluoro-3,3 -dimethyl-1-(4-methylbenzimidazol-1-yl)isoquinoline, N'-[5bromo-2-methyl-6-(1-methyl-2-npropoxyethoxy)-3-pyridyl]-N-ethyl-N-methylformamidine , K'-[5-chloro-2methyl-6 -(1 -methyl-2-propoxyethoxy)-3-pyridyl]-N-ethyl-N-methylformamidine, N'-[5-bromo-2-methyl-6 - (1methyl-2-propoxyethoxy)-3-pyridyl]-N-isopropyl-N-methylformamidine, ^isopropyl-N'^-methoxy^methyl-4-(2,2,2-Ίriforo-1-hydroxy-1-phenylethyl )phenyl]-N-methylformamidine, N-methoxy-N-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropanecarboxamide, N,2-dimethoxy-N- [[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, N-ethyl-2-methyl-N-[[4-[5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]phenyl] methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]urea, 3-ethyl-1-methoxy-1-[ [4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, ethyl 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazole -3-yl]phenyl]methyl]pyrazol-4-carboxylate, N,N-dimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl] -1,2,4-Ίriazol-3-amine, methyl-(2)-3-methoxy-2-[2-methyl-5-[3-(trifluoromethyl)pyrazol-1-yl]phenoxy]prop-2- enoate, methyl-(2)-3methoxy-2-[2-methyl-5-(3-propylpyrazol-1-yl)phenoxy]prop-2-enoate, methyl-(2)-2-[5-(3- isopropylpyrazol-1-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-(4-propyltriazol-2-yl)phenoxy] prop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-[4-(trifluoromethyl)triazol-2-yl]phenoxy]prop-2-enoate, methyl-(2) -2-(5-cyclohexyl-2-methylphenoxy)-3-methoxyprop-2-enoate, methyl-(2)2-(5-cyclopentyl-2-methylphenoxy)-3-methoxyprop-2-enoate, methyl-(2 )-2-[5-(4-cyclohexylthiazol-2-yl)2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-2-[5-[4-(ethoxymethyl)thiazol-2- yl]-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-2-[5-(4-bromothiazol-2-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl- (2)-3-methoxy-2-[2-methyl-5-[5-(trifluoromethyl)thiazol-2-yl]phenoxy]prop-2-enoate, bix

- 34 046368 hair dryer, fosetyl aluminum, TAEGRO®, Timorex Gold™ and methylpicoxamide, where the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably from 5:1 to 1 :5).

In another preferred composition according to the present invention, component (A) is Compound No. X.02, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-M-cyclobutyl-5methylthiazol-4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxade, fluopyram , isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florylpicoxamide, acibenzolar^-methyl, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metal xyla-M, aminopyrifene, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, cyflufenamide, metrafenone, N'-[2-χλορ-4-(2fluorophenoxy)-5-methylphenyl]-N-ethyl-N-methylformamidine, I-[4-(2-bromophenoxy)-5- chloro-2methylphenyl]-N-ethyl-N-methylformamidine, N-(1-benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro- 1 -methylpropyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3 chloro-1-methylbut-3-enyl)-8-fluoroquinoline-3-carboxamide, 1 -(6,7-dimethylpyrazolo [1 ,5-a]pyridin-3-yl)4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl-1-(7-methylpyrazolo[1,5-a] pyridin-3yl)isoquinoline, 1 -(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,6-trifluoro-3,3-dimethylisoquinoline, 1 (4,5-dimethylbenzimidazol- 1-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 1-(4,5-dimethylbenzimidazol-1yl)-4,4-difluoro-3,3-dimethylisoquinoline, 6-chloro-4,4 -difluoro-3,3-dimethyl-1 -(4-methylbenzimidazol-1 yl)isoquinoline, H'-[5-bromo-2-methyl-6-(1-methyl-2-propoxyethoxy)-3-pyridyl]- H-ethyl-N-methylformamidine, H'-[5-chloro-2-methyl-6-(1-methyl-2-propoxyethoxy)-3-pyridyl]-N-ethyl-N-methylformamidine, H'-[5 -bromo-2-methyl-6-(1-methyl-2-propoxyethoxy)-3-pyridyl]-H-isopropyl-N-methylformamidine, Nisopropyl-H'-[5-methoxy-2-methyl-4-(2 ,2,2-trifluoro-1-hydroxy-1-phenylethyl)phenyl]-N-methylformamidine, N-methoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl ]phenyl]methyl]cyclopropanecarboxamide, H,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, Nethyl-2-methyl- N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, 1-methoxy-3 methyl-1-[[4-[5-(trifluoromethyl) -1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl ]methyl]urea, 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, ethyl-1-[[ 4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]pyrazole-4-carboxylate, N,N-dimethyl-1-[[4-[5-(trifluoromethyl)-1, 2,4-oxadiazol-3yl]phenyl]methyl]-1,2,4-triazol-3-amine, methyl-(2)-3-methoxy-2-[2-methyl-5-[3-(trifluoromethyl) pyrazol-1yl]phenoxy]prop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-(3-propylpyrazol-1-yl)phenoxy]prop-2-enoate, methyl-(2 )-2-[5-(3-isopropylpyrazol-1-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)3-methoxy-2-[2-methyl-5-(4 -propyltriazol-2-yl)phenoxy]prop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl5-[4-(trifluoromethyl)triazol-2-yl]phenoxy]prop-2- enoate, methyl (2)-2-(5-cyclohexyl-2-methylphenoxy)3-methoxyprop-2-enoate, methyl (2)-2-(5-cyclopentyl-2-methylphenoxy)-3-methoxyprop-2 -enoate, methyl(2)-2-[5-(4-cyclohexylthiazol-2-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-2-[5-[4- (ethoxymethyl)thiazol-2-yl]-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl (2)-2-[5-(4-bromothiazol-2-yl)-2methylphenoxy]-3-methoxyprop -2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-[5-(trifluoromethyl)thiazol-2yl]phenoxy]prop-2-enoate, bixaphen, fosetyl aluminum, TAEGRO® , Timorex Gold™ and methylpicoxamide, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably from 5:1 to 1:5).

In another preferred composition according to the present invention, component (A) is Compound No. X.03, 2-(N-cyano-3,5-difluoroanilino)-N-(2,2-dimethylcyclobutyl)-5methylthiazol-4-carboxamide , or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mephentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxade, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florylpicoxamide, acibenzolar^-methyl, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodine ila, metalaxyl-M, aminopyrifene, folpet, ipflufenoquin , quinofumeline, tricyclazole, pyroquilone, cyflufenamide, metrafenone, N-[2-chloro-4-(2fluorophenoxy)-5-methylphenyl]-N-ethyl-N-methylformamidine, N'-[4-(2-bromophenoxy)-5 -chloro-2methylphenyl]-N-ethyl-N-methylformamidine, N-(1-benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro -1-methylpropyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3chloro-1-methylbut-3-enyl)-8-fluoroquinoline-3-carboxamide, 1-(6,7-dimethylpyrazolo[ 1,5-a]pyridin-3-yl)4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl-1-(7-methylpyrazolo[1,5-a ]pyridin-3yl)isoquinoline, 1 -(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,6-trifluoro-3,3-dimethylisoquinoline, 1 (4,5-dimethylbenzimidazole -1 -yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 1 -(4,5-dimethylbenzimidazol-1 - 35 046368 yl)-4,4-difluoro-3,3-dimethylisoquinoline, 6- chloro-4,4-difluoro-3,3-dimethyl-1 -(4-methylbenzimidazol-1 yl)isoquinoline, N-[5-bromo-2-methyl-6-(1-methyl-2-propoxyethoxy)-3 -pyrvdyl]-N-ethyl-N-methylformamidine, N-[5-chloro-2-methyl-6-(1-methyl-2-propoxyethoxy)-3-pyrvdyl]-N-ethyl-N-methylformamidine, N' [5-bromo-2-methyl-6-(1-methyl-2-propoxyethoxy)-3-pyrrvdyl]-N-isopropyl-N-methylformamvdine, N-isopropyl-M'-[5-methoxy-2-methyl- 4-(2,2,2-trifluoro-1-hydroxy-1-phenylethyl)phenyl]-N-methylformamidine, ^methoxy^-[[4-[5-(tri(|)tormethyl)-1,2,4 -oxadiazol-3-yl|(|)enyl|methyl|cycl.topropanecarboxamide, N,2dimethoxy-H-[[4-[5-(tri(|)tormethyl)-1,2,4-oxadiazol-3-yl |(|)enyl|methyl|propanamide, Nethyl-2-methyl-N[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, 1-methoxy -3-methyl-1-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5- (trifluoromethyl)1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol- 3-yl]phenyl]methyl]urea, ethyl 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrazole-4-carboxylate, N,N -dimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]-1,2,4triazol-3-amine, methyl-(2)-3 -methoxy-2-[2-methyl-5-[3 -(trifluoromethyl)pyrazol-1 -yl| phenoxy|prop-2-enoate, methyl-(2)-3 -methoxy-2-[2-methyl-5 -(3 -propylpyrazol-1 -yl)phenoxy|prop-2-enoate, methyl-(2)-2- [5 (3-isopropylpyrazol-1-yl)-2-methylphenoxy|-3-methoxyprop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5(4-propyltriazol-2- yl)phenoxy|prop-2-enoate, methyl (2)-3-methoxy-2-[2-methyl-5-[4-(trifluoromethyl)triazol-2-yl]phenoxy]prop-2-enoate, methyl -(2)-2-(5-cyclohexyl-2-methylphenoxy)-3-methoxyprop2-enoate, methyl-^)-2-(5-cyclopentyl-2-methylphenoxy)-3-methoxyprop-2-enoate, methyl- (2)-2-[5-(4cyclohexylthiazol-2-yl)-2-methylphenoxy|-3-methoxyprop-2-enoate, methyl (2)-2-[5-[4-(ethoxymethyl)thiazol-2 -yl]-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-2-[5-(4-bromothiazol-2-yl)-2-methylphenoxy|-3-methoxyprop-2-enoate , methyl-(2)-3-methoxy-2-[2-methyl-5-[5-(trifluoromethyl)thiazol-2yl]phenoxy]prop-2-enoate, bixafen, fosetyl aluminum, TAEGRO®, Timorex Gold™ and methylpicoxamide, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably from 5:1 to 1:5).

In another preferred composition according to the present invention, component (A) is Compound No. X.04, 2-[cyano-(5-fluoro-3-pyridyl)amino]-N-(2,2dimethylcyclobutyl)-5-methylthiazol- 4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, tri(oxystrobin, methyltetraprole, di(enoconazole, hexaconazole, propiconazole, prothioconazole, me (entri(luconazole, (enpropidine, (enpropimor(a, (luxapyroxade, (luopyram, isopyrazam, sedaxane, benzovindi(lupira, pidi(lumeto(ene), iso(lucipram, iso(etamide, pyrapropone, (luindapir, fenpicoxamide, florylpicoxamide, ACIBENZOLAR^-methyla, chlorotalonil, mancosa, mandypropamide, oxatiapyproline, Flyuzinam, fludioxonil, cyprodinil, metalaxil-m, aminopyric, folpet, ipflufeninin, xvinofumeline, tricyclavilon, pirocylona, metrafenamide, n '-[ 2-chloro-4- ( 2-fluorophenoxy)-5-methylphenyl]-N-ethyl-N-methylformamidine, N'-[4-(2bromophenoxy)-5-chloro-2-methylphenyl| -N-ethyl-N-methylformamidine, N-(1-benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro-1-methylpropyl) -8 -fluoroquinoline-3-carboxamide, N-(1-benzyl-3-chloro-1-methylbut-3-enyl)-8-fluoroquinoline-3-carboxamide, 1 -(6,7-dimethylpyrazolo[1,5-a| pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl-1-(7methylpyrazolo[1,5-a|pyridin-3-yl) isoquinoline, 1-(6.7-dimethylpyrazolo[1.5-a|pyridin-3-yl)-4.4.6trifluoro-3,3-dimethylisoquinoline, 1 -(4,5-dimethylbenzimidazol-1 -yl)-4,4,5- trifluoro-3,3-dimethylisoquinoline, 1 -(4,5-dimethylbenzimidazol-1 -yl)-4,4-difluoro-3,3-dimethylisoquinoline, 6-chloro-4,4-difluoro-3,3dimethyl-1- (4-methylbenzimidazol-1-yl)isoquinoline, N'-[5-bromo-2-methyl-6-(1-methyl-2-propoxyethoxy)3-pyridyl]-N-ethyl-N-methylformamidine, N'- [5-chloro-2-methyl-6-(1-methyl-2-propoxyethoxy)-3-pyridyl]N-ethyl-N-methylformamidine, N'-[5-bromo-2-methyl-6-(1- methyl 2-propoxyethoxy)-3-pyridyl]-N-isopropyl-N-methylformamidine, N-isopropyl-N'-[5-methoxy-2-methyl-4-(2,2,2-trifluoro-1-hydroxy -1-phenylethyl)phenyl]-N-methylformamidine, N-methoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropanecarboxamide, N,2 -dimethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]propanamide, N-ethyl-2-methyl-N-[[4-[5-( trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl|methyl|propanamide, 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol- 3-yl]phenyl]methyl|urea, 1,3-dimethoxy-1-[[4-[5-(Ίriforomethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 3ethyl-1 -methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, ethyl-1-[[4-[5(trifluoromethyl)-1, 2,4-oxadiazol-3-yl]phenyl]methyl]pyrazol-4-carboxylate, N,N-dimethyl-1-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl| phenyl|methyl| -1,2,4-triazol-3-amine, methyl-(2)-3-methoxy-2-[2methyl-5-[3-(Ίriforomethyl)pyrazol-1-yl]phenoxy]prop-2-enoate, methyl (2)-3-methoxy-2-[2-methyl-5-(3propylpyrazol-1-yl)phenoxy|prop-2-enoate, methyl (2)-2-[5-(3-isopropylpyrazol- 1-yl)-2-methylphenoxy|-3-methoxyprop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-(4-propyltriazol-2-yl)phenoxy|prop- 2enoate, methyl-(Z)-3-methoxy-2-[2-methyl-5-[4-(trifluoromethyl)triazol-2-yl]phenoxy]prop-2-enoate, methyl(2)-2-(5 -cyclohexyl-2-methylphenoxy)-3-methoxyprop-2-enoate, methyl-(2)-2-(5-cyclopentyl-2-methylphenoxy)-3-methoxyprop-2-enoate, methyl-(2)-2- [5-(4-cyclohexylthiazol-2-yl)-2-methylphenoxy|-3-methoxyprop-2-enoate, methyl-(Z)-2-[5-[4-(ethoxymethyl)thiazol-2-yl]- 2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-^)-2-[5-(4-bromothiazol-2-yl)-2-methylphenoxy|-3-methoxyprop-2-enoate, methyl-^)-3

- 36 046368 methoxy-2-[2-methyl-5-[5-(trifluoromethyl)thiazol-2-yl]phenoxy]prop-2-enoate, bixaphen, fosetylaluminum, TAEGRO®, Timorex Gold™ and methylarylpicoxamide, where the ratio by weight component (A) and component (B) is from 10:1 to 1:10 (or even more preferably from 5:1 to 1:5).

In another preferred composition according to the present invention, component (A) is Compound No. X.05, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-H-(2,2dimethylcyclobutyl)-5- methylthiazole-4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine , fenpropimorph, fluxapyroxad, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapyr, fenpicoxamide, florylpicoxamide, acibenzolar^-methyl, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifene, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, cyflufenamide, metrafenone, N-[2-chloro-4-(2-fluorophenoxy)-5-methylphenyl]-N-ethyl-N-methylformamidine, N'-[4- (2bromophenoxy)-5-chloro-2-methylphenyl]-N-ethyl-N-methylformamidine, N-(1-benzyl-1,3-dimethylbutyl)-8fluoroquinoline-3-carboxamide, N-(1-benzyl-3, 3,3-trifluoro-1-methylpropyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3-chloro-1-methylbut-3-enyl)-8-fluoroquinoline-3-carboxamide, 1 -( 6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl-1-(7methylpyrazolo[ 1,5-a]pyridin-3-yl)isoquinoline, 1-(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,6trifluoro-3,3-dimethylisoquinoline, 1- (4,5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4-difluoro-3,3- dimethylisoquinoline, 6-chloro-4,4-difluoro3,3-dimethyl-1-(4-methylbenzimidazol-1-yl)isoquinoline, N-[5-bromo-2-methyl-6-(1-methyl-2-propoxyethoxy )-3-pyridyl]-N-ethyl-N-methylformamidine, No.-[5-chloro-2-methyl-6-(1-methyl-2-propoxyethoxy)-3pyridyl]-N-ethyl-N-methylformamidine, No. -[5-bromo-2-methyl-6-(1-methyl-2-propoxyethoxy)-3-pyridyl]Nisopropyl-N-methylformamidine, Nisopropyl-H'-[5-methoxy-2-methyl-4- (2,2,2-trifluoro-1-hydroxy-1phenylethyl)phenyl]-N-methylformamidine, N-methoxy-H-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl] methyl]cyclopropanecarboxamide, N2-dimethoxy-H-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]propanamide, Nethyl-2-methyl-H-[[4 -[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1,2 ,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl] urea, 3ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, ethyl-1-[[4-[5( trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrazole-4-carboxylate, KH-dimethyl-1-||4-|5(trifluoromethyl)-1,2,4-oxadiazol-3 -yl]phenyl]methyl] - 1,2,4-triazol-3-amine, methyl-(2)-3-methoxy-2-[2methyl-5-[3-(trifluoromethyl)pyrazol-1-yl]phenoxy ]prop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-(3propylpyrazol-1-yl)phenoxy]prop-2-enoate, methyl-(2)-2-[ 5-(3-isopropylpyrazol-1-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-(4-propyltriazol-2 -yl)phenoxy]prop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-[4-(trifluoromethyl)triazol-2-yl]phenoxy]prop-2-enoate, methyl( 2)-2-(5-cyclohexyl-2-methylphenoxy)-3-methoxyprop-2-enoate, methyl (2)-2-(5-cyclopentyl-2-methylphenoxy)-3-methoxyprop-2-enoate, methyl -(2)-2-[5-(4-cyclohexylthiazol-2-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl (2)-2-[5-[4-(ethoxymethyl) thiazol-2-yl]-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-2-[5-(4-bromothiazol-2-yl)-2-methylphenoxy]-3-methoxyprop- 2-enoate, methyl-(2)-3-methoxy-2-[2methyl-5-[5-(trifluoromethyl)thiazol-2-yl]phenoxy]prop-2-enoate, bixaphen, fosetyl aluminum, TAEGRO®, Timorex Gold™ and methylpicoxamide, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably from 5:1 to 1:5).

In another preferred composition according to the present invention, component (A) is Compound No. X.06, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-N-(2,2dimethylcyclobutyl)-5- formamidothiazole-4-carboxamide, or a salt, enantiomer, tautomer or Noxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph , fluxapyroxad, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florylpicoxamide, acibenzolar^-methyl, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fl udioxonil, cyprodinil, metalaxyl-M, aminopyrifene, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, cyflufenamide, metrafenone, N-[2-chloro-4-(2-fluorophenoxy)-5-methylphenyl]-N-ethyl-N-methylformamidine, N'-[4-(2bromophenoxy )-5-chloro-2-methylphenyl]-N-ethyl-N-methylformamidine, N-(1-benzyl-1,3-dimethylbutyl)-8fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3, 3-trifluoro-1-methylpropyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3-chloro-1-methylbut-3-enyl)-8-fluoroquinoline-3-carboxamide, 1 -(6, 7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl-1-(7methylpyrazolo[1, 5-a]pyridin-3-yl)isoquinoline, 1-(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,6trifluoro-3,3-dimethylisoquinoline, 1 -(4 ,5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3,3-dimethylisochemical

- 37 046368 noline, 1 -(4,5-dimethylbenzimidazol-1-yl)-4,4-difluoro-3,3-dimethylisoquinoline, 6-chloro-4,4-difluoro-3,3dimethyl-1-(4- methylbenzimidazol-1-yl)isoquinoline, H'-[5-bromo-2-methyl-6-(1-methyl-2-propoxyethoxy)3-pyridyl]-N-ethyl-N-methylformamidine, H'-[5- chloro-2-methyl-6-(1-methyl-2-propoxyethoxy)-3-pyridyl]N-ethyl-N-methylformamidine, I-[5-bromo-2-methyl-6-(1-methyl-2- propoxyethoxy)-3-pyridyl|-H-isopropyl-N-methylformamidine, H-isopropyl-H'-[5-methoxy-2-methyl-4-(2,2,2-trifluoro-1-hydroxy-1phenylethyl)phenyl ]-H-methylformamidine, H-methoxy-H-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]cyclopropanecarboxamide, H,2-dimethoxy-H-[[4 -[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]propanamide, N-ethyl-2-methyl-H-[[4-[5-(trifluoromethyl)-1,2,4 -oxadiazol-3-yl]phenyl]methyl]propanamide, 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl] urea, 1,3-dimethoxy-1-[[4-[5-(1fluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 3-ethyl-1methoxy-1-[[4 -[5-(1fluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, ethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3 -yl]phenyl]methyl]pyrazol-4-carboxylate, HH-dimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3 -yl]phenyl]methyl]-1,2 ,4-triazol-3-amine, methyl-(2)-.3-methoxy-2-[2-methyl-5-[3 (trifluoromethyl)pyrazol-1-yl]phenoxy]prop-2-enoate, methyl- (2)-3-methoxy-2-[2-methyl-5-(3-propylpyrazol-1-yl)phenoxy]prop-2-enoate, methyl-(2)-2-[5-(3-isopropylpyrazol- 1-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-(4-propyltriazol-2-yl)phenoxy]prop- 2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-[4-(trifluoromethyl)triazol-2-yl]phenoxy]prop-2-enoate, methyl-(2)-2 -(5cyclohexyl-2-methylphenoxy)-3-methoxyprop-2-enoate, methyl-(2)-2-(5-cyclopentyl-2-methylphenoxy)-3methoxyprop-2-enoate, methyl-(2)-2-[ 5-(4-cyclohexylthiazol-2-yl)-2-methylphenoxy]-3-methoxyprop-2enoate, methyl-(2)-2-[5-[4-(ethoxymethyl)thiazol-2-yl]-2-methylphenoxy ]-3-methoxyprop-2-enoate, methyl(2)-2-[5-(4-bromothiazol-2-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-3 -methoxy-2-[2-methyl5-[5-(trifluoromethyl)thiazol-2-yl]phenoxy]prop-2-enoate, bixafen, fosetyl aluminum, TAEGRO®, Timorex Gold™ and methylpicoxamide, where the weight ratio of the component ( A) and component (B) is from 10:1 to 1:10 (or even more preferably from 5:1 to 1:5).

In another preferred composition according to the present invention, component (A) is Compound No. X.07, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-5-methyl-Hspiro[3.4]octane- 3-yl-thiazol-4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole , mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxade, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapyr, fenpicoxamide, florylpicoxamide, acibenzolar^-methyl, chlorothalonil, mancose ba, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifene, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, cyflufenamide, metrafenone, H'-[2-chloro-4-(2-fluorophenoxy)-5-methylphenyl]-N-ethyl-N-methylformamidine, H '-[4-(2-bromophenoxy)-5chloro-2-methylphenyl]-N-ethyl-N-methylformamidine, N-(1-benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3 carboxamide, H-( 1-benzyl-3,3,3-trifluoro-1-methylpropyl)-8-fluoroquinoline-3-carboxamide, H-(1-benzyl3-chloro-1-methylbut-3-enyl)-8-fluoroquinoline-3-carboxamide , 1 -(6,7-dimethylpyrazolo[1,5-a]pyridin-3 yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl-1 - (7-methylpyrazolo[1,5-a]pyridin3-yl)isoquinoline, 1-(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,6-trifluoro-3,3 -dimethylisoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 1-(4,5-dimethylbenzimidazol1 -yl)-4,4-difluoro-3 ,3-dimethylisoquinoline, 6-chloro-4,4-difluoro-3,3-dimethyl-1-(4-methylbenzimidazol-1yl)isoquinoline, H'-[5-bromo-2-methyl-6-(1-methyl -2-propoxyethoxy)-3-pyridyl]-H-ethyl-Nmethylformamidine, H'-[5-chloro-2-methyl-6-(1-methyl-2-propoxyethoxy)-3-pyridyl]-H-ethyl- Nmethylformamidine, H'-[5-bromo-2-methyl-6-(1-methyl-2-propoxyethoxy)-3-pyridyl]-H-isopropyl-Nmethylformamidine, H-isopropyl-H'-[5-methoxy-2 -methyl-4-(2,2,2-trifluoro-1-hydroxy-1 phenylethyl)phenyl]-H-methylformamidine, N-methoxy-H-[[4-[5-(trifluoromethyl)-1,2,4 -oxadiazol-3yl]phenyl]methyl]cyclopropanecarboxamide, H,2-dimethoxy-H-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]propanamide, H-ethyl- 2-methyl-H-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, 1-methoxy-3-methyl-1-[[4-[ 5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazole -3-yl]phenyl]methyl]urea, 3ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, ethyl- 1-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrazole-4-carboxylate, H,H-dimethyl-1-[[4-[5(trifluoromethyl )-1,2,4-oxadiazol-3-yl]phenyl]methyl] - 1,2,4-triazol-3-amine, methyl-(2)-3-methoxy-2-[2methyl-5-[3 -(trifluoromethyl)pyrazol-1-yl]phenoxy]prop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-(3πpropyliirazol-1-yl)phenoxy]πprop-2- enoate, methyl (2)-2-[5-(3-isopropylpyrazol-1-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl (2)-3-methoxy-2-[2 -methyl-5-(4-propyltriazol-2-yl)phenoxy]prop2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-[4-(trifluoromethyl)triazol-2-yl ]phenoxy]prop-2-enoate, methyl (2)-2-(5-cyclohexyl-2-methylphenoxy)-3-methoxyprop-2-enoate, methyl (2)-2-(5-cyclopentyl-2methylphenoxy) -3-methoxyprop-2-enoate, methyl-(2)-2-[5-(4-cyclohexylthiazol-2-yl)-2-methylphenoxy]-3methoxyprop-2-enoate, methyl-(2)-2-[ 5-[4-(ethoxymethyl)thiazol-2-yl]-2-methylphenoxy]-3-methoxyprop-2

- 38 046368 enoate, methyl-(2)-2-[5-(4-bromothiazol-2-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-3methoxy-2-[ 2-methyl-5-[5-(trifluoromethyl)thiazol-2-yl]phenoxy]prop-2-enoate, bixaphen, fosetylaluminum, TAEGRO®, Timorex Gold™ and methylpicoxamide, where the weight ratio of component (A) and component (B ) is from 10:1 to 1:10 (or even more preferably from 5:1 to 1:5).

In another preferred composition according to the present invention, component (A) is Compound No. X.08, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-5-methyl-Nspiro[cyclobutane-2, 2'-indan]-1-yl-thiazol-4-carboxamide, or a salt, enantiomer, tautomer or Noxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole , propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxad, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapyr, fenpicoxamide, florylpicoxamide, acibenzolar^ -methyl, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifen, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, cyflufenamide, metrafenone, N-[2-chloro-4-(2-fluorophenoxy)-5-methylphenyl]-N-ethyl-N-methylformamidine, N'-[4-(2bromophenoxy)-5-chloro-2-methylphenyl]-N-ethyl-N-methylformamidine, N-(1-benzyl-1,3-dimethylbutyl)-8fluoroquinoline-3-carboxamide, N-( 1-benzyl-3,3,3-trifluoro-1-methylpropyl)-8-fluoroquinoline-3 carboxamide, N-(1-benzyl-3-chloro-1-methylbut-3-enyl)-8-fluoroquinoline-3 - carboxamide, 1-(6,7dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl1-(7 -methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline, 1-(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,6trifluoro-3,3-dimethylisoquinoline , 1-(4,5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4-difluoro-3 ,3-dimethylisoquinoline, 6-chloro-4,4-difluoro3,3-dimethyl-1 -(4 -methylbenzimidazol-1 -yl)isoquinoline, N'-[5-bromo-2-methyl-6-( 1 -methyl -2-propoxyethoxy)-3-pyridyl]-N-ethyl-N-methylformamidine, N-[5-chloro-2-methyl-6-(1-methyl-2-propoxyethoxy)-3pyridyl]-N-ethyl-S -methylformamidine, Na-[5-bromo-2-methyl-6-(1-methyl-2-propoxyethoxy)-3-pyridyl]Ni-isopropyl-N-methylformamidine, Na-isopropyl-N'-[5-methoxy-2- methyl-4-(2,2,2-trifluoro-1-hydroxy-1phenylethyl)phenyl]-N-methylformamidine, Nmethoxy-H-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol- 3yl]phenyl]methyl]cyclopropanecarboxamide, N2-dimethoxy-H-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]propanamide, Nethyl-2-methyl-H -[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl) -1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl] phenyl]methyl]urea, 3ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, ethyl-1-[[4 -[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrazole-4-carboxylate, KH-dimethyl-1-||4-|5(trifluoromethyl)-1,2,4 -oxadiazol-3-yl]phenyl]methyl] - 1,2,4-triazol-3-amine, methyl-(2)-3-methoxy-2-[2methyl-5-[3-(trifluoromethyl)pyrazol-1 -yl]phenoxy]prop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-(3propylpyrazol-1-yl)phenoxy]prop-2-enoate, methyl-(2) -2-[5-(3-isopropylpyrazol-1-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-(4 -propyltriazol-2-yl)phenoxy]prop2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-[4-(trifluoromethyl)triazol-2-yl]phenoxy]prop-2- enoate, methyl (2)-2-(5-cyclohexyl-2-methylphenoxy)-3-methoxyprop-2-enoate, methyl (2)-2-(5-cyclopentyl-2methylphenoxy)-3-methoxyprop-2- enoate, methyl (2)-2-[5-(4-cyclohexylthiazol-2-yl)-2-methylphenoxy]-3methoxyprop-2-enoate, methyl (2)-2-[5-[4-(ethoxymethyl )thiazol-2-yl]-2-methylphenoxy]-3-methoxyprop-2enoate, methyl-(2)-2-[5-(4-bromothiazol-2-yl)-2-methylphenoxy]-3-methoxyprop-2 -enoate, methyl-(2)-3methoxy-2-[2-methyl-5-[5-(trifluoromethyl)thiazol-2-yl]phenoxy]prop-2-enoate, bixaphen, fosetylaluminum, TAEGRO®, Timorex Gold™ and methylpicoxamide, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably from 5:1 to 1:5).

In another preferred composition according to the present invention, component (A) is Compound No. X.09, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-5-methyl-Nspiro[3.3]heptane- 3-yl-thiazol-4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole , mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxade, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapyr, fenpicoxamide, florylpicoxamide, acibenzolar^-methyl, chlorothalonil, mancose ba, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifene, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, cyflufenamide, metrafenone, N-[2-chloro-4-(2-fluorophenoxy)-5-methylphenyl]-N-ethyl-N-methylformamidine, N- [4-(2-bromophenoxy)-5chloro-2-methylphenyl]-N-ethyl-N-methylformamidine, N-(1-benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3 carboxamide, N-(1 - benzyl-3,3,3-trifluoro-1-methylpropyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl3-chloro-1-methylbut-3-enyl)-8-fluoroquinoline-3-carboxamide, 1 -(6,7-dimethylpyrazolo[1,5-a]pyridin-3 yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl-1 -(7 -methylpyrazolo[1,5-a]pyridin3-yl)isoquinoline, 1-(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,6-trifluoro-3,3-dimethylisoquinoline ,

- 39 046368

1-(4,5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 1-(4,5-dimethylbenzimidazol1 -yl)-4,4-difluoro-3,3- dimethylisoquinoline, 6-chloro-4,4-difluoro-3,3-dimethyl-1-(4-methylbenzimidazol-1yl)isoquinoline, N'-[5 -bromo-2-methyl-6-( 1 -methyl-2- propoxyethoxy)-3-pyridyl] -Ν-μήλ-Νmethylformamidine, I-|5-chloro-2-methyl-6-(1-methyl-2-propoxyethoxy)-3-pyridyl|^-ethyl^methylformamidine, No-[ 5-bromo-2-methyl-6-(1-methyl-2-propoxyethoxy)-3-pyridyl]-Nisopropyl-N methylformamidine, N-isopropyl-N-[5-methoxy-2-methyl-4-(2, 2,2-trifluoro-1-hydroxy-1 phenylethyl)phenyl]-Nmethylformamidine, Nmethoxy-N[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]cyclopropanecarboxamide, ^2-dimethoxy-N[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]propanamide, Nethyl-2-methyl-N[4-[5-(trifluoromethyl)- 1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl ]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 3ethyl-1-methoxy- 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, ethyl-1-[[4-[5(trifluoromethyl)-1,2,4 -oxadiazol-3-yl]phenyl]methyl]pyrazol-4-carboxylate, ^Ndimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl] -1,2,4-triazol-3-amine, methyl-(2)-3-methoxy-2-[2-methyl5-[3-(trifluoromethyl)pyrazol-1-yl]phenoxy]prop-2-enoate, methyl (2)-.3 -methoxy-2-[2-methyl-5 -(3 -propylpyrazol-1 -yl)phenoxy]prop-2-enoate, methyl (2)-2-[5-(3 -isopropylpyrazol-1-yl)-2-methylphenoxy]-3 methoxyprop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-(4-propyltriazol-2-yl)phenoxy] prop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-[4-(trifluoromethyl)triazol-2-yl]phenoxy]prop-2-enoate, methyl-(2) -2(5-cyclohexyl-2-methylphenoxy)-3-methoxyprop-2-enoate, methyl-(2)-2-(5-cyclopentyl-2-methylphenoxy)-3-methoxyprop-2-enoate, methyl-(2 )-2-[5-(4-cyclohexylthiazol-2-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl (2)-2-[5-[4-(ethoxymethyl)thiazol-2 -yl]-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-2-[5-(4-bromothiazol-2-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl -(2)-.3methoxy-2-[2-methyl-5-[5-(trifluoromethyl)thiazol-2-yl]phenoxy]prop-2-enoate, bixaphen, fosetylaluminum, TAEGRO®, Timorex Gold™ and methylpicoxamide, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably from 5:1 to 1:5).

In another preferred composition according to the present invention, component (A) is Compound No. X.10, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-No[[1(cyclopropylmethyl)cyclopropyl]methyl ]-5-methylthiazol-4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole , mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxade, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapyr, fenpicoxamide, florylpicoxamide, acibenzolar^-methyl, chlorothalonil, mancose ba, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifene, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, cyflufenamide, metrafenone, N-[2-chloro-4-(2-fluorophenoxy)-5-methylphenyl]-Nethyl-Nmethylformamidine, N'-[ 4-(2bromophenoxy)-5-chloro-2-methylphenyl]-Nethyl-Nmethylformamidine, N-(1-benzyl-1,3-dimethylbutyl)-8fluoroquinoline-3-carboxamide, N-(1-benzyl-3, 3,3-trifluoro-1-methylpropyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3-chloro-1-methylbut-3-enyl)-8-fluoroquinoline-3-carboxamide, 1-(6 ,7dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl1-(7-methylpyrazolo[1,5 -a]pyridin-3-yl)isoquinoline, 1-(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,6trifluoro-3,3-dimethylisoquinoline, 1-(4, 5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4-difluoro-3,3-dimethylisoquinoline, 6 -chloro-4,4-difluoro3,3-dimethyl-1-(4-methylbenzimidazol-1-yl)isoquinoline, N-[5-bromo-2-methyl-6-(1-methyl-2-propoxyethoxy)-3 -pyridyl]-Nethyl-Nmethylformamidine, N-[5-chloro-2-methyl-6-(1-methyl-2-propoxyethoxy)-3pyridyl]-Nethyl-Nmethylformamidine, N-[5-bromo-2 -methyl-6-(1-methyl-2-propoxyethoxy)-3-pyridyl]Nisopropyl-Nmethylformamidine, Nisopropyl-N-[5-methoxy-2-methyl-4-(2,2,2-trifluoro- 1-hydroxy-1phenylethyl)phenyl]-Nmethylformamidine, Nmethoxy-N[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]cyclopropanecarboxamide, N2-dimethoxy-N[ 4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]propanamide, Nethyl-2-methyl-N[[4-[5-(trifluoromethyl)-1,2,4- oxadiazol-3-yl]phenyl]methyl]propanamide, 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea , 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 3-ethyl-1methoxy-1-[[4- [5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, ethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3- yl]phenyl]methyl]pyrazol-4-carboxylate, ^Ndimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]-1,2, 4-triazol-3-amine, methyl-(2)-3-methoxy-2-[2-methyl-5-[3 (trifluoromethyl)pyrazol-1-yl]phenoxy]prop-2-enoate, methyl-(2 )-3-methoxy-2-[2-methyl-5-(3-propylpyrazol-1-yl)phenoxy]prop-2-enoate, methyl-(2)-2-[5-(3-isopropylpyrazol-1- yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-(4-propyltriazol-2-yl)phenoxy]prop-2- enoate, methyl (2)-3-methoxy-2-[2-methyl-5-[4-(trifluoromethyl)triazol-2-yl]phenoxy]prop-2-enoate, methyl (2)-2-( 5cyclohexyl-2-methylphenoxy)-3-methoxyprop-2-enoate, methyl (2)-2-(5-cyclopentyl-2-methylphenoxy)-3methoxyprop-2-enoate, methyl (2)-2-[5- (4-cyclohexylthiazol-2-yl)-2-methylphenoxy]-3-methoxyprop-2enoate, methyl (2)-2-[5-[4-(ethoxymethyl)thiazol-2-yl]-2-methylphenoxy]- 3-methoxyprop-2-enoate, methyl- 40 046368 (2)-2-[5-(4-bromothiazol-2-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)- 3-methoxy-2-[2-methyl5-[5-(trifluoromethyl)thiazol-2-yl]phenoxy]prop-2-enoate, bixafen, fosetyl aluminum, TAEGRO®, Timorex Gold™ and methylpicoxamide, where the weight ratio of the component (A) and component (B) is from 10:1 to 1:10 (or even more preferably from 5:1 to 1:5).

In another preferred composition according to the present invention, component (A) is Compound No. X.11, 2-(Ncyano-3,5-difluoroanilino)-5-methyl-N-(1methylcyclopentyl)thiazole-4-carboxamide, or its salt, enantiomer, tautomer or N-oxide, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxade, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florylpicoxamide, acibenzolar^-methyl, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl -M, aminopyrifene, folpet, ipflufenoquin, quinofumeline , tricyclazole, pyroquilone, cyflufenamide, metrafenone, N'-[2chloro-4-(2-fluorophenoxy)-5-methylphenyl]-N-ethyl-N-methylformamidine, N-[4-(2-bromophenoxy)-5-chloro -2methylphenyl]-N-ethyl-N-methylformamidine,

N-(1-benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro-1-methylpropyl)-8-fluoroquinoline-3-carboxamide, N -(1-benzyl3-chloro-1-methylbut-3-enyl)-8-fluoroquinoline-3-carboxamide, 1 -(6,7-dimethylpyrazolo[1,5-a]pyridin-3 yl)-4,4, 5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl-1-(7-methylpyrazolo[1,5-a]pyridin3 -yl)isoquinoline, 1 -(6,7-dimethylpyrazolo[ 1,5-a]pyridin-3-yl)-4,4,6-trifluoro-3,3-dimethylisoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3 ,3-dimethylisoquinoline, 1-(4,5-dimethylbenzimidazol1 -yl)-4,4-difluoro-3,3-dimethylisoquinoline, 6-chloro-4,4-difluoro-3,3-dimethyl-1-(4- methylbenzimidazol-1yl)isoquinoline, methylformamidine, methylformamidine, methylformamidine,

N'-[5-bromo-2-methyl-6-(1-methyl-2-propoxyethoxy)-3-pyridyl]-N-arnnT-N№-[5-chloro-2-methyl-6-(1- methyl-2-propoxyethoxy)-3-pyridyl]-No.ethyl-No.-[5-bromo-2-methyl-6-(1-methyl-2-propoxyethoxy)-3-pyridyl]-N-isopropyl-NNo. isopropyl-N'-[5-methoxy-2-methyl-4-(2,2,2-trifluoro-1-hydroxy-1-phenylethyl)phenyl]-N-methylformamidine, Nmethoxy-N[[4-[5 -(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropanecarboxamide, nil]methyl]propanamide,

K2-dimethoxy^-[[4-[5-(tri(|)tormethyl)-1.2.4-oxadiazol-3-yl|(|)eNethyl-2-methyl-N[[4-[5-( trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol- 3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3 -yl]phenyl]methyl]urea, 3-ethyl -1 methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, ethyl-1-[[4-[5-(trifluoromethyl)- 1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrazol-4-carboxylate, KH-dimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl ]phenyl]methyl]-1,2,4-triazol-3-amine, methyl-(2)-3-methoxy-2-[2-methyl-5-[3 (trifluoromethyl)pyrazol-1-yl]phenoxy] prop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-(3-propylpyrazol-1-yl)phenoxy] prop-2-enoate, methyl-(2)-2- [5-(3-isopropylpyrazol-1-yl)-2-methylphenoxy]-3 methoxyprop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-(4-propyltriazol-2 -yl)phenoxy]prop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-[4-(trifluoromethyl)triazol-2-yl]phenoxy]prop-2-enoate, methyl (2)-2(5-cyclohexyl-2-methylphenoxy)-3-methoxyprop-2-enoate, methyl (2)-2-(5-cyclopentyl-2-methylphenoxy)-3-methoxyprop-2-enoate , methyl-(2)-2-[5-(4-cyclohexylthiazol-2-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-2-[5-[4-( ethoxymethyl)thiazol-2-yl]-2-methylphenoxy]-3-methoxyprop-2enoate, methyl-(2)-2-[5-(4-bromothiazol-2-yl)-2-methylphenoxy]-3-methoxyprop- 2-enoate, methyl-(2)-3methoxy-2-[2-methyl-5-[5-(trifluoromethyl)thiazol-2-yl]phenoxy]prop-2-enoate, bixaphen, fosetylaluminum, TAEGRO®, Timorex Gold ™ and methylpicoxamide, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably from 5:1 to 1:5).

In another preferred composition according to the present invention, component (A) is Compound No. X.12, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-5-methyl-N-(1methylcyclopentyl)thiazole -4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxad, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapyr, fenpicoxamide, florylpicoxamide, acibenzolar^-methyl, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, flu azinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifene , folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, cyflufenamide, metrafenone, N'-[2chloro-4-(2-fluorophenoxy)-5-methylphenyl]-N-ethyl-N-methylformamidine, N-[4-(2- bromophenoxy)-5-chloro-2methylphenyl]-N-ethyl-N-methylformamidine, N-(1-benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3 carboxamide, N-(1-benzyl-3,3, 3-trifluoro-1-methylpropyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl3-chloro-1-methylbut-3-enyl)-8-fluoroquinoline-3-carboxamide, 1 -(6,7- dimethylpyrazolo[1,5-a]pyridin-3yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl-1-(7-methylpyrazolo[1,5 -a]pyridin3 -yl)isoquinoline, 1 -(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,6-trifluoro-3,3-dimethylisoquinoline,

- 41 046368

1-(4,5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 1-(4,5-dimethylbenzimidazol1 -yl)-4,4-difluoro-3,3- dimethylisoquinoline, 6-chloro-4,4-difluoro-3,3-dimethyl-1-(4-methylbenzimidazol-1yl)isoquinoline, N'-[5 -bromo-2-methyl-6-( 1 -methyl-2- propoxyethoxy)-3-pyridyl]-Ν-μήλ-Νmethylformamidine, I-|5-chloro-2-methyl-6-(1-methyl-2-propoxyethoxy)-3-pyridyl|^-ethyl^methylformamidine, No-[ 5-bromo-2-methyl-6-(1-methyl-2-propoxyethoxy)-3-pyridyl]-Nisopropyl-N methylformamidine, N-isopropyl-N-[5-methoxy-2-methyl-4-(2, 2,2-trifluoro-1-hydroxy-1 phenylethyl)phenyl]-Nmethylformamidine, Nmethoxy-N[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]cyclopropanecarboxamide, ^2-dimethoxy-N[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]propanamide, Nethyl-2-methyl-N[[4-[5-(trifluoromethyl) -1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3- yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 3-ethyl-1methoxy -1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, ethyl-1-[[4-[5-(trifluoromethyl)-1,2 ,4-oxadiazol-3-yl]phenyl]methyl]pyrazol-4-carboxylate, ^Ndimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] methyl]-1,2,4-triazol-3-amine, methyl-(2)-3-methoxy-2-[2-methyl-5-[3 (trifluoromethyl)pyrazol-1-yl]phenoxy]prop-2 -enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-(3-propylpyrazol-1-yl)phenoxy]prop-2-enoate, methyl-(2)-2-[5- (3-isopropylpyrazol-1-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl (2)-3-methoxy-2-[2-methyl-5-(4-propyltriazol-2-yl) )phenoxy]prop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-[4-(trifluoromethyl)triazol-2-yl]phenoxy]prop-2-enoate, methyl- (2)-2-(5cyclohexyl-2-methylphenoxy)-3-methoxyprop-2-enoate, methyl-(2)-2-(5-cyclopentyl-2-methylphenoxy)-3methoxyprop-2-enoate, methyl-(2 )-2-[5-(4-cyclohexylthiazol-2-yl)-2-methylphenoxy]-3-methoxyprop-2enoate, methyl-(2)-2-[5-[4-(ethoxymethyl)thiazol-2-yl ]-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl(2)-2-[5-(4-bromothiazol-2-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl- (2)-3-methoxy-2-[2-methyl5-[5-(trifluoromethyl)thiazol-2-yl]phenoxy]prop-2-enoate, bixaphen, fosetyl aluminum, TAEGRO®, Timorex Gold™ and methylpicoxamide, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably from 5:1 to 1:5).

In another preferred composition according to the present invention, component (A) is Compound No. X.13, 2-[cyano-(5-fluoro-3-pyridyl)amino]-Nhexyl-5-methylthiazol-4carboxamide, or a salt thereof , enantiomer, tautomer or N-oxide, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxade, fluopyram, isopyrase ma, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapyr, fenpicoxamide, florylpicoxamide, acibenzolar-methyl, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M, ami nopyrifen, folpet, ipflufenoquin, quinofumeline, tricyclazole , pyroquilone, cyflufenamide, metrafenone, N-[2-chloro-4-(2-fluorophenoxy)-5methylphenyl]-Nethyl-Nmethylformamidine, N-[4-(2-bromophenoxy)-5-chloro-2-methylphenyl] -Ν-'Τγπλ-Νmethylformamidine, N-(1-benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3trifluoro-1-methylpropyl)-8- fluoroquinoline-3-carboxamide, N-(1-benzyl-3-chloro-1-methylbut-3-enyl)-8fluoroquinoline-3-carboxamide, 1 -(6,7-dimethylpyrazolo[1,5-a]pyridine-3 -yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl-1-(7-methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline , 1-(6,7dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,6-trifluoro-3,3-dimethylisoquinoline, 1 -(4,5-dimethylbenzimidazol-1-yl)-4 ,4,5-trifluoro-3,3-dimethylisoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4-difluoro3,3-dimethylisoquinoline, 6-chloro-4,4-difluoro-3,3 -dimethyl-1-(4-methylbenzimidazol-1 -yl)isoquinoline, N'[5-bromo-2-methyl-6-(1-methyl-2-propoxyethoxy)-3-pyridyl]-Nethyl-Nmethylformamidine, N-[5-chloro-2methyl-6 -(1 -methyl-2-propoxyethoxy)-3-pyridyl]-N-ethyl-N-methylformamidine, N'-[5-bromo-2-methyl-6 -(1methyl -2-propoxyethoxy)-3-pyridyl]-Nisopropyl-Nmethylformamidine, N-isopropyl-N-[5-methoxy-2methyl-4-(2,2,2-trifluoro-1-hydroxy-1-phenylethyl)phenyl] -Nmethylformamidine, Nmethoxy-N[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropanecarboxamide, N2-dimethoxy-N[[4-[5(trifluoromethyl )-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, Nethyl-2-methyl-N[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl] phenyl]methyl]propanamide, 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy- 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol3-yl]phenyl]methyl]urea, 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)- 1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, ethyl 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrazole -4-carboxylate, ^Ndimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]-1,2,4-triazol-3amine, methyl -(2)-3-methoxy-2-[2-methyl-5-[3-(trifluoromethyl)pyrazol-1-yl]phenoxy]prop-2-enoate, methyl(2)-3-methoxy-2-[ 2-methyl-5-(3-propylpyrazol-1-yl)phenoxy]prop-2-enoate, methyl-(2)-2-[5-(3-isopropylpyrazol-1-yl)-2-methylphenoxy]-3 -methoxyprop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-(4-propyltriazol-2-yl)phenoxy]prop-2-enoate, methyl-(2)-3 -methoxy-2-[2-methyl-5-[4-(trifluoromethyl)triazol-2yl]phenoxy]prop-2-enoate, methyl-(2)-2-(5-cyclohexyl-2-methylphenoxy)-3- methoxyprop-2-enoate, methyl-(2)-2-(5-cyclopentyl-2-methylphenoxy)-3-methoxyprop-2-enoate, methyl-(2)-2-[5-(4-cyclohexylthiazol-2- yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-2-[5-[4-(ethoxymethyl)thiazol-2-yl]-2

- 42 046368 methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-2-[5-(4-bromothiazol-2-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl- (2)-3-methoxy-2-[2-methyl-5-[5-(trifluoromethyl)thiazol-2-yl|phenoxy|prop-2enoate, bixaphen, fosetyl aluminum, TAEGRO®, Timorex Gold™ and methylpicoxamide, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably from 5:1 to 1:5).

In another preferred composition according to the present invention, component (A) is Compound No. X.14, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-M-hexyl-5methylthiazol-4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxade, fluopyram , isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florylpicoxamide, acibenzolar^-methyl, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metal xyla-M, aminopyrifene, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, cyflufenamide, metrafenone, H'-[2-chloro-4-(2fluorophenoxy)-5-methylphenyl]-H-ethyl-N-methylformamidine, I-[4-(2-bromophenoxy)-5- chloro-2methylphenyl]-N-ethyl-N-methylformamidine, N-(1-benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro- 1 -methylpropyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3 chloro-1-methylbut-3-enyl)-8-fluoroquinoline-3-carboxamide, 1 -(6,7-dimethylpyrazolo [1 ,5-a]pyridin-3-yl)4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl-1-(7-methylpyrazolo[1,5-a] pyridin-3yl)isoquinoline, 1 -(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,6-trifluoro-3,3-dimethylisoquinoline, 1 (4,5-dimethylbenzimidazol- 1-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 1-(4,5-dimethylbenzimidazol-1yl)-4,4-difluoro-3,3-dimethylisoquinoline, 6-chloro-4,4 -difluoro-3,3-dimethyl-1 -(4-methylbenzimidazol-1 yl)isoquinoline, N'-[5-bromo-2-methyl-6-(1-methyl-2-propoxyethoxy)-3-pyridyl]- N-ethyl-N-methylformamidine, N'-[5-chloro-2-methyl-6-(1-methyl-2-propoxyethoxy)-3-pyridyl]-N-ethyl-N-methylformamidine, N'-[5 -bromo-2-methyl-6-(1-methyl-2-propoxyethoxy)-3-pyridyl]-N-isopropyl-N-methylformamidine, Nisopropyl-N'-[5-methoxy-2-methyl-4-(2 ,2,2-trifluoro-1-hydroxy-1-phenylethyl)phenyl]-N-methylformamidine, N-methoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl ]phenyl]methyl]cyclopropanecarboxamide, N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, Nethyl-2-methyl- M-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, 1-methoxy-3 methyl-1-[[4-[5-(trifluoromethyl) -1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl ]methyl]urea, 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, ethyl-1-[[ 4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]pyrazole-4-carboxylate, N,N-dimethyl-1-[[4-[5-(trifluoromethyl)-1, 2,4-oxadiazol-3yl]phenyl]methyl]-1,2,4-triazol-3-amine, methyl-(2)-3-methoxy-2-[2-methyl-5-[3-(trifluoromethyl) pyrazol-1yl]phenoxy]prop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-(3-propylpyrazol-1-yl)phenoxy]prop-2-enoate, methyl-(2 )-2-[5-(3-isopropylpyrazol-1-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)3-methoxy-2-[2-methyl-5-(4 -propyltriazol-2-yl)phenoxy]prop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl5-[4-(trifluoromethyl)triazol-2-yl]phenoxy]prop-2- enoate, methyl (2)-2-(5-cyclohexyl-2-methylphenoxy)3-methoxyprop-2-enoate, methyl (2)-2-(5-cyclopentyl-2-methylphenoxy)-3-methoxyprop-2 -enoate, methyl(2)-2-[5-(4-cyclohexylthiazol-2-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-2-[5-[4- (ethoxymethyl)thiazol-2-yl]-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl (2)-2-[5-(4-bromothiazol-2-yl)-2methylphenoxy]-3-methoxyprop -2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-[5-(trifluoromethyl)thiazol-2yl]phenoxy]prop-2-enoate, bixaphen, fosetyl aluminum, TAEGRO® , Timorex Gold™ and methylpicoxamide, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably from 5:1 to 1:5).

In another preferred composition according to the present invention, component (A) is Compound No. X.15, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-M-isobutyl-5methylthiazol-4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxade, fluopyram , isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florylpicoxamide, acibenzolar^-methyl, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metal xyla-M, aminopyrifene, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, cyflufenamide, metrafenone, N-[2-chloro-4-(2fluorophenoxy)-5-methylphenyl]-N-ethyl-N-methylformamidine, N'-[4-(2-bromophenoxy)-5- chloro-2methylphenyl]-N-ethyl-N-methylformamidine, N-(1-benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro- 1 -methylpropyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3 chloro-1-methylbut-3-enyl)-8-fluoroquinoline-3-carboxamide, 1 -(6,7-dimethylpyrazolo [1 ,5-a]pyridin-3-yl)4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl-1-(7-methylpyrazolo[1,5-a] pyridin-3- 43 046368 yl)isoquinoline, 1 -(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,6-trifluoro-3,3-dimethylisoquinoline, 1 (4, 5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 1-(4,5-dimethylbenzimidazol-1yl)-4,4-difluoro-3,3-dimethylisoquinoline, 6-chloro -4,4-difluoro-3,3-dimethyl-1 -(4-methylbenzimidazol-1 yl)isoquinoline, H'-[5-bromo-2-methyl-6-(1-methyl-2-propoxyethoxy)-3 -pyridyl|-H-ethyl-N-methyl(|yurmamidine, H'-[5-chloro-2-methyl-6-(1-methyl-2-propoxyethoxy)-3-pyridyl|-H-ethyl-H- methyl((yurmamidin. I-[5-bromo-2-methyl-6-(1-methyl-2-propoxyethoxy)-3-pyridyl|-H-isopropyl-N-methyl((yurmamidine. Nisopropyl-H'-[5-methoxy-2 -methyl-4-(2,2,2-trifluoro-1-hydroxy-1-phenylethyl)phenyl]-N-methylformamidine, Nmethoxy-N[[4-[5-(trifluoromethyl)-1,2,4- oxadiazol-3-yl]phenyl]methyl]cyclopropanecarboxamide, ^2-dimethoxy-N[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, Nethyl-2 -methyl-H-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, 1-methoxy-3 methyl-1-[[4-[5- (trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3- yl]phenyl]methyl]urea, 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, ethyl-1 -[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]pyrazole-4-carboxylate, ^Ndimethyl-1-[[4-[5-(trifluoromethyl)-1 ,2,4-oxadiazol-3yl]phenyl]methyl]-1,2,4-triazol-3-amine, methyl-(2)-3-methoxy-2-[2-methyl-5-[3-(trifluoromethyl )pyrazol-1yl]phenoxy]prop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-(3-propylpyrazol-1-yl)phenoxy]prop-2-enoate, methyl-( 2)-2-[5-(.3-isopropylpyrazol-1-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)3-methoxy-2-[2-methyl-5- (4-propyltriazol-2-yl)phenoxy]prop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl5-[4-(trifluoromethyl)triazol-2-yl]phenoxy]prop- 2-enoate, methyl (2)-2-(5-cyclohexyl-2-methylphenoxy)3-methoxyprop-2-enoate, methyl (2)-2-(5-cyclopentyl-2-methylphenoxy)-3-methoxyprop -2-enoate, methyl(2)-2-[5-(4-cyclohexylthiazol-2-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-2-[5-[ 4-(ethoxymethyl)thiazol-2-yl]-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-2-[5-(4-bromothiazol-2-yl)-2methylphenoxy]-3 -methoxyprop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-[5-(trifluoromethyl)thiazol-2yl]phenoxy]prop-2-enoate, bixafen, fosetyl aluminum, TAEGRO®, Timorex Gold™ and methylpicoxamide, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably from 5:1 to 1:5).

In another preferred composition according to the present invention, component (A) is Compound No. X.16, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-5-methyl-H-(1phenylethyl)thiazole -4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, tri(oxystrobin, methyltetraprole, di(enoconazole, hexaconazole, propiconazole, prothioconazole, me(entri(luconazole, (enpropidine, (enpropimor(a, (luxapyroxade, (luopyram, isopyrazam, sedaxane, benzovindi(lupira, pidi(lumeto(ene), iso(lucipram, iso(etamide, pyrapropone, (luindapyra, (enpicoxamide, florylpicoxamide, acibenzolar-methyl, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifen, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, cyflufenamide, metrafenone, N'-[ 2chlor-4-( 2-fluorophenoxy)-5-methylphenyl]-N-ethyl-N-methylformamidine, N-[4-(2-bromophenoxy)-5-chloro-2methylphenyl]-N-ethyl-N-methylformamidine, N-(1-benzyl -1,3-dimethylbutyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro-1-methylpropyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl -3-chloro-1-methylbut-3-enyl)-8-fluoroquinoline-3-carboxamide, 1 -(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)4,4,5-trifluoro- 3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl-1-(7-methylpyrazolo[1,5-a]pyridin-3yl)isoquinoline, 1 -(6,7-dimethylpyrazolo[1,5- a]pyridin-3 -yl)-4,4,6-trifluoro-3,3-dimethylisoquinoline, 1 (4,5-dimethylbenzimidazol-1 -yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 1 -(4,5-dimethylbenzimidazol-1 yl)-4,4-difluoro-3,3-dimethylisoquinoline, 6-chloro-4,4-difluoro-3,3-dimethyl-1 -(4-methylbenzimidazol-1 yl )isoquinoline, N'-[5-bromo-2-methyl-6-(1-methyl-2-propoxyethoxy)-3-pyridyl]-N-ethyl-N-methylformamidine, N'-[5-chloro-2- methyl-6-(1-methyl-2-propoxyethoxy)-3-pyridyl]-N-ethyl-N-methylformamidine, N'-[5-bromo-2-methyl-6-(1-methyl-2-propoxyethoxy) -3-pyridyl]-N-isopropyl-N-methylformamidine, Nisopropyl-H'-[5-methoxy-2-methyl-4-(2,2,2-trifluoro-1-hydroxy-1-phenylethyl)phenyl]- N-methylformamidine, N-methoxy-N-[[4-[5-(Ίrifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropanecarboxamide, N,2-dimethoxy-N-[[4 -[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, Nethyl-2-methyl-H-[[4-[5-(trifluoromethyl)-1,2,4 -oxadiazol-3-yl]phenyl]methyl]propanamide, 1-methoxy-3 methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea , 1,3-dimethoxy-1-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 3-ethyl-1-methoxy-1-[[4 -[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, ethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl ]phenyl]methyl]pyrazol-4-carboxylate, N,N-dimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]-1,2,4 -triazol-3-amine, methyl-(2)-3-methoxy-2-[2-methyl-5-[3-(trifluoromethyl)pyrazol-1yl]phenoxy]prop-2-enoate, methyl-(2)- 3-methoxy-2-[2-methyl-5-(3-propylpyrazol-1-yl)phenoxy]prop-2enoate, methyl-(2)-2-[5-(3-isopropylpyrazol-1-yl)-2 -methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)3-methoxy-2-[2-methyl-5-(4-propyltriazol-2-yl)phenoxy]prop-2-enoate, methyl-( 2)-3-methoxy-2-[2-methyl5-[4-(trifluoromethyl)triazol-2-yl]phenoxy]prop-2-enoate, methyl (2)-2-(5-cyclohexyl-2-methylphenoxy )3-methoxyprop-2-enoate, methyl (2)-2-(5-cyclopentyl-2-methylphenoxy)-3-methoxyprop-2-enoate, methyl(2)-2-[5-(4-cyclohexylthiazol- 2-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(/)-2-[5-[4- 44 046368 (ethoxymethyl)thiazol-2-yl]-2-methylphenoxy]-3 -methoxyprop-2-enoate, methyl-(2)-2-[5-(4-bromothiazol-2yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-3-methoxy-2 -[2-methyl-5-[5-(trifluoromethyl)thiazol-2-yl]phenoxy]prop-2-enoate, bixaphen, fosetyl aluminum, TAEGRO®, Timorex Gold™ and methylpicoxamide, where the weight ratio of component (A) and component (B) is from 10:1 to 1:10 (or even more preferably from 5:1 to 1:5).

In another preferred composition according to the present invention, component (A) is Compound No. X.17, 2-[cyano-(5-fluoro-3-pyridyl)amino]-H-(2,2-dimethylpropyl)-5methylthiazol- 4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph , fluxapyroxad, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florylpicoxamide, acibenzolar^-methyl, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fl udioxonil, cyprodinil, metalaxyl-M, aminopyrifene, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, cyflufenamide, metrafenone, N'-[2-χλορ-4-(2fluorophenoxy)-5-methylphenyl]-N-ethyl-N-methylformamidine, I-[4-(2-bromophenoxy )-5-chloro-2methylphenyl]-N-ethyl-N-methylformamidine, N-(1-benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3, 3-trifluoro-1-methylpropyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3 chloro-1-methylbut-3-enyl)-8-fluoroquinoline-3-carboxamide, 1 -(6,7 -dimethylpyrazolo[1,5-a]pyridin-3-yl)4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl-1-(7-methylpyrazolo[1, 5-a]pyridin-3yl)isoquinoline, 1 -(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,6-trifluoro-3,3-dimethylisoquinoline, 1 (4, 5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 1 -(4,5-dimethylbenzimidazol-1 yl)-4,4-difluoro-3,3-dimethylisoquinoline, 6- chloro-4,4-difluoro-3,3-dimethyl-1 -(4-methylbenzimidazol-1 yl)isoquinoline, H'-[5-bromo-2-methyl-6-(1-methyl-2-propoxyethoxy)- 3-pyridyl]-N-ethyl-N-methylformamidine, H'-[5-chloro-2-methyl-6-(1-methyl-2-propoxyethoxy)-3-pyridyl]-N-ethyl-N-methylformamidine, H'-[5-bromo-2-methyl-6-(1-methyl-2-propoxyethoxy)-3-pyridyl]-H-isopropyl-N-methylformamidine, Nisopropyl-H'-[5-methoxy-2-methyl -4-(2,2,2-trifluoro-1-hydroxy-1-phenylethyl)phenyl]-N-methylformamidine, H-methoxy-N-[[4-[5-(trifluoromethyl)-1,2,4- oxadiazol-3-yl]phenyl]methyl]cyclopropanecarboxamide, H,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, Nethyl -2-methyl-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, 1-methoxy-3 methyl-1-[[4-[ 5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol- 3-yl]phenyl]methyl]urea, 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, ethyl -1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]pyrazole-4-carboxylate, N,N-dimethyl-1-[[4-[5-( trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]-1,2,4-triazol-3-amine, methyl-(2)-3-methoxy-2-[2-methyl-5-[ 3-(trifluoromethyl)pyrazol-1yl]phenoxy]prop-2-enoate, methyl (2)-3-methoxy-2-[2-methyl-5-(3-propylpyrazol-1-yl)phenoxy]prop-2enoate , methyl-(2)-2-[5-(3-isopropylpyrazol-1-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)3-methoxy-2-[2-methyl -5-(4-propyltriazol-2-yl)phenoxy]prop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl5-[4-(trifluoromethyl)triazol-2-yl]phenoxy ]prop-2-enoate, methyl-(2)-2-(5-cyclohexyl-2-methylphenoxy)3-methoxyprop-2-enoate, methyl-(2)-2-(5-cyclopentyl-2-methylphenoxy)- 3-methoxyprop-2-enoate, methyl(2)-2-[5-(4-cyclohexylthiazol-2-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-2-[ 5-[4-(ethoxymethyl)thiazol-2-yl]-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-2-[5-(4-bromothiazol-2-yl)-2methylphenoxy ]-3-methoxyprop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-[5-(trifluoromethyl)thiazol-2yl]phenoxy]prop-2-enoate, bixafen, fosetyl -aluminium, TAEGRO®, Timorex Gold™ and methylpicoxamide, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably from 5:1 to 1:5).

In another preferred composition according to the present invention, component (A) is Compound No. X.18, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-M-(2,2dimethylpropyl)-5 - methylthiazole-4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine , fenpropimorph, fluxapyroxad, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapyr, fenpicoxamide, florylpicoxamide, acibenzolar^-methyl, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifene, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, cyflufenamide, metrafenone, N'-[2-chloro-4-(2-fluorophenoxy)-5-methylphenyl]-M-ethyl-M-methylformamidine, N'-[4 -(2bromophenoxy)-5-chloro-2-methylphenyl]-N-ethyl-N-methylformamidine, N-(1-benzyl-1,3-dimethylbutyl)-8fluoroquinoline-3-carboxamide, N-(1-benzyl-3 ,3,3-trifluoro-1-methylpropyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3-chloro-1-methylbut-3-enyl)-8-fluoroquinoline-3-carboxamide, 1 - (6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl-1-(7 - 45 046368 methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline, 1-(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,6trifluoro-3,3 -dimethylisoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4-difluoro -3,3-dimethylisoquinoline, 6-chloro-4,4-difluoro3,3-dimethyl-1 -(4-methylbenzimidazol-1 -yl)isoquinoline, N'-[5-bromo-2-methyl-6-( 1 -methyl-2-propoxyethoxy)-3-pyridyl|-N-e'tyl-N-me'tyl(|yurmamidina, N-[5-chloro-2-methyl-6-(1-methyl-2-propoxyethoxy) -3pyridyl]-Nethyl-Nmethylformamidine, N-[5-bromo-2-methyl-6-(1-methyl-2-propoxyethoxy)-3-pyridyl]Nisopropyl-Nmethylformamidine, N-isopropyl-N-[5 -methoxy-2-methyl-4-(2,2,2-trifluoro-1-hydroxy-1phenylethyl)phenyl]-Nmethylformamidine, Nmethoxy-N[[4-[5-(trifluoromethyl)-1,2,4 -oxadiazol-3yl]phenyl]methyl]cyclopropanecarboxamide, N2-dimethoxy-N[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]propanamide, Nethyl-2-methyl- No.[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl) -1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl] phenyl]methyl]urea, 3-ethyl-1methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, ethyl-1-[[4 -[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrazole-4-carboxylate, ^Ndimethyl-1-[[4-[5-(trifluoromethyl)-1,2 ,4-oxadiazol-3-yl]phenyl]methyl]-1,2,4-triazol-3-amine, methyl-(2)-3-methoxy-2-[2-methyl-5-[3 (trifluoromethyl) pyrazol-1-yl]phenoxy]prop-2-enoate, methyl (2)-3-methoxy-2-[2-methyl-5-(3-propylpyrazol-1 -yl)phenoxy]prop-2-enoate, methyl-(2)-2-[5-(3-isopropylpyrazol-1-yl)-2-methylphenoxy]-3 methoxyprop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl- 5-(4-propyltriazol-2-yl)phenoxy]prop-2-enoate, methyl (2)-3-methoxy-2-[2-methyl-5-[4-(trifluoromethyl)triazol-2-yl] phenoxy]prop-2-enoate, methyl (2)-2(5-cyclohexyl-2-methylphenoxy)-3-methoxyprop-2-enoate, methyl (2)-2-(5-cyclopentyl-2-methylphenoxy) -3-methoxyprop-2-enoate, methyl-(2)-2-[5-(4-cyclohexylthiazol-2-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-2 -[5-[4-(ethoxymethyl)thiazol-2-yl]-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-2-[5-(4-bromothiazol-2-yl) -2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-3-methoxy-2-[2methyl-5-[5-(trifluoromethyl)thiazol-2-yl]phenoxy]prop-2-enoate , bixafen, fosetyl aluminum, TAEGRO®, Timorex Gold™ and methylpicoxamide, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably from 5:1 to 1:5 ).

In another preferred composition according to the present invention, component (A) is Compound No. X.19, 2-[cyano-(5-fluoro-3-pyridyl)amino]-5-methyl-Npentylthiazol-4carboxamide, or a salt thereof , enantiomer, tautomer or N-oxide, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxade, fluopyram, isopyrase ma, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapyr, fenpicoxamide, florylpicoxamide, acibenzolar-methyl, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M, ami nopyrifen, folpet, ipflufenoquin, quinofumeline, tricyclazole , pyroquilone, cyflufenamide, metrafenone, I-[2-chloro-4-(2-fluorophenoxy)-5methylphenyl]-Nethyl-Nmethylformamidine, I-[4-(2-bromophenoxy)-5-chloro-2-methylphenyl] -N-'mia-Nmethylformamidine, N-(1-benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3trifluoro-1-methylpropyl)-8- fluoroquinoline-3-carboxamide, N-(1-benzyl-3-chloro-1-methylbut-3-enyl)-8fluoroquinoline-3-carboxamide, 1 -(6,7-dimethylpyrazolo[1,5-a]pyridine-3 -yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl-1-(7-methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline , 1-(6,7dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,6-trifluoro-3,3-dimethylisoquinoline, 1 -(4,5-dimethylbenzimidazol-1-yl)-4 ,4,5-trifluoro-3,3-dimethylisoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4-difluoro3,3-dimethylisoquinoline, 6-chloro-4,4-difluoro-3,3 -dimethyl-1-(4-methylbenzimidazol-1 -yl)isoquinoline, N'[5-bromo-2-methyl-6-(1-methyl-2-propoxyethoxy)-3-pyridyl]-Nethyl-Nmethylformamidine, I-[5-chloro-2methyl-6-(1-methyl-2-propoxyethoxy)-3-pyridyl]-Nethyl-Nmethylformamidine, N-[5-bromo-2-methyl-6-(1methyl-2- propoxyethoxy)-3-pyridyl]-Ni-isopropyl-N-methylformamidine, N-isopropyl-N-[5-methoxy-2methyl-4-(2,2,2-trifluoro-1-hydroxy-1-phenylethyl)phenyl]-N-methylformamidine , Nmethoxy-N[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropanecarboxamide, K2-dimethoxy^-[[4-[5(trifluoromethyl)-1, 2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, Nethyl-2-methyl-N[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl] propanamide, 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[ 4-[5-(trifluoromethyl)-1,2,4-oxadiazol3-yl]phenyl]methyl]urea, 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2, 4-oxadiazol-3-yl]phenyl]methyl]urea, ethyl 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrazole-4carboxylate, ^ No.dimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]-1,2,4-triazol3-amine, methyl-(2)-3 -methoxy-2-[2-methyl-5-[3-(trifluoromethyl)pyrazol-1-yl]phenoxy]prop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5 -(3-propylpyrazol-1-yl)phenoxy]prop-2-enoate, methyl-(2)-2-[5-(3-isopropylpyrazol-1-yl)-2-methylphenoxy]-3-methoxyprop-2- enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-(4propyltriazol-2-yl)phenoxy]prop-2-enoate, methyl-(2)-3-methoxy-2-[2 -methyl-5-[4-(trifluoromethyl)triazol-2-yl]phenoxy]prop-2-enoate, methyl (2)-2-(5-cyclohexyl-2-methylphenoxy)-3-methoxyprop-2-enoate , methyl-(2)-2-(5-cyclopentyl-2-methylphenoxy)-3-methoxyprop-2-enoate, methyl-(2)-2-[5-(4-cyclohexylthiazol-2-yl)-2- methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-2-[5-[4-(ethoxymethyl)thiazol-2-yl]-2

- 46 046368 methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-2-[5-(4-bromothiazol-2-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl- (2)-3-methoxy-2-[2-methyl-5-[5-(trifluoromethyl)thiazol-2-yl|phenoxy|prop-2enoate, bixaphen, fosetyl aluminum, TAEGRO®, Timorex Gold™ and methylpicoxamide, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably from 5:1 to 1:5).

In another preferred composition according to the present invention, component (A) is Compound No. X.20, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-5-methyl-Mpentylthiazole-4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxade, fluopyram , isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florylpicoxamide, acibenzolar^-methyl, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metal xyla-M, aminopyrifene, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, cyflufenamide, metrafenone, I-[2-chloro4-(2-fluorophenoxy)-5-methylphenyl]-N-ethyl-N-methylformamidine, I-[4-(2-bromophenoxy)-5-chloro -2methylphenyl]-N-ethyl-N-methylformamidine, N-(1-benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro-1 -methylpropyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3-chloro-1-methylbut-3-enyl)-8-fluoroquinoline-3-carboxamide, 1-(6,7-dimethylpyrazolo [1, 5-a]pyridin-3-yl)4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl-1-(7-methylpyrazolo[1,5-a]pyridine -3yl)isoquinoline, 1 -(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,6-trifluoro-3,3-dimethylisoquinoline, 1 (4,5-dimethylbenzimidazol-1 -yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 1-(4,5-dimethylbenzimidazol-1yl)-4,4-difluoro-3,3-dimethylisoquinoline, 6-chloro-4,4- difluoro-3,3-dimethyl-1 -(4-methylbenzimidazol-1 yl)isoquinoline, N'-[5-bromo-2-methyl-6-(1-methyl-2-propoxyethoxy)-3-pyridyl]-N -ethyl-N-methylformamidine, N'-[5-chloro-2-methyl-6-(1-methyl-2-propoxyethoxy)-3-pyridyl]-N-ethyl-N-methylformamidine, N'-[5- bromo-2-methyl-6-(1-methyl-2-propoxyethoxy)-3-pyridyl]-N-isopropyl-N-methylformamidine, Nisopropyl-N'-[5-methoxy-2-methyl-4-(2, 2,2-trifluoro-1-hydroxy-1-phenylethyl)phenyl]-N-methylformamidine, N-methoxy-N-[[4-[5-(Ίriforomethyl)-1,2,4-oxadiazol-3-yl] phenyl]methyl]cyclopropanecarboxamide, N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, Nethyl-2-methyl-M -[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, 1 -methoxy-3 methyl-1-[[4-[5-(trifluoromethyl)- 1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] methyl]urea, 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, ethyl-1-[[4 -[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]pyrazole-4-carboxylate, N,N-dimethyl-1-[[4-[5-(trifluoromethyl)-1,2 ,4-oxadiazol-3yl]phenyl]methyl]-1,2,4-triazol-3-amine, methyl-(2)-3-methoxy-2-[2-methyl-5-[3-(trifluoromethyl)pyrazole -1yl]phenoxy]prop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-(3-propylpyrazol-1-yl)phenoxy]prop-2enoate, methyl-(2) -2-[5-(3-isopropylpyrazol-1-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)3-methoxy-2-[2-methyl-5-(4- propyltriazol-2-yl)phenoxy]prop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl5-[4-(trifluoromethyl)triazol-2-yl]phenoxy]prop-2-enoate , methyl (2)-2-(5-cyclohexyl-2-methylphenoxy)3-methoxyprop-2-enoate, methyl (2)-2-(5-cyclopentyl-2-methylphenoxy)-3-methoxyprop-2- enoate, methyl(2)-2-[5-(4-cyclohexylthiazol-2-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-2-[5-[4-( ethoxymethyl)thiazol-2-yl]-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-2-[5-(4-bromothiazol-2-yl)-2methylphenoxy]-3-methoxyprop- 2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-[5-(trifluoromethyl)thiazol-2yl]phenoxy]prop-2-enoate, bixaphen, fosetyl aluminum, TAEGRO®, Timorex Gold™ and methylpicoxamide, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably from 5:1 to 1:5).

In another preferred composition according to the present invention, component (A) is Compound No. X.21, 2-[cyano-(5-fluoro-3-pyridyl)amino]-M-isopentyl-5methylthiazol-4-carboxamide, or a salt, enantiomer, tautomer or N-oxide, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxade, fluopyram, isopyrase ma ... aminopyrifene, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, cyflufenamide, metrafenone, N-[2-chloro-4-(2fluorophenoxy)-5-methylphenyl]-N-ethyl-N-methylformamidine, N'-[4-(2-bromophenoxy)-5-chloro- 2methylphenyl]-N-ethyl-N-methylformamidine, N-(1-benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro-1 - methylpropyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3chloro-1-methylbut-3-enyl)-8-fluoroquinoline-3-carboxamide, 1-(6,7-dimethylpyrazolo[1,5 -a]pyridin-3-yl)4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl-1-(7-methylpyrazolo[1,5-a]pyridin- 3- 47 046368 yl)isoquinoline, 1 -(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,6-trifluoro-3,3-dimethylisoquinoline, 1 (4,5- dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 1-(4,5-dimethylbenzimidazol-1yl)-4,4-difluoro-3,3-dimethylisoquinoline, 6-chloro-4 ,4-difluoro-3,3-dimethyl-1 -(4-methylbenzimidazol-1 yl)isoquinoline, H'-[5-bromo-2-methyl-6-(1-methyl-2-propoxyethoxy)-3-pyridyl |-H-ethyl-N-methyl(|yurmamidine, H'-[5-chloro-2-methyl-6-(1-methyl-2-propoxyethoxy)-3-pyridyl|-H-ethyl-N-methyl( (yurmamidina. I-[5-bromo-2-methyl-6-(1-methyl-2-propoxyethoxy)-3-pyridyl|-H-isopropyl-N-methyl((yurmamidine. Nisopropyl-H'-[5-methoxy-2 -methyl-4-(2,2,2-trifluoro-1-hydroxy-1-phenylethyl)phenyl]-N-methylformamidine, Nmethoxy-N[[4-[5-(trifluoromethyl)-1,2,4- oxadiazol-3-yl]phenyl]methyl]cyclopropanecarboxamide, N2-dimethoxy-N[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, N-ethyl2 -methyl-H-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, 1-methoxy-3-methyl-1[[4-[5- (trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3 -yl]phenyl]methyl]urea, 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]phenyl]methyl]urea, ethyl-1- [[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrazole-4-carboxylate, ^Ndimethyl-1-[[4-[5-(trifluoromethyl)- 1,2,4-oxadiazol-3-yl]phenyl]methyl]1,2,4-triazol-3-amine, methyl-(2)-3-methoxy-2-[2-methyl-5-[3 - (trifluoromethyl)pyrazol-1-yl]phenoxy]prop2-enoate, methyl (2)-3-methoxy-2-[2-methyl-5-(3-propylpyrazol-1-yl)phenoxy]prop-2-enoate , methyl-(2)-2[5-(3-isopropylpyrazol-1-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-3-methoxy-2-[2methyl-5 -(4-propyltriazol-2-yl)phenoxy]prop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-[4-(trifluoromethyl)triazol-2-yl]phenoxy ]prop-2-enoate, methyl (2)-2-(5-cyclohexyl-2-methylphenoxy)-3-methoxyprop-2-enoate, methyl (2)-2-(5-cyclopentyl-2-methylphenoxy) -3-methoxyprop-2-enoate, methyl-(2)-2-[5-(4cyclohexylthiazol-2-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-2-[ 5-[4-(ethoxymethyl)thiazol-2-yl]-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-2-[5-(4-bromothiazol-2-yl)-2 -methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-[5-(trifluoromethyl)thiazol-2-yl]phenoxy]prop-2-enoate , bixafen, fosetyl aluminum, TAEGRO®, Timorex Gold™ and methylpicoxamide, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably from 5:1 to 1:5 ).

In another preferred composition according to the present invention, component (A) is Compound No. X.22, No. [[3,5-bis(trifluoromethyl)phenyl]methyl]-2-[cyano-(2,6-difluoro4-pyridyl )amino]-5-methylthiazol-4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, tri(oxystrobin, methyltetraprole, di(enoconazole , hexaconazole, propiconazole, prothioconazole, me(entri(luconazole, (enpropidine, (enpropimor(a), (luxapyroxad, (luopyram, isopyrazam, sedaxane, benzovindi(lupira, pidi(lumeto(ene), iso(lucipram, iso(etamide, pyrapropone) , (luindapir, fenpicoxamide, florylpicoxamide, acibenzolar^-methyl, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifene, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, cyflufenamide, metrafenone, No.-[ 2-chloro-4-(2-fluorophenoxy)-5-methylphenyl]-N-ethyl-N-methylformamidine, N'-[4-(2bromophenoxy)-5-chloro-2-methylphenyl]-N-ethyl-N- methylformamidine, N-(1-benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro-1-methylpropyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3-chloro-1-methylbut-3-enyl)-8-fluoroquinoline-3-carboxamide, 1 -(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)- 4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl-1-(7methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline, 1-(6, 7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,6trifluoro-3,3-dimethylisoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro -3,3-dimethylisoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4-difluoro-3,3-dimethylisoquinoline, 6-chloro-4,4-difluoro3,3-dimethyl-1 -( 4 -methylbenzimidazol-1 -yl)isoquinoline, N'-[5-bromo-2-methyl-6-(1 -methyl-2-propoxyethoxy)-3-pyridyl]-N-ethyl-N-methylformamidine, N'- [5-chloro-2-methyl-6-(1-methyl-2-propoxyethoxy)-3pyridyl]-N-ethyl-N-methylformamidine, N'-[5-bromo-2-methyl-6-(1-methyl -2-propoxyethoxy)-3-pyridyl]N-isopropyl-N-methylformamidine, N-isopropyl-N'-[5-methoxy-2-methyl-4-(2,2,2-Ίriforo-1-hydroxy-1phenylethyl )phenyl]-N-methylformamidine, N-methoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]cyclopropanecarboxamide, N,2-dimethoxy-N-[ [4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]propanamide, N-ethyl-2-methyl-N-[[4-[5-(trifluoromethyl)-1,2 ,4-oxadiazol-3-yl]phenyl]methyl]propanamide, 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 3-ethyl-1methoxy-1-[ [4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, ethyl 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazole -3-yl]phenyl]methyl]pyrazol-4-carboxylate, N,N-dimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl] -1,2,4-triazol-3-amine, methyl-(2)-3-methoxy-2-[2-methyl-5-[3 (trifluoromethyl)pyrazol-1-yl]phenoxy]prop-2-enoate , methyl-(2)-3-methoxy-2-[2-methyl-5-(3-propylpyrazol-1-yl)phenoxy]prop-2-enoate, methyl-(2)-2-[5-(3 -isopropylpyrazol-1-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-(4-propyltriazol-2-yl)phenoxy ]prop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-[4-(trifluoromethyl)triazol-2-yl]phenoxy]prop-2-enoate, methyl-(2 )-2-(5cyclohexyl-2-methylphenoxy)-3-methoxyprop-2-enoate, methyl-(2)-2-(5-cyclopentyl-2-methylphenoxy)-3methoxyprop-2-enoate, methyl-(2)- 2-[5-(4-cyclohexylthiazol-2-yl)-2-methylphenoxy]-3-methoxyprop-2

- 48 046368 enoate, methyl-(2)-2-[5-[4-(ethoxymethyl)thiazol-2-yl]-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl(2)-2-[ 5-(4-bromothiazol-2-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl5-[5-(trifluoromethyl)thiazol- 2-yl]phenoxy]prop-2-enoate, bixafen, fosetyl aluminum, TAEGRO®, Timorex Gold™ and methylpicoxamide, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably 5:1 to 1:5).

In another preferred composition according to the present invention, component (A) is Compound No. X.23, N-benzyl-2-[cyano-(2,6-difluoro-4-pyridyl)amino]-5methylthiazol-4-carboxamide, or its salt, enantiomer, tautomer or N-oxide, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxade, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapyr, fenpicoxamide, florylpicoxamide, acibenzolar-methyl, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl -M, aminopyrifene, folpet, ipflufenoquin, quinofumeline , tricyclazole, pyroquilone, cyflufenamide, metrafenone, N'-[2-χλορ-4-(2fluorophenoxy)-5-methylphenyl]-N-ethyl-N-methylformamidine, I-[4-(2-bromophenoxy)-5-chloro -2methylphenyl]-N-ethyl-N-methylformamidine, N-(1-benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3 carboxamide, N-(1-benzyl-3,3,3-trifluoro-1- methylpropyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl3-chloro-1-methylbut-3-enyl)-8-fluoroquinoline-3-carboxamide, 1-(6,7-dimethylpyrazolo[1,5- a]pyridin-3 yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl-1 -(7-methylpyrazolo [1,5-a]pyridin3 -yl )isoquinoline, 1 -(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,6-trifluoro-3,3-dimethylisoquinoline, 1-(4,5-dimethylbenzimidazol-1- yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 1-(4,5-dimethylbenzimidazol1 -yl)-4,4-difluoro-3,3-dimethylisoquinoline, 6-chloro-4,4-difluoro -3,3-dimethyl-1-(4-methylbenzimidazol-1yl)isoquinoline, N'-[5-bromo-2-methyl-6-(1-methyl-2-propoxyethoxy)-3-pyridyl]-N-ethyl -N-methylformamidine, N'-[5-chloro-2-methyl-6-(1-methyl-2-nropoxyethoxy)-3-pyridyl]-N-ethyl-N-methylformamidine, N'-[5-bromo- 2-methyl-6-(1-methyl-2-propoxyethoxy)-3-pyridyl]-N-isopropyl-N-methylformamidine, Nisopropyl-H'-[5-methoxy-2-methyl-4-(2,2, 2-trifluoro-1-hydroxy-1-phenylethyl)phenyl]-N-methylformamidine, N-methoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxαdiazol-3-yl]phenyl] methyl]cyclopropancarboxamide, N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]nropαnamide, Nethyl-2-methyl-M-[ [4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, 1-methoxy-3 methyl-1-[[4-[5-(trifluoromethyl)-1, 2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl] urea, 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, ethyl-1-[[4-[ 5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]pyrazole-4-carboxylate, N,N-dimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4 -oxαdiαzol-3yl]phenyl]methyl]-1,2,4-triazol-3-amine, methyl-(2)-3-methoxy-2-[2-methyl-5-[3-(trifluoromethyl)pyrazol-1yl ]phenoxy]prop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-(3-propylpyrazol-1-yl)phenoxy]prop-2enoate, methyl-(2)-2 -[5-(3-isopropylpyrazol-1-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)3-methoxy-2-[2-methyl-5-(4-propyltriazol- 2-yl)phenoxy]prop-2-enoate, methyl (2)-3-methoxy-2-[2-methyl5-[4-(trifluoromethyl)triazol-2-yl]phenoxy]prop-2-enoate, methyl -(2)-2-(5-cyclohexyl-2-methylphenoxy)3-methoxyprop-2-enoate, methyl (2)-2-(5-cyclopentyl-2-methylphenoxy)-3-methoxyprop-2-enoate, methyl(2)-2-[5-(4-cyclohexylthiazol-2-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl(2)-2-[5-[4-(ethoxymethyl) thiazol-2-yl]-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-2-[5-(4-bromothiazol-2-yl)-2methylphenoxy]-3-methoxyprop-2- enoate, methyl (2)-3-methoxy-2-[2-methyl-5-[5-(trifluoromethyl)thiazol-2yl]phenoxy]prop-2-enoate, bixafen, fosetyl aluminum, TAEGRO®, Timorex Gold ™ and methylpicoxamide, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably from 5:1 to 1:5).

In another preferred composition according to the present invention, component (A) is Compound No. X.24, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-[cyano-(2,6-difluoro4- pyridyl)amino]-5-methylthiazol-4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxad, fluopyram, isopyrazam, sedaxane, benzovindiflupir, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florylpicoxamide, acibenzolar^-methyl a, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxonil , cyprodinil, metalaxyl-M, aminopyrifen, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, cyflufenamide, metrafenone, N'-[2-chloro-4-(2-fluorophenoxy)-5-methylphenyl]-N-ethyl-N- methylformamidine, N'-[4-(2bromophenoxy)-5-chloro-2-methylphenyl]-N-ethyl-N-methylformamidine, N-(1-benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3-carboxamide, N -(1-benzyl-3,3,3-trifluoro-1-methylpropyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3-chloro-1-methylbut-3-enyl)-8-fluoroquinoline -3-carboxamide, 1 -(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3 -dimethyl-1-(7- 49 046368 methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline, 1-(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4, 4,6-trifluoro-3,3-dimethylisoquinoline, 1 -(4,5-dimethylbenzimidazol-1 -yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 1 -(4,5-dimethylbenzimidazol-1 -yl )-4,4-difluoro-3,3-dimethylisoquinoline, 6-chloro-4,4-difluoro-3,3dimethyl-1-(4-methylbenzimidazol-1-yl)isoquinoline, I-[5-bromo-2- methyl-6-(1-methyl-2-propoxyethoxy)3-pyridyl|-H-ethyl-N-methyl(|yurmamidine. I-[5-chloro-2-methyl-6-(1-methyl-2-propoxyethoxy)-3-pyridyl|Nethyl-N-methylformamidine, I-[5-bromo-2-methyl-6-(1- methyl-2-propoxyethoxy)-3-pyridyl|-H-isopropyl-N-methylformamidine, N-isopropyl-H'-[5-methoxy-2-methyl-4-(2,2,2-trifluoro-1-hydroxy- 1phenylethyl)phenyl]-N-methylformamidine, N-methoxy-H-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropanecarboxamide, N,2-dimethoxy- N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]propanamide, N-ethyl-2-methyl-N-[[4-[5-(trifluoromethyl)- 1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl ]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 3-ethyl-1methoxy- 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, ethyl-1-[[4-[5-(trifluoromethyl)-1,2, 4-oxadiazol-3-yl]phenyl]methyl]pyrazol-4-carboxylate, N,N-dimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl ]methyl]-1,2,4-triazol-3-amine, methyl-(2)-3-methoxy-2-[2-methyl-5-[3 (trifluoromethyl)pyrazol-1 -yl]phenoxy]prop- 2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-(3-propylpyrazol-1-yl)phenoxy]prop-2-enoate, methyl-(2)-2-[5 -(3-isopropylpyrazol-1-yl)-2-methylphenoxy]-3 methoxyprop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-(4-propyltriazol-2-yl) )phenoxy]prop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-[4-(trifluoromethyl)triazol-2-yl]phenoxy]prop-2-enoate, methyl- (2)-2(5-cyclohexyl-2-methylphenoxy)-3-methoxyprop-2-enoate, methyl (2)-2-(5-cyclopentyl-2-methylphenoxy)-3-methoxyprop-2-enoate, methyl -(2)-2-[5-(4-cyclohexylthiazol-2-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl (2)-2-[5-[4-(ethoxymethyl) thiazol-2-yl]-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-2-[5-(4-bromothiazol-2-yl)-2-methylphenoxy]-3-methoxyprop- 2-enoate, methyl-(2)-3-methoxy-2-[2methyl-5-[5-(trifluoromethyl)thiazol-2-yl]phenoxy]prop-2-enoate, bixaphen, fosetyl aluminum, TAEGRO®, Timorex Gold™ and methylpicoxamide, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably from 5:1 to 1:5).

In a preferred composition according to the present invention, component (A) is Compound No. X.01, 2-[cyano-(5-fluoro-3-pridyl)amino]-N-cyclobutyl-5-methylthiazol-4carboxamide, or a salt thereof , enantiomer, tautomer or N-oxide, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxade, fluopyram, isopyrase ma, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapyr, fenpicoxamide, florylpicoxamide, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifene, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, N- (1-benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3 trifluoro-1-methylpropyl)-8-fluoroquinoline-3-carboxamide, 1 -( 6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl-1-(7-methylpyrazolo [1,5-a]pyridin-3yl)isoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline and 1-(4,5dimethylbenzimidazol-1- yl)-4,4-difluoro-3,3-dimethylisoquinoline, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably from 5:1 to 1:5) .

In a preferred composition according to the present invention, component (A) is Compound No. X.02, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-N-cyclobutyl-5methylthiazol-4-carboxamide, or its salt, enantiomer, tautomer or N-oxide, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxade, fluopyram, isopyrazam, sedaxane, benzovindiflupir, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florylpicoxamide, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifene, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, N-(1-benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro-1-methylpropyl)-8-fluoroquinoline-3-carboxamide, 1- (6,7-dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl-1 -(7 methylpyrazolo[ 1,5-a]pyridin-3-yl)isoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3,3dimethylisoquinoline and 1-(4,5-dimethylbenzimidazol-1 -yl)-4,4-difluoro-3,3-dimethylisoquinoline, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably from 5:1 to 1:5 ).

In another preferred composition according to the present invention, component (A) is Compound No. X.03, 2-(N-cyano-3,5-difluoroanilino)-N-(2,2-dimethylcyclobutyl)-5methylthiazol-4-carboxamide , or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole,

- 50 046368 fenpropidine, fenpropimorph, fluxapyroxad, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florylpicoxamide, chlorothalonil, mancozeb, mandipropamide, oxati apiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifene , folpeta, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, N-(1-benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro-1-methylpropyl)- 8-fluoroquinoline-3-carboxamide, 1-(6,7-dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3, 3-dimethyl-1-(7 methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3,3dimethylisoquinoline and 1-(4,5-dimethylbenzimidazol-1-yl)-4,4-difluoro-3,3-dimethylisoquinoline, where the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably 5:1 to 1:5).

In another preferred composition according to the present invention, component (A) is Compound No. X.04, 2-[cyano-(5-fluoro-3-pyridyl)amino]-N-(2,2dimethylcyclobutyl)-5-methylthiazol- 4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph , fluxapiroxad, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florylpicoxamide, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil , metalaxyl-M, aminopyrifene, folpet, ipflufenoquin, quinofumeline , tricyclazole, pyroquilone, N-(1-benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro-1-methylpropyl)-8-fluoroquinoline-3 - carboxamide, 1 -(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro3,3-dimethyl-1 - (7-methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline, 1 -(4,5-dimethylbenzimidazol-1 -yl)4,4,5-trifluoro-3,3-dimethylisoquinoline and 1 -(4 ,5-dimethylbenzimidazol-1-yl)-4,4-difluoro-3,3dimethylisoquinoline, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably from 5:1 up to 1:5).

In another preferred composition according to the present invention, component (A) is Compound No. X.05, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-N-(2,2dimethylcyclobutyl)-5- methylthiazole-4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine , fenpropimorpha, fluxapyroxad, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florylpicoxamide, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxon yl, cyprodinil, metalaxyl-M, aminopyrifene, folpet, ipflufenoquin , quinofumeline, tricyclazole, pyroquilone, N-(1-benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro-1-methylpropyl)-8-fluoroquinoline- 3-carboxamide, 1-(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro3,3-dimethyl- 1-(7-methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)4,4,5-trifluoro-3,3-dimethylisoquinoline and 1- (4,5-dimethylbenzimidazol-1-yl)-4,4-difluoro-3,3-dimethylisoquinoline, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably from 5:1 to 1:5).

In another preferred composition according to the present invention, component (A) is Compound No. X.06, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-N-(2,2dimethylcyclobutyl)-5- formamidothiazole-4-carboxamide, or a salt, enantiomer, tautomer or Noxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph , fluxapiroxad, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florilpicoxamide, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil , metalaxyl-M, aminopyrifene, folpet, ipflufenoquin, quinofumeline , tricyclazole, pyroquilone, N-(1-benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro-1-methylpropyl)-8-fluoroquinoline-3 - carboxamide, 1 -(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro3,3-dimethyl-1 - (7-methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)4,4,5-trifluoro-3,3-dimethylisoquinoline and 1-(4 ,5-dimethylbenzimidazol-1-yl)-4,4-difluoro-3,3-dimethylisoquinoline, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably from 5 :1 to 1:5).

In another preferred composition according to the present invention, component (A) is Compound No. X.07, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-5-methyl-Nspiro[3.4]octane- 3-yl-thiazol-4-carboxamide, or its salt, enantiomer, tautomer or N-oxide, and compos

- 51 046368 nent (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxad, fluopyram, isopyrazam, sedax na, benzovindiflupyr, pidiflumetofen, isoflucipram , isofetamide, pyrapropone, fluindapyr, fenpicoxamide, florilpicoxamide, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifene, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone , No(1-benzyl-1,3 -dimethylbutyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro-1-methylpropyl)-8-fluoroquinoline-3-carboxamide, 1-(6,7dimethylpyrazolo[1,5-a ]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl1-(7-methylpyrazolo[1,5-a]pyridin-3-yl )isoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro3,3-dimethylisoquinoline and 1-(4,5-dimethylbenzimidazol-1-yl)-4,4-difluoro-3 ,3-dimethylisoquinoline, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably from 5:1 to 1:5).

In another preferred composition according to the present invention, component (A) is Compound No. X.08, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-5-methyl-Nspiro[cyclobutane-2, 2'-indane]-1-yl-thiazol-4-carboxamide, or a salt, enantiomer, tautomer or Noxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole , propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxad, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florylpicoxamide, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl -M, aminopyrifene, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, N-(1-benzyl-1,3-dimethylbutyl)-8fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro-1 -methylpropyl)-8-fluoroquinoline-3-carboxamide, 1 -(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4, 4-difluoro3,3-dimethyl-1 -(7-methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline, 1 -(4,5-dimethylbenzimidazol-1 -yl)4,4,5-trifluoro- 3,3-dimethylisoquinoline and 1-(4,5-dimethylbenzimidazol-1-yl)-4,4-difluoro-3,3dimethylisoquinoline, where the weight ratio of component (A) and component (B) is from 10:1 to 1: 10 (or even more preferably 5:1 to 1:5).

In another preferred composition according to the present invention, component (A) is Compound No. X.09, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-5-methyl-Nspiro[3.3]heptane- 3-yl-thiazol-4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole , mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxad, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florylpicoxamide, chlorothalonil, mancozeb, mandipropamide, o xathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifene , folpeta, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, N-(1-benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3carboxamide, N-(1-benzyl-3,3,3-trifluoro-1-methylpropyl) - 8-fluoroquinolin-3-carboxamide, 1-(6,7dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3, 3-dimethyl1-(7-methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro3,3-dimethylisoquinoline and 1 -(4,5-dimethylbenzimidazol-1-yl)-4,4-difluoro-3,3-dimethylisoquinoline, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably from 5:1 to 1:5).

In another preferred composition according to the present invention, component (A) is Compound No. X.10, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-N-[[1(cyclopropylmethyl)cyclopropyl] methyl]-5-methylthiazole-4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxad, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florylpicoxamide, chlorothalonil, mancozeb, mandipro pamida, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifene, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, N-(1-benzyl-1,3-dimethylbutyl)-8fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro-1-methylpropyl) -8-fluoroquinoline-3-carboxamide, 1-(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro -3,3dimethyl-1-(7-methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4,5trifluoro-3,3- dimethylisoquinoline and 1-(4,5-dimethylbenzimidazol-1-yl)-4,4-difluoro-3,3-dimethylisoquinoline, where the weight ratio of component (A) and component (B) is from 10:1 to 1:10 ( or even more preferably from 5:1 to 1:5).

In another preferred composition according to the present invention, component (A)

- 52 046368 is compound No. X.11, 2-(Ncyano-3,5-difluoroanilino)-5-methyl-N-(1methylcyclopentyl)thiazole-4-carboxamide, or its salt, enantiomer, tautomer or N-oxide and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxad, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florilpicoxamide, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifene, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, no. (1-benzyl-1,3- dimethylbutyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro-1-methylpropyl)-8-fluoroquinoline-3-carboxamide, 1-(6,7dimethylpyrazolo[1,5-a] pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl1-(7-methylpyrazolo[1,5-a]pyridin-3-yl) isoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro3,3-dimethylisoquinoline and 1-(4,5-dimethylbenzimidazol-1-yl)-4,4-difluoro-3, 3-dimethylisoquinoline, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably from 5:1 to 1:5).

In another preferred composition according to the present invention, component (A) is Compound No. X.12, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-5-methyl-N-(1methylcyclopentyl)thiazole -4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxad, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florylpicoxamide, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifene, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, N-(1-benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3carboxamide, N-(1-benzyl-3,3,3-trifluoro-1-methylpropyl)-8-fluoroquinoline-3 -carboxamide, 1 -(6,7 dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl1- (7-methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro3,3-dimethylisoquinoline and 1-(4, 5-dimethylbenzimidazol-1-yl)-4,4-difluoro-3,3-dimethylisoquinoline, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably from 5: 1 to 1:5).

In a preferred composition according to the present invention, component (A) is Compound No. X.13, 2-[cyano-(5-fluoro-3-pyridyl)amino]-N-hexyl-5-methylthiazol-4carboxamide, or a salt thereof , enantiomer, tautomer or N-oxide, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxade, fluopyram, isopyrase ma, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapyr, fenpicoxamide, florylpicoxamide, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifene, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, N- (1-benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3 trifluoro-1-methylpropyl)-8-fluoroquinoline-3-carboxamide, 1 -( 6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl-1-(7-methylpyrazolo [1,5-a]pyridin-3yl)isoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline and 1-(4,5dimethylbenzimidazol-1- yl)-4,4-difluoro-3,3-dimethylisoquinoline, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably from 5:1 to 1:5) .

In a preferred composition according to the present invention, component (A) is Compound No. X.14, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-N-hexyl-5-methylthiazol-4carboxamide, or its salt, enantiomer, tautomer or N-oxide, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxade, fluopyram, isopyrazam, sedaxane, benzovindiflupir, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florylpicoxamide, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifene, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, N-(1-benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3 trifluoro-1-methylpropyl)-8-fluoroquinoline-3-carboxamide, 1 -(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl-1-(7 -methylpyrazolo[1,5-a]pyridin-3yl)isoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline and 1-(4,5dimethylbenzimidazol- 1-yl)-4,4-difluoro-3,3-dimethylisoquinoline, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably from 5:1 to 1: 5).

In a preferred composition according to the present invention, component (A) is Compound No. X.15, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-N-isobutyl-5-methylthiazole4 -carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxad, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florilpicoxamide, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, meta laxila-M, aminopyrifene, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, N-(1-benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3 trifluoro-1-methylpropyl)-8-fluoroquinoline-3 -carboxamide, 1 -(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl- 1-(7-methylpyrazolo[1,5-a]pyridin-3yl)isoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline and 1-( 4,5dimethylbenzimidazol-1-yl)-4,4-difluoro-3,3-dimethylisoquinoline, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably from 5: 1 to 1:5).

In another preferred composition according to the present invention, component (A) is Compound No. X.16, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-5-methyl-N-(1phenylethyl)thiazole -4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxad, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florylpicoxamide, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifene, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, N-(1-benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro-1-methylpropyl)-8-fluoroquinoline -3-carboxamide, 1 -(6,7-dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl -1-(7 methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3,3dimethylisoquinoline and 1-( 4,5-dimethylbenzimidazol-1-yl)-4,4-difluoro-3,3-dimethylisoquinoline, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably from 5:1 to 1:5).

In another preferred composition according to the present invention, component (A) is Compound No. X.17, 2-[cyano-(5-fluoro-3-pyridyl)amino]-N-(2,2-dimethylpropyl)-5methylthiazol- 4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph , fluxapiroxad, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florilpicoxamide, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil , metalaxyl-M, aminopyrifene, folpet, ipflufenoquin, quinofumeline , tricyclazole, pyroquilone, N-(1-benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro-1-methylpropyl)-8-fluoroquinoline-3 - carboxamide, 1-(6,7-dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl-1 - (7 methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3,3dimethylisoquinoline and 1-(4,5 -dimethylbenzimidazol-1-yl)-4,4-difluoro-3,3-dimethylisoquinoline, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably from 5:1 up to 1:5).

In another preferred composition according to the present invention, component (A) is Compound No. X.18, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-N-(2,2dimethylpropyl)-5 - methylthiazole-4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine , fenpropimorpha, fluxapyroxad, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florylpicoxamide, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxon yl, cyprodinil, metalaxyl-M, aminopyrifene, folpet, ipflufenoquin , quinofumeline, tricyclazole, pyroquilone, N-(1-benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro-1-methylpropyl)-8-fluoroquinoline- 3-carboxamide, 1 -(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro3,3-dimethyl- 1-(7-methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)4,4,5-trifluoro-3,3-dimethylisoquinoline and 1- (4,5-dimethylbenzimidazol-1-yl)-4,4-difluoro-3,3-dimethylisoquinoline, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably from 5:1 to 1:5).

- 54 046368

In a preferred composition according to the present invention, component (A) is Compound No. X.19, 2-[cyano-(5-fluoro-3-pyridyl)amino]-5-methyl-H-pentylthiazole-4carboxamide, or a salt thereof , enantiomer, tautomer or N-oxide, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxade, fluopyram, isopyrase ma, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapyr, fenpicoxamide, florylpicoxamide, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifene, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, N- (1-benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3 trifluoro-1-methylpropyl)-8-fluoroquinoline-3-carboxamide, 1 -( 6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl-1-(7-methylpyrazolo [1,5-a]pyridin-3yl)isoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline and 1-(4,5dimethylbenzimidazol-1- yl)-4,4-difluoro-3,3-dimethylisoquinoline, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably from 5:1 to 1:5) .

In a preferred composition according to the present invention, component (A) is Compound No. X.20, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-5-methyl-N-pentylthiazol-4carboxamide, or its salt, enantiomer, tautomer or N-oxide, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxade, fluopyram, isopyrazam, sedaxane, benzovindiflupir, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florylpicoxamide, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifene, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, N-(1-benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3 trifluoro-1-methylpropyl)-8-fluoroquinoline-3-carboxamide, 1 -(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-d iforo-3,3-dimethyl-1-( 7-methylpyrazolo[1,5-a]pyridin-3yl)isoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline and 1-(4,5dimethylbenzimidazole -1-yl)-4,4-difluoro-3,3-dimethylisoquinoline, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably from 5:1 to 1 :5).

In a preferred composition according to the present invention, component (A) is Compound No. X.21, 2-[cyano-(5-fluoro-3-pyridyl)amino]-N-isopentyl-5-methylthiazol-4carboxamide, or a salt thereof , enantiomer, tautomer or N-oxide, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxade, fluopyram, isopyrase ma, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapyr, fenpicoxamide, florylpicoxamide, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifene, folpet, ipflufenoquin, quinofumelin, tricyclazole, pyroquilone, N- (1-benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3 trifluoro-1-methylpropyl)-8-fluoroquinoline-3-carboxamide, 1 -( 6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl-1-(7-methylpyrazolo [1,5-a]pyridin-3yl)isoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline and 1-(4,5dimethylbenzimidazol-1- yl)-4,4-difluoro-3,3-dimethylisoquinoline, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably from 5:1 to 1:5) .

In another preferred composition according to the present invention, component (A) is Compound No. X.22, No. [[3,5-bis(trifluoromethyl)phenyl]methyl]-2-[cyano-(2,6-difluoro4-pyridyl )amino]-5-methylthiazol-4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole , prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxad, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florylpicoxamide, chlorothalonil, mancozeb, man dipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M , aminopyrifene, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, N-(1-benzyl-1,3-dimethylbutyl)-8fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro-1-methylpropyl )-8-fluoroquinoline-3-carboxamide, 1-(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4- difluoro-3,3dimethyl-1-(7-methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4,5trifluoro-3,3 -dimethylisoquinoline and 1 -(4,5-dimethylbenzimidazol-1-yl)-4,4-difluoro-3,3-dimethylisoquinoline, where the weight ratio of component (A) and component (B) is from 10:1 to 1:10 (or even more preferably 5:1 to 1:5).

In another preferred composition according to the present invention, component (A)

- 55 046368 is compound No. X.23, N-benzyl-2-[cyano-(2,6-di(|)tor-4-pyridyl)amino|-5methylthiazol-4-carboxamide, or its salt, enantiomer, tautomer or N-oxide, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, di(enoconazole, hexaconazole, propiconazole, prothioconazole, me(entri(luconazole, fenpropidine, fenpropimorph, fluxapyroxad, fluopyram , isopyrazam, sedaxane, benzovindiflupir, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florylpicoxamide, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrif ena, folpeta, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone , N-(1-benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro-1-methylpropyl)-8-fluoroquinoline-3-carboxamide, 1- (6,7-dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl-1 -(7 methylpyrazolo[ 1,5-a]pyridin-3-yl)isoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3,3dimethylisoquinoline and 1-(4,5-dimethylbenzimidazol-1 -yl)-4,4-difluoro-3,3-dimethylisoquinoline, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably from 5:1 to 1:5 ).

In another preferred composition according to the present invention, component (A) is Compound No. X.24, No. [[3,5-bis(trifluoromethyl)phenyl]methyl]-2-[cyano-(2,6-difluoro4-pyridyl )amino]-5-methylthiazol-4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole , prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxad, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florylpicoxamide, chlorothalonil, mancozeb, man dipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M , aminopyrifene, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, N-(1-benzyl-1,3-dimethylbutyl)-8fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro-1-methylpropyl ) -8-fluoroquinoline-3-carboxamide, 1 -(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4- difluoro3,3-dimethyl-1 -(7-methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline, 1 -(4,5-dimethylbenzimidazol-1 -yl)4,4,5-trifluoro-3, 3-dimethylisoquinoline and 1-(4,5-dimethylbenzimidazol-1-yl)-4,4-difluoro-3,3-dimethylisoquinoline, where the weight ratio of component (A) to component (B) is from 10:1 to 1: 10 (or even more preferably 5:1 to 1:5).

In a preferred composition according to the present invention, component (A) is Compound No. X.05, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-H-(2,2-dimethylcyclobutyl)5 -methylthiazole-4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxad, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florilpicoxamide, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifene, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, N-(1-benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro-1-methylpropyl)-8-fluoroquinoline -3-carboxamide, 1-(6,7-dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl -1 -(7 methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3,3dimethylisoquinoline, 1 -( 4,5-dimethylbenzimidazol-1-yl)-4,4-difluoro-3,3-dimethylisoquinoline, N'-[5bromo-2-methyl-6-(1-methyl-2-propoxyethoxy)-3-pyridyl]- H-ethyl-N-methylformamidine, H-isopropyl-H'[5-methoxy-2-methyl-4-(2,2,2-trifluoro-1-hydroxy-1-phenylethyl)phenyl]-N-methylformamidine, TAEGRO ®, Timorex GoldTM, acibenzolar^-methyl, cyflufenamide, metrafenone, fosetyl-aluminum, methylpicoxamide, methyl-(2)-3-methoxy-2-[2-methyl-5-[3 -(trifluoromethyl)pyrazol-1 -yl ]phenoxy]prop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-(3-propylpyrazol-1-yl)phenoxy]prop-2-enoate, methyl-(2) -2-(5-cyclohexyl-2-methylphenoxy)-3-methoxyprop-2-enoate, methyl-(2)-2-(5-cyclopentyl-2-methylphenoxy)-3-methoxyprop-2-enoate, methyl-( 2)-2-[5-(3-isopropylpyrazol-1-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5- (4-propyltriazol-2-yl)phenoxy]prop-2-enoate, methyl-(2)-3-methoxy2-[2-methyl-5-[4-(trifluoromethyl)triazol-2-yl]phenoxy]prop- 2-enoate, N-methoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropanecarboxamide, N,2-dimethoxy-N-[[4 -[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, N-ethyl-2-methyl-N-[[4-[5-(trifluoromethyl)1,2, 4-oxadiazol-3-yl]phenyl]methyl]propanamide, 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]phenyl]methyl]urea , 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]urea, 3-ethyl-1-methoxy-1-[[4- [5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea and ethyl 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3- yl]phenyl]methyl]pyrazole-4-carboxylate, wherein the weight ratio of component (A) to component (B) is from 15:1 to 1:30, where preferably the weight ratio of component (A) to component (B) is from 10 :1 to 1:10 or even

- 56 046368 more preferably from 5:1 to 1:5.

In another preferred composition according to the present invention, component (A) is Compound No. X.07, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-5-methyl-Nspiro[3.4]octane -3-yl-thiazol-4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxad, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florylpicoxamide, chlorothalonil, mancozeb, mandipro pamida, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifene, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, N-(1-benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3carboxamide, N-(1-benzyl-3,3,3-trifluoro-1-methylpropyl) -8-fluoroquinoline-3-carboxamide, 1-(6,7dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3 ,3-dimethyl1-(7-methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro3,3-dimethylisoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4-difluoro-3,3-dimethylisoquinoline, N'-[5bromo-2-methyl-6-(1-methyl-2-propoxyethoxy)-3- pyridyl]-N-ethyl-N-methylformamidine, N-isopropyl-N[5-methoxy-2-methyl-4-(2,2,2-trifluoro-1-hydroxy-1-phenylethyl)phenyl]-N-methylformamidine, TAEGRO®, Timorex GoldTM, acibenzolar^-methyl, cyflufenamide, metrafenone, fosetyl-aluminum, methylpicoxamide, methyl-(2)-3-methoxy-2-[2-methyl-5-[3-(trifluoromethyl)pyrazol-1- yl]phenoxy]prop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-(3-propylpyrazol-1-yl)phenoxy]prop-2-enoate, methyl-(2 )-2-(5cyclohexyl-2-methylphenoxy)-3-methoxyprop-2-enoate, methyl-(2)-2-(5-cyclopentyl-2-methylphenoxy)-3methoxyprop-2-enoate, methyl-(2)- 2-[5-(3-isopropylpyrazol-1-yl)-2-methylphenoxy]-3-methoxyprop-2enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-(4-propyltriazol- 2-yl)phenoxy]prop-2-enoate, methyl (2)-3methoxy-2-[2-methyl-5-[4-(trifluoromethyl)triazol-2-yl]phenoxy]prop-2-enoate, No. methoxy-N[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropanecarboxamide, K2-dimethoxy^-||4-|5(trifluoromethyl)-1,2, 4-oxadiazol-3-yl]phenyl]methyl]propanamide, Nethyl-2-methyl-N[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, 1-methoxy-3-methyl-1-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4- [5-(trifluoromethyl)1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4oxadiazole -3-yl]phenyl]methyl]urea and ethyl 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrazole-4-carboxylate, where wt. the ratio of component (A) to component (B) is from 15:1 to 1:30, where preferably the weight ratio of component (A) to component (B) is from 10:1 to 1:10, or even more preferably from 5:1 up to 1:5.

In a further preferred composition according to the present invention, component (A) is Compound No. X.14, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-N-hexyl-5methylthiazol-4-carboxamide , or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mephentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxade, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florylpicoxamide, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifene, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, N-(1-benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro-1-methylpropyl)-8-fluoroquinoline-3-carboxamide, 1 -(6,7-dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl-1 -(7 methylpyrazolo [1,5-a]pyridin-3-yl)isoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3,3dimethylisoquinoline, 1 -(4,5-dimethylbenzimidazol- 1 -yl)-4,4-difluoro-3,3-dimethylisoquinoline, N'-[5bromo-2-methyl-6-(1-methyl-2-propoxyethoxy)-3-pyridyl]-H-ethyl-N- methylformamidine, H-isopropyl-H'[5-methoxy-2-methyl-4-(2,2,2-trifluoro-1-hydroxy-1-phenylethyl)phenyl]-N-methylformamidine, TAEGRO®, Timorex GoldTM, acibenzolar ^-methyl, cyflufenamide, metrafenone, fosetyl-aluminum, methylpicoxamide, methyl-(2)-3-methoxy-2-[2-methyl-5-[3-(trifluoromethyl)pyrazol-1-yl]phenoxy]prop-2 -enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-(3-propylpyrazol-1-yl)phenoxy]prop-2-enoate, methyl-(2)-2-(5cyclohexyl- 2-methylphenoxy)-3-methoxyprop-2-enoate, methyl-(2)-2-(5-cyclopentyl-2-methylphenoxy)-3methoxyprop-2-enoate, methyl-(2)-2-[5-(3 -isopropylpyrazol-1-yl)-2-methylphenoxy]-3-methoxyprop-2enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-(4-propyltriazol-2-yl)phenoxy]prop -2-enoate, methyl-(2)-3methoxy-2-[2-methyl-5-[4-(trifluoromethyl)triazol-2-yl]phenoxy]prop-2-enoate, N-methoxy-N-[[ 4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropanecarboxamide, N,2-dimethoxy-N-[[4-[5(trifluoromethyl)-1,2,4- oxadiazol-3-yl]phenyl]methyl]propanamide, N-ethyl-2-methyl-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide , 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4 -[5-(trifluoromethyl)-1,2,4-oxadiazol3-yl]phenyl]methyl]urea, 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4 -oxadiazol-3-yl]phenyl]me

- 57 046368 til]urea and ethyl 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrazole-4-carboxylate, where the weight ratio of the component (A ) and component (B) is from 15:1 to 1:30, where preferably the weight ratio of component (A) to component (B) is from 10:1 to 1:10 or even more preferably from 5:1 to 1:5 .

The term fungicide as used herein means a compound that controls, modifies or prevents the growth of fungi. The term fungicidal effective amount means an amount of such a compound or combination of such compounds that is capable of providing an effect on the growth of fungi. Controlling or modifying effects include all deviations from natural development, such as destruction, inhibition of development, etc., and prevention involves a barrier or other protective formation in or on the plant to prevent fungal infection.

The term plant refers to all the physical parts of a plant, including seeds, seedlings, saplings, roots, tubers, stems, petioles, leaves and fruits.

The term plant propagation material refers to all the generative parts of a plant, such as seeds or vegetative parts of plants such as cuttings and tubers. It includes seeds in the narrow sense, as well as roots, fruits, tubers, bulbs, rhizomes and plant parts.

The term growing site as used herein means the fields in which or in which plants are grown, or where the seeds of cultivated plants are sown, or where the seeds will be placed in the soil. It provides soil, seeds and seedlings, as well as already grown vegetation.

Throughout this document, the expression composition means various mixtures or combinations of components (A) and (B) (including embodiments as defined above), for example, in a separate form of a ready-mix, in a combination spray mixture made up of individual compositions from separately the components of the active ingredients, such as a tank mixture, and in the combined use of the individual active ingredients in the case of application in a sequential manner, i.e. one after another in a fairly short period of time, such as a few hours or days. The order in which components (A) and (B) are used is not critical to the implementation of the present invention.

The composition according to the present invention is effective against harmful microorganisms, such as microorganisms that cause phytopathogenic diseases, in particular against phytopathogenic fungi and bacteria.

The composition of the present invention can be used to control plant diseases caused by a wide range of fungal plant pathogens in the classes Basidiomycete, Ascomycete, Oomycete and/or Deuteromycete, Blasocladiomycete, Chrytidiomycete, Glomeromycete and/or Mucoromycete.

The composition is effective for controlling a wide range of plant diseases, such as those caused by pathogens affecting the leaves of ornamental, lawn, vegetable, field, grain and fruit crops.

Such pathogens may include oomycetes, including diseases caused by Phytophthora, such as those caused by Phytophthora capsici, Phytophthora infestans, Phytophthora sojae, Phytophthora fragariae, Phytophthora nicotianae, Phytophthora cinnamomi, Phytophthora citricola, Phytophthora citrophthora and Ph ytophthora erythroseptica; diseases caused by Pythium, such as those caused by Pythium aphanidermatum, Pythium arrhenomanes, Pythium graminicola, Pythium irregulare and Pythium ultimum diseases caused by Peronosporales, such as those caused by Peronospora destructor, Peronospora parasitica, Plasmopara viticola, Plasmopara halstedii, Pseudoperonos pora cubensis, Albugo Candida, Sclerophthora macrospora and Bremia lactucae; and others such as those caused by Aphanomyces cochlioides, Labyrinthula zosterae, Peronosclerospora sorghi and Sclerospora graminicola;

ascomycetes, including those causing blotch, blotch, blast or scorch and/or rot varieties, for example those caused by Pleosporales such as Stemphylium solani, Stagonospora tainanensis, Spilocaea oleaginea, Setosphaeria turcica, Pyrenochaeta lycoperisici, Pleospora herbarum, Phoma destructiva, Phae osphaeria herpotrichoides , Phaeocryptocus gaeumannii, Ophiosphaerella graminicola, Ophiobolus graminis, Leptosphaeria maculans, Hendersonia creberrima, Helminthosporium triticirepentis, Setosphaeria turcica, Drechslera glycines, Didymella bryoniae, Cycloconium oleagineum, Corynespora cassiicola, Cochliobolus sativus, Bipolari s cactivora, Venturia inaequalis, Pyrenophora teres, Pyrenophora tritici-repentis , Alternaria alternata, Alternaria brassicicola, Alternaria solani and Alternaria tomatophila, Capnodiales such as Septoria tritici, Septoria nodorum, Septoria glycines, Cercospora arachidicola, Cercospora sojina, Cercospora zeaemaydis, Cercosporella capsellae and Cercosporella herpotrichoides, Cladosporium carpophilum , Cladosporium effusum, Passalora fulva, Cladosporium oxysporum, Dothistroma septosporum, Isariopsis clavispora, Mycosphaerella fijiensis, Mycosphaerella graminicola, Mycovellosiella koepkeii, Phaeoisariopsis bataticola, Pseudocercospora vitis, Pseudocercosporella herpotrichoides, Ramularia beticola, Ramularia collo-cygni, Magna porthales, such as Gaeumannomyces graminis, Magnaporthe grisea, Pyricularia oryzae, Diaporthales, such as Anisogramma anomala, Apiognomonia errabunda, Cytospora platani, Diaporthe phaseolorum, Dis

- 58 046368 cula destructiva, Gnomonia fructicola, Greeneria uvicola, Melanconium juglandinum, Phomopsis viticola, Sirococcus clavigignenti-juglandacearum, Tubakia dryina, Dicarpella spp., Valsa ceratosperma, and others, such as Actinothyrium graminis, Ascochyta pisi, Aspergillus flavus, Aspergillus fumigatus, Aspergillus nidulans, Asperisporium caricae, Blumeriella jaapii, Candida spp., Capnodium ramosum, Cephaloascus spp., Cephalosporium gramineum, Ceratocystis paradoxa, Chaetomium spp., Hymenoscyphus pseudoalbidus, Coccidioides spp., Cylindrosporium padi, Diplocarpon malae, Drepanopeziza campestris , Elsinoe ampelina, Epicoccum nigrum, Epidermophyton spp., Eutypa lata, Geotrichum candidum, Gibellina cerealis, Gloeocercospora sorghi, Gloeodes pomigena, Gloeosporium perennans; Gloeotinia temulenta, Griphospaeria corticola, Kabatiella lini, Leptographium microsporum, Leptosphaerulinia crassiasca, Lophodermium seditiosum, Marssonina graminicola, Microdochium nivale, Monilinia fructicola, Monographella albescens, Monosporascus cannonballus, Naemacyclus spp., Ophiostoma novo- ulmi, Paracoccidioides brasiliensis, Penicillium expansum, Pestalotia rhododendri , Petriellidium spp., Pezicula spp., Phialophora gregata, Phyllachora pomigena, Phymatotrichum omnivora, Physalospora abdita, Plectosporium tabacinum, Polyscytalum pustulans, Pseudopeziza medicaginis, Pyrenopeziza brassicae, Ramulispora sorghi, Rhabdocline pseudotsugae , Rhynchosporium secalis, Sacrocladium oryzae, Scedosporium spp., Schizothyrium pomi, Sclerotinia sclerotiorum, Sclerotinia minor, Sclerotium spp., Typhula ishikariensis, Seimatosporium mariae, Lepteutypa cupressi, Septocyta ruborum, Sphaceloma perseae, Sporonema phacidioides, Stigmina palmivora, Tapesia yallundae, Taphrina bullata, Thielviopsis basicola, Trichoseptoria fructigena , Zygophiala jamaicensis; leading to powdery mildew varieties such as diseases caused by Erysiphales such as Blumeria graminis, Erysiphe polygoni, Uncinula necator, Sphaerotheca fuligena, Podosphaera leucotricha, Podospaera macularis Golovinomyces cichoracearum, Leveillula taurica, Microsphaera diffusa, Oidiopsis gossypii, Phyllac tinia guttata and Oidium amchidis; leading to mold species such as those caused by Botryosphaeriales such as Dothiorella aromatica, Diplodia seriata, Guignardia bidwellii, Botrytis cinerea, Botryotinia allii, Botryotinia fabae, Fusicoccum amygdali, Lasiodiplodia theobromae, Macrophoma theicola, Macrophomina phaseolina, Phyllosticta cucurbitacear um; anthracnoses for example caused by Glommerelales such as Colletotrichum gloeosporioides, Colletotrichum lagenarium, Colletotrichum gossypii, Glomerella cingulata, and Colletotrichum graminicola; and leading to varieties of wilt or scorch, such as those caused by Hypocreales such as Acremonium strictum, Claviceps purpurea, Fusarium culmorum, Fusarium graminearum, Fusarium virguliforme, Fusarium oxysporum, Fusarium subglutinans, Fusarium oxysporum f.sp. cubense, Gerlachia nivale, Gibberella fujikuroi, Gibberella zeae, Gliocladium spp., Myrothecium verrucaria, Nectria ramulariae, Trichoderma viride, Trichothecium roseum, and Verticillium theobromae;

Basidiomycetes, including those leading to smut varieties, for example, caused by Ustilaginales, such as Ustilaginoidea virens, Ustilago nuda, Ustilago tritici, Ustilago zeae, leading to rust varieties, for example, caused by Pucciniales, such as Cerotelium fici, Chrysomyxa arctostaphyli, Coleosporium ipomoeae, Hemileia vastatrix, Puccinia arachidis, Puccinia cacabata, Puccinia graminis, Puccinia recondita, Puccinia sorghi, Puccinia hordei, Puccinia striiformis f.sp. Hordei, Puccinia striiformis f.sp. Secalis, Pucciniastrum coryli, or Uredinales, such as Cronartium ribicola, Gymnosporangium juniperi-viginianae, Melampsora medusae, Phakopsora pachyrhizi, Phragmidium mucronatum, Physopella ampelosidis, Tranzschelia discolor and Uromyces viciae-fabae; and leading to other types of rot and diseases, such as those caused by Cryptococcus spp., Exobasidium vexans, Marasmiellus inoderma, Mycena spp., Sphacelotheca reiliana, Typhula ishikariensis, Urocystis agropyri, Itersonilia perplexans, Corticium invisum, Laetisaria fuciformis, Waitea circinata, Rhizoctonia solani, Thanetephorus cucurmeris, Entyloma dahliae, Entylomella microspora, Neovossia moliniae and Tilletia caries;

blastocladiomycetes such as Physoderma maydis;

mucoromycetes such as Choanephora cucurbitarum; Mucor spp.; Rhizopus arrhizus;

as well as diseases caused by other species and genera that are closely related to those listed above.

In addition to their fungicidal activity, the compositions may also be characterized by activity against bacteria such as Erwinia amylovora, Erwinia caratovora, Xanthomonas campestris, Pseudomonas syringae, Strptomyces scabies and other related species, as well as certain protozoa.

The composition according to the present invention is particularly effective against phytopathogenic fungi belonging to the following classes: ascomycetes (eg Venturia, Podosphaera, Erysiphe, Monilinia, Mycosphaerella, Uncinula); basidiomycetes (for example, the genus Hemileia, Rhizoctonia, Phakopsora, Puccinia, Ustilago, Tilletia); imperfect fungi (also known as deuteromycetes; e.g. Botrytis, Helminthosporium, Rhynchosporium, Fusarium, Septoria, Cercospora, Alternaria, Pyricularia and Pseudocercosporella); oomycetes (e.g. Phytophthora, Peronospora, Pseudoperonospora, Albugo, Bremia, Pythium, Pseudosclerospora, Plasmopara).

Beneficial plant crops to which the composition of the present invention can be used include perennial and annual crops such as berry plants, for example, varieties of blackberries, blueberries, cranberries, raspberries and strawberries; grains, e.g. barley, maize (corn), millet, oats, rice, rye, sorghum, triticale

- 59 046368 and wheat; fibrous plants such as cotton, flax, hemp, jute and sisal; field crops, such as sugar and fodder beets, coffee, hops, mustard, oilseed rape (canola), poppy, sugar cane, sunflower, tea bush and tobacco; fruit trees such as apple, apricot, avocado, banana, cherry, citrus, nectarine, peach, pear and plum; herbaceous plants, such as Bermuda grass, bluegrass, bentgrass, Eremochloa serpentine, fescue, ryegrass, Augustine grass and Japanese zoysia; herbs such as basil, borage, chives, coriander, lavender, lovage, mint, oregano, parsley, rosemary, sage and thyme; legumes, such as beans, lentils, peas and soybeans; nuts such as almonds, cashews, groundnuts, hazelnuts, peanuts, pecans, pistachios and walnuts; palm trees, such as oil palm; ornamental plants such as flowers, shrubs and trees; other trees such as cocoa tree, coconut tree, olive tree and rubber tree; vegetable crops, e.g. asparagus, eggplant, broccoli, cabbage, carrots, cucumber, garlic, lettuce, zucchini, melon, okra, onions, peppers, potatoes, pumpkin, rhubarb, spinach and tomato, and tree vines, e.g. grape.

It should be understood that crops also include those crops that occur naturally, are produced by conventional breeding methods, or are produced through genetic engineering. They involve crops that are characterized by so-called introduced traits (for example, improved shelf life, higher nutritional value and improved flavor).

Crop crops also include those crops that have been made tolerant of herbicides such as bromoxynil or classes of herbicides such as ALS, EPSPS, GS, HPPD and PPO inhibitors. An example of a crop that has been engineered to tolerate imidazolinones, such as imazamox, through conventional breeding techniques is Clearfield® spring canola. Examples of crops that have been genetically engineered to tolerate herbicides include, for example, glyphosate- and glufosinate-resistant maize varieties commercially available under the trade names RoundupReady®, Herculex I®, and LibertyLink®.

Crops should also be understood as crops that are inherently resistant, or crops that have been given resistance to insect pests. They involve plants transformed using recombinant DNA technologies, for example, so that they are capable of synthesizing one or more selective toxins, such as those known, for example, from toxin-producing bacteria. Examples of toxins that may be expressed include 5-endotoxins, vegetative insecticidal proteins (Vip), insecticidal proteins of bacteria colonizing nematodes, and toxins produced by scorpions, arachnids, wasps and fungi.

An example of a crop that has been modified to express a Bacillus thuringiensis toxin is KnockOut® Bt maize (Syngenta Seeds). An example of a crop that contains more than one gene that confers insect resistance and thus expresses more than one toxin is VipCot® (Syngenta Seeds). Crops or their seeds can also be resistant to several types of pests (so-called gene-stacked transgenics if produced through genetic modification). For example, a plant may be characterized by the ability to express an insecticidal protein while also being tolerant of herbicides, such as Herculex I® (Dow AgroSciences, Pioneer Hi-Bred International).

The term beneficial plants should be understood to also include beneficial plants that have been transformed through the use of recombinant DNA techniques such that they are capable of synthesizing one or more selective toxins such as those known, for example, from toxin-producing bacteria, e.g. genus Bacillus.

Examples of such plants are YieldGard® (a maize variety expressing the CryIA(b) toxin); YieldGard Rootworm ® (maize variety expressing CryIIIB(b1) toxin); YieldGard Plus® (maize variety expressing CryIA(b) toxin and CryIIIB(b1) toxin); Starlink® (a maize variety expressing the Cry9(c) toxin); Herculex I® (a maize variety expressing the CryIF(a2) toxin and the enzyme phosphinothricin-Nacetyltransferase (PAT) to provide tolerance to the herbicide glufosinate ammonium); NuCOTN 33B® (cotton variety expressing CryIA(c) toxin); Bollgard I® (cotton variety expressing CryIA(c) toxin); Bollgard II® (cotton variety expressing CryIA(c) toxin and CryIIA(b) toxin); VIPCOT® (cotton variety expressing VIP toxin); NewLeaf ® (a potato variety expressing the CryIIIA toxin); NatureGard® Agrisure® GT Advantage (GA21 with glyphosate tolerance trait), Agrisure® CB Advantage (Bt11 with corn borer (CB) trait), Agrisure® RW (with Western corn rootworm resistance trait) and Protecta®.

The term crops should be understood to also include crops

- 60 046368 plants that have been transformed by the use of recombinant DNA techniques in such a way that they are capable of synthesizing one or more selective toxins, such as those known, for example, from toxin-producing bacteria, in particular bacteria of the genus Bacillus.

Toxins that may be expressed by such transgenic plants include, for example, insecticidal proteins from Bacillus cereus or Bacillus popilliae; or insecticidal proteins from Bacillus thuringiensis, such as δ-endotoxins, for example Cry1Ab, Cry1Ac, Cry1F, Cry1Fa2, Cry2Ab, Cry3A. Cry3Bb1 or Cry9C, or vegetative insecticidal proteins (Vips), for example Vipl, Vip2, Vip3 or Vip3A; or insecticidal proteins from bacteria colonizing nematodes, such as Photorhabdus spp. or Xenorhabdus spp., such as Photorhabdus luminescens, Xenorhabdus nematophilus; toxins produced by animals such as scorpion toxins, arachnid toxins, wasp toxins and other insect-specific neurotoxins; toxins produced by fungi such as Streptomycetes toxins, plant lectins such as pea lectins, barley lectins or snowdrop lectins; agglutinins; proteinase inhibitors such as trypsin inhibitors, serine protease inhibitors, patatin inhibitors, cystatin inhibitors, papain inhibitors; ribosome inactivating proteins (RIPs), such as ricin, maize RIP, abrin, luffin, saporin or bryodin; Steroid metabolic enzymes such as 3hydroxysteroid oxidase, ecdysteroid UDP glycosyltransferase, cholesterol oxidases, ecdysone inhibitors, HMG-COA reductase, ion channel blockers such as sodium or calcium channel blockers, juvenile hormone esterase, diuretic hormone receptors, stilbene synthase , dibenzyl synthase, chitinases and glucanases.

In the context of the present invention, δ-endotoxins, for example CrylAb, CrylAc, CrylF, Cry1Fa2, Cry2Ab, Cry3A, Cry3Bb1 or Cry9C, or vegetative insecticidal proteins (Vip), for example Vipl, Vip2, Vip3 or Vip3A, should also be understood explicitly as hybrid toxins , truncated toxins and modified toxins. Hybrid toxins are produced recombinantly by novel combinations of different domains of such proteins (see, for example, WO 02/15701). Truncated toxins are known, for example, truncated CrylAb. In the case of modified toxins, one or more amino acids of the naturally occurring toxin are replaced. With such amino acid substitutions, sequences recognized by proteases that are not present in the natural toxin are preferably introduced into the toxin, for example, in the case of Cry3A055, a sequence recognized by cathepsin G is introduced into the Cry3 toxin (see WO 03/018810).

Examples of such toxins or transgenic plants capable of synthesizing such toxins are disclosed, for example, in EP-A-0374753, WO 93/07278, WO 95/34656, EP-A-0427529, EP-A-451878 and WO 03/052073.

Methods for producing such transgenic plants are generally known to one skilled in the art and are described, for example, in the publications mentioned above. CryI-type deoxyribonucleic acids and their preparation are known, for example, from WO 95/34656, EP-A-0367474, EP-A-0401979 and WO 90/13651.

The toxin contained in transgenic plants gives the plants tolerance to harmful insects. Such insects can belong to any taxonomic group of insects, but are especially common among beetles (Coleoptera), dipterans (Diptera) and butterflies (Lepidoptera).

Transgenic plants containing one or more genes that encode insect resistance and express one or more toxins are known, and some of them are commercially available. Examples of such plants are YieldGard® (maize variety expressing the Cry1Ab toxin), YieldGard Rootworm® (maize variety expressing the Cry3Bb1 toxin), YieldGard Plus® (maize variety expressing the Cry1Ab toxin and Cry3Bb1), Starlink® (maize variety expressing the Cry9C toxin ), Herculex I® (a maize variety expressing the Cry1Fa2 toxin and the enzyme phosphinothricin N-acetyltransferase (PAT) with tolerance to the herbicide glufosinate ammonium), NuCOTN 33B® (a cotton variety expressing the Cry1Ac toxin), Bollgard I® (a cotton variety expressing the toxin Cry1Ac), Bollgard II® (cotton variety expressing Cry1Ac and Cry2Ab toxin), VipCot® (cotton variety expressing Vip3A and Cry1Ab toxin), NewLeaf® (potato variety expressing Cry3A toxin), NatureGard® Agrisure® GT Advantage (GA21 with glyphosate tolerance trait), Agrisure® CB Advantage (Bt11 with corn borer resistance trait) and Protecta®.

Additional examples of such transgenic crops are the following.

1. Maize Bt11 from Syngenta Seeds SAS, Chemin de l'Hobit 27, F-31 790 Saint-Sauveur, France, registration number C/FR/96/05/10. A genetically modified Zea mays that has been rendered resistant to corn borer (Ostrinia nubilalis and Sesamia nonagrioides) by transgenic expression of a truncated Cry1Ab toxin. Btll maize also transgenically expresses the PAT enzyme to provide tolerance to the herbicide glufosinate ammonium.

- 61 046368

2. Maize Bt176 from Syngenta Seeds SAS, Chemin de I'Hobit 27, F-31 790 Saint-Sauveur, France, registration number C/FR/96/05/10. Genetically modified Zea mays that has been rendered resistant to corn borer (Ostrinia nubilalis and Sesamia nonagrioides) through transgenic expression of the Cry1Ab toxin. Bt176 maize also transgenically expresses the PAT enzyme to provide tolerance to the herbicide glufosinate ammonium.

3. Maize MIR604 from Syngenta Seeds SaS, Chemin de l'Hobit 27, F-31 790 Saint-Sauveur, France, registration number C/FR/96/05/10. Maize that has been rendered insect resistant by transgenic expression of a modified Cry3A toxin. This toxin is Cry3A055 modified by insertion of a sequence recognized by the protease cathepsin G. The production of such transgenic maize plants is described in WO 03/018810.

4. Maize MON 863 from Monsanto Europe S.A. 270-272 Avenue de Tervuren, B-1150 Brussels, Belgium, registration number C/DE/02/9. MON 863 expresses the Cry3Bb1 toxin and is resistant to some insects of the order Coleoptera.

5. Cotton plant IPC 531 from Monsanto Europe S.A. 270-272 Avenue de Tervuren, B-1150 Brussels, Belgium, registration number C/ES/96/02.

6. Maize 1507 from Pioneer Overseas Corporation, Avenue Tedesco, 7 B-1160 Brussels, Belgium, registration number C/NL/00/10. Maize genetically modified to express the Cry1F protein to provide resistance to certain Lepidoptera insects and the PAT protein to provide tolerance to the herbicide glufosinate ammonium.

7. Maize NK603 x MON 810 from Monsanto Europe S.A. 270-272 Avenue de Tervuren, B-1150 Brussels, Belgium, registration number C/GB/02/M3/03. Consists of hybrid maize varieties obtained through traditional breeding by crossing the genetically modified varieties NK603 and MON 810. Maize NK603 x MON 810 transgenically expresses the CP4 EPSPS protein, derived from Agrobacterium sp., strain CP4, which confers tolerance to the herbicide Roundup® (contains glyphosate) , as well as the Cry1Ab toxin derived from Bacillus thuringiensis subsp. kurstaki, which provides tolerance to certain members of the order Lepidoptera, including the corn borer.

In addition, to date, no cross-resistance has been observed between a composition containing a mixture of components (A) and (B) and any fungicidal solutions used to provide control of phytopathogenic fungi such as Absidia corymbifera, Alternaria spp, Aphanomyces spp, Ascochyta spp, Aspergillus spp. including A. flavus, A. fumigatus, A. nidulans, A. niger, A. terrus, Aureobasidium spp. including A. pullulans, Blastomyces dermatitidis, Blumeria graminis, Bremia lactucae, Botryosphaeria spp. including B. dothidea, B. obtusa, Botrytis spp. including B. cinerea, Candida spp. including C. albicans, C. glabrata, C. krusei, C. lusitaniae, C. parapsilosis, C. tropicalis, Cephaloascus fragrans, Ceratocystis spp, Cercospora spp. including C. arachidicola, Cercosporidium personatum, Cladosporium spp, Claviceps purpurea, Coccidioides immitis, Cochliobolus spp, Colletotrichum spp. including C. musae, Cryptococcus neoformans, Diaporthe spp, Didymella spp, Drechslera spp, Elsinoe spp, Epidermophyton spp, Erwinia amylovora, Erysiphe spp. including E. cichoracearum, Eutypa lata, Fusarium spp. including F. culmorum, F. graminearum, F. langsethiae, F. moniliforme, F. oxysporum, F. proliferatum, F. subglutinans, F. solani, Gaeumannomyces graminis, Gibberella fujikuroi, Gloeodes pomigena, Gloeosporium musarum, Glomerella cingulate, Guignardia bidwellii, Gymnosporangium juniperi-virginianae, Helminthosporium spp, Hemileia spp, Histoplasma spp. including H. capsulatum, Laetisaria fuciformis, Leptographium lindbergi, Leveillula taurica, Lophodermium seditiosum, Microdochium nivale, Microsporum spp, Monilinia spp, Mucor spp, Mycosphaerella spp. including M. graminicola, M. pomi, Oncobasidium theobromaeon, Ophiostoma piceae, Paracoccidioides spp, Penicillium spp. including P. digitatum, P. italicum, Petriellidium spp, Peronosclerospora spp. including P. maydis, P. philippinensis and P. sorghi, Peronospora spp, Phaeosphaeria nodorum, Phakopsora pachyrhizi, Phellinus igniarus, Phialophora spp, Phoma spp, Phomopsis viticola, Phytophthora spp. including P. infestans, Plasmopara spp. including P. halstedii, P. viticola, Pleospora spp., Podosphaera spp. including P. leucotricha, Polymyxa graminis, Polymyxa betae, Pseudocercosporella herpotrichoides, Pseudomonas spp, Pseudoperonospora spp. including P. cubensis, P. humuli, Pseudopeziza tracheiphila, Puccinia Spp. including P. hordei, P. recondita, P. striiformis, P. triticina, Pyrenopeziza spp, Pyrenophora spp, Pyricularia spp. including P. oryzae, Pythium spp. including P. ultimum, Ramularia spp, Rhizoctonia spp, Rhizomucor pusillus, Rhizopus arrhizus, Rhynchosporium spp, Scedosporium spp. including S. apiospermum and S. prolificans, Schizothyrium pomi, Sclerotinia spp, Sclerotium spp, Septoria spp, including S. nodorum, S. tritici, Sphaerotheca macularis, Sphaerotheca fusca (Sphaerotheca fuliginea), Sporothorix spp, Stagonospora nodorum, Stemphylium spp., Stereum hirsutum, Thanatephorus cucumeris, Thielaviopsis basicola, Tilletia spp, Trichoderma spp., including T. harzianum, T. pseudokoningii, T. viride, Trichophyton spp, Typhula spp, Uncinula necator, Urocystis spp, Ustilago spp, Venturia spp. including V. inaequalis, Verticillium spp, and Xanthomonas spp., in particular, Zymoseptoria tritici, Puccinia recondita, Puccinia striiformis, Erysiphe graminis, Uncinula necator, Sphaerotheca fuliginea, Leveillula taurica, Phakopsora pachyrhizi, Pyricularia oryzae, Alternaria solani, Alternaria alterna ta , Mycosphaerella fijiensis, Colletotrichum lagenarium, Didymella bryoniae, Ascochyta pisii, Verticillium dahliae, Pyrenophora teres, Cercospora beticola, Ramularia collo-cygni, Botrytis cinerea, Sclerotinia

- 62 046368 sclerotiorum, Monilinia laxa, Monographaella nivalis and Venturia inaequalis.

Indeed, fungicide-resistant strains have been reported in the scientific literature in any of the species listed above, with the strains being resistant to one or more fungicides from at least one of the following classes of fungicides by mechanism of action: External quinone-binding site inhibitors (QoI) , internal quinone-binding site inhibitors (QiI), succinate dehydrogenase inhibitors (SDHI) and sterol demethylation inhibitors (DMI). Such fungicide-resistant strains may contain the following.

A mutation in the mitochondrial cytochrome b gene that confers resistance to Qo inhibitors, where the mutation is G143A, F129L, or G137R. See for example: Gisi et al., Pest Manag Sci 56, 833-841 (2000), Lucas, Pestic Outlook 14(6), 268-70 (2003), Fraaije et al., Phytopathol 95(8), 933- 41 (2005), Sierotzki et al., Pest Manag Sci 63(3), 225-233 (2007), Semar et al., Journal of Plant Diseases and Protection (3), 117-119 (2007); and Pasche et al., Crop Protection 27(3-5), 427-435 (2008).

A mutation in the mitochondrial cytochrome b gene conferring resistance to Qi inhibitors, where the mutation is G37A/C/D/S/V. See for example: Meunier et al., Pest Manag Sci 2019; 75: 21072114.

A mutation in the genes encoding the subunits SdhB, C, D, conferring resistance to SDHI inhibitors, and the mutation is present in the following major pathogens:

Botrytis cinerea: B-P225H/L/T/Y/F, B-N230I, B-H272L/Y/R, C-P80H/L, C-N87S;

Alternaria solani: B-H278R/Y, C-H134R/Q, D-D123E, D-H133R and C-H134R;

Zymoseptoria tritici: sdhB: N225T, N225I, R265P, T268I, T268A. In sdhC: T79N, T79I, W80S, W80A, A84F, N86S, N86A, P127A, R151M/S/T/G, R151S, R151T, H152R/Y, V166M, T168R. In sdhD: I50F, M114V, D129G, T20P+K186R;

Pyrenophora teres: B sdhB: S66P, N235I, H277Y. In sdhC: K49E, R64K, N75S, G79R, H134R, S135R. In sdhD: D124E, H134R, G138V, D145G;

Ramularia collo-cygni: In sdhB: N224T, T267I. In sdhC: N87S, G91R, H146R/L, G171D, H153R;

Phakopsora pachyrhizi: C-I86F; Sclerotinia sclerotiorum: B sdhB: H273Y. In sdhC: G91R, H146R. In sdhD: T108K, H132R, G150R.

The main source of information is www.frac.info, Sierotzki and Scalliet Phytopathology (2013) 103(9): 880-887 and Simoes et al., J Plant Dis Prot (2018) 125: 21-2.

A mutation or combination of mutations in the CYP51 gene conferring resistance to DMI inhibitors, where the mutations are: L50S, D134G, V136A/C, Y137F, S188N, A379G, I381V, deletion 459-460, Y461H/S, N513K, S524T. The main source of information is www.frac.info, Cools et al., Plant Pathol (2013) 62: 36-42 and Schmitz HK et al., Pest Manag Sci (2014) 70: 378-388.

Thus, in a preferred embodiment, compositions according to the present invention containing a mixture of components (A) and (B) are used to provide control of fungal strains that are resistant to one or more fungicides from any of the following MoA fungicide classes: inhibitors external quinone-binding site inhibitors (QoI), internal quinone-binding site inhibitors (QiI), succinate dehydrogenase inhibitors (SDHI) and sterol demethylation inhibitors (DMI).

The compounds of the present invention can be prepared as shown in the following diagrams, in which, unless otherwise indicated, the definition of each variable is as defined above for the compound of formula (I).

The compounds of formula (I) of the present invention, where R ¹ , R ² , X and Y are as defined for formula (I), can be prepared by converting the compound of formula (II), where R ¹ , R ² , X and Y are as defined for formula (I), using a compound of formula (III) wherein R ¹¹ is a halogen, preferably bromine, either by thermal heating or by a base, preferably sodium hydride or lithium base. This is shown in Diagram 1 below.

Scheme 1

Compounds of formula (II) wherein R ¹ , R ² , X and Y are as defined for formula (I) can be prepared by converting a compound of formula (IV) wherein X and Y are as defined for formula (I ), using a compound of formula (V), wherein R ¹ and R ² are as defined for formula (I), and R ¹² is a halogen, preferably bromine, either by thermal heating or by a base or under conditions catalyzed by a transition

- 63 046368 amination metal according to Buchwald-Hartwig. This is shown in Diagram 2 below.

Scheme 2

Compounds of formula (V) wherein R ¹ and R ² are as defined for formula (I) and R ¹² is halogen, preferably bromine, can be prepared by converting a compound of formula (VI) wherein R ¹ is as is defined for formula (I), and R ¹² is a halogen, preferably bromine, and compounds of formula (VII), where R ² is as defined for formula (I), either through the use of an acid chloride intermediate or directly using a peptide bond forming agent. This is shown in Diagram 3 below.

Scheme 3

Compounds of formula (VI) wherein R ¹ is as defined for formula (I) and R ¹² is halogen, preferably bromine, can be prepared by converting a compound of formula (VIII) wherein R ¹ is as defined for formula (I), R ¹² represents halogen, preferably bromine, and R ¹³ represents C ₁ -C ₆ -alkyl, with a base. This is shown in Figure 4 below.

Scheme 4

Alternatively, compounds of formula (II) wherein R ¹ , R ² , X and Y are as defined for formula (I) can be prepared by converting a compound of formula (IX) wherein R ¹ , X and Y are as defined as defined for formula (I), using a compound of formula (VII) wherein R ² is as defined for formula (I), either by using an acid chloride intermediate or directly by using a peptide bond forming agent. This is shown in Figure 5 below.

Scheme 5

Compounds of formula (IX) wherein R ¹ , X and Y are as defined for formula (I) can be prepared by converting a compound of formula (X) wherein R ¹ , X and Y are as defined for formula (I ), and R ¹³ represents C ₁ -C ₆ -alkyl, using a base. This is shown in Figure 6 below.

Scheme 6

Compounds of formula (X) wherein R ¹ , X, and Y are as defined for formula (I) and R ¹³ is C ₁ -C ₆ -alkyl can be prepared by converting a compound of formula (IV) where X and Y are as defined for formula (I), using a compound of formula (VII), where R ¹ is as defined for formula (I), R ¹² is halogen, preferably bromine,

- 64 046368 and R ¹³ represents C ₁ -C ₆ -alkyl, either by thermal heating, or with the help of a base, or under conditions of transition metal catalyzed amination according to Buchwald-Hartwig. This is shown in Figure 7 below.

Scheme 7

Alternatively, compounds of formula (X), wherein R ¹ , X and Y are as defined for formula (I), and R ¹³ is C1-C6 alkyl, can be prepared by converting a compound of formula (XI), where X and Y are as defined for formula (I), and R ¹² is a halogen, preferably bromine or iodo, using a compound of formula (XII), where R ¹ is as defined for formula (I), and R ¹³ is C1- _C6 -alkyl, under the conditions of transition metal catalyzed Buchwald-Hartwig amination. This is shown in Figure 8 below.

Scheme 8

Alternatively, compounds of formula (II) wherein R ¹ , R ² , X and Y are as defined for formula (I) can be prepared by converting a compound of formula (XI) wherein X and Y are as defined for formula (I), and R ¹² is a halogen, preferably bromine or iodine, using a compound of formula (XIII), where R ¹ and R ² are as defined for formula (I), either by thermal heating or by base, or under transition metal-catalyzed Buchwald-Hartwig amination conditions. This is shown in Figure 9 below.

Scheme 9

Alternatively, compounds of formula (I) of the present invention, where R ¹ , R ² , X and Y are as defined for formula (I), can be prepared by converting a compound of formula (V), where R ¹ and R ² are as defined for formula (I), and R ¹² is a halogen, preferably bromine, using a compound of formula (XIV), where X and Y are as defined for formula (I), either by thermal heating or using a base, or under transition metal-catalyzed Buchwald-Hartwig amination conditions. This is shown in diagram 10 below.

Scheme 10

Compounds of formula (XIV), wherein X and Y are as defined for formula (I), can be prepared by converting a compound of formula (XV), wherein X and Y are as defined for formula (I), with a compound of formula (I) (III) wherein R ¹¹ is halogen, preferably bromine, either by thermal heating or by a base. This is shown in diagram 11 below.

- 65 046368

Scheme 11

The compositions of the present invention, including all of the embodiments disclosed above and their preferred examples, can be mixed with one or more additional pesticides, including additional fungicides, insecticides, nematicides, bactericides, acaricides, growth regulators, chemosterilants, chemical signal agents , repellents, attractants, pheromones, nutritional stimulants or other biologically active compounds to form a multicomponent pesticide that provides an even wider range of crop protection.

Examples of such agricultural protective agents with which the present invention can be formulated are fungicides such as etridiazole, fluazinam, benalaxyl, benalaxyl-M (kyralaxyl), furalaxyl, metalaxyl, metalaxyl-M (mefenoxam), dodicine, No-( 2,5-dimethyl-4-phenoxyphenyl)-Nethyl-Nmethylformamidine, N-[4-(4,5-dichlorothiazol-2-yloxy)-2,5-dimethylphenyl]-Nethyl-Nmethylformamidine, N-[ 4-[[3-[(4-chlorophenyl)methyl]-1,2,4-thiadaazol-5-yl]oxy]-2,5-dimethylphenyl]-Nethyl-Nmethylformamidine, ethirimol, 3'-chloro- 2-methoxy-N-[(3RS)-tetrahydro-2-oxofuran-3-yl]acet-2',6'-xylidide (closilacone), cyprodinil, mepanipyrim, pyrimethanil, dithianone, aureofungin, blasticidin-S, biphenyl, chloroneb, dicloran, benzovindiflupyr, pidiflumetofen, hexachlorobenzene, quintozene, tecnazene, (TCNB), tolcofos-methyl, metrafenone, 2,6-dichloro-N(4-trifluoromethylbenzyl)benzamide, fluopicolide (flupicolide), thioximide, flusulfamide, benomyl, carbendazim , carbendazim hydrochloride, chlorphenazole, fuberidazole, thiabendazole, thiophanate-methyl, benthiavalicarb, chlobenthiazone, probenazole, acibenzolar, betoxazine, pyriophenone (IKF-309), acibenzolar^-methyl, pyribencarb (KIF-7767), butylamine, 3-iodo-2propynyl -n-butylcarbamate (IPBC), iodocarb (isopropanylbutylcarbamate), isopropanylbutylcarbamate (iodocarb), picarbutrazox, polycarbamate, propamocarb, tolprocarb, 3-(difluoromethyl)-N(7-fluoro1,1,3,3-tetramethylindan-4-yl) -1-methylpyrazole-4-carboxamide, diclocimet, N[(5-chloro-2-isopropylphenyl)methyl]-Ncyclopropyl-3-(difluoromethyl)-5-fluoro-1-methylpyrazole-4-carboxamide, N-cyclopropyl3- (difluoromethyl)-5-fluoro-N[(2-isopropylphenyl)methyl]-1-methylpyrazole-4-carboxamide, carpropamide, chlorothalonil, flumorph, copper oxine, cymoxanil, fenamacryl, cyazofamide, flutianil, thithiophene, chlozolinate, iprodione, procymidone , vinclozolin, bupirimate, dinoctone, dinopentone, dinobuton, dinocap, meptyldinocap, diphenylamine, phosdiphene, 2,6-dimethyl-[1,4]dithiino[2,3-c:5,6-c']dipyrrole-1,3 ,5,7(2H,6H)tetraone, azithiram, etem, ferbam, mancozeb, maneb, metam, metiram (polyram), metiram-zinc, nabam, propineb, thiram, vapam (metham-sodium), zineb, ziram, dithioether , isoprothiolane, ethaboxam, fosetyl, fosetyl-Al (fosetyl-Al), methyl bromide, methyl iodide, methyl isothiocyanate, cyclafuramide, fenfuram, validamycin, streptomycin, (2RS)-2-bromo-2-(bromomethyl)glutaronitrile (bromotalonil), dodine, doguadine, guazatin, iminoctadine, iminoctadine triacetate, 2,4-D, 2,4-DB, kasugamycin, dimethyrimol, fenhexamide, hymexazole, hydroxyisoxazole, imazalil, imazalil sulfate, oxpoconazole, pefurazoate, prochloraz, triflumizole, fenamidone, Bordeaux mixture , calcium polysulfide, copper acetate, copper carbonate, copper hydroxide, copper naphthenate, copper oleate, copper oxychloride, copper oxyquinolate, copper silicate, copper sulfate, copper tallate, copper oxide, sulfur, carbaryl, phthalide (phthalide), Dingjunezuo (Jun Si Qi), oxathiapiproline, fluorimide, mandipropamide, KSF-1002, benzamorph, dimethomorph, fenpropimorph, tridemorph, dodemorph, diethofencarb, fentin acetate, fentin hydroxide, carboxin, oxycarboxin, drazoxolone, famoxadone, m-phenylphenol, p-phenylphenol, tribromophenol (TBP ), 2-[2-[(7,8-difluoro-2-methyl-3-quinolyl)oxy]-6fluorophenyl]propan-2-ol, 2-[2-fluoro-6-[(8-fluoro-2 -methyl-3-quinolyl)oxy]phenyl]propan-2-ol, cyflufenamide, ofuras, oxadixil, flutolanil, mepronil, isofetamide, fenpiclonil, fludioxonil, pencicuron, edifenfos, iprobenfos, pyrazophos, phosphoric acids, teklofthalam, captafol, captan, ditalifos, triforin, fenpropidine, piperaline, osthole, 1-methylcyclopropene, 4-CPA, chlormequat, clofencet, dichlorprop, dimethipine, endothal, ethephon, flumetralin, forchlorfenuron, gibberellic acid, gibberellins, gymexazole, maleic hydrazide, mepiquat, naphthalene acetamide, pak lobutrazole, prohexadione, prohexadione calcium, thidiazuron, tribufos (tributyl phosphorotrithioate), trinexapac, uniconazole, α-naphthalene acetic acid, polyoxin D (polyoxrim), BLAD, chitosan, phenoxanil, folpet, 3(difluoromethyl)-Nmethoxy-1-methyl-N[ 1-methyl-2-(2,4,6-trichlorophenyl)ethyl]pyrazole-4-carboxamide, bixafen, fluxapyroxad, furamethpyr, isopyrazam, penflufen, penthiopyrad, sedaxane, fenpyrazamine, diclomesin, pyrifenox, boscalid, fluopyram, diflumetorim, fenarimol , 5-fluoro-2-(ptolylmethoxy)pyrimidin-4-amine, ferimzone, dimethachlon (dimethaclon), pyroquilone, proquinazide, ethoxyquin, quinoxifene, 4,4,5-trifluoro-3,3-dimethyl-1 -(3- quinolyl)isoquinoline, 4,4-difluoro-3,3-dimethyl-1 (3-quinolyl)isoquinoline, 5-fluoro-3,3,4,4-tetramethyl-1 -(3-quinolyl)isoquinoline, 9-fluoro -2,2-dimethyl-5-(3quinolyl)-3H-1,4-benzoxazepine, tebufloquin, oxolinic acid, quinomethionate (hydroxythioquinox,

- 66 046368 quinoxymethionate), spiroxamine, (E)-Nmethyl-2-[2-(2,5-dimethylphenoxymethyl)phenyl]-2-methoxyiminoacetamide (mandestrobin), azoxystrobin, cumoxystrobin, dimoxystrobin, enestroburin, enoxastrobin, phenamistrobin, fluphenoxystrobin , fluoxastrobin, kresoxim-methyl, mandestrobin, metaminostrobin, metominostrobin, orysastrobin, picoxystrobin, pyraclostrobin, pyrametostrobin, pyraoxystrobin, trichloropyricarb, trifloxystrobin, amisulbrom, dichlofluanid, tolylfluanid, but3-ynyl-No[6-[[(2)-[(1 -methyltetrazol-5-yl)phenylmethylene]amino]oxymethyl]-2-pyridyl]carbamate, dazomet, isothianil, tiadinil, tifluzamide, benthiazole (TCMTV), silthiopham, zoxamide, anilazine, tricyclazole, (+-)-cis-1- (4-chlorophenyl)-2-(III-1,2,4-triazol-1-yl)cycloheptanol (Huanjunzuo), 1-(5-bromo-2pyridyl)-2-(2,4-difluorophenyl)-1, 1 -difluoro-3 -(1,2,4-triazol-1 -yl)propan-2-ol, 2-(1 -tert-butyl)-1 -(2-chlorophenyl)-3-(1,2, 4-triazol-1-yl)propan-2-ol (TCDP), aconazole, bitertanol (biloxazole), bromuconazole, climbazole, cyproconazole, difenoconazole, dimethconazole, diniconazole, diniconazole-M, epoxiconazole, etaconazole, fenbuconazole, fluquinconazole, flusilazole, flutriafol, hexaconazole, imibenconazole, ipconazole, ipfentrifluconazole, metconazole, myclobutanil, penconazole, propiconazole, prothioconazole, simeconazole, tebuconazole, tetraconazole, triadimefon, triadimenol, triazoxide, triticonazole, mefentrifluconazole, 2-[[(^^)-5- [(4 -fluorophenyl)methyl]-1-hydroxy-2,2-dimethylcyclopentyl]methyl]-4H1,2,4-triazol-3-thione, 2-[[3-(2-chlorophenyl)-2-(2,4- difluorophenyl)oxiran-2-yl]methyl]-4H-1,2,4-triazole-3thione, amethoctradine (imidium), iprovalicarb, valifenalate, 2-benzyl-4-chlorophenol (chlorophen), allyl alcohol, azaphenidine, benzalkonium chloride , chloropicrin, cresol, daracid, dichlorophen (dichlorophene), diphenzoquat, dipyrithione, N(2-p-chlorobenzoylethyl)hexaminium chloride, NNF-0721, octylinone, oxasulfuron, propamidine and propionic acid, insecticides such as abamectin, acephate, acetamiprid, Amidoflum (S-1955), Avermectin, Azadihitin, Azinfos Meetil, Bephantrin, Bephenazate, Buprofuzin, Carbofuran, Cartap, Clarantleliprol (DPX-E2Y45), Chloropenapir, Chlorfaluzuron, Chlorpirifos, Cromaphenoside, Clotianidine, Clotianidine, Clotianidine, Clotianidine, Clotianidine, Clotianidine, Clotianidine , digiturine, beta-cyfluthrin, cyhalothrin, lambda-cyhalothrin, cypermethrin, cyromazine, deltamethrin, diafenthiuron, diazinon, dieldrin, diflubenzuron, dimefluthrin, dimethoate, dinotefuran, diophenolan, emamectin, endosulfan, esfenvalerate, ethiprole, phenothiocarb, fenoxycarb, fen propathrine, fenvalerate, fipronil, flonicamid, flubendiamide, flucitrinate, tau-fluvalinate, flufenerim (UR-50701), flufenoxuron, fonofos, halofenoside, hexaflumuron, hydramethylnon, imidacloprid, indoxacarb, isofenphos, lufenuron, malathion, metaflumizone, metaldehyde, methamidophos, methidathione, methomyl , methoprene, methoxychlor , metofluthrin, monocrotophos, methoxyfenozide, nitenpyram, nithiazine, novaluron, noviflumuron (XDE-007), oxamyl, parathion, parathion-methyl, permethrin, phorate, fosalone, phosmet, phosphamidon, pirimicarb, profenofos, profluthrin, pymetrozine, pyrafluprol, pyrethrin, pyridalyl, pyrifluquinazone, pyriprole, pyriproxyfen, rotenone, ryanodine, spinetoram, spinosad, spirodiclofen, spiromesifen (BSN 2060), spirotetramate, sulprofos, tebufenozide, teflubenzuron, tefluthrin, terbufos, tetrachlorvinphos, thiacloprid, thiamethoxam, thiodicarb , thiosultap sodium, tralomethrine, triazamate, trichlorfon and triflumuron;

bactericides such as streptomycin;

acaricides such as amitraz, quinomethionate, chlorobenzilate, cyenopyrafen, cyhexatin, dicofol, dienochlor, etoxazole, phenazaquin, fenbutatin oxide, fenpropathrin, fenpyroximate, hexythiazox, propargite, pyridabene and tebufenpyrad, and biologicals such as Bacillus thuringiensis, Bacillus delta-endotoxin thuringiensis, baculovirus and entomopathogenic bacteria, virus and fungi.

Other examples of typical mixture compositions include the following (wherein the term TX represents a compound (as defined in component (A) of the compositions of the present invention) selected from Compound Nos. X.01, X.02, X.03, X.04 , Х.05, Х.06, Х.07, Х.08, Х.09, Х.10, Х.11, Х.12, Х.13, Х.14, Х.15, Х.16, Х .17, X.18, X.19, X.20, X.21, X.22, X.23 and X.24, as defined in Table X above): a compound selected from the group of substances consisting of petroleum oils + TX, 1,1-bis(4-chlorophenyl)-2-ethoxyethanol + TX, 2,4-dichlorophenylbenzenesulfonate + TX, 2-fluoro-NmethylN-1-naphtylacetamide + TX, 4-chlorophenylphenylsulfone + TX, acetoprole + TX , aldoxycarb + TX, amidithione + TX, amidothioate + TX, amitone + TX, amitone hydroxalate + TX, amitraz + TX, aramite + TX, arsenic oxide + TX, azobenzene + TX, azotoate + TX, benomyl + TX, benoxaphos + TX , benzyl benzoate + TX, bixafen + TX, brofenvalerate + TX, bromocyclene + TX, bromophos + TX, bromopropylate + TX, buprofezin + TX, butocarboxim + TX, butoxycarboxim + TX, butylpyridabene + TX, calcium polysulfide + TX, camphechlor + TX, carbanolate + TC, carbophenothione + TC, cimiazole + TC, quinomethionate + TC, chlorobenzide + TC, chlordimeform + TC, chlordimeform hydrochloride + TC, chlorphenetol + TC, chlorphenson + TC, chlorphensulfide + TC, chlorobenzilate + TC, chloromebuform + TC, chloromethiuron + TC, chloropropylate + TC, chlorothiophos + TC, cinerin I + TC, cinerin II + TC, cinerin + TC, closantel + TC, coumaphos + TC, crotamiton + TC, crotoxyphos + TC, kufraneb + TC, cyanoate + TC, DCPM + TX, DDT + TX, demefion + TX, demefion-O + TX, demefionS + TX, demeton-methyl + TX, demeton-O + TX, demeton-O-methyl + TX, demeton-S + TX, demeton-Smethyl + TX, demeton^-methylsulfone + TX, dichlorfluanid + TX, dichlorvos + TX, diclifos + TX, dienochlor + TX, dimefox + TX, dinex + TX, dinex-diclexin + TX, dinocap-4 + TX, dinocap

- 67 046368 + TX, dinoctone + TX, dinopentone + TX, dinosulfone + TX, dinoterbo + TX, dioxathion + TX, diphenylsulfone + TX, disulfiram + TX, DNOC + TX, dophenapine + TX, doramectin + TX, endothione + TX, eprinomectin + TX, methyl ethoate + TX, etrimphos + TX, phenazaflor + TX, fenbutatin oxide + TX, phenothiocarb + TX, fenpyrade + TX, fenpyroximate + TX, fenpyrazamine + TX, fenzone + TX, fentrifanil + TX, flubenzymine + TX , flucycloxuron + TX, fluenethyl + TX, fluorbenzide + TX, FMC 1137 + TX, formethanate + TX, formatenate hydrochloride + TX, formparanate + TX, gammaHCN + TX, gliodin + TX, galfenprox + TX, hexadecyl cyclopropane carboxylate + TX, isocarbophos + TX, jasmoline I + TX, jasmoline II + TX, iodofenphos + TX, lindane + TX, malonobene + TX, mecarbam + TX, mephospholane + TX, mesulfene + TX, metacryphos + TX, methyl bromide + TX, metolcarb + TX, mexacarbate + TQ, milbemycin oxime + TQ, mipafoxa + TQ, monocrotophos + TQ, morphothione + TQ, moxidectin + TQ, naleda + TQ, 4-chloro-2-(2-chloro-2-methylpropyl)-5-[(6-iodine -3pyridyl)methoxy]pyridazin-3-one + TX, nifluridide + TX, nikkomycin + TX, nitrilecarb + TX, nitrilecarb complex: zinc chloride 1:1 + TX, omethoate + TX, oxideprophos + TX, oxydisulfoton + TX, pp' -DDT + TX, parathion + TX, permethrin + TX, phencapton + TX, fosalone + TX, phospholan + TX, phosphamidon + TX, polychlorterpenes + TX, polynactins + TX, proclonol + TX, promacil + TX, propoxura + TX, protidathion + TX, protoate + TX, pyrethrin I + TX, pyrethrin II + TX, pyrethrins + TX, pyridafenthione + TX, pyrimitate + TX, quinalphos + TX, quinthiophos + TX, R-1492 + TX, phosglycine + TX, rotenone + TX , shradana + TX, sebuphos + TX, selamectin + TX, sofamide + TX, SSI-121 + TX, sulfiram + TX, sulfluramide + TX, sulfotepa + TX, sulfur + TX, difluvidazine + TX, tau-fluvalinate + TX, TERP + TX, terbama + TX, tetradiphone + TX, tetrasula + TX, thiaphenoxa + TX, thiocarboxyme + TX, thiophanox + TX, thiometon + TX, thioquinoxa + TX, thuringiensin + TX, triamiphos + TX, triarathene + TX, triazophos + TX , triazuron + TX, triphenofos + TX, trinactin + TX, vamidothione + TX, vaniliprol + TX, betoxazin + TX, copper dioctanoate + TX, copper sulfate + TX, cibutrin + TX, dichlorophen + TX, dichlorophen + TX, endothal + TX , fentine + TX, slaked lime + TX, nabama + TX, quinoclamine + TX, quinonamide + TX, simazine + TX, triphenyltine acetate + TX, triphenyltine hydroxide + TX, crufomate + TX, piperazine + TX, thiophanate + TX, chloralose + TX, fenthion + TX, pyridin-4-amine + TX, strychnine + TX, 1-hydroxy-III-pyridine-2-thione + TX, 4(quinoxalin-2-ylamino)benzenesulfonamide + TX, 8-hydroxyquinoline sulfate + TX , bronopol + TC, copper hydroxide + TC, cresol + TC, dipyrithione + TC, dodicine + TC, fenaminosulfa + TC, formaldehyde + TC, hydrargafen + TC, kasugamycin + TC, kasugamycin hydrochloride hydrate + TC, nickel bis(dimethyldithiocarbamate) + TX, nitrapyrine + TX, octylinone + TX, oxolinic acid + TX, oxytetracycline + TX, potassium hydroxyquinoline sulfate + TX, probenazole + TX, streptomycin + TX, streptomycin sesquisulfate + TX, teclophthalam + TX, thiomersal + TX, Adoxophyes orana GV + TX, Agrobacterium radiobacter + TX, Amblyseius spp. + TX, Anagrapha falcifera NPV + TX, Anagrus atomus + TX, Aphelinus abdominalis + TX, Aphidius colemani + TX, Aphidoletes aphidimyza + TX, Autographa californica NPV + TX, Bacillus sphaericus Neide + TX, Beauveria brongniartii + TX, Chrysoperla carnea + TX , Cryptolaemus montrouzieri + TX, Cydia pomonella GV + TX, Dacnusa sibirica + TX, Diglyphus isae + TX, Encarsia formosa + TX, Eretmocerus eremicus + TX, Heterorhabditis bacteriophora and N. megidis + TX, Hippodamia convergens + TX, Leptomastix dactylopii + TX , Macrolophus caliginosus + TX, Mamestra brassicae NPV + TX, Metaphycus helvolus + TX, Metarhizium anisopliae var. acridum + TX, Metarhizium anisopliae var. anisopliae + TX, Neodiprion sertifer NPV and N. lecontei NPV + TX, Orius spp. + TX, Paecilomyces fumosoroseus + TX, Phytoseiulus persimilis + TX, Steinernema bibionis + TX, Steinernema carpocapsae + TX, Steinernema feltiae + TX, Steinernema glaseri + TX, Steinernema riobrave + TX, Steinernema riobravis + TX, Steinernema scapterisci + TX, Steinernema spp . + TX, Trichogramma spp. + TX, Typhlodromus occidentalis + TX, Verticillium lecanii + TX, afolate + TX, bisazira + TX, busulfan + TX, dimatifa + TX, hemela + TX, hemp + TX, meteps + TX, methiotepas + TX, methyl afolate + TX, morzide + TX, penfluron + TX, tepa + TX, thiochempa + TX, thiotepa + TX, tretamine + TX, uredepa + TX, (E)-dec-5-en-1-yl acetate with (E)-dec5-ene -1-olom + TX, (E)-tridec-4-en-1-yl acetate + TX, (E)-6-methylhept-2-en-4-ol + TX, (E,2)-tetradeca4, 10-dien-1-yl acetate + TX, (2)-dodec-7-en-1-yl acetate + TX, (2)-hexadec-11-enal + TX, (2)-hexadec11-en-1- yl acetate + TX, (2)-hexadec-13-en-11-yn-1-yl acetate + TX, (/)-icos-13-en-10-one + TX, (Z)tetradec-7-ene -1-ala + TX, ^)-tetradec-9-en-1-ol + TX, ^)-tetradec-9-en-1-yl acetate + TX, (7E,9Z)dodeca-7,9-diene -1-yl acetate + TX, ^,11E)-tetradeca-9,11-dien-1-yl acetate + TX, ^,12E)-tetradeca9,12-dien-1-yl acetate + TX, 14-methyloctadec- 1-ene + TX, 4-methylnonan-5-ol with 4-methylnonan-5-one + TX, alpha-multistriatina + TX, brevicomin + TX, codelur + TX, codlemon + TX, quelur + TX, disparlura + TX, dodec-8-en-1-yl acetate + TX, dodec-9-en-1-yl acetate + TX, dodeca-8 + TX, 10-dien-1yl acetate + TX, dodec-9-en-1-yl acetate + TX, ethyl 4-methyloctanoate + TX, eugenol + TX, frontalina + TX, grandlura + TX, grandlura I + TX, grandlura II + TX, grandlura III + TX, grandlura IV + TX, hexalura + TX, ipsdienol + TX, ipsenol + TX, japonilura + TX, lineatine + TX, litlur + TX, luplura + TX, medlura + TX, megatomic acid + TX, methyl eugenol + TX, muscalure + TX, octadeca-2,13-dien-1yl acetate + TX, octadeca-3,13-dien- 1-yl acetate + TX, orphralur + TX, oryctalur + TX, ostramon + TX, siglur + TX, sordidine + TX, sulcatol + TX, tetradec-11-en-1-yl acetate + TX, trimedlur + TX, trimedlur A + TX, trimedlura Bi + TX, trimedlura B ₂ + TX, trimedlura C + TX, trunk-colla + TX, 2

- 68 046368 (octylthio)ethanol + TX, butopyronoxyl + TX, butoxy(polypropylene glycol) + TX, dibutyl adipate + TX, dibutyl phthalate + TX, dibutyl succinate + TX, diethyltoluamide + TX, dimethyl carbate + TX, dimethyl phthalate + TX, ethylhexanediol + TX, hexamide + TX, methoquin-butyl + TX, methylneodecanamide + TX, oxamate + TX, icaridin + TX, 1-dichloro-1-nitroethane + TX, 1,1-dichloro-2,2-bis(4ethylphenyl)ethane + TX, 1,2-dichloropropane with 1,3-dichloropropene + TX, 1-bromo-2-chloroethane + TX, 2,2,2trichloro-1-(3,4-dichlorophenyl)ethyl acetate + TX, 2,2-dichlorovinyl-2 -ethylsulfinylethyl methylphosphate + TX, 2-(1,3-dithiolan-2-yl)phenyldimethylcarbamate + TX, 2-(2-butoxyethoxy)ethyl thiocyanate + TX, 2(4,5-dimethyl-1,3-dioxolan-2-yl )phenylmethylcarbamate + TX, 2-(4-chloro-3,5-xylyloxy)ethanol + TX, 2-chlorovinyl diethyl phosphate + TX, 2-imidazolidone + TX, 2-isovalerylindane-1,3-dione + TX, 2methyl(prop-2- inyl)aminophenylmethylcarbamate + TX, 2-thiocyanatoethyl laurate + TX, 3-bromo-1chloroprop-1-ene + TX, 3-methyl-1-phenylpyrazol-5-yldimethylcarbamate + TX, 4-methyl(prop-2inyl)amino-3, 5-xylylmethylcarbamate + TX, 5,5-dimethyl-3-oxocyclohex-1-enyldimethylcarbamate + TX, acethione + TX, acrylonitrile + TX, aldrin + TX, allosamidine + TX, allixycarb + TX, alphaecdysone + TX, aluminum phosphide + TX , aminocarb + TX, anabasine + TX, atidation + TX, azametifos + TX, delta endotoxins Bacillus thuringiensis + TX, barium hexafluorosilicate + TX, barium polysulfide + TX, bartrin + TX, Bayer 22/190 + TX, Bayer 22408 + TX, beta-cyfluthrin + TX, betacypermethrin + TX, bioethanometrin + TX, biopermethrin + TX, bis(2-chloroethyl) ether + TX, borax + TX, bromfenvinphos + TX, bromine-DDT + TX, bufencarb + TX, butacarb + TX, butathiophos + TC, butonate + TC, calcium arsenate + TC, calcium cyanide + TC, carbon disulfide + TC, carbon tetrachloride + TC, cartap hydrochloride + TC, kevadin + TC, chlorobicyclene + TC, chlordane + TC, chlordecone + TC, chloroform + TC , chloropicrin + TX, chlorphoxime + TX, chlorprazophos + TX, cis-resmethrin + TX, cismethrin + TX, clocitrin + TX, copper acetoarsenite + TX, copper arsenate + TX, copper oleate + TX, cumitoate + TX, cryolite + TX, CS 708 + TX, cyanophenphos + TX, cyanophos + TX, cycletrin + TX, cythioate + TX, d-tetramethrin + TX, DAEP + TX, dazomet + TX, decarbofuran + TX, diamidaphos + TX, dicaptone + TX, dichlorofenthion + TX , dicresyl + TX, dicyclanil + TX, dieldrin + TX, diethyl-5methylpyrazol-3-ylphosphate + TX, dilor + TX, dimefluthrin + TX, dimethane + TX, dimetrin + TX, dimethylvinphos + TX, dimethylane + TX, dinoprop + TX , dinosama + TX, dinoseb + TX, diophenolan + TX, dioxabenzophos + TX, diticrophos + TX, DSP + TX, ecdysterone + TX, EI 1642 + TX, EMPC + TX, ERBP + TX, ethaphos + TX, etiophencarb + TX, ethyl formate + TX, ethylene dibromide + TX, ethylene dichloride + TX, ethylene oxide + TX, EXD + TX, fenchlorvos + TX, fenetacarb + TX, fenitrothion + TX, fenoxacrim + TX, fenpyritrin + TX, fensulfothione + TX, fenthion-ethyl + TX , flucofuron + TX, fosmethylane + TX, fospirate + TX, fostiethane + TX, furatiocarb + TX, furethrin + TX, guazatin + TX, guazatin acetates + TX, sodium tetrathiocarbonate + TX, galfenprox + TX, NCH + TX, HEOD + TX , heptachlor + TX, heterophos + TX, HHDN + TX, hydrocyanic acid + TX, hiquincarb + TX, IPSP + TX, isazophos + TX, isobenzan + TX, isodrin + TX, isofenphos + TX, isolane + TX, isoprothiolane + TX, isoxathione + TX, juvenile hormone I + TX, juvenile hormone II + TX, juvenile hormone III + TX, kelevan + TX, kinoprene + TX, lead arsenate + TX, leptophos + TX, lyrimphos + TX, litidathion + TX, m-cumenylmethylcarbamate + TC, magnesium phosphide + TC, mazidoxa + TC, mecarphone + TC, menasone + TC, mercuric chloride + TC, mesulfenphos + TC, metam + TC, metampotassium + TC, metam-sodium + TC, methanesulfonyl fluoride + TC, metocrotophos + TC , methoprene + TX, methotrine + TX, methoxychlor + TX, methyl isothiocyanate + TX, methyl chloroform + TX, methylene chloride + TX, methoxadiazone + TX, mirex + TX, naphthalophos + TX, naphthalene + TX, NC-170 + TX, nicotine + TX , nicotine sulfate + TX, nithiazine + TX, nornicotine + TX, O-5-dichloro-4-iodophenyl-O-ethylethylphosphonothioate + TX, O,O-diethyl-O-4-methyl-2-oxo-2H-chromen- 7-ylphosphorothioate + TX, O,Odiethyl-O-6-methyl-2-propylpyrimidin-4-ylphosphorothioate + TX, O,O,O',O'-tetrapropyldithiopyrophosphate + TX, oleic acid + TX, para-dichlorobenzene + TX , parathion-methyl + TX, pentachlorophenol + TX, pentachlorophenyl laurate + TX, pH 60-38 + TX, phencapton + TX, phosnichlor + TX, phosphine + TX, phoxim-methyl + TX, pyrimethaphos + TX, isomers of polychlorodicyclopentadiene + TX, arsenite potassium + TX, potassium thiocyanate + TX, precocene I + TX, precocene II + TX, precocene III + TX, primidophos + TX, profluthrin + TX, promecarb + TX, prothiophos + TX, pyrazophos + TX, pyresmethrin + TX, quassia + TX, quinalphos-methyl + TX, quinothione + TX, rafoxanide + TX, resmethrin + TX, rotenone + TX, cadetrin + TX, ryanium + TX, ryanodine + TX, sabadilla) + TX, shradana + TX, sebuphos + TX, SI -0009 + TX, tiapronil + TX, sodium arsenite + TX, sodium cyanide + TX, sodium fluoride + TX, sodium hexafluorosilicate + TX, sodium pentachlorophenoxide + TX, sodium selenate + TX, sodium thiocyanate + TX, sulcofuron + TX, sulcofuron- sodium + TX, sulfur fluoride + TX, sulprofos + TX, tar oils + TX, tazimkarb + TX, TDE + TX, tebupirimphos + TX, temephos + TX, terallethrin + TX, tetrachloroethane + TX, ticrofos + TX, thiocyclam + TX, thiocyclam hydroxalate + TX, thionazine + TX, thiosultap + TX, thiosultap-sodium + TX, tralomethrin + TX, transpermethrin + TX, triazamate + TX, trichlorometaphos-3 + TX, trichloronate + TX, trimetacarb + TX, tolprocarb + TX, trichloropyricarb + TC, triprene + TC, veratridine + TC, veratrin + TC, CMS + TC, zetamethrin + TC, zinc phosphide + TC, zolaprophos + TC and meperfluthrin + TC, tetramethylfluthrin + TC, bis(tributyltin) oxide + TC, bromoacetamide + TC, iron phosphate + TC, niclosamide-olamine + TC, oxy

- 69 046368 yes tributyltin + TX, pyrimorph + TX, triphenmorph + TX, 1,2-dibromo-3-chloropropane + TX, 1,3dichloropropene + TX, 3,4-dichlorotetrahydrothiophene 1,1-dioxide + TX, 3-( 4-chlorophenyl)-5-methylrhodanine + TX, 5-methyl-6-thioxo-1,3,5-thiadiazinan-3-ylacetic acid + TX, 6-isopentenylaminopurine + TX, anisiflupurine + TX, benclothiase + TX, cytokinins + TX, DCIP + TX, furfural + TX, isamidophos + TX, kinetin + TX, compositions of Myrothecium verrucaria + TX, tetrachlorothiophene + TX, xylenols + TX, zeatin + TX, potassium ethyl xanthate + TX, acibenzolar + TX, acibenzolar^-methyl + TX, Reynoutria sachalinensis extract + TX, alpha-chlorohydrin + TX, antu + TX, barium carbonate + TX, bisthiosemium + TX, brodifacoum + TX, bromadiolone + TX, bromethalin + TX, chlorophacinone + TX, cholecalciferol + TX, coumachlor + TX , coumafuril + TX, coumatetral + TX, crimidine + TX, difenacoum + TX, difethialone + TX, diphacinone + TX, ergocalciferol + TX, flocumafen + TX, fluoroacetamide + TX, flupropadine + TX, flupropadine hydrochloride + TX, norbormide + TX, fosacetim + TX, phosphorus + TX, pindone + TX, pyrinuron + TX, skilliroside + TX, sodium fluoroacetate + TX, thallium sulfate + TX, warfarin + TX, 2-(2-butoxyethoxy)ethyl piperonylate + TX, 5-(1, 3-benzodioxol-5-yl)-3-hexylcyclohex-2-enone + TX, farnesol with nerolidol + TX, verbutin + TX, MGK 264 + TX, piperonyl butoxide + TX, piprotal + TX, propyl isomer + TX, S421 + TX, sesamex + TC, sesasmolin + TC, sulfoxide + TC, anthraquinone + TC, copper naphthenate + TC, copper oxychloride + TC, dicyclopentadiene + TC, thiram + TC, zinc naphthenate + TC, ziram + TC, imanin + TC, ribavirin + TC, clopinconazide + TX, mercuric oxide + TX, thiophanate-methyl + TX, azaconazole + TX, bitertanol + TX, bromuconazole + TX, cyproconazole + TX, difenoconazole + TX, diniconazole + TX, epoxiconazole + TX, fenbuconazole + TX, fluquinconazole + TX , flusilazole + TX, flutriafol + TX, furamethpyr + TX, hexaconazole + TX, imazalil + TX, imibenconazole + TX, ipconazole + TX, metconazole + TX, myclobutanil + TX, paclobutrazol + TX, pefurazoate + TX, penconazole + TX, prothioconazole a + TX, pyrifenox + TX, prochloraz + TX, propiconazole + TX, pyrizoxazole + TX, simeconazole + TX, tebuconazole + TX, tetraconazole + TX, triadimefon + TX, triadimenol + TX, triflumizole + TX, triticonazole + TX, ancymidol + TX , fenarimol + TX, nuarimol + TX, bupirimate + TX, dimethirimol + TX, ethirimol + TX, dodemorph + TX, fenpropidine + TX, fenpropimorph + TX, spiroxamine + TX, tridemorph + TX, cyprodinil + TX, mepanipyrim + TX, pyrimethanil + TX, fenpiclonil + TX, fludioxonil + TX, benalaxyl + TX, furalaxyl + TX, metalaxyl + TX, R-metalaxyl + TX, ofuras + TX, oxadixil + TX, carbendazim + TX, debacarb + TX, fuberidazole + TX, thiabendazole + TX, chlozolinate + TX, dichlozolin + TX, myclozolin + TX, procymidone + TX, vinclozolin + TX, boscalid + TX, carboxin + TX, fenfuram + TX, flutolanil + TX, mepronil + TX, oxycarboxin + TX, pentiopyrad + TX , tifluzamide + TX, dodine + TX, iminoctadine + TX, azoxystrobin + TX, dimoxystrobin + TX, enoxastrobin + TX, phenaminestrobin + TX, flufenoxystrobin + TX, fluoxastrobin + TX, xeroxim-methyl + TX, metominostrobin + TX, trifloxystrobin + TX , orysastrobin + TX, picoxystrobin + TX, pyraclostrobin + TX, pyramethostrobin + TX, pyraoxystrobin + TX, ferbam + TX, mancozeb + TX, maneba + TX, metyram + TX, propineba + TX, cineba + TX, captafol + TX, captan + TC, fluoromide + TC, folpeta + TC, tolylfluanide + TC, Bordeaux mixture + TC, copper oxide + TC, mancopper + TC, oxine copper + TC, nitrotal isopropyl + TC, edifenphos + TC, iprobenphos + TC, phosdifene + TX, tolclofos-methyl + TX, anilazine + TX, benthiavalicarb + TX, blasticidin-S + TX, chloroneb + TX, chlorothalonil + TX, cyflufenamide + TX, cymoxanil + TX, cyclobutrifluram + TX, diclocimet + TX, diclomesine + TX, dicloran + TX, diethofencarb + TX, dimethomorph + TX, flumorph + TX, dithianone + TX, ethaboxam + TX, etridiazole + TX, famoxadone + TX, fenamidone + TX, fenoxanil + TX, ferimzone + TX, fluazinam + TX, flumethylsulforim + TX, fluopicolide + TX, fluoxythioconazole + TX, flusulfamide + TX, fluxapyroxade + TX, fenhexamide + TX, fosetyl-aluminum + TX, himexazole + TX, iprovalicarb + TX, cyazofamide + TX, metasulfocarb + TX, metrafenone + TX, pencycuron + TX, phthalide + TX, polyoxins + TX, propamocarb + TX, pyribencarb + TX, proquinazide + TX, pyroquilone + TX, pyriophenone + TX, quinoxifene + TX, quintozene + TX, tiadinil + TX, triazoxide + TX, tricyclazole + TX, triforin + TX, validamycin + TX, valifenalate + TX, zoxamide + TX, mandipropamide + TX, flubeneteram + TX, isopyrazam + TX, sedaxane + TX, benzovindiflupyr + TX, pidiflumetofen + TX, 3-difluoromethyl-1-methyl-1H- pyrazole-4-carboxylic acid (3',4',5'-trifluorobiphenyl-2-yl)-amide + TX, isoflucipram + TX, isothianyl + TX, dipimethytrone + TX, 6-ethyl-5,7dioxo-pyrrolo [4 ,5][1,4]dithiino [1,2-c]isothiazol-3-carbonitrile + TX, 2-(difluoromethyl)-N-[3-ethyl-1,1dimethylindan-4-yl]pyridin-3-carboxamide + TX, 4-(2,6-difluorophenyl)-6-methyl-5-phenylpyridazin-3carbonitrile + TX, ^)-3-(difluoromethyl)-1-methyl-N-[1,1,3-trimethylindan-4 -yl]pyrazol-4-carboxamide + TX, 4-(2-bromo-4-fluorophenyl)-N-(2-chloro-6-fluorophenyl)-2,5-dimethylpyrazol-3-amine + TX, 4-( 2-bromo-4fluorophenyl)-N-(2-chloro-6-fluorophenyl)-1,3-dimethyl-1H-pyrazol-5-amine + TX, fluindapir + TX, coumethoxystrobin jiaxiangjunzhi) + TX, lvbenmixianan + TX, dichlorobenthiazox + TX, mandestrobin + TX, 3-(4,4-difluoro-3,4-dihydro-3,3-dimethylisoquinolin-1-yl)quinolone + TX, 2-[2-fluoro-6-[(8-fluoro -2methyl-3-quinolyl)oxy]phenyl]propan-2-ol + TX, oxathiapiproline + TX, tert-butyl-N-[6-[[[(1methyltetrazol-5-yl)-phenyl-methylene]amino]oxymethyl ]-2-pyridyl]carbamate + TX, pyraziflumide + TX, inpirfluxam + TX, trolprocarb + TX, mefentrifluconazole + TX, ipfentrifluconazole + TX,

- 70 046368

2-(difluoromethyl)-N-[(3R)-3-ethyl-1,1-dimethylindan-4-yl]pyridin-3-carboxamide + TC, N-(2,5-dimethyl4-phenoxyphenyl)-N-ethyl -N-methylformamidine + TX, N-[4-(4,5-dichlorothiazol-2-yl)oxy-2,5dimethylphenyl]-N-ethyl-N-methylformamdine + TX, [2-[3-[2-[ 1-[2-[3,5-bis(difluoromethyl)pyrazol-1yl]acetyl]-4-piperidyl]thiazol-4-yl]-4,5-dihydroisoxazol-5-yl]-3-chlorophenyl]methanesulfonate + TX , but-3-ynyl-H-[6-[[(2)-[(1-methyltetrazol-5-yl)-phenyl-methylene|amino|oxymethyl|-2-pyridyl|carbamate + TX, methyl-H- [[5-[4-(2,4-dimethylphenyl)triazol-2-yl]-2-methyl-phenyl]methyl]carbamate + TC, 3-chloro-6methyl-5-(enyl-4-(2,4 ,6-tri(tor(enyl)pyridazine + TX, pyridachloromethyl + TX, 3-(di(tormethyl)-1methyl-H-[1.1,3-trimethylindan-4-yl|pyrazol-4-carboxamide + TX, 1- [2-[[1-(4-chlorophenyl)pyrazol-3yl|hydroxymethyl|-3-methyl-(enyl|-4-methyltetrazol-5-one + TX, 1-methyl-4-[3-methyl-2- [[2-methyl-4-(3,4,5trimethylpyrazol-1-yl)(enoxy|methyl|(enyl|tetrazol-5-one + TX, aminopyri(ene + TX, ametoctradine + TX, amisulbrom + TX, penflufen + TX, (Z,2E)-5-[1-(4-chlorophenyl)pyrazol-3-yl]oxy-2methoxyimino-K3-dimethylpent-3-enamide + TX, florylpicoxamide + TX, phenpicoxamide + TX, methylpicoxamide + TX , tebufloquin + TX, ipflufenoquin + TX, quinofumeline + TX, isofetamide + TX, N-[2-[2,4-dichlorophenoxy]phenyl]-3-(difluoromethyl)-1-methylpyrazole-4-carboxamide + TX, N- [2-[2chloro-4-(trifluoromethyl)phenoxy]phenyl]-3-(difluoromethyl)-1-methylpyrazole-4-carboxamide + TX, benzothiostrobin + TX, fenamacryl + TX, 5-amino-1,3,4- thiadiazol-2-thiol: zinc salt (2:1) + TX, fluopyram + TX, flufenoxadiazam + TX, flutianil + TX, fluopimomide + TX, pyrapropone + TX, picarbutrazox + TX, 2-(difluoromethyl)-H-(3 -ethyl-1,1-dimethylindan-4-yl)pyridin-3-carboxamide + TX, 2(difluoromethyl)-N-((3R)-1,1,3-trimethylindan-4-yl)pyridin-3-carboxamide + TX, 4-[[6-[2-(2,4difluorophenyl)-1,1-difluoro-2-hydroxy-3-(1,2,4-triazol-1-yl)propyl| -3-pyridyl]oxy]benzonitrile + TX, methyltetraprole + TX, 2-(difluoromethyl)-N-((3R)-1, 1,3-trimethylindan-4-yl)pyridin-3-carboxamide + TX, α- (1,1-dimethylethyl)-α-[4'-(trifluoromethoxy)[1,1'-biphenyl]-4-yl]-5-pyrimidinemethanol + TX, fluoxapiproline + TX, enoxastrobin + TX, 4-[[6 -[2-(2,4-difluorophenyl)-1,1-difluoro-2-hydroxy-3-(1,2,4triazol-1-yl)propyl]-3-pyridyl]oxy]benzonitrile + TX, 4- [[6-[2-(2,4-difluorophenyl)-1,1-difluoro-2hydroxy-3-(5-sulfanyl-1,2,4-triazol-1-yl)propyl]-3-pyridyl]oxy ]benzonitrile + TX, 4-[[6-[2-(2,4difluorophenyl)-1,1-difluoro-2-hydroxy-3 -(5-thioxo-4H-1,2,4-triazol-1 -yl )drank| -3-pyridyl]oxy]benzonitrile + TX, trinexapac + TX, cumoxystrobin + TX, zhongshenmicin + TX, copper thiadiazole + TX, zinc thiazole + TX, amectotractin + TX, iprodione + TX, seboctylamine + TX; I-[5-bromo-2methyl-6-[(1S)-1-methyl-2-propoxyethoxy]-3-pyridyl]-N-ethyl-N-methylformamidine + TX, I-[5-bromo-2methyl-6 -[(1R)-1-methyl-2-propoxyethoxy]-3-pyridyl]-N-ethyl-N-methylformamidine + TX, I-[5-bromo-2methyl-6-(1-methyl-2-propoxyethoxy) -3-pyridyl]-N-ethyl-N-methylformamidine + TX, I-[5-chloro-2methyl-6-(1-methyl-2-propoxyethoxy)-3-pyridyl]-N-ethyl-N-methylformamidine + TX, I-[5-bromo-2methyl-6-(1-methyl-2-propoxyethoxy)-3-pyridyl]-N-isopropyl-N-methylformamidine + TX (these compounds can be prepared according to the methods described in WO 2015 /155075); I-[5-bromo-2-methyl6-(2-propoxypropoxy)-3-pyridyl]-N-ethyl-N-methylformamidine + TX (these compounds can be prepared according to the methods described in IPCOM000249876D); N-isopropyl-N'-[5-methoxy-2-methyl-4(2,2,2-trifluoro-1-hydroxy-1-phenylethyl)phenyl]-N-methylformamidine + TX, N-[4-(1- cyclopropyl-2,2,2trifluoro-1-hydroxyethyl)-5-methoxy-2-methylphenyl]-N-isopropyl-N-methylformamidine + TX (these compounds can be prepared according to the methods described in WO 2018/228896); No.ethyl-No.-[5methoxy-2-methyl-4-[(2-trifluoromethyl)oxetan-2-yl]phenyl]-N-methylformamidine + TX, No.ethyl-No.-[5methoxy-2-methyl-4-[ (2-trifluoromethyl)tetrahydrofuran-2-yl]phenyl]-N methylformamidine + TX (these compounds can be prepared according to the methods described in WO 2019/110427); N-[(1R)-1benzyl-3-chloro-1-methyl-but-3-enyl]-8-fluoroquinoline-3-carboxamide + TX, H-[(^)-1-benzyl-3-chloro-1methylbut -3-enyl|-8-fluoroquinoline-3-carboxamide + TX, N[(^)-1-benzyl-3,3,3-trifluoro-1methylpropyl]-8-fluoroquinoline-3-carboxamide + TX, N-[ (1S)-1-benzyl-3,3,3-trifluoro-1-methylpropyl]-8fluoroquinoline-3-carboxamide + TX, N-[(1R-)-1-benzyl-1,3-dimethylbutyl]-7, 8-difluoroquinoline-3-carboxamide + TX, N-[(1S)-1-benzyl-1,3-dimethylbutyl]-7,8-difluoroquinoline-3-carboxamide + TX, 8fluoro-K-[(1I.)-1- [(3-fluorophenyl)methyl]-1,3-dimethylbutyl]quinoline-3-carboxamide + TX, 8-fluoro-N-[( 1S)1-[(3-fluorophenyl)methyl]-1,3-dimethylbutyl] quinoline-3-carboxamide + TX, N-[(1K)-1-benzyl-1,3-dimethylbutyl]-8-fluoroquinoline-3-carboxamide + TX, N-[(1S)-1-benzyl-1,3-dimethylbutyl ]-8-fluoroquinoline-3-carboxamide + TX, H-((1K)-1-benzyl-3-chloro-1-methylbut-3-enyl)-8-fluoroquinoline-3-carboxamide + TX, No((^)-1- benzyl-3-chloro-1-methylbut-3-enyl)-8-fluoroquinoline-3-carboxamide + TX (these compounds can be prepared according to the methods described in WO 2017/153380); 1-(6,7dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline + TQ, 1-(6,7dimethylpyrazolo[1,5-a]pyridine -3-yl)-4,4,6-trifluoro-3,3-dimethylisoquinoline + TX, 4,4-difluoro-3,3dimethyl-1-(6-methylpyrazolo[1,5-a|pyridin-3-yl )isoquinoline + TX, 4,4-difluoro-3,3-dimethyl-1-(7methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline + TX, 1-(6-chloro-7-methylpyrazolo[1 ,5-a]pyridin-3-yl)4,4-difluoro-3,3-dimethylisoquinoline + TX (these compounds can be prepared according to the methods described in WO 2017/025510); 1-(4,5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline + TX, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4-difluoro- 3,3-dimethylisoquinoline + TX, 6-chloro4,4-difluoro-3,3-dimethyl-1-(4-methylbenzimidazol-1-yl)isoquinoline + TX, 4,4-difluoro-1-(5-fluoro- 4methylbenzimidazol-1-yl)-3,3-dimethylisoquinoline + TX, 3-(4,4-difluoro-3,3-dimethyl-1-isoquinolyl)-7.8

- 71 046368 dihydro-6H-cyclopenta[e]benzimidazole + TX (these compounds can be obtained according to the methods described in WO 2016/156085); Nmethoxy-H-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]cyclopropanecarboxamide + TC, K2-dimethoxy-H-[[4-[5-(tri( |)tormethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide + TX, Nethyl-2-methyl-H-[[4-[5-(trifluoromethyl)-1,2,4 -oxadiazol3-yl]phenyl]methyl]propanamide + TX, 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl](enyl]methyl]urea + TX, 1,3-dimethoxy-1-[[4-[5-(tri(tormethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]urea + TX, 3-ethyl-1-methoxy- 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]urea + TC, No[[4-[5-(trifluoromethyl)-1,2,4-oxadiazole -3-yl]phenyl]methyl]propanamide + TX, 4,4-dimethyl-2-[[4-[5-(tri(tormethyl)-1,2,4-oxadiazol-3-yl](enyl]methyl ]isoxazolidin-3one + TX, 5,5-dimethyl-2-[[4-[5-(tri(tormethyl)-1,2,4-oxadiazol-3-yl](enyl]methyl]isoxazolidin-3-one + TX, ethyl-1-[[4-[5-(tri(tormethyl)-1,2,4-oxadiazol-3-yl](enyl]methyl]pyrazole-4-carboxylate + TX, KH-dimethyl-1 -[[4-[5-(tri(()tormethyl)-1.2.4-oxadiazol-3-yl|(()enyl|methyl|-1.2.4-triazol-3-amine + TX. The compounds of this paragraph can be prepared according to the methods described in WO 2017/055473, WO 2017/055469, WO 2017/093348 and WO 2017/118689; 2-[6-(4-chlorophenoxy)-2-(trifluoromethyl)-3pyridyl]-1-(1,2,4-triazol-1-yl)propan-2-ol + TX (this compound can be prepared according to the methods , described in WO 2017/029179); 2-[6-(4-bromophenoxy)-2-(1fluoromethyl)-3-pyridyl]-1-(1,2,4triazol-1-yl)propan-2-ol + TX (this compound can be prepared according to the methods , described in WO 2017/029179); 3-[2-(1-chlorocyclopropyl)-3-(2-fluorophenyl)-2-hydroxypropyl]imidazole-4carbonitrile + TX (this compound can be prepared according to the methods described in WO 2016/156290); 3-[2-(1-chlorocyclopropyl)-3-(3-chloro-2-fluorophenyl)-2-hydroxypropyl]imidazole-4-carbonitrile + TX (this compound can be prepared according to the methods described in WO 2016/156290) ; (4-(enoxy(enyl)methyl-2-amino-6-methylpyridin-3-carboxylate + TX (this compound can be prepared according to the methods described in WO 2014/006945); 2,6-dimethyl-1H,5H[ 1,4]dithiino[2,3-c:5,6-c']dipyrrole-1,3,5,7(2H,6H)-tetron + TX (this compound can be prepared according to the methods described in WO 2011 /138281); No.methyl-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]benzenecarbothioamide + TX; No.methyl-4-[5-(trifluoromethyl)-1,2,4-oxadiazol- 3-yl]benzamide + TX; (2,2E)-5-[1-(2,4-dichlorophenyl)pyrazol-3-yl]oxy-2-methoxyimino-N,3-dimethyl-pent-3-enamide + TX (this compound can be prepared according to the methods described in WO 2018/153707); N'-(2chloro-5-methyl-4-phenoxyphenyl)-N-ethyl-N-methylformamidine + TX; N-[2-chloro- 4-(2-fluorophenoxy)-5methylphenyl]-N-ethyl-N-methylformamidine + TX (this compound can be prepared according to the methods described in WO 2016/202742); 2-(difluoromethyl)-N-[(3S)- 3-ethyl-1,1-dimethylindan-4-yl]pyridin3-carboxamide + TX (this compound can be prepared according to the methods described in WO 2014/095675); (5-methyl-2-pyridyl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methanone + TX, (3methylisoxazol-5-yl)-[4-[ 5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methanone + TX (these compounds can be prepared according to the methods described in WO 2017/220485); 2-oxo-N-propyl-2-[4[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]acetamide + TX (this compound can be prepared according to the methods described in WO 2018/ 065414); ethyl 1-[[5-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl|-2-thienyl|methyl|pyrazole-4-carboxylate + TX (this compound can be prepared according to the methods described in WO 2018/158365); 2,2-difluoro-N-methyl-2-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol3-yl]phenyl]acetamide + TX, N[(E)-methoxyiminomethyl]-4-[ 5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]benzamide + TX, N[(2)-methoxyiminomethyl]-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl] benzamide + TX, N[N-methoxy-C-methylcarbonimidoyl]-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide + TX (these compounds can be prepared according to the methods described in WO 2018/202428).

In typical mixture-based compositions, mixtures of compounds of formula (I) (selected from table X (above)) with the active ingredients described above contain a compound selected from table. X (above), and the active ingredient described above, preferably at a mixture ratio of 100:1 to 1:100, particularly 50:1 to 1:50, more particularly at a mixture ratio of 20:1 to 1:20, even more specifically from 10:1 to 1:10, namely from 5:1 and 1:5, particular preference is given to the ratio from 2:1 to 1:2, and the ratio from 4:1 to 2:1 is also preferred, especially total with a ratio of 1:1, or 5:1, or 5:2, or 5:3, or 5:4, or 4:1, or 4:2, or 4:3, or 3:1, or 3: 2, or 2:1, or 1:5, or 2:5, or 3:5, or 4:5, or 1:4, or 2:4, or 3:4, or 1:3, or 2: 3, or 1:2, or 1:600, or 1:300, or 1:150, or 1:35, or 2:35, or 4:35, or 1:75, or 2:75, or 4: 75, or 1:6000, or 1:3000, or 1:1500, or 1:350, or 2:350, or 4:350, or 1:750, or 2:750, or 4:750. These mixture ratios are given by weight.

The mixture compositions described above (according to the present invention and the exemplary mixture compositions) can be used in a method of performing pest control that involves applying a composition containing the mixture described above to pests or their environment.

Mixtures containing a compound (formula (I) selected from Table X (above) and one or more of the active ingredients described above can be used, for example, in a separate ready-mix form, in a combination spray mixture made up of individual formulations from individual components of the active ingredients, such as a tank mixture, and in the combined use of individual active ingredients when applied in a sequential manner, i.e. one at a time

- 72 046368 to others over a fairly short period of time, such as a few hours or days. The order of application of compounds of formula (I) selected from table. X (above) and the active ingredients described above are not essential to the practice of the present invention.

The compositions of the present invention can also be used to improve crops. According to the present invention, the term crop improvement means improved plant vigor, improved plant quality, improved tolerance to stress factors and/or improved resource utilization.

According to the present invention, the term improvement in plant vigor means that certain traits are improved qualitatively or quantitatively compared to the same trait in a control plant that was grown under the same conditions without applying the method of the present invention. Such traits include, but are not limited to, early and/or improved germination, improved germination, ability to use less seed, increased root growth, more developed root system, increased root nodule formation, increased seedling growth rate, increased tillering rate, stronger shoots, more productive shoots, increased or improved plant density, less plant fall (lodging), increased and/or improved plant height, increased plant weight (fresh or dry), larger leaf blades, greener leaf color, increased pigment content, increased photosynthetic activity , earlier flowering, longer panicles, earlier grain maturation, increased seed, fruit or pod size, increased number of pods or ears, increased number of seeds per pod or ear, increased seed weight, increased seed filling, fewer dead lower leaves, retention aging, improved plant viability, increased levels of amino acids in storage tissues and/or lower inputs of required resources (eg, less fertilizer, water and/or labor costs). A plant with improved vigor may be characterized by improvement in any of the above-mentioned traits, or any combination or two or more of the above-mentioned traits.

According to the present invention, the term improvement in plant quality means that certain traits are improved qualitatively or quantitatively compared to the same trait in a control plant that was grown under the same conditions without applying the method of the present invention. Such attributes include, but are not limited to, improved plant appearance, reduced amount of ethylene (reduced production and/or reception inhibition), improved quality of harvested material, e.g., seeds, fruits, leaves, vegetables (such improved quality may be manifested as improved appearance of harvested material) , improved carbohydrate content (e.g., increased amounts of sugar and/or starch, improved sugar-acid ratio, reduced reducing sugars, increased sugar production), improved protein content, improved oil content and composition, improved nutritional value, reduced non-nutritive compounds, improved organoleptic properties (e.g. improved palatability) and/or increased consumer health benefits (e.g. increased levels of vitamins and antioxidants)), improved post-harvest characteristics (e.g. increased shelf life and/or shelf stability, improved chemical processability, facilitated extraction of compounds), more uniform crop development (eg synchronized germination, flowering and/or fruiting of plants) and/or improved seed quality (eg for use in subsequent seasons). An improved quality plant may be characterized by an improvement in any of the above-mentioned traits, or any combination or two or more of the above-mentioned traits.

According to the present invention, the term improved tolerance to stress factors means that certain traits are improved qualitatively or quantitatively compared to the same trait in a control plant that was grown under the same conditions without using the method of the present invention. Such traits include, but are not limited to, increased tolerance and/or resistance to abiotic stressors that result in suboptimal growing conditions, such as drought (e.g., any stress that results in insufficient plant water content, insufficient water uptake capacity, or reduced plant water supply ), cold exposure, heat exposure, osmotic stress, UV stress, flooding, increased salinity (e.g. in soil), increased mineral exposure, ozone exposure, exposure to high intensity lighting, and/or limited nutrient availability (e.g., nitrogen and/or or phosphorus-containing nutrients). A plant with improved stress tolerance may be characterized by an improvement in any of the above-mentioned traits or any combination of two or more of the above-mentioned traits. In the case of stress caused by drought and nutrient deficiencies, such improved tolerance may be due to, for example, more efficient absorption, application or retention of water and nutrients.

According to the present invention, the term improved resource utilization

- 73 046368 means that the plants are able to grow more efficiently using given levels of resources compared to the growth of control plants that are grown under the same conditions without using the method of the present invention. Specifically, resources include, but are not limited to, fertilizer (eg, nitrogen, phosphorus, potassium, and micronutrients), light, and water. A plant with improved resource utilization may be characterized by improved utilization of any of the above-mentioned resources or any combination of two or more of the above-mentioned resources.

Other crop improvements of the present invention include reduced plant height or reduced tillering, which are preferred properties for crops or conditions where less biomass and fewer shoots are desired.

Any or all of the above crop improvements may result in improved yield by improving, for example, plant physiology, plant growth and development, and/or plant architecture. In the context of the present invention, the term yield includes, without limitation, (i) an increase in the rate of biomass production, grain yield, starch content, oil content and/or protein content, which may result from (a) an increase in the amount produced by the plant per se, or (b) improved ability to harvest plant material, (ii) improved composition of harvested material (e.g., improved sugar-acid ratios, improved oil composition, increased nutritional value, reduced non-nutritive compounds, increased consumer health benefits), and/or (iii) increased/lighter ability crop harvesting, improved suitability for crop processing, better storage stability/extended shelf life. Increased crop yield means that when a quantitative measurement can be made, the yield of the corresponding plant product is increased by a measurable amount compared to the yield of the same plant product produced under the same conditions but without the use of the present invention. According to the present invention, it is preferable that the yield is increased by at least 0.5%, more preferably by at least 1%, even more preferably by at least 2%, even more preferably by at least 4%, preferably 5% or even more.

Any or all of the above crop improvements could also lead to better land use, e.g. land that was previously inaccessible or suboptimal for cultivation may become available. For example, plants that exhibit an increased ability to survive drought conditions can be cultivated in areas with suboptimal rainfall, such as those likely bordering a desert or even located in the desert itself.

In one aspect of the present invention, crop improvements are carried out in the substantially free environment of pests and/or diseases and/or abiotic stress. In a further aspect of the present invention, improvements in plant vigor, stress tolerance, quality and/or yield are achieved with virtually no pest and/or disease exposure. For example, pests and/or diseases can be controlled through pesticide treatments that are applied prior to or concurrently with the method of the present invention. In yet another additional aspect of the present invention, improvements in plant vigor, stress tolerance, quality and/or yield are accomplished in the absence of pest and/or disease exposure. In a further embodiment, improvements in plant vigor, quality and/or yield are accomplished in the absence or substantially the absence of abiotic stress.

The compositions of the present invention can also be used in the field of protecting stored goods from fungal attack. According to the present invention, the term stored goods is understood to mean natural substances of plant and/or animal origin and their processed forms, which have been taken from the natural life cycle and for which long-term protection is required. Stored goods of plant origin, such as plants or parts thereof, such as petioles, leaves, tubers, seeds, fruits or grains, may be protected in a freshly harvested state or in a processed form such as pre-dried, moistened, crushed, ground, pressed or roasted . Also included in the definition of warehoused goods is timber, either in the form of unprocessed timber such as structural timber, power poles and fencing, or in the form of finished products such as furniture or items made from wood. Stored goods of animal origin are hides, skins, furs, hair, etc. The composition of the present invention can prevent adverse effects such as rotting, discoloration or molding. Preferably, the term warehoused goods is understood to mean natural plant substances and/or processed forms thereof, more preferably fruits and their processed forms, such as pome fruits, stone fruits, berries and citrus fruits, as well as processed forms thereof. In another preferred embodiment

- 74 046368 implementation of the present invention, the term warehoused goods is understood to mean wood.

Therefore, a further aspect of the present invention is a method of protecting stored goods, which includes applying to the stored goods a composition in accordance with the present invention.

The composition of the present invention can also be used in the field of protecting technical materials from fungal attack. According to the present invention, the term technical material includes paper; carpets; structures; cooling and heating systems; facing slabs; ventilation and air conditioning systems, etc.; Preferably, the term technical material is understood to mean cladding boards. The composition of the present invention can prevent adverse effects such as rotting, discoloration or molding.

The composition of the present invention is typically formulated by various methods using formulation aids such as carriers, solvents and surfactants. The compositions may be present in various physical forms, for example, sprayable powders, gels, wettable powders, water-dispersible granules, water-dispersible tablets, effervescent pellets, emulsifiable concentrates, microemulsion concentrates, oil-in-water emulsions, oil-based pourable formulations, aqueous dispersions, oil dispersions, suspoemulsions, capsule suspensions, emulsifiable granules, soluble liquids, water-soluble concentrates (with water or a water-miscible organic solvent as a carrier), impregnated polymer films or in other forms known, for example, from the Manual on Development and Use of FAO and WHO Specifications for Pesticides, United Nations, First Edition, Second Revision (2010). Such formulations can either be applied directly or diluted before use. Dilutions can be carried out, for example, with water, liquid fertilizers, micronutrients, biological organisms, oil or solvents.

The compositions can be prepared, for example, by mixing the active ingredient with formulation auxiliaries to obtain compositions in the form of fine solids, granules, solutions, dispersions or emulsions. The active ingredients may also be formulated with other excipients, for example, fine solids, mineral oils, vegetable or animal oils, modified vegetable or animal oils, organic solvents, water, surfactants, or combinations thereof.

The active ingredients may also be contained in microcapsules. Microcapsules contain active ingredients in a porous carrier. This allows the active ingredients to be released into the environment in controlled quantities (eg slow release). Microcapsules typically have a diameter ranging from 0.1 to 500 microns. They contain active ingredients in amounts ranging from approximately 25 to 95% by weight of the capsule. The active ingredients may be in the form of a monolithic solid, in the form of fine particles in a solid or liquid dispersion, or in the form of a suitable solution. Encapsulating membranes may contain, for example, natural and synthetic rubbers, cellulose, styrene-butadiene copolymers, polyacrylonitrile, polyacrylate, polyesters, polyamides, polyureas, polyurethane or chemically modified polymers and starch xanthates or other polymers that are known to one skilled in the art. Alternatively, very fine microcapsules can be prepared in which the active ingredient is contained as fine particles in a solid matrix of the base material, but the microcapsules are not themselves encapsulated.

Formulation aids which are suitable for preparing the compositions according to the present invention are known per se. Liquid carriers that can be used are water, toluene, xylene, petroleum ether, vegetable oils, acetone, methyl ethyl ketone, cyclohexanone, acid anhydrides, acetonitrile, acetophenone, amyl acetate, 2-butanone, butylene carbonate, chlorobenzene, cyclohexane, cyclohexanol, alkyl esters of acetic acid , diacetone alcohol, 1,2dichloropropane, diethanolamine, p-diethylbenzene, diethylene glycol, diethylene glycol abietate, diethylene glycol butyl ether, diethylene glycol ethyl ether, diethylene glycol methyl ether, KH-dimethyl tformamide. dimethyl sulfoxide, 1,4-dioxane, dipropylene glycol, dipropylene glycol methyl ether, dipropylene glycol dibenzoate, diproxitol, alkylpyrrolidone, ethyl acetate, 2-ethylhexanol, ethylene carbonate, 1,1,1-trichloroethane, 2-heptanone, alpha-pinene, d-limonene, ethyl lactate, ethylene glycol, ethylene glycol butyl ether, ethylene glycol methyl ether, gamma-butyrolactone, glycerin, glycerol acetate, glycerol diacetate, glycerol triacetate, hexadecane, hexylene glycol, isoamyl acetate, isobornyl acetate, isooctane, isophorone, isopropylbenzene, isopropyl myristate , lactic acid, laurylamine, mesityloxide, methoxypropanol, methylisoamyl ketone, methyl isobutyl ketone, methyl laurate, methyl octanoate, methyl oleate, methylene chloride, m-xylene, n-hexane, noctylamine, octadecanoic acid, octylamine acetate, oleic acid, oleylamine, o-xylene, phenol, polyethylene glycol, propionic acid acid, propyl lactate, propylene carbonate , propylene glycol, plain

- 75 046368 propylene glycol methyl ether, p-xylene, toluene, triethyl phosphate, triethylene glycol, xylene sulfonic acid, paraffin, mineral oil, trichloroethylene, perchlorethylene, ethyl acetate, amyl acetate, butyl acetate, propylene glycol methyl ether, diethylene glycol methyl ether, methanol, ethanol, isopropanol and high molecular weight alcohols such as amyl alcohol, tetrahydrofurfuryl alcohol, hexanol, octanol, ethylene glycol, propylene glycol, glycerin, N-methyl-2-pyrrolidone and the like.

Suitable solid carriers are, for example, talc, titanium dioxide, pyrophyllite clay, silica, attapulgite clay, diatomaceous earth, limestone, calcium carbonate, bentonite, calcium montmorillonite, cottonseed hulls, wheat flour, soybean flour, pumice, wood flour, ground shells walnuts, lignin and similar substances.

A large number of surfactants can be used successfully in both solid and liquid formulations, especially in those formulations that can be diluted with a vehicle before use. Surfactants may be anionic, cationic, nonionic, or polymeric, and may be used as emulsifiers, wetting agents or suspending agents, or for other purposes. Typical surfactants include, for example, alkyl sulfate salts such as diethanolammonium lauryl sulfate; alkylaryl sulfonate salts such as calcium dodecylbenzenesulfonate; alkylphenol/alkylene oxide addition products such as nonylphenol ethoxylate; alcohol/alkylene oxide addition products such as tridecyl alcohol ethoxylate; soaps such as sodium stearate, alkyl naphthalene sulfonate salts such as sodium dibutyl naphthalene sulfonate; dialkyl esters of sulfosuccinate salts such as sodium di(2ethylhexyl)sulfosuccinate; sorbitol esters; such as sorbitoleate, quaternary amines such as lauryl trimethyl ammonium chloride; polyethylene glycol fatty acid esters such as polyethylene glycol stearate; block copolymers of ethylene oxide and propylene oxide; and salts of mono- and dialkyl phosphate esters; as well as additional substances described, for example, in McCutcheon's Detergents and Emulsifiers Annual, MC Publishing Corp., Ridgewood New Jersey (1981).

Additional adjuvants that may be used in pesticide formulations include crystallization inhibitors, viscosity modifiers, suspending agents, colorants, antioxidants, foaming agents, light absorbers, mixing aids, defoamers, complexing agents, neutralizing or pH-modifying agents, and buffers. corrosion inhibitors, fragrances, wetting agents, absorption enhancers, micronutrients, plasticizers, glidants, lubricants, dispersants, thickeners, antifreeze, microbicides, and liquid and solid fertilizers.

The compositions of the present invention may contain an additive containing a vegetable or animal oil, mineral oil, alkyl esters of such oils, or mixtures of such oils and oil derivatives. The amount of oil additive in the composition according to the present invention is usually from 0.01 to 10% based on the amount of the mixture to be used. For example, the oil additive can be added to the sprayer reservoir at the required concentration after the spray mixture is prepared. Preferred oil additives contain mineral or vegetable oils, such as canola oil, olive oil or sunflower oil, emulsified vegetable oil, alkyl esters of vegetable oils, such as methyl derivatives, or an animal oil, such as fish oil or beef tallow. Preferred oil additives contain alkyl esters of C8-C22 fatty acids, in particular methyl derivatives of _C12 - _C18 fatty acids, for example, methyl esters of lauric acid, palmitic acid and oleic acid (methyl laurate, methyl palmitate and methyl oleate, respectively). Many oil derivatives are known from Compendium of Herbicide Adjuvants, ^10th Edition, Southern Illinois University, 2010.

The compositions typically contain from 0.1 to 99% by weight, in particular from 0.1 to 95% by weight of the compounds of component (A) and component (B) and from 1 to 99.9% by weight of a formulation aid, which preferably contains from 0 to 25% by weight of surfactant. Since commercial products may preferably be formulated as concentrates, the end user will typically use diluted formulations.

Application rates vary widely and depend on soil properties, method of application, crop plant, pest being controlled, prevailing climatic conditions and other factors determined by application method, time of application and target crop. As a general recommendation, the compounds can be applied at a rate of 1 to 2000 l/ha, in particular 10 to 1000 l/ha.

Certain mixture compositions containing the compound of formula (I) described above may exhibit a synergistic effect. It is observed whenever the effectiveness of a combination of active ingredients is greater than the sum of the effectiveness values of the individual components. The expected potency E for a given combination of active ingredients obeys the so-called Colby formula and can be calculated as follows (COLBY, S.R. Calc synulatinger

- 76 046368 gistic and antagonistic responses of herbicide combination. Weeds, Vol. 15, pp. 20-22; 1967):

ppm = milligrams of active ingredient (= a.i.) per liter of spray mixture,

X = % potency of active ingredient (A) using p ppm of active ingredient, Y = % potency of active ingredient (B) using q ppm of active ingredient.

According to the Colby formula, the expected (additive) effectiveness of the active ingredients (A) + (B) in the case of using p + q ppm of the active ingredient is e = x + y-2LX oo

If the actual observed efficiency (O) is greater than the expected efficiency (E), then the efficiency of the combination is superadditive, i.e. there is a synergistic effect. In mathematical terms, synergy corresponds to a positive difference (O-E). In the case of only additional addition of activity indicators (expected activity), the specified difference (O-E) is equal to zero. A negative value of the indicated difference (O-E) indicates a loss of activity compared to the expected activity.

However, in addition to the actual synergistic effect with respect to fungicidal activity, the composition according to the present invention may also be characterized by additional unexpected advantageous properties. Examples of such advantageous properties that can be cited are more efficient degradability; improved toxicological and/or ecotoxicological properties; improved beneficial plant characteristics including germination, crop yield, more developed root system, increased tillering rate, increased plant height, larger leaf blade, fewer dead lower leaves, stronger shoots, greener leaf color, less fertilizer requirement, less seed requirement, more productive shoots, earlier flowering, earlier grain maturation, less plant drop (lodging), increased seedling growth rate, improved plant vigor and earlier germination.

The composition according to the present invention can be applied to phytopathogenic microorganisms, beneficial plants, their habitat, their propagation material, stored goods or technical materials that are at risk of attack by microorganisms.

The composition according to the present invention can be used before or after microorganism contamination of useful plants, their propagation material, stored goods or technical materials.

The amount in which the composition of the present invention will be used will depend on various factors such as the compounds used; the object of treatment, such as, for example, plants, soil or seeds; type of treatment, such as, for example, spraying, pollination or seed dressing; the purpose of the processing, such as, for example, prophylactic or therapeutic; type of fungus to be controlled or time of application.

When applied to useful plants, component (A) is generally applied at a rate of 5 to 2000 g ai/ha, in particular 10 to 1000 g ai/ha, for example 50, 75, 100 or 200 g a.i./ha, usually together with from 1 to 5000 g a.i./ha, in particular from 2 to 2000 g a.i./ha, for example 100, 250, 500, 800, 1000, 1500 g a.i./ha component (B).

In agricultural practice, application rates of the composition according to the present invention depend on the type of effect desired, and are generally in the range from 20 to 4000 g of the total composition per hectare.

If the composition according to the present invention is used for treating seeds, rates of from 0.001 to 50 g of the compound as component (A) per kg of seeds are usually sufficient, preferably from 0.01 to 10 g per kg of seeds and from 0.001 to 50 g of the compound as component (B) per kg of seeds, preferably from 0.01 to 10 g per kg of seeds.

To avoid doubt of interpretation, when a literary citation, patent application, or patent is cited in the text of this application, the full text of said citation is incorporated herein by reference.

Examples

The following examples serve to illustrate the present invention. The compounds (and compositions) of the present invention can be distinguished from known compounds (and compositions) by their higher effectiveness at low application rates, which can be verified by one skilled in the art using the experimental procedures set forth in the Examples section, using, if necessary, lower application rates, for example 50 ppm, 12.5 ppm, 6 ppm, 3 ppm, 1.5 ppm or 0.2 ppm active ingredient(s). Throughout this description, temperatures are given in degrees Celsius (°C), and m.p. means melting point. LC/MS means liquid chromatography with mass spectrometry and the description of the apparatus and methods are as follows. Method A: ACQUITY UPLC from Waters, Waters UPLC HSS T3, 1.8 µm particle size, 30 x 2.1 mm column, 0.85 ml/min, 60°C, H ₂ O/MeOH 95:5 + 0, 05% HCOOH (90%)/CH ₃ CN + 0.05% HCOOH

- 77 046368 (10%) - 1.2 min - CH3CN + 0.05% HCOOH (100%) - 0.30 min, ACQUITY SQD mass spectrometer from Waters, ionization method: electrospray (ESI), polarity: positive ions , capillary voltage (kV) 3.00, cone voltage (V) 30.00, extractor voltage (V) 2.00, initial temperature (°C) 150, desolvation temperature (°C) 350, gas flow at cone (l/hour) 0, desolvation gas flow (l/hour) 650).

Method B: ACQUITY UPLC from Waters, Waters UPLC HSS T3, 1.8 µm particle size, 30 x 2.1 mm column, 0.85 ml/min, 60°C, H ₂ O/MeOH 95:5 + 0, 05% HCOOH (90%)/CH ₃ CN + 0.05% HCOOH (10%) - 2.7 min - CH3CN + 0.05% HCOOH (100%) - 0.30 min, ACQUITY SQD mass spectrometer from Waters, ionization method: electrospray (ESI), polarity: positive ion, capillary voltage (kV) 3.00, cone voltage (V) 30.00, extractor voltage (V) 2.00, initial temperature (°C ) 150, desolvation temperature (°C) 350, gas flow in the cone (l/h) 0, desolvation gas flow (l/h) 650)).

Method C: MS: Waters ZQ mass spectrometer (single quadrupole mass spectrometer) Instrument parameters: ionization method: electrospray, polarity: positive (negative) ions, capillary voltage (kV) 3.00, cone voltage (V) 30 .00, extractor voltage (V) 2.00, gas temperature (°C) 350, drying gas flow (ml/min.) 9.8, nozzle pressure 45 psi. in., mass range: 90 to 1000 Da.

HPLC: Agilent HP 1100 HPLC: Solvent degasser, ZCQ/ZDQ pump, heated column space, and diode array detector. Column: porpshell 120 C18, particle size 2.7 µm, 120 angstroms, 4.6 x 50 mm, temperature: 30°C, DAD wavelength range (nm): 190 to 400, solvent gradient: A = water + 0.1% NCOOH. B = acetonitrile + 0.08% HCOOH

Time (min.) A% B% Flow (ml/min.) 0.00 85.0 15.0 0.6 4.00 5.00 95.00 0.6 10.00 5.00 95.00 0.6 Examples of compositions: Wettable powders A) b) With) active ingredients [components (A) and (B)] 25% 50% 75% sodium lignosulfonate 5% 5% - sodium lauryl sulfate 3% - 5% sodium diisobutylnaphthalene sulfonate - 6% 10% polyethylene glycol phenol ether - 2% - (7-8 mol ethylene oxide) highly dispersed silicic acid 5% 10% 10% kaolin 62% 27%

The active ingredient is thoroughly mixed with the excipients and the mixture is thoroughly ground in a suitable mill to obtain wettable powders which can be diluted with water to obtain suspensions of the required concentration.

Powders for dry seed treatment A) b) With) active ingredients [components (A) and (B)] 25% 50% 75% light mineral oil 5% 5% 5% highly dispersed silicic acid 5% 5% - kaolin 65% 40% - talc - - 20%

The active ingredient is thoroughly mixed with the excipients and the mixture is thoroughly ground in a suitable mill to obtain powders which can be directly used for seed treatment.

- 78 046368

Emulsifiable concentrate: active ingredients [components (A) and (B)] 10% polyethylene glycol octylphenol ether 3% (4-5 mol ethylene oxide) calcium dodecylbenzenesulfonate 3% castor oil polyglycol ether 4% (3-5 mol ethylene oxide) cyclohexanone 30% xylene mixture 50%

From this concentrate, by diluting with water, emulsions of any required degree of dilution can be obtained, which can be used for plant protection.

Dust preparations A) b) With) active ingredients [components (A) and (B)] 5 % 6% 4% talc 95% - - kaolin - 94% - mineral filler - - 96%

Ready-to-use powdered preparations are prepared by mixing the active ingredient with the carrier and grinding the mixture in a suitable mill. Such powders can also be used for dry seed dressing. Extruded granules: active ingredients [components (A) 15% and (B)] sodium lignosulfonate 2% carboxymethylcellulose 1% kaolin 82%

The active ingredient is mixed and crushed with the excipients and the mixture is moistened with water. The mixture is extruded and then dried in a stream of air.

Coated granules: active ingredients [components (A) 8% and (B)] polyethylene glycol (molecular weight 3% 200) kaolin 89%

The finely ground active ingredient is evenly applied to the kaolin moistened with polyethylene glycol in a mixing device. In this way, dust-free, coated granules are obtained.

Suspension concentrate:

active ingredients [components (A) and (B)] 40% propylene glycol 10% nonylphenol polyethylene glycol ether (15 mol 6% ethylene oxide) sodium lignosulfonate 10% carboxymethylcellulose 1% silicone oil (as a 75% emulsion in water) 1% water 32%

The finely divided active ingredient is thoroughly mixed with the excipients to obtain a suspension concentrate from which suspensions of any desired degree of dilution can be prepared by dilution with water. Using such diluted solutions, living plants, as well as plant propagation material, can be treated and protected from contamination by microorganisms by spraying, watering or dipping.

- 79 046368

Flowable seed treatment concentrate:

active ingredients [components (A) and (B)] 40% propylene glycol 5% copolymer of butanol and PO/EO 2% tristyrene enol with 10-20 moles of EO 2%

1,2-benzisothiazolin-3-one (as a 20% solution in water) 0.5% calcium salt of monoazopigment 5% silicone oil (as a 75% emulsion in water) 0.2% water 45.3%

The finely divided active ingredient is thoroughly mixed with the excipients to obtain a suspension concentrate from which suspensions of any desired degree of dilution can be prepared by dilution with water. Using such diluted solutions, living plants, as well as plant propagation material, can be treated and protected from contamination by microorganisms by spraying, watering or dipping. Slow-release capsule suspension

Mix 28 parts of the combination of active ingredients [components (A) and (B)] with 2 parts of an aromatic solvent and 7 parts of a mixture of toluene diisocyanate/polymethylene polyphenyl isocyanate (8:1). This mixture is emulsified in a mixture of 1.2 parts polyvinyl alcohol, 0.05 parts antifoam and 51.6 parts water to obtain the desired particle size. To this emulsion is added a mixture of 2.8 parts 1,6-diaminohexane in 5.3 parts water. The mixture is stirred until the polymerization reaction is completed. The resulting capsule suspension is stabilized by adding 0.25 parts thickener and 3 parts dispersant. The composition of the capsule suspension contains 28% active ingredients. The average diameter of capsules is 8-15 microns. The resulting composition is applied to the seeds in the form of an aqueous suspension in a device suitable for the purpose.

List of abbreviations bs = broad singlet, °C = degrees Celsius, CDCl ₃ = chloroform-d, d = doublet, Pd ₂ (dba) ₃ = tris(dibenzylideneacetone)dipalladium(0), DIPEA = MK-diisonronylethylamine, DMF = dimethylformamide, h = clock, HATU = 1-[bis(dimethylamino)methylene]-1H-1,2,3triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate, m = multiplet, MHz = megahertz, mp = melting point, N = normal, ppm = parts per million, s = singlet, THF = tetrahydrofuran, Xantphos = 4,5bis(diphenylphosphino)-9,9-dimethylxanthene

Examples of receiving

Using the synthetic procedures described above and below, compounds of formula (I) can be prepared accordingly.

Example 1.

This example illustrates the preparation of 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-K-(2,2dimethylcyclobutyl)-5-methylthiazol-4-carboxamide (compound X.05):

a) Preparation of methyl 2-[(2,6-difluoro-4-pyridyl)amino]-5-methylthiazole-4-carboxylate

Under argon, Xantphos (0.2 eq), Pd ₂ (dba) ₃ (0.1 eq) and cesium carbonate (2 eq) were added to the degassed stirred mixture of methyl 2-bromo-5-methylthiazol-4- carboxylate (4.6 g, 18.5 mmol, 1 eq.) and 2,6-difluoropyridin-4-amine (1 eq.) in 1,4-dioxane (660 ml). The reaction mixture was heated to reflux temperature and stirred for 4 hours, after which the temperature was allowed to drop to room temperature. The mixture was diluted with ethyl acetate and filtered through celite, and the resulting filtrate was concentrated using a rotary evaporator. Purification by silica gel column chromatography (cyclohexane/ethyl acetate eluting mixture) provided the desired methyl 2-[(2,6-difluoro-4-pyridyl)amino]-5-methylthiazole-4carboxylate (1.8 g, 6 .31 mmol). 1H-NMR (400 MHz, CDCl ₃ ): δ = 2.73 (s, 3H), 3.94 (s, 3H), 6.75 (s, 1H).

b) Preparation of 2-[(2,6-difluoro-4-pyridyl)amino]-5-methylthiazole-4-carboxylic acid

- 80 046368

Add lithium hydroxide monohydrate (4 eq.) to a solution of 2-[(2,6-difluoro-4-pyridyl)amino]-5methylthiazole-4-carboxylic acid (1.8 g, 6.31 mmol) in a mixture of tetrahydrofuran (35 ml) and water (12 ml). The reaction mixture was stirred for 16 h at room temperature, then the solvents were removed in vacuo. The precipitate was diluted with ethyl acetate and water, then 2N was added slowly. hydrochloric acid until pH reaches 3-4. The resulting precipitate was isolated by filtration and washed twice with water to give the desired product 2-[(2,6-difluoro-4pyridyl)amino]-5-methylthiazole-4-carboxylic acid (1.55 g, 5.71 mmol) . 1H-NMR (400 MHz, (CD3)2SO): δ = 2.69 (s, 3H), 7.30 (s, 2H), 11.35 (bs, 1H), 12.90 (bs, 1H) .

c) Preparation of 2-[(2,6-difluoro-4-pyridyl)amino]-N(2,2-dimethylcyclobutyl)-5-methylthiazole-4-carboxamide

(2,2-Dimethylcyclobutyl)ammonium chloride (1.1 eq.), HATU (1.1 eq.) and DIPEA (2.6 eq.) were added sequentially to a solution of 2-[(2,6-difluoro-4- pyridyl)amino]-5-methylthiazole-4-carboxylic acid (250 mg, 0.92 mmol, 1 eq.) in DMF (9.2 ml). The resulting solution was stirred at room temperature for 1 hour until the starting material was completely consumed (monitored by LCMS). Then a saturated NaHCO3 solution was added to the mixture and the solution was extracted three times with ethyl acetate. The organic phases were combined, dried over sodium sulfate and volatiles were removed using a rotary evaporator. Purification by column chromatography on silica gel (eluent: cyclohexane/ethyl acetate mixtures) gave the desired product, 2-[(2,6difluoro-4-pyridyl)amino]-N(2,2-dimethylcyclobutyl)-5-methylthiazole -4-carboxamide (280 mg, 86% yield).

1H-NMR (400 MHz, CDCl ₃ ): δ = 1.17 (s, 3H), 1.20 (s, 3H), 1.50-1.75 (m, 2H), 1.86-1, 92 (m, 1H), 2.29 2.36 (m, 1H), 2.79 (s, 3H), 4.25-4.31 (m, 1H), 6.87 (s, 2H), 7.32 (d, 1H), 7.67 (s, 1H).

d) 2-[Cyano-(2,6-difluoro-4-pyridyl)amino]-N(2,2-dimethylcyclobutyl)-5-methylthiazol-4-carboxamide (compound X.05)

N

Add butyllithium (2.5 M solution in hexane, 1.25 eq.) at -78°C to a stirred solution of 2[(2,6-difluoro-4-pyridyl)amino]-Na(2,2-dimethylcyclobutyl)- 5-methylthiazole-4-carboxamide (300 mg, 0.85 mmol, 1 eq.) in THF (4.3 ml). After 30 minutes, cyanogen bromide was added to the solution, the reaction mixture was allowed to reach room temperature, and it was stirred for 2 hours. The reaction mixture was then quenched with a saturated aqueous NaHCO ₃ solution and the aqueous phase was extracted three times with ethyl acetate. The combined organic phases were dried over sodium sulfate and volatiles were removed using a rotary evaporator. Purification by column chromatography on silica gel (eluent: cyclohexane/ethyl acetate mixtures) gave the desired product as 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-N(2,2-dimethylcyclobutyl) -5-methylthiazol-4-carboxamide (190 mg, 0.50 mmol, 59% yield).

1H-NMR (400 MHz, CDCI3): δ = 1.10 (s, 3H), 1.21 (s, 3H), 1.55-1.69 (m, 2H), 1.80-1.93 (m, 1H), 2.25-235 (m, 1H), 2.90 (s, 3H), 4.25-4.31 (m, 1H), 6.92 (s, 2H), 7, 12 (d, 1H).

Methyl (2)-2-(5-cyclopentyl-2-methylphenoxy)-3-methoxyprop-2-enoate can be prepared as follows.

Under argon, a 1 M solution of zinc chloride in THF (2.54 mmol) was added to a 2 M solution of cyclopentylmagnesium bromide in THF (2.54 mmol) and the pale yellow suspension was stirred at room temperature for 10 minutes, at which time a slight exothermic effect was observed. A solution of methyl (2)-2-(5-bromo-2-methylphenoxy)-3-methoxyprop-2-enoate (0.153 g, 0.51 mmol) in tetrahydrofuran (2.5 ml) and PdCl ₂ (dppf) was then added ) (0.19 g, 0.025 mmol) and the pale yellow suspension was heated at 50°C for 3 hours. The reaction mixture was then allowed to reach room temperature and quenched with a saturated aqueous solution

- 81 046368

NH ₄ Cl and extracted with tert-butyl methyl ether. The total combined organic fraction was then washed with water and brine, dried over sodium sulfate, filtered and concentrated under reduced pressure. The resulting crude residue was purified by flash chromatography (cyclohexane:EEAc gradient) to obtain 0.106 mg of the title compound as a white solid (mp 80-83°C).

1H NMR (400 MHz, CDCI3) δ ppm: 7.35 (s, 1H), 7.09 (d, 1H), 6.82 (d, 1H), 6.60 (s, 1H), 3.90 (s, 3H), 3.72 (s, 3H), 2.91 (m, 1H), 2.32 (s, 3H), 2.10-1.97 (m, 2H), 1.85- 1.75 (m, 2H), 1.74-1.65 (m, 2H), 1.60-1.45 (m, 2H).

One skilled in the art will appreciate that methyl (2)-2-(5-cyclohexyl-2methylphenoxy)-3-methoxyprop-2-enoate can be synthesized using an equivalent method by replacing cyclopentylmagnesium bromide with cyclohexylmagnesium bromide.

Methyl (2)-2-[5-(4-bromothiazol-2-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate can be prepared as follows. Under argon, add a solution of [3-[(2)-2-methoxy-1-methoxycarbonylvinyloxy]-4methylphenyl]boronic acid (1 g, 3.76 mmol, 1.00 eq.) and 2,4-dibromothiazole (1, 37 g, 5.64 mmol, 1.50 eq.) in 1,4-dioxane (15 ml) and water (3 ml) added sodium carbonate (1.19 g, 11.28 mmol, 3 eq.) and Pd (dppf)Cl ₂ -DCM (0.157 g, 0.188 mmol, 0.05 eq.). The reaction mixture was heated to 90°C and stirred at this temperature for 2 hours. The resulting dark brown solution was cooled to RT, diluted with EtOAc and washed with aq. saturated NaHCO ₃ solution. The organic layer was washed with brine, dried over Na ₂ SO ₄ , filtered and concentrated in vacuo. The residue was purified by flash chromatography (cyclohexane:EEAc) to give methyl (2)2-[5-(4-bromothiazol-2-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate as an orange solid substances.

1H NMR (400 MHz, CDCI3) δ ppm = 7.43-7.47 (dd, 1H), 7.32-7.34 (d, 1H), 7.28-7.30 (s, 1H), 7.21-7.25 (m, 1H), 7.18 (s, 1H), 3.93 (s, 3H), 3.74 (s, 3H), 2.41 (s, 3H).

Methyl (2)-3-methoxy-2-[2-methyl-5-[5-(trifluoromethyl)thiazol-2-yl]phenoxy]prop-2-enoate can be prepared as follows. To a solution of methyl (2)-3-methoxy-2-[2-methyl-5-(4,4,5,5-tetramethyl1,3,2-dioxaborolan-2-yl)phenoxy]prop-2-enoate ( 5.00 g, 14.4 mmol) to tetrahydrofuran:water (4:1, v/v, 72 mL) was added sodium periodate (9.31 g, 43.1 mmol, 3.00 eq.) with followed by the addition of aqueous HCl (2.0 M, 1.79 mL, 3.59 mmol, 0.25 eq.). The resulting white suspension was stirred at room temperature for 4 hours, then EtOAc and water were added. The layers were separated and the aqueous phase was extracted with EtOAc. The total combined organic layer was washed with brine, dried with Na ₂ SO ₄ , filtered and concentrated in vacuo to give [3[(2)-2-methoxy-1-methoxycarbonylvinyloxy]-4-methylphenyl]boronic acid as a white solid. .

1H NMR (400 MHz, DMSO) δ ppm 7.96 (brs, 2H), 7.54 (s, 1H), 7.33 (d, 1H), 7.12 (m, 2H), 3.85 ( s, 3H), 3.64 (s, 3H), 2.23 (s, 3H).

Then to a solution of [3-[(2)-2-methoxy-1-methoxycarbonylvinyloxy]-4methylphenyl]boronic acid (5.0 g, 19 mmol) and 2-bromo-5-(trifluoromethyl)thiazole (1.2) degassed with argon eq.) in 1,4dioxane (38 ml) and water (3.8 ml), X-Phos Pd G2 (0.032 eq.) was added, followed by cesium carbonate (2.0 eq.). The reaction mixture was stirred at 90°C for 2 hours. The dark brown solution was allowed to return to room temperature, diluted with EtOAc and washed with aq. NaHCO ₃ solution and saline solution. The organic layer was dried with MgSO ₄ , filtered and concentrated in vacuo. The residue was purified by flash chromatography (cyclohexane:EEAc) to give methyl (2)-3-methoxy-2-[2-methyl-5-[5-(trifluoromethyl)thiazol-2-yl]phenoxy]prop-2 -enoate.

One skilled in the art will appreciate that methyl (2)-2-[5-(4-cyclohexylthiazol-2yl)-2-methylphenoxy]-3-methoxyprop-2-enoate and methyl (2)-2-[ 5-[4-(ethoxymethyl)thiazol-2-yl]-2-methylphenoxy]-3-methoxyprop-2-enoate can be synthesized using an equivalent method by replacing 2-bromo-5-(trifluoromethyl)thiazole with a suitable thiazole group.

- 82 046368

Table T1. Data on melting temperature (mp) and/or retention time (Rt) for compounds X.01 - X.24 in accordance with formula (I)

Connection name

Structure

T. pl. (°C)

LC/MS

X.01

X.02

H.OZ

X.04

- [Cyano-(2,6-difluoro-4pyridyl)amino]-Ncyclobutyl-5methylthiazol-4carboxamide

2-[Cyano-(5-fluoro-3pyridyl)amino]-Ncyclobutyl-5methylthiazol-4carboxamide

2-[Cyano-(5-fluoro-3pyridyl)amino]-C-(2,2dimethylcyclobutyl)-5 methylthiazol-4carboxamide

2-(M-Cyano-3.5difluoroaniline)-M-(2,2dimethylcyclobutyl)-5 methylthiazol-4carboxamide

126 - 127

136-137

165 - 166

150 - 152

R, = 4.08 minutes (C); MS: mass/charge = 332 (M+1)

R, = 4.53 minutes (C); MS: mass/charge = 350 (M+1)

R, = 5.22 minutes (C); MS: mass/charge = 377 (M+1)

R, = 4.82 minutes (C); MS: mass/charge = 360 (M+1)

- 83 046368

X.06

X.07

X.08

X.09

- [Cyano -(2,6-difluoro-4 pyridyl)amino]-N-(2,2dimethylcyclobutyl)-5formamidothiazol-4carboxamide

- [Cyano-(2,6-difluoro-4pyridyl)amino]-5 methyl-Nspiro[cyclobutane-2,2'indan]-1 -yl-thiazo l-4 carboxamide

- [Cyano-(2,6-difluoro-4pyridyl)amino]-5 methyl-Nspiro [3.3] heptan-3-ylthiazol-4-carboxamide

183 - 185

122 - 124

67-69

100 - 102

2-[Cyano-(2,6-difluoro-4pyridyl)amino]-5 methyl-Nspiro[3.4]octan-3-ylthiazol-4-carboxamide

R _t = 1.09 minutes (A); MS: mass/charge = 453 (M+1)

R, = 1.20 minutes (A); MS: mass/charge = 404 (M+1)

R _t = 1.20 minutes (A); MS: mass/charge = 452 (M+l)

R _t = 1.16 minutes (A); MS: mass/charge = 390 (M+1)

- 84 046368

- 85 046368

- 86 046368

Biological examples of minutes (C);

MS: mass/charge = 352 (M+1) minutes (S):

MS: mass/charge = 348 (M+1

2-Cyano-(5-fluoro-3pyridyl)amino I-N isopentyl-5 methylthiazol-4carboxamide k, = 4.56 minutes (C);

MS: mass/charge = 348 (M+1

R, = 4.96 minutes (C);

MS: mass/charge = 366 (M+1

R, = 4.71 minutes (C):

MS: mass/charge = 386 (M+1)

2-[Cyano-(2,6-difluoro-4pyridyl)amino I-5 methyl-N-pentylthiazo l4-carboxamide

2-[Cyano-(5-fluoro-3pyridyl)amino I-5 methyl-N-pentylthiazo l4-carboxamide

R, = 5.28 minutes (C):

MS: mass/charge = 522 (M+1

M-Benzyl-2-cyano-(2,6difluoro-4pyridyl)amino I-5methylthiazol-4carboxamide

X-util-2-1cyano-(2.6difluoro-4pyridyl)amino I -5 methylthiazol-4carboxamide

N- 3,5bis(Trifluoromethyl)phenylmethyl 1-2-cyano-(2,6difluoro-4pyridyl)amino I -5methylthiazol-4carboxamide

Example A1. Treatment of leaf disk/tomato/Alternaria solani (alternaria blight)

Baby tomato leaf disks were placed on agar in multi-well plates (24-well format) and sprayed with the formulated test compound diluted in water. Leaf discs were inoculated with a suspension of fungal spores 2 days after application. The inoculated leaf disks were incubated at 23°C/21°C (day/night) and 80% relative humidity under a 12/12 h (light/dark) light cycle in a climate chamber and the activity of the compound was assessed as a percentage of disease control. compared to untreated material when the corresponding degree of disease damage was demonstrated on untreated leaf discs representing control discs (5-7 days after application). The following compounds provided at least 80% control of Alternaria solani at 200 ppm compared to the untreated control, which showed extensive disease development under the same conditions: X.02, X.03,

- 87 046368

X.05, X.07, X.12, X.15, X.17, X.21.

Example A2. Treatment of liquid culture of Botryotinia fuckeliana (Botrytis stegea)/(grey rot)

Fungal conidia from cryogenic storage were directly mixed with nutrient broth (Vogel broth) containing 200 μM SHAM. After adding the solution (DMSO) of the test compound, a nutrient broth containing fungal spores is added to a microtiter plate (96-well format). The test compound plates were incubated at 24°C and growth inhibition was determined photometrically 3-4 days after application. The following compounds provided at least 80% control of Botryotinia fuckeliana at 20 ppm compared to the untreated control, which showed extensive disease development under the same conditions: X.05, X.07, X.14, X.18, X.23.

Example A3. Treatment of liquid culture of Glomerella lagenarium (Colletotrichum lagenarium)/(anthracnose)

Fungal conidia from cryogenic storage were directly mixed with nutrient broth (potato dextrose broth, PDB). After adding the solution (DMSO) of the test compound, nutrient broth containing fungal spores was added to a microtiter plate (96-well format). Test plates were incubated at 24°C and growth inhibition was measured photometrically 3-4 days after application. The following compounds provided at least 80% control of Glomerella lagenarium at 20 ppm compared to the untreated control, which showed extensive disease development under the same conditions: X.01, X.03, X.04, X.05, X.06, Х.07, Х.08, Х.09, Х.10, Х.11, Х.12, Х.13, Х.14, Х.15, Х.16, Х.17, Х.18, Х. 19, Х.20, Х.21, Х.23, Х.24.

Example A4. Treatment to prevent leaf disc infection/wheat/Blumeria graminis f. sp. tritici (Erysiphe graminis f. sp. tritici) (powdery mildew of wheat)

Leaf segments of the wheat variety Kanzler were placed on agar in a multiwell plate (24-well format) and sprayed with the formulated test compound diluted in water. Leaf discs were inoculated by shaking powdery mildew-infected plants over test plates 1 day after application. Inoculated leaf discs were incubated at 20°C and 60% relative humidity under a 24-hour dark followed by 12-hour light/12-hour dark environment and compound activity was assessed as a percentage of disease control compared to untreated material at manifestation of the corresponding degree of damage due to the disease on untreated control leaf segments (6-8 days after application). The following compounds provided at least 80% control of Blumeria graminis f. sp. tritici at 200 ppm compared to the untreated control, which under the same conditions showed extensive disease development: X.02, X.03, X.04, X.05, X.07, X.08, X.09, X. 10, Х.11, Х.12, Х.14, Х.15, Х.16, Х.17, Х.18, Х.20, Х.21, Х.23, Х.24.

Example A5. Treatment to prevent leaf disc infection/wheat/Phaeosphaeria nodorum (Septoria nodorum) (septoria glume blight)

Leaf segments of the wheat variety Kanzler were placed on agar in a multiwell plate (24-well format) and sprayed with the formulated test compound diluted in water. Leaf discs were inoculated with a suspension of fungal spores 2 days after application. The inoculated test leaf disks were incubated at 20°C and 75% relative humidity under a 12-hour light/12-hour dark cycle in a climate chamber and the activity of the compound was assessed as a percentage of disease control compared to untreated material when exhibiting the appropriate degree of damage. due to disease on untreated control leaf disks (5-7 days after application). The following compounds provided at least 80% control of Phaeosphaeria nodorum at 200 ppm compared to the untreated control, which under the same conditions showed extensive disease development: X.02, X.05, X.08, X.10, X.12, X.15, X.17, X.18.

Example A6. Liquid culture treatment/Monographella nivalis (Microdochium nivale) (cereal root rot)

Fungal conidia from cryogenic storage were directly mixed with nutrient broth (potato dextrose broth, PDB). After adding the solution (DMSO) of the test compound, nutrient broth containing fungal spores was added to a microtiter plate (96-well format). The test compound plates were incubated at 24°C and growth inhibition was determined photometrically 4-5 days after application. The following compounds provided at least 80% control of Monographella nivalis at 20 ppm compared to the untreated control, which under the same conditions showed extensive disease development: X.01, X.02, X.03, X.04, X.05, X.06, X.07, X.08, X.09, X.10, X.11, X.12, X.13, X.14, X.15, X.16, X.17, X. 18, X.19, X.20, X.21, X.23, X.24.

Example A7. Liquid culture treatment/Mycosphaerella arachidis (Cercospora arachidicola) (early leaf blight)

Fungal conidia from cryogenic storage were directly mixed with nutrient broth (potato dextrose broth, PDB). After adding a solution (DMSO) of the test compound

- 88 046368 a nutrient broth containing fungal spores was added to a microtiter plate (96-well format). The test compound plates were incubated at 24°C and growth inhibition was determined photometrically 4-5 days after application. The following compounds provided at least 80% control of Mycosphaerella arachidis at 20 ppm compared to the untreated control, which under the same conditions showed extensive disease development: X.01, X.03, X.04, X.05, X.07, X.08, X.09, X.10, X.11, X.12, X.13, X.14, X.15, X.17, X.18, X.19, X.20, X. 21, X.23, X.24.

Example A8. Treatment to prevent infestation/soybean/Phakopsora pachyrhizi (soybean rust)

Soybean leaf disks were placed on aqueous agar solution in multiwell plates (24-well format) and sprayed with the formulated test compound diluted in water. One day after application, leaf discs were inoculated by spraying a spore suspension onto the lower surface of the leaf. After an incubation period of 24-36 hours in the climate chamber in the dark at 20°C and 75% relative humidity, the leaf disc was kept at 20°C with 12 hours of light/day and 75% relative humidity. Compound activity was assessed as a percentage of disease control compared to untreated material when the appropriate degree of disease damage was observed on untreated control leaf discs (12-14 days after application). The following compounds provided at least 80% control of Phakopsora pachyrhizi at 200 ppm compared to the untreated control, which showed extensive disease development under the same conditions: X.05, X.10, X.12, X.14, X.15, X.20, X.24.

Example A9. Treatment to prevent leaf disc infection / wheat / Puccinia reconditaf. sp. tritici (brown rust)

Segments of wheat leaves of the Kanzler variety were placed on agar in multiwell plates (24-well format). Leaf segments were inoculated with a suspension of fungal spores. The plates were stored in the dark at 19°C and 75% relative humidity. The formulated test compound, diluted in water, was applied 1 day after inoculation. Leaf segments were incubated at 19°C and 75% relative humidity under a 12-hour light/12-hour dark cycle in a climate chamber and compound activity was assessed as the percentage of disease control compared to untreated material exhibiting the appropriate degree of disease damage. on untreated control leaf segments (6-8 days after application). The following compounds provided at least 80% control of Puccinia recondita f. sp. tritici at 200 ppm compared to the untreated control, which under the same conditions showed extensive disease development: X.05, X.07, X.14, X.15, X.18, X.20, X.24.

Example A10. Treatment to prevent leaf disc infection/wheat/Puccinia recondita f. sp. tritici (brown rust)

Wheat leaf segments of the cultivar Kanzler were placed on agar in multiwell plates (24-well format) and sprayed with the formulated test compound diluted in water. Leaf discs were inoculated with a suspension of fungal spores 1 day after application. The inoculated leaf segments were incubated at 19°C and 75% relative humidity under a 12-hour light/12-hour dark climate chamber and compound activity was assessed as a percentage of disease control compared to untreated material exhibiting the appropriate degree of damage due to diseases on untreated control leaf segments (7-9 days after application). The following compounds provided at least 80% control of Puccinia recondita f. sp. tritici at 200 ppm compared to the untreated control, which under the same conditions showed extensive disease development: X.01, X.02, X.03, X.04, X.05, X.07, X.08, X. 09, Х.10, Х.11, Х.12, Х.13, Х.14, Х.15, Х.16, Х.18, Х.19, Х.20, Х.21, Х.23, X.24.

Example A11. Treatment to prevent leaf disk/rice/Magnaporthe grisea (Pyricularia oryzae) infection (rice blast)

Ballila rice leaf segments were placed on agar in a multi-well plate (24-well format) and sprayed with the formulated test compound diluted in water. Leaf segments were inoculated with a suspension of fungal spores 2 days after application. The inoculated leaf segments were incubated at 22°C and 80% relative humidity under a light regime of 24 hours dark followed by 12 hours light/12 hours dark in a climate chamber and the activity of the compound was assessed as a percentage of disease control compared to untreated material at manifestation of the corresponding degree of damage due to the disease on untreated control leaf segments (5-7 days after application). The following compounds provided at least 80% control of Magnaporthe grisea at 200 ppm compared to the untreated control, which under the same conditions showed extensive disease development: X.01, X.02, X.03, X.04, X.05, Х.07, Х.08, Х.09, Х.10, Х.11, Х.12, Х.14, Х.15, Х.16, Х.17, Х.18, Х.19, Х. 20, X.21, X.23, X.24.

Example A12. Treatment to prevent leaf disc infection/barley/Pyrenophora teres (net spot)

Hasso barley leaf segments were placed on agar in a multi-well plate (24-well format) and sprayed with the formulated test compound diluted in water. Leaf segments were inoculated with a suspension of fungal spores 2 days after application. Inoculated segments

- 89 046368 leaves were incubated at 20°C and 65% relative humidity under a light regime of 12 hours light/12 hours dark in a climate chamber and the activity of the compound was assessed as an indicator of disease control, expressed as a percentage, compared with untreated material when showing the corresponding degree of damage due to disease on untreated control leaf segments (5-7 days after application). The following compounds provided at least 80% control of Pyrenophora teres at 200 ppm compared to the untreated control, which under the same conditions showed extensive disease development: X.02, X.04, X.05, X.07, X.08, X.12, X.15, X.18, X.24.

Example A13. Treatment of liquid culture of Sclerotinia sclerotiorum I (white rot)

Mycelium fragments from a newly grown fungal culture in liquid medium were directly mixed with nutrient broth (potato dextrose broth, PDB). After adding the solution (DMSO) of the test compound, nutrient broth containing the fungal material was added to the microtiter plate (96-well format). The test compound plates were incubated at 24°C and growth inhibition was determined photometrically 3-4 days after application. The following compounds provided at least 80% control of Sclerotinia sclerotiorum at 20 ppm compared to the untreated control, which under the same conditions showed extensive disease development: X.04, X.05, X.07, X.10, X.12, X.14, X.15.

Example A14. Treatment of liquid culture of Mycosphaerella graminicola (Septoria d-III^)/(septoria)

Fungal conidia from cryogenic storage were directly mixed with nutrient broth (potato dextrose broth, PDB). After adding the solution (DMSO) of the test compound, nutrient broth containing fungal spores was added to a microtiter plate (96-well format). The test compound plates were incubated at 24°C and growth inhibition was determined photometrically 4-5 days after application. The following compounds provided at least 80% control of Mycosphaerella graminicola at 20 ppm compared to the untreated control, which under the same conditions showed extensive disease development: X.02, X.03, X.04, X.05, X.06, Х.07, Х.08, Х.09, Х.10, Х.12, Х.13, Х.14, Х.15, Х.16, Х.17, Х.18, Х.19, Х. 20, Х.21, Х.23, Х.24.

Additional examples of biological tests related to fungicidal compositions containing a mixture of components (A) and (B) as active ingredients.

Example B1. Activity against Zymoseptoria tritici (leaf spot) Fungal conidia from cryogenic storage were directly mixed with nutrient broth (potato dextrose broth, PDB). A solution of test compounds in DMSO was added to a microtiter plate (96-well format) and nutrient broth containing fungal spores was added. Plates of test compounds were incubated at 24°C and growth inhibition was determined photometrically after 72 hours. The following mixture compositions (A:B) at the indicated concentration (in ppm) provided at least 80% disease control in this test.

Component A (connection) Component B A:B ratio Conc, (ppm) (A:B) X.05 Azoxystrobin 3:1 6:2 X.05 Azoxystrobin 30:1 6:0.2 X.05 Azoxystrobin 1:3.3 0.6:2 X.05 Azoxystrobin 3:1 0.6:0.2 X.05 Trifloxystrobin 3:1 6:2 X.05 Trifloxystrobin 30:1 6:0.2 X.05 Trifloxystrobin 1:3.3 0.6:2 X.05 Trifloxystrobin 3:1 0.6:0.2

- 90 046368

X.05 Methyltetraprole 3:1 6:2 X.05 Methyltetraprole 30:1 6:0.2 X.05 Methyltetraprole 1:3.3 0.6:2 X.05 Methyltetraprole 3:1 0.6:0.2 X.05 Difenoconazole 1:1 6:6 X.05 Difenoconazole 10:1 6:0.6 X.05 Difenoconazole 1:10 0.6:6 X.05 Difenoconazole 1:1 0.6:0.6 X.05 Hexaconazole 1:1 6:6 X.05 Hexaconazole 10:1 6:0.6 X.05 Hexaconazole 1:10 0.6:6 X.05 Hexaconazole 1:1 0.6:0.6 X.05 Propiconazole 1:1 6:6 X.05 Propiconazole 10:1 6:0.6 X.05 Propiconazole 1:10 0.6:6 X.05 Propiconazole 1:1 0.6:0.6 X.05 Prothioconazole 1:1 6:6 X.05 Prothioconazole 10:1 6:0.6 X.05 Prothioconazole 1:10 0.6:6 X.05 Prothioconazole 1:1 0.6:0.6 X.05 Mefentrifluconazole 1:1 6:6 X.05 Mefentrifluconazole 10:1 6:0.6 X.05 Mefentrifluconazole 1:10 0.6:6 X.05 Mefentrifluconazole 1:1 0.6:0.6 X.05 Fenpropidine 1:3.3 6:20 X.05 Fenpropidine 3:1 6:2 X.05 Fenpropidine 1:33.3 0.6:20 X.05 Fenpropidine 1:3.3 0.6:2 X.05 Phenpropimorph 1:3.3 6:20 X.05 Phenpropimorph 3:1 6:2 X.05 Phenpropimorph 1:33.3 0.6:20 X.05 Phenpropimorph 1:3.3 0.6:2 X.05 Fluxapyroxad 3:1 6:2 X.05 Fluxapyroxad 30:1 6:0.2 X.05 Fluxapyroxad 1:3.3 0.6:2 X.05 Fluxapyroxad 3:1 0.6:0.2 X.05 Fluopyram 3:1 6:2 X.05 Fluopyram 30:1 6:0.2

- 91 046368

X.05 Fluopyram 1:3.3 0.6:2 X.05 Fluopyram 3:1 0.6:0.2 X.05 Isopyrase 3:1 6:2 X.05 Isopyrase 30:1 6:0.2 X.05 Isopyrase 1:3.3 0.6:2 X.05 Isopyrase 3:1 0.6:0.2 X.05 Sedaksan 3:1 6:2 X.05 Sedaksan 30:1 6:0.2 X.05 Sedaksan 1:3.3 0.6:2 X.05 Sedaksan 3:1 0.6:0.2 X.05 Benzovindiflupir 3:1 6:2 X.05 Benzovindiflupir 30:1 6:0.2 X.05 Benzovindiflupir 1:3.3 0.6:2 X.05 Benzovindiflupir 3:1 0.6:0.2 X.05 Pidiflumetofen 3:1 6:2 X.05 Pidiflumetofen 30:1 6:0.2 X.05 Pidiflumetofen 1:3.3 0.6:2 X.05 Pidiflumetofen 3:1 0.6:0.2 X.05 Isoflucipram 3:1 6:2 X.05 Isoflucipram 30:1 6:0.2 X.05 Isoflucipram 1:3.3 0.6:2 X.05 Isoflucipram 3:1 0.6:0.2 X.05 Isofetamide 3:1 6:2 X.05 Isofetamide 30:1 6:0.2 X.05 Isofetamide 1:3.3 0.6:2 X.05 Isofetamide 3:1 0.6:0.2 X.05 Pyrapropoin 3:1 6:2 X.05 Pyrapropoin 30:1 6:0.2 X.05 Pyrapropoin 1:3.3 0.6:2 X.05 Pyrapropoin 3:1 0.6:0.2 X.05 Fluindapir 3:1 6:2 X.05 Fluindapir 30:1 6:0.2 X.05 Fluindapir 1:3.3 0.6:2 X.05 Fluindapir 3:1 0.6:0.2 X.05 Phenpicoxamide 1:1 6:6 X.05 Phenpicoxamide 10:1 6:0.6 X.05 Phenpicoxamide 1:10 0.6:6 X.05 Phenpicoxamide 1:1 0.6:0.6

- 92 046368

X.05 Florylpicoxamide 3:1 6:2 X.05 Florylpicoxamide 30:1 6:0.2 X.05 Florylpicoxamide 1:3.3 0.6:2 X.05 Florylpicoxamide 3:1 0.6:0.2 X.05 Chlorothalonil 1:1 6:6 X.05 Chlorothalonil 10:1 6:0.6 X.05 Chlorothalonil 1:10 0.6:6 X.05 Chlorothalonil 1:1 0.6:0.6 X.05 Mankozeb 1:3.3 6:20 X.05 Mankozeb 1:1 6:6 X.05 Mankozeb 1:33.3 0.6:20 X.05 Mankozeb 1:10 0.6:6 X.05 Mandipropamide 1:3.3 6:20 X.05 Mandipropamide 1:1 6:6 X.05 Mandipropamide 1:33.3 0.6:20 X.05 Mandipropamide 1:10 0.6:6 X.05 Oxathiapiproline 1:3.3 6:20 X.05 Oxathiapiproline 1:1 6:6 X.05 Oxathiapiproline 1:33.3 0.6:20 X.05 Oxathiapiproline 1:10 0.6:6 X.05 Fluazinam 3:1 6:2 X.05 Fluazinam 30:1 6:0.2 X.05 Fluazinam 1:3.3 0.6:2 X.05 Fluazinam 3:1 0.6:0.2 X.05 Fludioxonil 1:1 6:6 X.05 Fludioxonil 10:1 6:0.6 X.05 Fludioxonil 1:10 0.6:6 X.05 Fludioxonil 1:1 0.6:0.6 X.05 Cyprodinil 1:1 6:6 X.05 Cyprodinil 10:1 6:0.6 X.05 Cyprodinil 1:10 0.6:6 X.05 Cyprodinil 1:1 0.6:0.6 X.05 Metalaxyl-M 1:3.3 6:20 X.05 Metalaxyl-M 1:1 6:6 X.05 Metalaxyl-M 1:33.3 0.6:20 X.05 Metalaxyl-M 1:10 0.6:6 X.05 Aminopyrifene 3:1 6:2 X.05 Aminopyrifene 30:1 6:0.2 X.05 Aminopyrifene 1:3.3 0.6:2

- 93 046368

X.05 Aminopyrifene | 3:1 1 0.6:0.2 X.05 Folpet 1:1 6:6 X.05 Folpet 3:1 6:2 X.05 Folpet 1:10 0.6:6 X.05 Folpet 1:3.3 0.6:2 X.05 Ipflufenoquin 3:1 6:2 X.05 Ipflufenoquin 30:1 6:0.2 X.05 Ipflufenoquin 1:3.3 0.6:2 X.05 Ipflufenoquin 3:1 0.6:0.2 X.05 Quinofumelin 3:1 6:2 X.05 Quinofumelin 30:1 6:0.2 X.05 Quinofumelin 1:3.3 0.6:2 X.05 Quinofumelin 3:1 0.6:0.2 X.05 Tricyclic azole 1:3.3 6:20 X.05 Tricyclic azole 1:1 6:6 X.05 Tricyclic azole 1:33.3 0.6:20 X.05 Tricyclic azole 1:10 0.6:6 X.05 Pyroquilon 1:3.3 6:20 X.05 Pyroquilon 1:1 6:6 X.05 Pyroquilon 1:33.3 0.6:20 X.05 Pyroquilon 1:10 0.6:6 X.05 X-(1-Benzyl-1,3dimethylbutyl)-8fluoroquinoline-3carboxamide 3:1 6:2 X.05 X-(1-Benzyl-1,3dimethylbutyl)-8fluoroquinoline-3carboxamide 30:1 6:0.2 X.05 X-(1-Benzyl-1,3dimethylbutyl)-8fluoroquinoline-3carboxamide 1:3.3 0.6:2 X.05 X-(1-Benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 3:1 0.6:0.2 X.05 T\G-(1-Benzyl-3,3,3trifluoro-1methylpropyl)-8fluoroquinoline-3 carboxamide 3:1 6:2

- 94 046368

X.05 N-(l -Benzyl-3,3,3trifluoro-1methylpropyl)-8fluoroquinoline-3 carboxamide 30:1 6:0.2 X.05 X-(1-Benzyl-3,3,3trifluoro-1methylpropyl)-8fluoroquinoline-3carboxamide 1:3.3 0.6:2 X.05 X-(1-Benzyl-3,3,3trifluoro-1methylpropyl)-8fluoroquinoline-3 carboxamide 3:1 0.6:0.2 X.05 1-(6,7Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 3:1 6:2 X.05 1-(6,7Dimethylpyrazolo[1,5а]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 30:1 6:0.2 X.05 1-(6,7Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 1:3.3 0.6:2 X.05 1-(6,7Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 3:1 0.6:0.2 X.05 4,4-Difluoro-3,3-d imethyl1 -(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 3:1 6:2 X.05 4,4-Difluoro-3,3-d imethyl1 -(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 30:1 6:0.2 X.05 4,4-Difluoro-3,3-d imethyl1 -(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 1:3.3 0.6:2 X.05 4,4-Difluoro-3,3-dimethyl- 3:1 0.6:0.2

- 95 046368

1 -(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 1-(4.5- X.05 Dimethylbenzimide azole-1 - 3:1 6:2 yl)-4,4,5 -trifluoro-3,3 - dimethylisoquinoline 1-(4.5- X.05 Dimethylbenzimide azole-1 - 30:1 6:0.2 yl)-4,4,5 -trifluoro-3,3 - dimethylisoquinoline 1-(4.5- X.05 Dimethylbenzimide azole-1 - 1:3.3 0.6:2 yl)-4,4,5 -trifluoro-3,3 - dimethylisoquinoline 1-(4.5- X.05 Dimethylbenzimide azole-1 - 3:1 0.6:0.2 yl)-4,4,5 -trifluoro-3,3 - dimethylisoquinoline 1-(4.5- X.05 Dimethylbenzimide azole-1 - 3:1 6:2 yl)-4,4-difluoro-3,3 - dimethylisoquinoline 1-(4.5- X.05 Dimethylbenzimide azole-1 - 30:1 6:0.2 yl)-4,4-difluoro-3,3 - dimethylisoquinoline 1-(4.5- X.05 Dimethylbenzimide azol-1 yl)-4,4-difluoro-3,3 - 1:3.3 0.6:2 dimethylisoquinoline 1-(4.5- X.05 Dimethylbenzimide azole-1 - 3:1 0.6:0.2 yl)-4,4-difluoro-3,3 - dimethylisoquinoline

Component A (connection) Component B A:B ratio Conc, (ppm) (A:B) X.07 Azoxystrobin 3:1 6:2 X.07 Azoxystrobin 30:1 6:0.2 X.07 Azoxystrobin 1:3.3 0.6:2 X.07 Azoxystrobin 3:1 0.6:0.2 X.07 Trifloxystrobin 3:1 6:2 X.07 Trifloxystrobin 30:1 6:0.2 X.07 Trifloxystrobin 1:3.3 0.6:2

- 96 046368

X.07 Trifloxystrobin 3:1 0.6:0.2 X.07 Methyltetraprole 3:1 6:2 X.07 Methyltetraprole 30:1 6:0.2 X.07 Methyltetraprole 1:3.3 0.6:2 X.07 Methyltetraprole 3:1 0.6:0.2 X.07 Difenoconazole 1:1 6:6 X.07 Difenoconazole 10:1 6:0.6 X.07 Difenoconazole 1:10 0.6:6 X.07 Difenoconazole 1:1 0.6:0.6 X.07 Hexaconazole 1:1 6:6 X.07 Hexaconazole 10:1 6:0.6 X.07 Hexaconazole 1:10 0.6:6 X.07 Hexaconazole 1:1 0.6:0.6 X.07 Propiconazole 1:1 6:6 X.07 Propiconazole 10:1 6:0.6 X.07 Propiconazole 1:10 0.6:6 X.07 Propiconazole 1:1 0.6:0.6 X.07 Prothioconazole 1:1 6:6 X.07 Prothioconazole 10:1 6:0.6 X.07 Prothioconazole 1:10 0.6:6 X.07 Prothioconazole 1:1 0.6:0.6 X.07 Mefentrifluconazole 1:1 6:6 X.07 Mefentrifluconazole 10:1 6:0.6 X.07 Mefentrifluconazole 1:10 0.6:6 X.07 Mefentrifluconazole 1:1 0.6:0.6 X.07 Fenpropidine 1:3.3 6:20 X.07 Fenpropidine 3:1 6:2 X.07 Fenpropidine 1:33.3 0.6:20 X.07 Fenpropidine 1:3.3 0.6:2 X.07 Phenpropimorph 1:3.3 6:20 X.07 Phenpropimorph 3:1 6:2 X.07 Phenpropimorph 1:33.3 0.6:20 X.07 Phenpropimorph 1:3.3 0.6:2 X.07 Fluxapyroxad 3:1 6:2 X.07 Fluxapyroxad 30:1 6:0.2 X.07 Fluxapyroxad 1:3.3 0.6:2 X.07 Fluxapyroxad 3:1 0.6:0.2 X.07 Fluopyram 3:1 6:2

- 97 046368

X.07 Fluopyram 30:1 6:0.2 X.07 Fluopyram 1:3.3 0.6:2 X.07 Fluopyram 3:1 0.6:0.2 X.07 Isopyrase 3:1 6:2 X.07 Isopyrase 30:1 6:0.2 X.07 Isopyrase 1:3.3 0.6:2 X.07 Isopyrase 3:1 0.6:0.2 X.07 Sedaksan 3:1 6:2 X.07 Sedaksan 30:1 6:0.2 X.07 Sedaksan 1:3.3 0.6:2 X.07 Sedaksan 3:1 0.6:0.2 X.07 Benzovindiflupir 3:1 6:2 X.07 Benzovindiflupir 30:1 6:0.2 X.07 Benzovindiflupir 1:3.3 0.6:2 X.07 Benzovindiflupir 3:1 0.6:0.2 X.07 Pid if lu metof her 3:1 6:2 X.07 Pid if lu metof her 30:1 6:0.2 X.07 Pid iflu metof her 1:3.3 0.6:2 X.07 Pid iflu metof her 3:1 0.6:0.2 X.07 Isoflucipram 3:1 6:2 X.07 Isoflucipram 30:1 6:0.2 X.07 Isoflucipram 1:3.3 0.6:2 X.07 Isoflucipram 3:1 0.6:0.2 X.07 Isofetamide 3:1 6:2 X.07 Isofetamide 30:1 6:0.2 X.07 Isofetamide 1:3.3 0.6:2 X.07 Isofetamide 3:1 0.6:0.2 X.07 Pyrapropoin 3:1 6:2 X.07 Pyrapropoin 30:1 6:0.2 X.07 Pyrapropoin 1:3.3 0.6:2 X.07 Pyrapropoin 3:1 0.6:0.2 X.07 Fluindapir 3:1 6:2 X.07 Fluindapir 30:1 6:0.2 X.07 Fluindapir 1:3.3 0.6:2 X.07 Fluindapir 3:1 0.6:0.2 X.07 Phenpicoxamide 1:1 6:6 X.07 Phenpicoxamide 10:1 6:0.6 X.07 Phenpicoxamide 1:10 0.6:6 X.07 Phenpicoxamide 1:1 0.6:0.6

- 98 046368

X.07 Florylpicoxamide 3:1 6:2 X.07 Florylpicoxamide 30:1 6:0.2 X.07 Florylpicoxamide 1:3.3 0.6:2 X.07 Florylpicoxamide 3:1 0.6:0.2 X.07 Chlorothalonil 1:1 6:6 X.07 Chlorothalonil 10:1 6:0.6 X.07 Chlorothalonil 1:10 0.6:6 X.07 Chlorothalonil 1:1 0.6:0.6 X.07 Mankozeb 1:3.3 6:20 X.07 Mankozeb 1:1 6:6 X.07 Mankozeb 1:33.3 0.6:20 X.07 Mankozeb 1:10 0.6:6 X.07 Mandipropamide 1:3.3 6:20 X.07 Mandipropamide 1:1 6:6 X.07 Mandipropamide 1:33.3 0.6:20 X.07 Mandipropamide 1:10 0.6:6 X.07 Oxathiapiproline 1:3.3 6:20 X.07 Oxathiapiproline 1:1 6:6 X.07 Oxathiapiproline 1:33.3 0.6:20 X.07 Oxathiapiproline 1:10 0.6:6 X.07 Flu Azinam 3:1 6:2 X.07 Flu Azinam 30:1 6:0.2 X.07 Flu Azinam 1:3.3 0.6:2 X.07 Flu Azinam 3:1 0.6:0.2 X.07 Fludioxonil 1:1 6:6 X.07 Fludioxonil 10:1 6:0.6 X.07 Fludioxonil 1:10 0.6:6 X.07 Fludioxonil 1:1 0.6:0.6 X.07 Cyprodinil 1:1 6:6 X.07 Cyprodinil 10:1 6:0.6 X.07 Cyprodinil 1:10 0.6:6 X.07 Cyprodinil 1:1 0.6:0.6 X.07 Metalaxyl-M 1:3.3 6:20 X.07 Metalaxyl-M 1:1 6:6 X.07 Metalaxyl-M 1:33.3 0.6:20 X.07 Metalaxyl-M 1:10 0.6:6 X.07 Aminopyrifene 3:1 6:2 X.07 Aminopyrifene 30:1 6:0.2

- 99 046368

X.07 Aminopyrifene 1:3.3 0.6:2 X.07 Aminopyrifene 3:1 0.6:0.2 X.07 Folpet 1:1 6:6 X.07 Folpet 3:1 6:2 X.07 Folpet 1:10 0.6:6 X.07 Folpet 1:3.3 0.6:2 X.07 Ipflufenoquin 3:1 6:2 X.07 Ipflufenoquin 30:1 6:0.2 X.07 Ipflufenoquin 1:3.3 0.6:2 X.07 Ipflufenoquin 3:1 0.6:0.2 X.07 Quinofumelin 3:1 6:2 X.07 Quinofumelin 30:1 6:0.2 X.07 Quinofumelin 1:3.3 0.6:2 X.07 Quinofumelin 3:1 0.6:0.2 X.07 Tricyclazole 1:3.3 6:20 X.07 Tricyclazole 1:1 6:6 X.07 Tricyclazole 1:33.3 0.6:20 X.07 Tricyclazole 1:10 0.6:6 X.07 Pyroquilon 1:3.3 6:20 X.07 Pyroquilon 1:1 6:6 X.07 Pyroquilon 1:33.3 0.6:20 X.07 Pyroquilon 1:10 0.6:6 X.07 N-(l -Benzyl-1,3 dimethylbutyl)-8fluoroquinoline-3 carboxamide 3:1 6:2 X.07 N-(l -Benzyl-1,3 dimethylbutyl)-8fluoroquinoline-3carboxamide 30:1 6:0.2 X.07 N-(l -Benzyl-1,3 dimethylbutyl)-8fluoroquinoline-3 carboxamide 1:3.3 0.6:2 X.07 N-(l -Benzyl-1,3 dimethylbutyl)-8fluoroquinoline-3carboxamide 3:1 0.6:0.2 X.07 N-(l-Benzyl-3,3,3trifluoro-1methylpropyl)-8fluoroquinoline-3 - 3:1 6:2

- 100 046368

carboxamide X.07 N-(1-Benzyl-3,3,3 trifluoro-1 methylpropyl)-8fluoroquinoline-3 carboxamide 30:1 6:0.2 X.07 N-(l-Benzyl-3,3,3trifluoro-1methylpropyl)-8fluoroquinoline-3carboxamide 1:3.3 0.6:2 X.07 N-(1-Benzyl-3,3,3 trifluoro-1 methylpropyl)-8fluoroquinoline-3 carboxamide 3:1 0.6:0.2 X.07 1-(6,7Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 3:1 6:2 X.07 1-(6,7Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 30:1 6:0.2 X.07 1-(6,7Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 1:3.3 0.6:2 X.07 1-(6,7Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 3:1 0.6:0.2 X.07 4,4-Difluoro-3,3-dimethyl1-(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 3:1 6:2 X.07 4,4-Difluoro-3,3-dimethyl1-(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 30:1 6:0.2 X.07 4,4-Difluoro-3,3-dimethyl1-(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 1:3.3 0.6:2

- 101 046368

X.07 4,4-Difluoro-3,3-dimethyl1-(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 3:1 0.6:0.2 X.07 1-(4,5Dimethylbenzimidazol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 3:1 6:2 X.07 1-(4,5Dimethylbenzimidazol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 30:1 6:0.2 X.07 1-(4,5Dimethylbenzimidazol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 1:3.3 0.6:2 X.07 1-(4,5Dimethylbenzimidazol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 3:1 0.6:0.2 X.07 1-(4,5Dimethylbenzimidazol-1 yl)-4,4-difluoro-3,3dimethylisoquinoline 3:1 6:2 X.07 1-(4,5Dimethylbenzimidazol-1 yl)-4,4-difluoro-3,3dimethylisoquinoline 30:1 6:0.2 X.07 1-(4,5Dimethylbenzimidazol-1yl)-4,4-difluoro-3,3dimethylisoquinoline 1:3.3 0.6:2 X.07 1-(4,5Dimethylbenzimidazol-1yl)-4,4-difluoro-3,3dimethylisoquinoline 3:1 0.6:0.2

Component A (connection) Component B A:B ratio Conc, (ppm) (A:B) X.14 Azoxystrobin 3:1 6:2 X.14 Azoxystrobin 30:1 6:0.2 X.14 Azoxystrobin 1:3.3 0.6:2 X.14 Azoxystrobin 3:1 0.6:0.2 X.14 Trifloxystrobin 3:1 6:2 X.14 Trifloxystrobin 30:1 6:0.2 X.14 Trifloxystrobin 1:3.3 0.6:2

- 102 046368

X.14 Trifloxystrobin 3:1 0.6:0.2 X.14 Methyltetraprole 3:1 6:2 X.14 Methyltetraprole 30:1 6:0.2 X.14 Methyltetraprole 1:3.3 0.6:2 X.14 Methyltetraprole 3:1 0.6:0.2 X.14 Difenoconazole 1:1 6:6 X.14 Difenoconazole 10:1 6:0.6 X.14 Difenoconazole 1:10 0.6:6 X.14 Difenoconazole 1:1 0.6:0.6 X.14 Hexaconazole 1:1 6:6 X.14 Hexaconazole 10:1 6:0.6 X.14 Hexaconazole 1:10 0.6:6 X.14 Hexaconazole 1:1 0.6:0.6 X.14 Propiconazole 1:1 6:6 X.14 Propiconazole 10:1 6:0.6 X.14 Propiconazole 1:10 0.6:6 X.14 Propiconazole 1:1 0.6:0.6 X.14 Prothioconazole 1:1 6:6 X.14 Prothioconazole 10:1 6:0.6 X.14 Prothioconazole 1:10 0.6:6 X.14 Prothioconazole 1:1 0.6:0.6 X.14 Mefentrifluconazole 1:1 6:6 X.14 Mefentrifluconazole 10:1 6:0.6 X.14 Mefentrifluconazole 1:10 0.6:6 X.14 Mefentrifluconazole 1:1 0.6:0.6 X.14 Fenpropidine 1:3.3 6:20 X.14 Fenpropidine 3:1 6:2 X.14 Fenpropidine 1:33.3 0.6:20 X.14 Fenpropidine 1:3.3 0.6:2 X.14 Phenpropimorph 1:3.3 6:20 X.14 Phenpropimorph 3:1 6:2 X.14 Phenpropimorph 1:33.3 0.6:20 X.14 Phenpropimorph 1:3.3 0.6:2 X.14 Fluxapyroxad 3:1 6:2 X.14 Fluxapyroxad 30:1 6:0.2 X.14 Fluxapyroxad 1:3.3 0.6:2 X.14 Fluxapyroxad 3:1 0.6:0.2 X.14 Fluopyram 3:1 6:2

- 103 046368

X.14 Fluopyram 30:1 6:0.2 X.14 Fluopyram 1:3.3 0.6:2 X.14 Fluopyram 3:1 0.6:0.2 X.14 Isopyrase 3:1 6:2 X.14 Isopyrase 30:1 6:0.2 X.14 Isopyrase 1:3.3 0.6:2 X.14 Isopyrase 3:1 0.6:0.2 X.14 Sedaksan 3:1 6:2 X.14 Sedaksan 30:1 6:0.2 X.14 Sedaksan 1:3.3 0.6:2 X.14 Sedaksan 3:1 0.6:0.2 X.14 Benzovindiflupir 3:1 6:2 X.14 Benzovindiflupir 30:1 6:0.2 X.14 Benzovindiflupir 1:3.3 0.6:2 X.14 Benzovindiflupir 3:1 0.6:0.2 X.14 Pidiflumetofen 3:1 6:2 X.14 Pidiflumetofen 30:1 6:0.2 X.14 Pidiflumetofen 1:3.3 0.6:2 X.14 Pidiflumetofen 3:1 0.6:0.2 X.14 Isoflucipram 3:1 6:2 X.14 Isoflucipram 30:1 6:0.2 X.14 Isoflucipram 1:3.3 0.6:2 X.14 Isoflucipram 3:1 0.6:0.2 X.14 Isofetamide 3:1 6:2 X.14 Isofetamide 30:1 6:0.2 X.14 Isofetamide 1:3.3 0.6:2 X.14 Isofetamide 3:1 0.6:0.2 X.14 Pyrapropoin 3:1 6:2 X.14 Pyrapropoin 30:1 6:0.2 X.14 Pyrapropoin 1:3.3 0.6:2 X.14 Pyrapropoin 3:1 0.6:0.2 X.14 Fluindapir 3:1 6:2 X.14 Fluindapir 30:1 6:0.2 X.14 Fluindapir 1:3.3 0.6:2 X.14 Fluindapir 3:1 0.6:0.2 X.14 Phenpicoxamide 1:1 6:6 X.14 Phenpicoxamide 10:1 6:0.6 X.14 Phenpicoxamide 1:10 0.6:6 X.14 Phenpicoxamide 1:1 0.6:0.6

- 104 046368

X.14 Florylpicoxamide 3:1 6:2 X.14 Florylpicoxamide 30:1 6:0.2 X.14 Florylpicoxamide 1:3.3 0.6:2 X.14 Florylpicoxamide 3:1 0.6:0.2 X.14 Chlorothalonil 1:1 6:6 X.14 Chlorothalonil 10:1 6:0.6 X.14 Chlorothalonil 1:10 0.6:6 X.14 Chlorothalonil 1:1 0.6:0.6 X.14 Mankozeb 1:3.3 6:20 X.14 Mankozeb 1:1 6:6 X.14 Mankozeb 1:33.3 0.6:20 X.14 Mankozeb 1:10 0.6:6 X.14 Mandipropamide 1:3.3 6:20 X.14 Mandipropamide 1:1 6:6 X.14 Mandipropamide 1:33.3 0.6:20 X.14 Mandipropamide 1:10 0.6:6 X.14 Oxathiapiproline 1:3.3 6:20 X.14 Oxathiapiproline 1:1 6:6 X.14 Oxathiapiproline 1:33.3 0.6:20 X.14 Oxathiapiproline 1:10 0.6:6 X.14 Fluazinam 3:1 6:2 X.14 Fluazinam 30:1 6:0.2 X.14 Fluazinam 1:3.3 0.6:2 X.14 Fluazinam 3:1 0.6:0.2 X.14 Fludioxonil 1:1 6:6 X.14 Fludioxonil 10:1 6:0.6 X.14 Fludioxonil 1:10 0.6:6 X.14 Fludioxonil 1:1 0.6:0.6 X.14 Cyprodinil 1:1 6:6 X.14 Cyprodinil 10:1 6:0.6 X.14 Cyprodinil 1:10 0.6:6 X.14 Cyprodinil 1:1 0.6:0.6 X.14 Metalaxyl-M 1:3.3 6:20 X.14 Metalaxyl-M 1:1 6:6 X.14 Metalaxyl-M 1:33.3 0.6:20 X.14 Metalaxyl-M 1:10 0.6:6 X.14 Aminopyrifene 3:1 6:2 X.14 Aminopyrifene 30:1 6:0.2

- 105 046368

X.14 Aminopyrifene 1:3.3 0.6:2 X.14 Aminopyrifene 3:1 0.6:0.2 X.14 Folpet 1:1 6:6 X.14 Folpet 3:1 6:2 X.14 Folpet 1:10 0.6:6 X.14 Folpet 1:3.3 0.6:2 X.14 Ipflufenoquin 3:1 6:2 X.14 Ipflufenoquin 30:1 6:0.2 X.14 Ipflufenoquin 1:3.3 0.6:2 X.14 Ipflufenoquin 3:1 0.6:0.2 X.14 Quinofumelin 3:1 6:2 X.14 Quinofumelin 30:1 6:0.2 X.14 Quinofumelin 1:3.3 0.6:2 X.14 Quinofumelin 3:1 0.6:0.2 X.14 Tricyclic azole 1:3.3 6:20 X.14 Tricyclic azole 1:1 6:6 X.14 Tricyclic azole 1:33.3 0.6:20 X.14 Tricyclic azole 1:10 0.6:6 X.14 Pirokv ILON 1:3.3 6:20 X.14 Pirokv ILON 1:1 6:6 X.14 Pirokv ILON 1:33.3 0.6:20 X.14 Pirokv ILON 1:10 0.6:6 X.14 T4-(1-Benzyl-1,3dimethylbutyl)-8fluoroquinoline-3carboxamide 3:1 6:2 X.14 X-(1-Benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 30:1 6:0.2 X.14 X-(1-Benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 1:3.3 0.6:2 X.14 X-(1-Benzyl-1,3dimethylbutyl)-8fluoroquinoline-3carboxamide 3:1 0.6:0.2 X.14 N-(l-Benzyl-3,3,3trifluoro-1methylpropyl)-8fluoroquinoline-3- 3:1 6:2

- 106 046368

carboxamide X.14 X-(1-Benzyl-3,3,3trifluoro-1methylpropyl)-8fluoroquinoline-3 carboxamide 30:1 6:0.2 X.14 T4-(1-Benzyl-3,3,3trifluoro-1methylpropyl)-8fluoroquinoline-3carboxamide 1:3.3 0.6:2 X.14 X-(1-Benzyl-3,3,3trifluoro-1methylpropyl)-8fluoroquinoline-3 carboxamide 3:1 0.6:0.2 X.14 1-(6,7Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 3:1 6:2 X.14 1-(6,7Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 30:1 6:0.2 X.14 1-(6,7Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 1:3.3 0.6:2 X.14 1-(6,7Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 3:1 0.6:0.2 X.14 4,4-Difluoro-3,3-d imethyl1 -(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 3:1 6:2 X.14 4,4-Difluoro-3,3-d imethyl1 -(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 30:1 6:0.2 X.14 4,4-Difluoro-3,3-d imethyl1 -(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 1:3.3 0.6:2

- 107 046368

X.14 4,4-Difluoro-3,3-d imethyl1 -(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 3:1 0.6:0.2 X.14 1-(4,5Dimethylbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 3:1 6:2 X.14 1-(4,5Dimethylbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 30:1 6:0.2 X.14 1-(4,5Dimethylbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 1:3.3 0.6:2 X.14 1-(4,5Dimethylbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 3:1 0.6:0.2 X.14 1-(4,5Dimethylbenzimide azol-1 yl)-4,4-difluoro-3,3 dimethylisoquinoline 3:1 6:2 X.14 1-(4,5Dimethylbenzimide azol-1 yl)-4,4-difluoro-3,3 dimethylisoquinoline 30:1 6:0.2 X.14 1-(4,5Dimethylbenzimide azol-1 yl)-4,4-difluoro-3,3 dimethylisoquinoline 1:3.3 0.6:2 X.14 1-(4,5Dimethylbenzimide azol-1 yl)-4,4-difluoro-3,3 dimethylisoquinoline 3:1 0.6:0.2

Example B2. Activity against Botrytis cinerea (grey mold)

Fungal conidia from cryostorage were directly mixed with nutrient broth (Minimal Vogel Media) containing 200 μmol SHAM. A solution of test compounds in DMSO was added to a microtiter plate (96-well format) and nutrient broth containing fungal spores was added. Plates containing test compounds were incubated at 24°C and growth inhibition was determined photometrically after 72 hours. The following mixture based compositions (A:B) at the indicated concentration (in ppm) provided at least 80% disease control in this test.

- 108 046368

Component A (connection) Component B A:B ratio Conc, (ppm) (A:B) X.05 Azoxystrobin 3:1 6:2 X.05 Azoxystrobin 30:1 6:0.2 X.05 Azoxystrobin 1:3.3 0.6:2 X.05 Azoxystrobin 3:1 0.6:0.2 X.05 Trifloxystrobin 3:1 6:2 X.05 Trifloxystrobin 30:1 6:0.2 X.05 Trifloxystrobin 1:3.3 0.6:2 X.05 Trifloxystrobin 3:1 0.6:0.2 X.05 Methyltetraprole 3:1 6:2 X.05 Methyltetraprole 30:1 6:0.2 X.05 Methyltetraprole 1:3.3 0.6:2 X.05 Methyltetraprole 3:1 0.6:0.2 X.05 Difenoconazole 1:1 6:6 X.05 Difenoconazole 10:1 6:0.6 X.05 Difenoconazole 1:10 0.6:6 X.05 Difenoconazole 1:1 0.6:0.6 X.05 Hexaconazole 1:1 6:6 X.05 Hexaconazole 10:1 6:0.6 X.05 Hexaconazole 1:10 0.6:6 X.05 Hexaconazole 1:1 0.6:0.6 X.05 Propiconazole 1:1 6:6 X.05 Propiconazole 10:1 6:0.6 X.05 Propiconazole 1:10 0.6:6 X.05 Propiconazole 1:1 0.6:0.6

- 109 046368

X.05 Prothioconazole 1:1 6:6 X.05 Prothioconazole 10:1 6:0.6 X.05 Prothioconazole 1:10 0.6:6 X.05 Prothioconazole 1:1 0.6:0.6 X.05 Mefentrifluconazole 1:1 6:6 X.05 Mefentrifluconazole 10:1 6:0.6 X.05 Mefentrifluconazole 1:10 0.6:6 X.05 Mefentrifluconazole 1:1 0.6:0.6 X.05 Fenpropidine 1:3.3 6:20 X.05 Fenpropidine 3:1 6:2 X.05 Fenpropidine 1:33.3 0.6:20 X.05 Fenpropidine 1:3.3 0.6:2 X.05 Phenpropimorph 1:3.3 6:20 X.05 Phenpropimorph 3:1 6:2 X.05 Phenpropimorph 1:33.3 0.6:20 X.05 Phenpropimorph 1:3.3 0.6:2 X.05 Fluxapyroxad 3:1 6:2 X.05 Fluxapyroxad 30:1 6:0.2 X.05 Fluxapyroxad 1:3.3 0.6:2 X.05 Fluxapyroxad 3:1 0.6:0.2 X.05 Fluopyram 3:1 6:2 X.05 Fluopyram 30:1 6:0.2 X.05 Fluopyram 1:3.3 0.6:2 X.05 Fluopyram 3:1 0.6:0.2 X.05 Isopyrase 3:1 6:2 X.05 Isopyrase 30:1 6:0.2

- 110 046368

X.05 Isopyrase 1:3.3 0.6:2 X.05 Isopyrase 3:1 0.6:0.2 X.05 Sedaksan 3:1 6:2 X.05 Sedaksan 30:1 6:0.2 X.05 Sedaksan 1:3.3 0.6:2 X.05 Sedaksan 3:1 0.6:0.2 X.05 Benzovindiflupir 3:1 6:2 X.05 Benzovindiflupir 30:1 6:0.2 X.05 Benzovindiflupir 1:3.3 0.6:2 X.05 Benzovindiflupir 3:1 0.6:0.2 X.05 Pidiflumetofen 3:1 6:2 X.05 Pidiflumetofen 30:1 6:0.2 X.05 Pidiflumetofen 1:3.3 0.6:2 X.05 Pidiflumetofen 3:1 0.6:0.2 X.05 Isoflucipram 3:1 6:2 X.05 Isoflucipram 30:1 6:0.2 X.05 Isoflucipram 1:3.3 0.6:2 X.05 Isoflucipram 3:1 0.6:0.2 X.05 Isofetamide 3:1 6:2 X.05 Isofetamide 30:1 6:0.2 X.05 Isofetamide 1:3.3 0.6:2 X.05 Isofetamide 3:1 0.6:0.2 X.05 Pyrapropoin 3:1 6:2 X.05 Pyrapropoin 30:1 6:0.2 X.05 Pyrapropoin 1:3.3 0.6:2 X.05 Pyrapropoin 3:1 0.6:0.2

- 111 046368

X.05 Fluindapir 3:1 6:2 X.05 Fluindapir 30:1 6:0.2 X.05 Fluindapir 1:3.3 0.6:2 X.05 Fluindapir 3:1 0.6:0.2 X.05 Phenpicoxamide 1:1 6:6 X.05 Phenpicoxamide 10:1 6:0.6 X.05 Phenpicoxamide 1:10 0.6:6 X.05 Phenpicoxamide 1:1 0.6:0.6 X.05 Florylpicoxamide 3:1 6:2 X.05 Florylpicoxamide 30:1 6:0.2 X.05 Florylpicoxamide 1:3.3 0.6:2 X.05 Florylpicoxamide 3:1 0.6:0.2 X.05 Chlorothalonil 1:1 6:6 X.05 Chlorothalonil 10:1 6:0.6 X.05 Chlorothalonil 1:10 0.6:6 X.05 Chlorothalonil 1:1 0.6:0.6 X.05 Mankozeb 1:3.3 6:20 X.05 Mankozeb 1:1 6:6 X.05 Mankozeb 1:33.3 0.6:20 X.05 Mankozeb 1:10 0.6:6 X.05 Mandipropamide 1:3.3 6:20 X.05 Mandipropamide 1:1 6:6 X.05 Mandipropamide 1:33.3 0.6:20 X.05 Mandipropamide 1:10 0.6:6 X.05 Oxathiapiproline 1:3.3 6:20 X.05 Oxathiapiproline 1:1 6:6 X.05 Oxathiapiproline 1:33.3 0.6:20

- 112 046368

X.05 Oxathiapiproline 1:10 0.6:6 X.05 Fluazinam 3:1 6:2 X.05 Fluazinam 30:1 6:0.2 X.05 Fluazinam 1:3.3 0.6:2 X.05 Fluazinam 3:1 0.6:0.2 X.05 Fludioxonil 1:1 6:6 X.05 Fludioxonil 10:1 6:0.6 X.05 Fludioxonil 1:10 0.6:6 X.05 Fludioxonil 1:1 0.6:0.6 X.05 Cyprodinil 1:1 6:6 X.05 Cyprodinil 10:1 6:0.6 X.05 Cyprodinil 1:10 0.6:6 X.05 Cyprodinil 1:1 0.6:0.6 X.05 Metalaxyl-M 1:3.3 6:20 X.05 Metalaxyl-M 1:1 6:6 X.05 Metalaxyl-M 1:33.3 0.6:20 X.05 Metalaxyl-M 1:10 0.6:6 X.05 Aminopyrifene 3:1 6:2 X.05 Aminopyrifene 30:1 6:0.2 X.05 Aminopyrifene 1:3.3 0.6:2 X.05 Aminopyrifene 3:1 0.6:0.2 X.05 Folpet 1:1 6:6 X.05 Folpet 3:1 6:2 X.05 Folpet 1:10 0.6:6 X.05 Folpet 1:3.3 0.6:2 X.05 Ipflufenoquin 3:1 6:2

- 113 046368

X.05 Ipflufenoquin 30:1 6:0.2 X.05 Ipflufenoquin 1:3.3 0.6:2 X.05 Ipflufenoquin 3:1 0.6:0.2 X.05 Quinofumelin 3:1 6:2 X.05 Quinofumelin 30:1 6:0.2 X.05 Quinofumelin 1:3.3 0.6:2 X.05 Quinofumelin 3:1 0.6:0.2 X.05 Tricyclic azole 1:3.3 6:20 X.05 Tricyclic azole 1:1 6:6 X.05 Tricyclic azole 1:33.3 0.6:20 X.05 Tricyclic azole 1:10 0.6:6 X.05 Pirokv ILON 1:3.3 6:20 X.05 Pirokv ILON 1:1 6:6 X.05 Pirokv ILON 1:33.3 0.6:20 X.05 Pirokv ILON 1:10 0.6:6 X.05 X-(1-Benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 3:1 6:2 X.05 X-(1-Benzyl-1,3- dimethylbutyl)-8fluoroquinoline-3carboxamide 30:1 6:0.2 X.05 X-(1-Benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 1:3.3 0.6:2 X.05 X-(1-Benzyl-1,3- dimethylbutyl)-8- 3:1 0.6:0.2

- 114 046368

fluoroquinoline-3carboxamide X.05 X-(1-Benzyl-3,3,3trifluoro-1methylpropyl)-8fluoroquinoline-3carboxamide 3:1 6:2 X.05 N-(l -Benzyl-3,3,3trifluoro-1methylpropyl)-8fluoroquinoline-3carboxamide 30:1 6:0.2 X.05 X-(1-Benzyl-3,3,3trifluoro-1methylpropyl)-8fluoroquinoline-3 carboxamide 1:3.3 0.6:2 X.05 X-(1-Benzyl-3,3,3trifluoro-1methylpropyl)-8fluoroquinoline-3carboxamide 3:1 0.6:0.2 X.05 1-(6.7- Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 3:1 6:2 X.05 1-(6.7- Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3- 30:1 6:0.2

- 115 046368

dimethylisoquinoline X.05 1-(6.7- Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 1:3.3 0.6:2 X.05 1-(6.7- Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 3:1 0.6:0.2 X.05 4,4-Difluoro-3,3-d imethyl1 -(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 3:1 6:2 X.05 4,4-Difluoro-3,3-d imethyl1 -(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 30:1 6:0.2 X.05 4,4-Difluoro-3,3-d imethyl1 -(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 1:3.3 0.6:2 X.05 4,4-Difluoro-3,3-d imethyl1 -(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 3:1 0.6:0.2 X.05 1-(4,5Dimethylbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 3:1 6:2

- 116 046368

X.05 1-(4,5Dimethylbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 30:1 6:0.2 X.05 1-(4,5Dimethylbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 1:3.3 0.6:2 X.05 1-(4,5Dimethylbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 3:1 0.6:0.2 X.05 1-(4.5- Dimethylbenzimide azol-1 yl)-4,4-difluoro-3,3 dimethylisoquinoline 3:1 6:2 X.05 1-(4.5- Dimethylbenzimide azol-1 yl)-4,4-difluoro-3,3 dimethylisoquinoline 30:1 6:0.2 X.05 1-(4.5- Dimethylbenzimide azol-1 yl)-4,4-difluoro-3,3 dimethylisoquinoline 1:3.3 0.6:2 X.05 1-(4.5- Dimethylbenzimide azol-1 yl)-4,4-difluoro-3,3 dimethylisoquinoline 3:1 0.6:0.2

Component A (connection) Component B A:B ratio Conc, (ppm) (A : B) X.07 Azoxystrobin 3:1 6:2 X.07 Azoxystrobin 30:1 6:0.2 X.07 Azoxystrobin 1:3.3 0.6:2

- 117 046368

X.07 Azoxystrobin 3:1 0.6:0.2 X.07 Trifloxystrobin 3:1 6:2 X.07 Trifloxystrobin 30:1 6:0.2 X.07 Trifloxystrobin 1:3.3 0.6:2 X.07 Trifloxystrobin 3:1 0.6:0.2 X.07 Methyltetraprole 3:1 6:2 X.07 Methyltetraprole 30:1 6:0.2 X.07 Methyltetraprole 1:3.3 0.6:2 X.07 Methyltetraprole 3:1 0.6:0.2 X.07 Difenoconazole 1:1 6:6 X.07 Difenoconazole 10:1 6:0.6 X.07 Difenoconazole 1:10 0.6:6 X.07 Difenoconazole 1:1 0.6:0.6 X.07 Hexaconazole 1:1 6:6 X.07 Hexaconazole 10:1 6:0.6 X.07 Hexaconazole 1:10 0.6:6 X.07 Hexaconazole 1:1 0.6:0.6 X.07 Propiconazole 1:1 6:6 X.07 Propiconazole 10:1 6:0.6 X.07 Propiconazole 1:10 0.6:6 X.07 Propiconazole 1:1 0.6:0.6 X.07 Prothioconazole 1:1 6:6 X.07 Prothioconazole 10:1 6:0.6 X.07 Prothioconazole 1:10 0.6:6 X.07 Prothioconazole 1:1 0.6:0.6 X.07 Mefentrifluconazole 1:1 6:6 X.07 Mefentrifluconazole 10:1 6:0.6 X.07 Mefentrifluconazole 1:10 0.6:6 X.07 Mefentrifluconazole 1:1 0.6:0.6 X.07 Fenpropidine 1:3.3 6:20 X.07 Fenpropidine 3:1 6:2 X.07 Fenpropidine 1:33.3 0.6:20 X.07 Fenpropidine 1:3.3 0.6:2 X.07 Phenpropimorph 1:3.3 6:20 X.07 Phenpropimorph 3:1 6:2 X.07 Phenpropimorph 1:33.3 0.6:20 X.07 Phenpropimorph 1:3.3 0.6:2 X.07 Fluxapyroxad 3:1 62

- 118 046368

X.07 Fluxapyroxad 30:1 6:0.2 X.07 Fluxapyroxad 1:3.3 0.6:2 X.07 Fluxapyroxad 3:1 0.6:0.2 X.07 Fluopyram 3:1 6:2 X.07 Fluopyram 30:1 6:0.2 X.07 Fluopyram 1:3.3 0.6:2 X.07 Fluopyram 3:1 0.6:0.2 X.07 Isopyrase 3:1 6:2 X.07 Isopyrase 30:1 6:0.2 X.07 Isopyrase 1:3.3 0.6:2 X.07 Isopyrase 3:1 0.6:0.2 X.07 Sedaksan 3:1 6:2 X.07 Sedaksan 30:1 6:0.2 X.07 Sedaksan 1:3.3 0.6:2 X.07 Sedaksan 3:1 0.6:0.2 X.07 Benzovindiflupir 3:1 6:2 X.07 Benzovindiflupir 30:1 6:0.2 X.07 Benzovindiflupir 1:3.3 0.6:2 X.07 Benzovindiflupir 3:1 0.6:0.2 X.07 Pidiflumetofen 3:1 6:2 X.07 Pidiflumetofen 30:1 6:0.2 X.07 Pidiflumetofen 1:3.3 0.6:2 X.07 Pidiflumetofen 3:1 0.6:0.2 X.07 Isoflucipram 3:1 6:2 X.07 Isoflucipram 30:1 6:0.2 X.07 Isoflucipram 1:3.3 0.6:2 X.07 Isoflucipram 3:1 0.6:0.2 X.07 Isofetamide 3:1 6:2 X.07 Isofetamide 30:1 6:0.2 X.07 Isofetamide 1:3.3 0.6:2 X.07 Isofetamide 3:1 0.6:0.2 X.07 Pyrapropoin 3:1 6:2 X.07 Pyrapropoin 30:1 6:0.2 X.07 Pyrapropoin 1:3.3 0.6:2 X.07 Pyrapropoin 3:1 0.6:0.2 X.07 Fluindapir 3:1 6:2 X.07 Fluindapir 30:1 6:0.2 X.07 Fluindapir 1:3.3 0.6:2 X.07 Fluindapir 3:1 0.6:0.2

- 119 046368

X.07 Phenpicoxamide 1:1 6:6 X.07 Phenpicoxamide 10:1 6:0.6 X.07 Phenpicoxamide 1:10 0.6:6 X.07 Phenpicoxamide 1:1 0.6:0.6 X.07 Florylpicoxamide 3:1 6:2 X.07 Florylpicoxamide 30:1 6:0.2 X.07 Florylpicoxamide 1:3.3 0.6:2 X.07 Florylpicoxamide 3:1 0.6:0.2 X.07 Chlorothalonil 1:1 6:6 X.07 Chlorothalonil 10:1 6:0.6 X.07 Chlorothalonil 1:10 0.6:6 X.07 Chlorothalonil 1:1 0.6:0.6 X.07 Mankozeb 1:3.3 6:20 X.07 Mankozeb 1:1 6:6 X.07 Mankozeb 1:33.3 0.6:20 X.07 Mankozeb 1:10 0.6:6 X.07 Mandipropamide 1:3.3 6:20 X.07 Mandipropamide 1:1 6:6 X.07 Mandipropamide 1:33.3 0.6:20 X.07 Mandipropamide 1:10 0.6:6 X.07 Oxathiapiproline 1:3.3 6:20 X.07 Oxathiapiproline 1:1 6:6 X.07 Oxathiapiproline 1:33.3 0.6:20 X.07 Oxathiapiproline 1:10 0.6:6 X.07 Fluazinam 3:1 6:2 X.07 Fluazinam 30:1 6:0.2 X.07 Fluazinam 1:3.3 0.6:2 X.07 Fluazinam 3:1 0.6:0.2 X.07 Fludioxonil 1:1 6:6 X.07 Fludioxonil 10:1 6:0.6 X.07 Fludioxonil 1:10 0.6:6 X.07 Fludioxonil 1:1 0.6:0.6 X.07 Cyprodinil 1:1 6:6 X.07 Cyprodinil 10:1 6:0.6 X.07 Cyprodinil 1:10 0.6:6 X.07 Cyprodinil 1:1 0.6:0.6 X.07 Metalaxyl-M 1:3.3 6:20 X.07 Metalaxyl-M 1:1 6:6

- 120 046368

X.07 Metalaxyl-M 1:33.3 0.6:20 X.07 Metalaxyl-M 1:10 0.6:6 X.07 Aminopyrifene 3:1 6:2 X.07 Aminopyrifene 30:1 6:0.2 X.07 Aminopyrifene 1:3.3 0.6:2 X.07 Aminopyrifene 3:1 0.6:0.2 X.07 Folpet 1:1 6:6 X.07 Folpet 3:1 6:2 X.07 Folpet 1:10 0.6:6 X.07 Folpet 1:3.3 0.6:2 X.07 Ipflufenoquin 3:1 6:2 X.07 Ipflufenoquin 30:1 6:0.2 X.07 Ipflufenoquin 1:3.3 0.6:2 X.07 Ipflufenoquin 3:1 0.6:0.2 X.07 Quinofumelin 3:1 6:2 X.07 Quinofumelin 30:1 6:0.2 X.07 Quinofumelin 1:3.3 0.6:2 X.07 Quinofumelin 3:1 0.6:0.2 X.07 Tricyclic azole 1:3.3 6:20 X.07 Tricyclic azole 1:1 6:6 X.07 Tricyclic azole 1:33.3 0.6:20 X.07 Tricyclic azole 1:10 0.6:6 X.07 Pirokv ILON 1:3.3 6:20 X.07 Pirokv ILON 1:1 6:6 X.07 Pirokv ILON 1:33.3 0.6:20 X.07 Pirokv ILON 1:10 0.6:6 X.07 X-(1-Benzyl-1,3dimethylbutyl)-8fluoroquinoline-3carboxamide 3:1 6:2 X.07 X-(1-Benzyl-1,3dimethylbutyl)-8fluoroquinoline-3carboxamide 30:1 6:0.2 X.07 X-(1-Benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 1:3.3 0.6:2 X.07 X-(1-Benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 3:1 0.6:0.2

- 121 046368

X.07 N-(l -Benzyl-3,3,3trifluoro-1methylpropyl)-8fluoroquinoline-3carboxamide 3:1 6:2 X.07 N-(l-Benzyl-3,3,3trifluoro-1methylpropyl)-8fluoroquinoline-3carboxamide 30:1 6:0.2 X.07 N-(l-Benzyl-3,3,3trifluoro-1methylpropyl)-8fluoroquinoline-3carboxamide 1:3.3 0.6:2 X.07 X-(1-Benzyl-3,3,3trifluoro-1methylpropyl)-8fluoroquinoline-3carboxamide 3:1 0.6:0.2 X.07 1-(6,7Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 3:1 6:2 X.07 1-(6,7Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 30:1 6:0.2 X.07 1-(6,7Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 1:3.3 0.6:2 X.07 1-(6,7Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 3:1 0.6:0.2 X.07 4,4-Difluoro-3,3-d imethyl1 -(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 3:1 6:2 X.07 4,4-Difluoro-3,3-d and methyl1-(7-methylpyrazolo[1,5а]pyridine-3- 30:1 6:0.2

- 122 046368

yl)isoquinoline X.07 4,4-Difluoro-3,3-d-imethyl1 -(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 1:3.3 0.6:2 X.07 4,4-Difluoro-3,3-d imethyl1 -(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 3:1 0.6:0.2 X.07 1-(4,5Dimethylbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 3:1 6:2 X.07 1-(4,5Dimethylbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 30:1 6:0.2 X.07 1-(4,5Dimethylbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 1:3.3 0.6:2 X.07 1-(4,5Dimethylbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 3:1 0.6:0.2 X.07 1-(4,5Dimethylbenzimide azol-1 yl)-4,4-difluoro-3,3 dimethylisoquinoline 3:1 6:2 X.07 1-(4,5Dimethylbenzimide azol-1 yl)-4,4-difluoro-3,3 dimethylisoquinoline 30:1 6:0.2 X.07 1-(4,5Dimethylbenzimide azol-1 yl)-4,4-difluoro-3,3 dimethylisoquinoline 1:3.3 0.6:2 X.07 1-(4,5Dimethylbenzimide azol-1 yl)-4,4-difluoro-3,3 dimethylisoquinoline 3:1 0.6:0.2

Component A (connection) Component B A:B ratio Conc, (ppm) (A:B) X.14 Azoxystrobin 3:1 6:2 X.14 Azoxystrobin 30:1 6:0.2 X.14 Azoxystrobin 1:3.3 0.6:2

- 123 046368

X.14 Azoxystrobin | 3:1 1 0.6:0.2 X.14 Trifloxystrobin 3:1 6:2 X.14 Trifloxystrobin 30:1 6:0.2 X.14 Trifloxystrobin 1:3.3 0.6:2 X.14 Trifloxystrobin 3:1 0.6:0.2 X.14 Methyltetraprole 3:1 6:2 X.14 Methyltetraprole 30:1 6:0.2 X.14 Methyltetraprole 1:3.3 0.6:2 X.14 Methyltetraprole 3:1 0.6:0.2 X.14 Difenoconazole 1:1 6:6 X.14 Difenoconazole 10:1 6:0.6 X.14 Hexaconazole 1:1 6:6 X.14 Hexaconazole 10:1 6:0.6 X.14 Hexaconazole 1:10 0.6:6 X.14 Propiconazole 1:1 6:6 X.14 Propiconazole 10:1 6:0.6 X.14 Propiconazole 1:10 0.6:6 X.14 Prothioconazole 1:1 6:6 X.14 Prothioconazole 10:1 6:0.6 X.14 Prothioconazole 1:10 0.6:6 X.14 Prothioconazole 1:1 0.6:0.6 X.14 Mefentrifluconazole 1:1 6:6 X.14 Mefentrifluconazole 10:1 6:0.6 X.14 Mefentrifluconazole 1:10 0.6:6 X.14 Fenpropidine 1:3.3 6:20 X.14 Fenpropidine 3:1 6:2 X.14 Phenpropimorph 1:3.3 6:20 X.14 Phenpropimorph 3:1 6:2 X.14 Phenpropimorph 1:33.3 0.6:20 X.14 Fluxapyroxad 3:1 6:2 X.14 Fluxapyroxad 30:1 6:0.2 X.14 Fluopyram 3:1 6:2 X.14 Fluopyram 30:1 6:0.2 X.14 Isopyrase 3:1 6:2 X.14 Isopyrase 30:1 6:0.2 X.14 Isopyrase 1:3.3 0.6:2

- 124 046368

X.14 Sedaksan 3:1 6:2 X.14 Sedaksan 30:1 6:0.2 X.14 Benzovindiflupir 3:1 6:2 X.14 Benzovindiflupir 30:1 6:0.2 X.14 Benzovindiflupir 1:3.3 0.6:2 X.14 Pidiflumetofen 3:1 6:2 X.14 Pidiflumetofen 30:1 6:0.2 X.14 Pidiflumetofen 1:3.3 0.6:2 X.14 Pidiflumetofen 3:1 0.6:0.2 X.14 Isoflucipram 3:1 6:2 X.14 Isoflucipram 30:1 6:0.2 X.14 Isoflucipram 1:3.3 0.6:2 X.14 Isofetamide 3:1 6:2 X.14 Isofetamide 30:1 6:0.2 X.14 Pyrapropoin 3:1 6:2 X.14 Pyrapropoin 30:1 6:0.2 X.14 Pyrapropoin 1:3.3 0.6:2 X.14 Pyrapropoin 3:1 0.6:0.2 X.14 Fluindapir 3:1 6:2 X.14 Fluindapir 30:1 6:0.2 X.14 Phenpicoxamide 1:1 6:6 X.14 Phenpicoxamide 10:1 6:0.6 X.14 Phenpicoxamide 1:10 0.6:6 X.14 Phenpicoxamide 1:1 0.6:0.6 X.14 Florylpicoxamide 3:1 6:2 X.14 Florylpicoxamide 30:1 6:0.2 X.14 Florylpicoxamide 1:3.3 0.6:2 X.14 Florylpicoxamide 3:1 0.6:0.2 X.14 Chlorothalonil 1:1 6:6 X.14 Chlorothalonil 10:1 6:0.6 X.14 Chlorothalonil 1:10 0.6:6 X.14 Chlorothalonil 1:1 0.6:0.6 X.14 Mankozeb 1:3.3 6:20 X.14 Mankozeb 1:1 6:6 X.14 Mankozeb 1:33.3 0.6:20 X.14 Mankozeb 1:10 0.6:6

- 125 046368

X.14 Mandipropamide 1:3.3 6:20 X.14 Mandipropamide 1:1 6:6 X.14 Oxathiapiproline 1:3.3 6:20 X.14 Oxathiapiproline 1:1 6:6 X.14 Fluazinam 3:1 6:2 X.14 Fluazinam 30:1 6:0.2 X.14 Fluazinam 1:3.3 0.6:2 X.14 Fluazinam 3:1 0.6:0.2 X.14 Fludioxonil 1:1 6:6 X.14 Fludioxonil 10:1 6:0.6 X.14 Fludioxonil 1:10 0.6:6 X.14 Cyprodinil 1:1 6:6 X.14 Cyprodinil 10:1 6:0.6 X.14 Cyprodinil 1:10 0.6:6 X.14 Cyprodinil 1:1 0.6:0.6 X.14 Metalaxyl-M 1:3.3 6:20 X.14 Metalaxyl-M 1:1 6:6 X.14 Metalaxyl-M 1:33.3 0.6:20 X.14 Metalaxyl-M 1:10 0.6:6 X.14 X.14 Aminopyrifene 3:1 6:2 X.14 Aminopyrifene 30:1 6:0.2 X.14 Aminopyrifene 1:3.3 0.6:2 X.14 Folpet 1:1 6:6 X.14 Folpet 3:1 6:2 X.14 Folpet 1:10 0.6:6 X.14 Folpet 1:3.3 0.6:2 X.14 Ipflufenoquin 3:1 6:2 X.14 Ipflufenoquin 30:1 6:0.2 X.14 Ipflufenoquin 1:3.3 0.6:2 X.14 Ipflufenoquin 3:1 0.6:0.2 X.14 Quinofumelin 3:1 6:2 X.14 Quinofumelin 30:1 6:0.2 X.14 Quinofumelin 1:3.3 0.6:2 X.14 Quinofumelin 3:1 0.6:0.2 X.14 Tricyclic azole 1:3.3 6:20 X.14 Tricyclic azole 1:1 6:6 X.14 Pirokv ILON 1:3.3 6:20

- 126 046368

X.14 Pyroquilon 1:1 | 6:6 X.14 M-(1-Benzyl-1,3dimethylbutyl)-8fluoroquinoline-3carboxamide 3:1 6:2 X.14 X-(1-Benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 30:1 6:0.2 X.14 M-(1-Benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 1:3.3 0.6:2 X.14 M-(1-Benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 3:1 0.6:0.2 X.14 X-(1-Benzyl-3,3,3trifluoro-1methylpropyl)-8fluoroquinoline-3carboxamide 3:1 6:2 X.14 X-(1-Benzyl-3,3,3trifluoro-1methylpropyl)-8fluoroquinoline-3carboxamide 30:1 6:0.2 X.14 X-(1-Benzyl-3,3,3trifluoro-1methylpropyl)-8fluoroquinoline-3carboxamide 1:3.3 0.6:2 X.14 X-(1-Benzyl-3,3,3trifluoro-1methylpropyl)-8fluoroquinoline-3carboxamide 3:1 0.6:0.2 X.14 1-(6,7Dimethylpyrazolo[1,5а]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 3:1 6:2 X.14 1-(6,7Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 30:1 6:0.2

- 127 046368

1-(6.7- Dimethylpyrazolo[1,5- X.14 a] pyridin-3-yl)-4,4,5 - 1:3.3 0.6:2 trifluoro-3,3- dimethylisoquinoline 1-(6.7- Dimethylpyrazolo[1,5- X.14 a] pyridin-3-yl)-4,4,5 - 3:1 0.6:0.2 trifluoro-3,3- dimethylisoquinoline X.14 4,4-Difluoro-3,3-d methyl1 -(7-methylpyrazolo[1,5- 31 6:2 a] pyridin-3yl)isoquinoline X.14 4,4-Difluoro-3,3-d methyl1 -(7-methylpyrazolo[1,5- 30:1 6:0.2 a] pyridin-3yl)isoquinoline X.14 4,4-Difluoro-3,3-d methyl1 -(7-methylpyrazolo[1,5- 1:3.3 0.6:2 a] pyridin-3yl)isoquinoline X.14 4,4-Difluoro-3,3-d methyl1 -(7-methylpyrazolo[1,5- 31 0.6:0.2 a] pyridin-3yl)isoquinoline 1-(4.5- X.14 Dimethylbenzimide azole-1 - VI 6:2 yl)-4,4,5 -trifluoro-3,3 - dimethylisoquinoline 1-(4.5- X.14 Dimethylbenzimide azole-1 - 30:1 6:0.2 yl)-4,4,5 -trifluoro-3,3 - dimethylisoquinoline 1-(4.5- X.14 Dimethylbenzimide azole-1 - 1:3.3 0.6:2 yl)-4,4,5 -trifluoro-3,3 - dimethylisoquinoline 1-(4.5- X.14 Dimethylbenzimide azole-1 - 31 0.6:0.2 yl)-4,4,5 -trifluoro-3,3 - dimethylisoquinoline 1-(4.5- X.14 Dimethylbenzimide azole-1 - 3:1 6:2 yl)-4,4-difluoro-3,3 - dimethylisoquinoline X.14 1-(4.5- 30:1 6:0.2 Dimethylbenzimidazole-1 - yl)-4,4-difluoro-3,3 - dimethylisoquinoline 1-(4.5- X.14 Dimethylbenzimidazole-1 - 1:3.3 0.6:2 yl)-4,4-difluoro-3,3 - dimethylisoquinoline 1-(4.5- X.14 Dimethylbenzimidazole-1 - 31 0.6:0.2 yl)-4,4-difluoro-3,3 - dimethylisoquinoline

Example B3. Activity against Glomerella lagenarium syn. Colletotrichum lagenarium (cucurbit anthracnose)

Fungal conidia from cryogenic storage were directly mixed with nutrient broth (potato dextrose broth, PDB). A solution of test compounds in DMSO was added to a microtiter plate (96-well format) and nutrient broth containing fungal spores was added. Plates with test compounds were incubated at 24°C and growth inhibition was determined photometrically after 72 h at 620 nm. The following mixture-based formulations (A:B) at the indicated concentrations (in ppm) provided at least 70% disease control in this test.

- 128 046368

Component A (connection) Component B A:B ratio Conc, (ppm) (A:B) X.05 Azoxystrobin 3:1 6:2 X.05 Azoxystrobin 30:1 6:0.2 X.05 Azoxystrobin 1:3.3 0.6:2 X.05 Azoxystrobin 3:1 0.6:0.2 X.05 Trifloxystrobin 3:1 6:2 X.05 Trifloxystrobin 30:1 6:0.2 X.05 Trifloxystrobin 1:3.3 0.6:2 X.05 Trifloxystrobin 3:1 0.6:0.2 X.05 Methyltetraprole 3:1 6:2 X.05 Methyltetraprole 30:1 6:0.2 X.05 Methyltetraprole 1:3.3 0.6:2 X.05 Methyltetraprole 3:1 0.6:0.2 X.05 Difenoconazole 1:1 6:6 X.05 Difenoconazole 10:1 6:0.6 X.05 Difenoconazole 1:10 0.6:6 X.05 Difenoconazole 1:1 0.6:0.6 X.05 Hexaconazole 1:1 6:6 X.05 Hexaconazole 10:1 6:0.6 X.05 Hexaconazole 1:10 0.6:6 X.05 Hexaconazole 1:1 0.6:0.6 X.05 Propiconazole 1:1 6:6 X.05 Propiconazole 10:1 6:0.6 X.05 Propiconazole 1:10 0.6:6 X.05 Propiconazole 1:1 0.6:0.6 X.05 Prothioconazole 1:1 6:6 X.05 Prothioconazole 10:1 6:0.6 X.05 Prothioconazole 1:10 0.6:6 X.05 Prothioconazole 1:1 0.6:0.6 X.05 Mefentrifluconazole 1:1 6:6 X.05 Mefentrifluconazole 10:1 6:0.6 X.05 Mefentrifluconazole 1:10 0.6:6 X.05 Mefentrifluconazole 1:1 0.6:0.6 X.05 Fenpropidine 1:3.3 6:20 X.05 Fenpropidine 3:1 6:2 X.05 Fenpropidine 1:33.3 0.6:20 X.05 Fenpropidine 1:3.3 0.6:2 X.05 Phenpropimorph 1:3.3 6:20 X.05 Phenpropimorph 3:1 6:2 X.05 Phenpropimorph 1:33.3 0.6:20 X.05 Phenpropimorph 1:3.3 0.6:2 X.05 Fluxapyroxad 3:1 6:2 X.05 Fluxapyroxad 30:1 6:0.2 X.05 Fluxapyroxad 1:3.3 0.6:2 X.05 Fluxapyroxad 3:1 0.6:0.2 X.05 Fluopyram 3:1 6:2 X.05 Fluopyram 30:1 6:0.2 X.05 Fluopyram 1:3.3 0.6:2 X.05 Fluopyram 3:1 0.6:0.2 X.05 Isopyrase 3:1 6:2 X.05 Isopyrase 30:1 6:0.2 X.05 Isopyrase 1:3.3 0.6:2 X.05 Isopyrase 3:1 0.6:0.2 X.05 Sedaksan 3:1 6:2 X.05 Sedaksan 30:1 6:0.2 X.05 Sedaksan 1:3.3 0.6:2

- 129 046368

X.05 Sedaksan 3:1 0.6:0.2 X.05 Benzovindiflupir 3:1 6:2 X.05 Benzovindiflupir 30:1 6:0.2 X.05 Benzovindiflupir 1:3.3 0.6:2 X.05 Benzovindiflupir 3:1 0.6:0.2 X.05 Pidiflumetofen 3:1 6:2 X.05 Pidiflumetofen 30:1 6:0.2 X.05 Pidiflumetofen 1:3.3 0.6:2 X.05 Pidiflumetofen 3:1 0.6:0.2 X.05 Isoflucipram 3:1 6:2 X.05 Isoflucipram 30:1 6:0.2 X.05 Isoflucipram 1:3.3 0.6:2 X.05 Isoflucipram 3:1 0.6:0.2 X.05 Isofetamide 3:1 6:2 X.05 Isofetamide 30:1 6:0.2 X.05 Isofetamide 1:3.3 0.6:2 X.05 Isofetamide 3:1 0.6:0.2 X.05 Pyrapropoin 3:1 6:2 X.05 Pyrapropoin 30:1 6:0.2 X.05 Pyrapropoin 1:3.3 0.6:2 X.05 Pyrapropoin 3:1 0.6:0.2 X.05 Fluindapir 3:1 6:2 X.05 Fluindapir 30:1 6:0.2 X.05 Fluindapir 1:3.3 0.6:2 X.05 Fluindapir 3:1 0.6:0.2 X.05 Phenpicoxamide 1:1 6:6 X.05 Phenpicoxamide 10:1 6:0.6 X.05 Phenpicoxamide 1:10 0.6:6 X.05 Phenpicoxamide 1:1 0.6:0.6 X.05 Florylpicoxamide 3:1 6:2 X.05 Florylpicoxamide 30:1 6:0.2 X.05 Florylpicoxamide 1:3.3 0.6:2 X.05 Florylpicoxamide 3:1 0.6:0.2 X.05 Chlorothalonil 1:1 6:6 X.05 Chlorothalonil 10:1 6:0.6 X.05 Chlorothalonil 1:10 0.6:6 X.05 Chlorothalonil 1:1 0.6:0.6 X.05 Mankozeb 1:3.3 6:20

- 130 046368

X.05 Mankozeb 1:1 6:6 X.05 Mankozeb 1:33.3 0.6:20 X.05 Mankozeb 1:10 0.6:6 X.05 Mandipropamide 1:3.3 6:20 X.05 Mandipropamide 1:1 6:6 X.05 Mandipropamide 1:33.3 0.6:20 X.05 Mandipropamide 1:10 0.6:6 X.05 Oxathiapiproline 1:3.3 6:20 X.05 Oxathiapiproline 1:1 6:6 X.05 Oxathiapiproline 1:33.3 0.6:20 X.05 Oxathiapiproline 1:10 0.6:6 X.05 Fluazinam 3:1 6:2 X.05 Fluazinam 30:1 6:0.2 X.05 Fluazinam 1:3.3 0.6:2 X.05 Fluazinam 3:1 0.6:0.2 X.05 Fludioxonil 1:1 6:6 X.05 Fludioxonil 10:1 6:0.6 X.05 Fludioxonil 1:10 0.6:6 X.05 Fludioxonil 1:1 0.6:0.6 X.05 Cyprodinil 1:1 6:6 X.05 Cyprodinil 10:1 6:0.6 X.05 Cyprodinil 1:10 0.6:6 X.05 Cyprodinil 1:1 0.6:0.6 X.05 Metalaxyl-M 1:3.3 6:20 X.05 Metalaxyl-M 1:1 6:6 X.05 Metalaxyl-M 1:33.3 0.6:20 X.05 Metalaxyl-M 1:10 0.6:6 X.05 Aminopyrifene 3:1 6:2 X.05 Aminopyrifene 30:1 6:0.2 X.05 Aminopyrifene 1:3.3 0.6:2 X.05 Aminopyrifene 3:1 0.6:0.2 X.05 Folpet 1:1 6:6 X.05 Folpet 3:1 6:2 X.05 Folpet 1:10 0.6:6 X.05 Folpet 1:3.3 0.6:2 X.05 Ipflufenoquin 3:1 6:2 X.05 Ipflufenoquin 30:1 6:0.2 X.05 Ipflufenoquin 1:3.3 0.6:2 X.05 Ipflufenoquin 3:1 0.6:0.2

- 131 046368

X.05 Quinofumelin 3:1 6:2 X.05 Quinofumelin 30:1 6:0.2 X.05 Quinofumelin 1:3.3 0.6:2 X.05 Quinofumelin 3:1 0.6:0.2 X.05 Tricyclic azole 1:3.3 6:20 X.05 Tricyclic azole 1:1 6:6 X.05 Tricyclic azole 1:33.3 0.6:20 X.05 Tricyclic azole 1:10 0.6:6 X.05 Pirokv ILON 1:3.3 6:20 X.05 Pirokv ILON 1:1 6:6 X.05 Pirokv ILON 1:33.3 0.6:20 X.05 Pirokv ILON 1:10 0.6:6 X.05 X-(1-Benzyl-1,3dimethylbutyl)-8fluoroquinoline-3carboxamide 3:1 6:2 X.05 X-(1-Benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 30:1 6:0.2 X.05 X-(1-Benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 1:3.3 0.6:2 X.05 X-(1-Benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 3:1 0.6:0.2 X.05 X-(1-Benzyl-3,3,3trifluoro-1methylpropyl)-8fluoroquinoline-3carboxamide 3:1 6:2 X.05 X-(1-Benzyl-3,3,3trifluoro-1methylpropyl)-8fluoroquinoline-3 carboxamide 30:1 6:0.2 X.05 X-(1-Benzyl-3,3,3trifluoro-1methylpropyl)-8fluoroquinoline-3carboxamide 1:3.3 0.6:2 X.05 X-(1-Benzyl-3,3,3- 3:1 0.6:0.2

- 132 046368

trifluoro-1methylpropyl)-8 fluoroquinoline-3 carboxamide X.05 1-(6,7Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 3:1 6:2 X.05 1-(6,7Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 30:1 6:0.2 X.05 1-(6,7Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 1:3.3 0.6:2 X.05 1-(6,7Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 3:1 0.6:0.2 X.05 4,4-Difluoro-3,3-d imethyl1 -(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 3:1 6:2 X.05 4,4-Difluoro-3,3-d imethyl1 -(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 30:1 6:0.2 X.05 4,4-Difluoro-3,3-d imethyl1 -(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 1:3.3 0.6:2 X.05 4,4-Difluoro-3,3-d imethyl1 -(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 3:1 0.6:0.2 X.05 1-(4.5- Dimethylbenzimidazol-1yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 3:1 6:2 X.05 1-(4.5- Dimethylbenzimidazol-1yl)-4,4,5-trifluoro-3,3- 30:1 6:0.2

- 133 046368

X.05 X.05 dimethylisoquinoline 1-(4,5- Dimethylbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 1-(4,5- Dimethylbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 1:3.3 3:1 0.6:2 0.6:0.2 1-(4.5- X.05 Dimethylbenzimide azol-1 yl)-4,4-difluoro-3,3 dimethylisoquinoline 1-(4,5- 3:1 6:2 X.05 Dimethylbenzimide azole-1 - 30:1 6:0.2 yl)-4,4-difluoro-3,3 dimethylisoquinoline 1-(4,5- X.05 Dimethylbenzimide azole-1 - 1:3.3 0.6:2 yl)-4,4-difluoro-3,3 dimethylisoquinoline 1-(4,5- X.05 Dimethylbenzimide azole-1 - 3:1 0.6:0.2 yl)-4,4-difluoro-3,3 dimethylisoquinoline

Component A (connection) Component B A:B ratio Conc, (ppm) (A:B) X.07 Azoxystrobin 3:1 6:2 X.07 Azoxystrobin 30:1 6:0.2 X.07 Azoxystrobin 1:3.3 0.6:2 X.07 Azoxystrobin 3:1 0.6:0.2 X.07 Trifloxystrobin 3:1 6:2 X.07 Trifloxystrobin 30:1 6:0.2 X.07 Trifloxystrobin 1:3.3 0.6:2 X.07 Trifloxystrobin 3:1 0.6:0.2 X.07 Methyltetraprole 3:1 6:2 X.07 Methyltetraprole 30:1 6:0.2

- 134 046368

X.07 Methyltetraprole 1:3.3 0.6:2 X.07 Methyltetraprole 3:1 0.6:0.2 X.07 Difenoconazole 1:1 6:6 X.07 Difenoconazole 10:1 6:0.6 X.07 Difenoconazole 1:10 0.6:6 X.07 Difenoconazole 1:1 0.6:0.6 X.07 Hexaconazole 1:1 6:6 X.07 Hexaconazole 10:1 6:0.6 X.07 Hexaconazole 1:10 0.6:6 X.07 Hexaconazole 1:1 0.6:0.6 X.07 Propiconazole 1:1 6:6 X.07 Propiconazole 10:1 6:0.6 X.07 Propiconazole 1:10 0.6:6 X.07 Propiconazole 1:1 0.6:0.6 X.07 Prothioconazole 1:1 6:6 X.07 Prothioconazole 10:1 6:0.6 X.07 Prothioconazole 1:10 0.6:6 X.07 Prothioconazole 1:1 0.6:0.6 X.07 Mefentrifluconazole 1:1 6:6 X.07 Mefentrifluconazole 10:1 6:0.6 X.07 Mefentrifluconazole 1:10 0.6:6 X.07 Mefentrifluconazole 1:1 0.6:0.6 X.07 Fenpropidine 1:3.3 6:20 X.07 Fenpropidine 3:1 6:2 X.07 Fenpropidine 1:33.3 0.6:20 X.07 Fenpropidine 1:3.3 0.6:2

- 135 046368

X.07 Phenpropimorph 1:3.3 6:20 X.07 Phenpropimorph 3:1 6:2 X.07 Phenpropimorph 1:33.3 0.6:20 X.07 Phenpropimorph 1:3.3 0.6:2 X.07 Fluxapyroxad 3:1 6:2 X.07 Fluxapyroxad 30:1 6:0.2 X.07 Fluxapyroxad 1:3.3 0.6:2 X.07 Fluxapyroxad 3:1 0.6:0.2 X.07 Fluopyram 3:1 6:2 X.07 Fluopyram 30:1 6:0.2 X.07 Fluopyram 1:3.3 0.6:2 X.07 Fluopyram 3:1 0.6:0.2 X.07 Isopyrase 3:1 6:2 X.07 Isopyrase 30:1 6:0.2 X.07 Isopyrase 1:3.3 0.6:2 X.07 Isopyrase 3:1 0.6:0.2 X.07 Sedaksan 3:1 6:2 X.07 Sedaksan 30:1 6:0.2 X.07 Sedaksan 1:3.3 0.6:2 X.07 Sedaksan 3:1 0.6:0.2 X.07 Benzovindiflupir 3:1 6:2 X.07 Benzovindiflupir 30:1 6:0.2 X.07 Benzovindiflupir 1:3.3 0.6:2 X.07 Benzovindiflupir 3:1 0.6:0.2 X.07 Pidiflumetofen 3:1 6:2 X.07 Pidiflumetofen 30:1 6:0.2 X.07 Pidiflumetofen 1:3.3 0.6:2

- 136 046368

X.07 Pidiflumetofen 3:1 0.6:0.2 X.07 Isoflucipram 3:1 6:2 X.07 Isoflucipram 30:1 6:0.2 X.07 Isoflucipram 1:3.3 0.6:2 X.07 Isoflucipram 3:1 0.6:0.2 X.07 Isofetamide 3:1 6:2 X.07 Isofetamide 30:1 6:0.2 X.07 Isofetamide 1:3.3 0.6:2 X.07 Isofetamide 3:1 0.6:0.2 X.07 Pyrapropoin 3:1 6:2 X.07 Pyrapropoin 30:1 6:0.2 X.07 Pyrapropoin 1:3.3 0.6:2 X.07 Pyrapropoin 3:1 0.6:0.2 X.07 Fluindapir 3:1 6:2 X.07 Fluindapir 30:1 6:0.2 X.07 Fluindapir 1:3.3 0.6:2 X.07 Fluindapir 3:1 0.6:0.2 X.07 Phenpicoxamide 1:1 6:6 X.07 Phenpicoxamide 10:1 6:0.6 X.07 Phenpicoxamide 1:10 0.6:6 X.07 Phenpicoxamide 1:1 0.6:0.6 X.07 Florylpicoxamide 3:1 6:2 X.07 Florylpicoxamide 30:1 6:0.2 X.07 Florylpicoxamide 1:3.3 0.6:2 X.07 Florylpicoxamide 3:1 0.6:0.2 X.07 Chlorothalonil 1:1 6:6

- 137 046368

X.07 Chlorothalonil 10:1 6:0.6 X.07 Chlorothalonil 1:10 0.6:6 X.07 Chlorothalonil 1:1 0.6:0.6 X.07 Mankozeb 1:3.3 6:20 X.07 Mankozeb 1:1 6:6 X.07 Mankozeb 1:33.3 0.6:20 X.07 Mankozeb 1:10 0.6:6 X.07 Mandipropamide 1:3.3 6:20 X.07 Mandipropamide 1:1 6:6 X.07 Mandipropamide 1:33.3 0.6:20 X.07 Mandipropamide 1:10 0.6:6 X.07 Oxathiapiproline 1:3.3 6:20 X.07 Oxathiapiproline 1:1 6:6 X.07 Oxathiapiproline 1:33.3 0.6:20 X.07 Oxathiapiproline 1:10 0.6:6 X.07 Fluazinam 3:1 6:2 X.07 Fluazinam 30:1 6:0.2 X.07 Fluazinam 1:3.3 0.6:2 X.07 Fluazinam 3:1 0.6:0.2 X.07 Fludioxonil 1:1 6:6 X.07 Fludioxonil 10:1 6:0.6 X.07 Fludioxonil 1:10 0.6:6 X.07 Fludioxonil 1:1 0.6:0.6 X.07 Cyprodinil 1:1 6:6 X.07 Cyprodinil 10:1 6:0.6 X.07 Cyprodinil 1:10 0.6:6 X.07 Cyprodinil 1:1 0.6:0.6

- 138 046368

X.07 Metalaxyl-M 1:3.3 6:20 X.07 Metalaxyl-M 1:1 6:6 X.07 Metalaxyl-M 1:33.3 0.6:20 X.07 Metalaxyl-M 1:10 0.6:6 X.07 Aminopyrifene 3:1 6:2 X.07 Aminopyrifene 30:1 6:0.2 X.07 Aminopyrifene 1:3.3 0.6:2 X.07 Aminopyrifene 3:1 0.6:0.2 X.07 Folpet 1:1 6:6 X.07 Folpet 3:1 6:2 X.07 Folpet 1:10 0.6:6 X.07 Folpet 1:3.3 0.6:2 X.07 Ipflufenoquin 3:1 6:2 X.07 Ipflufenoquin 30:1 6:0.2 X.07 Ipflufenoquin 1:3.3 0.6:2 X.07 Ipflufenoquin 3:1 0.6:0.2 X.07 Quinofumelin 3:1 6:2 X.07 Quinofumelin 30:1 6:0.2 X.07 Quinofumelin 1:3.3 0.6:2 X.07 Quinofumelin 3:1 0.6:0.2 X.07 Tricyclic azole 1:3.3 6:20 X.07 Tricyclic azole 1:1 6:6 X.07 Tricyclic azole 1:33.3 0.6:20 X.07 Tricyclic azole 1:10 0.6:6 X.07 Pyroquilon 1:3.3 6:20 X.07 Pyroquilon 1:1 6:6

- 139 046368

X.07 Pirokv ILON 1:33.3 0.6:20 X.07 Pirokv ILON 1:10 0.6:6 X.07 X-(1-Benzyl-1,3dimethylbutyl)-8fluoroquinoline-3carboxamide 3:1 6:2 X.07 X-(1-Benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 30:1 6:0.2 X.07 X-(1-Benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 1:3.3 0.6:2 X.07 X-(1-Benzyl-1,3dimethylbutyl)-8fluoroquinoline-3carboxamide 3:1 0.6:0.2 X.07 X-(1-Benzyl-3,3,3trifluoro-1methylpropyl)-8fluoroquinoline-3carboxamide 3:1 6:2 X.07 X-(1-Benzyl-3,3,3trifluoro-1methylpropyl)-8fluoroquinoline-3 carboxamide 30:1 6:0.2 X.07 X-(1-Benzyl-3,3,3trifluoro-1methylpropyl)-8- 1:3.3 0.6:2

- 140 046368

fluoroquinoline-3 carboxamide X.07 N-(l-Benzyl-3,3,3trifluoro-1methylpropyl)-8fluoroquinoline-3carboxamide 3:1 0.6:0.2 X.07 1-(6.7- Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 3:1 6:2 X.07 1-(6.7- Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 30:1 6:0.2 X.07 1-(6.7- Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 1:3.3 0.6:2 X.07 1-(6.7- Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 3:1 0.6:0.2 X.07 4,4-Difluoro-3,3-d imethyl1 -(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 3:1 6:2

- 141 046368

X.07 4,4-Difluoro-3,3-d-imethyl1 -(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 30:1 6:0.2 X.07 4,4-Difluoro-3,3-d imethyl1 -(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 1:3.3 0.6:2 X.07 4,4-Difluoro-3,3-d imethyl1 -(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 3:1 0.6:0.2 X.07 1-(4,5Dimethylbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 3:1 6:2 X.07 1-(4,5Dimethylbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 30:1 6:0.2 X.07 1-(4,5Dimethylbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 1:3.3 0.6:2 X.07 1-(4,5Dimethylbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 3:1 0.6:0.2 X.07 1-(4.5- Dimethylbenzimide azol-1 yl)-4,4-difluoro-3,3 - 3:1 6:2

- 142 046368

dimethylisoquinoline X.07 1-(4.5- Dimethylbenzimide azol-1 yl)-4,4-difluoro-3,3 dimethylisoquinoline 30:1 6:0.2 X.07 1-(4.5- Dimethylbenzimide azol-1 yl)-4,4-difluoro-3,3 dimethylisoquinoline 1:3.3 0.6:2 X.07 1-(4.5- Dimethylbenzimide azol-1 yl)-4,4-difluoro-3,3 dimethylisoquinoline 3:1 0.6:0.2

Component A (connection) Component B A:B ratio Conc, (ppm) (A:B) X.14 Azoxystrobin 3:1 6:2 X.14 Azoxystrobin 30:1 6:0.2 X.14 Azoxystrobin 1:3.3 0.6:2 X.14 Azoxystrobin 3:1 0.6:0.2 X.14 Trifloxystrobin 3:1 6:2 X.14 Trifloxystrobin 30:1 6:0.2 X.14 Trifloxystrobin 1:3.3 0.6:2 X.14 Trifloxystrobin 3:1 0.6:0.2 X.14 Methyltetraprole 3:1 6:2 X.14 Methyltetraprole 30:1 6:0.2 X.14 Methyltetraprole 1:3.3 0.6:2 X.14 Methyltetraprole 3:1 0.6:0.2 X.14 Difenoconazole 1:1 6:6 X.14 Difenoconazole 10:1 6:0.6 X.14 Difenoconazole 1:10 0.6:6 X.14 Hexaconazole 1:1 6:6 X.14 Hexaconazole 10:1 6:0.6 X.14 Propiconazole 1:1 6:6 X.14 Propiconazole 10:1 6:0.6 X.14 Propiconazole 1:10 0.6:6

- 143 046368

X.14 Prothioconazole 1:1 6:6 X.14 Prothioconazole 10:1 6:0.6 X.14 Prothioconazole 1:10 0.6:6 X.14 Prothioconazole 1:1 0.6:0.6 X.14 Mefentrifluconazole 1:1 6:6 X.14 Mefentrifluconazole 10:1 6:0.6 X.14 Mefentrifluconazole 1:10 0.6:6 X.14 Fenpropidine 1:3.3 6:20 X.14 Fenpropidine 3:1 6:2 X.14 Phenpropimorph 1:3.3 6:20 X.14 Phenpropimorph 3:1 6:2 X.14 Phenpropimorph 1:33.3 0.6:20 X.14 Fluxapyroxad 3:1 6:2 X.14 Fluxapyroxad 30:1 6:0.2 X.14 Fluopyram 3:1 6:2 X.14 Fluopyram 30:1 6:0.2 X.14 Isopyrase 3:1 6:2 X.14 Isopyrase 30:1 6:0.2 X.14 Sedaksan 3:1 6:2 X.14 Sedaksan 30:1 6:0.2 X.14 Benzovindiflupir 3:1 6:2 X.14 Benzovindiflupir 30:1 6:0.2 X.14 Benzovindiflupir 1:3.3 0.6:2 X.14 Benzovindiflupir 3:1 0.6:0.2 X.14 Pidiflumetofen 3:1 6:2 X.14 Pidiflumetofen 30:1 6:0.2 X.14 Isoflucipram 3:1 6:2 X.14 Isoflucipram 30:1 6:0.2 X.14 Isofetamide 3:1 6:2 X.14 Isofetamide 30:1 6:0.2 X.14 Pyrapropoin 3:1 6:2 X.14 Pyrapropoin 30:1 6:0.2 X.14 Fluindapir 3:1 6:2 X.14 Fluindapir 30:1 6:0.2 X.14 Fluindapir 1:3.3 0.6:2

- 144 046368

X.14 Phenpicoxamide 1:1 6:6 X.14 Phenpicoxamide 10:1 6:0.6 X.14 Phenpicoxamide 1:10 0.6:6 X.14 Phenpicoxamide 1:1 0.6:0.6 X.14 Florylpicoxamide 3:1 6:2 X.14 Florylpicoxamide 30:1 6:0.2 X.14 Florylpicoxamide 1:3.3 0.6:2 X.14 Chlorothalonil 1:1 6:6 X.14 Chlorothalonil 10:1 6:0.6 X.14 Chlorothalonil 1:10 0.6:6 X.14 Mankozeb 1:3.3 6:20 X.14 Mankozeb 1:1 6:6 X.14 Mankozeb 1:33.3 0.6:20 X.14 Mankozeb 1:10 0.6:6 X.14 Mandipropamide 1:3.3 6:20 X.14 Mandipropamide 1:1 6:6 X.14 Mandipropamide 1:33.3 0.6:20 X.14 Oxathiapiproline 1:3.3 6:20 X.14 Oxathiapiproline 1:1 6:6 X.14 Fluazinam 3:1 6:2 X.14 Fluazinam 30:1 6:0.2 X.14 Fluazinam 1:3.3 0.6:2 X.14 Fluazinam 3:1 0.6:0.2 X.14 Fludioxonil 1:1 6:6 X.14 Fludioxonil 10:1 6:0.6 X.14 Fludioxonil 1:10 0.6:6 X.14 Fludioxonil 1:1 0.6:0.6 X.14 Cyprodinil 1:1 6:6 X.14 Cyprodinil 10:1 6:0.6 X.14 Cyprodinil 1:10 0.6:6 X.14 Metalaxyl-M 1:3.3 6:20 X.14 Metalaxyl-M 1:1 6:6 X.14 Aminopyrifene 3:1 6:2 X.14 Aminopyrifene 30:1 6:0.2 X.14 Aminopyrifene 1:3.3 0.6:2 X.14 Aminopyrifene 3:1 0.6:0.2

- 145 046368

X.14 Folpet 1:1 6:6 X.14 Folpet 3:1 6:2 X.14 Folpet 1:10 0.6:6 X.14 Folpet 1:3.3 0.6:2 X.14 Ipflufenoquin 3:1 6:2 X.14 Ipflufenoquin 30:1 6:0.2 X.14 Ipflufenoquin 1:3.3 0.6:2 X.14 Ipflufenoquin 3:1 0.6:0.2 X.14 Quinofumelin 3:1 6:2 X.14 Quinofumelin 30:1 6:0.2 X.14 Quinofumelin 1:3.3 0.6:2 X.14 Quinofumelin 3:1 0.6:0.2 X.14 Tricyclic azole 1:3.3 6:20 X.14 Tricyclic azole 1:1 6:6 X.14 Pirokv ILON 1:3.3 6:20 X.14 Pirokv ILON 1:1 6:6 X.14 X-(1-Benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 3:1 6:2 X.14 T4-(1-Benzyl-1,3dimethylbutyl)-8fluoroquinoline-3carboxamide 30:1 6:0.2 X.14 X-(1-Benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 1:3.3 0.6:2 X.14 X-(1-Benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 3:1 0.6:0.2 X.14 N-(l -Benzyl-3,3,3trifluoro-1methylpropyl)-8fluoroquinoline-3carboxamide 3:1 6:2 X.14 N-(l-Benzyl-3,3,3trifluoro-1methylpropyl)-8fluoroquinoline-3 carboxamide 30:1 6:0.2 X.14 T4-(1-Benzyl-3,3,3- 1:3.3 0.6:2

- 146 046368

trifluoro-1methylpropyl)-8 fluoroquinoline-3 carboxamide X.14 1-(6,7Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 3:1 6:2 X.14 1-(6,7Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 30:1 6:0.2 X.14 1-(6,7Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 1:3.3 0.6:2 X.14 1-(6,7Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 3:1 0.6:0.2 X.14 4,4-Difluoro-3,3-d imethyl1 -(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 3:1 6:2 X.14 4,4-Difluoro-3,3-d imethyl1 -(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 30:1 6:0.2 X.14 4,4-Difluoro-3,3-d imethyl1 -(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 1:3.3 0.6:2 X.14 4,4-Difluoro-3,3-d imethyl1 -(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 3:1 0.6:0.2 X.14 1-(4,5Dimethylbenzimide azol-1yl)-4,4,5-trifluoro-3,3dimethylisoquinoline 3:1 6:2 X.14 1-(4,5Dimethylbenzimide azol-1 yl)-4,4,5-trifluoro-3,3- 30:1 6:0.2 X.14 X.14 dimethylisoquinoline 1-(4,5- Dimethylbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 1-(4,5- Dimethylbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 1:3.3 3:1 0.6:2 0.6:0.2 X.14 X.14 1-(4,5Dimethylbenzimide azol-1 yl)-4,4-difluoro-3,3 dimethylisoquinoline 1-(4,5Dimethylbenzimide azol-1 yl)-4,4-difluoro-3,3 dimethylisoquinoline 3:1 30:1 6:2 6:0.2 X.14 1-(4,5Dimethylbenzimide azol-1 yl)-4,4-difluoro-3,3 dimethylisoquinoline 1:3.3 0.6:2 X.14 1-(4,5Dimethylbenzimide azol-1 yl)-4,4-difluoro-3,3 dimethylisoquinoline 3:1 0.6:0.2

- 147 046368

Example B4. Activity against Mycosphaerella arachidis syn. Cercospora arachidicola (peanut brown leaf spot)

Fungal conidia from cryogenic storage were directly mixed with nutrient broth (potato dextrose broth, PDB). A solution of test compounds in DMSO was added to a microtiter plate (96-well format) and nutrient broth containing fungal spores was added. Plates containing test compounds were incubated at 24°C and growth inhibition was determined photometrically after approximately 5-6 days at 620 nm. The following mixture-based formulations (A:B) at the indicated concentrations (in ppm) provided at least 70% disease control in this test.

Component A (connection) Component B A:B ratio Conc, (ppm) (A:B) X.05 Azoxystrobin 3:1 6:2 X.05 Azoxystrobin 30:1 6:0.2 X.05 Azoxystrobin 1:3.3 0.6:2 X.05 Azoxystrobin 3:1 0.6:0.2 X.05 Trifloxystrobin 3:1 6:2 X.05 Trifloxystrobin 30:1 6:0.2 X.05 Trifloxystrobin 1:3.3 0.6:2 X.05 Trifloxystrobin 3:1 0.6:0.2 X.05 Methyltetraprole 3:1 6:2 X.05 Methyltetraprole 30:1 6:0.2 X.05 Methyltetraprole 1:3.3 0.6:2 X.05 Methyltetraprole 3:1 0.6:0.2 X.05 Difenoconazole 1:1 6:6 X.05 Difenoconazole 10:1 6:0.6 X.05 Difenoconazole 1:10 0.6:6 X.05 Difenoconazole 1:1 0.6:0.6 X.05 Hexaconazole 1:1 6:6 X.05 Hexaconazole 10:1 6:0.6 X.05 Hexaconazole 1:10 0.6:6 X.05 Hexaconazole 1:1 0.6:0.6 X.05 Propiconazole 1:1 6:6 X.05 Propiconazole 10:1 6:0.6 X.05 Propiconazole 1:10 0.6:6 X.05 Propiconazole 1:1 0.6:0.6 X.05 Prothioconazole 1:1 6:6 X.05 Prothioconazole 10:1 6:0.6 X.05 Prothioconazole 1:10 0.6:6 X.05 Prothioconazole 1:1 0.6:0.6 X.05 Mefentrifluconazole 1:1 6:6 X.05 Mefentrifluconazole 10:1 6:0.6 X.05 Mefentrifluconazole 1:10 0.6:6 X.05 Mefentrifluconazole 1:1 0.6:0.6 X.05 Fenpropidine 1:3.3 6:20 X.05 Fenpropidine 3:1 6:2 X.05 Fenpropidine 1:33.3 0.6:20 X.05 Phenpropimorph 1:3.3 6:20 X.05 Phenpropimorph 3:1 6:2 X.05 Phenpropimorph 1:33.3 0.6:20 X.05 Phenpropimorph 1:3.3 0.6:2 X.05 Fluxapyroxad 3:1 6:2 X.05 Fluxapyroxad 30:1 6:0.2 X.05 Fluopyram 3:1 6:2

- 148 046368

X.05 Fluopyram 30:1 6:0.2 X.05 Fluopyram 1:3.3 0.6:2 X.05 Isopyrase 3:1 6:2 X.05 Isopyrase 30:1 6:0.2 X.05 Isopyrase 1:3.3 0.6:2 X.05 Isopyrase 3:1 0.6:0.2 X.05 Sedaksan 3:1 6:2 X.05 Sedaksan 30:1 6:0.2 X.05 Benzovindiflupir 3:1 6:2 X.05 Benzovindiflupir 30:1 6:0.2 X.05 Benzovindiflupir 1:3.3 0.6:2 X.05 Benzovindiflupir 3:1 0.6:0.2 X.05 Pidiflumetofen 3:1 6:2 X.05 Pidiflumetofen 30:1 6:0.2 X.05 Pidiflumetofen 1:3.3 0.6:2 X.05 Pidiflumetofen 3:1 0.6:0.2 X.05 Isoflucipram 3:1 6:2 X.05 Isoflucipram 30:1 6:0.2 X.05 Isoflucipram 1:3.3 0.6:2 X.05 Isoflucipram 3:1 0.6:0.2 X.05 Isofetamide 3:1 6:2 X.05 Isofetamide 30:1 6:0.2 X.05 Isofetamide 1:3.3 0.6:2 X.05 Pyrapropoin 3:1 6:2 X.05 Pyrapropoin 30:1 6:0.2 X.05 Pyrapropoin 1:3.3 0.6:2 X.05 Pyrapropoin 3:1 0.6:0.2 X.05 Fluindapir 3:1 6:2 X.05 Fluindapir 30:1 6:0.2 X.05 Fluindapir 1:3.3 0.6:2 X.05 Phenpicoxamide 1:1 6:6 X.05 Phenpicoxamide 10:1 6:0.6 X.05 Phenpicoxamide 1:10 0.6:6 X.05 Florylpicoxamide 3:1 6:2 X.05 Florylpicoxamide 30:1 6:0.2 X.05 Florylpicoxamide 1:3.3 0.6:2 X.05 Florylpicoxamide 3:1 0.6:0.2

- 149 046368

X.05 Chlorothalonil 1:1 6:6 X.05 Chlorothalonil 10:1 6:0.6 X.05 Chlorothalonil 1:10 0.6:6 X.05 Mankozeb 1:3.3 6:20 X.05 Mankozeb 1:1 6:6 X.05 Mandipropamide 1:3.3 6:20 X.05 Mandipropamide 1:1 6:6 X.05 Oxathiapiproline 1:3.3 6:20 X.05 Oxathiapiproline 1:1 6:6 X.05 Fluazinam 3:1 6:2 X.05 Fluazinam 30:1 6:0.2 X.05 Fluazinam 1:3.3 0.6:2 X.05 Fludioxonil 1:1 6:6 X.05 Fludioxonil 1:10 0.6:6 X.05 Cyprodinil 1:1 6:6 X.05 Cyprodinil 10:1 6:0.6 X.05 Metalaxyl-M 1:3.3 6:20 X.05 Metalaxyl-M 1:1 6:6 X.05 Aminopyrifene 3:1 6:2 X.05 Aminopyrifene 30:1 6:0.2 X.05 Aminopyrifene 1:3.3 0.6:2 X.05 Aminopyrifene 3:1 0.6:0.2 X.05 Folpet 1:1 6:6 X.05 Folpet 3:1 6:2 X.05 Ipflufenoquin 3:1 6:2 X.05 Ipflufenoquin 30:1 6:0.2 X.05 Quinofumelin 3:1 6:2 X.05 Quinofumelin 30:1 6:0.2 X.05 Tricyclic azole 1:3.3 6:20 X.05 Tricyclic azole 1:1 6:6 X.05 Pirokv ILON 1:3.3 6:20 X.05 Pirokv ILON 1:1 6:6 X.05 X-(1-Benzyl-1,3dimethylbutyl)-8fluoroquinoline-3- 3:1 6:2

- 150 046368

carboxamide X.05 M-(1-Benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 30:1 6:0.2 X.05 X-(1-Benzyl-3,3,3trifluoro-1methylpropyl)-8fluoroquinoline-3carboxamide 3:1 6:2 X.05 X-(1-Benzyl-3,3,3trifluoro-1methylpropyl)-8fluoroquinoline-3carboxamide 30:1 6:0.2 X.05 1-(6,7Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 3:1 6:2 X.05 1-(6,7Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 30:1 6:0.2 X.05 4,4-Difluoro-3,3-d imethyl1 -(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 3:1 6:2 X.05 4,4-Difluoro-3,3-d imethyl1 -(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 30:1 6:0.2 X.05 1-(4,5Dimethylbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 3:1 6:2 X.05 1-(4,5Dimethylbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 30:1 6:0.2 X.05 1-(4,5Dimethylbenzimide azol-1 yl)-4,4-difluoro-3,3 dimethylisoquinoline 3:1 6:2

- 151 046368

X.05 1-(4,5Dimethylbenzimide azol-1 yl)-4,4-difluoro-3,3 dimethylisoquinoline 30:1 6:0.2

Component A (connection) Component B A:B ratio Conc, (ppm) (A:B) X.07 Azoxystrobin 3:1 6:2 X.07 Azoxystrobin 30:1 6:0.2 X.07 Azoxystrobin 1:3.3 0.6:2 X.07 Azoxystrobin 3:1 0.6:0.2 X.07 Trifloxystrobin 3:1 6:2 X.07 Trifloxystrobin 30:1 6:0.2 X.07 Trifloxystrobin 1:3.3 0.6:2 X.07 Trifloxystrobin 3:1 0.6:0.2 X.07 Methyltetraprole 3:1 6:2 X.07 Methyltetraprole 30:1 6:0.2 X.07 Methyltetraprole 1:3.3 0.6:2 X.07 Methyltetraprole 3:1 0.6:0.2 X.07 Difenoconazole 1:1 6:6 X.07 Difenoconazole 10:1 6:0.6 X.07 Difenoconazole 1:10 0.6:6 X.07 Difenoconazole 1:1 0.6:0.6 X.07 Hexaconazole 1:1 6:6 X.07 Hexaconazole 10:1 6:0.6 X.07 Hexaconazole 1:10 0.6:6 X.07 Hexaconazole 1:1 0.6:0.6 X.07 Propiconazole 1:1 6:6 X.07 Propiconazole 10:1 6:0.6

- 152 046368

X.07 Propiconazole 1:10 0.6:6 X.07 Propiconazole 1:1 0.6:0.6 X.07 Prothioconazole 1:1 6:6 X.07 Prothioconazole 10:1 6:0.6 X.07 Prothioconazole 1:10 0.6:6 X.07 Prothioconazole 1:1 0.6:0.6 X.07 Mefentrifluconazole 1:1 6:6 X.07 Mefentrifluconazole 10:1 6:0.6 X.07 Mefentrifluconazole 1:10 0.6:6 X.07 Mefentrifluconazole 1:1 0.6:0.6 X.07 Fenpropidine 1:3.3 6:20 X.07 Fenpropidine 3:1 6:2 X.07 Fenpropidine 1:33.3 0.6:20 X.07 Phenpropimorph 1:3.3 6:20 X.07 Phenpropimorph 3:1 6:2 X.07 Phenpropimorph 1:33.3 0.6:20 X.07 Phenpropimorph 1:3.3 0.6:2 X.07 Fluxapyroxad 3:1 6:2 X.07 Fluxapyroxad 30:1 6:0.2 X.07 Fluopyram 3:1 6:2 X.07 Fluopyram 30:1 6:0.2 X.07 Fluopyram 1:3.3 0.6:2 X.07 Isopyrase 3:1 6:2 X.07 Isopyrase 30:1 6:0.2 X.07 Isopyrase 1:3.3 0.6:2 X.07 Isopyrase 3:1 0.6:0.2

- 153 046368

X.07 Sedaksan 3:1 6:2 X.07 Sedaksan 30:1 6:0.2 X.07 Benzovindiflupir 3:1 6:2 X.07 Benzovindiflupir 30:1 6:0.2 X.07 Benzovindiflupir 1:3.3 0.6:2 X.07 Benzovindiflupir 3:1 0.6:0.2 X.07 Pidiflumetofen 3:1 6:2 X.07 Pidiflumetofen 30:1 6:0.2 X.07 Pidiflumetofen 1:3.3 0.6:2 X.07 Pidiflumetofen 3:1 0.6:0.2 X.07 Isoflucipram 3:1 6:2 X.07 Isoflucipram 30:1 6:0.2 X.07 Isoflucipram 1:3.3 0.6:2 X.07 Isoflucipram 3:1 0.6:0.2 X.07 Isofetamide 3:1 6:2 X.07 Isofetamide 30:1 6:0.2 X.07 Isofetamide 1:3.3 0.6:2 X.07 Pyrapropoin 3:1 6:2 X.07 Pyrapropoin 30:1 6:0.2 X.07 Pyrapropoin 1:3.3 0.6:2 X.07 Pyrapropoin 3:1 0.6:0.2 X.07 Fluindapir 3:1 6:2 X.07 Fluindapir 30:1 6:0.2 X.07 Fluindapir 1:3.3 0.6:2 X.07 Phenpicoxamide 1:1 6:6

- 154 046368

X.07 Phenpicoxamide 10:1 6:0.6 X.07 Phenpicoxamide 1:10 0.6:6 X.07 Florylpicoxamide 3:1 6:2 X.07 Florylpicoxamide 30:1 6:0.2 X.07 Florylpicoxamide 1:3.3 0.6:2 X.07 Florylpicoxamide 3:1 0.6:0.2 X.07 Chlorothalonil 1:1 6:6 X.07 Chlorothalonil 10:1 6:0.6 X.07 Chlorothalonil 1:10 0.6:6 X.07 Mankozeb 1:3.3 6:20 X.07 Mankozeb 1:1 6:6 X.07 Oxathiapiproline 1:3.3 6:20 X.07 Oxathiapiproline 1:1 6:6 X.07 Fluazinam 3:1 6:2 X.07 Fluazinam 30:1 6:0.2 X.07 Fluazinam 1:3.3 0.6:2 X.07 Fludioxonil 1:1 6:6 X.07 Fludioxonil 1:10 0.6:6 X.07 Cyprodinil 1:1 6:6 X.07 Cyprodinil 10:1 6:0.6 X.07 Metalaxyl-M 1:3.3 6:20 X.07 Metalaxyl-M 1:1 6:6 X.07 Aminopyrifene 3:1 6:2 X.07 Aminopyrifene 30:1 6:0.2

- 155 046368

X.07 Aminopyrifene 1:3.3 0.6:2 X.07 Aminopyrifene 3:1 0.6:0.2 X.07 Folpet 1:1 6:6 X.07 Folpet 3:1 6:2 X.07 Ipflufenoquin 3:1 6:2 X.07 Ipflufenoquin 30:1 6:0.2 X.07 Quinofumelin 3:1 6:2 X.07 Quinofumelin 30:1 6:0.2 X.07 Tricyclic azole 1:3.3 6:20 X.07 Tricyclic azole 1:1 6:6 X.07 Pirokv ILON 1:3.3 6:20 X.07 Pirokv ILON 1:1 6:6 X.07 X-(1-Benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 3:1 6:2 X.07 X-(1-Benzyl-1,3- dimethylbutyl)-8fluoroquinoline-3carboxamide 30:1 6:0.2 X.07 N-(l -Benzyl-3,3,3trifluoro-1methylpropyl)-8fluoroquinoline-3 carboxamide 3:1 6:2 X.07 N-(l-Benzyl-3,3,3- 30:1 6:0.2

- 156 046368

trifluoro-1methylpropyl)-8fluoroquinoline-3carboxamide X.07 1-(6.7- Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 3:1 6:2 X.07 1-(6.7- Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 30:1 6:0.2 X.07 4,4-Difluoro-3,3-d imethyl1 -(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 3:1 6:2 X.07 4,4-Difluoro-3,3-d imethyl1 -(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 30:1 6:0.2 X.07 1-(4,5Dimethylbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 3:1 6:2 X.07 1-(4,5Dimethylbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 30:1 6:0.2

- 157 046368

X.07 1-(4.5- Dimethylbenzimide azol-1 yl)-4,4-difluoro-3,3 dimethylisoquinoline 3:1 6:2 X.07 1-(4.5- Dimethylbenzimide azol-1 yl)-4,4-difluoro-3,3 dimethylisoquinoline 30:1 6:0.2

Component A (connection) Component B A:B ratio Conc, (ppm) (A:B) X.14 Azoxystrobin 3:1 6:2 X.14 Azoxystrobin 30:1 6:0.2 X.14 Azoxystrobin 1:3.3 0.6:2 X.14 Azoxystrobin 3:1 0.6:0.2 X.14 Trifloxystrobin 3:1 6:2 X.14 Trifloxystrobin 30:1 6:0.2 X.14 Trifloxystrobin 1:3.3 0.6:2 X.14 Trifloxystrobin 3:1 0.6:0.2 X.14 Methyltetraprole 3:1 6:2 X.14 Methyltetraprole 30:1 6:0.2 X.14 Methyltetraprole 1:3.3 0.6:2 X.14 Methyltetraprole 3:1 0.6:0.2 X.14 Difenoconazole 1:1 6:6 X.14 Difenoconazole 10:1 6:0.6 X.14 Difenoconazole 1:10 0.6:6 X.14 Difenoconazole 1:1 0.6:0.6 X.14 Hexaconazole 1:1 6:6 X.14 Hexaconazole 10:1 6:0.6 X.14 Hexaconazole 1:10 0.6:6 X.14 Hexaconazole 1:1 0.6:0.6 X.14 Propiconazole 1:1 6:6 X.14 Propiconazole 10:1 6:0.6 X.14 Propiconazole 1:10 0.6:6 X.14 Propiconazole 1:1 0.6:0.6 X.14 Prothioconazole 1:1 6:6 X.14 Prothioconazole 10:1 6:0.6

- 158 046368

X.14 Prothioconazole 1:10 0.6:6 X.14 Prothioconazole 1:1 0.6:0.6 X.14 Mefentrifluconazole 1:1 6:6 X.14 Mefentrifluconazole 10:1 6:0.6 X.14 Mefentrifluconazole 1:10 0.6:6 X.14 Mefentrifluconazole 1:1 0.6:0.6 X.14 Fenpropidine 1:3.3 6:20 X.14 Fenpropidine 3:1 6:2 X.14 Fenpropidine 1:33.3 0.6:20 X.14 Phenpropimorph 1:3.3 6:20 X.14 Phenpropimorph 3:1 6:2 X.14 Phenpropimorph 1:33.3 0.6:20 X.14 Phenpropimorph 1:3.3 0.6:2 X.14 Fluxapyroxad 3:1 6:2 X.14 Fluxapyroxad 30:1 6:0.2 X.14 Fluopyram 3:1 6:2 X.14 Fluopyram 1:3.3 0.6:2 X.14 Isopyrase 3:1 6:2 X.14 Isopyrase 30:1 6:0.2 X.14 Isopyrase 1:3.3 0.6:2 X.14 Isopyrase 3:1 0.6:0.2 X.14 Sedaxan 3:1 6:2 X.14 Sedaksan 30:1 6:0.2 X.14 Benzovindiflupir 3:1 6:2 X.14 Benzovindiflupir 30:1 6:0.2 X.14 Benzovindiflupir 1:3.3 0.6:2 X.14 Benzovindiflupir 3:1 0.6:0.2 X.14 Pidiflumetofen 3:1 6:2 X.14 Pidiflumetofen 30:1 6:0.2 X.14 Pidiflumetofen 1:3.3 0.6:2 X.14 Pidiflumetofen 3:1 0.6:0.2 X.14 Isoflucipram 3:1 6:2 X.14 Isoflucipram 30:1 6:0.2 X.14 Isoflucipram 1:3.3 0.6:2 X.14 Isoflucipram 3:1 0.6:0.2 X.14 Isofetamide 3:1 6:2 X.14 Isofetamide 30:1 6:0.2

- 159 046368

X.14 Isofetamide 1:3.3 0.6:2 X.14 Pyrapropoin 3:1 6:2 X.14 Pyrapropoin 30:1 6:0.2 X.14 Pyrapropoin 1:3.3 0.6:2 X.14 Pyrapropoin 3:1 0.6:0.2 X.14 Fluindapir 3:1 6:2 X.14 Fluindapir 30:1 6:0.2 X.14 Fluindapir 1:3.3 0.6:2 X.14 Phenpicoxamide 1:1 6:6 X.14 Phenpicoxamide 10:1 6:0.6 X.14 Phenpicoxamide 1:10 0.6:6 X.14 Florylpicoxamide 3:1 6:2 X.14 Florylpicoxamide 30:1 6:0.2 X.14 Florylpicoxamide 1:3.3 0.6:2 X.14 Florylpicoxamide 3:1 0.6:0.2 X.14 Chlorothalonil 1:1 6:6 X.14 Chlorothalonil 10:1 6:0.6 X.14 Chlorothalonil 1:10 0.6:6 X.14 Mankozeb 1:3.3 6:20 X.14 Mankozeb 1:1 6:6 X.14 Mandipropamide 1:3.3 6:20 X.14 Mandipropamide 1:1 6:6 X.14 Oxathiapiproline 1:3.3 6:20 X.14 Oxathiapiproline 1:1 6:6 X.14 Fluazinam 3:1 6:2 X.14 Fluazinam 30:1 6:0.2 X.14 Fluazinam 1:3.3 0.6:2 X.14 Fludioxonil 1:1 6:6 X.14 Fludioxonil 1:10 0.6:6 X.14 Cyprodinil 1:1 6:6 X.14 Cyprodinil 10:1 6:0.6 X.14 Metalaxyl-M 1:3.3 6:20 X.14 Metalaxyl-M 1:1 6:6 X.14 Aminopyrifene 3:1 6:2 X.14 Aminopyrifene 30:1 6:0.2

- 160 046368

X.14 Aminopyrifene 1:3.3 0.6:2 X.14 Aminopyrifene 3:1 0.6:0.2 X.14 Folpet 1:1 6:6 X.14 Folpet 3:1 6:2 X.14 Ipflufenoquin 3:1 6:2 X.14 Ipflufenoquin 30:1 6:0.2 X.14 Quinofumelin 3:1 6:2 X.14 Quinofumelin 30:1 6:0.2 X.14 Tricyclic azole 1:3.3 6:20 X.14 Tricyclic azole 1:1 6:6 X.14 Pirokv ILON 1:3.3 6:20 X.14 X-(1-Benzyl-1,3dimethylbutyl)-8fluoroquinoline-3carboxamide 3:1 6:2 X.14 X-(1-Benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 30:1 6:0.2 X.14 X-(1-Benzyl-3,3,3trifluoro-1methylpropyl)-8fluoroquinoline-3 carboxamide 3:1 6:2 X.14 X-(1-Benzyl-3,3,3trifluoro-1methylpropyl)-8fluoroquinoline-3carboxamide 30:1 6:0.2 X.14 1-(6,7Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 3:1 6:2 X.14 1-(6,7Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 30:1 6:0.2 X.14 X.14 4,4-Difluoro-3,3-dimethyl1-(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 4,4-Difluoro-3,3-d imethyl1 -(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 3:1 30:1 6:2 6:0.2 X.14 X.14 1-(4,5Dimethylbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 1-(4,5Dimethylbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 3:1 30:1 6:2 6:0.2 X.14 1-(4,5Dimethylbenzimide azol-1 yl)-4,4-difluoro-3,3 dimethylisoquinoline 3:1 6:2 X.14 1-(4,5Dimethylbenzimide azol-1 yl)-4,4-difluoro-3,3 dimethylisoquinoline 30:1 6:0.2

- 161 046368

Example B5. Activity against Pyricularia oryzae (rice blast disease)

Fungal conidia from cryogenic storage were directly mixed with nutrient broth (potato dextrose broth, PDB). A solution of test compounds in DMSO was added to a microtiter plate (96-well format) and nutrient broth containing fungal spores was added. Plates containing test compounds were incubated at 24°C and growth inhibition was determined photometrically after 72 hours. The following mixture based compositions (A:B) at the indicated concentration (in ppm) provided at least 80% disease control in this test.

Component A (connection) Component B A:B ratio Conc, (ppm) (A:B) X.05 Azoxystrobin 3:1 6:2 X.05 Azoxystrobin 30:1 6:0.2 X.05 Azoxystrobin 1:3.3 0.6:2 X.05 Azoxystrobin 3:1 0.6:0.2 X.05 Trifloxystrobin 3:1 6:2 X.05 Trifloxystrobin 30:1 6:0.2 X.05 Trifloxystrobin 1:3.3 0.6:2 X.05 Trifloxystrobin 3:1 0.6:0.2 X.05 Methyltetraprole 3:1 6:2 X.05 Methyltetraprole 30:1 6:0.2 X.05 Methyltetraprole 1:3.3 0.6:2 X.05 Methyltetraprole 3:1 0.6:0.2 X.05 Difenoconazole 1:1 6:6 X.05 Difenoconazole 10:1 6:0.6 X.05 Difenoconazole 1:10 0.6:6 X.05 Difenoconazole 1:1 0.6:0.6 X.05 Hexaconazole 1:1 6:6 X.05 Hexaconazole 10:1 6:0.6 X.05 Hexaconazole 1:10 0.6:6 X.05 Hexaconazole 1:1 0.6:0.6 X.05 Propiconazole 1:1 6:6 X.05 Propiconazole 10:1 6:0.6 X.05 Propiconazole 1:10 0.6:6 X.05 Propiconazole 1:1 0.6:0.6 X.05 Prothioconazole 1:1 6:6 X.05 Prothioconazole 10:1 6:0.6 X.05 Prothioconazole 1:10 0.6:6 X.05 Prothioconazole 1:1 0.6:0.6 X.05 Mefentrifluconazole 1:1 6:6 X.05 Mefentrifluconazole 10:1 6:0.6 X.05 Mefentrifluconazole 1:10 0.6:6 X.05 Mefentrifluconazole 1:1 0.6:0.6 X.05 Fenpropidine 1:3.3 6:20 X.05 Fenpropidine 3:1 6:2 X.05 Fenpropidine 1:33.3 0.6:20 X.05 Fenpropidine 1:3.3 0.6:2 X.05 Phenpropimorph 1:3.3 6:20 X.05 Phenpropimorph 3:1 6:2 X.05 Phenpropimorph 1:33.3 0.6:20 X.05 Phenpropimorph 1:3.3 0.6:2 X.05 Fluxapyroxad 3:1 6:2 X.05 Fluxapyroxad 30:1 6:0.2 X.05 Fluxapyroxad 1:3.3 0.6:2 X.05 Fluxapyroxad 3:1 0.6:0.2 X.05 | Fluopyram | 3:1 I 6:2

- 162 046368

X.05 Fluopyram 30:1 6:0.2 X.05 Fluopyram 1:3.3 0.6:2 X.05 Fluopyram 3:1 0.6:0.2 X.05 Isopyrase 3:1 6:2 X.05 Isopyrase 30:1 6:0.2 X.05 Isopyrase 1:3.3 0.6:2 X.05 Isopyrase 3:1 0.6:0.2 X.05 Sedaksan 3:1 6:2 X.05 Sedaksan 30:1 6:0.2 X.05 Sedaksan 1:3.3 0.6:2 X.05 Sedaksan 3:1 0.6:0.2 X.05 Benzovindiflupir 3:1 6:2 X.05 Benzovindiflupir 30:1 6:0.2 X.05 Benzovindiflupir 1:3.3 0.6:2 X.05 Benzovindiflupir 3:1 0.6:0.2 X.05 Pidiflumetofen 3:1 6:2 X.05 Pidiflumetofen 30:1 6:0.2 X.05 Pidiflumetofen 1:3.3 0.6:2 X.05 Pidiflumetofen 3:1 0.6:0.2 X.05 Isoflucipram 3:1 6:2 X.05 Isoflucipram 30:1 6:0.2 X.05 Isoflucipram 1:3.3 0.6:2 X.05 Isoflucipram 3:1 0.6:0.2 X.05 Isofetamide 3:1 6:2 X.05 Isofetamide 30:1 6:0.2 X.05 Isofetamide 1:3.3 0.6:2 X.05 Isofetamide 3:1 0.6:0.2 X.05 Pyrapropoin 3:1 6:2 X.05 Pyrapropoin 30:1 6:0.2 X.05 Pyrapropoin 1:3.3 0.6:2 X.05 Pyrapropoin 3:1 0.6:0.2 X.05 Fluindapir 3:1 6:2 X.05 Fluindapir 30:1 6:0.2 X.05 Fluindapir 1:3.3 0.6:2 X.05 Fluindapir 3:1 0.6:0.2 X.05 Phenpicoxamide 1:1 6:6 X.05 Phenpicoxamide 10:1 6:0.6 X.05 Phenpicoxamide 1:10 0.6:6 X.05 Phenpicoxamide 1:1 0.6:0.6

- 163 046368

X.05 Florylpicoxamide 3:1 6:2 X.05 Florylpicoxamide 30:1 6:0.2 X.05 Florylpicoxamide 1:3.3 0.6:2 X.05 Florylpicoxamide 3:1 0.6:0.2 X.05 Chlorothalonil 1:1 6:6 X.05 Chlorothalonil 10:1 6:0.6 X.05 Chlorothalonil 1:10 0.6:6 X.05 Chlorothalonil 1:1 0.6:0.6 X.05 Mankozeb 1:3.3 6:20 X.05 Mankozeb 1:1 6:6 X.05 Mankozeb 1:33.3 0.6:20 X.05 Mankozeb 1:10 0.6:6 X.05 Mandipropamide 1:3.3 6:20 X.05 Mandipropamide 1:1 6:6 X.05 Mandipropamide 1:33.3 0.6:20 X.05 Mandipropamide 1:10 0.6:6 X.05 Oxathiapiproline 1:3.3 6:20 X.05 Oxathiapiproline 1:1 6:6 X.05 Oxathiapiproline 1:33.3 0.6:20 X.05 Oxathiapiproline 1:10 0.6:6 X.05 Fluazinam 3:1 6:2 X.05 Fluazinam 30:1 6:0.2 X.05 Fluazinam 1:3.3 0.6:2 X.05 Fluazinam 3:1 0.6:0.2 X.05 Fludioxonil 1:1 6:6 X.05 Fludioxonil 10:1 6:0.6 X.05 Fludioxonil 1:10 0.6:6 X.05 Fludioxonil 1:1 0.6:0.6 X.05 Cyprodinil 1:1 6:6 X.05 Cyprodinil 10:1 6:0.6 X.05 Cyprodinil 1:10 0.6:6 X.05 Cyprodinil 1:1 0.6:0.6 X.05 Metalaxyl-M 1:3.3 6:20 X.05 Metalaxyl-M 1:1 6:6 X.05 Metalaxyl-M 1:33.3 0.6:20 X.05 Metalaxyl-M 1:10 0.6:6 X.05 Aminopyrifene 3:1 6:2 X.05 Aminopyrifene 30:1 6:0.2

- 164 046368

X.05 Aminopyrifene 1:3.3 0.6:2 X.05 Aminopyrifene 3:1 0.6:0.2 X.05 Folpet 1:1 6:6 X.05 Folpet 3:1 6:2 X.05 Folpet 1:10 0.6:6 X.05 Folpet 1:3.3 0.6:2 X.05 Ipflufenoquin 3:1 6:2 X.05 Ipflufenoquin 30:1 6:0.2 X.05 Ipflufenoquin 1:3.3 0.6:2 X.05 Ipflufenoquin 3:1 0.6:0.2 X.05 Quinofumelin 3:1 6:2 X.05 Quinofumelin 30:1 6:0.2 X.05 Quinofumelin 1:3.3 0.6:2 X.05 Quinofumelin 3:1 0.6:0.2 X.05 Tricyclic azole 1:3.3 6:20 X.05 Tricyclic azole 1:1 6:6 X.05 Tricyclic azole 1:33.3 0.6:20 X.05 Tricyclic azole 1:10 0.6:6 X.05 Pirokv ILON 1:3.3 6:20 X.05 Pirokv ILON 1:1 6:6 X.05 Pirokv ILON 1:33.3 0.6:20 X.05 Pirokv ILON 1:10 0.6:6 X.05 X-(1-Benzyl-1,3dimethylbutyl)-8fluoroquinoline-3carboxamide 3:1 6:2 X.05 X-(1-Benzyl-1,3dimethylbutyl)-8fluoroquinoline-3carboxamide 30:1 6:0.2 X.05 X-(1-Benzyl-1,3dimethylbutyl)-8fluoroquinoline-3carboxamide 1:3.3 0.6:2 X.05 X-(1-Benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 3:1 0.6:0.2 X.05 X-(1-Benzyl-3,3,3trifluoro-1methylpropyl)-8fluoroquinoline-3- 3:1 6:2

- 165 046368

carboxamide X.05 N-(l-Benzyl-3,3,3trifluoro-1methylpropyl)-8fluoroquinoline-3carboxamide 30:1 6:0.2 X.05 N-(l-Benzyl-3,3,3trifluoro-1methylpropyl)-8fluoroquinoline-3carboxamide 1:3.3 0.6:2 X.05 N-(l-Benzyl-3,3,3trifluoro-1methylpropyl)-8fluoroquinoline-3 carboxamide 3:1 0.6:0.2 X.05 1-(6,7Dimethylpyrazolo[1,5а]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 3:1 6:2 X.05 1-(6,7Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 30:1 6:0.2 X.05 1-(6,7Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 1:3.3 0.6:2 X.05 1-(6,7Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 3:1 0.6:0.2 X.05 4,4-Difluoro-3,3-d imethyl1 -(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 3:1 6:2 X.05 4,4-Difluoro-3,3-d imethyl1 -(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 30:1 6:0.2 X.05 4,4-Difluoro-3,3-d imethyl1 -(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 1:3.3 0.6:2

- 166 046368

X.05 4,4-Difluoro-3,3-dimethyl1-(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 3:1 0.6:0.2 X.05 1-(4,5Dimethylbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 3:1 6:2 X.05 1-(4,5Dimethylbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 30:1 6:0.2 X.05 1-(4,5Dimethylbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 1:3.3 0.6:2 X.05 1-(4,5Dimethylbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 3:1 0.6:0.2 X.05 1-(4,5Dimethylbenzimide azol-1 yl)-4,4-difluoro-3,3 dimethylisoquinoline 3:1 6:2 X.05 1-(4,5Dimethylbenzimide azol-1 yl)-4,4-difluoro-3,3 dimethylisoquinoline 30:1 6:0.2 X.05 1-(4,5Dimethylbenzimide azol-1 yl)-4,4-difluoro-3,3 dimethylisoquinoline 1:3.3 0.6:2 X.05 1-(4,5Dimethylbenzimide azol-1 yl)-4,4-difluoro-3,3 dimethylisoquinoline 3:1 0.6:0.2

Component A (connection) Component B A:B ratio Conc, (ppm) (A:B) X.07 Azoxystrobin 3:1 6:2 X.07 Azoxystrobin 30:1 6:0.2 X.07 Azoxystrobin 1:3.3 0.6:2 X.07 Azoxystrobin 3:1 0.6:0.2 X.07 Trifloxystrobin 3:1 6:2 X.07 Trifloxystrobin 30:1 6:0.2 X.07 Trifloxystrobin 1:3.3 0.6:2

- 167 046368

X.07 Trifloxystrobin I 3:1 I 0.6:0.2 X.07 Methyltetraprole 3:1 6:2 X.07 Methyltetraprole 30:1 6:0.2 X.07 Methyltetraprole 1:3.3 0.6:2 X.07 Methyltetraprole 3:1 0.6:0.2 X.07 Difenoconazole 1:1 6:6 X.07 Difenoconazole 10:1 6:0.6 X.07 Difenoconazole 1:10 0.6:6 X.07 Difenoconazole 1:1 0.6:0.6 X.07 Hexaconazole 1:1 6:6 X.07 Hexaconazole 10:1 6:0.6 X.07 Hexaconazole 1:10 0.6:6 X.07 Hexaconazole 1:1 0.6:0.6 X.07 Propiconazole 1:1 6:6 X.07 Propiconazole 10:1 6:0.6 X.07 Propiconazole 1:10 0.6:6 X.07 Propiconazole 1:1 0.6:0.6 X.07 Prothioconazole 1:1 6:6 X.07 Prothioconazole 10:1 6:0.6 X.07 Prothioconazole 1:10 0.6:6 X.07 Prothioconazole 1:1 0.6:0.6 X.07 Mefentrifluconazole 1:1 6:6 X.07 Mefentrifluconazole 10:1 6:0.6 X.07 Mefentrifluconazole 1:10 0.6:6 X.07 Mefentrifluconazole 1:1 0.6:0.6 X.07 Fenpropidine 1:3.3 6:20 X.07 Fenpropidine 3:1 6:2 X.07 Fenpropidine 1:33.3 0.6:20 X.07 Fenpropidine 1:3.3 0.6:2 X.07 Phenpropimorph 1:3.3 6:20 X.07 Phenpropimorph 3:1 6:2 X.07 Phenpropimorph 1:33.3 0.6:20 X.07 Phenpropimorph 1:3.3 0.6:2 X.07 Fluxapyroxad 3:1 6:2 X.07 Fluxapyroxad 30:1 6:0.2 X.07 Fluxapyroxad 1:3.3 0.6:2 X.07 Fluxapyroxad 3:1 0.6:0.2 X.07 | Fluopyram | 3:1 I 6:2

- 168 046368

X.07 Fluopyram 30:1 6:0.2 X.07 Fluopyram 1:3.3 0.6:2 X.07 Fluopyram 3:1 0.6:0.2 X.07 Isopyrase 3:1 6:2 X.07 Isopyrase 30:1 6:0.2 X.07 Isopyrase 1:3.3 0.6:2 X.07 Isopyrase 3:1 0.6:0.2 X.07 Sedaksan 3:1 6:2 X.07 Sedaksan 30:1 6:0.2 X.07 Sedaksan 1:3.3 0.6:2 X.07 Sedaksan 3:1 0.6:0.2 X.07 Benzovindiflupir 3:1 6:2 X.07 Benzovindiflupir 30:1 6:0.2 X.07 Benzovindiflupir 1:3.3 0.6:2 X.07 Benzovindiflupir 3:1 0.6:0.2 X.07 Pidiflumetofen 3:1 6:2 X.07 Pidiflumetofen 30:1 6:0.2 X.07 Pidiflumetofen 1:3.3 0.6:2 X.07 Pidiflumetofen 3:1 0.6:0.2 X.07 Isoflucipram 3:1 6:2 X.07 Isoflucipram 30:1 6:0.2 X.07 Isoflucipram 1:3.3 0.6:2 X.07 Isoflucipram 3:1 0.6:0.2 X.07 Isofetamide 3:1 6:2 X.07 Isofetamide 30:1 6:0.2 X.07 Isofetamide 1:3.3 0.6:2 X.07 Isofetamide 3:1 0.6:0.2 X.07 Pyrapropoin 3:1 6:2 X.07 Pyrapropoin 30:1 6:0.2 X.07 Pyrapropoin 1:3.3 0.6:2 X.07 Pyrapropoin 3:1 0.6:0.2 X.07 Fluindapir 3:1 6:2 X.07 Fluindapir 30:1 6:0.2 X.07 Fluindapir 1:3.3 0.6:2 X.07 Fluindapir 3:1 0.6:0.2 X.07 Phenpicoxamide 1:1 6:6 X.07 Phenpicoxamide 10:1 6:0.6 X.07 Phenpicoxamide 1:10 0.6:6 X.07 Phenpicoxamide 1:1 0.6:0.6

- 169 046368

X.07 Florylpicoxamide 3:1 6:2 X.07 Florylpicoxamide 30:1 6:0.2 X.07 Florylpicoxamide 1:3.3 0.6:2 X.07 Florylpicoxamide 3:1 0.6:0.2 X.07 Chlorothalonil 1:1 6:6 X.07 Chlorothalonil 10:1 6:0.6 X.07 Chlorothalonil 1:10 0.6:6 X.07 Chlorothalonil 1:1 0.6:0.6 X.07 Mankozeb 1:3.3 6:20 X.07 Mankozeb 1:1 6:6 X.07 Mankozeb 1:33.3 0.6:20 X.07 Mankozeb 1:10 0.6:6 X.07 Mandipropamide 1:3.3 6:20 X.07 Mandipropamide 1:1 6:6 X.07 Mandipropamide 1:33.3 0.6:20 X.07 Mandipropamide 1:10 0.6:6 X.07 Oxathiapiproline 1:3.3 6:20 X.07 Oxathiapiproline 1:1 6:6 X.07 Oxathiapiproline 1:33.3 0.6:20 X.07 Oxathiapiproline 1:10 0.6:6 X.07 Fluazinam 3:1 6:2 X.07 Fluazinam 30:1 6:0.2 X.07 Fluazinam 1:3.3 0.6:2 X.07 Fluazinam 3:1 0.6:0.2 X.07 Fludioxonil 1:1 6:6 X.07 Fludioxonil 10:1 6:0.6 X.07 Fludioxonil 1:10 0.6:6 X.07 Fludioxonil 1:1 0.6:0.6 X.07 Cyprodinil 1:1 6:6 X.07 Cyprodinil 10:1 6:0.6 X.07 Cyprodinil 1:10 0.6:6 X.07 Cyprodinil 1:1 0.6:0.6 X.07 Metalaxyl-M 1:3.3 6:20 X.07 Metalaxyl-M 1:1 6:6 X.07 Metalaxyl-M 1:33.3 0.6:20 X.07 Metalaxyl-M 1:10 0.6:6 X.07 Aminopyrifene 3:1 6:2 X.07 Aminopyrifene 30:1 6:0.2

- 170 046368

X.07 Aminopyrifene 1:3.3 0.6:2 X.07 Aminopyrifene 3:1 0.6:0.2 X.07 Folpet 1:1 6:6 X.07 Folpet 3:1 6:2 X.07 Folpet 1:10 0.6:6 X.07 Folpet 1:3.3 0.6:2 X.07 Ipflufenoquin 3:1 6:2 X.07 Ipflufenoquin 30:1 6:0.2 X.07 Ipflufenoquin 1:3.3 0.6:2 X.07 Ipflufenoquin 3:1 0.6:0.2 X.07 Quinofumelin 3:1 6:2 X.07 Quinofumelin 30:1 6:0.2 X.07 Quinofumelin 1:3.3 0.6:2 X.07 Quinofumelin 3:1 0.6:0.2 X.07 Tricyclic azole 1:3.3 6:20 X.07 Tricyclic azole 1:1 6:6 X.07 Tricyclic azole 1:33.3 0.6:20 X.07 Tricyclic azole 1:10 0.6:6 X.07 Pirokv ILON 1:3.3 6:20 X.07 Pirokv ILON 1:1 6:6 X.07 Pirokv ILON 1:33.3 0.6:20 X.07 Pirokv ILON 1:10 0.6:6 X.07 X-(1-Benzyl-1,3dimethylbutyl)-8fluoroquinoline-3carboxamide 3:1 6:2 X.07 X-(1-Benzyl-1,3dimethylbutyl)-8fluoroquinoline-3carboxamide 30:1 6:0.2 X.07 X-(1-Benzyl-1,3dimethylbutyl)-8fluoroquinoline-3carboxamide 1:3.3 0.6:2 X.07 X-(1-Benzyl-1,3dimethylbutyl)-8fluoroquinoline-3carboxamide 3:1 0.6:0.2 X.07 X-(1-Benzyl-3,3,3trifluoro-1methylpropyl)-8fluoroquinoline-3- 3:1 6:2

- 171 046368

carboxamide X.07 N-(l-Benzyl-3,3,3trifluoro-1methylpropyl)-8fluoroquinoline-3carboxamide 30:1 6:0.2 X.07 N-(l-Benzyl-3,3,3trifluoro-1methylpropyl)-8fluoroquinoline-3carboxamide 1:3.3 0.6:2 X.07 N-(l-Benzyl-3,3,3trifluoro-1methylpropyl)-8fluoroquinoline-3 carboxamide 3:1 0.6:0.2 X.07 1-(6,7Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 3:1 6:2 X.07 1-(6,7Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 30:1 6:0.2 X.07 1-(6,7Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 1:3.3 0.6:2 X.07 1-(6,7Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 3:1 0.6:0.2 X.07 4,4-Difluoro-3,3-d imethyl1 -(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 3:1 6:2 X.07 4,4-Difluoro-3,3-d imethyl1 -(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 30:1 6:0.2 X.07 4,4-Difluoro-3,3-d imethyl1 -(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 1:3.3 0.6:2

- 172 046368

X.07 4,4-Difluoro-3, 3-d methyl1 -(7-methylpyrazolo[ 1,5 - 31 0.6:0.2 a] pyridin-3yl)isoquinoline 1-(4.5- X.07 Dimethylbenzimide azole-1 - VI 6:2 yl)-4,4,5 -trifluoro-3,3 - dimethylisoquinoline 1-(4.5- X.07 Dimethylbenzimide azol-1 yl)-4,4,5 -trifluoro-3,3 - 30:1 6:0.2 dimethylisoquinoline 1-(4.5- X.07 Dimethylbenzimide azole-1 - 1:3.3 0.6:2 yl)-4,4,5 -trifluoro-3,3 - dimethylisoquinoline 1-(4.5- X.07 Dimethylbenzimide azole-1 - VI 0.6:0.2 yl)-4,4,5 -trifluoro-3,3 - dimethylisoquinoline 1-(4.5- X.07 Dimethylbenzimide azole-1 - VI 6:2 yl)-4,4-difluoro-3,3 - dimethylisoquinoline 1-(4.5- X.07 Dimethylbenzimide azol-1 yl)-4,4-difluoro-3,3 - 30:1 6:0.2 dimethylisoquinoline 1-(4.5- X.07 Dimethylbenzimide azol-1 yl)-4,4-difluoro-3,3 - 1:3.3 0.6:2 dimethylisoquinoline 1-(4.5- X.07 Dimethylbenzimide azol-1 yl)-4,4-difluoro-3,3 - 3:1 0.6:0.2 dimethylisoquinoline

Component A (connection) Component B A:B ratio Conc, (ppm) (A:B) X.14 Azoxystrobin 3:1 6:2 X.14 Azoxystrobin 30:1 6:0.2 X.14 Azoxystrobin 1:3.3 0.6:2 X.14 Azoxystrobin 3:1 0.6:0.2

- 173 046368

X.14 Trifloxystrobin 3:1 6:2 X.14 Trifloxystrobin 30:1 6:0.2 X.14 Trifloxystrobin 1:3.3 0.6:2 X.14 Trifloxystrobin 3:1 0.6:0.2 X.14 Methyltetraprole 3:1 6:2 X.14 Methyltetraprole 30:1 6:0.2 X.14 Methyltetraprole 1:3.3 0.6:2 X.14 Methyltetraprole 3:1 0.6:0.2 X.14 Difenoconazole 1:1 6:6 X.14 Difenoconazole 10:1 6:0.6 X.14 Difenoconazole 1:10 0.6:6 X.14 Difenoconazole 1:1 0.6:0.6 X.14 Hexaconazole 1:1 6:6 X.14 Hexaconazole 10:1 6:0.6 X.14 Hexaconazole 1:10 0.6:6 X.14 Hexaconazole 1:1 0.6:0.6 X.14 Propiconazole 1:1 6:6 X.14 Propiconazole 10:1 6:0.6 X.14 Propiconazole 1:10 0.6:6 X.14 Propiconazole 1:1 0.6:0.6 X.14 Prothioconazole 1:1 6:6 X.14 Prothioconazole 10:1 6:0.6 X.14 Prothioconazole 1:10 0.6:6 X.14 Prothioconazole 1:1 0.6:0.6 X.14 Mefentrifluconazole 1:1 6:6 X.14 Mefentrifluconazole 10:1 6:0.6 X.14 Mefentrifluconazole 1:10 0.6:6

- 174 046368

X.14 Mefentrifluconazole 1:1 0.6:0.6 X.14 Fenpropidine 1:3.3 6:20 X.14 Fenpropidine 3:1 6:2 X.14 Fenpropidine 1:33.3 0.6:20 X.14 Fenpropidine 1:3.3 0.6:2 X.14 Phenpropimorph 1:3.3 6:20 X.14 Phenpropimorph 3:1 6:2 X.14 Phenpropimorph 1:33.3 0.6:20 X.14 Phenpropimorph 1:3.3 0.6:2 X.14 Fluxapyroxad 3:1 6:2 X.14 Fluxapyroxad 30:1 6:0.2 X.14 Fluxapyroxad 1:3.3 0.6:2 X.14 Fluxapyroxad 3:1 0.6:0.2 X.14 Fluopyram 3:1 6:2 X.14 Fluopyram 30:1 6:0.2 X.14 Fluopyram 1:3.3 0.6:2 X.14 Fluopyram 3:1 0.6:0.2 X.14 Isopyrase 3:1 6:2 X.14 Isopyrase 30:1 6:0.2 X.14 Isopyrase 1:3.3 0.6:2 X.14 Isopyrase 3:1 0.6:0.2 X.14 Sedaksan 3:1 6:2 X.14 Sedaksan 30:1 6:0.2 X.14 Sedaksan 1:3.3 0.6:2 X.14 Sedaksan 3:1 0.6:0.2 X.14 Benzovindiflupir 3:1 6:2

- 175 046368

X.14 Benzovindiflupir 30:1 6:0.2 X.14 Benzovindiflupir 1:3.3 0.6:2 X.14 Benzovindiflupir 3:1 0.6:0.2 X.14 Pidiflumetofen 3:1 6:2 X.14 Pidiflumetofen 30:1 6:0.2 X.14 Pidiflumetofen 1:3.3 0.6:2 X.14 Pidiflumetofen 3:1 0.6:0.2 X.14 Isoflucipram 3:1 6:2 X.14 Isoflucipram 30:1 6:0.2 X.14 Isoflucipram 1:3.3 0.6:2 X.14 Isoflucipram 3:1 0.6:0.2 X.14 Isofetamide 3:1 6:2 X.14 Isofetamide 30:1 6:0.2 X.14 Isofetamide 1:3.3 0.6:2 X.14 Isofetamide 3:1 0.6:0.2 X.14 Pyrapropoin 3:1 6:2 X.14 Pyrapropoin 30:1 6:0.2 X.14 Pyrapropoin 1:3.3 0.6:2 X.14 Pyrapropoin 3:1 0.6:0.2 X.14 Fluindapir 3:1 6:2 X.14 Fluindapir 30:1 6:0.2 X.14 Fluindapir 1:3.3 0.6:2 X.14 Fluindapir 3:1 0.6:0.2 X.14 Phenpicoxamide 1:1 6:6 X.14 Phenpicoxamide 10:1 6:0.6 X.14 Phenpicoxamide 1:10 0.6:6 X.14 Phenpicoxamide 1:1 0.6:0.6

- 176 046368

X.14 Florylpicoxamide 3:1 6:2 X.14 Florylpicoxamide 30:1 6:0.2 X.14 Florylpicoxamide 1:3.3 0.6:2 X.14 Florylpicoxamide 3:1 0.6:0.2 X.14 Chlorothalonil 1:1 6:6 X.14 Chlorothalonil 10:1 6:0.6 X.14 Chlorothalonil 1:10 0.6:6 X.14 Chlorothalonil 1:1 0.6:0.6 X.14 Mankozeb 1:3.3 6:20 X.14 Mankozeb 1:1 6:6 X.14 Mankozeb 1:33.3 0.6:20 X.14 Mankozeb 1:10 0.6:6 X.14 Mandipropamide 1:3.3 6:20 X.14 Mandipropamide 1:1 6:6 X.14 Mandipropamide 1:33.3 0.6:20 X.14 Mandipropamide 1:10 0.6:6 X.14 Oxathiapiproline 1:3.3 6:20 X.14 Oxathiapiproline 1:1 6:6 X.14 Oxathiapiproline 1:33.3 0.6:20 X.14 Oxathiapiproline 1:10 0.6:6 X.14 Fluazinam 3:1 6:2 X.14 Fluazinam 30:1 6:0.2 X.14 Fluazinam 1:3.3 0.6:2 X.14 Fluazinam 3:1 0.6:0.2 X.14 Fludioxonil 1:1 6:6 X.14 Fludioxonil 10:1 6:0.6

- 177 046368

X.14 Fludioxonil 1:10 0.6:6 X.14 Fludioxonil 1:1 0.6:0.6 X.14 Cyprodinil 1:1 6:6 X.14 Cyprodinil 10:1 6:0.6 X.14 Cyprodinil 1:10 0.6:6 X.14 Cyprodinil 1:1 0.6:0.6 X.14 Metalaxyl-M 1:3.3 6:20 X.14 Metalaxyl-M 1:1 6:6 X.14 Metalaxyl-M 1:33.3 0.6:20 X.14 Metalaxyl-M 1:10 0.6:6 X.14 Aminopyrifene 3:1 6:2 X.14 Aminopyrifene 30:1 6:0.2 X.14 Aminopyrifene 1:3.3 0.6:2 X.14 Aminopyrifene 3:1 0.6:0.2 X.14 Folpet 1:1 6:6 X.14 Folpet 3:1 6:2 X.14 Folpet 1:10 0.6:6 X.14 Folpet 1:3.3 0.6:2 X.14 Ipflufenoquin 3:1 6:2 X.14 Ipflufenoquin 30:1 6:0.2 X.14 Ipflufenoquin 1:3.3 0.6:2 X.14 Ipflufenoquin 3:1 0.6:0.2 X.14 Quinofumelin 3:1 6:2 X.14 Quinofumelin 30:1 6:0.2 X.14 Quinofumelin 1:3.3 0.6:2 X.14 Quinofumelin 3:1 0.6:0.2

- 178 046368

X.14 Tricyclic azole 1:3.3 6:20 X.14 Tricyclic azole 1:1 6:6 X.14 Tricyclic azole 1:33.3 0.6:20 X.14 Tricyclic azole 1:10 0.6:6 X.14 Pirokv ILON 1:3.3 6:20 X.14 Pirokv ILON 1:1 6:6 X.14 Pirokv ILON 1:33.3 0.6:20 X.14 Pirokv ILON 1:10 0.6:6 X.14 X-(1-Benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 3:1 6:2 X.14 X-(1-Benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 30:1 6:0.2 X.14 X-(1-Benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 1:3.3 0.6:2 X.14 T\G-(1-Benzyl-1,3dimethylbutyl)-8fluoroquinoline-3carboxamide 3:1 0.6:0.2 X.14 M-(1-Benzyl-3,3,3trifluoro-1methylpropyl)-8fluoroquinoline-3carboxamide 3:1 6:2 X.14 X-(1-Benzyl-3,3,3- 30:1 6:0.2

- 179 046368

trifluoro-1methylpropyl)-8fluoroquinoline-3carboxamide X.14 T4-(1-Benzyl-3,3,3trifluoro-1methylpropyl)-8fluoroquinoline-3carboxamide 1:3.3 0.6:2 X.14 T4-(1-Benzyl-3,3,3trifluoro-1methylpropyl)-8fluoroquinoline-3carboxamide 3:1 0.6:0.2 X.14 1-(6.7- Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 3:1 6:2 X.14 1-(6.7- Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 30:1 6:0.2 X.14 1-(6.7- Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 1:3.3 0.6:2 X.14 1-(6.7- Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 - 3:1 0.6:0.2

- 180 046368

trifluoro-3,3- dimethylisoquinoline X.14 4,4-Difluoro-3,3-d imethyl1 -(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 3:1 6:2 X.14 4,4-Difluoro-3,3-d imethyl1 -(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 30:1 6:0.2 X.14 4,4-Difluoro-3,3-d imethyl1 -(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 1:3.3 0.6:2 X.14 4,4-Difluoro-3,3-d imethyl1 -(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 3:1 0.6:0.2 X.14 1-(4,5Dimethylbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 3:1 6:2 X.14 1-(4,5Dimethylbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 30:1 6:0.2 X.14 1-(4,5Dimethylbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 1:3.3 0.6:2 X.14 1-(4.5- 3:1 0.6:0.2

- 181 046368

Dimethylbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline X.14 1-(4.5- Dimethylbenzimide azol-1 yl)-4,4-difluoro-3,3 dimethylisoquinoline 3:1 6:2 X.14 1-(4.5- Dimethylbenzimide azol-1 yl)-4,4-difluoro-3,3 dimethylisoquinoline 30:1 6:0.2 X.14 1-(4.5- Dimethylbenzimide azol-1 yl)-4,4-difluoro-3,3 dimethylisoquinoline 1:3.3 0.6:2 X.14 1-(4.5- Dimethylbenzimide azol-1 yl)-4,4-difluoro-3,3 dimethylisoquinoline 3:1 0.6:0.2

Example B6. Activity against Monographaella nivalis syn. Microdochium nivale (snow mold, root rot of cereals)

Fungal conidia from cryogenic storage were directly mixed with nutrient broth (potato dextrose broth, PDB). A solution of test compounds in DMSO was added to a microtiter plate (96-well format) and nutrient broth containing fungal spores was added. Plates with test compounds were incubated at 24°C and growth inhibition was determined photometrically after 72 h at 620 nm. The following mixture-based formulations (A:B) at the indicated concentrations (in ppm) provided at least 80% disease control in this test.

- 182 046368

Component A (connection) Component B X.05 Azoxystrobin X.05 Azoxystrobin X.05 Azoxystrobin X.05 Azoxystrobin X.05 Trifloxystrobin X.05 Trifloxystrobin X.05 Trifloxystrobin X.05 Trifloxystrobin X.05 Methyltetraprole X.05 Methyltetraprole X.05 Methyltetraprole X.05 Methyltetraprole X.05 Difenoconazole X.05 Difenoconazole X.05 Difenoconazole X.05 Difenoconazole X.05 Hexaconazole X.05 Hexaconazole X.05 Hexaconazole X.05 Hexaconazole X.05 Propiconazole X.05 Propiconazole X.05 Propiconazole X.05 Propiconazole X.05 Prothioconazole X.05 Prothioconazole X.05 Prothioconazole

A:B ratio Conc, (ppm) (A:B) 3:1 6:2 30:1 6:0.2 1:3.3 0.6:2 3:1 0.6:0.2 3:1 6:2 30:1 6:0.2 1:3.3 0.6:2 3:1 0.6:0.2 3:1 6:2 30:1 6:0.2 1:3.3 0.6:2 3:1 0.6:0.2 1:1 6:6 10:1 6:0.6 1:10 0.6:6 1:1 0.6:0.6 1:1 6:6 10:1 6:0.6 1:10 0.6:6 1:1 0.6:0.6 1:1 6:6 10:1 6:0.6 1:10 0.6:6 1:1 0.6:0.6 1:1 6:6 10:1 6:0.6 1:10 0.6:6

- 183 046368

X.05 Prothioconazole 1:1 0.6:0.6 X.05 Mefentrifluconazole 1:1 6:6 X.05 Mefentrifluconazole 10:1 6:0.6 X.05 Mefentrifluconazole 1:10 0.6:6 X.05 Mefentrifluconazole 1:1 0.6:0.6 X.05 Fenpropidine 1:3.3 6:20 X.05 Fenpropidine 3:1 6:2 X.05 Fenpropidine 1:33.3 0.6:20 X.05 Fenpropidine 1:3.3 0.6:2 X.05 Phenpropimorph 1:3.3 6:20 X.05 Phenpropimorph 3:1 6:2 X.05 Phenpropimorph 1:33.3 0.6:20 X.05 Phenpropimorph 1:3.3 0.6:2 X.05 Fluxapyroxad 3:1 6:2 X.05 Fluxapyroxad 30:1 6:0.2 X.05 Fluxapyroxad 1:3.3 0.6:2 X.05 Fluxapyroxad 3:1 0.6:0.2 X.05 Fluopyram 3:1 6:2 X.05 Fluopyram 30:1 6:0.2 X.05 Fluopyram 1:3.3 0.6:2 X.05 Fluopyram 3:1 0.6:0.2 X.05 Isopyrase 3:1 6:2 X.05 Isopyrase 30:1 6:0.2 X.05 Isopyrase 1:3.3 0.6:2 X.05 Isopyrase 3:1 0.6:0.2 X.05 Sedaksan 3:1 6:2

- 184 046368

X.05 Sedaksan 30:1 6:0.2 X.05 Sedaksan 1:3.3 0.6:2 X.05 Sedaksan 3:1 0.6:0.2 X.05 Benzovindiflupir 3:1 6:2 X.05 Benzovindiflupir 30:1 6:0.2 X.05 Benzovindiflupir 1:3.3 0.6:2 X.05 Benzovindiflupir 3:1 0.6:0.2 X.05 Pidiflumetofen 3:1 6:2 X.05 Pidiflumetofen 30:1 6:0.2 X.05 Pidiflumetofen 1:3.3 0.6:2 X.05 Pidiflumetofen 3:1 0.6:0.2 X.05 Isoflucipram 3:1 6:2 X.05 Isoflucipram 30:1 6:0.2 X.05 Isoflucipram 1:3.3 0.6:2 X.05 Isoflucipram 3:1 0.6:0.2 X.05 Isofetamide 3:1 6:2 X.05 Isofetamide 30:1 6:0.2 X.05 Isofetamide 1:3.3 0.6:2 X.05 Isofetamide 3:1 0.6:0.2 X.05 Pyrapropoin 3:1 6:2 X.05 Pyrapropoin 30:1 6:0.2 X.05 Pyrapropoin 1:3.3 0.6:2 X.05 Pyrapropoin 3:1 0.6:0.2 X.05 Fluindapir 3:1 6:2 X.05 Fluindapir 30:1 6:0.2 X.05 Fluindapir 1:3.3 0.6:2 X.05 Fluindapir 3:1 0.6:0.2

- 185 046368

X.05 Phenpicoxamide 1:1 6:6 X.05 Phenpicoxamide 10:1 6:0.6 X.05 Phenpicoxamide 1:10 0.6:6 X.05 Phenpicoxamide 1:1 0.6:0.6 X.05 Florylpicoxamide 3:1 6:2 X.05 Florylpicoxamide 30:1 6:0.2 X.05 Florylpicoxamide 1:3.3 0.6:2 X.05 Florylpicoxamide 3:1 0.6:0.2 X.05 Chlorothalonil 1:1 6:6 X.05 Chlorothalonil 10:1 6:0.6 X.05 Chlorothalonil 1:10 0.6:6 X.05 Chlorothalonil 1:1 0.6:0.6 X.05 Mankozeb 1:3.3 6:20 X.05 Mankozeb 1:1 6:6 X.05 Mankozeb 1:33.3 0.6:20 X.05 Mankozeb 1:10 0.6:6 X.05 Mandipropamide 1:3.3 6:20 X.05 Mandipropamide 1:1 6:6 X.05 Mandipropamide 1:33.3 0.6:20 X.05 Mandipropamide 1:10 0.6:6 X.05 Oxathiapiproline 1:3.3 6:20 X.05 Oxathiapiproline 1:1 6:6 X.05 Oxathiapiproline 1:33.3 0.6:20 X.05 Oxathiapiproline 1:10 0.6:6 X.05 Fluazinam 3:1 6:2 X.05 Fluazinam 30:1 6:0.2

- 186 046368

X.05 Fluazinam 1:3.3 0.6:2 X.05 Fluazinam 3:1 0.6:0.2 X.05 Fludioxonil 1:1 6:6 X.05 Fludioxonil 10:1 6:0.6 X.05 Fludioxonil 1:10 0.6:6 X.05 Fludioxonil 1:1 0.6:0.6 X.05 Cyprodinil 1:1 6:6 X.05 Cyprodinil 10:1 6:0.6 X.05 Cyprodinil 1:10 0.6:6 X.05 Cyprodinil 1:1 0.6:0.6 X.05 Metalaxyl-M 1:3.3 6:20 X.05 Metalaxyl-M 1:1 6:6 X.05 Metalaxyl-M 1:33.3 0.6:20 X.05 Metalaxyl-M 1:10 0.6:6 X.05 Aminopyrifene 3:1 6:2 X.05 Aminopyrifene 30:1 6:0.2 X.05 Aminopyrifene 1:3.3 0.6:2 X.05 Aminopyrifene 3:1 0.6:0.2 X.05 Folpet 1:1 6:6 X.05 Folpet 3:1 6:2 X.05 Folpet 1:10 0.6:6 X.05 Folpet 1:3.3 0.6:2 X.05 Ipflufenoquin 3:1 6:2 X.05 Ipflufenoquin 30:1 6:0.2 X.05 Ipflufenoquin 1:3.3 0.6:2 X.05 Ipflufenoquin 3:1 0.6:0.2

- 187 046368

X.05 Quinofumelin 3:1 6:2 X.05 Quinofumelin 30:1 6:0.2 X.05 Quinofumelin 1:3.3 0.6:2 X.05 Quinofumelin 3:1 0.6:0.2 X.05 Tricyclic azole 1:3.3 6:20 X.05 Tricyclic azole 1:1 6:6 X.05 Tricyclic azole 1:33.3 0.6:20 X.05 Tricyclic azole 1:10 0.6:6 X.05 Pirokv ILON 1:3.3 6:20 X.05 Pirokv ILON 1:1 6:6 X.05 Pirokv ILON 1:33.3 0.6:20 X.05 Pirokv ILON 1:10 0.6:6 X.05 X-(1-Benzyl-1,3- dimethylbutyl)-8fluoroquinoline-3carboxamide 3:1 6:2 X.05 X-(1-Benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 30:1 6:0.2 X.05 X-(1-Benzyl-1,3- dimethylbutyl)-8fluoroquinoline-3carboxamide 1:3.3 0.6:2 X.05 X-(1-Benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 3:1 0.6:0.2 X.05 N-(l-Benzyl-3,3,3- 3:1 6:2

- 188 046368

trifluoro-1methylpropyl)-8fluoroquinoline-3 carboxamide X.05 N-(l-Benzyl-3,3,3trifluoro-1methylpropyl)-8fluoroquinoline-3carboxamide 30:1 6:0.2 X.05 X-(1-Benzyl-3,3,3trifluoro-1methylpropyl)-8fluoroquinoline-3 carboxamide 1:3.3 0.6:2 X.05 X-(1-Benzyl-3,3,3trifluoro-1methylpropyl)-8fluoroquinoline-3 carboxamide 3:1 0.6:0.2 X.05 1-(6.7- Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5trifluoro-3,3dimethylisoquinoline 3:1 6:2 X.05 1-(6.7- Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5trifluoro-3,3dimethylisoquinoline 30:1 6:0.2 X.05 1-(6.7- Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5- 1:3.3 0.6:2

- 189 046368

trifluoro-3,3- dimethylisoquinoline X.05 1-(6,7Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 3:1 0.6:0.2 X.05 4,4-Difluoro-3,3-d imethyl1 -(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 3:1 6:2 X.05 4,4-Difluoro-3,3-d imethyl1 -(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 30:1 6:0.2 X.05 4,4-Difluoro-3,3-d imethyl1 -(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 1:3.3 0.6:2 X.05 4,4-Difluoro-3,3-d imethyl1 -(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 3:1 0.6:0.2 X.05 1-(4,5Dimethylbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 3:1 6:2 X.05 1-(4,5Dimethylbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 30:1 6:0.2

- 190 046368

X.05 1-(4,5Dimethylbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 1:3.3 0.6:2 X.05 1-(4,5Dimethylbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 3:1 0.6:0.2 X.05 1-(4.5- Dimethylbenzimide azol-1 yl)-4,4-difluoro-3,3 dimethylisoquinoline 3:1 6:2 X.05 1-(4.5- Dimethylbenzimide azol-1 yl)-4,4-difluoro-3,3 dimethylisoquinoline 30:1 6:0.2 X.05 1-(4.5- Dimethylbenzimide azol-1 yl)-4,4-difluoro-3,3 dimethylisoquinoline 1:3.3 0.6:2 X.05 1-(4.5- Dimethylbenzimide azol-1 yl)-4,4-difluoro-3,3 dimethylisoquinoline 3:1 0.6:0.2

Component A (connection) Component B A:B ratio Conc, (ppm) (A:B) X.07 Azoxystrobin 3:1 6:2 X.07 Azoxystrobin 30:1 6:0.2 X.07 Azoxystrobin 1:3.3 0.6:2 X.07 Azoxystrobin 3:1 0.6:0.2

- 191 046368

X.07 Trifloxystrobin 3:1 6:2 X.07 Trifloxystrobin 30:1 6:0.2 X.07 Trifloxystrobin 1:3.3 0.6:2 X.07 Trifloxystrobin 3:1 0.6:0.2 X.07 Methyltetraprole 3:1 6:2 X.07 Methyltetraprole 30:1 6:0.2 X.07 Methyltetraprole 1:3.3 0.6:2 X.07 Methyltetraprole 3:1 0.6:0.2 X.07 Difenoconazole 1:1 6:6 X.07 Difenoconazole 10:1 6:0.6 X.07 Difenoconazole 1:10 0.6:6 X.07 Difenoconazole 1:1 0.6:0.6 X.07 Hexaconazole 1:1 6:6 X.07 Hexaconazole 10:1 6:0.6 X.07 Hexaconazole 1:10 0.6:6 X.07 Hexaconazole 1:1 0.6:0.6 X.07 Propiconazole 1:1 6:6 X.07 Propiconazole 10:1 6:0.6 X.07 Propiconazole 1:10 0.6:6 X.07 Propiconazole 1:1 0.6:0.6 X.07 Prothioconazole 1:1 6:6 X.07 Prothioconazole 10:1 6:0.6 X.07 Prothioconazole 1:10 0.6:6 X.07 Prothioconazole 1:1 0.6:0.6 X.07 Mefentrifluconazole 1:1 6:6 X.07 Mefentrifluconazole 10:1 6:0.6 X.07 Mefentrifluconazole 1:10 0.6:6

- 192 046368

X.07 Mefentrifluconazole 1:1 0.6:0.6 X.07 Fenpropidine 1:3.3 6:20 X.07 Fenpropidine 3:1 6:2 X.07 Fenpropidine 1:33.3 0.6:20 X.07 Fenpropidine 1:3.3 0.6:2 X.07 Phenpropimorph 1:3.3 6:20 X.07 Phenpropimorph 3:1 6:2 X.07 Phenpropimorph 1:33.3 0.6:20 X.07 Phenpropimorph 1:3.3 0.6:2 X.07 Fluxapyroxad 3:1 6:2 X.07 Fluxapyroxad 30:1 6:0.2 X.07 Fluxapyroxad 1:3.3 0.6:2 X.07 Fluxapyroxad 3:1 0.6:0.2 X.07 Fluopyram 3:1 6:2 X.07 Fluopyram 30:1 6:0.2 X.07 Fluopyram 1:3.3 0.6:2 X.07 Fluopyram 3:1 0.6:0.2 X.07 Isopyrase 3:1 6:2 X.07 Isopyrase 30:1 6:0.2 X.07 Isopyrase 1:3.3 0.6:2 X.07 Isopyrase 3:1 0.6:0.2 X.07 Sedaksan 3:1 6:2 X.07 Sedaksan 30:1 6:0.2 X.07 Sedaksan 1:3.3 0.6:2 X.07 Sedaksan 3:1 0.6:0.2 X.07 Benzovindiflupir 3:1 6:2

- 193 046368

X.07 Benzovindiflupir 30:1 6:0.2 X.07 Benzovindiflupir 1:3.3 0.6:2 X.07 Benzovindiflupir 3:1 0.6:0.2 X.07 Pidiflumetofen 3:1 6:2 X.07 Pidiflumetofen 30:1 6:0.2 X.07 Pidiflumetofen 1:3.3 0.6:2 X.07 Pidiflumetofen 3:1 0.6:0.2 X.07 Isoflucipram 3:1 6:2 X.07 Isoflucipram 30:1 6:0.2 X.07 Isoflucipram 1:3.3 0.6:2 X.07 Isoflucipram 3:1 0.6:0.2 X.07 Isofetamide 3:1 6:2 X.07 Isofetamide 30:1 6:0.2 X.07 Isofetamide 1:3.3 0.6:2 X.07 Isofetamide 3:1 0.6:0.2 X.07 Pyrapropoin 3:1 6:2 X.07 Pyrapropoin 30:1 6:0.2 X.07 Pyrapropoin 1:3.3 0.6:2 X.07 Pyrapropoin 3:1 0.6:0.2 X.07 Fluindapir 3:1 6:2 X.07 Fluindapir 30:1 6:0.2 X.07 Fluindapir 1:3.3 0.6:2 X.07 Fluindapir 3:1 0.6:0.2 X.07 Phenpicoxamide 1:1 6:6 X.07 Phenpicoxamide 10:1 6:0.6 X.07 Phenpicoxamide 1:10 0.6:6 X.07 Phenpicoxamide 1:1 0.6:0.6

- 194 046368

X.07 Florylpicoxamide 3:1 6:2 X.07 Florylpicoxamide 30:1 6:0.2 X.07 Florylpicoxamide 1:3.3 0.6:2 X.07 Florylpicoxamide 3:1 0.6:0.2 X.07 Chlorothalonil 1:1 6:6 X.07 Chlorothalonil 10:1 6:0.6 X.07 Chlorothalonil 1:10 0.6:6 X.07 Chlorothalonil 1:1 0.6:0.6 X.07 Mankozeb 1:3.3 6:20 X.07 Mankozeb 1:1 6:6 X.07 Mankozeb 1:33.3 0.6:20 X.07 Mankozeb 1:10 0.6:6 X.07 Mandipropamide 1:3.3 6:20 X.07 Mandipropamide 1:1 6:6 X.07 Mandipropamide 1:33.3 0.6:20 X.07 Mandipropamide 1:10 0.6:6 X.07 Oxathiapiproline 1:3.3 6:20 X.07 Oxathiapiproline 1:1 6:6 X.07 Oxathiapiproline 1:33.3 0.6:20 X.07 Oxathiapiproline 1:10 0.6:6 X.07 Fluazinam 3:1 6:2 X.07 Fluazinam 30:1 6:0.2 X.07 Fluazinam 1:3.3 0.6:2 X.07 Fluazinam 3:1 0.6:0.2 X.07 Fludioxonil 1:1 6:6 X.07 Fludioxonil 10:1 6:0.6

- 195 046368

X.07 Fludioxonil 1:10 0.6:6 X.07 Fludioxonil 1:1 0.6:0.6 X.07 Cyprodinil 1:1 6:6 X.07 Cyprodinil 10:1 6:0.6 X.07 Cyprodinil 1:10 0.6:6 X.07 Cyprodinil 1:1 0.6:0.6 X.07 Metalaxyl-M 1:3.3 6:20 X.07 Metalaxyl-M 1:1 6:6 X.07 Metalaxyl-M 1:33.3 0.6:20 X.07 Metalaxyl-M 1:10 0.6:6 X.07 Aminopyrifene 3:1 6:2 X.07 Aminopyrifene 30:1 6:0.2 X.07 Aminopyrifene 1:3.3 0.6:2 X.07 Aminopyrifene 3:1 0.6:0.2 X.07 Folpet 1:1 6:6 X.07 Folpet 3:1 6:2 X.07 Folpet 1:10 0.6:6 X.07 Folpet 1:3.3 0.6:2 X.07 Ipflufenoquin 3:1 6:2 X.07 Ipflufenoquin 30:1 6:0.2 X.07 Ipflufenoquin 1:3.3 0.6:2 X.07 Ipflufenoquin 3:1 0.6:0.2 X.07 Quinofumelin 3:1 6:2 X.07 Quinofumelin 30:1 6:0.2 X.07 Quinofumelin 1:3.3 0.6:2 X.07 Quinofumelin 3:1 0.6:0.2

- 196 046368

X.07 Tricyclic azole 1:3.3 6:20 X.07 Tricyclic azole 1:1 6:6 X.07 Tricyclic azole 1:33.3 0.6:20 X.07 Tricyclic azole 1:10 0.6:6 X.07 Pirokv ILON 1:3.3 6:20 X.07 Pirokv ILON 1:1 6:6 X.07 Pirokv ILON 1:33.3 0.6:20 X.07 Pirokv ILON 1:10 0.6:6 X.07 X-(1-Benzyl-1,3dimethylbutyl)-8fluoroquinoline-3carboxamide 3:1 6:2 X.07 X-(1-Benzyl-1,3dimethylbutyl)-8fluoroquinoline-3carboxamide 30:1 6:0.2 X.07 X-(1-Benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 1:3.3 0.6:2 X.07 X-(1-Benzyl-1,3dimethylbutyl)-8fluoroquinoline-3carboxamide 3:1 0.6:0.2 X.07 X-(1-Benzyl-3,3,3trifluoro-1methylpropyl)-8fluoroquinoline-3carboxamide 3:1 6:2 X.07 X-(1-Benzyl-3,3,3- 30:1 6:0.2

- 197 046368

trifluoro-1methylpropyl)-8fluoroquinoline-3carboxamide X.07 X-(1-Benzyl-3,3,3trifluoro-1methylpropyl)-8fluoroquinoline-3carboxamide 1:3.3 0.6:2 X.07 X-(1-Benzyl-3,3,3trifluoro-1methylpropyl)-8fluoroquinoline-3carboxamide 3:1 0.6:0.2 X.07 1-(6.7- Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 3:1 6:2 X.07 1-(6.7- Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 30:1 6:0.2 X.07 1-(6.7- Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 1:3.3 0.6:2 X.07 1-(6.7- Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 - 3:1 0.6:0.2

- 198 046368

trifluoro-3,3- dimethylisoquinoline X.07 4,4-Difluoro-3, 3-d imethyl1 -(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 3:1 6:2 X.07 4,4-Difluoro-3, 3-d-methyl1 -(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 30:1 6:0.2 X.07 4,4-Difluoro-3, 3-d imethyl1 -(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 1:3.3 0.6:2 X.07 4,4-Difluoro-3, 3-d imethyl1 -(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 3:1 0.6:0.2 X.07 1-(4,5Dimethylbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 3:1 6:2 X.07 1-(4,5Dimethylbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 30:1 6:0.2 X.07 1-(4,5Dimethylbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 1:3.3 0.6:2 X.07 1-(4.5- 3:1 0.6:0.2

- 199 046368

Dimethylbenzimidazol-1 yl)-4,4,5-trifluoro-3,3dimethylisoquinoline X.07 1-(4.5- Dimethylbenzimide azol-1 yl)-4,4-difluoro-3,3 dimethylisoquinoline 3:1 6:2 X.07 1-(4.5- Dimethylbenzimide azol-1 yl)-4,4-difluoro-3,3 dimethylisoquinoline 30:1 6:0.2 X.07 1-(4.5- Dimethylbenzimide azol-1 yl)-4,4-difluoro-3,3 dimethylisoquinoline 1:3.3 0.6:2 X.07 1-(4.5- Dimethylbenzimide azol-1 yl)-4,4-difluoro-3,3 dimethylisoquinoline 3:1 0.6:0.2

Component A (connection) Component B A:B ratio Conc, (ppm) (A:B) X.14 Azoxystrobin 3:1 6:2 X.14 Azoxystrobin 30:1 6:0.2 X.14 Azoxystrobin 1:3.3 0.6:2 X.14 Azoxystrobin 3:1 0.6:0.2 X.14 Trifloxystrobin 3:1 6:2 X.14 Trifloxystrobin 30:1 6:0.2 X.14 Trifloxystrobin 1:3.3 0.6:2 X.14 Trifloxystrobin 3:1 0.6:0.2

- 200 046368

X.14 Methyltetraprole 3:1 6:2 X.14 Methyltetraprole 30:1 6:0.2 X.14 Methyltetraprole 1:3.3 0.6:2 X.14 Methyltetraprole 3:1 0.6:0.2 X.14 Difenoconazole 1:1 6:6 X.14 Difenoconazole 10:1 6:0.6 X.14 Difenoconazole 1:10 0.6:6 X.14 Difenoconazole 1:1 0.6:0.6 X.14 Hexaconazole 1:1 6:6 X.14 Hexaconazole 10:1 6:0.6 X.14 Hexaconazole 1:10 0.6:6 X.14 Hexaconazole 1:1 0.6:0.6 X.14 Propiconazole 1:1 6:6 X.14 Propiconazole 10:1 6:0.6 X.14 Propiconazole 1:10 0.6:6 X.14 Propiconazole 1:1 0.6:0.6 X.14 Prothioconazole 1:1 6:6 X.14 Prothioconazole 10:1 6:0.6 X.14 Prothioconazole 1:10 0.6:6 X.14 Prothioconazole 1:1 0.6:0.6 X.14 Mefentrifluconazole 1:1 6:6 X.14 Mefentrifluconazole 10:1 6:0.6 X.14 Mefentrifluconazole 1:10 0.6:6 X.14 Mefentrifluconazole 1:1 0.6:0.6 X.14 Fenpropidine 1:3.3 6:20 X.14 Fenpropidine 3:1 6:2 X.14 Fenpropidine 1:33.3 0.6:20

- 201 046368

X.14 Fenpropidine 1:3.3 0.6:2 X.14 Phenpropimorph 1:3.3 6:20 X.14 Phenpropimorph 3:1 6:2 X.14 Phenpropimorph 1:33.3 0.6:20 X.14 Phenpropimorph 1:3.3 0.6:2 X.14 Fluxapyroxad 3:1 6:2 X.14 Fluxapyroxad 30:1 6:0.2 X.14 Fluxapyroxad 1:3.3 0.6:2 X.14 Fluxapyroxad 3:1 0.6:0.2 X.14 Fluopyram 3:1 6:2 X.14 Fluopyram 30:1 6:0.2 X.14 Fluopyram 1:3.3 0.6:2 X.14 Fluopyram 3:1 0.6:0.2 X.14 Isopyrase 3:1 6:2 X.14 Isopyrase 30:1 6:0.2 X.14 Isopyrase 1:3.3 0.6:2 X.14 Isopyrase 3:1 0.6:0.2 X.14 Sedaksan 3:1 6:2 X.14 Sedaxan 30:1 6:0.2 X.14 Sedaksan 1:3.3 0.6:2 X.14 Sedaksan 3:1 0.6:0.2 X.14 Benzovindiflupir 3:1 6:2 X.14 Benzovindiflupir 30:1 6:0.2 X.14 Benzovindiflupir 1:3.3 0.6:2 X.14 Benzovindiflupir 3:1 0.6:0.2 X.14 Pidiflumetofen 3:1 6:2

- 202 046368

X.14 Pidiflumetofen 30:1 6:0.2 X.14 Pidiflumetofen 1:3.3 0.6:2 X.14 Pidiflumetofen 3:1 0.6:0.2 X.14 Isoflucipram 3:1 6:2 X.14 Isoflucipram 30:1 6:0.2 X.14 Isoflucipram 1:3.3 0.6:2 X.14 Isoflucipram 3:1 0.6:0.2 X.14 Isofetamide 3:1 6:2 X.14 Isofetamide 30:1 6:0.2 X.14 Isofetamide 1:3.3 0.6:2 X.14 Isofetamide 3:1 0.6:0.2 X.14 Pyrapropoin 3:1 6:2 X.14 Pyrapropoin 30:1 6:0.2 X.14 Pyrapropoin 1:3.3 0.6:2 X.14 Pyrapropoin 3:1 0.6:0.2 X.14 Fluindapir 3:1 6:2 X.14 Fluindapir 30:1 6:0.2 X.14 Fluindapir 1:3.3 0.6:2 X.14 Fluindapir 3:1 0.6:0.2 X.14 Phenpicoxamide 1:1 6:6 X.14 Phenpicoxamide 10:1 6:0.6 X.14 Phenpicoxamide 1:10 0.6:6 X.14 Phenpicoxamide 1:1 0.6:0.6 X.14 Florylpicoxamide 3:1 6:2 X.14 Florylpicoxamide 30:1 6:0.2 X.14 Florylpicoxamide 1:3.3 0.6:2 X.14 Florylpicoxamide 3:1 0.6:0.2

- 203 046368

X.14 Chlorothalonil 1:1 6:6 X.14 Chlorothalonil 10:1 6:0.6 X.14 Chlorothalonil 1:10 0.6:6 X.14 Chlorothalonil 1:1 0.6:0.6 X.14 Mankozeb 1:3.3 6:20 X.14 Mankozeb 1:1 6:6 X.14 Mankozeb 1:33.3 0.6:20 X.14 Mankozeb 1:10 0.6:6 X.14 Mandipropamide 1:3.3 6:20 X.14 Mandipropamide 1:1 6:6 X.14 Mandipropamide 1:33.3 0.6:20 X.14 Mandipropamide 1:10 0.6:6 X.14 Oxathiapiproline 1:3.3 6:20 X.14 Oxathiapiproline 1:1 6:6 X.14 Oxathiapiproline 1:33.3 0.6:20 X.14 Oxathiapiproline 1:10 0.6:6 X.14 Fluazinam 3:1 6:2 X.14 Fluazinam 30:1 6:0.2 X.14 Fluazinam 1:3.3 0.6:2 X.14 Fluazinam 3:1 0.6:0.2 X.14 Fludioxonil 1:1 6:6 X.14 Fludioxonil 10:1 6:0.6 X.14 Fludioxonil 1:10 0.6:6 X.14 Fludioxonil 1:1 0.6:0.6 X.14 Cyprodinil 1:1 6:6 X.14 Cyprodinil 10:1 6:0.6

- 204 046368

X.14 Cyprodinil 1:10 0.6:6 X.14 Cyprodinil 1:1 0.6:0.6 X.14 Metalaxyl-M 1:3.3 6:20 X.14 Metalaxyl-M 1:1 6:6 X.14 Metalaxyl-M 1:33.3 0.6:20 X.14 Metalaxyl-M 1:10 0.6:6 X.14 Aminopyrifene 3:1 6:2 X.14 Aminopyrifene 30:1 6:0.2 X.14 Aminopyrifene 1:3.3 0.6:2 X.14 Aminopyrifene 3:1 0.6:0.2 X.14 Folpet 1:1 6:6 X.14 Folpet 3:1 6:2 X.14 Folpet 1:10 0.6:6 X.14 Folpet 1:3.3 0.6:2 X.14 Ipflufenoquin 3:1 6:2 X.14 Ipflufenoquin 30:1 6:0.2 X.14 Ipflufenoquin 1:3.3 0.6:2 X.14 Ipflufenoquin 3:1 0.6:0.2 X.14 Quinofumelin 3:1 6:2 X.14 Quinofumelin 30:1 6:0.2 X.14 Quinofumelin 1:3.3 0.6:2 X.14 Quinofumelin 3:1 0.6:0.2 X.14 Tricyclic azole 1:3.3 6:20 X.14 Tricyclic azole 1:1 6:6 X.14 Tricyclic azole 1:33.3 0.6:20 X.14 Tricyclic azole 1:10 0.6:6

- 205 046368

X.14 Pirokv ILON 1:3.3 6:20 X.14 Pirokv ILON 1:1 6:6 X.14 Pirokv ILON 1:33.3 0.6:20 X.14 Pirokv ILON 1:10 0.6:6 X.14 X-(1-Benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 3:1 6:2 X.14 T4-(1-Benzyl-1,3dimethylbutyl)-8fluoroquinoline-3carboxamide 30:1 6:0.2 X.14 T4-(1-Benzyl-1,3dimethylbutyl)-8fluoroquinoline-3carboxamide 1:3.3 0.6:2 X.14 T4-(1-Benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 3:1 0.6:0.2 X.14 N-(l -Benzyl-3,3,3trifluoro-1methylpropyl)-8fluoroquinoline-3 carboxamide 3:1 6:2 X.14 T4-(1-Benzyl-3,3,3trifluoro-1methylpropyl)-8fluoroquinoline-3 carboxamide 30:1 6:0.2 X.14 T4-(1-Benzyl-3,3,3- 1:3.3 0.6:2

- 206 046368

trifluoro-1methylpropyl)-8fluoroquinoline-3 carboxamide X.14 X-(1-Benzyl-3,3,3trifluoro-1methylpropyl)-8fluoroquinoline-3 carboxamide 3:1 0.6:0.2 X.14 1-(6.7- Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 3:1 6:2 X.14 1-(6.7- Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 30:1 6:0.2 X.14 1-(6.7- Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 1:3.3 0.6:2 X.14 1-(6.7- Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 3:1 0.6:0.2 X.14 4,4-Difluoro-3,3-d methyl1 -(7-methylpyrazolo[1,5- 3:1 6:2

- 207 046368

a] pyridin-3yl)isoquinoline X.14 4,4-Difluoro-3,3-d-imethyl1 -(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 30:1 6:0.2 X.14 4,4-Difluoro-3,3-d imethyl1 -(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 1:3.3 0.6:2 X.14 4,4-Difluoro-3,3-d imethyl1 -(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 3:1 0.6:0.2 X.14 1-(4.5- Dimethylbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 3:1 6:2 X.14 1-(4,5Dimethylbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 30:1 6:0.2 X.14 1-(4,5Dimethylbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 1:3.3 0.6:2 X.14 1-(4,5Dimethylbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 3:1 0.6:0.2 X.14 1-(4.5- 3:1 6:2 X.14 X.14 Dimethylbenzimide azol-1 yl)-4,4-difluoro-3,3 dimethylisoquinoline 1-(4,5- Dimethylbenzimide azol-1 yl)-4,4-difluoro-3,3 dimethylisoquinoline 1-(4,5- Dimethylbenzimide azol-1 yl)-4,4-difluoro-3,3 dimethylisoquinoline 30:1 1:3.3 6:0.2 0.6:2 X.14 1-(4.5- Dimethylbenzimide azol-1 yl)-4,4-difluoro-3,3 dimethylisoquinoline 3:1 0.6:0.2

Example B7. Activity against Cercospora beticola (leaf spot)

Fungal conidia from cryogenic storage were directly mixed with nutrient broth

- 208 046368 (potato dextrose broth, PDB). A solution of test compounds in DMSO was added to a microtiter plate (96-well format) and nutrient broth containing fungal spores was added. Plates with test compounds were incubated at 24°C and growth inhibition was determined photometrically after 3-4 days at 620 nm. The following mixture-based formulations (A:B) at the indicated concentrations (in ppm) provided at least 70% disease control in this test.

Component Conc, (ppm) A Component B A:B ratio (A:B) (compound) X.05 Azoxystrobin 3.3:1 20:6 X.05 Azoxystrobin 33.3:1 20:0.6 X.05 Azoxystrobin 1:3 2:6 X.05 Trifloxystrobin 3.3:1 20:6 X.05 Trifloxystrobin 33.3:1 20:0.6 X.05 Trifloxystrobin 1:3 2:6 X.05 Methyltetraprole 3.3:1 20:6 X.05 Methyltetraprole 33.3:1 20:0.6 X.05 Methyltetraprole 1:3 2:6 X.05 Methyltetraprole 3.3:1 2:0.6 X.05 Difenoconazole 3.3:1 20:6 X.05 Difenoconazole 33.3:1 20:0.6 X.05 Difenoconazole 1:3 2:6 X.05 Difenoconazole 3.3:1 2:0.6 X.05 Hexaconazole 3.3:1 20:6 X.05 Hexaconazole 33.3:1 20:0.6 X.05 Hexaconazole 1:3 2:6 X.05 Hexaconazole 3.3:1 2:0.6 X.05 Propiconazole 3.3:1 20:6 X.05 Propiconazole 33.3:1 20:0.6 X.05 Propiconazole 1:3 2:6 X.05 Propiconazole 3.3:1 2:0.6 X.05 Prothioconazole 3.3:1 20:6 X.05 Prothioconazole 33.3:1 20:0.6 X.05 Prothioconazole 1:3 2:6 X.05 Prothioconazole 3.3:1 2:0.6 X.05 Mefentrifluconazole 3.3:1 20:6 X.05 Mefentrifluconazole 33.3:1 20:0.6 X.05 Mefentrifluconazole 1:3 2:6 X.05 Mefentrifluconazole 3.3:1 2:0.6

- 209 046368

X.05 Fenpropidine 1:1 20:20 X.05 Fenpropidine 3.3:1 20:6 X.05 Fenpropidine 1:10 2:20 X.05 Fenpropidine 1:3 2:6 X.05 Phenpropimorph 1:1 20:20 X.05 Phenpropimorph 3.3:1 20:6 X.05 Phenpropimorph 1:10 2:20 X.05 Phenpropimorph 1:3 2:6 X.05 Fluxapyroxad 3.3:1 20:6 X.05 Fluxapyroxad 33.3:1 20:0.6 X.05 Fluxapyroxad 1:3 2:6 X.05 Fluxapyroxad 3.3:1 2:0.6 X.05 Fluopyram 3.3:1 20:6 X.05 Fluopyram 33.3:1 20:0.6 X.05 Fluopyram 1:3 2:6 X.05 Fluopyram 3.3:1 2:0.6 X.05 Benzovindiflupir 3.3:1 20:6 X.05 Benzovindiflupir 33.3:1 20:0.6 X.05 Benzovindiflupir 1:3 2:6 X.05 Benzovindiflupir 3.3:1 2:0.6 X.05 Pid if lu metof her 3.3:1 20:6 X.05 Pid if lu metof her 33.3:1 20:0.6 X.05 Pid iflu metof her 1:3 2:6 X.05 Pid iflu metof her 3.3:1 2:0.6 X.05 Isoflucipram 3.3:1 20:6 X.05 Isoflucipram 33.3:1 20:0.6 X.05 Isoflucipram 1:3 2:6

- 210 046368

X.05 Isoflucipram 3.3:1 2:0.6 X.05 Fluindapir 3.3:1 20:6 X.05 Florylpicoxamide 3.3:1 20:6 X.05 Florylpicoxamide 33.3:1 20:0.6 X.05 Florylpicoxamide 1:3 2:6 X.05 Florylpicoxamide 3.3:1 2:0.6 X.05 Metharylpicoxamide 3.3:1 20:6 X.05 Metharylpicoxamide 33.3:1 20:0.6 X.05 Metharylpicoxamide 1:3 2:6 X.05 Metharylpicoxamide 3.3:1 2:0.6 X.05 Chlorothalonil 3.3:1 20:6 X.05 Chlorothalonil 33.3:1 20:0.6 X.05 Chlorothalonil 1:3 2:6 X.05 Chlorothalonil 3.3:1 2:0.6 X.05 Mankozeb 1:1 20:20 X.05 Mankozeb 3.3:1 20:6 X.05 Oxathiapiproline 1:1 20:20 X.05 Fluazinam 3.3:1 20:6 X.05 Fluazinam 33.3:1 20:0.6 X.05 Fluazinam 1:3 2:6 X.05 Fluazinam 3.3:1 2:0.6 X.05 Fludioxonil 3.3:1 20:6 X.05 Fludioxonil 33.3:1 20:0.6 X.05 Fludioxonil 1:3 2:6 X.05 Fludioxonil 3.3:1 2:0.6

- 211 046368

X.05 Cyprodinil 3.3:1 20:6 X.05 Cyprodinil 33.3:1 20:0.6 X.05 Cyprodinil 1:3 2:6 X.05 Cyprodinil 3.3:1 2:0.6 X.05 Folpet 3.3:1 20:6 X.05 Folpet 10:1 20:2 X.05 Folpet 1:3 2:6 X.05 Folpet 1:1 2:2 X.05 Aminopyrifene 3.3:1 20:6 X.05 Aminopyrifene 33.3:1 20:0.6 X.05 Aminopyrifene 1:3 2:6 X.05 Aminopyrifene 3.3:1 2:0.6 X.05 T4-(1-Benzyl-1,3dimethylbutyl)-8fluoroquinoline-3carboxamide 3.3:1 20:6 X.05 X-(1-Benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 1:3 2:6 X.05 N-(l-Benzyl-3,3,3trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide 3.3:1 20:6 X.05 N-(l-Benzyl-3,3,3trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide 33.3:1 20:0.6

- 212 046368

X.05 1-(6.7- Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 3.3:1 20:6 X.05 1-(6.7- Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 33.3:1 20:0.6 X.05 1-(6.7- Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 1:3 2:6 X.05 1-(6.7- Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 3.3:1 2:0.6 X.05 4,4-Difluoro-3,3-d imethyl1 -(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 3.3:1 20:6 X.05 4,4-Difluoro-3,3-d imethyl1 -(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 33.3:1 20:0.6 X.05 4,4-Difluoro-3,3-d and methyl1-(7-methylpyrazolo[1,5а]pyridine-3- 1:3 2:6

- 213 046368

yl)isoquinoline X.05 4,4-Difluoro-3,3-d-imethyl1 -(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 3.3:1 2:0.6 X.05 1-(4,5Dimethylbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 3.3:1 20:6 X.05 1-(4,5Dimethylbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 33.3:1 20:0.6 X.05 1-(4,5Dimethylbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 1:3 2:6 X.05 1-(4.5- Dimethylbenzimide azol-1yl)-4,4-difluoro-3,3dimethylisoquinoline 3.3:1 20:6 X.05 1-(4.5- Dimethylbenzimide azol-1yl)-4,4-difluoro-3,3dimethylisoquinoline 33.3:1 20:0.6 X.05 1-(4.5- Dimethylbenzimide azol-1yl)-4,4-difluoro-3,3dimethylisoquinoline 1:3 2:6 X.05 1-(4.5- Dimethylbenzimide azole-1 - 3.3:1 2:0.6

- 214 046368

yl)-4,4-difluoro-3,3- dimethylisoquinoline X.05 Isopyrase 3.3:1 20:6 X.05 Isopyrase 33.3:1 20:0.6 X.05 Isopyrase 1:3 2:6 X.05 Isopyrase 3.3:1 2:0.6 X.05 Sedaksan 3.3:1 20:6 X.05 Sedaksan 33.3:1 20:0.6 X.05 Sedaksan 1:3 2:6 X.05 Sedaksan 3.3:1 2:0.6 X.05 Isofetamide 3.3:1 20:6 X.05 Isofetamide 33.3:1 20:0.6 X.05 Isofetamide 1:3 2:6 X.05 Isofetamide 3.3:1 2:0.6 X.05 Ipflufenoquin 3.3:1 20:6 X.05 Ipflufenoquin 33.3:1 20:0.6 X.05 Ipflufenoquin 1:3 2:6 X.05 Ipflufenoquin 3.3:1 2:0.6 X.05 Quinofumelin 3.3:1 20:6 X.05 Quinofumelin 33.3:1 20:0.6 X.05 Quinofumelin 1:3 2:6 X.05 Quinofumelin 3.3:1 2:0.6

Component A (connection) Component B A:B ratio Conc, (ppm) (A:B) X.07 Methyltetraprole 3.3:1 20:6 X.07 Methyltetraprole 33.3:1 20:0.6

- 215 046368

X.07 Methyltetraprole 1:3 2:6 X.07 Methyltetraprole 3.3:1 2:0.6 X.07 Difenoconazole 3.3:1 20:6 X.07 Difenoconazole 1:3 2:6 X.07 Hexaconazole 3.3:1 20:6 X.07 Hexaconazole 1:3 2:6 X.07 Propiconazole 3.3:1 20:6 X.07 Propiconazole 33.3:1 20:0.6 X.07 Propiconazole 1:3 2:6 X.07 Propiconazole 3.3:1 2:0.6 X.07 Prothioconazole 3.3:1 20:6 X.07 Prothioconazole 33.3:1 20:0.6 X.07 Prothioconazole 1:3 2:6 X.07 Prothioconazole 3.3:1 2:0.6 X.07 Mefentrifluconazole 3.3:1 20:6 X.07 Mefentrifluconazole 1:3 2:6 X.07 Mefentrifluconazole 3.3:1 2:0.6 X.07 Fenpropidine 1:1 20:20 X.07 Fenpropidine 3.3:1 20:6 X.07 Fenpropidine 1:10 2:20 X.07 Fenpropidine 1:3 2:6 X.07 Phenpropimorph 1:1 20:20 X.07 Phenpropimorph 3.3:1 20:6 X.07 Phenpropimorph 1:10 2:20 X.07 Phenpropimorph 1:3 2:6

- 216 046368

X.07 Benzovindiflupir 1:3 2:6 X.07 Pid if lu metof en 3.3:1 20:6 X.07 Pid if lu metof en 33.3:1 20:0.6 X.07 Pid iflu metof en 1:3 2:6 X.07 Pid iflu metof en 3.3:1 2:0.6 X.07 Isoflucipram 3.3:1 20:6 X.07 Isoflucipram 33.3:1 20:0.6 X.07 Isoflucipram 1:3 2:6 X.07 Isoflucipram 3.3:1 2:0.6 X.07 Florylpicoxamide 3.3:1 20:6 X.07 Florylpicoxamide 33.3:1 20:0.6 X.07 Florylpicoxamide 1:3 2:6 X.07 Florylpicoxamide 3.3:1 2:0.6 X.07 Metharylpicoxamide 3.3:1 20:6 X.07 Metharylpicoxamide 33.3:1 20:0.6 X.07 Metharylpicoxamide 1:3 2:6 X.07 Metharylpicoxamide 3.3:1 2:0.6 X.07 Chlorothalonil 3.3:1 20:6 X.07 Chlorothalonil 1:3 2:6 X.07 Mankozeb 1:1 20:20 X.07 Mankozeb 3.3:1 20:6 X.07 Mankozeb 1:10 2:20 X.07 Mankozeb 1:3 2:6 X.07 Fluazinam 3.3:1 20:6 X.07 Fluazinam 33.3:1 20:0.6 X.07 Fluazinam 1:3 2:6

- 217 046368

X.07 Fluazinam 3.3:1 2:0.6 X.07 Fludioxonil 3.3:1 20:6 X.07 Fludioxonil 33.3:1 20:0.6 X.07 Fludioxonil 1:3 2:6 X.07 Fludioxonil 3.3:1 2:0.6 X.07 Cyprodinil 3.3:1 20:6 X.07 Cyprodinil 1:3 2:6 X.07 Folpet 3.3:1 20:6 X.07 Folpet 10:1 20:2 X.07 Folpet 1:3 2:6 X.07 Folpet 1:1 2:2 X.07 Aminopyrifene 3.3:1 20:6 X.07 Aminopyrifene 33.3:1 20:0.6 X.07 Aminopyrifene 1:3 2:6 X.07 Aminopyrifene 3.3:1 2:0.6 X.07 X-(1-Benzyl-1,3dimethylbutyl)-8fluoroquinoline-3carboxamide 3.3:1 20:6 X.07 X-(1-Benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 1:3 2:6 X.07 1-(6.7- Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3- 3.3:1 20:6

- 218 046368

dimethylisoquinoline X.07 1-(6.7- Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 33.3:1 20:0.6 X.07 1-(6.7- Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 1:3 2:6 X.07 1-(6.7- Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 3.3:1 2:0.6 X.07 4,4-Difluoro-3,3-d imethyl1 -(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 3.3:1 20:6 X.07 4,4-Difluoro-3,3-d imethyl1 -(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 33.3:1 20:0.6 X.07 4,4-Difluoro-3,3-d imethyl1 -(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 1:3 2:6 X.07 1-(4.5- Dimethylbenzimide azol-1 yl)-4,4,5 -trifluoro-3,3 - 3.3:1 20:6

- 219 046368

dimethylisoquinoline X.07 1-(4.5- Dimethylbenzimidazol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 33.3:1 20:0.6 X.07 1-(4.5- Dimethylbenzimidazol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 1:3 2:6 X.07 1-(4.5- Dimethylbenzimidazol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 3.3:1 2:0.6 X.07 1-(4.5- Dimethylbenzimidazol-1 yl)-4,4-difluoro-3,3dimethylisoquinoline 3.3:1 20:6 X.07 1-(4.5- Dimethylbenzimidazol-1 yl)-4,4-difluoro-3,3dimethylisoquinoline 33.3:1 20:0.6 X.07 1-(4.5- Dimethylbenzimidazol-1 yl)-4,4-difluoro-3,3dimethylisoquinoline 1:3 2:6 X.07 1-(4.5- Dimethylbenzimidazol-1 yl)-4,4-difluoro-3,3dimethylisoquinoline 3.3:1 2:0.6 X.07 Ipflufenoquin 3.3:1 20:6 X.07 Ipflufenoquin 33.3:1 20:0.6

- 220 046368

X.07 Ipflufenoquin 1:3 2:6 X.07 Ipflufenoquin 3.3:1 2:0.6 X.07 Quinofumelin 3.3:1 20:6 X.07 Quinofumelin 1:3 2:6 X.07 Quinofumelin 3.3:1 2:0.6

Component A (connection) Component B A:B ratio Conc, (ppm) (A:B) X.14 Azoxystrobin 3.3:1 20:6 X.14 Azoxystrobin 33.3:1 20:0.6 X.14 Trifloxystrobin 3.3:1 20:6 X.14 Trifloxystrobin 33.3:1 20:0.6 X.14 Methyltetraprole 3.3:1 20:6 X.14 Methyltetraprole 33.3:1 20:0.6 X.14 Methyltetraprole 1:3 2:6 X.14 Methyltetraprole 3.3:1 2:0.6 X.14 Difenoconazole 3.3:1 20:6 X.14 Difenoconazole 33.3:1 20:0.6 X.14 Difenoconazole 1:3 2:6 X.14 Difenoconazole 3.3:1 2:0.6 X.14 Hexaconazole 3.3:1 20:6 X.14 Hexaconazole 33.3:1 20:0.6 X.14 Hexaconazole 1:3 2:6 X.14 Hexaconazole 3.3:1 2:0.6 X.14 Propiconazole 3.3:1 20:6 X.14 Propiconazole 33.3:1 20:0.6

- 221 046368

X.14 Propiconazole 1:3 2:6 X.14 Propiconazole 3.3:1 2:0.6 X.14 Prothioconazole 3.3:1 20:6 X.14 Prothioconazole 33.3:1 20:0.6 X.14 Prothioconazole 1:3 2:6 X.14 Prothioconazole 3.3:1 2:0.6 X.14 Mefentrifluconazole 3.3:1 20:6 X.14 Mefentrifluconazole 33.3:1 20:0.6 X.14 Mefentrifluconazole 1:3 2:6 X.14 Mefentrifluconazole 3.3:1 2:0.6 X.14 Fenpropidine 1:1 20:20 X.14 Fenpropidine 3.3:1 20:6 X.14 Fenpropidine 1:10 2:20 X.14 Fenpropidine 1:3 2:6 X.14 Phenpropimorph 1:1 20:20 X.14 Phenpropimorph 3.3:1 20:6 X.14 Phenpropimorph 1:10 2:20 X.14 Phenpropimorph 1:3 2:6 X.14 Fluxapyroxad 3.3:1 20:6 X.14 Fluxapyroxad 33.3:1 20:0.6 X.14 Fluxapyroxad 1:3 2:6 X.14 Fluopyram 3.3:1 20:6 X.14 Fluopyram 33.3:1 20:0.6 X.14 Benzovindiflupir 3.3:1 20:6 X.14 Benzovindiflupir 33.3:1 20:0.6 X.14 Benzovindiflupir 1:3 2:6

- 222 046368

X.14 Pid iflu metof her 3.3:1 20:6 X.14 Pid iflu metof her 33.3:1 20:0.6 X.14 Pid iflu metof her 1:3 2:6 X.14 Pid iflu metof her 3.3:1 2:0.6 X.14 Isoflucipram 3.3:1 20:6 X.14 Isoflucipram 33.3:1 20:0.6 X.14 Isoflucipram 1:3 2:6 X.14 Isoflucipram 3.3:1 2:0.6 X.14 Fluindapir 3.3:1 20:6 X.14 Fluindapir 33.3:1 20:0.6 X.14 Florylpicoxamide 3.3:1 20:6 X.14 Florylpicoxamide 33.3:1 20:0.6 X.14 Florylpicoxamide 1:3 2:6 X.14 Florylpicoxamide 3.3:1 2:0.6 X.14 Metharylpicoxamide 3.3:1 20:6 X.14 Metharylpicoxamide 33.3:1 20:0.6 X.14 Metharylpicoxamide 1:3 2:6 X.14 Metharylpicoxamide 3.3:1 2:0.6 X.14 Chlorothalonil 3.3:1 20:6 X.14 Chlorothalonil 33.3:1 20:0.6 X.14 Chlorothalonil 1:3 2:6 X.14 Chlorothalonil 3.3:1 2:0.6 X.14 Mankozeb 1:1 20:20 X.14 Mankozeb 3.3:1 20:6 X.14 Mankozeb 1:10 2:20 X.14 Mankozeb 1:3 2:6

- 223 046368

X.14 Fluazinam 3.3:1 20:6 X.14 Fluazinam 33.3:1 20:0.6 X.14 Fluazinam 1:3 2:6 X.14 Fluazinam 3.3:1 2:0.6 X.14 Fludioxonil 3.3:1 20:6 X.14 Fludioxonil 33.3:1 20:0.6 X.14 Fludioxonil 1:3 2:6 X.14 Fludioxonil 3.3:1 2:0.6 X.14 Cyprodinil 3.3:1 20:6 X.14 Cyprodinil 33.3:1 20:0.6 X.14 Cyprodinil 1:3 2:6 X.14 Metalaxyl-M 1:1 20:20 X.14 Folpet 3.3:1 20:6 X.14 Folpet 10:1 20:2 X.14 Folpet 1:3 2:6 X.14 Folpet 1:1 2:2 X.14 Aminopyrifene 3.3:1 20:6 X.14 Aminopyrifene 33.3:1 20:0.6 X.14 Aminopyrifene 1:3 2:6 X.14 Aminopyrifene 3.3:1 2:0.6 X.14 1-(6.7- Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 3.3:1 20:6 X.14 1-(6.7- 33.3:1 20:0.6

- 224 046368

Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline X.14 1-(6.7- Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 1:3 2:6 X.14 1-(6.7- Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 3.3:1 2:0.6 X.14 4,4-Difluoro-3,3-d imethyl1 -(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 3.3:1 20:6 X.14 4,4-Difluoro-3,3-d imethyl1 -(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 1:3 2:6 X.14 4,4-Difluoro-3,3-d imethyl1 -(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 3.3:1 2:0.6 X.14 1-(4,5Dimethylbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 3.3:1 20:6 X.14 1-(4.5- 33.3:1 20:0.6

- 225 046368

Dimethylbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 1-(4,5- Dimethylbenzimide azole-1 - X.14 1:3 2:6 yl)-4,4,5 -trifluoro-3,3 - dimethylisoquinoline 1-(4,5- Dimethylbenzimide azole-1 - X.14 3.3:1 2:0.6 yl)-4,4,5 -trifluoro-3,3 - dimethylisoquinoline 1-(4.5- Dimethylbenzimide azole-1 - X.14 3.3:1 20:6 yl)-4,4-difluoro-3,3dimethylisoquinoline 1-(4.5- Dimethylbenzimide azole-1 - X.14 33.3:1 20:0.6 yl)-4,4-difluoro-3,3dimethylisoquinoline 1-(4.5- Dimethylbenzimide azole-1 - X.14 1:3 2:6 yl)-4,4-difluoro-3,3dimethylisoquinoline 1-(4.5- Dimethylbenzimide azole-1 - X.14 3.3:1 2:0.6 yl)-4,4-difluoro-3,3dimethylisoquinoline X.14 Isopyrazam 3.3:1 20:6 X.14 Isopyrazam 33.3:1 20:0.6 X.14 Isopyrazam 1:3 2:6 X.14 Isopyrazam 3.3:1 2:0.6 X.14 Sedaksan 3.3:1 20:6 X.14 Sedaxan 33.3:1 20:0.6 X.14 Isofetamide 3.3:1 20:6 X.14 Isofetamide 33.3:1 20:0.6 X.14 Isofetamide 1:3 2:6 X.14 Ipflufenoquin 3.3:1 20:6 X.14 Ipflufenoquin 33.3:1 20:0.6 X.14 Ipflufenoquin 1:3 2:6 X.14 Ipflufenoquin 3.3:1 2:0.6 X.14 Quinofumelin 3.3:1 20:6 X.14 Quinofumelin 33.3:1 20:0.6 X.14 Quinofumelin 1:3 2:6

Example B8. Activity against Pyrenophora teres (net spot)

Fungal conidia from cryogenic storage were directly mixed with nutrient broth

- 226 046368 (potato dextrose broth, PDB). A solution of test compounds in DMSO was added to a microtiter plate (96-well format) and nutrient broth containing fungal spores was added. Plates with test compounds were incubated at 24°C and growth inhibition was determined photometrically after 72 h at 620 nm. The following mixture-based compositions (A:B) at the indicated concentration (in ppm) provided at least 70% disease control in this test.

Component A (connection) Component B A:B ratio Conc, (ppm) (A:B) X.05 Azoxystrobin 3:1 6:2 X.05 Azoxystrobin 30:1 6:0.2 X.05 Azoxystrobin 1:3.3 0.6:2 X.05 Azoxystrobin 3:1 0.6:0.2

X.05 Trifloxystrobin 3:1 6:2 X.05 Trifloxystrobin 30:1 6:0.2 X.05 Trifloxystrobin 1:3.3 0.6:2 X.05 Trifloxystrobin 3:1 0.6:0.2 X.05 Methyltetraprole 3:1 6:2 X.05 Methyltetraprole 30:1 6:0.2 X.05 Methyltetraprole 1:3.3 0.6:2 X.05 Methyltetraprole 3:1 0.6:0.2 X.05 Difenoconazole 1:1 6:6 X.05 Difenoconazole 10:1 6:0.6 X.05 Difenoconazole 1:10 0.6:6 X.05 Difenoconazole 1:1 0.6:0.6 X.05 Hexaconazole 1:1 6:6 X.05 Hexaconazole 10:1 6:0.6 X.05 Hexaconazole 1:10 0.6:6 X.05 Propiconazole 1:1 6:6 X.05 Propiconazole 10:1 6:0.6 X.05 Propiconazole 1:10 0.6:6 X.05 Prothioconazole 1:1 6:6 X.05 Prothioconazole 10:1 6:0.6 X.05 Prothioconazole 1:10 0.6:6 X.05 Prothioconazole 1:1 0.6:0.6 X.05 Mefentrifluconazole 1:1 6:6 X.05 Mefentrifluconazole 10:1 6:0.6 X.05 Fenpropidine 1:3.3 6:20 X.05 Fenpropidine 3:1 6:2

- 227 046368

X.05 Phenpropimorph 1:3.3 6:20 X.05 Phenpropimorph 3:1 6:2 X.05 Fluxapyroxad 3:1 6:2 X.05 Fluxapyroxad 30:1 6:0.2 X.05 Fluopyram 3:1 6:2 X.05 Fluopyram 30:1 6:0.2 X.05 Fluopyram 1:3.3 0.6:2 X.05 Isopyrase 3:1 6:2 X.05 Isopyrase 30:1 6:0.2 X.05 Isopyrase 1:3.3 0.6:2 X.05 Sedaksan 3:1 6:2 X.05 Sedaksan 30:1 6:0.2 X.05 Benzovindiflupir 3:1 6:2 X.05 Benzovindiflupir 30:1 6:0.2 X.05 Benzovindiflupir 1:3.3 0.6:2 X.05 Pidiflumetofen 3:1 6:2 X.05 Pidiflumetofen 30:1 6:0.2 X.05 Pidiflumetofen 1:3.3 0.6:2 X.05 Pidiflumetofen 3:1 0.6:0.2 X.05 Isoflucipram 3:1 6:2 X.05 Isoflucipram 30:1 6:0.2 X.05 Isoflucipram 1:3.3 0.6:2 X.05 Isoflucipram 3:1 0.6:0.2 X.05 Isofetamide 3:1 6:2

- 228 046368

X.05 Isofetamide 30:1 6:0.2 X.05 Pyrapropoin 3:1 6:2 X.05 Pyrapropoin 30:1 6:0.2 X.05 Pyrapropoin 1:3.3 0.6:2 X.05 Pyrapropoin 3:1 0.6:0.2 X.05 Fluindapir 3:1 6:2 X.05 Fluindapir 30:1 6:0.2 X.05 Phenpicoxamide 1:1 6:6 X.05 Phenpicoxamide 10:1 6:0.6 X.05 Phenpicoxamide 1:10 0.6:6 X.05 Florylpicoxamide 3:1 6:2 X.05 Florylpicoxamide 30:1 6:0.2 X.05 Chlorothalonil 1:1 6:6 X.05 Chlorothalonil 10:1 6:0.6 X.05 Chlorothalonil 1:10 0.6:6 X.05 Mankozeb 1:1 6:6 X.05 Mandipropamide 1:3.3 6:20 X.05 Mandipropamide 1:1 6:6 X.05 Oxathiapiproline 1:3.3 6:20 X.05 Oxathiapiproline 1:1 6:6 X.05 Fluazinam 3:1 6:2 X.05 Fluazinam 30:1 6:0.2 X.05 Fluazinam 1:3.3 0.6:2 X.05 Fluazinam 3:1 0.6:0.2

- 229 046368

X.05 Fludioxonil 1:1 6:6 X.05 Fludioxonil 10:1 6:0.6 X.05 Fludioxonil 1:10 0.6:6 X.05 Fludioxonil 1:1 0.6:0.6 X.05 Cyprodinil 1:1 6:6 X.05 Cyprodinil 10:1 6:0.6 X.05 Cyprodinil 1:10 0.6:6 X.05 Cyprodinil 1:1 0.6:0.6 X.05 Metalaxyl-M 1:3.3 6:20 X.05 Metalaxyl-M 1:1 6:6 X.05 Aminopyrifene 3:1 6:2 X.05 Aminopyrifene 30:1 6:0.2 X.05 Folpet 1:1 6:6 X.05 Folpet 3:1 6:2 X.05 Ipflufenoquin 3:1 6:2 X.05 Ipflufenoquin 30:1 6:0.2 X.05 Ipflufenoquin 1:3.3 0.6:2 X.05 Ipflufenoquin 3:1 0.6:0.2 X.05 Quinofumelin 3:1 6:2 X.05 Quinofumelin 30:1 6:0.2 X.05 Quinofumelin 1:3.3 0.6:2 X.05 Quinofumelin 3:1 0.6:0.2 X.05 Tricyclazole 1:3.3 6:20 X.05 Tricyclazole 1:1 6:6

- 230 046368

X.05 Pirokv ILON 1:3.3 6:20 X.05 Pirokv ILON 1:1 6:6 X.05 X-(1-Benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 3:1 6:2 X.05 X-(1-Benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 30:1 6:0.2 X.05 X-(1-Benzyl-1,3dimethylbutyl)-8fluoroquinoline-3carboxamide 1:3.3 0.6:2 X.05 X-(1-Benzyl-3,3,3trifluoro-1methylpropyl)-8fluoroquinoline-3carboxamide 3:1 6:2 X.05 X-(1-Benzyl-3,3,3trifluoro-1methylpropyl)-8fluoroquinoline-3 carboxamide 30:1 6:0.2 X.05 N-(l -Benzyl-3,3,3trifluoro-1methylpropyl)-8fluoroquinoline-3 carboxamide 1:3.3 0.6:2 X.05 1-(6.7- 3:1 6:2

- 231 046368

Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline X.05 1-(6.7- Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 30:1 6:0.2 X.05 1-(6.7- Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 1:3.3 0.6:2 X.05 1-(6.7- Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 3:1 0.6:0.2 X.05 4,4-Difluoro-3,3-d imethyl1 -(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 3:1 6:2 X.05 4,4-Difluoro-3,3-d imethyl1 -(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 30:1 6:0.2 X.05 4,4-Difluoro-3,3-d imethyl1 -(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 1:3.3 0.6:2 X.05 4,4-Difluoro-3,3-dimethyl- 3:1 0.6:0.2

- 232 046368

1 -(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline X.05 1-(4,5Dimethylbenzimide azol-1yl)-4,4,5-trifluoro-3,3dimethylisoquinoline 3:1 6:2 X.05 1-(4,5Dimethylbenzimide azol-1yl)-4,4,5-trifluoro-3,3dimethylisoquinoline 30:1 6:0.2 X.05 1-(4,5Dimethylbenzimide azol-1yl)-4,4,5-trifluoro-3,3dimethylisoquinoline 1:3.3 0.6:2 X.05 1-(4,5Dimethylbenzimide azol-1yl)-4,4,5-trifluoro-3,3dimethylisoquinoline 3:1 0.6:0.2 X.05 1-(4.5- Dimethylbenzimide azol-1 yl)-4,4-difluoro-3,3 dimethylisoquinoline 3:1 6:2 X.05 1-(4.5- Dimethylbenzimide azol-1 yl)-4,4-difluoro-3,3 dimethylisoquinoline 30:1 6:0.2 X.05 1-(4.5- Dimethylbenzimide azol-1 yl)-4,4-difluoro-3,3 dimethylisoquinoline 1:3.3 0.6:2

- 233 046368

X.05 1-(4.5- Dimethylbenzimide azol-1 yl)-4,4-difluoro-3,3 dimethylisoquinoline 3:1 0.6:0.2

Component A (connection) Component B A:B ratio Conc, (ppm) (A:B) X.07 Azoxystrobin 3:1 6:2 X.07 Azoxystrobin 30:1 6:0.2 X.07 Azoxystrobin 1:3.3 0.6:2 X.07 Azoxystrobin 3:1 0.6:0.2 X.07 Trifloxystrobin 3:1 6:2 X.07 Trifloxystrobin 30:1 6:0.2 X.07 Trifloxystrobin 1:3.3 0.6:2 X.07 Trifloxystrobin 3:1 0.6:0.2 X.07 Methyltetraprole 3:1 6:2 X.07 Methyltetraprole 30:1 6:0.2 X.07 Methyltetraprole 1:3.3 0.6:2 X.07 Methyltetraprole 3:1 0.6:0.2 X.07 Difenoconazole 1:1 6:6 X.07 Difenoconazole 10:1 6:0.6 X.07 Difenoconazole 1:10 0.6:6 X.07 Difenoconazole 1:1 0.6:0.6 X.07 Hexaconazole 1:1 6:6 X.07 Hexaconazole 10:1 6:0.6 X.07 Hexaconazole 1:10 0.6:6 X.07 Propiconazole 1:1 6:6 X.07 Propiconazole 10:1 6:0.6

- 234 046368

X.07 Propiconazole 1:10 0.6:6 X.07 Prothioconazole 1:1 6:6 X.07 Prothioconazole 10:1 6:0.6 X.07 Prothioconazole 1:10 0.6:6 X.07 Prothioconazole 1:1 0.6:0.6 X.07 Mefentrifluconazole 1:1 6:6 X.07 Mefentrifluconazole 10:1 6:0.6 X.07 Fenpropidine 1:3.3 6:20 X.07 Fenpropidine 3:1 6:2 X.07 Phenpropimorph 1:3.3 6:20 X.07 Phenpropimorph 3:1 6:2 X.07 Fluxapyroxad 3:1 6:2 X.07 Fluxapyroxad 30:1 6:0.2 X.07 Fluopyram 3:1 6:2 X.07 Fluopyram 30:1 6:0.2 X.07 Fluopyram 1:3.3 0.6:2 X.07 Isopyrase 3:1 6:2 X.07 Isopyrase 30:1 6:0.2 X.07 Isopyrase 1:3.3 0.6:2 X.07 Sedaksan 3:1 6:2 X.07 Sedaksan 30:1 6:0.2 X.07 Benzovindiflupir 3:1 6:2 X.07 Benzovindiflupir 30:1 6:0.2 X.07 Benzovindiflupir 1:3.3 0.6:2

- 235 046368

X.07 Pidiflumetofen 3:1 6:2 X.07 Pidiflumetofen 30:1 6:0.2 X.07 Pidiflumetofen 1:3.3 0.6:2 X.07 Pidiflumetofen 3:1 0.6:0.2 X.07 Isoflucipram 3:1 6:2 X.07 Isoflucipram 30:1 6:0.2 X.07 Isoflucipram 1:3.3 0.6:2 X.07 Isoflucipram 3:1 0.6:0.2 X.07 Isofetamide 3:1 6:2 X.07 Isofetamide 30:1 6:0.2 X.07 Pyrapropoin 3:1 6:2 X.07 Pyrapropoin 30:1 6:0.2 X.07 Pyrapropoin 1:3.3 0.6:2 X.07 Pyrapropoin 3:1 0.6:0.2 X.07 Fluindapir 3:1 6:2 X.07 Fluindapir 30:1 6:0.2 X.07 Phenpicoxamide 1:1 6:6 X.07 Phenpicoxamide 10:1 6:0.6 X.07 Phenpicoxamide 1:10 0.6:6 X.07 Florylpicoxamide 3:1 6:2 X.07 Florylpicoxamide 30:1 6:0.2 X.07 Chlorothalonil 1:1 6:6 X.07 Chlorothalonil 10:1 6:0.6 X.07 Mankozeb 1:1 6:6

- 236 046368

X.07 Mandipropamide 1:3.3 6:20 X.07 Mandipropamide 1:1 6:6 X.07 Oxathiapiproline 1:3.3 6:20 X.07 Oxathiapiproline 1:1 6:6 X.07 Fluazinam 3:1 6:2 X.07 Fluazinam 30:1 6:0.2 X.07 Fluazinam 1:3.3 0.6:2 X.07 Fluazinam 3:1 0.6:0.2 X.07 Fludioxonil 1:1 6:6 X.07 Fludioxonil 10:1 6:0.6 X.07 Fludioxonil 1:10 0.6:6 X.07 Cyprodinil 1:1 6:6 X.07 Cyprodinil 10:1 6:0.6 X.07 Cyprodinil 1:10 0.6:6 X.07 Cyprodinil 1:1 0.6:0.6 X.07 Metalaxyl-M 1:3.3 6:20 X.07 Metalaxyl-M 1:1 6:6 X.07 Aminopyrifene 3:1 6:2 X.07 Aminopyrifene 30:1 6:0.2 X.07 Folpet 1:1 6:6 X.07 Folpet 3:1 6:2 X.07 Ipflufenoquin 3:1 6:2 X.07 Ipflufenoquin 30:1 6:0.2 X.07 Ipflufenoquin 1:3.3 0.6:2

- 237 046368

X.07 Ipflufenoquin 3:1 0.6:0.2 X.07 Quinofumelin 3:1 6:2 X.07 Quinofumelin 30:1 6:0.2 X.07 Quinofumelin 1:3.3 0.6:2 X.07 Quinofumelin 3:1 0.6:0.2 X.07 Tricyclic azole 1:3.3 6:20 X.07 Tricyclic azole 1:1 6:6 X.07 Pyroquilon 1:3.3 6:20 X.07 Pyroquilon 1:1 6:6 X.07 PM-(1-Benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 3:1 6:2 X.07 X-(1-Benzyl-1,3dimethylbutyl)-8fluoroquinoline-3carboxamide 30:1 6:0.2 X.07 X-(1-Benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 1:3.3 0.6:2 X.07 X-(1-Benzyl-3,3,3trifluoro-1methylpropyl)-8fluoroquinoline-3 carboxamide 3:1 6:2 X.07 X-(1-Benzyl-3,3,3trifluoro-1- 30:1 6:0.2

- 238 046368

methylpropyl)-8fluoroquinoline-3carboxamide X.07 X-(1-Benzyl-3,3,3trifluoro-1methylpropyl)-8fluoroquinoline-3carboxamide 1:3.3 0.6:2 X.07 1-(6,7Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 3:1 6:2 X.07 1-(6.7- Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 30:1 6:0.2 X.07 1-(6.7- Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 1:3.3 0.6:2 X.07 1-(6.7- Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 3:1 0.6:0.2 X.07 4,4-Difluoro-3,3-d and methyl1-(7-methylpyrazolo[1,5а]pyridine-3- 3:1 6:2

- 239 046368

yl)isoquinoline X.07 4,4-Difluoro-3,3-d-imethyl1 -(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 30:1 6:0.2 X.07 4,4-Difluoro-3,3-d imethyl1 -(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 1:3.3 0.6:2 X.07 1-(4,5Dimethylbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 3:1 6:2 X.07 1-(4,5Dimethylbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 30:1 6:0.2 X.07 1-(4,5Dimethylbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 1:3.3 0.6:2 X.07 1-(4,5Dimethylbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 3:1 0.6:0.2 X.07 1-(4.5- Dimethylbenzimide azol-1 yl)-4,4-difluoro-3,3 dimethylisoquinoline 3:1 6:2 X.07 1-(4.5- Dimethylbenzimide azole-1 - 30:1 6:0.2

- 240 046368

yl)-4,4-difluoro-3,3 - dimethylisoquinoline X.07 1-(4.5- Dimethylbenzimide azol-1 yl)-4,4-difluoro-3,3 dimethylisoquinoline 1:3.3 0.6:2 X.07 1-(4.5- Dimethylbenzimide azol-1 yl)-4,4-difluoro-3,3 dimethylisoquinoline 3:1 0.6:0.2

Component A (connection) Component B A:B ratio Conc, (ppm) (A:B) X.14 Azoxystrobin 3:1 6:2 X.14 Azoxystrobin 30:1 6:0.2 X.14 Azoxystrobin 1:3.3 0.6:2 X.14 Azoxystrobin 3:1 0.6:0.2 X.14 Trifloxystrobin 3:1 6:2 X.14 Trifloxystrobin 30:1 6:0.2 X.14 Trifloxystrobin 1:3.3 0.6:2 X.14 Trifloxystrobin 3:1 0.6:0.2 X.14 Methyltetraprole 3:1 6:2 X.14 Methyltetraprole 30:1 6:0.2 X.14 Methyltetraprole 1:3.3 0.6:2 X.14 Methyltetraprole 3:1 0.6:0.2 X.14 Difenoconazole 1:1 6:6 X.14 Difenoconazole 10:1 6:0.6 X.14 Difenoconazole 1:10 0.6:6 X.14 Hexaconazole 1:1 6:6

- 241 046368

X.14 Hexaconazole 1:10 0.6:6 X.14 Propiconazole 1:1 6:6 X.14 Propiconazole 1:10 0.6:6 X.14 Prothioconazole 1:1 6:6 X.14 Prothioconazole 10:1 6:0.6 X.14 Prothioconazole 1:10 0.6:6 X.14 Prothioconazole 1:1 0.6:0.6 X.14 Fluopyram 3:1 6:2 X.14 Isopyrase 3:1 6:2 X.14 Isopyrase 1:3.3 0.6:2 X.14 Benzovindiflupir 3:1 6:2 X.14 Benzovindiflupir 1:3.3 0.6:2 X.14 Pidiflumetofen 3:1 6:2 X.14 Pidiflumetofen 30:1 6:0.2 X.14 Pidiflumetofen 1:3.3 0.6:2 X.14 Pidiflumetofen 3:1 0.6:0.2 X.14 Isoflucipram 3:1 6:2 X.14 Isoflucipram 30:1 6:0.2 X.14 Isoflucipram 1:3.3 0.6:2 X.14 Pyrapropoin 3:1 6:2 X.14 Pyrapropoin 30:1 6:0.2 X.14 Pyrapropoin 1:3.3 0.6:2 X.14 Phenpicoxamide 1:1 6:6 X.14 Phenpicoxamide 1:10 0.6:6

- 242 046368

X.14 Fluazinam 3:1 6:2 X.14 Fluazinam 30:1 6:0.2 X.14 Fluazinam 1:3.3 0.6:2 X.14 Fluazinam 3:1 0.6:0.2 X.14 Fludioxonil 1:1 6:6 X.14 Fludioxonil 10:1 6:0.6 X.14 Fludioxonil 1:10 0.6:6 X.14 Cyprodinil 1:1 6:6 X.14 Cyprodinil 10:1 6:0.6 X.14 Cyprodinil 1:10 0.6:6 X.14 Cyprodinil 1:1 0.6:0.6 X.14 Ipflufenoquin 3:1 6:2 X.14 Ipflufenoquin 30:1 6:0.2 X.14 Quinofumelin 3:1 6:2 X.14 Quinofumelin 30:1 6:0.2 X.14 T4-(1-Benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 3:1 6:2 X.14 T4-(1-Benzyl-3,3,3trifluoro-1methylpropyl)-8fluoroquinoline-3 carboxamide 3:1 6:2 X.14 1-(6.7- 3:1 6:2

- 243 046368

Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline X.14 1-(6.7- Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 30:1 6:0.2 X.14 4,4-Difluoro-3,3-d imethyl1 -(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 3:1 6:2 X.14 4,4-Difluoro-3,3-d imethyl1 -(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 30:1 6:0.2 X.14 1-(4,5Dimethylbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 3:1 6:2 X.14 1-(4,5Dimethylbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 30:1 6:0.2 X.14 1-(4.5- Dimethylbenzimide azol-1 yl)-4,4-difluoro-3,3 dimethylisoquinoline 3:1 6:2 X.14 1-(4.5- 30:1 6:0.2

Dimethylbenzimidazol-1yl)-4,4-difluoro-3,3 dimethyl from oquinol

Example B9. Activity against Alternaria solani (tomato/potato Alternaria blight)

Fungal conidia from cryogenic storage were directly mixed with nutrient broth (potato dextrose broth, PDB). A solution of test compounds in DMSO was added to a microtiter plate (96-well format) and nutrient broth containing fungal spores was added. Plates of test compounds were incubated at 24°C and growth inhibition was determined photometrically after 48 hours. The following mixture formulations (A:B) at the indicated concentration (in ppm) provided at least 70% disease control in this test.

- 244 046368

Component A (connection) Component B A:B ratio Conc, (ppm) (A:B) X.05 Azoxystrobin 3:1 6:2 X.05 Azoxystrobin 30:1 6:0.2 X.05 Azoxystrobin 1:3.3 0.6:2 X.05 Azoxystrobin 3:1 0.6:0.2 X.05 Trifloxystrobin 3:1 6:2 X.05 Trifloxystrobin 30:1 6:0.2 X.05 Trifloxystrobin 1:3.3 0.6:2 X.05 Trifloxystrobin 3:1 0.6:0.2 X.05 Methyltetraprole 3:1 6:2 X.05 Methyltetraprole 30:1 6:0.2 X.05 Methyltetraprole 1:3.3 0.6:2 X.05 Difenoconazole 1:1 6:6 X.05 Difenoconazole 10:1 6:0.6 X.05 Difenoconazole 1:10 0.6:6

- 245 046368

X.05 Hexaconazole 1:1 6:6 X.05 Hexaconazole 10:1 6:0.6 X.05 Hexaconazole 1:10 0.6:6 X.05 Propiconazole 1:1 6:6 X.05 Propiconazole 10:1 6:0.6 X.05 Propiconazole 1:10 0.6:6 X.05 Propiconazole 1:1 0.6:0.6 X.05 Prothioconazole 1:1 6:6 X.05 Prothioconazole 10:1 6:0.6 X.05 Prothioconazole 1:10 0.6:6 X.05 Mefentrifluconazole 1:1 6:6 X.05 Mefentrifluconazole 10:1 6:0.6 X.05 Mefentrifluconazole 1:10 0.6:6 X.05 Mefentrifluconazole 1:1 0.6:0.6 X.05 Fenpropidine 1:3.3 6:20 X.05 Fenpropidine 3:1 6:2 X.05 Phenpropimorph 1:3.3 6:20 X.05 Phenpropimorph 3:1 6:2 X.05 Phenpropimorph 1:33.3 0.6:20 X.05 Fluxapyroxad 3:1 6:2 X.05 Fluxapyroxad 30:1 6:0.2 X.05 Fluopyram 3:1 6:2 X.05 Fluopyram 30:1 6:0.2 X.05 Fluopyram 1:3.3 0.6:2 X.05 Fluopyram 3:1 0.6:0.2

- 246 046368

X.05 Isopyrase 3:1 6:2 X.05 Isopyrase 30:1 6:0.2 X.05 Isopyrase 1:3.3 0.6:2 X.05 Isopyrase 3:1 0.6:0.2 X.05 Sedaksan 3:1 6:2 X.05 Sedaksan 30:1 6:0.2 X.05 Sedaksan 1:3.3 0.6:2 X.05 Benzovindiflupir 3:1 6:2 X.05 Benzovindiflupir 30:1 6:0.2 X.05 Benzovindiflupir 1:3.3 0.6:2 X.05 Benzovindiflupir 3:1 0.6:0.2 X.05 Pidiflumetofen 3:1 6:2 X.05 Pidiflumetofen 30:1 6:0.2 X.05 Pidiflumetofen 1:3.3 0.6:2 X.05 Pidiflumetofen 3:1 0.6:0.2 X.05 Isoflucipram 3:1 6:2 X.05 Isoflucipram 30:1 6:0.2 X.05 Isoflucipram 1:3.3 0.6:2 X.05 Isoflucipram 3:1 0.6:0.2 X.05 Isofetamide 3:1 6:2 X.05 Isofetamide 30:1 6:0.2 X.05 Isofetamide 1:3.3 0.6:2 X.05 Pyrapropoin 3:1 6:2 X.05 Pyrapropoin 30:1 6:0.2 X.05 Pyrapropoin 1:3.3 0.6:2 X.05 Pyrapropoin 3:1 0.6:0.2

- 247 046368

X.05 Fluindapir 3:1 6:2 X.05 Fluindapir 30:1 6:0.2 X.05 Fluindapir 1:3.3 0.6:2 X.05 Phenpicoxamide 1:1 6:6 X.05 Phenpicoxamide 1:10 0.6:6 X.05 Florylpicoxamide 3:1 6:2 X.05 Chlorothalonil 1:1 6:6 X.05 Chlorothalonil 10:1 6:0.6 X.05 Chlorothalonil 1:10 0.6:6 X.05 Mankozeb 1:3.3 6:20 X.05 Mankozeb 1:1 6:6 X.05 Mandipropamide 1:3.3 6:20 X.05 Mandipropamide 1:1 6:6 X.05 Oxathiapiproline 1:3.3 6:20 X.05 Oxathiapiproline 1:1 6:6 X.05 Fluazinam 3:1 6:2 X.05 Fluazinam 30:1 6:0.2 X.05 Fluazinam 1:3.3 0.6:2 X.05 Fludioxonil 1:1 6:6 X.05 Fludioxonil 10:1 6:0.6 X.05 Fludioxonil 1:10 0.6:6 X.05 Fludioxonil 1:1 0.6:0.6 X.05 Cyprodinil 1:1 6:6

- 248 046368

X.05 Cyprodinil 10:1 6:0.6 X.05 Cyprodinil 1:10 0.6:6 X.05 Cyprodinil 1:1 0.6:0.6 X.05 Metalaxyl-M 1:3.3 6:20 X.05 Metalaxyl-M 1:1 6:6 X.05 Metalaxyl-M 1:33.3 0.6:20 X.05 Metalaxyl-M 1:10 0.6:6 X.05 Aminopyrifene 3:1 6:2 X.05 Aminopyrifene 30:1 6:0.2 X.05 Folpet 1:1 6:6 X.05 Folpet 3:1 6:2 X.05 Folpet 1:10 0.6:6 X.05 Ipflufenoquin 3:1 6:2 X.05 Ipflufenoquin 30:1 6:0.2 X.05 Ipflufenoquin 1:3.3 0.6:2 X.05 Ipflufenoquin 3:1 0.6:0.2 X.05 Quinofumelin 3:1 6:2 X.05 Quinofumelin 30:1 6:0.2 X.05 Quinofumelin 1:3.3 0.6:2 X.05 Quinofumelin 3:1 0.6:0.2 X.05 Tricyclic azole 1:3.3 6:20 X.05 Tricyclic azole 1:1 6:6 X.05 Tricyclic azole 1:33.3 0.6:20 X.05 Pirokv ILON 1:3.3 6:20 X.05 Pirokv ILON 1:1 6:6 X.05 Pirokv ILON 1:33.3 0.6:20

- 249 046368

X.05 Pirokv ILON 1:10 0.6:6 X.05 X-(1-Benzyl-1,3dimethylbutyl)-8fluoroquinoline-3carboxamide 3:1 6:2 X.05 X-(1-Benzyl-1,3dimethylbutyl)-8fluoroquinoline-3carboxamide 30:1 6:0.2 X.05 X-(1-Benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 1:3.3 0.6:2 X.05 X-(1-Benzyl-1,3dimethylbutyl)-8fluoroquinoline-3carboxamide 3:1 0.6:0.2 X.05 N-(l -Benzyl-3,3,3trifluoro-1methylpropyl)-8fluoroquinoline-3 carboxamide 3:1 6:2 X.05 N-(l-Benzyl-3,3,3trifluoro-1methylpropyl)-8fluoroquinoline-3 carboxamide 30:1 6:0.2 X.05 N-(l-Benzyl-3,3,3trifluoro-1methylpropyl)-8fluoroquinoline-3- 1:3.3 0.6:2

- 250 046368

carboxamide X.05 X-(1-Benzyl-3,3,3trifluoro-1methylpropyl)-8fluoroquinoline-3carboxamide 3:1 0.6:0.2 X.05 1-(6.7- Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 3:1 6:2 X.05 1-(6.7- Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 30:1 6:0.2 X.05 1-(6.7- Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 1:3.3 0.6:2 X.05 1-(6.7- Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 3:1 0.6:0.2 X.05 4,4-Difluoro-3, 3-d imethyl1 -(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 3:1 6:2 X.05 4,4-Difluoro-3, 3-dimethyl- 30:1 6:0.2

- 251 046368

1 -(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline X.05 4,4-Difluoro-3, 3-d imethyl1 -(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 1:3.3 0.6:2 X.05 4,4-Difluoro-3, 3-d imethyl1 -(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 3:1 0.6:0.2 X.05 1-(4,5Dimethylbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 3:1 6:2 X.05 1-(4,5Dimethylbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 30:1 6:0.2 X.05 1-(4,5Dimethylbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 1:3.3 0.6:2 X.05 1-(4,5Dimethylbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 3:1 0.6:0.2 X.05 1-(4.5- Dimethylbenzimide azol-1 yl)-4,4-difluoro-3,3 dimethylisoquinoline 3:1 6:2

- 252 046368

X.05 1-(4.5- Dimethylbenzimide azol-1 yl)-4,4-difluoro-3,3 dimethylisoquinoline 30:1 6:0.2 X.05 1-(4.5- Dimethylbenzimide azol-1 yl)-4,4-difluoro-3,3 dimethylisoquinoline 1:3.3 0.6:2 X.05 1-(4.5- Dimethylbenzimide azol-1 yl)-4,4-difluoro-3,3 dimethylisoquinoline 3:1 0.6:0.2

Component A (connection) Component B A:B ratio Conc, (ppm) (A:B) X.07 Azoxystrobin 3:1 6:2 X.07 Azoxystrobin 30:1 6:0.2 X.07 Azoxystrobin 1:3.3 0.6:2 X.07 Azoxystrobin 3:1 0.6:0.2 X.07 Trifloxystrobin 3:1 6:2 X.07 Trifloxystrobin 30:1 6:0.2 X.07 Trifloxystrobin 1:3.3 0.6:2 X.07 Methyltetraprole 3:1 6:2 X.07 Methyltetraprole 30:1 6:0.2 X.07 Methyltetraprole 1:3.3 0.6:2 X.07 Difenoconazole 1:1 6:6 X.07 Difenoconazole 10:1 6:0.6 X.07 Difenoconazole 1:10 0.6:6 X.07 Hexaconazole 1:1 6:6

- 253 046368

X.07 Hexaconazole 10:1 6:0.6 X.07 Hexaconazole 1:10 0.6:6 X.07 Propiconazole 1:1 6:6 X.07 Propiconazole 10:1 6:0.6 X.07 Propiconazole 1:10 0.6:6 X.07 Prothioconazole 1:1 6:6 X.07 Prothioconazole 10:1 6:0.6 X.07 Prothioconazole 1:10 0.6:6 X.07 Mefentrifluconazole 1:1 6:6 X.07 Mefentrifluconazole 10:1 6:0.6 X.07 Mefentrifluconazole 1:10 0.6:6 X.07 Fenpropidine 1:3.3 6:20 X.07 Fenpropidine 3:1 6:2 X.07 Fenpropidine 1:33.3 0.6:20 X.07 Phenpropimorph 1:3.3 6:20 X.07 Phenpropimorph 3:1 6:2 X.07 Fluxapyroxad 3:1 6:2 X.07 Fluxapyroxad 30:1 6:0.2 X.07 Fluopyram 3:1 6:2 X.07 Fluopyram 30:1 6:0.2 X.07 Fluopyram 1:3.3 0.6:2 X.07 Fluopyram 3:1 0.6:0.2 X.07 Isopyrase 3:1 6:2 X.07 Isopyrase 30:1 6:0.2 X.07 Isopyrase 1:3.3 0.6:2

- 254 046368

X.07 Isopyrase 3:1 0.6:0.2 X.07 Sedaksan 3:1 6:2 X.07 Sedaksan 30:1 6:0.2 X.07 Sedaksan 1:3.3 0.6:2 X.07 Benzovindiflupir 3:1 6:2 X.07 Benzovindiflupir 30:1 6:0.2 X.07 Benzovindiflupir 1:3.3 0.6:2 X.07 Benzovindiflupir 3:1 0.6:0.2 X.07 Pidiflumetofen 3:1 6:2 X.07 Pidiflumetofen 30:1 6:0.2 X.07 Pidiflumetofen 1:3.3 0.6:2 X.07 Pidiflumetofen 3:1 0.6:0.2 X.07 Isoflucipram 3:1 6:2 X.07 Isoflucipram 30:1 6:0.2 X.07 Isoflucipram 1:3.3 0.6:2 X.07 Isoflucipram 3:1 0.6:0.2 X.07 Isofetamide 3:1 6:2 X.07 Isofetamide 30:1 6:0.2 X.07 Isofetamide 1:3.3 0.6:2 X.07 Pyrapropoin 3:1 6:2 X.07 Pyrapropoin 30:1 6:0.2 X.07 Pyrapropoin 1:3.3 0.6:2 X.07 Pyrapropoin 3:1 0.6:0.2 X.07 Fluindapir 3:1 6:2 X.07 Fluindapir 30:1 6:0.2 X.07 Fluindapir 1:3.3 0.6:2

- 255 046368

X.07 Phenpicoxamide 1:1 6:6 X.07 Phenpicoxamide 10:1 6:0.6 X.07 Florylpicoxamide 3:1 6:2 X.07 Florylpicoxamide 30:1 6:0.2 X.07 Chlorothalonil 1:1 6:6 X.07 Chlorothalonil 10:1 6:0.6 X.07 Mankozeb 1:3.3 6:20 X.07 Mankozeb 1:1 6:6 X.07 Mandipropamide 1:3.3 6:20 X.07 Mandipropamide 1:1 6:6 X.07 Oxathiapiproline 1:3.3 6:20 X.07 Oxathiapiproline 1:1 6:6 X.07 Fluazinam 3:1 6:2 X.07 Fluazinam 30:1 6:0.2 X.07 Fluazinam 1:3.3 0.6:2 X.07 Fludioxonil 1:1 6:6 X.07 Fludioxonil 10:1 6:0.6 X.07 Fludioxonil 1:10 0.6:6 X.07 Fludioxonil 1:1 0.6:0.6 X.07 Cyprodinil 1:1 6:6 X.07 Cyprodinil 10:1 6:0.6 X.07 Cyprodinil 1:10 0.6:6 X.07 Cyprodinil 1:1 0.6:0.6

- 256 046368

X.07 Metalaxyl-M 1:3.3 6:20 X.07 Metalaxyl-M 1:1 6:6 X.07 Metalaxyl-M 1:33.3 0.6:20 X.07 Metalaxyl-M 1:10 0.6:6 X.07 Aminopyrifene 3:1 6:2 X.07 Aminopyrifene 30:1 6:0.2 X.07 Folpet 1:1 6:6 X.07 Folpet 3:1 6:2 X.07 Ipflufenoquin 3:1 6:2 X.07 Ipflufenoquin 30:1 6:0.2 X.07 Ipflufenoquin 1:3.3 0.6:2 X.07 Ipflufenoquin 3:1 0.6:0.2 X.07 Quinofumelin 3:1 6:2 X.07 Quinofumelin 30:1 6:0.2 X.07 Quinofumelin 1:3.3 0.6:2 X.07 Quinofumelin 3:1 0.6:0.2 X.07 Tricyclic azole 1:3.3 6:20 X.07 Tricyclic azole 1:1 6:6 X.07 Tricyclic azole 1:33.3 0.6:20 X.07 Pirokv ILON 1:3.3 6:20 X.07 Pirokv ILON 1:1 6:6 X.07 X-(1-Benzyl-1,3dimethylbutyl)-8fluoroquinoline-3carboxamide 3:1 6:2 X.07 X-(1-Benzyl-1,3- 30:1 6:0.2

- 257 046368

dimethylbutyl)-8fluoroquinoline-3carboxamide X.07 X-(1-Benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 1:3.3 0.6:2 X.07 X-(1-Benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 3:1 0.6:0.2 X.07 X-(1-Benzyl-3,3,3trifluoro-1methylpropyl)-8fluoroquinoline-3 carboxamide 3:1 6:2 X.07 N-(l -Benzyl-3,3,3trifluoro-1methylpropyl)-8fluoroquinoline-3carboxamide 30:1 6:0.2 X.07 N-(l-Benzyl-3,3,3trifluoro-1methylpropyl)-8fluoroquinoline-3 carboxamide 1:3.3 0.6:2 X.07 X-(1-Benzyl-3,3,3trifluoro-1methylpropyl)-8fluoroquinoline-3carboxamide 3:1 0.6:0.2

- 258 046368

X.07 1-(6.7- Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 3:1 6:2 X.07 1-(6.7- Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 30:1 6:0.2 X.07 1-(6.7- Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 1:3.3 0.6:2 X.07 1-(6.7- Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 3:1 0.6:0.2 X.07 4,4-Difluoro-3, 3-d-methyl1 -(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 3:1 6:2 X.07 4,4-Difluoro-3, 3-d imethyl1 -(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 30:1 6:0.2 X.07 4,4-Difluoro-3, 3-d methyl1 -(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 1:3.3 0.6:2

- 259 046368

X.07 4,4-Difluoro-3,3-d imethyl1 -(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 3:1 0.6:0.2 X.07 1-(4,5Dimethylbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 3:1 6:2 X.07 1-(4,5Dimethylbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 30:1 6:0.2 X.07 1-(4,5Dimethylbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 1:3.3 0.6:2 X.07 1-(4,5Dimethylbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 3:1 0.6:0.2 X.07 1-(4.5- Dimethylbenzimide azol-1 yl)-4,4-difluoro-3,3 dimethylisoquinoline 3:1 6:2 X.07 1-(4.5- Dimethylbenzimide azol-1 yl)-4,4-difluoro-3,3 dimethylisoquinoline 30:1 6:0.2 X.07 1-(4.5- Dimethylbenzimide azol-1 yl)-4,4-difluoro-3,3 - 1:3.3 0.6:2

- 260 046368

- 261 046368

X.14 Isopyrase 3:1 6:2 X.14 Isopyrase 1:3.3 0.6:2 X.14 Benzovindiflupir 3:1 6:2 X.14 Benzovindiflupir 1:3.3 0.6:2 X.14 Pidiflumetofen 3:1 6:2 X.14 Pidiflumetofen 30:1 6:0.2 X.14 Pidiflumetofen 1:3.3 0.6:2 X.14 Pidiflumetofen 3:1 0.6:0.2 X.14 Isoflucipram 3:1 6:2 X.14 Isoflucipram 30:1 6:0.2 X.14 Isoflucipram 1:3.3 0.6:2 X.14 Isoflucipram 3:1 0.6:0.2 X.14 Pyrapropoin 3:1 6:2 X.14 Pyrapropoin 30:1 6:0.2 X.14 Pyrapropoin 1:3.3 0.6:2 X.14 Pyrapropoin 3:1 0.6:0.2 X.14 Phenpicoxamide 1:1 6:6 X.14 Phenpicoxamide 10:1 6:0.6 X.14 Phenpicoxamide 1:10 0.6:6 X.14 Florylpicoxamide 3:1 6:2 X.14 Fluazinam 3:1 6:2 X.14 Fluazinam 1:3.3 0.6:2 X.14 Fludioxonil 1:1 6:6 X.14 Fludioxonil 1:10 0.6:6

- 262 046368

X.14 Cyprodinil 1:1 6:6 X.14 Cyprodinil 10:1 6:0.6 X.14 Cyprodinil 1:10 0.6:6 X.14 Cyprodinil 1:1 0.6:0.6 X.14 Metalaxyl-M 1:3.3 6:20 X.14 Ipflufenoquin 3:1 6:2 X.14 Ipflufenoquin 30:1 6:0.2 X.14 Ipflufenoquin 1:3.3 0.6:2 X.14 Quinofumelin 3:1 6:2 X.14 Quinofumelin 30:1 6:0.2 X.14 Quinofumelin 1:3.3 0.6:2 X.14 X-(1-Benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 3:1 6:2 X.14 X-(1-Benzyl-1,3- dimethylbutyl)-8fluoroquinoline-3 carboxamide 30:1 6:0.2 X.14 X-(1-Benzyl-1,3dimethylbutyl)-8fluoroquinoline-3carboxamide 1:3.3 0.6:2 X.14 N-(l-Benzyl-3,3,3trifluoro-1methylpropyl)-8fluoroquinoline-3- 3:1 6:2

- 263 046368

carboxamide X.14 T4-(1-Benzyl-3,3,3trifluoro-1methylpropyl)-8fluoroquinoline-3 carboxamide 30:1 6:0.2 X.14 N-(l -Benzyl-3,3,3trifluoro-1methylpropyl)-8fluoroquinoline-3carboxamide 1:3.3 0.6:2 X.14 1-(6.7- Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 3:1 6:2 X.14 1-(6,7Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 30:1 6:0.2 X.14 1-(6.7- Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 1:3.3 0.6:2 X.14 1-(6.7- Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 3:1 0.6:0.2

- 264 046368

X.14 4,4-Difluoro-3,3-d imethyl1 -(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 3:1 6:2 X.14 X.14 X.14 X.14 X.14 X.14 X.14 4,4-Difluoro-3,3-d imethyl1 -(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 4,4-Difluoro-3,3-d imethyl1 -(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 1-(4.5- Dimethylbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 1-(4,5- Dimethylbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 1-(4,5- Dimethylbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 1-(4,5- Dimethylbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 1-(4.5- Dimethylbenzimide azol-1 yl)-4,4-difluoro-3,3 - dimethylisoquinoline 30:1 1:3.3 3:1 30:1 1:3.3 3:1 3:1 6:0.2 0.6:2 6:2 6:0.2 0.6:2 0.6:0.2 6:2 X.14 1-(4.5- Dimethylbenzimide azol-1 yl)-4,4-difluoro-3,3 dimethylisoquinoline 30:1 6:0.2 X.14 1-(4.5- Dimethylbenzimide azol-1 yl)-4,4-difluoro-3,3 dimethylisoquinoline 1:3.3 0.6:2 X.14 1-(4.5- Dimethylbenzimide azol-1 yl)-4,4-difluoro-3,3 dimethylisoquinoline 3:1 0.6:0.2

Example B10. Treatment of liquid culture of Sclerotinia sclerotiorum I (white rot)

Mycelial fragments of a newly grown fungal culture in liquid medium were directly mixed with nutrient broth (Minimal Vogel Media) containing 200 μmol of SHAM. After

- 265 046368 adding a solution (DMSO) of the test compounds to a microtiter plate (96-well format), a nutrient broth containing fungal material was added. The test compound plates were incubated at 24°C and growth inhibition was determined photometrically 3-4 days after application. The following mixture-based formulations (A:B) at the indicated concentration (in ppm) provided at least 80% disease control in this test compared to the untreated control, which showed extensive disease development under the same conditions.

Component Conc, (ppm) A Component B A:B ratio (A:B) (compound) X.05 Azoxystrobin 3.3:1 20:6 X.05 Azoxystrobin 33.3:1 20:0.6 X.05 Azoxystrobin 1:3 2:6 X.05 Azoxystrobin 3.3:1 2:0.6 X.05 Trifloxystrobin 3.3:1 20:6 X.05 Trifloxystrobin 33.3:1 20:0.6 X.05 Trifloxystrobin 1:3 2:6 X.05 Trifloxystrobin 3.3:1 2:0.6 X.05 Methyltetraprole 3.3:1 20:6 X.05 Methyltetraprole 33.3:1 20:0.6 X.05 Methyltetraprole 1:3 2:6 X.05 Methyltetraprole 3.3:1 2:0.6 X.05 Difenoconazole 3.3:1 20:6 X.05 Difenoconazole 33.3:1 20:0.6 X.05 Difenoconazole 1:3 2:6 X.05 Difenoconazole 3.3:1 2:0.6 X.05 Hexaconazole 3.3:1 20:6 X.05 Hexaconazole 33.3:1 20:0.6 X.05 Hexaconazole 1:3 2:6 X.05 Hexaconazole 3.3:1 2:0.6 X.05 Propiconazole 3.3:1 20:6 X.05 Propiconazole 33.3:1 20:0.6 X.05 Propiconazole 1:3 2:6 X.05 Propiconazole 3.3:1 2:0.6 X.05 Prothioconazole 3.3:1 20:6 X.05 Prothioconazole 33.3:1 20:0.6 X.05 Prothioconazole 1:3 2:6 X.05 Prothioconazole 3.3:1 2:0.6 X.05 Mefentrifluconazole 3.3:1 20:6 X.05 Mefentrifluconazole 33.3:1 20:0.6 X.05 Mefentrifluconazole 1:3 2:6

- 266 046368

X.05 Mefentrifluconazole 3.3:1 2:0.6 X.05 Fenpropidine 1:1 20:20 X.05 Fenpropidine 3.3:1 20:6 X.05 Fenpropidine 1:10 2:20 X.05 Fenpropidine 1:3 2:6 X.05 Phenpropimorph 1:1 20:20 X.05 Phenpropimorph 3.3:1 20:6 X.05 Phenpropimorph 1:10 2:20 X.05 Phenpropimorph 1:3 2:6 X.05 Fluxapyroxad 3.3:1 20:6 X.05 Fluxapyroxad 33.3:1 20:0.6 X.05 Fluxapyroxad 1:3 2:6 X.05 Fluxapyroxad 3.3:1 2:0.6 X.05 Fluopyram 3.3:1 20:6 X.05 Fluopyram 33.3:1 20:0.6 X.05 Fluopyram 1:3 2:6 X.05 Fluopyram 3.3:1 2:0.6 X.05 Benzovindiflupir 3.3:1 20:6 X.05 Benzovindiflupir 33.3:1 20:0.6 X.05 Benzovindiflupir 1:3 2:6 X.05 Benzovindiflupir 3.3:1 2:0.6 X.05 Pid if lu metof her 3.3:1 20:6 X.05 Pid if lu metof her 33.3:1 20:0.6 X.05 Pid iflu metof her 1:3 2:6 X.05 Pid iflu metof her 3.3:1 2:0.6 X.05 Isoflucipram 3.3:1 20:6

- 267 046368

X.05 Isoflucipram 33.3:1 20:0.6 X.05 Isoflucipram 1:3 2:6 X.05 Isoflucipram 3.3:1 2:0.6 X.05 Fluindapir 3.3:1 20:6 X.05 Fluindapir 33.3:1 20:0.6 X.05 Fluindapir 1:3 2:6 X.05 Fluindapir 3.3:1 2:0.6 X.05 Florylpicoxamide 3.3:1 20:6 X.05 Florylpicoxamide 33.3:1 20:0.6 X.05 Florylpicoxamide 1:3 2:6 X.05 Florylpicoxamide 3.3:1 2:0.6 X.05 Metharylpicoxamide 3.3:1 20:6 X.05 Metharylpicoxamide 33.3:1 20:0.6 X.05 Metharylpicoxamide 1:3 2:6 X.05 Metharylpicoxamide 3.3:1 2:0.6 X.05 Chlorothalonil 3.3:1 20:6 X.05 Chlorothalonil 33.3:1 20:0.6 X.05 Chlorothalonil 1:3 2:6 X.05 Chlorothalonil 3.3:1 2:0.6 X.05 Mankozeb 1:1 20:20 X.05 Mankozeb 3.3:1 20:6 X.05 Mankozeb 1:10 2:20 X.05 Mankozeb 1:3 2:6 X.05 Mandipropamide 1:1 20:20 X.05 Mandipropamide 3.3:1 20:6 X.05 Mandipropamide 1:10 2:20 X.05 Mandipropamide 1:3 2:6

- 268 046368

X.05 Oxathiapiproline 1:1 20:20 X.05 Oxathiapiproline 3.3:1 20:6 X.05 Oxathiapiproline 1:10 2:20 X.05 Oxathiapiproline 1:3 2:6 X.05 Fluazinam 3.3:1 20:6 X.05 Fluazinam 33.3:1 20:0.6 X.05 Fluazinam 1:3 2:6 X.05 Fluazinam 3.3:1 2:0.6 X.05 Fludioxonil 3.3:1 20:6 X.05 Fludioxonil 33.3:1 20:0.6 X.05 Fludioxonil 1:3 2:6 X.05 Fludioxonil 3.3:1 2:0.6 X.05 Cyprodinil 3.3:1 20:6 X.05 Cyprodinil 33.3:1 20:0.6 X.05 Cyprodinil 1:3 2:6 X.05 Cyprodinil 3.3:1 2:0.6 X.05 Metalaxyl-M 1:1 20:20 X.05 Metalaxyl-M 3.3:1 20:6 X.05 Metalaxyl-M 1:10 2:20 X.05 Metalaxyl-M 1:3 2:6 X.05 Folpet 3.3:1 20:6 X.05 Folpet 10:1 20:2 X.05 Folpet 1:3 2:6 X.05 Folpet 1:1 2:2 X.05 Aminopyrifene 3.3:1 20:6 X.05 Aminopyrifene 33.3:1 20:0.6

- 269 046368

X.05 Aminopyrifene 1:3 2:6 X.05 Aminopyrifene 3.3:1 2:0.6 X.05 X-(1-Benzyl-1,3dimethylbutyl)-8fluoroquinoline-3carboxamide 3.3:1 20:6 X.05 X-(1-Benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 33.3:1 20:0.6 X.05 X-(1-Benzyl-1,3- dimethylbutyl)-8fluoroquinoline-3carboxamide 1:3 2:6 X.05 X-(1-Benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 3.3:1 2:0.6 X.05 N-(1-Benzyl-3,3,3 trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide 3.3:1 20:6 X.05 N-(1-Benzyl-3,3,3 trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide 33.3:1 20:0.6 X.05 X-(1-Benzyl-3,3,3trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide 1:3 2:6 X.05 X-(1-Benzyl-3,3,3- 3.3:1 2:0.6

- 270 046368

trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide X.05 1-(6.7- Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 3.3:1 20:6 X.05 1-(6.7- Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 33.3:1 20:0.6 X.05 1-(6.7- Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 1:3 2:6 X.05 1-(6.7- Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 3.3:1 2:0.6 X.05 4,4-Difluoro-3,3-d imethyl1 -(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 3.3:1 20:6 X.05 4,4-Difluoro-3,3-d imethyl1 -(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 33.3:1 20:0.6

- 271 046368

X.05 4,4-Difluoro-3,3-d-imethyl1-(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 1:3 2:6 X.05 4,4-Difluoro-3,3-d imethyl1 -(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 3.3:1 2:0.6 X.05 1-(4.5- Dimethylbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 3.3:1 20:6 X.05 1-(4.5- Dimethylbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 33.3:1 20:0.6 X.05 1-(4.5- Dimethylbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 1:3 2:6 X.05 1-(4.5- Dimethylbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 3.3:1 2:0.6 X.05 1-(4.5- Dimethylbenzimide azol-1yl)-4,4-difluoro-3,3dimethylisoquinoline 3.3:1 20:6 X.05 1-(4.5- Dimethylbenzimide azol-1 yl)-4,4-difluoro-3,3- 33.3:1 20:0.6

- 272 046368

dimethylisoquinoline X.05 1-(4.5- Dimethylbenzimide azol-1yl)-4,4-difluoro-3,3dimethylisoquinoline 1:3 2:6 X.05 1-(4.5- Dimethylbenzimide azol-1yl)-4,4-difluoro-3,3dimethylisoquinoline 3.3:1 2:0.6 X.05 Isopyrase 3.3:1 20:6 X.05 Isopyrase 33.3:1 20:0.6 X.05 Isopyrase 1:3 2:6 X.05 Isopyrase 3.3:1 2:0.6 X.05 Sedaksan 3.3:1 20:6 X.05 Sedaksan 33.3:1 20:0.6 X.05 Sedaksan 1:3 2:6 X.05 Sedaksan 3.3:1 2:0.6 X.05 Isofetamide 3.3:1 20:6 X.05 Isofetamide 33.3:1 20:0.6 X.05 Isofetamide 1:3 2:6 X.05 Isofetamide 3.3:1 2:0.6 X.05 Ipflufenoquin 3.3:1 20:6 X.05 Ipflufenoquin 33.3:1 20:0.6 X.05 Ipflufenoquin 1:3 2:6 X.05 Ipflufenoquin 3.3:1 2:0.6 X.05 Quinofumelin 3.3:1 20:6 X.05 Quinofumelin 33.3:1 20:0.6 X.05 Quinofumelin 1:3 2:6

- 273 046368

X.05 Quinofumelin 3.3:1 2:0.6

Component A (connection) Component B A:B ratio Conc, (ppm) (A:B) X.07 Azoxystrobin 3.3:1 20:6 X.07 Azoxystrobin 33.3:1 20:0.6 X.07 Azoxystrobin 1:3 2:6 X.07 Azoxystrobin 3.3:1 2:0.6 X.07 Trifloxystrobin 3.3:1 20:6 X.07 Trifloxystrobin 33.3:1 20:0.6 X.07 Trifloxystrobin 1:3 2:6 X.07 Trifloxystrobin 3.3:1 2:0.6 X.07 Methyltetraprole 3.3:1 20:6 X.07 Methyltetraprole 33.3:1 20:0.6 X.07 Methyltetraprole 1:3 2:6 X.07 Methyltetraprole 3.3:1 2:0.6 X.07 Difenoconazole 3.3:1 20:6 X.07 Difenoconazole 33.3:1 20:0.6 X.07 Difenoconazole 1:3 2:6 X.07 Difenoconazole 3.3:1 2:0.6 X.07 Hexaconazole 3.3:1 20:6 X.07 Hexaconazole 33.3:1 20:0.6 X.07 Hexaconazole 1:3 2:6 X.07 Hexaconazole 3.3:1 2:0.6 X.07 Propiconazole 3.3:1 20:6 X.07 Propiconazole 33.3:1 20:0.6 X.07 Propiconazole 1:3 2:6

- 274 046368

X.07 Propiconazole 3.3:1 2:0.6 X.07 Prothioconazole 3.3:1 20:6 X.07 Prothioconazole 33.3:1 20:0.6 X.07 Prothioconazole 1:3 2:6 X.07 Prothioconazole 3.3:1 2:0.6 X.07 Mefentrifluconazole 3.3:1 20:6 X.07 Mefentrifluconazole 33.3:1 20:0.6 X.07 Mefentrifluconazole 1:3 2:6 X.07 Mefentrifluconazole 3.3:1 2:0.6 X.07 Fenpropidine 1:1 20:20 X.07 Fenpropidine 3.3:1 20:6 X.07 Fenpropidine 1:10 2:20 X.07 Fenpropidine 1:3 2:6 X.07 Phenpropimorph 1:1 20:20 X.07 Phenpropimorph 3.3:1 20:6 X.07 Phenpropimorph 1:10 2:20 X.07 Phenpropimorph 1:3 2:6 X.07 Fluxapyroxad 3.3:1 20:6 X.07 Fluxapyroxad 33.3:1 20:0.6 X.07 Fluxapyroxad 1:3 2:6 X.07 Fluxapyroxad 3.3:1 2:0.6 X.07 Fluopyram 3.3:1 20:6 X.07 Fluopyram 33.3:1 20:0.6 X.07 Fluopyram 1:3 2:6 X.07 Fluopyram 3.3:1 2:0.6 X.07 Benzovindiflupir 3.3:1 20:6

- 275 046368

X.07 Benzovindiflupir 33.3:1 20:0.6 X.07 Benzovindiflupir 1:3 2:6 X.07 Benzovindiflupir 3.3:1 2:0.6 X.07 Pid if lu metof her 3.3:1 20:6 X.07 Pid if lu metof her 33.3:1 20:0.6 X.07 Pid iflu metof her 1:3 2:6 X.07 Pid iflu metof her 3.3:1 2:0.6 X.07 Isoflucipram 3.3:1 20:6 X.07 Isoflucipram 33.3:1 20:0.6 X.07 Isoflucipram 1:3 2:6 X.07 Isoflucipram 3.3:1 2:0.6 X.07 Fluindapir 3.3:1 20:6 X.07 Fluindapir 33.3:1 20:0.6 X.07 Fluindapir 1:3 2:6 X.07 Fluindapir 3.3:1 2:0.6 X.07 Florylpicoxamide 3.3:1 20:6 X.07 Florylpicoxamide 33.3:1 20:0.6 X.07 Florylpicoxamide 1:3 2:6 X.07 Florylpicoxamide 3.3:1 2:0.6 X.07 Metharylpicoxamide 3.3:1 20:6 X.07 Metharylpicoxamide 33.3:1 20:0.6 X.07 Metharylpicoxamide 1:3 2:6 X.07 Metharylpicoxamide 3.3:1 2:0.6 X.07 Chlorothalonil 3.3:1 20:6 X.07 Chlorothalonil 33.3:1 20:0.6 X.07 Chlorothalonil 1:3 2:6 X.07 Chlorothalonil 3.3:1 2:0.6

- 276 046368

X.07 Mankozeb 1:1 20:20 X.07 Mankozeb 3.3:1 20:6 X.07 Mankozeb 1:10 2:20 X.07 Mankozeb 1:3 2:6 X.07 Mandipropamide 1:1 20:20 X.07 Mandipropamide 3.3:1 20:6 X.07 Mandipropamide 1:10 2:20 X.07 Mandipropamide 1:3 2:6 X.07 Oxathiapiproline 1:1 20:20 X.07 Oxathiapiproline 3.3:1 20:6 X.07 Oxathiapiproline 1:10 2:20 X.07 Oxathiapiproline 1:3 2:6 X.07 Fluazinam 3.3:1 20:6 X.07 Fluazinam 33.3:1 20:0.6 X.07 Fluazinam 1:3 2:6 X.07 Fluazinam 3.3:1 2:0.6 X.07 Fludioxonil 3.3:1 20:6 X.07 Fludioxonil 33.3:1 20:0.6 X.07 Fludioxonil 1:3 2:6 X.07 Fludioxonil 3.3:1 2:0.6 X.07 Cyprodinil 3.3:1 20:6 X.07 Cyprodinil 33.3:1 20:0.6 X.07 Cyprodinil 1:3 2:6 X.07 Cyprodinil 3.3:1 2:0.6 X.07 Metalaxyl-M 1:1 20:20 X.07 Metalaxyl-M 3.3:1 20:6

- 277 046368

X.07 Metalaxyl-M 1:10 2:20 X.07 Metalaxyl-M 1:3 2:6 X.07 Folpet 3.3:1 20:6 X.07 Folpet 10:1 20:2 X.07 Folpet 1:3 2:6 X.07 Folpet 1:1 2:2 X.07 Aminopyrifene 3.3:1 20:6 X.07 Aminopyrifene 33.3:1 20:0.6 X.07 Aminopyrifene 1:3 2:6 X.07 Aminopyrifene 3.3:1 2:0.6 X.07 X-(1-Benzyl-1,3- dimethylbutyl)-8fluoroquinoline-3 carboxamide 3.3:1 20:6 X.07 X-(1-Benzyl-1,3dimethylbutyl)-8fluoroquinoline-3carboxamide 33.3:1 20:0.6 X.07 X-(1-Benzyl-1,3dimethylbutyl)-8fluoroquinoline-3carboxamide 1:3 2:6 X.07 X-(1-Benzyl-1,3dimethylbutyl)-8fluoroquinoline-3carboxamide 3.3:1 2:0.6 X.07 N-(l-Benzyl-3,3,3trifluoro-1-methylpropyl)8-fluoroquinoline-3 - 3.3:1 20:6

- 278 046368

carboxamide X.07 N-(1-Benzyl-3,3,3 trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide 33.3:1 20:0.6 X.07 X-(1-Benzyl-3,3,3trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide 1:3 2:6 X.07 N-(1-Benzyl-3,3,3 trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide 3.3:1 2:0.6 X.07 1-(6.7- Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 3.3:1 20:6 X.07 1-(6.7- Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 33.3:1 20:0.6 X.07 1-(6.7- Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 1:3 2:6 X.07 1-(6.7- Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3- 3.3:1 2:0.6

- 279 046368

dimethylisoquinoline X.07 4,4-Difluoro-3,3-d-imethyl1 -(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 3.3:1 20:6 X.07 4,4-Difluoro-3,3-d imethyl1 -(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 33.3:1 20:0.6 X.07 4,4-Difluoro-3,3-d imethyl1 -(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 1:3 2:6 X.07 4,4-Difluoro-3,3-d imethyl1 -(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 3.3:1 2:0.6 X.07 1-(4,5Dimethylbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 3.3:1 20:6 X.07 1-(4,5Dimethylbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 33.3:1 20:0.6 X.07 1-(4,5Dimethylbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 1:3 2:6 X.07 1-(4.5- Dimethylbenzimide azole-1 - 3.3:1 2:0.6

- 280 046368

yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline X.07 1-(4.5- Dimethylbenzimide azol-1yl)-4,4-difluoro-3,3dimethylisoquinoline 3.3:1 20:6 X.07 1-(4.5- Dimethylbenzimide azol-1yl)-4,4-difluoro-3,3dimethylisoquinoline 33.3:1 20:0.6 X.07 1-(4.5- Dimethylbenzimide azol-1yl)-4,4-difluoro-3,3dimethylisoquinoline 1:3 2:6 X.07 1-(4.5- Dimethylbenzimide azol-1yl)-4,4-difluoro-3,3dimethylisoquinoline 3.3:1 2:0.6 X.07 Isopyrase 3.3:1 20:6 X.07 Isopyrase 33.3:1 20:0.6 X.07 Isopyrase 1:3 2:6 X.07 Isopyrase 3.3:1 2:0.6 X.07 Sedaksan 3.3:1 20:6 X.07 Sedaksan 33.3:1 20:0.6 X.07 Sedaksan 1:3 2:6 X.07 Sedaksan 3.3:1 2:0.6 X.07 Isofetamide 3.3:1 20:6 X.07 Isofetamide 33.3:1 20:0.6 X.07 Isofetamide 1:3 2:6

- 281 046368

X.07 Isofetamide 3.3:1 2:0.6 X.07 Ipflufenoquin 3.3:1 20:6 X.07 Ipflufenoquin 33.3:1 20:0.6 X.07 Ipflufenoquin 1:3 2:6 X.07 Ipflufenoquin 3.3:1 2:0.6 X.07 Quinofumelin 3.3:1 20:6 X.07 Quinofumelin 33.3:1 20:0.6 X.07 Quinofumelin 1:3 2:6 X.07 Quinofumelin 3.3:1 2:0.6

Component A (connection) Component B A:B ratio Conc, (ppm) (A:B) X.14 Azoxystrobin 3.3:1 20:6 X.14 Azoxystrobin 33.3:1 20:0.6 X.14 Azoxystrobin 1:3 2:6 X.14 Azoxystrobin 3.3:1 2:0.6 X.14 Trifloxystrobin 3.3:1 20:6 X.14 Trifloxystrobin 33.3:1 20:0.6 X.14 Trifloxystrobin 1:3 2:6 X.14 Trifloxystrobin 3.3:1 2:0.6 X.14 Methyltetraprole 3.3:1 20:6 X.14 Methyltetraprole 33.3:1 20:0.6 X.14 Methyltetraprole 1:3 2:6 X.14 Methyltetraprole 3.3:1 2:0.6 X.14 Difenoconazole 3.3:1 20:6 X.14 Difenoconazole 33.3:1 20:0.6 X.14 Difenoconazole 1:3 2:6

- 282 046368

X.14 Difenoconazole 3.3:1 2:0.6 X.14 Hexaconazole 3.3:1 20:6 X.14 Hexaconazole 33.3:1 20:0.6 X.14 Hexaconazole 1:3 2:6 X.14 Hexaconazole 3.3:1 2:0.6 X.14 Propiconazole 3.3:1 20:6 X.14 Propiconazole 33.3:1 20:0.6 X.14 Propiconazole 1:3 2:6 X.14 Propiconazole 3.3:1 2:0.6 X.14 Prothioconazole 3.3:1 20:6 X.14 Prothioconazole 33.3:1 20:0.6 X.14 Prothioconazole 1:3 2:6 X.14 Prothioconazole 3.3:1 2:0.6 X.14 Mefentrifluconazole 3.3:1 20:6 X.14 Mefentrifluconazole 33.3:1 20:0.6 X.14 Mefentrifluconazole 1:3 2:6 X.14 Mefentrifluconazole 3.3:1 2:0.6 X.14 Fenpropidine 1:1 20:20 X.14 Fenpropidine 3.3:1 20:6 X.14 Fenpropidine 1:10 2:20 X.14 Fenpropidine 1:3 2:6 X.14 Phenpropimorph 1:1 20:20 X.14 Phenpropimorph 3.3:1 20:6 X.14 Phenpropimorph 1:10 2:20 X.14 Phenpropimorph 1:3 2:6 X.14 Fluxapyroxad 3.3:1 20:6

- 283 046368

X.14 Fluxapyroxad 33.3:1 20:0.6 X.14 Fluxapyroxad 1:3 2:6 X.14 Fluxapyroxad 3.3:1 2:0.6 X.14 Fluopyram 3.3:1 20:6 X.14 Fluopyram 33.3:1 20:0.6 X.14 Fluopyram 1:3 2:6 X.14 Fluopyram 3.3:1 2:0.6 X.14 Benzovindiflupir 3.3:1 20:6 X.14 Benzovindiflupir 33.3:1 20:0.6 X.14 Benzovindiflupir 1:3 2:6 X.14 Benzovindiflupir 3.3:1 2:0.6 X.14 Pid if lu metof her 3.3:1 20:6 X.14 Pid if lu metof her 33.3:1 20:0.6 X.14 Pid iflu metof her 1:3 2:6 X.14 Pid iflu metof her 3.3:1 2:0.6 X.14 Isoflucipram 3.3:1 20:6 X.14 Isoflucipram 33.3:1 20:0.6 X.14 Isoflucipram 1:3 2:6 X.14 Isoflucipram 3.3:1 2:0.6 X.14 Fluindapir 3.3:1 20:6 X.14 Fluindapir 33.3:1 20:0.6 X.14 Fluindapir 1:3 2:6 X.14 Fluindapir 3.3:1 2:0.6 X.14 Florylpicoxamide 3.3:1 20:6 X.14 Florylpicoxamide 33.3:1 20:0.6 X.14 Florylpicoxamide 1:3 2:6 X.14 Florylpicoxamide 3.3:1 2:0.6

- 284 046368

X.14 Metharylpicoxamide 3.3:1 20:6 X.14 Metharylpicoxamide 33.3:1 20:0.6 X.14 Metharylpicoxamide 1:3 2:6 X.14 Metharylpicoxamide 3.3:1 2:0.6 X.14 Chlorothalonil 3.3:1 20:6 X.14 Chlorothalonil 33.3:1 20:0.6 X.14 Chlorothalonil 1:3 2:6 X.14 Chlorothalonil 3.3:1 2:0.6 X.14 Mankozeb 1:1 20:20 X.14 Mankozeb 3.3:1 20:6 X.14 Mankozeb 1:10 2:20 X.14 Mankozeb 1:3 2:6 X.14 Mandipropamide 1:1 20:20 X.14 Mandipropamide 3.3:1 20:6 X.14 Mandipropamide 1:10 2:20 X.14 Mandipropamide 1:3 2:6 X.14 Oxathiapiproline 1:1 20:20 X.14 Oxathiapiproline 3.3:1 20:6 X.14 Oxathiapiproline 1:10 2:20 X.14 Oxathiapiproline 1:3 2:6 X.14 Fluazinam 3.3:1 20:6 X.14 Fluazinam 33.3:1 20:0.6 X.14 Fluazinam 1:3 2:6 X.14 Fluazinam 3.3:1 2:0.6 X.14 Fludioxonil 3.3:1 20:6 X.14 Fludioxonil 33.3:1 20:0.6

- 285 046368

X.14 Fludioxonil 1:3 2:6 X.14 Fludioxonil 3.3:1 2:0.6 X.14 Cyprodinil 3.3:1 20:6 X.14 Cyprodinil 33.3:1 20:0.6 X.14 Cyprodinil 1:3 2:6 X.14 Cyprodinil 3.3:1 2:0.6 X.14 Metalaxyl-M 1:1 20:20 X.14 Metalaxyl-M 3.3:1 20:6 X.14 Metalaxyl-M 1:10 2:20 X.14 Metalaxyl-M 1:3 2:6 X.14 Folpet 3.3:1 20:6 X.14 Folpet 10:1 20:2 X.14 Folpet 1:3 2:6 X.14 Folpet 1:1 2:2 X.14 Aminopyrifene 3.3:1 20:6 X.14 Aminopyrifene 33.3:1 20:0.6 X.14 Aminopyrifene 1:3 2:6 X.14 Aminopyrifene 3.3:1 2:0.6 X.14 T4-(1-Benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 3.3:1 20:6 X.14 T4-(1-Benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 33.3:1 20:0.6 X.14 X-(1-Benzyl-1,3- dimethylbutyl)-8- 1:3 2:6

- 286 046368

fluoroquinoline-3 carboxamide X.14 T\G-(1-Benzyl-1,3dimethylbutyl)-8fluoroquinoline-3carboxamide 3.3:1 2:0.6 X.14 X-(1-Benzyl-3,3,3trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide 3.3:1 20:6 X.14 N-(1-Benzyl-3,3,3 trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide 33.3:1 20:0.6 X.14 N-(1-Benzyl-3,3,3 trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide 1:3 2:6 X.14 N-(1-Benzyl-3,3,3 trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide 3.3:1 2:0.6 X.14 1-(6.7- Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 3.3:1 20:6 X.14 1-(6.7- Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3- 33.3:1 20:0.6

- 287 046368

dimethylisoquinoline X.14 1-(6.7- Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 1:3 2:6 X.14 1-(6.7- Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 3.3:1 2:0.6 X.14 4,4-Difluoro-3, 3-d methyl1 -(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 3.3:1 20:6 X.14 4,4-Difluoro-3, 3-d methyl1 -(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 33.3:1 20:0.6 X.14 4,4-Difluoro-3, 3-d methyl1 -(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 1:3 2:6 X.14 4,4-Difluoro-3, 3-d methyl1 -(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 3.3:1 2:0.6 X.14 1-(4.5- Dimethylbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 3.3:1 20:6

- 288 046368

X.14 1-(4,5Dimethylbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 33.3:1 20:0.6 X.14 1-(4,5Dimethylbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 1:3 2:6 X.14 1-(4,5Dimethylbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 3.3:1 2:0.6 X.14 1-(4.5- Dimethylbenzimide azol-1yl)-4,4-difluoro-3,3dimethylisoquinoline 3.3:1 20:6 X.14 1-(4.5- Dimethylbenzimide azol-1yl)-4,4-difluoro-3,3dimethylisoquinoline 33.3:1 20:0.6 X.14 1-(4.5- Dimethylbenzimide azol-1 yl)-4,4-difluoro-3,3dimethylisoquinoline 1:3 2:6 X.14 1-(4.5- Dimethylbenzimide azol-1yl)-4,4-difluoro-3,3dimethylisoquinoline 3.3:1 2:0.6 X.14 Isopyrase 3.3:1 20:6 X.14 Isopyrase 33.3:1 20:0.6 X.14 Isopyrase 1:3 2:6

- 289 046368

X.14 Isopyrase 3.3:1 2:0.6 X.14 Sedaksan 3.3:1 20:6 X.14 Sedaksan 33.3:1 20:0.6 X.14 Sedaxan 1:3 2:6 X.14 Sedaksan 3.3:1 2:0.6 X.14 Isofetamide 3.3:1 20:6 X.14 Isofetamide 33.3:1 20:0.6 X.14 Isofetamide 1:3 2:6 X.14 Isofetamide 3.3:1 2:0.6 X.14 Ipflufenoquin 3.3:1 20:6 X.14 Ipflufenoquin 33.3:1 20:0.6 X.14 Ipflufenoquin 1:3 2:6 X.14 Ipflufenoquin 3.3:1 2:0.6 X.14 Quinofumelin 3.3:1 20:6 X.14 Quinofumelin 33.3:1 20:0.6 X.14 Quinofumelin 1:3 2:6 X.14 Quinofumelin 3.3:1 2:0.6

Example B11. Treatment to prevent leaf disc infection/wheat/Blumeria graminis f. sp. tritici (Erysiphe graminis f. sp. tritici) (wheat powdery mildew)

Leaf segments of the wheat variety Kanzler were placed on agar in a multiwell plate (24-well format) and sprayed with the formulated test compounds diluted in water. Leaf discs were inoculated by shaking powdery mildew-infected plants over test plates 1 day after application. Inoculated leaf discs were incubated at 20°C and 60% relative humidity under a 24-hour dark followed by 12-hour light/12-hour dark environment and compound activity was assessed as a percentage of disease control compared to untreated material at manifestation of the corresponding degree of damage due to the disease on untreated control leaf segments (6-8 days after application). The following mixture-based formulations (A:B) at the indicated concentration (in ppm) provided at least 80% disease control in this test compared to the untreated control, which showed extensive disease development under the same conditions.

- 290 046368

Component A (connection) Component B A:B ratio Conc, (ppm) (A:B) X.05 Azoxystrobin 1.6:1 100:60 X.05 Azoxystrobin 5:1 100:20 X.05 Azoxystrobin 1:2 30:60 X.05 Azoxystrobin 3:2 30:20 X.05 Trifloxystrobin 1.6:1 100:60 X.05 Trifloxystrobin 5:1 100:20 X.05 Trifloxystrobin 1:2 30:60 X.05 Trifloxystrobin 3:2 30:20 X.05 Methyltetraprole 1.6:1 100:60 X.05 Methyltetraprole 5:1 100:20 X.05 Methyltetraprole 1:2 30:60 X.05 Methyltetraprole 3:2 30:20 X.05 Difenoconazole 1.6:1 100:60 X.05 Difenoconazole 5:1 100:20 X.05 Difenoconazole 1:2 30:60 X.05 Difenoconazole 3:2 30:20 X.05 Hexaconazole 1.6:1 100:60 X.05 Hexaconazole 5:1 100:20 X.05 Hexaconazole 1:2 30:60 X.05 Hexaconazole 3:2 30:20

- 291 046368

X.05 Propiconazole 1.6:1 100:60 X.05 Propiconazole 5:1 100:20 X.05 Propiconazole 1:2 30:60 X.05 Propiconazole 3:2 30:20 X.05 Prothioconazole 1.6:1 100:60 X.05 Prothioconazole 5:1 100:20 X.05 Prothioconazole 1:2 30:60 X.05 Prothioconazole 3:2 30:20 X.05 Mefentrifluconazole 1.6:1 100:60 X.05 Mefentrifluconazole 5:1 100:20 X.05 Mefentrifluconazole 1:2 30:60 X.05 Mefentrifluconazole 3:2 30:20 X.05 Fenpropidine 1:1 100:100 X.05 Fenpropidine 3.3:1 100:30 X.05 Fenpropidine 1:3.3 30:100 X.05 Fenpropidine 1:1 30:30 X.05 Phenpropimorph 1.6:1 100:60 X.05 Phenpropimorph 5:1 100:20 X.05 Phenpropimorph 1:2 30:60 X.05 Phenpropimorph 3:2 30:20 X.05 Fluxapyroxad 1.6:1 100:60 X.05 Fluxapyroxad 5:1 100:20 X.05 Fluxapyroxad 1:2 30:60 X.05 Fluxapyroxad 3:2 30:20 X.05 Fluopyram 1:1 100:100 X.05 Fluopyram 3.3:1 100:30

- 292 046368

X.05 Fluopyram 1:3.3 30:100 X.05 Fluopyram 1:1 30:30 X.05 Benzovindiflupir 1.6:1 100:60 X.05 Benzovindiflupir 5:1 100:20 X.05 Benzovindiflupir 1:2 30:60 X.05 Benzovindiflupir 3:2 30:20 X.05 Pid if lu metof en 1.6:1 100:60 X.05 Pid if lu metof en 5:1 100:20 X.05 Pid iflu metof en 1:2 30:60 X.05 Pid iflu metof en 3:2 30:20 X.05 Isoflucipram 1.6:1 100:60 X.05 Isoflucipram 5:1 100:20 X.05 Isoflucipram 1:2 30:60 X.05 Isoflucipram 3:2 30:20 X.05 Florylpicoxamide 1.6:1 100:60 X.05 Florylpicoxamide 5:1 100:20 X.05 Florylpicoxamide 1:2 30:60 X.05 Florylpicoxamide 3:2 30:20 X.05 Metharylpicoxamide 1:1 100:100 X.05 Metharylpicoxamide 3.3:1 100:30 X.05 Metharylpicoxamide 1:3.3 30:100 X.05 Metharylpicoxamide 1:1 30:30 X.05 Fosetyl aluminum 1:1 100:100 X.05 Fosetyl aluminum 3.3:1 100:30 X.05 Fosetyl aluminum 1:3.3 30:100 X.05 Fosetyl aluminum 1:1 30:30

- 293 046368

X.05 Chlorothalonil 1:1 100:100 X.05 Chlorothalonil 3.3:1 100:30 X.05 Chlorothalonil 1:3.3 30:100 X.05 Chlorothalonil 1:1 30:30 X.05 Mankozeb 1:1 100:100 X.05 Mankozeb 3.3:1 100:30 X.05 Mankozeb 1:3.3 30:100 X.05 Mankozeb 1:1 30:30 X.05 Mandipropamide 1:1 100:100 X.05 Mandipropamide 3.3:1 100:30 X.05 Mandipropamide 1:3.3 30:100 X.05 Mandipropamide 1:1 30:30 X.05 Oxathiapiproline 1:1 100:100 X.05 Oxathiapiproline 3.3:1 100:30 X.05 Oxathiapiproline 1:3.3 30:100 X.05 Oxathiapiproline 1:1 30:30 X.05 Fluazinam 1:1 100:100 X.05 Fluazinam 3.3:1 100:30 X.05 Fluazinam 1:3.3 30:100 X.05 Fluazinam 1:1 30:30 X.05 Fludioxonil 1:1 100:100 X.05 Fludioxonil 3.3:1 100:30 X.05 Fludioxonil 1:3.3 30:100 X.05 Fludioxonil 1:1 30:30 X.05 Cyprodinil 1:1 100:100 X.05 Cyprodinil 3.3:1 100:30 X.05 Cyprodinil 1:3.3 30:100

- 294 046368

X.05 Cyprodinil 1:1 30:30 X.05 Metalaxyl-M 1:1 100:100 X.05 Metalaxyl-M 3.3:1 100:30 X.05 Metalaxyl-M 1:3.3 30:100 X.05 Metalaxyl-M 1:1 30:30 X.05 Folpet 1:1 100:100 X.05 Folpet 3.3:1 100:30 X.05 Folpet 1:3.3 30:100 X.05 Folpet 1:1 30:30 X.05 X'-[5-Bromo-2-methyl-6-(1methyl-2-propoxyethoxy)3-pyridyl]-X-ethyl-Xmethylformamidine 1:1 100:100 X.05 X'-[5-Bromo-2-methyl-6-(1methyl-2-propoxyethoxy)3-pyridyl]-X-ethyl-Xmethylformamidine 3.3:1 100:30 X.05 X'-[5-Bromo-2-methyl-6-(1methyl-2-propoxyethoxy)3-pyridyl]-X-ethyl-Xmethylformamidine 1:3.3 30:100 X.05 X'-[5-Bromo-2-methyl-6-(1methyl-2-propoxyethoxy)3-pyridyl]-X-ethyl-Xmethylformamidine 1:1 30:30 X.05 X-Isopropyl-T4'-[5methoxy-2-methyl-4-(2,2,2trifluoro-1-hydroxy-1 phenylethyl)phenyl] -N- 1:1 100:100

- 295 046368

methylformamidine X.05 Ν-Η3θπροπιιπ-Ν'-[5methoxy-2-methyl-4-(2,2,2trifluoro-1-hydroxy-1 phenylethyl)phenyl]-Νmethylformamidine 3.3:1 100:30 X.05 X-Isopropyl-X'-[5methoxy-2-methyl-4-(2,2,2trifluoro-1-hydroxy-1 phenylethyl)phenyl]-Nmethylformamidine 1:3.3 30:100 X.05 X-Isopropyl-X'-[5methoxy-2-methyl-4-(2,2,2trifluoro-1-hydroxy-1 phenylethyl)phenyl]-Nmethylformamidine 1:1 30:30 X.05 TAEGRO® 1:1 100:100 X.05 TAEGRO® 3.3:1 100:30 X.05 TAEGRO® 1:3.3 30:100 X.05 TAEGRO® 1:1 30:30 X.05 Timorex GoldTM 1:1 100:100 X.05 Timorex GoldTM 3.3:1 100:30 X.05 Timorex GoldTM 1:3.3 30:100 X.05 Timorex GoldTM 1:1 30:30 X.05 Isofetamide 1.6:1 100:60 X.05 Isofetamide 5:1 100:20 X.05 Isofetamide 1:2 30:60 X.05 Isofetamide 3:2 30:20 X.05 Acibenzolar-8-methyl 1:1 100:100

- 296 046368

X.05 Acibenzolar-8-methyl 3.3:1 100:30 X.05 Acibenzolar-8-methyl 1:3.3 30:100 X.05 Acibenzolar-8-methyl 1:1 30:30 X.05 Aminopyrifene 1:1 100:100 X.05 Aminopyrifene 3.3:1 100:30 X.05 Aminopyrifene 1:3.3 30:100 X.05 Aminopyrifene 1:1 30:30 X.05 Cyflufenamide 5:1 100:20 X.05 Cyflufenamide 50:1 100:2 X.05 Cyflufenamide 3:2 30:20 X.05 Cyflufenamide 15:1 30:2 X.05 Metraphenone 5:1 100:20 X.05 Metraphenone 50:1 100:2 X.05 Metraphenone 3:2 30:20 X.05 Metraphenone 15:1 30:2 X.05 18G-(1-Benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 1:1 100:100 X.05 X-(1-Benzyl-1,3- dimethylbutyl)-8fluoroquinoline-3carboxamide 3.3:1 100:30 X.05 18G-(1-Benzyl-1,3dimethylbutyl)-8fluoroquinoline-3carboxamide 1:3.3 30:100 X.05 18G-(1-Benzyl-1,3dimethylbutyl)-8- 1:1 30:30

- 297 046368

fluoroquinoline-3carboxamide X.05 N-(1-Benzyl-3,3,3 trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide 1:1 100:100 X.05 N-(1-Benzyl-3,3,3 trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide 3.3:1 100:30 X.05 N-(1-Benzyl-3,3,3 trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide 1:3.3 30:100 X.05 N-(1-Benzyl-3,3,3 trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide 1:1 30:30 X.05 1-(6.7- Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 1:1 100:100 X.05 1-(6.7- Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 3.3:1 100:30 X.05 1-(6.7- Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 - 1:3.3 30:100

- 298 046368

trifluoro-3,3- dimethylisoquinoline X.05 1-(6.7- Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 1:1 30:30 X.05 4,4-Difluoro-3, 3-d imethyl1 -(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 1:1 100:100 X.05 4,4-Difluoro-3, 3-d imethyl1 -(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 3.3:1 100:30 X.05 4,4-Difluoro-3, 3-d imethyl1 -(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 1:3.3 30:100 X.05 4,4-Difluoro-3, 3-d imethyl1 -(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 1:1 30:30 X.05 1-(4.5- Dimethylbenzimidazol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 1:1 100:100 X.05 1-(4.5- Dimethylbenzimidazol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 3.3:1 100:30

- 299 046368

X.05 1-(4.5- Dimethylbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 1:3.3 30:100 X.05 1-(4.5- Dimethylbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 1:1 30:30 X.05 1-(4.5- Dimethylbenzimide azol-1yl)-4,4-difluoro-3,3dimethylisoquinoline 1:1 100:100 X.05 1-(4.5- Dimethylbenzimide azol-1 yl)-4,4-difluoro-3,3dimethylisoquinoline 3.3:1 100:30 X.05 1-(4.5- Dimethylbenzimide azol-1 yl)-4,4-difluoro-3,3dimethylisoquinoline 1:3.3 30:100 X.05 1-(4.5- Dimethylbenzimide azol-1yl)-4,4-difluoro-3,3dimethylisoquinoline 1:1 30:30

Component A (connection) Component B A:B ratio Conc, (ppm) (A:B) X.07 Azoxystrobin 1.6:1 100:60 X.07 Azoxystrobin 5:1 100:20 X.07 Azoxystrobin 1:2 30:60 X.07 Azoxystrobin 3:2 30:20

- 300 046368

X.07 Trifloxystrobin 1.6:1 100:60 X.07 Trifloxystrobin 5:1 100:20 X.07 Trifloxystrobin 1:2 30:60 X.07 Trifloxystrobin 3:2 30:20 X.07 Methyltetraprole 1.6:1 100:60 X.07 Methyltetraprole 5:1 100:20 X.07 Methyltetraprole 1:2 30:60 X.07 Methyltetraprole 3:2 30:20 X.07 Difenoconazole 1.6:1 100:60 X.07 Difenoconazole 5:1 100:20 X.07 Difenoconazole 1:2 30:60 X.07 Difenoconazole 3:2 30:20 X.07 Hexaconazole 1.6:1 100:60 X.07 Hexaconazole 5:1 100:20 X.07 Hexaconazole 1:2 30:60 X.07 Hexaconazole 3:2 30:20 X.07 Propiconazole 1.6:1 100:60 X.07 Propiconazole 5:1 100:20 X.07 Propiconazole 1:2 30:60 X.07 Propiconazole 3:2 30:20 X.07 Prothioconazole 1.6:1 100:60 X.07 Prothioconazole 5:1 100:20 X.07 Prothioconazole 1:2 30:60 X.07 Prothioconazole 3:2 30:20 X.07 Mefentrifluconazole 1.6:1 100:60 X.07 Mefentrifluconazole 5:1 100:20

- 301 046368

X.07 Mefentrifluconazole 1:2 30:60 X.07 Mefentrifluconazole 3:2 30:20 X.07 Fenpropidine 1:1 100:100 X.07 Fenpropidine 3.3:1 100:30 X.07 Fenpropidine 1:3.3 30:100 X.07 Fenpropidine 1:1 30:30 X.07 Phenpropimorph 1.6:1 100:60 X.07 Phenpropimorph 5:1 100:20 X.07 Phenpropimorph 1:2 30:60 X.07 Phenpropimorph 3:2 30:20 X.07 Fluxapyroxad 1.6:1 100:60 X.07 Fluxapyroxad 5:1 100:20 X.07 Fluxapyroxad 1:2 30:60 X.07 Fluxapyroxad 3:2 30:20 X.07 Fluopyram 1:1 100:100 X.07 Fluopyram 3.3:1 100:30 X.07 Fluopyram 1:3.3 30:100 X.07 Fluopyram 1:1 30:30 X.07 Benzovindiflupir 1.6:1 100:60 X.07 Benzovindiflupir 5:1 100:20 X.07 Benzovindiflupir 1:2 30:60 X.07 Benzovindiflupir 3:2 30:20 X.07 Pid if lu metof her 1.6:1 100:60 X.07 Pid if lu metof her 5:1 100:20 X.07 Pid iflu metof her 1:2 30:60 X.07 Pid iflu metof her 3:2 30:20

- 302 046368

X.07 Isoflucipram 1.6:1 100:60 X.07 Isoflucipram 5:1 100:20 X.07 Isoflucipram 1:2 30:60 X.07 Isoflucipram 3:2 30:20 X.07 Florylpicoxamide 1.6:1 100:60 X.07 Florylpicoxamide 5:1 100:20 X.07 Florylpicoxamide 1:2 30:60 X.07 Florylpicoxamide 3:2 30:20 X.07 Metharylpicoxamide 1:1 100:100 X.07 Metharylpicoxamide 3.3:1 100:30 X.07 Metharylpicoxamide 1:3.3 30:100 X.07 Metharylpicoxamide 1:1 30:30 X.07 Fosetyl aluminum 1:1 100:100 X.07 Fosetyl aluminum 3.3:1 100:30 X.07 Fosetyl aluminum 1:3.3 30:100 X.07 Fosetyl aluminum 1:1 30:30 X.07 Chlorothalonil 1:1 100:100 X.07 Chlorothalonil 3.3:1 100:30 X.07 Chlorothalonil 1:3.3 30:100 X.07 Chlorothalonil 1:1 30:30 X.07 Mankozeb 1:1 100:100 X.07 Mankozeb 3.3:1 100:30 X.07 Mankozeb 1:3.3 30:100 X.07 Mankozeb 1:1 30:30 X.07 Mandipropamide 1:1 100:100 X.07 Mandipropamide 3.3:1 100:30 X.07 Mandipropamide 1:3.3 30:100

- 303 046368

X.07 Mandipropamide 1:1 30:30 X.07 Oxathiapiproline 1:1 100:100 X.07 Oxathiapiproline 3.3:1 100:30 X.07 Oxathiapiproline 1:3.3 30:100 X.07 Oxathiapiproline 1:1 30:30 X.07 Fluazinam 1:1 100:100 X.07 Fluazinam 3.3:1 100:30 X.07 Fluazinam 1:3.3 30:100 X.07 Fluazinam 1:1 30:30 X.07 Fludioxonil 1:1 100:100 X.07 Fludioxonil 3.3:1 100:30 X.07 Fludioxonil 1:3.3 30:100 X.07 Fludioxonil 1:1 30:30 X.07 Cyprodinil 1:1 100:100 X.07 Cyprodinil 3.3:1 100:30 X.07 Cyprodinil 1:3.3 30:100 X.07 Cyprodinil 1:1 30:30 X.07 Metalaxyl-M 1:1 100:100 X.07 Metalaxyl-M 3.3:1 100:30 X.07 Metalaxyl-M 1:3.3 30:100 X.07 Metalaxyl-M 1:1 30:30 X.07 Folpet 1:1 100:100 X.07 Folpet 3.3:1 100:30 X.07 Folpet 1:3.3 30:100 X.07 Folpet 1:1 30:30 X.07 X'-[5-Bromo-2-methyl-6-(1- 1:1 100:100

- 304 046368

methyl-2-propoxyethoxy)3-pyridyl]-X-ethyl-Xmethylformamidine X.07 X'-[5-Bromo-2-methyl-6-(1methyl-2-propoxyethoxy)3-pyridyl]-X-ethyl-Xmethylformamidine 3.3:1 100:30 X.07 X'-[5-Bromo-2-methyl-6-(1methyl-2-propoxyethoxy)3-pyridyl]-X-ethyl-Xmethylformamidine 1:3.3 30:100 X.07 X'-[5-Bromo-2-methyl-6-(1methyl-2-propoxyethoxy)3-pyridyl]-X-ethyl-Xmethylformamidine 1:1 30:30 X.07 X-Isopropyl-X'-[5methoxy-2-methyl-4-(2,2,2trifluoro-1-hydroxy-1 phenylethyl)phenyl]-Nmethylformamidine 1:1 100:100 X.07 X-Isopropyl-X'-[5methoxy-2-methyl-4-(2,2,2trifluoro-1-hydroxy-1 phenylethyl)phenyl]-Nmethylformamidine 3.3:1 100:30 X.07 X-Isopropyl-X'-[5methoxy-2-methyl-4-(2,2,2trifluoro-1-hydroxy-1 phenylethyl)phenyl]-Nmethylformamidine 1:3.3 30:100 X.07 X-Isopropyl-X'-[5methoxy-2-methyl-4-(2,2,2- 1:1 30:30

- 305 046368

trifluoro-1-hydroxy-1 phenylethyl)phenyl]-Nmethylformamidine X.07 TAEGRO® 1:1 100:100 X.07 TAEGRO® 3.3:1 100:30 X.07 TAEGRO® 1:3.3 30:100 X.07 TAEGRO® 1:1 30:30 X.07 Timorex GoldTM 1:1 100:100 X.07 Timorex GoldTM 3.3:1 100:30 X.07 Timorex GoldTM 1:3.3 30:100 X.07 Timorex GoldTM 1:1 30:30 X.07 Isofetamide 1.6:1 100:60 X.07 Isofetamide 5:1 100:20 X.07 Isofetamide 1:2 30:60 X.07 Isofetamide 3:2 30:20 X.07 Acibenzolar-8-methyl 1:1 100:100 X.07 Acibenzolar-8-methyl 3.3:1 100:30 X.07 Acibenzolar-8-methyl 1:3.3 30:100 X.07 Acibenzolar-8-methyl 1:1 30:30 X.07 Aminopyrifene 1:1 100:100 X.07 Aminopyrifene 3.3:1 100:30 X.07 Aminopyrifene 1:3.3 30:100 X.07 Aminopyrifene 1:1 30:30 X.07 Cyflufenamide 5:1 100:20 X.07 Cyflufenamide 50:1 100:2 X.07 Cyflufenamide 3:2 30:20 X.07 Cyflufenamide 15:1 30:2

- 306 046368

X.07 Metraphenone 5:1 100:20 X.07 Metraphenone 50:1 100:2 X.07 Metraphenone 3:2 30:20 X.07 Metraphenone 15:1 30:2 X.07 X-(1-Benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 1:1 100:100 X.07 X-(1-Benzyl-1,3dimethylbutyl)-8fluoroquinoline-3carboxamide 3.3:1 100:30 X.07 X-(1-Benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 1:3.3 30:100 X.07 X-(1-Benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 1:1 30:30 X.07 X-(1-Benzyl-3,3,3trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide 1:1 100:100 X.07 N-(1-Benzyl-3,3,3 trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide 3.3:1 100:30 X.07 X-(1-Benzyl-3,3,3trifluoro-1-methylpropyl)- 1:3.3 30:100

- 307 046368

8-fluoroquinoline-3 carboxamide X.07 T4-(1-Benzyl-3,3,3trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide 1:1 30:30 X.07 1-(6.7- Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 1:1 100:100 X.07 1-(6.7- Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 3.3:1 100:30 X.07 1-(6.7- Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 1:3.3 30:100 X.07 1-(6.7- Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 1:1 30:30 X.07 4,4-Difluoro-3,3-d imethyl1-(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 1:1 100:100 X.07 4,4-Difluoro-3,3-dimethyl- 3.3:1 100:30

- 308 046368

1 -(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline X.07 4,4-Difluoro-3,3-d-imethyl1 -(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 1:3.3 30:100 X.07 4,4-Difluoro-3,3-d imethyl1 -(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 1:1 30:30 X.07 1-(4,5Dimethylbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 1:1 100:100 X.07 1-(4,5Dimethylbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 3.3:1 100:30 X.07 1-(4,5Dimethylbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 1:3.3 30:100 X.07 1-(4,5Dimethylbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 1:1 30:30 X.07 1-(4.5- Dimethylbenzimide azol-1 yl)-4,4-difluoro-3,3dimethylisoquinoline 1:1 100:100

- 309 046368

X.07 1-(4.5- Dimethylbenzimide azol-1 yl)-4,4-difluoro-3,3dimethylisoquinoline 3.3:1 100:30 X.07 1-(4.5- Dimethylbenzimide azol-1 yl)-4,4-difluoro-3,3dimethylisoquinoline 1:3.3 30:100 X.07 1-(4.5- Dimethylbenzimide azol-1 yl)-4,4-difluoro-3,3dimethylisoquinoline 1:1 30:30

Component A (connection) Component B A:B ratio Conc, (ppm) (A:B) X.14 Azoxystrobin 1.6:1 100:60 X.14 Azoxystrobin 5:1 100:20 X.14 Azoxystrobin 1:2 30:60 X.14 Azoxystrobin 3:2 30:20 X.14 Trifloxystrobin 1.6:1 100:60 X.14 Trifloxystrobin 5:1 100:20 X.14 Trifloxystrobin 1:2 30:60 X.14 Trifloxystrobin 3:2 30:20 X.14 Methyltetraprole 1.6:1 100:60 X.14 Methyltetraprole 5:1 100:20 X.14 Methyltetraprole 1:2 30:60 X.14 Methyltetraprole 3:2 30:20 X.14 Difenoconazole 1.6:1 100:60 X.14 Difenoconazole 5:1 100:20

- 310 046368

X.14 Difenoconazole 1:2 30:60 X.14 Difenoconazole 3:2 30:20 X.14 Hexaconazole 1.6:1 100:60 X.14 Hexaconazole 5:1 100:20 X.14 Hexaconazole 1:2 30:60 X.14 Hexaconazole 3:2 30:20 X.14 Propiconazole 1.6:1 100:60 X.14 Propiconazole 5:1 100:20 X.14 Propiconazole 1:2 30:60 X.14 Propiconazole 3:2 30:20 X.14 Prothioconazole 1.6:1 100:60 X.14 Prothioconazole 5:1 100:20 X.14 Prothioconazole 1:2 30:60 X.14 Prothioconazole 3:2 30:20 X.14 Mefentrifluconazole 1.6:1 100:60 X.14 Mefentrifluconazole 5:1 100:20 X.14 Mefentrifluconazole 1:2 30:60 X.14 Mefentrifluconazole 3:2 30:20 X.14 Fenpropidine 1:1 100:100 X.14 Fenpropidine 3.3:1 100:30 X.14 Fenpropidine 1:3.3 30:100 X.14 Fenpropidine 1:1 30:30 X.14 Phenpropimorph 1.6:1 100:60 X.14 Phenpropimorph 5:1 100:20 X.14 Phenpropimorph 1:2 30:60 X.14 Phenpropimorph 3:2 30:20

- 311 046368

X.14 Fluxapyroxad 1.6:1 100:60 X.14 Fluxapyroxad 5:1 100:20 X.14 Fluxapyroxad 1:2 30:60 X.14 Fluxapyroxad 3:2 30:20 X.14 Fluopyram 1:1 100:100 X.14 Fluopyram 3.3:1 100:30 X.14 Fluopyram 1:3.3 30:100 X.14 Fluopyram 1:1 30:30 X.14 Benzovindiflupir 1.6:1 100:60 X.14 Benzovindiflupir 5:1 100:20 X.14 Benzovindiflupir 1:2 30:60 X.14 Benzovindiflupir 3:2 30:20 X.14 Pid iflu metof her 1.6:1 100:60 X.14 Pid iflu metof her 5:1 100:20 X.14 Pid iflu metof her 1:2 30:60 X.14 Pid iflu metof her 3:2 30:20 X.14 Isoflucipram 1.6:1 100:60 X.14 Isoflucipram 5:1 100:20 X.14 Isoflucipram 1:2 30:60 X.14 Isoflucipram 3:2 30:20 X.14 Florylpicoxamide 1.6:1 100:60 X.14 Florylpicoxamide 5:1 100:20 X.14 Florylpicoxamide 1:2 30:60 X.14 Florylpicoxamide 3:2 30:20 X.14 Metharylpicoxamide 1:1 100:100 X.14 Metharylpicoxamide 3.3:1 100:30 X.14 Metharylpicoxamide 1:3.3 30:100

- 312 046368

X.14 Metharylpicoxamide 1:1 30:30 X.14 Fosetyl aluminum 1:1 100:100 X.14 Fosetyl aluminum 3.3:1 100:30 X.14 Fosetyl aluminum 1:3.3 30:100 X.14 Fosetyl aluminum 1:1 30:30 X.14 Chlorothalonil 1:1 100:100 X.14 Chlorothalonil 3.3:1 100:30 X.14 Chlorothalonil 1:3.3 30:100 X.14 Chlorothalonil 1:1 30:30 X.14 Mankozeb 1:1 100:100 X.14 Mankozeb 3.3:1 100:30 X.14 Mankozeb 1:3.3 30:100 X.14 Mankozeb 1:1 30:30 X.14 Mandipropamide 1:1 100:100 X.14 Mandipropamide 3.3:1 100:30 X.14 Mandipropamide 1:3.3 30:100 X.14 Mandipropamide 1:1 30:30 X.14 Oxathiapiproline 1:1 100:100 X.14 Oxathiapiproline 3.3:1 100:30 X.14 Oxathiapiproline 1:3.3 30:100 X.14 Oxathiapiproline 1:1 30:30 X.14 Fluazinam 1:1 100:100 X.14 Fluazinam 3.3:1 100:30 X.14 Fluazinam 1:3.3 30:100 X.14 Fluazinam 1:1 30:30 X.14 Fludioxonil 1:1 100:100

- 313 046368

X.14 Fludioxonil 3.3:1 100:30 X.14 Fludioxonil 1:3.3 30:100 X.14 Fludioxonil 1:1 30:30 X.14 Cyprodinil 1:1 100:100 X.14 Cyprodinil 3.3:1 100:30 X.14 Cyprodinil 1:3.3 30:100 X.14 Cyprodinil 1:1 30:30 X.14 Metalaxyl-M 1:1 100:100 X.14 Metalaxyl-M 3.3:1 100:30 X.14 Metalaxyl-M 1:3.3 30:100 X.14 Metalaxyl-M 1:1 30:30 X.14 Folpet 1:1 100:100 X.14 Folpet 3.3:1 100:30 X.14 Folpet 1:3.3 30:100 X.14 Folpet 1:1 30:30 X.14 T\G-[5-Bromo-2-methyl-6-(1methyl-2-propoxyethoxy)3-pyridyl]-T4-ethyl-Xmethylformamidine 1:1 100:100 X.14 T\G-[5-Bromo-2-methyl-6-(1methyl-2-propoxyethoxy)3-pyridyl]-T4-ethyl-Xmethylformamidine 3.3:1 100:30 X.14 M'-[5-Bromo-2-methyl-6-(1methyl-2-propoxyethoxy)3-pyridyl]-T4-ethyl-Xmethylformamidine 1:3.3 30:100 X.14 T\G-[5-Bromo-2-methyl-6-(1- methyl-2-propoxyethoxy)- 1:1 30:30

- 314 046368

3-pyridyl]-X-ethyl-Xmethylformamidine X.14 X-Isopropyl-X-[5methoxy-2-methyl-4-(2,2,2trifluoro-1-hydroxy-1 phenylethyl)phenyl]-Nmethylformamidine 1:1 100:100 X.14 Ν-Π3θπροπΗπ-Ν'-[5methoxy-2-methyl-4-(2,2,2trifluoro-1-hydroxy-1 phenylethyl)phenyl]-Νmethylformamidine 3.3:1 100:30 X.14 X-Isopropyl-X'-[5methoxy-2-methyl-4-(2,2,2trifluoro-1-hydroxy-1 phenylethyl)phenyl]-Nmethylformamidine 1:3.3 30:100 X.14 Ν-Π3θπροπΗπ-Ν'-[5methoxy-2-methyl-4-(2,2,2trifluoro-1-hydroxy-1 phenylethyl)phenyl]-Νmethylformamidine 1:1 30:30 X.14 TAEGRO® 1:1 100:100 X.14 TAEGRO® 3.3:1 100:30 X.14 TAEGRO® 1:3.3 30:100 X.14 TAEGRO® 1:1 30:30 X.14 Timorex GoldTM 1:1 100:100 X.14 Timorex GoldTM 3.3:1 100:30 X.14 Timorex GoldTM 1:3.3 30:100 X.14 Timorex GoldTM 1:1 30:30

- 315 046368

X.14 Isofetamide 1.6:1 100:60 X.14 Isofetamide 5:1 100:20 X.14 Isofetamide 1:2 30:60 X.14 Isofetamide 3:2 30:20 X.14 Acibenz ol ar - S -methyl 1:1 100:100 X.14 Acibenz ol ar - S -methyl 3.3:1 100:30 X.14 Acibenz ol ar - S -methyl 1:3.3 30:100 X.14 Acibenz ol ar - S -methyl 1:1 30:30 X.14 Aminopyrifene 1:1 100:100 X.14 Aminopyrifene 3.3:1 100:30 X.14 Aminopyrifene 1:3.3 30:100 X.14 Aminopyrifene 1:1 30:30 X.14 Cyflufenamide 5:1 100:20 X.14 Cyflufenamide 50:1 100:2 X.14 Cyflufenamide 3:2 30:20 X.14 Cyflufenamide 15:1 30:2 X.14 Metraphenone 5:1 100:20 X.14 Metraphenone 50:1 100:2 X.14 Metraphenone 3:2 30:20 X.14 Metraphenone 15:1 30:2 X.14 T4-(1-Benzyl-1,3dimethylbutyl)-8fluoroquinoline-3carboxamide 1:1 100:100 X.14 X-(1-Benzyl-1,3- dimethylbutyl)-8fluoroquinoline-3 - 3.3:1 100:30

- 316 046368

carboxamide X.14 T\G-(1-Benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 1:3.3 30:100 X.14 M-(1-Benzyl-1,3dimethylbutyl)-8fluoroquinoline-3carboxamide 1:1 30:30 X.14 X-(1-Benzyl-3,3,3trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide 1:1 100:100 X.14 N-(1-Benzyl-3,3,3 trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide 3.3:1 100:30 X.14 N-(1-Benzyl-3,3,3 trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide 1:3.3 30:100 X.14 X-(1-Benzyl-3,3,3trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide 1:1 30:30 X.14 1-(6.7- Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 1:1 100:100 X.14 1-(6.7- 3.3:1 100:30

- 317 046368

Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline X.14 1-(6.7- Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 1:3.3 30:100 X.14 1-(6.7- Dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 1:1 30:30 X.14 4,4-Difluoro-3,3-d imethyl1 -(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 1:1 100:100 X.14 4,4-Difluoro-3,3-d imethyl1 -(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 3.3:1 100:30 X.14 4,4-Difluoro-3,3-d imethyl1 -(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 1:3.3 30:100 X.14 4,4-Difluoro-3,3-d imethyl1 -(7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 1:1 30:30 X.14 1-(4.5- 1:1 100:100

- 318 046368

Dimethylbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline X.14 1-(4.5- Dimethylbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 3.3:1 100:30 X.14 1-(4.5- Dimethylbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 1:3.3 30:100 X.14 1-(4.5- Dimethylbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 1:1 30:30 X.14 1-(4.5- Dimethylbenzimide azol-1yl)-4,4-difluoro-3,3dimethylisoquinoline 1:1 100:100 X.14 1-(4.5- Dimethylbenzimide azol-1yl)-4,4-difluoro-3,3dimethylisoquinoline 3.3:1 100:30 X.14 1-(4.5- Dimethylbenzimide azol-1yl)-4,4-difluoro-3,3dimethylisoquinoline 1:3.3 30:100 X.14 1-(4.5- Dimethylbenzimide azol-1yl)-4,4-difluoro-3,3dimethylisoquinoline 1:1 30:30

Example B12. Treatment to prevent leaf disc infection/wheat/Puccinia recondita f. sp. tritici (brown rust)

Leaf segments of the wheat variety Kanzler were placed on agar in multiwell plates (24-well format) and sprayed with the formulated test compounds diluted in water. Leaf discs were inoculated with a suspension of fungal spores 1 day after application. The inoculated leaf segments were incubated at 19°C and 75% relative humidity under a 12-hour light/12-hour dark climate chamber and compound activity was assessed as a percentage of disease control compared to untreated material exhibiting the appropriate degree of damage due to diseases on untreated control leaf segments (7-9 days after application). The following mixture-based formulations (A:B) at the indicated concentration (in ppm) provided at least 80% disease control in this test compared to the untreated control, which under the same conditions showed extensive disease development.

- 319 046368

Component A (connection) Component B A:B ratio Conc, (ppm) (A:B) X.05 Azoxystrobin 1.6:1 100:60 X.05 Azoxystrobin 5:1 100:20 X.05 Azoxystrobin 1:2 30:60 X.05 Azoxystrobin 3:2 30:20 X.05 Trifloxystrobin 1.6:1 100:60 X.05 Trifloxystrobin 5:1 100:20 X.05 Trifloxystrobin 1:2 30:60 X.05 Trifloxystrobin 3:2 30:20 X.05 Methyltetraprole 1.6:1 100:60 X.05 Methyltetraprole 5:1 100:20 X.05 Methyltetraprole 1:2 30:60 X.05 Methyltetraprole 3:2 30:20

- 320 046368

X.05 Ciproconazole 1.6:1 100:60 X.05 Cyproconazole 5:1 100:20 X.05 Cyproconazole 1:2 30:60 X.05 Cyproconazole 3:2 30:20 X.05 Difenoconazole 1:1 100:100 X.05 Difenoconazole 3.3:1 100:30 X.05 Difenoconazole 1:3.3 30:100 X.05 Difenoconazole 1:1 30:30 X.05 Hexaconazole 1:1 100:100 X.05 Hexaconazole 3.3:1 100:30 X.05 Hexaconazole 1:3.3 30:100 X.05 Hexaconazole 1:1 30:30 X.05 Propiconazole 1:1 100:100 X.05 Propiconazole 3.3:1 100:30 X.05 Propiconazole 1:3.3 30:100 X.05 Propiconazole 1:1 30:30 X.05 Prothioconazole 1:1 100:100 X.05 Prothioconazole 3.3:1 100:30 X.05 Prothioconazole 1:3.3 30:100 X.05 Prothioconazole 1:1 30:30 X.05 Mefentrifluconazole 1.6:1 100:60 X.05 Mefentrifluconazole 5:1 100:20 X.05 Mefentrifluconazole 1:2 30:60 X.05 Mefentrifluconazole 3:2 30:20 X.05 Fenpropidine 1:1 100:100 X.05 Fenpropidine 3.3:1 100:30 X.05 Fenpropidine 1:3.3 30:100

- 321 046368

X.05 Fenpropidine 1:1 30:30 X.05 Phenpropimorph 1:1 100:100 X.05 Phenpropimorph 3.3:1 100:30 X.05 Phenpropimorph 1:3.3 30:100 X.05 Phenpropimorph 1:1 30:30 X.05 Bixafen 1:1 100:60 X.05 Bixafen 3.3:1 100:20 X.05 Bixafen 1:2 30:60 X.05 Bixafen 3:2 30:20 X.05 Fluxapyroxad 1.6:1 100:60 X.05 Fluxapyroxad 5:1 100:20 X.05 Fluxapyroxad 1:2 30:60 X.05 Fluxapyroxad 3:2 30:20 X.05 Fluopyram 1:1 100:100 X.05 Fluopyram 3.3:1 100:30 X.05 Fluopyram 1:3.3 30:100 X.05 Fluopyram 1:1 30:30 X.05 Benzovindiflupir 1.6:1 100:60 X.05 Benzovindiflupir 5:1 100:20 X.05 Benzovindiflupir 1:2 30:60 X.05 Benzovindiflupir 3:2 30:20 X.05 Pid if lu metof her 1:1 100:100 X.05 Pid if lu metof her 3.3:1 100:30 X.05 Pid iflu metof her 1:3.3 30:100 X.05 Pid iflu metof her 1:1 30:30 X.05 Isoflucipram 1.6:1 100:60

- 322 046368

X.05 Isoflucipram 5:1 100:20 X.05 Isoflucipram 1:2 30:60 X.05 Isoflucipram 3:2 30:20 X.05 Fluindapir 1.6:1 100:60 X.05 Fluindapir 5:1 100:20 X.05 Fluindapir 1:2 30:60 X.05 Fluindapir 3:2 30:20 X.05 Florylpicoxamide 1:1 100:100 X.05 Florylpicoxamide 3.3:1 100:30 X.05 Florylpicoxamide 1:3.3 30:100 X.05 Florylpicoxamide 1:1 30:30 X.05 Metharylpicoxamide 1.6:1 100:60 X.05 Metharylpicoxamide 5:1 100:20 X.05 Metharylpicoxamide 1:2 30:60 X.05 Metharylpicoxamide 3:2 30:20 X.05 Fosetyl aluminum 1:1 100:100 X.05 Fosetyl aluminum 3.3:1 100:30 X.05 Fosetyl aluminum 1:3.3 30:100 X.05 Fosetyl aluminum 1:1 30:30 X.05 Chlorothalonil 1:1 100:100 X.05 Chlorothalonil 3.3:1 100:30 X.05 Chlorothalonil 1:3.3 30:100 X.05 Chlorothalonil 1:1 30:30 X.05 Mankozeb 1:1 100:100 X.05 Mankozeb 3.3:1 100:30 X.05 Mankozeb 1:3.3 30:100 X.05 Mankozeb 1:1 30:30

- 323 046368

X.05 Mandipropamide 1:1 100:100 X.05 Mandipropamide 3.3:1 100:30 X.05 Mandipropamide 1:3.3 30:100 X.05 Mandipropamide 1:1 30:30 X.05 Oxathiapiproline 1:1 100:100 X.05 Oxathiapiproline 3.3:1 100:30 X.05 Oxathiapiproline 1:3.3 30:100 X.05 Oxathiapiproline 1:1 30:30 X.05 Fluazinam 1:1 100:100 X.05 Fluazinam 3.3:1 100:30 X.05 Fluazinam 1:3.3 30:100 X.05 Fluazinam 1:1 30:30 X.05 Fludioxonil 1:1 100:100 X.05 Fludioxonil 3.3:1 100:30 X.05 Fludioxonil 1:3.3 30:100 X.05 Fludioxonil 1:1 30:30 X.05 Cyprodinil 1:1 100:100 X.05 Cyprodinil 3.3:1 100:30 X.05 Cyprodinil 1:3.3 30:100 X.05 Cyprodinil 1:1 30:30 X.05 Metalaxyl-M 1:1 100:100 X.05 Metalaxyl-M 3.3:1 100:30 X.05 Metalaxyl-M 1:3.3 30:100 X.05 Metalaxyl-M 1:1 30:30 X.05 Folpet 1:1 100:100 X.05 Folpet 3.3:1 100:30

- 324 046368

X.05 Folpet 1:3.3 30:100 X.05 Folpet 1:1 30:30 X.05 X'-[5-Bromo-2-methyl-6-(1methyl-2-propoxyethoxy)3-pyridyl]-X-ethyl-Xmethylformamidine 1.6:1 100:60 X.05 X'-[5-Bromo-2-methyl-6-(1methyl-2-propoxyethoxy)3-pyridyl]-X-ethyl-Xmethylformamidine 5:1 100:20 X.05 X'-[5-bromo-2-methyl-6-(1methyl-2-propoxyethoxy)3-pyridyl]-M-ethyl-Mmethylformamidine 1:2 30:60 X.05 X'-[5-Bromo-2-methyl-6-(1methyl-2-propoxyethoxy)3-pyridyl]-X-ethyl-Xmethylformamidine 3:2 30:20 X.05 X-Isopropyl-X'-[5methoxy-2-methyl-4-(2,2,2trifluoro-1-hydroxy-1 phenylethyl)phenyl]-Nmethylformamidine 1.6:1 100:60 X.05 X-Isopropyl-X'-[5methoxy-2-methyl-4-(2,2,2trifluoro-1-hydroxy-1 phenylethyl)phenyl]-Nmethylformamidine 5:1 100:20 X.05 X-Isopropyl-X'-[5methoxy-2-methyl-4-(2,2,2trifluoro-1 -hydroxy-1 - 1:2 30:60

- 325 046368

phenylethyl)phenyl]-Nmethylformamidine X.05 Ν-Π3θπροπΗπ-Ν'-[5methoxy-2-methyl-4-(2,2,2trifluoro-1-hydroxy-1 phenylethyl)phenyl]-Νmethylformamidine 3:2 30:20 X.05 Methyl-(2)-3-methoxy-2-[2methyl-5-[3(trifluoromethyl)pyrazol-1 yl]phenoxy]prop-2-enoate 1.6:1 100:60 X.05 Methyl-(2)-3-methoxy-2-[2methyl-5-[3(trifluoromethyl)pyrazol-1 yl]phenoxy]prop-2-enoate 5:1 100:20 X.05 Methyl-(2)-3-methoxy-2-[2methyl-5-[3(trifluoromethyl)pyrazol-1 yl]phenoxy]prop-2-enoate 1:2 30:60 X.05 Methyl-(2)-3-methoxy-2-[2methyl-5-[3(trifluoromethyl)pyrazol-1 yl]phenoxy]prop-2-enoate 3:2 30:20 X.05 Methyl-(2)-3-methoxy-2-[2methyl-5-(3propylpyrazol-1 yl)phenoxy]prop-2-enoate 1.6:1 100:60 X.05 Methyl-(2)-3-methoxy-2-[2methyl-5-(3propylpyrazol-1 yl)phenoxy]prop-2-enoate 5:1 100:20

- 326 046368

X.05 Methyl-(2)-3-methoxy-2-[2methyl-5-(3propylpyrazol-1 yl)phenoxy]prop-2-enoate 1:2 30:60 X.05 Methyl-(2)-3-methoxy-2-[2methyl-5-(3propylpyrazol-1 yl)phenoxy]prop-2-enoate 3:2 30:20 X.05 Methyl-(2)-2-(5- cyclohexyl-2methylphenoxy)-3 methoxyprop-2-enoate 1.6:1 100:60 X.05 Methyl-(2)-2-(5- cyclohexyl-2methylphenoxy)-3 methoxyprop-2-enoate 5:1 100:20 X.05 Methyl-(2)-2-(5- cyclohexyl-2methylphenoxy)-3 methoxyprop-2-enoate 1:2 30:60 X.05 Methyl-(2)-2-(5- cyclohexyl-2methylphenoxy)-3 methoxyprop-2-enoate 3:2 30:20 X.05 Methyl-(2)-2-(5cyclopentyl-2methylphenoxy)-3 methoxyprop-2-enoate 1.6:1 100:60 X.05 Methyl-(2)-2-(5cyclopentyl-2methylphenoxy)-3 - 5:1 100:20

- 327 046368

methoxyprop-2-enoate X.05 Methyl-(2)-2-(5cyclopentyl-2methylphenoxy)-3 methoxyprop-2-enoate 1:2 30:60 X.05 Methyl-(2)-2-(5cyclopentyl-2methylphenoxy)-3 methoxyprop-2-enoate 3:2 30:20 X.05 Methyl (2)-2-[5-(3isopropylpyrazol-1 -yl)2-methylphenoxy]-3 methoxyprop-2-enoate 1.6:1 100:60 X.05 methyl (2)-2-[5-(3isopropylpyrazol-1 -yl)2-methylphenoxy]-3 methoxyprop-2-enoate 5:1 100:20 X.05 Methyl (2)-2-[5-(3isopropylpyrazol-1 -yl)2-methylphenoxy]-3 methoxyprop-2-enoate 1:2 30:60 X.05 Methyl (2)-2-[5-(3isopropylpyrazol-1 -yl)2-methylphenoxy]-3 methoxyprop-2-enoate 3:2 30:20 X.05 Methyl-(2)-3-methoxy-2-[2methyl-5-(4propyltriazol-2yl)phenoxy]prop-2-enoate 1.6:1 100:60 X.05 Methyl-(2)-3-methoxy-2-[2methyl-5-(4- 5:1 100:20

- 328 046368

propyltriazol-2yl)phenoxy] prop-2-enoate X.05 Methyl-(2)-3-methoxy-2-[2methyl-5-(4propyltriazol-2yl)phenoxy]prop-2-enoate 1:2 30:60 X.05 Methyl-(2)-3-methoxy-2-[2methyl-5-(4propyltriazol-2yl)phenoxy]prop-2-enoate 3:2 30:20 X.05 Methyl-(2)-3-methoxy-2-[2methyl-5-[4(trifluoromethyl)triazol-2yl]phenoxy]prop-2-enoate 1.6:1 100:60 X.05 Methyl-(2)-3-methoxy-2-[2methyl-5-[4(trifluoromethyl)triazol-2yl]phenoxy]prop-2-enoate 5:1 100:20 X.05 Methyl-(2)-3-methoxy-2-[2methyl-5-[4(trifluoromethyl)triazol-2yl]phenoxy]prop-2-enoate 1:2 30:60 X.05 Methyl-(2)-3-methoxy-2-[2methyl-5-[4(trifluoromethyl)triazol-2yl]phenoxy]prop-2-enoate 3:2 30:20

Component A (connection) Component B A:B ratio Conc, (ppm) (A:B) X.07 Azoxystrobin 1.6:1 100:60 X.07 Azoxystrobin 5:1 100:20

- 329 046368

X.07 Azoxystrobin 1:2 30:60 X.07 Azoxystrobin 3:2 30:20 X.07 Trifloxystrobin 1.6:1 100:60 X.07 Trifloxystrobin 5:1 100:20 X.07 Trifloxystrobin 1:2 30:60 X.07 Trifloxystrobin 3:2 30:20 X.07 Methyltetraprole 1.6:1 100:60 X.07 Methyltetraprole 5:1 100:20 X.07 Methyltetraprole 1:2 30:60 X.07 Methyltetraprole 3:2 30:20 X.07 Ciproconazole 1.6:1 100:60 X.07 Ciproconazole 5:1 100:20 X.07 Ciproconazole 1:2 30:60 X.07 Ciproconazole 3:2 30:20 X.07 Difenoconazole 1:1 100:100 X.07 Difenoconazole 3.3:1 100:30 X.07 Difenoconazole 1:3.3 30:100 X.07 Difenoconazole 1:1 30:30 X.07 Hexaconazole 1:1 100:100 X.07 Hexaconazole 3.3:1 100:30 X.07 Hexaconazole 1:3.3 30:100 X.07 Hexaconazole 1:1 30:30 X.07 Propiconazole 1:1 100:100 X.07 Propiconazole 3.3:1 100:30 X.07 Propiconazole 1:3.3 30:100 X.07 Propiconazole 1:1 30:30

- 330 046368

X.07 Prothioconazole 1:1 100:100 X.07 Prothioconazole 3.3:1 100:30 X.07 Prothioconazole 1:3.3 30:100 X.07 Prothioconazole 1:1 30:30 X.07 Mefentrifluconazole 1.6:1 100:60 X.07 Mefentrifluconazole 5:1 100:20 X.07 Mefentrifluconazole 1:2 30:60 X.07 Mefentrifluconazole 3:2 30:20 X.07 Fenpropidine 1:1 100:100 X.07 Fenpropidine 3.3:1 100:30 X.07 Fenpropidine 1:3.3 30:100 X.07 Fenpropidine 1:1 30:30 X.07 Phenpropimorph 1:1 100:100 X.07 Phenpropimorph 3.3:1 100:30 X.07 Phenpropimorph 1:3.3 30:100 X.07 Phenpropimorph 1:1 30:30 X.07 Bixafen 1:1 100:60 X.07 Bixafen 3.3:1 100:20 X.07 Bixafen 1:2 30:60 X.07 Bixafen 3:2 30:20 X.07 Fluxapyroxad 1.6:1 100:60 X.07 Fluxapyroxad 5:1 100:20 X.07 Fluxapyroxad 1:2 30:60 X.07 Fluxapyroxad 3:2 30:20 X.07 Fluopyram 1:1 100:100 X.07 Fluopyram 3.3:1 100:30 X.07 Fluopyram 1:3.3 30:100

- 331 046368

X.07 Fluopyram 1:1 30:30 X.07 Benzovindiflupir 1.6:1 100:60 X.07 Benzovindiflupir 5:1 100:20 X.07 Benzovindiflupir 1:2 30:60 X.07 Benzovindiflupir 3:2 30:20 X.07 Pid iflu metof her 1:1 100:100 X.07 Pid iflu metof her 3.3:1 100:30 X.07 Pid iflu metof her 1:3.3 30:100 X.07 Pid iflu metof her 1:1 30:30 X.07 Isoflucipram 1.6:1 100:60 X.07 Isoflucipram 5:1 100:20 X.07 Isoflucipram 1:2 30:60 X.07 Isoflucipram 3:2 30:20 X.07 Fluindapir 1.6:1 100:60 X.07 Fluindapir 5:1 100:20 X.07 Fluindapir 1:2 30:60 X.07 Fluindapir 3:2 30:20 X.07 Florylpicoxamide 1:1 100:100 X.07 Florylpicoxamide 3.3:1 100:30 X.07 Florylpicoxamide 1:3.3 30:100 X.07 Florylpicoxamide 1:1 30:30 X.07 Metharylpicoxamide 1.6:1 100:60 X.07 Metharylpicoxamide 5:1 100:20 X.07 Metharylpicoxamide 1:2 30:60 X.07 Metharylpicoxamide 3:2 30:20 X.07 Fosetyl aluminum 1:1 100:100

- 332 046368

X.07 Fosetyl aluminum 3.3:1 100:30 X.07 Fosetyl aluminum 1:3.3 30:100 X.07 Fosetyl aluminum 1:1 30:30 X.07 Chlorothalonil 1:1 100:100 X.07 Chlorothalonil 3.3:1 100:30 X.07 Chlorothalonil 1:3.3 30:100 X.07 Chlorothalonil 1:1 30:30 X.07 Mankozeb 1:1 100:100 X.07 Mankozeb 3.3:1 100:30 X.07 Mankozeb 1:3.3 30:100 X.07 Mankozeb 1:1 30:30 X.07 Mandipropamide 1:1 100:100 X.07 Mandipropamide 3.3:1 100:30 X.07 Mandipropamide 1:3.3 30:100 X.07 Mandipropamide 1:1 30:30 X.07 Oxathiapiproline 1:1 100:100 X.07 Oxathiapiproline 3.3:1 100:30 X.07 Oxathiapiproline 1:3.3 30:100 X.07 Oxathiapiproline 1:1 30:30 X.07 Fluazinam 1:1 100:100 X.07 Fluazinam 3.3:1 100:30 X.07 Fluazinam 1:3.3 30:100 X.07 Fluazinam 1:1 30:30 X.07 Fludioxonil 1:1 100:100 X.07 Fludioxonil 3.3:1 100:30 X.07 Fludioxonil 1:3.3 30:100 X.07 Fludioxonil 1:1 30:30

- 333 046368

X.07 Cyprodinil 1:1 100:100 X.07 Cyprodinil 3.3:1 100:30 X.07 Cyprodinil 1:3.3 30:100 X.07 Cyprodinil 1:1 30:30 X.07 Metalaxyl-M 1:1 100:100 X.07 Metalaxyl-M 3.3:1 100:30 X.07 Metalaxyl-M 1:3.3 30:100 X.07 Metalaxyl-M 1:1 30:30 X.07 Folpet 1:1 100:100 X.07 Folpet 3.3:1 100:30 X.07 Folpet 1:3.3 30:100 X.07 Folpet 1:1 30:30 X.07 X'-[5-Bromo-2-methyl-6-(1methyl-2-propoxyethoxy)3-pyridyl]-X-ethyl-Xmethylformamidine 1.6:1 100:60 X.07 X'-[5-Bromo-2-methyl-6-(1methyl-2-propoxyethoxy)3-pyridyl]-X-ethyl-Xmethylformamidine 5:1 100:20 X.07 X'-[5-Bromo-2-methyl-6-(1methyl-2-propoxyethoxy)3-pyridyl]-X-ethyl-Xmethylformamidine 1:2 30:60 X.07 X'-[5-Bromo-2-methyl-6-(1methyl-2-propoxyethoxy)3-pyridyl]-X-ethyl-Xmethylformamidine 3:2 30:20

- 334 046368

X.07 X-Isopropyl-X'-[5methoxy-2-methyl-4-(2,2,2trifluoro-1-hydroxy-1 phenylethyl)phenyl]-Nmethylformamidine 1.6:1 100:60 X.07 X-Isopropyl-X'-[5methoxy-2-methyl-4-(2,2,2trifluoro-1-hydroxy-1 phenylethyl)phenyl]-Nmethylformamidine 5:1 100:20 X.07 X-Isopropyl-X'-[5methoxy-2-methyl-4-(2,2,2trifluoro-1-hydroxy-1 phenylethyl)phenyl]-Nmethylformamidine 1:2 30:60 X.07 X-Isopropyl-X'-[5methoxy-2-methyl-4-(2,2,2trifluoro-1-hydroxy-1 phenylethyl)phenyl]-Nmethylformamidine 3:2 30:20 X.07 Methyl-(2)-3-methoxy-2-[2methyl-5-[3(trifluoromethyl)pyrazol-1 yl]phenoxy]prop-2-enoate 1.6:1 100:60 X.07 Methyl-(2)-3-methoxy-2-[2methyl-5-[3(trifluoromethyl)pyrazol-1 yl]phenoxy]prop-2-enoate 5:1 100:20 X.07 Methyl-(2)-3-methoxy-2-[2methyl-5-[3(trifluoromethyl)pyrazol-1 yl]phenoxy]prop-2-enoate 1:2 30:60

- 335 046368

X.07 Methyl-(2)-3-methoxy-2-[2methyl-5-[3(trifluoromethyl)pyrazol-1 yl]phenoxy]prop-2-enoate 3:2 30:20 X.07 Methyl-(2)-3-methoxy-2-[2methyl-5-(3propylpyrazol-1 yl)phenoxy]prop-2-enoate 1.6:1 100:60 X.07 Methyl-(2)-3-methoxy-2-[2methyl-5-(3propylpyrazol-1 yl)phenoxy]prop-2-enoate 5:1 100:20 X.07 Methyl-(2)-3-methoxy-2-[2methyl-5-(3propylpyrazol-1 yl)phenoxy]prop-2-enoate 1:2 30:60 X.07 Methyl-(2)-3-methoxy-2-[2methyl-5-(3propylpyrazol-1 yl)phenoxy]prop-2-enoate 3:2 30:20 X.07 Methyl-(2)-2-(5- cyclohexyl-2methylphenoxy)-3 methoxyprop-2-enoate 1.6:1 100:60 X.07 Methyl-(2)-2-(5- cyclohexyl-2methylphenoxy)-3 methoxyprop-2-enoate 5:1 100:20 X.07 Methyl-(2)-2-(5cyclohexyl-2methylphenoxy)-3 - 1:2 30:60

- 336 046368

methoxyprop-2-enoate X.07 Methyl-(2)-2-(5- cyclohexyl-2methylphenoxy)-3 methoxyprop-2-enoate 3:2 30:20 X.07 Methyl-(2)-2-(5cyclopentyl-2methylphenoxy)-3 methoxyprop-2-enoate 1.6:1 100:60 X.07 Methyl-(2)-2-(5cyclopentyl-2methylphenoxy)-3 methoxyprop-2-enoate 5:1 100:20 X.07 Methyl-(2)-2-(5cyclopentyl-2methylphenoxy)-3 methoxyprop-2-enoate 1:2 30:60 X.07 Methyl (2)-2-(5cyclopentyl-2methylphenoxy)-3 methoxyprop-2-enoate 3:2 30:20 X.07 Methyl (2)-2-[5-(3isopropylpyrazol-1 -yl)2-methylphenoxy]-3 methoxyprop-2-enoate 1.6:1 100:60 X.07 Methyl (2)-2-[5-(3isopropylpyrazol-1 -yl)2-methylphenoxy]-3 methoxyprop-2-enoate 5:1 100:20 X.07 Methyl-(2)-2-[5-(3isopropylpyrazol-1 -yl)- 1:2 30:60

- 337 046368

2-methylphenoxy]-3 methoxyprop-2-enoate X.07 Methyl (2)-2-[5-(3isopropylpyrazol-1 -yl)2-methylphenoxy]-3 methoxyprop-2-enoate 3:2 30:20 X.07 Methyl-(2)-3-methoxy-2-[2methyl-5-(4propyltriazol-2yl)phenoxy]prop-2-enoate 1.6:1 100:60 X.07 Methyl-(2)-3-methoxy-2-[2methyl-5-(4propyltriazol-2yl)phenoxy]prop-2-enoate 5:1 100:20 X.07 Methyl-(2)-3-methoxy-2-[2methyl-5-(4propyltriazol-2yl)phenoxy]prop-2-enoate 1:2 30:60 X.07 Methyl-(2)-3-methoxy-2-[2methyl-5-(4propyltriazol-2yl)phenoxy]prop-2-enoate 3:2 30:20 X.07 Methyl-(2)-3-methoxy-2-[2methyl-5-[4(trifluoromethyl)triazol-2yl]phenoxy]prop-2-enoate 1.6:1 100:60 X.07 Methyl-(2)-3-methoxy-2-[2methyl-5-[4(trifluoromethyl)triazol-2yl]phenoxy]prop-2-enoate 5:1 100:20 X.07 Methyl-(2)-3-methoxy-2-[2- 1:2 30:60

- 338 046368

methyl-5-[4- (trifluoromethyl)triazol-2yl]phenoxy]prop-2-enoate X.07 Methyl-(2)-3-methoxy-2-[2methyl-5-[4(trifluoromethyl)triazol-2yl]phenoxy]prop-2-enoate 3:2 30:20

Component A (connection) Component B A:B ratio Conc, (ppm) (A:B) X.14 Azoxystrobin 1.6:1 100:60 X.14 Azoxystrobin 5:1 100:20 X.14 Azoxystrobin 1:2 30:60 X.14 Azoxystrobin 3:2 30:20 X.14 Trifloxystrobin 1.6:1 100:60 X.14 Trifloxystrobin 5:1 100:20 X.14 Trifloxystrobin 1:2 30:60 X.14 Trifloxystrobin 3:2 30:20 X.14 Methyltetraprole 1.6:1 100:60 X.14 Methyltetraprole 5:1 100:20 X.14 Methyltetraprole 1:2 30:60 X.14 Methyltetraprole 3:2 30:20 X.14 Ciproconazole 1.6:1 100:60 X.14 Ciproconazole 5:1 100:20 X.14 Ciproconazole 1:2 30:60 X.14 Ciproconazole 3:2 30:20 X.14 Difenoconazole 1:1 100:100 X.14 Difenoconazole 3.3:1 100:30

- 339 046368

X.14 Difenoconazole 1:3.3 30:100 X.14 Difenoconazole 1:1 30:30 X.14 Hexaconazole 1:1 100:100 X.14 Hexaconazole 3.3:1 100:30 X.14 Hexaconazole 1:3.3 30:100 X.14 Hexaconazole 1:1 30:30 X.14 Propiconazole 1:1 100:100 X.14 Propiconazole 3.3:1 100:30 X.14 Propiconazole 1:3.3 30:100 X.14 Propiconazole 1:1 30:30 X.14 Prothioconazole 1:1 100:100 X.14 Prothioconazole 3.3:1 100:30 X.14 Prothioconazole 1:3.3 30:100 X.14 Prothioconazole 1:1 30:30 X.14 Mefentrifluconazole 1.6:1 100:60 X.14 Mefentrifluconazole 5:1 100:20 X.14 Mefentrifluconazole 1:2 30:60 X.14 Mefentrifluconazole 3:2 30:20 X.14 Fenpropidine 1:1 100:100 X.14 Fenpropidine 3.3:1 100:30 X.14 Fenpropidine 1:3.3 30:100 X.14 Fenpropidine 1:1 30:30 X.14 Phenpropimorph 1:1 100:100 X.14 Phenpropimorph 3.3:1 100:30 X.14 Phenpropimorph 1:3.3 30:100 X.14 Phenpropimorph 1:1 30:30

- 340 046368

X.14 Bixafen 1:1 100:60 X.14 Bixafen 3.3:1 100:20 X.14 Bixafen 1:2 30:60 X.14 Bixafen 3:2 30:20 X.14 Fluxapyroxad 1.6:1 100:60 X.14 Fluxapyroxad 5:1 100:20 X.14 Fluxapyroxad 1:2 30:60 X.14 Fluxapyroxad 3:2 30:20 X.14 Fluopyram 1:1 100:100 X.14 Fluopyram 3.3:1 100:30 X.14 Fluopyram 1:3.3 30:100 X.14 Fluopyram 1:1 30:30 X.14 Benzovindiflupir 1.6:1 100:60 X.14 Benzovindiflupir 5:1 100:20 X.14 Benzovindiflupir 1:2 30:60 X.14 Benzovindiflupir 3:2 30:20 X.14 Pid if lu metof her 1:1 100:100 X.14 Pid if lu metof her 3.3:1 100:30 X.14 Pid iflu metof her 1:3.3 30:100 X.14 Pid iflu metof her 1:1 30:30 X.14 Isoflucipram 1.6:1 100:60 X.14 Isoflucipram 5:1 100:20 X.14 Isoflucipram 1:2 30:60 X.14 Isoflucipram 3:2 30:20 X.14 Fluindapir 1.6:1 100:60 X.14 Fluindapir 5:1 100:20 X.14 Fluindapir 1:2 30:60

- 341 046368

X.14 Fluindapir 3:2 30:20 X.14 Florylpicoxamide 1:1 100:100 X.14 Florylpicoxamide 3.3:1 100:30 X.14 Florylpicoxamide 1:3.3 30:100 X.14 Florylpicoxamide 1:1 30:30 X.14 Metharylpicoxamide 1.6:1 100:60 X.14 Metharylpicoxamide 5:1 100:20 X.14 Metharylpicoxamide 1:2 30:60 X.14 Metharylpicoxamide 3:2 30:20 X.14 Fosetyl aluminum 1:1 100:100 X.14 Fosetyl aluminum 3.3:1 100:30 X.14 Fosetyl aluminum 1:3.3 30:100 X.14 Fosetyl aluminum 1:1 30:30 X.14 Chlorothalonil 1:1 100:100 X.14 Chlorothalonil 3.3:1 100:30 X.14 Chlorothalonil 1:3.3 30:100 X.14 Chlorothalonil 1:1 30:30 X.14 Mankozeb 1:1 100:100 X.14 Mankozeb 3.3:1 100:30 X.14 Mankozeb 1:3.3 30:100 X.14 Mankozeb 1:1 30:30 X.14 Mandipropamide 1:1 100:100 X.14 Mandipropamide 3.3:1 100:30 X.14 Mandipropamide 1:3.3 30:100 X.14 Mandipropamide 1:1 30:30 X.14 Oxathiapiproline 1:1 100:100

- 342 046368

X.14 Oxathiapiproline 3.3:1 100:30 X.14 Oxathiapiproline 1:3.3 30:100 X.14 Oxathiapiproline 1:1 30:30 X.14 Fluazinam 1:1 100:100 X.14 Fluazinam 3.3:1 100:30 X.14 Fluazinam 1:3.3 30:100 X.14 Fluazinam 1:1 30:30 X.14 Fludioxonil 1:1 100:100 X.14 Fludioxonil 3.3:1 100:30 X.14 Fludioxonil 1:3.3 30:100 X.14 Fludioxonil 1:1 30:30 X.14 Cyprodinil 1:1 100:100 X.14 Cyprodinil 3.3:1 100:30 X.14 Cyprodinil 1:3.3 30:100 X.14 Cyprodinil 1:1 30:30 X.14 Metalaxyl-M 1:1 100:100 X.14 Metalaxyl-M 3.3:1 100:30 X.14 Metalaxyl-M 1:3.3 30:100 X.14 Metalaxyl-M 1:1 30:30 X.14 Folpet 1:1 100:100 X.14 Folpet 3.3:1 100:30 X.14 Folpet 1:3.3 30:100 X.14 Folpet 1:1 30:30 X.14 T\G-[5-Bromo-2-methyl-6-(1methyl-2-propoxyethoxy)3-pyridyl]-Ν-οτηπ-Νmethylformamidine 1.6:1 100:60

- 343 046368

X.14 X'-[5-Bromo-2-methyl-6-(1methyl-2-propoxyethoxy)3-pyridyl]-T4-ethyl-Xmethylformamidine 5:1 100:20 X.14 X'-[5-Bromo-2-methyl-6-(1methyl-2-propoxyethoxy)3-pyridyl]-X-ethyl-T4methylformamidine 1:2 30:60 X.14 X'-[5-Bromo-2-methyl-6-(1methyl-2-propoxyethoxy)3-pyridyl]-X-ethyl-T4methylformamidine 3:2 30:20 X.14 X-Isopropyl-X'-[5methoxy-2-methyl-4-(2,2,2trifluoro-1-hydroxy-1 phenylethyl)phenyl]-Nmethylformamidine 1.6:1 100:60 X.14 X-Isopropyl-X'-[5methoxy-2-methyl-4-(2,2,2trifluoro-1-hydroxy-1 phenylethyl)phenyl]-Nmethylformamidine 5:1 100:20 X.14 X-Isopropyl-X'-[5methoxy-2-methyl-4-(2,2,2trifluoro-1-hydroxy-1 phenylethyl)phenyl]-Nmethylformamidine 1:2 30:60 X.14 X-Isopropyl-X'-[5methoxy-2-methyl-4-(2,2,2trifluoro-1-hydroxy-1 phenylethyl)phenyl]-Nmethylformamidine 3:2 30:20

- 344 046368

X.14 Methyl-(2)-3-methoxy-2-[2methyl-5-[3(trifluoromethyl)pyrazol-1 yl]phenoxy]prop-2-enoate 1.6:1 100:60 X.14 Methyl-(2)-3-methoxy-2-[2methyl-5-[3(trifluoromethyl)pyrazol-1 yl]phenoxy]prop-2-enoate 5:1 100:20 X.14 Methyl-(2)-3-methoxy-2-[2methyl-5-[3(trifluoromethyl)pyrazol-1 yl]phenoxy]prop-2-enoate 1:2 30:60 X.14 Methyl-(2)-3-methoxy-2-[2methyl-5-[3(trifluoromethyl)pyrazol-1 yl]phenoxy]prop-2-enoate 3:2 30:20 X.14 Methyl-(2)-3-methoxy-2-[2methyl-5-(3propylpyrazol-1 yl)phenoxy]prop-2-enoate 1.6:1 100:60 X.14 Methyl-(2)-3-methoxy-2-[2methyl-5-(3propylpyrazol-1 yl)phenoxy]prop-2-enoate 5:1 100:20 X.14 Methyl-(2)-3-methoxy-2-[2methyl-5-(3propylpyrazol-1 yl)phenoxy]prop-2-enoate 1:2 30:60 X.14 Methyl-(2)-3-methoxy-2-[2methyl-5-(3propylpyrazole-1 - 3:2 30:20

- 345 046368

yl)phenoxy]prop-2-enoate X.14 Methyl-(2)-2-(5- cyclohexyl-2methylphenoxy)-3 methoxyprop-2-enoate 1.6:1 100:60 X.14 Methyl-(2)-2-(5- cyclohexyl-2methylphenoxy)-3 methoxyprop-2-enoate 5:1 100:20 X.14 Methyl-(2)-2-(5- cyclohexyl-2methylphenoxy)-3 methoxyprop-2-enoate 1:2 30:60 X.14 Methyl-(2)-2-(5- cyclohexyl-2methylphenoxy)-3 methoxyprop-2-enoate 3:2 30:20 X.14 Methyl-(2)-2-(5cyclopentyl-2methylphenoxy)-3 methoxyprop-2-enoate 1.6:1 100:60 X.14 Methyl-(2)-2-(5cyclopentyl-2methylphenoxy)-3 methoxyprop-2-enoate 5:1 100:20 X.14 Methyl-(2)-2-(5cyclopentyl-2methylphenoxy)-3 methoxyprop-2-enoate 1:2 30:60 X.14 Methyl-(2)-2-(5cyclopentyl-2- 3:2 30:20

- 346 046368

methylphenoxy)-3 methoxyprop-2-enoate X.14 Methyl (2)-2-[5-(3isopropylpyrazol-1 -yl)2-methylphenoxy]-3 methoxyprop-2-enoate 1.6:1 100:60 X.14 Methyl (2)-2-[5-(3isopropylpyrazol-1 -yl)2-methylphenoxy]-3 methoxyprop-2-enoate 5:1 100:20 X.14 Methyl (2)-2-[5-(3isopropylpyrazol-1 -yl)2-methylphenoxy]-3 methoxyprop-2-enoate 1:2 30:60 X.14 Methyl (2)-2-[5-(3isopropylpyrazol-1 -yl)2-methylphenoxy]-3 methoxyprop-2-enoate 3:2 30:20 X.14 Methyl-(2)-3-methoxy-2-[2methyl-5-(4propyltriazol-2yl)phenoxy]prop-2-enoate 1.6:1 100:60 X.14 Methyl-(2)-3-methoxy-2-[2methyl-5-(4propyltriazol-2yl)phenoxy]prop-2-enoate 5:1 100:20 X.14 Methyl-(2)-3-methoxy-2-[2methyl-5-(4propyltriazol-2yl)phenoxy]prop-2-enoate 1:2 30:60 X.14 Methyl-(2)-3-methoxy-2-[2- 3:2 30:20

- 347 046368

methyl 5-(4propyltriazol-2yl)phenoxy]prop-2-enoate X.14 Methyl-(2)-3-methoxy-2-[2methyl-5-[4(trifluoromethyl)triazol-2yl]phenoxy]prop-2-enoate 1.6:1 100:60 X.14 Methyl-(2)-3-methoxy-2-[2methyl-5-[4(trifluoromethyl)triazol-2yl]phenoxy]prop-2-enoate 5:1 100:20 X.14 Methyl-(2)-3-methoxy-2-[2methyl-5-[4(trifluoromethyl)triazol-2yl]phenoxy]prop-2-enoate 1:2 30:60 X.14 Methyl-(2)-3-methoxy-2-[2methyl-5-[4(trifluoromethyl)triazol-2yl]phenoxy]prop-2-enoate 3:2 30:20

Example B13. Treatment to prevent infestation/soybean/Phakopsora pachyrhizi (soybean rust)

Soybean leaf disks were placed on aqueous agar solution in multiwell plates (24-well format) and sprayed with the formulated test compounds diluted in water. One day after application, leaf discs were inoculated by spraying a spore suspension onto the lower surface of the leaf. After an incubation period of 24-36 hours in the climate chamber in the dark at 20°C and 75% relative humidity, the leaf disc was kept at 20°C with 12 hours of light/day and 75% relative humidity. The activity of the mixture composition was assessed as a percentage of disease control compared to untreated material when the corresponding degree of disease damage was observed on untreated control leaf discs (12-14 days after application). The following mixture formulations (A:B) at the indicated concentration (in ppm) provided at least 70% disease control in this test compared to the untreated control, which showed extensive disease development under the same conditions.

- 348 046368

Component A (connection) Component B Ratio A:B Conc. (PPt) (A:B) X.05 Azoxystrobin 2:1 200:100 X.05 Azoxystrobin 6.6:1 200:30 X.05 Azoxystrobin 1:1.6 60:100 X.05 Azoxystrobin 2:1 60:30 X.05 Trifloxystrobin 2:1 200:100 X.05 Trifloxystrobin 6.6:1 200:30 X.05 Trifloxystrobin 1:1.6 60:100 X.05 Trifloxystrobin 2:1 60:30 X.05 Methyltetraprole 2:1 200:100 X.05 Methyltetraprole 6.6:1 200:30 X.05 Methyltetraprole 1:1.6 60:100 X.05 Methyltetraprole 2:1 60:30 X.05 Cyproconazole 2:1 200:100 X.05 Ciproconazole 6.6:1 200:30 X.05 Ciproconazole 1:1.6 60:100 X.05 Cyproconazole 2:1 60:30 X.05 Difenoconazole 2:1 200:100 X.05 Difenoconazole 6.6:1 200:30 X.05 Difenoconazole 1:1.6 60:100 X.05 Difenoconazole 2:1 60:30

- 349 046368

X.05 Hexaconazole 2:1 200:100 X.05 Hexaconazole 6.6:1 200:30 X.05 Hexaconazole 1:1.6 60:100 X.05 Hexaconazole 2:1 60:30 X.05 Prothioconazole 2:1 200:100 X.05 Prothioconazole 6.6:1 200:30 X.05 Prothioconazole 1:1.6 60:100 X.05 Prothioconazole 2:1 60:30 X.05 Mefentrifluconazole 2:1 200:100 X.05 Mefentrifluconazole 6.6:1 200:30 X.05 Mefentrifluconazole 1:1.6 60:100 X.05 Mefentrifluconazole 2:1 60:30 X.05 Fenpropidine 2:1 200:100 X.05 Fenpropidine 6.6:1 200:30 X.05 Fenpropidine 1:1.6 60:100 X.05 Fenpropidine 2:1 60:30 X.05 Phenpropimorph 2:1 200:100 X.05 Phenpropimorph 6.6:1 200:30 X.05 Phenpropimorph 1:1.6 60:100 X.05 Phenpropimorph 2:1 60:30 X.05 Fluxapyroxad 2:1 200:100 X.05 Fluxapyroxad 6.6:1 200:30 X.05 Fluxapyroxad 1:1.6 60:100 X.05 Fluxapyroxad 2:1 60:30 X.05 Fluopyram 2:1 200:100 X.05 Fluopyram 6.6:1 200:30 X.05 Fluopyram 1:1.6 60:100

- 350 046368

X.05 Fluopyram 2:1 60:30 X.05 Benzovindiflupir 33.3:1 200:6 X.05 Benzovindiflupir 100:1 200:2 X.05 Benzovindiflupir 10:1 60:6 X.05 Benzovindiflupir 30:1 60:2 X.05 Pidiflumetofen 2:1 200:100 X.05 Pidiflumetofen 6.6:1 200:30 X.05 Pidiflumetofen 1:1.6 60:100 X.05 Pidiflumetofen 2:1 60:30 X.05 Fluindapir 3.3:1 200:60 X.05 Fluindapir 33.3:1 200:6 X.05 Fluindapir 1:1 60:60 X.05 Fluindapir 10:1 60:6 X.05 Florylpicoxamide 2:1 200:100 X.05 Florylpicoxamide 6.6:1 200:30 X.05 Florylpicoxamide 1:1.6 60:100 X.05 Florylpicoxamide 2:1 60:30 X.05 Metharylpicoxamide 3.3:1 200:60 X.05 Metharylpicoxamide 33.3:1 200:6 X.05 Metharylpicoxamide 1:1 60:60 X.05 Metharylpicoxamide 10:1 60:6 X.05 Chlorothalonil 2:1 200:100 X.05 Chlorothalonil 6.6:1 200:30 X.05 Chlorothalonil 1:1.6 60:100 X.05 Chlorothalonil 2:1 60:30 X.05 Mankozeb 2:1 200:100

- 351 046368

X.05 Mankozeb 6.6:1 200:30 X.05 Mankozeb 1:1.6 60:100 X.05 Mankozeb 2:1 60:30 X.05 Mandipropamide 2:1 200:100 X.05 Mandipropamide 6.6:1 200:30 X.05 Mandipropamide 1:1.6 60:100 X.05 Mandipropamide 2:1 60:30 X.05 Oxathiapiproline 2:1 200:100 X.05 Oxathiapiproline 6.6:1 200:30 X.05 Oxathiapiproline 1:1.6 60:100 X.05 Oxathiapiproline 2:1 60:30 X.05 Fludioxonil 2:1 200:100 X.05 Fludioxonil 6.6:1 200:30 X.05 Fludioxonil 1:1.6 60:100 X.05 Fludioxonil 2:1 60:30 X.05 Cyprodinil 2:1 200:100 X.05 Cyprodinil 6.6:1 200:30 X.05 Cyprodinil 1:1.6 60:100 X.05 Cyprodinil 2:1 60:30 X.05 Metalaxyl-M 2:1 200:100 X.05 Metalaxyl-M 6.6:1 200:30 X.05 Metalaxyl-M 1:1.6 60:100 X.05 Metalaxyl-M 2:1 60:30 X.05 X'-[5-Bromo-2-methyl-6-(1-methyl-2propoxyethoxy)-3-pyridyl]-X-ethyl-Xmethylformamidine 2:1 200:100 X.05 X'-[5-Bromo-2-methyl-6-(1-methyl-2- 6.6:1 200:30

- 352 046368

propoxyethoxy)-3-pyridyl]-X-ethyl-Xmethylformamidine X.05 X'-[5-Bromo-2-methyl-6-(1-methyl-2propoxyethoxy)-3-pyridyl]-X-ethyl-Xmethylformamidine 1:1.6 60:100 X.05 T4'-[5-Bromo-2-methyl-6-(1-methyl-2propoxyethoxy)-3-pyridyl]-X-ethyl-Xmethylformamidine 2:1 60:30 X.05 X-Isopropyl-X'-[5-methoxy-2-methyl-4(2,2,2-trifluoro-1-hydroxy-1 phenylethyl)phenyl]-X-methylformamidine 2:1 200:100 X.05 X-Isopropyl-X'-[5-methoxy-2-methyl-4(2,2,2-trifluoro-1-hydroxy-1 phenylethyl)phenyl]-X-methylformamidine 6.6:1 200:30 X.05 X-Isopropyl-X'-[5-methoxy-2-methyl-4(2,2,2-trifluoro-1-hydroxy-1 phenylethyl)phenyl]-X-methylformamidine 1:1.6 60:100 X.05 X-Isopropyl-X'-[5-methoxy-2-methyl-4(2,2,2-trifluoro-1-hydroxy-1 phenylethyl)phenyl]-X-methylformamidine 2:1 60:30 X.05 Methyl-(2)-3-methoxy-2-[2-methyl-5-[3 (trifluoromethyl)pyrazol-1 yl]phenoxy]prop-2-enoate 2:1 200:100 X.05 Methyl-(2)-3-methoxy-2-[2-methyl-5-[3 (trifluoromethyl)pyrazol-1 yl]phenoxy]prop-2-enoate 6.6:1 200:30 X.05 Methyl-(2)-3-methoxy-2-[2-methyl-5-[3 (trifluoromethyl)pyrazol-1 yl]phenoxy]prop-2-enoate 1:1.6 60:100 X.05 Methyl-(2)-3-methoxy-2-[2-methyl-5 -[3 (trifluoromethyl)pyrazole-1 - 2:1 60:30

- 353 046368

yl]phenoxy]prop-2-enoate X.05 Methyl-(2)-3-methoxy-2-[2-methyl-5-(3 propylpyrazol-1-yl)phenoxy]prop-2enoate 2:1 200:100 X.05 Methyl-(2)-3-methoxy-2-[2-methyl-5-(3 propylpyrazol-1-yl)phenoxy]prop-2enoate 6.6:1 200:30 X.05 Methyl-(2)-3-methoxy-2-[2-methyl-5-(3 propylpyrazol-1-yl)phenoxy]prop-2enoate 1:1.6 60:100 X.05 Methyl-(2)-3-methoxy-2-[2-methyl-5-(3 propylpyrazol-1-yl)phenoxy]prop-2enoate 2:1 60:30 X.05 Methyl-(2)-2-(5-cyclohexyl-2methylphenoxy)-3-methoxyprop-2-enoate 2:1 200:100 X.05 Methyl-(2)-2-(5-cyclohexyl-2methylphenoxy)-3-methoxyprop-2-enoate 6.6:1 200:30 X.05 Methyl-(2)-2-(5-cyclohexyl-2methylphenoxy)-3-methoxyprop-2-enoate 1:1.6 60:100 X.05 Methyl-(2)-2-(5-cyclohexyl-2methylphenoxy)-3-methoxyprop-2-enoate 2:1 60:30 X.05 Methyl-(2)-2-(5-cyclopentyl-2methylphenoxy)-3-methoxyprop-2-enoate 2:1 200:100 X.05 Methyl-(2)-2-(5-cyclopentyl-2methylphenoxy)-3-methoxyprop-2-enoate 6.6:1 200:30 X.05 Methyl-(2)-2-(5-cyclopentyl-2methylphenoxy)-3-methoxyprop-2-enoate 1:1.6 60:100 X.05 Methyl-(2)-2-(5-cyclopentyl-2methylphenoxy)-3-methoxyprop-2-enoate 2:1 60:30

- 354 046368

X.05 Methyl-(2)-2-[5-(3-isopropylpyrazol-1 yl)-2-methylphenoxy]-3-methoxyprop-2enoate 2:1 200:100 X.05 Methyl-(2)-2-[5-(3-isopropylpyrazol-1 yl)-2-methylphenoxy]-3-methoxyprop-2enoate 6.6:1 200:30 X.05 Methyl-(2)-2-[5-(3-isopropylpyrazol-1 yl)-2-methylphenoxy]-3-methoxyprop-2enoate 1:1.6 60:100 X.05 Methyl-(2)-2-[5-(3-isopropylpyrazol-1 yl)-2-methylphenoxy]-3-methoxyprop-2enoate 2:1 60:30 X.05 Methyl-(2)-3-methoxy-2-[2-methyl-5-(4propyltriazol-2-yl)phenoxy]prop-2enoate 2:1 200:100 X.05 Methyl-(2)-3-methoxy-2-[2-methyl-5-(4propyltriazol-2-yl)phenoxy]prop-2enoate 6.6:1 200:30 X.05 Methyl-(2)-3-methoxy-2-[2-methyl-5-(4propyltriazol-2-yl)phenoxy]prop-2enoate 1:1.6 60:100 X.05 Methyl-(2)-3-methoxy-2-[2-methyl-5-(4propyltriazol-2-yl)phenoxy]prop-2enoate 2:1 60:30 X.05 Methyl-(2)-3-methoxy-2-[2-methyl-5-[4(trifluoromethyl)triazol-2yl]phenoxy]prop-2-enoate 2:1 200:100 X.05 Methyl-(2)-3-methoxy-2-[2-methyl-5-[4(trifluoromethyl)triazol-2yl]phenoxy]prop-2-enoate 6.6:1 200:30 X.05 Methyl-(2)-3-methoxy-2-[2-methyl-5 - [4- 1:1.6 60:100

- 355 046368

(trifluoromethyl)triazol-2yl]phenoxy]prop-2-enoate X.05 Methyl-(2)-3-methoxy-2-[2-methyl-5-[4(trifluoromethyl)triazol-2yl]phenoxy]prop-2-enoate 2:1 60:30 X.05 TAEGRO® 2:1 200:100 X.05 TAEGRO® 6.6:1 200:30 X.05 TAEGRO® 1:1.6 60:100 X.05 TAEGRO® 2:1 60:30 X.05 Timorex GoldTM 2:1 200:100 X.05 Timorex GoldTM 6.6:1 200:30 X.05 Timorex GoldTM 1:1.6 60:100 X.05 Timorex GoldTM 2:1 60:30 X.05 X-Methoxy-T4-[[4-[5-(trifluoromethyl)-1,2,4oxadiazol-3yl]phenyl]methyl]cyclopropanecarboxamide 3.3:1 200:60 X.05 X-Methoxy-X-[[4-[5-(trifluoromethyl)-1,2,4oxadiazol-3yl]phenyl]methyl]cyclopropanecarboxamide 33.3:1 200:6 X.05 X-Methoxy-X-[[4-[5-(trifluoromethyl)-1,2,4oxadiazol-3yl]phenyl]methyl]cyclopropanecarboxamide 1:1 60:60 X.05 X-Methoxy-X-[[4-[5-(trifluoromethyl)-1,2,4oxadiazol-3yl]phenyl]methyl]cyclopropanecarboxamide 10:1 60:6 X.05 X,2-Dimethoxy-T4-[[4-[5-(trifluoromethyl)1,2,4-oxadiazol-3 yl]phenyl]methyl]propanamide 3.3:1 200:60 X.05 X,2-Dimethoxy-X-[[4-[5-(trifluoromethyl)- 33.3:1 200:6

- 356 046368

1,2,4-oxadiazol-3 yl]phenyl]methyl]propanamide X.05 X,2-Dimethoxy-X-[[4-[5-(trifluoromethyl)1,2,4-oxadiazol-3 yl]phenyl]methyl]propanamide 1:1 60:60 X.05 X,2-Dimethoxy-X-[[4-[5-(trifluoromethyl)1,2,4-oxadiazol-3 yl]phenyl]methyl]propanamide 10:1 60:6 X.05 X-Ethyl-2-methyl-X-[[4-[5-(trifluoromethyl)1,2,4-oxadiazol-3 yl]phenyl]methyl]propanamide 3.3:1 200:60 X.05 X-Ethyl-2-methyl-X-[[4-[5-(trifluoromethyl)1,2,4-oxadiazol-3 yl]phenyl]methyl]propanamide 33.3:1 200:6 X.05 X-Ethyl-2-methyl-X-[[4-[5-(trifluoromethyl)1,2,4-oxadiazol-3 yl]phenyl]methyl]propanamide 1:1 60:60 X.05 X-Ethyl-2-methyl-X-[[4-[5-(trifluoromethyl)1,2,4-oxadiazol-3 yl]phenyl]methyl]propanamide 10:1 60:6 X.05 1-Methoxy-3-methyl-1-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3 yl]phenyl]methyl]urea 3.3:1 200:60 X.05 1-Methoxy-3-methyl-1-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3 yl]phenyl]methyl]urea 33.3:1 200:6 X.05 1-Methoxy-3-methyl-1-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3 yl]phenyl]methyl]urea 1:1 60:60 X.05 1 -Methoxy-3 -methyl-1 -[ [4-[5(trifluoromethyl)-1,2,4-oxadiazol-3 - 10:1 60:6

- 357 046368

yl]phenyl]methyl]urea X.05 1,3 - Dimethoxy-1 - [ [4- [ 5 -(trifluoromethyl)- 1,2,4-oxadiazol-3 yl]phenyl]methyl]urea 3.3:1 200:60 X.05 1,3 - Dimethoxy-1 - [[4-[5-(trifluoromethyl)1,2,4-oxadiazol-3 yl]phenyl]methyl]urea 33.3:1 200:6 X.05 1,3 - Dimethoxy-1 - [[4-[5-(trifluoromethyl)1,2,4-oxadiazol-3 yl]phenyl]methyl]urea 1:1 60:60 X.05 1,3 - Dimethoxy-1 - [[4-[5-(trifluoromethyl)1,2,4-oxadiazol-3 yl]phenyl]methyl]urea 10:1 60:6 X.05 3 -Ethyl-1-methoxy-1 - [[4-[5 (trifluoromethyl)-1,2,4-oxadiazol-3 yl]phenyl]methyl]urea 3.3:1 200:60 X.05 3 -Ethyl-1-methoxy-1 - [[4-[5 (trifluoromethyl)-1,2,4-oxadiazol-3 yl]phenyl]methyl]urea 33.3:1 200:6 X.05 3 -Ethyl-1-methoxy-1 - [[4-[5 (trifluoromethyl)-1,2,4-oxadiazol-3 yl]phenyl]methyl]urea 1:1 60:60 X.05 3 -Ethyl-1-methoxy-1 - [[4-[5 (trifluoromethyl)-1,2,4-oxadiazol-3 yl]phenyl]methyl]urea 10:1 60:6 X.05 Ethyl 1-[[4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]phenyl]methyl]pyrazole-4carboxylate 3.3:1 200:60 X.05 Ethyl-1-[[4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]phenyl]methyl]pyrazol-4- 33.3:1 200:6

- 358 046368

carboxylate X.05 Ethyl-1-[[4-[5-(trifluoromethyl)-1,2,4oxad iazol-3-yl]phenyl]methyl]pyrazole-4carboxylate 1:1 60:60 X.05 Ethyl-1-[[4-[5-(trifluoromethyl)-1,2,4oxad iazol-3-yl]phenyl]methyl]pyrazole-4carboxylate 10:1 60:6

Component A (connection) Component B Ratio A:B Conc. (PPt) (A:B) X.07 Azoxystrobin 2:1 200:100 X.07 Azoxystrobin 6.6:1 200:30 X.07 Azoxystrobin 1:1.6 60:100 X.07 Azoxystrobin 2:1 60:30 X.07 Trifloxystrobin 2:1 200:100 X.07 Trifloxystrobin 6.6:1 200:30 X.07 Trifloxystrobin 1:1.6 60:100 X.07 Trifloxystrobin 2:1 60:30 X.07 Methyltetraprole 2:1 200:100 X.07 Methyltetraprole 6.6:1 200:30 X.07 Methyltetraprole 1:1.6 60:100 X.07 Methyltetraprole 2:1 60:30 X.07 Ciproconazole 2:1 200:100 X.07 Ciproconazole 6.6:1 200:30 X.07 Ciproconazole 1:1.6 60:100 X.07 Cyproconazole 2:1 60:30 X.07 Difenoconazole 2:1 200:100 X.07 Difenoconazole 6.6:1 200:30

- 359 046368

X.07 Difenoconazole 1:1.6 60:100 X.07 Difenoconazole 2:1 60:30 X.07 Hexaconazole 2:1 200:100 X.07 Hexaconazole 6.6:1 200:30 X.07 Hexaconazole 1:1.6 60:100 X.07 Hexaconazole 2:1 60:30 X.07 Prothioconazole 2:1 200:100 X.07 Prothioconazole 6.6:1 200:30 X.07 Prothioconazole 1:1.6 60:100 X.07 Prothioconazole 2:1 60:30 X.07 Mefentrifluconazole 2:1 200:100 X.07 Mefentrifluconazole 6.6:1 200:30 X.07 Mefentrifluconazole 1:1.6 60:100 X.07 Mefentrifluconazole 2:1 60:30 X.07 Fenpropidine 2:1 200:100 X.07 Fenpropidine 6.6:1 200:30 X.07 Fenpropidine 1:1.6 60:100 X.07 Fenpropidine 2:1 60:30 X.07 Phenpropimorph 2:1 200:100 X.07 Phenpropimorph 6.6:1 200:30 X.07 Phenpropimorph 1:1.6 60:100 X.07 Phenpropimorph 2:1 60:30 X.07 Fluxapyroxad 2:1 200:100 X.07 Fluxapyroxad 6.6:1 200:30 X.07 Fluxapyroxad 1:1.6 60:100 X.07 Fluxapyroxad 2:1 60:30

- 360 046368

X.07 Fluopyram 2:1 200:100 X.07 Fluopyram 6.6:1 200:30 X.07 Fluopyram 1:1.6 60:100 X.07 Fluopyram 2:1 60:30 X.07 Benzovindiflupir 33.3:1 200:6 X.07 Benzovindiflupir 100:1 200:2 X.07 Benzovindiflupir 10:1 60:6 X.07 Benzovindiflupir 30:1 60:2 X.07 Pid if lu metof en 2:1 200:100 X.07 Pid if lu metof en 6.6:1 200:30 X.07 Pid iflu metof en 1:1.6 60:100 X.07 Pid iflu metof en 2:1 60:30 X.07 Fluindapir 3.3:1 200:60 X.07 Fluindapir 33.3:1 200:6 X.07 Fluindapir 1:1 60:60 X.07 Fluindapir 10:1 60:6 X.07 Florylpicoxamide 2:1 200:100 X.07 Florylpicoxamide 6.6:1 200:30 X.07 Florylpicoxamide 1:1.6 60:100 X.07 Florylpicoxamide 2:1 60:30 X.07 Metharylpicoxamide 3.3:1 200:60 X.07 Metharylpicoxamide 33.3:1 200:6 X.07 Metharylpicoxamide 1:1 60:60 X.07 Metharylpicoxamide 10:1 60:6 X.07 Chlorothalonil 2:1 200:100 X.07 Chlorothalonil 6.6:1 200:30 X.07 Chlorothalonil 1:1.6 60:100

- 361 046368

X.07 Chlorothalonil 2:1 60:30 X.07 Mankozeb 2:1 200:100 X.07 Mankozeb 6.6:1 200:30 X.07 Mankozeb 1:1.6 60:100 X.07 Mankozeb 2:1 60:30 X.07 Mandipropamide 6.6:1 200:30 X.07 Mandipropamide 1:1.6 60:100 X.07 Mandipropamide 2:1 60:30 X.07 Oxathiapiproline 1:1.6 60:100 X.07 Oxathiapiproline 2:1 60:30 X.07 Fludioxonil 1:1.6 60:100 X.07 Fludioxonil 2:1 60:30 X.07 Cyprodinil 1:1.6 60:100 X.07 Cyprodinil 2:1 60:30 X.07 Metalaxyl-M 1:1.6 60:100 X.07 Metalaxyl-M 2:1 60:30 X.07 X'-[5-Bromo-2-methyl-6-(1-methyl-2propoxyethoxy)-3-pyridyl]-Ν-3ΤΠΠ-Νmethylformamidine 2:1 200:100 X.07 X'-[5-Bromo-2-methyl-6-(1-methyl-2propoxyethoxy)-3-pyridyl]-Ν-3ΤΠΠ-Νmethylformamidine 6.6:1 200:30 X.07 X'-[5-Bromo-2-methyl-6-(1-methyl-2propoxyethoxy)-3-pyridyl]-Ν-3ΤΠΠ-Νmethylformamidine 1:1.6 60:100 X.07 X'-[5-Bromo-2-methyl-6-(1-methyl-2- 2:1 60:30

- 362 046368

propoxyethoxy)-3-pyridyl]-X-ethyl-Xmethylformamidine X.07 X-Isopropyl-X'-[5-methoxy-2-methyl-4(2,2,2-trifluoro-1-hydroxy-1 phenylethyl)phenyl]-X-methylformamidine 2:1 200:100 X.07 X-Isopropyl-X'-[5-methoxy-2-methyl-4(2,2,2-trifluoro-1-hydroxy-1 phenylethyl)phenyl]-X-methylformamidine 6.6:1 200:30 X.07 X-Isopropyl-X'-[5-methoxy-2-methyl-4(2,2,2-trifluoro-1-hydroxy-1 phenylethyl)phenyl]-X-methylformamidine 1:1.6 60:100 X.07 X-Isopropyl-X'-[5-methoxy-2-methyl-4(2,2,2-trifluoro-1-hydroxy-1 phenylethyl)phenyl]-X-methylformamidine 2:1 60:30 X.07 Methyl-(2)-3-methoxy-2-[2-methyl-5-[3 (trifluoromethyl)pyrazol-1 yl]phenoxy]prop-2-enoate 2:1 200:100 X.07 Methyl-(2)-3-methoxy-2-[2-methyl-5-[3 (trifluoromethyl)pyrazol-1 yl]phenoxy]prop-2-enoate 6.6:1 200:30 X.07 Methyl-(2)-3-methoxy-2-[2-methyl-5-[3 (trifluoromethyl)pyrazol-1 yl]phenoxy]prop-2-enoate 1:1.6 60:100 X.07 Methyl-(2)-3-methoxy-2-[2-methyl-5-[3 (trifluoromethyl)pyrazol-1 yl]phenoxy]prop-2-enoate 2:1 60:30 X.07 Methyl-(2)-3-methoxy-2-[2-methyl-5-(3 propylpyrazol-1-yl)phenoxy]prop-2enoate 2:1 200:100 X.07 Methyl-(2)-3-methoxy-2-[2-methyl-5 -(3 - 6.6:1 200:30

- 363 046368

propylpyrazol-1-yl)phenoxy] prop-2enoate X.07 Methyl-(2)-3-methoxy-2-[2-methyl-5-(3 propylpyrazol-1-yl)phenoxy]prop-2enoate 1:1.6 60:100 X.07 Methyl-(2)-3-methoxy-2-[2-methyl-5-(3 propylpyrazol-1-yl)phenoxy]prop-2enoate 2:1 60:30 X.07 Methyl (2)-2-(5-cyclohexyl-2methylphenoxy)-3-methoxyprop-2-enoate 2:1 200:100 X.07 Methyl (2)-2-(5-cyclohexyl-2methylphenoxy)-3-methoxyprop-2-enoate 6.6:1 200:30 X.07 Methyl (2)-2-(5-cyclohexyl-2methylphenoxy)-3-methoxyprop-2-enoate 1:1.6 60:100 X.07 Methyl (2)-2-(5-cyclohexyl-2methylphenoxy)-3-methoxyprop-2-enoate 2:1 60:30 X.07 Methyl (2)-2-(5-cyclopentyl-2methylphenoxy)-3-methoxyprop-2-enoate 2:1 200:100 X.07 Methyl (2)-2-(5-cyclopentyl-2methylphenoxy)-3-methoxyprop-2-enoate 6.6:1 200:30 X.07 Methyl (2)-2-(5-cyclopentyl-2methylphenoxy)-3-methoxyprop-2-enoate 1:1.6 60:100 X.07 Methyl (2)-2-(5-cyclopentyl-2methylphenoxy)-3-methoxyprop-2-enoate 2:1 60:30 X.07 Methyl-(2)-2-[5-(3-isopropylpyrazol-1 yl)-2-methylphenoxy]-3-methoxyprop-2enoate 2:1 200:100 X.07 Methyl-(2)-2-[5-(3-isopropylpyrazol-1 yl)-2-methylphenoxy]-3-methoxyprop-2enoate 6.6:1 200:30

- 364 046368

X.07 Methyl-(2)-2-[5-(3-isopropylpyrazol-1 yl)-2-methylphenoxy]-3-methoxyprop-2enoate 1:1.6 60:100 X.07 Methyl-(2)-2-[5-(3-isopropylpyrazol-1 yl)-2-methylphenoxy]-3-methoxyprop-2enoate 2:1 60:30 X.07 Methyl-(2)-3-methoxy-2-[2-methyl-5-(4propyltriazol-2-yl)phenoxy]prop-2enoate 2:1 200:100 X.07 Methyl-(2)-3-methoxy-2-[2-methyl-5-(4propyltriazol-2-yl)phenoxy]prop-2enoate 6.6:1 200:30 X.07 Methyl-(2)-3-methoxy-2-[2-methyl-5-(4propyltriazol-2-yl)phenoxy]prop-2enoate 1:1.6 60:100 X.07 Methyl-(2)-3-methoxy-2-[2-methyl-5-(4propyltriazol-2-yl)phenoxy]prop-2enoate 2:1 60:30 X.07 Methyl (2)-3-methoxy-2-[2-methyl-5-[4(trifluoromethyl)triazol-2yl]phenoxy]prop-2-enoate 2:1 200:100 X.07 Methyl (2)-3-methoxy-2-[2-methyl-5-[4(trifluoromethyl)triazol-2yl]phenoxy]prop-2-enoate 6.6:1 200:30 X.07 Methyl (2)-3-methoxy-2-[2-methyl-5-[4(trifluoromethyl)triazol-2yl]phenoxy]prop-2-enoate 1:1.6 60:100 X.07 Methyl (2)-3-methoxy-2-[2-methyl-5-[4(trifluoromethyl)triazol-2yl]phenoxy]prop-2-enoate 2:1 60:30

- 365 046368

X.07 TAEGRO® 2:1 200:100 X.07 TAEGRO® 6.6:1 200:30 X.07 TAEGRO® 1:1.6 60:100 X.07 TAEGRO® 2:1 60:30 X.07 Timorex GoldTM 2:1 200:100 X.07 Timorex GoldTM 1:1.6 60:100 X.07 Timorex GoldTM 2:1 60:30 X.07 X-Methoxy-X-[[4-[5-(trifluoromethyl)-1,2,4oxadiazol-3yl]phenyl]methyl]cyclopropanecarboxamide 3.3:1 200:60 X.07 X-Methoxy-X-[[4-[5-(trifluoromethyl)-1,2,4oxadiazol-3yl]phenyl]methyl]cyclopropanecarboxamide 33.3:1 200:6 X.07 X-Methoxy-X-[[4-[5-(trifluoromethyl)-1,2,4oxadiazol-3yl]phenyl]methyl]cyclopropanecarboxamide 1:1 60:60 X.07 X-Methoxy-X-[[4-[5-(trifluoromethyl)-1,2,4oxadiazol-3yl]phenyl]methyl]cyclopropanecarboxamide 10:1 60:6 X.07 X,2-Dimethoxy-X-[[4-[5-(trifluoromethyl)1,2,4-oxadiazol-3 yl]phenyl]methyl]propanamide 3.3:1 200:60 X.07 X,2-Dimethoxy-T4-[[4-[5-(trifluoromethyl)1,2,4-oxadiazol-3 yl]phenyl]methyl]propanamide 33.3:1 200:6 X.07 X,2-Dimethoxy-X-[[4-[5-(trifluoromethyl)1,2,4-oxadiazol-3 yl]phenyl]methyl]propanamide 1:1 60:60 X.07 X,2-Dimethoxy-X-[[4-[5-(trifluoromethyl)- 1,2,4-oxadiazole-3 - 10:1 60:6

- 366 046368

yl]phenyl]methyl]propanamide X.07 X-Ethyl-2-methyl-X-[[4-[5-(trifluoromethyl)1,2,4-oxadiazol-3 yl]phenyl]methyl]propanamide 3.3:1 200:60 X.07 X-Ethyl-2-methyl-X-[[4-[5-(trifluoromethyl)1,2,4-oxadiazol-3 yl]phenyl]methyl]propanamide 33.3:1 200:6 X.07 X-Ethyl-2-methyl-X-[[4-[5-(trifluoromethyl)1,2,4-oxadiazol-3 yl]phenyl]methyl]propanamide 1:1 60:60 X.07 X-Ethyl-2-methyl-X-[[4-[5-(trifluoromethyl)1,2,4-oxadiazol-3 yl]phenyl]methyl]propanamide 10:1 60:6 X.07 1-Methoxy-3-methyl-1 - [[4-[5 (trifluoromethyl)-1,2,4-oxadiazol-3 yl]phenyl]methyl]urea 3.3:1 200:60 X.07 1-Methoxy-3-methyl-1 - [[4-[5 (trifluoromethyl)-1,2,4-oxadiazol-3 yl]phenyl]methyl]urea 33.3:1 200:6 X.07 1-Methoxy-3-methyl-1 - [[4-[5 (trifluoromethyl)-1,2,4-oxadiazol-3 yl]phenyl]methyl]urea 1:1 60:60 X.07 1-Methoxy-3-methyl-1 - [[4-[5 (trifluoromethyl)-1,2,4-oxadiazol-3 yl]phenyl]methyl]urea 10:1 60:6 X.07 1,3 -Dimethoxy-1 -[ [4- [5 -(methyl trifluoro)- 1,2,4-oxadiazol-3 yl]phenyl]methyl]urea 3.3:1 200:60 X.07 1,3 -Dimethoxy-1 -[ [4- [5 -(methyl trifluoro)- 1,2,4-oxadiazole-3 - 33.3:1 200:6

- 367 046368

yl] phenyl] methyl] urea X.07 1,3-Dimethoxy-1-[[4-[5-(methyl trifluoro)- 1,2,4-oxadiazol-Zyl]phenyl]methyl]urea 1:1 60:60 X.07 1,3-Dimethoxy-1-[[4-[5-(trifluoromethyl)- 1,2,4-oxadiazole-3- yl]phenyl]methyl]urea 10:1 60:6 X.07 3 -Ethyl-1-methoxy-1-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-Zyl]phenyl]methyl]urea 3.3:1 200:60 X.07 3 -Ethyl-1-methoxy-1-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-Zyl]phenyl]methyl]urea 33.3:1 200:6 X.07 3 -Ethyl-1-methoxy-1-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-Zyl]phenyl]methyl]urea 1:1 60:60 X.07 3 -Ethyl-1-methoxy-1-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-Zyl]phenyl]methyl]urea 10:1 60:6 X.07 Ethyl 1-[[4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]phenyl]methyl]pyrazole-4carboxylate 3.3:1 200:60 X.07 Ethyl 1-[[4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]phenyl]methyl]pyrazole-4carboxylate 33.3:1 200:6 X.07 Ethyl 1-[[4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]phenyl]methyl]pyrazole-4carboxylate 1:1 60:60 X.07 Ethyl 1-[[4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]phenyl]methyl]pyrazole-4carboxylate 10:1 60:6

- 368 046368

Component A (connection) Component B Ratio A:B Conc. (PPt) (A:B) X.14 Azoxystrobin 2:1 200:100 X.14 Azoxystrobin 6.6:1 200:30 X.14 Azoxystrobin 1:1.6 60:100 X.14 Azoxystrobin 2:1 60:30 X.14 Trifloxystrobin 2:1 200:100 X.14 Trifloxystrobin 6.6:1 200:30 X.14 Trifloxystrobin 1:1.6 60:100 X.14 Trifloxystrobin 2:1 60:30 X.14 Methyltetraprole 2:1 200:100 X.14 Methyltetraprole 6.6:1 200:30 X.14 Methyltetraprole 1:1.6 60:100 X.14 Methyltetraprole 2:1 60:30 X.14 Cyproconazole 2:1 200:100 X.14 Cyproconazole 6.6:1 200:30 X.14 Cyproconazole 1:1.6 60:100 X.14 Ciproconazole 2:1 60:30 X.14 Difenoconazole 2:1 200:100 X.14 Difenoconazole 6.6:1 200:30 X.14 Difenoconazole 1:1.6 60:100 X.14 Difenoconazole 2:1 60:30 X.14 Hexaconazole 2:1 200:100 X.14 Hexaconazole 6.6:1 200:30 X.14 Hexaconazole 1:1.6 60:100 X.14 Hexaconazole 2:1 60:30

- 369 046368

X.14 Prothioconazole 2:1 200:100 X.14 Prothioconazole 6.6:1 200:30 X.14 Prothioconazole 1:1.6 60:100 X.14 Prothioconazole 2:1 60:30 X.14 Mefentrifluconazole 2:1 200:100 X.14 Mefentrifluconazole 6.6:1 200:30 X.14 Mefentrifluconazole 1:1.6 60:100 X.14 Mefentrifluconazole 2:1 60:30 X.14 Fenpropidine 2:1 200:100 X.14 Fenpropidine 6.6:1 200:30 X.14 Fenpropidine 1:1.6 60:100 X.14 Fenpropidine 2:1 60:30 X.14 Phenpropimorph 2:1 200:100 X.14 Phenpropimorph 6.6:1 200:30 X.14 Phenpropimorph 1:1.6 60:100 X.14 Phenpropimorph 2:1 60:30 X.14 Fluxapyroxad 2:1 200:100 X.14 Fluxapyroxad 6.6:1 200:30 X.14 Fluxapyroxad 1:1.6 60:100 X.14 Fluxapyroxad 2:1 60:30 X.14 Fluopyram 2:1 200:100 X.14 Fluopyram 6.6:1 200:30 X.14 Fluopyram 1:1.6 60:100 X.14 Fluopyram 2:1 60:30 X.14 Benzovindiflupir 33.3:1 200:6 X.14 Benzovindiflupir 100:1 200:2

- 370 046368

X.14 Benzovindiflupir 10:1 60:6 X.14 Benzovindiflupir 30:1 60:2 X.14 Pid iflu metof her 2:1 200:100 X.14 Pid iflu metof en 6.6:1 200:30 X.14 Pid iflu metof en 1:1.6 60:100 X.14 Pid iflu metof en 2:1 60:30 X.14 Fluindapir 3.3:1 200:60 X.14 Fluindapir 33.3:1 200:6 X.14 Fluindapir 1:1 60:60 X.14 Fluindapir 10:1 60:6 X.14 Florylpicoxamide 2:1 200:100 X.14 Florylpicoxamide 6.6:1 200:30 X.14 Florylpicoxamide 1:1.6 60:100 X.14 Florylpicoxamide 2:1 60:30 X.14 Metharylpicoxamide 3.3:1 200:60 X.14 Metharylpicoxamide 33.3:1 200:6 X.14 Metharylpicoxamide 1:1 60:60 X.14 Metharylpicoxamide 10:1 60:6 X.14 Chlorothalonil 2:1 200:100 X.14 Chlorothalonil 6.6:1 200:30 X.14 Chlorothalonil 1:1.6 60:100 X.14 Chlorothalonil 2:1 60:30 X.14 Mankozeb 2:1 200:100 X.14 Mankozeb 6.6:1 200:30 X.14 Mankozeb 1:1.6 60:100 X.14 Mankozeb 2:1 60:30

- 371 046368

X.14 Mandipropamide 2:1 200:100 X.14 Mandipropamide 6.6:1 200:30 X.14 Mandipropamide 1:1.6 60:100 X.14 Mandipropamide 2:1 60:30 X.14 Oxathiapiproline 2:1 200:100 X.14 Oxathiapiproline 6.6:1 200:30 X.14 Oxathiapiproline 1:1.6 60:100 X.14 Oxathiapiproline 2:1 60:30 X.14 Fludioxonil 2:1 200:100 X.14 Fludioxonil 6.6:1 200:30 X.14 Fludioxonil 1:1.6 60:100 X.14 Fludioxonil 2:1 60:30 X.14 Cyprodinil 2:1 200:100 X.14 Cyprodinil 6.6:1 200:30 X.14 Cyprodinil 1:1.6 60:100 X.14 Cyprodinil 2:1 60:30 X.14 Metalaxyl-M 2:1 200:100 X.14 Metalaxyl-M 6.6:1 200:30 X.14 Metalaxyl-M 1:1.6 60:100 X.14 Metalaxyl-M 2:1 60:30 X.14 GG-[5-Bromo-2-methyl-6-(1-methyl-2propoxyethoxy)-3-pyridyl]-Ν-3ΤΠΠ-Νmethylformamidine 2:1 200:100 X.14 GG-[5-Bromo-2-methyl-6-(1-methyl-2propoxyethoxy)-3-pyridyl]-Ν-3ΤΠΠ-Νmethylformamidine 6.6:1 200:30 X.14 T4'-[5-Bromo-2-methyl-6-(1-methyl-2propoxyethoxy)-3-pyridyl]-Ν-3ΤΠΠ-Ν- 1:1.6 60:100

- 372 046368

methylformamidine X.14 X'-[5-Bromo-2-methyl-6-(1-methyl-2propoxyethoxy)-3-pyridyl]-Ν-3ΤΠΠ-Νmethylformamidine 2:1 60:30 X.14 X-Isopropyl-X'-[5-methoxy-2-methyl-4(2,2,2-trifluoro-1-hydroxy-1 phenylethyl)phenyl]-X-methylformamidine 2:1 200:100 X.14 X-Isopropyl-X'-[5-methoxy-2-methyl-4(2,2,2-trifluoro-1-hydroxy-1 phenylethyl)phenyl]-X-methylformamidine 6.6:1 200:30 X.14 X-Isopropyl-X'-[5-methoxy-2-methyl-4(2,2,2-trifluoro-1-hydroxy-1 phenylethyl)phenyl]-X-methylformamidine 1:1.6 60:100 X.14 X-Isopropyl-X'-[5-methoxy-2-methyl-4(2,2,2-trifluoro-1-hydroxy-1 phenylethyl)phenyl]-X-methylformamidine 2:1 60:30 X.14 Methyl-(2)-3-methoxy-2-[2-methyl-5-[3 (trifluoromethyl)pyrazol-1 yl]phenoxy]prop-2-enoate 2:1 200:100 X.14 Methyl-(2)-3-methoxy-2-[2-methyl-5-[3 (trifluoromethyl)pyrazol-1 yl]phenoxy]prop-2-enoate 6.6:1 200:30 X.14 Methyl-(2)-3-methoxy-2-[2-methyl-5-[3 (trifluoromethyl)pyrazol-1 yl]phenoxy]prop-2-enoate 1:1.6 60:100 X.14 Methyl-(2)-3-methoxy-2-[2-methyl-5-[3 (trifluoromethyl)pyrazol-1 yl]phenoxy]prop-2-enoate 2:1 60:30 X.14 Methyl-(2)-3-methoxy-2-[2-methyl-5-(3 propylpyrazol-1-yl)phenoxy]prop-2- 2:1 200:100

- 373 046368

enoate X.14 Methyl-(2)-3-methoxy-2-[2-methyl-5-(3 propylpyrazol-1-yl)phenoxy]prop-2enoate 6.6:1 200:30 X.14 Methyl-(2)-3-methoxy-2-[2-methyl-5-(3 propylpyrazol-1-yl)phenoxy]prop-2enoate 1:1.6 60:100 X.14 Methyl-(2)-3-methoxy-2-[2-methyl-5-(3 propylpyrazol-1-yl)phenoxy]prop-2enoate 2:1 60:30 X.14 Methyl (2)-2-(5-cyclohexyl-2methylphenoxy)-3-methoxyprop-2-enoate 2:1 200:100 X.14 Methyl (2)-2-(5-cyclohexyl-2methylphenoxy)-3-methoxyprop-2-enoate 6.6:1 200:30 X.14 Methyl (2)-2-(5-cyclohexyl-2methylphenoxy)-3-methoxyprop-2-enoate 1:1.6 60:100 X.14 Methyl (2)-2-(5-cyclohexyl-2methylphenoxy)-3-methoxyprop-2-enoate 2:1 60:30 X.14 Methyl (2)-2-(5-cyclopentyl-2methylphenoxy)-3-methoxyprop-2-enoate 2:1 200:100 X.14 Methyl (2)-2-(5-cyclopentyl-2methylphenoxy)-3-methoxyprop-2-enoate 6.6:1 200:30 X.14 Methyl (2)-2-(5-cyclopentyl-2methylphenoxy)-3-methoxyprop-2-enoate 1:1.6 60:100 X.14 Methyl (2)-2-(5-cyclopentyl-2methylphenoxy)-3-methoxyprop-2-enoate 2:1 60:30 X.14 Methyl-(2)-2-[5-(3-isopropylpyrazol-1 yl)-2-methylphenoxy]-3-methoxyprop-2enoate 2:1 200:100 X.14 Methyl-(2)-2-[5-(3-isopropylpyrazole-1- 6.6:1 200:30

- 374 046368

yl)-2-methylphenoxy]-3-methoxyprop-2enoate X.14 Methyl-(2)-2-[5-(3-isopropylpyrazol-1 yl)-2-methylphenoxy]-3-methoxyprop-2enoate 1:1.6 60:100 X.14 Methyl-(2)-2-[5-(3-isopropylpyrazol-1 yl)-2-methylphenoxy]-3-methoxyprop-2enoate 2:1 60:30 X.14 Methyl (2)-3-methoxy-2-[2-methyl-5-(4propyltriazol-2-yl)phenoxy]prop-2enoate 2:1 200:100 X.14 Methyl (2)-3-methoxy-2-[2-methyl-5-(4propyltriazol-2-yl)phenoxy]prop-2enoate 6.6:1 200:30 X.14 Methyl (2)-3-methoxy-2-[2-methyl-5-(4propyltriazol-2-yl)phenoxy]prop-2enoate 1:1.6 60:100 X.14 Methyl (2)-3-methoxy-2-[2-methyl-5-(4propyltriazol-2-yl)phenoxy]prop-2enoate 2:1 60:30 X.14 Methyl (2)-3-methoxy-2-[2-methyl-5-[4(trifluoromethyl)triazol-2yl]phenoxy]prop-2-enoate 2:1 200:100 X.14 Methyl (2)-3-methoxy-2-[2-methyl-5-[4(trifluoromethyl)triazol-2yl]phenoxy]prop-2-enoate 6.6:1 200:30 X.14 Methyl (2)-3-methoxy-2-[2-methyl-5-[4(trifluoromethyl)triazol-2yl]phenoxy]prop-2-enoate 1:1.6 60:100 X.14 Methyl-(2)-3-methoxy-2-[2-methyl-5-[4(trifluoromethyl)triazol-2- 2:1 60:30

- 375 046368

yl]phenoxy]prop-2-enoate X.14 TAEGRO® 2:1 200:100 X.14 TAEGRO® 6.6:1 200:30 X.14 TAEGRO® 1:1.6 60:100 X.14 TAEGRO® 2:1 60:30 X.14 Timorex GoldTM 2:1 200:100 X.14 Timorex GoldTM 6.6:1 200:30 X.14 Timorex GoldTM 1:1.6 60:100 X.14 Timorex GoldTM 2:1 60:30 X.14 X-Methoxy-X-[[4-[5-(trifluoromethyl)-1,2,4oxadiazol-3yl]phenyl]methyl]cyclopropanecarboxamide 3.3:1 200:60 X.14 X-Methoxy-X-[[4-[5-(trifluoromethyl)-1,2,4oxadiazol-3yl]phenyl]methyl]cyclopropanecarboxamide 33.3:1 200:6 X.14 X-Methoxy-X-[[4-[5-(trifluoromethyl)-1,2,4oxadiazol-3yl]phenyl]methyl]cyclopropanecarboxamide 1:1 60:60 X.14 X-Methoxy-X-[[4-[5-(trifluoromethyl)-1,2,4oxadiazol-3yl]phenyl]methyl]cyclopropanecarboxamide 10:1 60:6 X.14 X,2-Dimethoxy-X-[[4-[5-(trifluoromethyl)1,2,4-oxadiazol-3 yl]phenyl]methyl]propanamide 3.3:1 200:60 X.14 X,2-Dimethoxy-X-[[4-[5-(trifluoromethyl)1,2,4-oxadiazol-3 yl]phenyl]methyl]propanamide 33.3:1 200:6 X.14 X,2-Dimethoxy-X-[[4-[5-(trifluoromethyl)- 1,2,4-oxadiazole-3 - 1:1 60:60

- 376 046368

yl]phenyl]methyl]propanamide X.14 X,2-Dimethoxy-X-[[4-[5-(trifluoromethyl)1,2,4-oxadiazol-3 yl]phenyl]methyl]propanamide 10:1 60:6 X.14 X-Ethyl-2-methyl-T4-[[4-[5-(trifluoromethyl)1,2,4-oxadiazol-3 yl]phenyl]methyl]propanamide 3.3:1 200:60 X.14 X-Ethyl-2-methyl-T4-[[4-[5-(trifluoromethyl)1,2,4-oxadiazol-3 yl]phenyl]methyl]propanamide 33.3:1 200:6 X.14 X-Ethyl-2-methyl-T4-[[4-[5-(trifluoromethyl)1,2,4-oxadiazol-3 yl]phenyl]methyl]propanamide 1:1 60:60 X.14 X-Ethyl-2-methyl-T4-[[4-[5-(trifluoromethyl)1,2,4-oxadiazol-3 yl]phenyl]methyl]propanamide 10:1 60:6 X.14 1-Methoxy-3-methyl-1 - [[4-[5 (trifluoromethyl)-1,2,4-oxadiazol-3 yl]phenyl]methyl]urea 3.3:1 200:60 X.14 1-Methoxy-3-methyl-1 - [[4-[5 (trifluoromethyl)-1,2,4-oxadiazol-3 yl]phenyl]methyl]urea 33.3:1 200:6 X.14 1-Methoxy-3-methyl-1 - [[4-[5 (trifluoromethyl)-1,2,4-oxadiazol-3 yl]phenyl]methyl]urea 1:1 60:60 X.14 1-Methoxy-3-methyl-1 - [[4-[5 (trifluoromethyl)-1,2,4-oxadiazol-3 yl]phenyl]methyl]urea 10:1 60:6 X.14 1,3 -Dimethoxy-1 -[ [4- [5 -(methyl trifluoro)- 1,2,4-oxadiazole-3 - 3.3:1 200:60

- 377 046368

yl]phenyl]methyl]urea X.14 1,3 -Dimethoxy-1 -[ [4- [5 -(methyl trifluoro)- 1,2,4-oxadiazol-3 yl]phenyl]methyl]urea 33.3:1 200:6 X.14 1,3 -Dimethoxy-1 -[ [4- [5 -(methyl trifluoro)- 1,2,4-oxadiazol-3 yl]phenyl]methyl]urea 1:1 60:60 X.14 1,3 -Dimethoxy-1 -[ [4- [5 -(methyl trifluoro)- 1,2,4-oxadiazol-3 yl]phenyl]methyl]urea 10:1 60:6 X.14 3 -Ethyl-1-methoxy-1 -[[4-[5 (trifluoromethyl)-1,2,4-oxadiazol-3 yl]phenyl]methyl]urea 3.3:1 200:60 X.14 3 -Ethyl-1-methoxy-1 -[[4-[5 (trifluoromethyl)-1,2,4-oxadiazol-3 yl]phenyl]methyl]urea 33.3:1 200:6 X.14 3 -Ethyl-1-methoxy-1 -[[4-[5 (trifluoromethyl)-1,2,4-oxadiazol-3 yl]phenyl]methyl]urea 1:1 60:60 X.14 3 -Ethyl-1-methoxy-1 -[[4-[5 (trifluoromethyl)-1,2,4-oxadiazol-3 yl]phenyl]methyl]urea 10:1 60:6 X.14 Ethyl 1-[[4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]phenyl]methyl]pyrazole-4carboxylate 3.3:1 200:60 X.14 Ethyl 1-[[4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]phenyl]methyl]pyrazole-4carboxylate 33.3:1 200:6 X.14 Ethyl 1-[[4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]phenyl]methyl]pyrazole-4carboxylate 1:1 60:60

X.14 Ethyl 1-[[4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]phenyl]methyl]pyrazole-4carboxylate 10:1 60:6

Claims (15)

1. A fungicidal composition containing a mixture of components (A) and (B) as active ingredients, where component (A) is a compound of formula (I) Y represents C-F or C-H; X represents N; R ¹ represents ^-^-alkyl, ^-^-alkoxy, C ₁ -C ₄ -haloalkyl or HC(O)NH-; R ² represents CrCg-alkyl, ^-^-cycloalkyl, C3-C8-cycloalkyl-C1-C2-alkyl, where the cycloalkyl groups are optionally substituted by 1-3 groups represented by R ³ , phenyl, phenyl-C1-C ₂ -alkyl wherein the phenyl rings are optionally substituted with 1-3 groups represented by R ³ or a 5-12 membered non-aromatic spirocyclic carbobi- or carbotricyclyl ring system; - 378 046368 R ³ represents C1-C ₃ -alkyl, C1-C ₃ -haloalkyl or C ₃ -C ₆ -cycloalkyl-C1-C ₂ -alkyl; or a salt or N-oxide thereof and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, pyraclostrobin, picoxystrobin, cumoxystrobin, methyltetraprole, cyproconazole, tebuconazole, difenoconazole, hexaconazole, propiconazole, fenhexamide, prothioconazole, mefentrifluconazole , prochloraz, fenpropidine, fenpropimorpha, fluxapyroxad, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, bixafen, pentiopyrad, inpirfluxam, isofetamide, pyrapropone, fluindapyr, fenpicoxamide, florylpicoxamide, acibenzolar^-methyl a, trinexepak-ethyl, fosetyl-aluminum, chlorothalonil , mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifen, folpet, ipflufenoquin, quinofumeline, tebufloquin, tolprocarb, tricyclazole, pyroquilone, cyflufenamide, metrafenone, No-[2-chloro-4-(2- fluorophenoxy )-5-methylphenyl]-N-ethyl-Nmethylformamidine, N-[4-(2-bromophenoxy)-5-chloro-2-methylphenyl]-N-ethyl-N-methylformamidine, N-(1benzyl-1,3 - dimethylbutyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro-1-methylpropyl)8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3-chloro-1 -methylbut-3-enyl)-8-fluoroquinolin-3-carboxamide, 1 -(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3- dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl-1 -(7-methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline, 1 -(6,7-dimethylpyrazolo[1,5a]pyridin- 3-yl)-4,4,6-trifluoro-3,3-dimethylisoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 1 -( 4,5-dimethylbenzimidazol-1-yl)-4,4-difluoro-3,3-dimethylisoquinoline, 6-chloro-4,4-difluoro-3,3-dimethyl-1 -(4-methylbenzimidazol-1 -yl) isoquinoline, N-[5-bromo-2-methyl-6-(1 methyl-2-propoxyethoxy)-3-pyridyl]-N-ethyl-N-methylformamidine, N'-[5-chloro-2-methyl-6 -(1-methyl-2-propoxyethoxy)-3-pyridyl]-N-ethyl-N-methylformamidine, N-[5-bromo-2-methyl-6-(1-methyl-2-propoxyethoxy)-3-pyridyl] -N-Isopropyl-N-methylformamidine, N-isopropyl-N'-[5-methoxy-2-methyl-4-(2,2,2trifluoro-1-hydroxy-1-phenylethyl)phenyl]-N-methylformamidine, N-methoxy -N-[[4-[5-(trifluoromethyl)1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropanecarboxamide, N2-dimethoxy-N-[[4-[5-(trifluoromethyl)1, 2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, Nethyl-2-methyl-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] methyl]propanamide, 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3 yl]phenyl]methyl]urea, 1,3-dimethoxy-1- [[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)- 1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, ethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrazole -4-carboxylate, N.N-dimethyl1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]-1,2,4-triazol-3-amine, methyl -(2)-3-methoxy-2-[2-methyl-5-[3-(trifluoromethyl)pyrazol-1-yl]phenoxy]prop-2-enoate, methyl (2)-3-methoxy-2- [2methyl-5-(3-propylpyrazol-1-yl)phenoxy]prop-2-enoate, methyl-(2)-2-[5-(3-isopropylpyrazol-1-yl)-2methylphenoxy]-3-methoxyprop- 2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-(4-propyltriazol-2-yl)phenoxy]prop-2-enoate, methyl-(2)-3-methoxy- 2-[2-methyl-5-[4-(trifluoromethyl)triazol-2-yl]phenoxy]prop-2enoate, methyl-(2)-2-(5-cyclohexyl-2-methylphenoxy)-3-methoxyprop-2 -enoate, methyl-(2)-2-(5-cyclopentyl-2-methylphenoxy)-3-methoxyprop-2-enoate, methyl-(2)-2-[5-(4-cyclohexylthiazol-2-yl)- 2-methylphenoxy]-3-methoxyprop-2-enoate, methyl (2)-2-[5-[4-(ethoxymethyl)thiazol-2-yl]-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl (2)-2-[5-(4-bromothiazol-2-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl(2)-3-methoxy-2-[2-methyl- 5-[5-(trifluoromethyl)thiazol-2-yl]phenoxy]prop-2-enoate, TAEGRO® (i.e. strain FZB24 Bacillus amyloliquefaciens), Timorex Gold™ and methylpicoxamide. 2. The fungicidal composition according to claim 1, wherein component (A) is a compound selected from 2-[cyano-(5-fluoro-3-pyridyl)amino]-N-cyclobutyl-5-methylthiazol-4-carboxamide (compound X.01); 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-N-cyclobutyl-5-methylthiazole-4-carboxamide (compound X.02); 2-(Ncyano-3,5-difluoroanilino)-N-(2,2-dimethylcyclobutyl)-5-methylthiazol-4-carboxamide (compound X.03); 2-[cyano-(5-fluoro-3-pyridyl)amino]-H-(2,2-dimethylcyclobutyl)-5-methylthiazole-4-carboxamide (compound X.04); 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methylthiazol-4-carboxamide (compound X.05); 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-N-(2,2-dimethylcyclobutyl)-5-formamidothiazol-4-carboxamide (compound X.06); 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-5-methyl-N-spiro[3.4]octan-3-yl-thiazol-4-carboxamide (compound X.07); 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-5-methyl-N-spiro[cyclobutane-2,2'-indan]-1-yl-thiazol-4carboxamide (compound X.08) ; 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-5-methyl-H-spiro[3.3]heptan-3-yl-thiazol-4-carboxamide (compound X.09); - 379 046368 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-N-[[1-(cyclopropylmethyl)cyclopropyl]methyl]-5-methylthiazol-4-carboxamide (compound X.10); 2-(Ncyano-3,5-difluoroanilino)-5-methyl-N-(1-methylcyclopentyl)thiazole-4-carboxamide (compound X.11); 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-5-methyl-N-(1-methylcyclopentyl)thiazole-4-carboxamide (compound X.12); 2-[cyano-(5-fluoro-3-pyridyl)amino]-N-hexyl-5-methylthiazol-4-carboxamide (compound X.13); 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-N-hexyl-5-methylthiazol-4-carboxamide (compound X.14); 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-N-isobutyl-5-methylthiazol-4-carboxamide (compound X.15); 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-5-methyl-N-(1-phenylethyl)thiazole-4-carboxamide (compound X.16); 2-[cyano-(5-fluoro-3-pyridyl)amino]-N-(2,2-dimethylpropyl)-5-methylthiazol-4-carboxamide (compound X.17); 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-N-(2,2-dimethylpropyl)-5-methylthiazol-4-carboxamide (compound X.18); 2-[cyano-(5-fluoro-3-pyridyl)amino]-5-methyl-N-pentylthiazole-4-carboxamide (compound X.19); 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-5-methyl-N-pentylthiazol-4-carboxamide (compound X.20); 2-[cyano-(5-fluoro-3-pyridyl)amino]-N-isopentyl-5-methylthiazol-4-carboxamide (compound X.21); N[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-[cyano-(2,6-difluoro-4-pyridyl)amino]-5-methylthiazol-4carboxamide (compound X.22); N-benzyl-2-[cyano-(2,6-difluoro-4-pyridyl)amino]-5-methylthiazol-4-carboxamide (compound X.23) and N-butyl-2-[cyano-(2,6-difluoro) -4-pyridyl)amino]-5-methylthiazole-4-carboxamide (compound X.24). 3. Fungicidal composition according to claim 1 or 2, where component (A) is 2-[cyano-(5-fluoro-3-pyridyl)amino]-N-cyclobutyl-5-methylthiazol-4-carboxamide (compound X.01); 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-N-cyclobutyl-5-methylthiazol-4-carboxamide (compound X.02); 2-(Ncyano-3,5-difluoroanilino)-N-(2,2-dimethylcyclobutyl)-5-methylthiazol-4-carboxamide (compound X.03); 2-[cyano-(5-fluoro-3-pyridyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methylthiazol-4-carboxamide (compound X.04); 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methylthiazol-4-carboxamide (compound X.05); 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-5-methyl-N-spiro[3.4]octan-3-yl-thiazol-4-carboxamide (compound X.07); 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-5-methyl-H-spiro[3.3]heptan-3-yl-thiazol-4-carboxamide (compound X.09); 2-(N-cyano-3,5-difluoroanilino)-5-methyl-N-(1-methylcyclopentyl)thiazole-4-carboxamide (compound X.11); 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-5-methyl-N-(1-methylcyclopentyl)thiazole-4-carboxamide (compound X.12); 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-N-hexyl-5-methylthiazol-4-carboxamide (compound X. 14); 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-N-isobutyl-5-methylthiazol-4-carboxamide (compound X.15); 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-5-methyl-N-(1-phenylethyl)thiazole-4-carboxamide (compound X.16); 2-[cyano-(5-fluoro-3-pyridyl)amino]-N-(2,2-dimethylpropyl)-5-methylthiazol-4-carboxamide (compound X.17); 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-N-(2,2-dimethylpropyl)-5-methylthiazol-4-carboxamide (compound X.18) and Nabutyl-2-[cyano -(2,6-difluoro-4-pyridyl)amino]-5-methylthiazol-4-carboxamide (compound X.24). 4. Fungicidal composition according to any one of claims 1 to 3, where component (A) is 2-[cyano-(5-fluoro-3-pyridyl)amino]-H-cyclobutyl-5-methylthiazol-4-carboxamide (compound X.01); 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-N-cyclobutyl-5-methylthiazol-4-carboxamide (compound X.02); 2-(K-cyano-3,5-difluoroanilino)-N-(2,2-dimethylcyclobutyl)-5-methylthiazol-4-carboxamide (compound X.03); 2-[cyano-(5-fluoro-3-pyridyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methylthiazol-4-carboxamide (co - 380 046368 unity X.04); 2-[cyano-(2,6-difluoro-4-pyrrvdyl)amino]-H-(2,2-dimethylcyclobutyl)-5-methylthiazol-4-carboxamvd (compound X.05); 2-[cyano-(2,6-difluoro-4-pyrrvdyl)amino]-5-methyl-H-spiro[3.4]octan-3-yl-thiazol-4-carboxamvd (compound X.07); 2-[cyano-(2,6-di(|)thoro-4-pyridyl)amino|-5-methyl-H-spiro[3.3|heptan-3-yl-thiazol-4-carboxamide (compound X.09) ; 2-(Ncyano-3,5-difluoroanilino)-5-methyl-H-(1-methylcycloientyl)thiazole-4-carboxamide (compound X.11); 2-[cyano-(2,6-difluoro-4-iridyl)amino]-5-methyl-H-(1-methylcycloientyl)thiazole-4-carboxamide (compound X.12); 2-[cyano-(2,6-difluoro-4-iridyl)amino]-H-hexyl-5-methylthiazol-4-carboxamide (compound X. 14) and 2-[cyano-(2,6-difluoro-4-iridyl)amino]-H-(2,2-dimethylproyl)-5-methylthiazol-4-carboxamide (compound X.18). 5. Fungicidal comiosis of any of 1-4, where component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetrayrol, difenoconazole, hexaconazole, iroicoconazole, irothioconazole, me(entri(luconazole, (eniroidine) , (eniroiimorpha, fluxairoxad, fluoiram, isoiirazam, sedaxane, benzovindifluir, iidiflumetofen, isofluciram, isofetamide, irairoion, fluindair, phenycoxamide, florilyicoxamide, acibenzolar^-methyl, chlorothalonil, mancozeb, mandiiroiamide, oxa thiaiiiirolina, fluazinam, fludioxonil, cyrodinil, metalaxyl-M , aminoirifen, foliet, iiflufenoquin, quinofumeline, tricyclazole, iiroquilone, cyflufenamide, metrafenone, I-[2-chloro-4-(2-fluorophenoxy)-5methylphenyl]-N-ethyl-N-methylformamidine, I-[4-(2 -bromophenoxy)-5-chloro-2-methylphenyl]-K-ethyl-K-methylformamidine, N-(1-benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl- 3,3,3trifluoro-1-methyliroyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3-chloro-1-methylbut-3-enyl)-8fluoroquinoline-3-carboxamide, 1 -(6, 7-dimethylyirazolo[1,5-a]iiridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl-1-(7-methylyirazolo[ 1,5-a]iiridin-3-yl)isoquinoline, 1-(6,7dimethylyirazolo[1,5-a]iiridin-3-yl)-4,4,6-trifluoro-3,3-dimethylisoquinoline, 1 - (4,5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4-difluoro-3,3dimethylisoquinoline, 6-chloro-4,4-difluoro-3,3-dimethyl-1-(4-methylbenzimidazol-1-yl)isoquinoline, N'-[5bromo-2-methyl-6-(1-methyl-2-proioxyethoxy) -3-iridyl]-N-ethyl-N-methylformamidine, N'-[5-chloro-2-methyl-6-(1-methyl-2-iroioxyethoxy)-3-iridyl]-N-ethyl-N-methylformamidine , N'-[5-bromo-2-methyl-6-(1 methyl-2-iroioxyethoxy)-3-iridyl]-N-isoiroyl-N-methylformamidine, N-isoiroyl-N'-[5-methoxy-2methyl -4-(2,2,2-Ίriforo-1-hydroxy-1-phenylethyl)phenyl]-N-methylformamidine, N-methoxy-N-[[4-[5(trifluoromethyl)-1,2,4-oxadiazole -3-yl]phenyl]methyl]cycloproiancarboxamide, N,2-dimethoxy-N-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]iroyanamide, N-ethyl -2-methyl-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]iroyanamide, 1-methoxy-3-methyl-1-[[4- [5-(trifluoromethyl)1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazole3 -yl]phenyl]methyl]urea, 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, ethyl- 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]yrazol-4-carboxylate, N,N-dimethyl-1-[[4-[5- (Ίrifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]-1,2,4-Ίriazol-3amine, methyl-(2)-3-methoxy-2-[2-methyl-5- [3-(trifluoromethyl)yrazol-1-yl]phenoxy]yro-2-enoate, methyl(Z)-3-methoxy-2-[2-methyl-5-(3-proyiliirazol-1-yl)phenoxy]yroy -2-enoate, methyl-^)-2-[5-(3-isoiroyilirazol-1-yl)-2-methylphenoxy]-3-methoxyiro-2-enoate, methyl-^)-3-methoxy-2-[ 2-methyl-5-(4-iroyyltriazol-2-yl)phenoxy]yro-2-enoate, methyl-^)-3-methoxy-2-[2-methyl-5-[4-(trifluoromethyl)triazol-2yl ]phenoxy]iroo-2-enoate, methyl-^)-2-(5-cyclohexyl-2-methylphenoxy)-3-methoxyiroo-2-enoate, methyl-(Z)-2-(5-cycloientyl-2-methylphenoxy )-3-methoxyproi-2-enoate, methyl-^)-2-[5-(4-cyclohexylthiazol-2-yl)-2-methylphenoxy]-3-methoxyiro-2-enoate, methyl-^)-2- [5-[4-(ethoxymethyl)thiazol-2-yl]-2methylphenoxy]-3-methoxyiroo-2-enoate, methyl-^)-2-[5-(4-bromothiazol-2-yl)-2-methylphenoxy ]-3-methoxyiroo-2-enoate, methyl-^)-3-methoxy-2-[2-methyl-5-[5-(trifluoromethyl)thiazol-2-yl]phenoxy]iroo-2enoate, bixafen, fosetyl- aluminum, TAEGRO®, Timorex Gold™ and metharyl icoxamide. 6. Fungicidal comiosis of any of 1-5, where component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetrairol, difenoconazole, hexaconazole, iroikonazole, irothioconazole, mefentrifluconazole, phenyroidine, phenyroimorph , fluxairoxada, fluoiram, isoiirazam, sedaxane, benzovindifluir, iidiflumetofen, isofluciram, isofetamide, irairoion, fluindair, phenycoxamide, florilyicoxamide, chlorothalonil, mancozeb, mandiiroiamide, oxathiaiiirolin, fluazinam, fludioxonil, cyrodinil, metalaxi la-M, aminoirifen, foliet, iiflufenoquin, quinofumeline, tricyclazole, iroquilone, N-(1-benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro1-methyliroyl)-8-fluoroquinoline-3-carboxamide, 1-(6,7-dimethylyirazolo[1,5-a]iiridin-3-yl)-4,4,5trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl-1-(7 -methylyirazolo [1,5-a]iiridin-3-yl)iso - 381 046368 quinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline and 1-(4,5-dimethylbenzimidazol-1-yl)-4,4 -difluoro-3,3-dimethylisoquinoline. 7. Fungicidal composition according to any one of claims 1 to 6, where the weight ratio of component (A) and component (B) is from 100:1 to 1:100. 8. Fungicidal composition according to any one of claims 1 to 7, where the weight ratio of component (A) and component (B) is from 20:1 to 1:40. 9. Fungicidal composition according to any one of claims 1 to 8, where the weight ratio of component (A) and component (B) is from 12:1 to 1:25. 10. Fungicidal composition according to any one of claims 1 to 9, where the weight ratio of component (A) and component (B) is from 5:1 to 1:15. 11. Fungicidal composition according to any one of claims 1 to 10, where the weight ratio of component (A) and component (B) is from 2:1 to 1:5. 12. A fungicidal composition according to any one of claims 1 to 11, where the composition contains one or more additional pesticides selected from the group consisting of a fungicide selected from etridiazole, fluazinam, benzovindiflupir, pidiflumetofen, benalaxyl, benalaxyl-M (kyralaxyl), furalaxyl , metalaxyl, metalaxyl-M (mefenoxam), dodicine, N-(2,5-dimethyl-4-phenoxyphenyl)-N-ethyl-N-methylformamidine, N-[4-(4,5-dichlorothiazol-2yloxy)-2 ,5-dimethylphenyl]-N-ethyl-N-methylformamidine, I-[4-[[3-[(4-chlorophenyl)methyl|-1.2.4thiadiazol-5-yl]oxy]-2,5-dimethylphenyl] - N-ethyl-N-methylformamidine, ethirimol, 3'-chloro-2-methoxy-N[(3RS)-tetrahydro-2-oxofuran-3-yl]acet-2',6'-xylidide (closilacone), cyprodinil, Mepanipirima, Pyrimetanil, Dytianon, Aureofungin, Blastecidine-S, Bephenila, Chloroneba, Dicroneran, Hexachlorbenzole, Quintozen, Teknazen (TCNB), Tolcomfosmetil, Metrafenon, 2.6-Dichlores (4-trifthormethylbenzil) Benzamide, Fluophyless (flopicolid), thioximide , flusulfamide, benomyl, carbendazim, carbendazim hydrochloride, chlorphenazole, fuberidazole, thiabendazole, thiophanate methyl, benthiavalicarb, chlobenthiazone, probenazole, acibenzolar, betoxazine, pyriophenone (IKF-309), acibenzolar^-methyl, pyribencarb (KIF-7 767), butylamine, 3 -iodo-2-propynyl-n-butylcarbamate (IPBC), iodocarb (isopropanylbutylcarbamate), isopropanylbutylcarbamate (iodocarb), picarbutrazox, polycarbamate, propamocarb, tolprocarb, 3-(difluoromethyl)-N(7-fluoro-1,1,3, 3-tetramethylindan-4-yl)1-methylpyrazol-4-carboxamide, diclocymet, N[(5-chloro-2-isopropylphenyl)methyl]-Ncyclopropyl-3(difluoromethyl)-5-fluoro-1-methylpyrazol-4- carboxamide, N-cyclopropyl-3-(difluoromethyl)-5-fluoro-N[(2isopropylphenyl)methyl]-1-methylpyrazole-4-carboxamide, carpropamide, chlorothalonil, flumorph, copper oxine, cymoxanil, fenamacryl, cyazofamide, flutianil, thicyophene, chlozolinate, iprodione, procymidone, vinclozolin, bupirimate, dinoctone, dinopentone, dinobutone, dinocap, meptyldinocap, diphenylamine, phosdiphene, 2,6-dimethyl-[1,4]dithiino[2,3-c:5,6-c'] dipyrrole-1,3,5,7(2H,6H)tetraone, azithiram, ethem, ferbam, mancozeb, maneb, metam, metyram (polyram), metyram-zinc, nabam, propineb, thiram, vapam (metham-sodium), zineba, cyram, dithioether, isoprothiolane, ethaboxam, fosetyl, fosetyl-aluminum (fosetyl-Al), methyl bromide, methyl iodide, methyl isothiocyanate, cyclafuramide, fenfuram, validamycin, streptomycin, (2RS)-2-bromo-2-(bromomethyl) glutaronicril (bromotalanil), dodine, doguadine, guazatine, iminoctadine, iminoctadine triacetate, 2,4-D, 2,4-DB, kasugamycin, dimethyrimol, fenhexamide, hymexazole, hydroxyisoxazole, imazalil, imazalil sulfate, oxpoconazole, pefurazoate, prochloraz , triflumizole , fenamidone, Bordeaux mixture, calcium polysulfide, copper acetate, copper carbonate, copper hydroxide, copper naphthenate, copper oleate, copper oxychloride, copper hydroxyquinolate, copper silicate, copper sulfate, copper tallate, copper oxide, sulfur, carbaryl, phthalide (phthalide) , dingjunezuo (Jun Si Qi), oxathiapiproline, fluorimide, mandipropamide, KSF-1002, benzomorph, dimethomorph, fenpropimorph, tridemorph, dodemorph, diethofencarb, fentin acetate, fentin hydroxide, carboxin, oxycarboxin, drazoxolone, famoxadone, m- phenylphenol, p- phenylphenol, tribromophenol (TBP), 2-[2-[(7,8-difluoro-2-methyl-3-quinolyl)oxy]-6-fluorophenyl]propan2-ol, 2-[2-fluoro-6-[( 8-fluoro-2-methyl-3-quinolyl)oxy]phenyl]propan-2-ol, cyflufenamide, ofuras, oxadixil, flutolanil, mepronil, isofetamide, fenpiclonil, fludioxonil, pencicuron, edifenphos, iprobenfos, pyrazophos, phosphoric acids, teclophthalam , captafol, captan, ditalifos, triforin, fenpropidine, piperaline, ostole, 1-methylcyclopropene, 4-CPA, chlormequat, clofencet, dichlorprop, dimethipine, endothal, ethephon, flumetraline, forchlorfenuron, gibberellic acid, gibberellins, hymexazole, maleic hydrazide, mepiquat , naphthalene acetamide, paclobutrazol, prohexadione, prohexadione-calcium, thidiazuron, tribufos (tributyl phosphorotrithioate), trinexapac, uniconazole, α-naphthaleneacetic acid, polyoxin D (polyoxrim), BLAD, chitosan, phenoxanil, folpet, 3-(difluoromethyl)-Nmethoxy- 1-methyl-N[1-methyl-2-(2,4,6trichlorophenyl)ethyl]pyrazole-4-carboxamide, bixafen, fluxapyroxade, furamethpyr, isopyrazam, penflufen, pentiopyrad, sedaxane, fenpyrazamine, diclomezine, pyrifenox, boscalid, fluopyram , diflumetorim, fenarimol, 5-fluoro-2-(p-tolylmethoxy)pyrimidin-4-amine, ferimzone, dimethathlon (dimethaclone), pyroquilone, proquinazide, ethoxyquin, quinoxifene, 4,4,5-trifluoro-3,3dimethyl-1 -(3-quinolyl)isoquinoline, 4,4-difluoro-3,3-dimethyl-1-(3-quinolyl)isoquinoline, 5-fluoro-3,3,4,4tetramethyl-1 -(3-quinolyl)isoquinoline, 9-fluoro-2,2-dimethyl-5 -(3-quinolyl)-3H-1,4-benzoxazepine, te- 382 046368 bufloquin, oxolinic acid, quinomethionate (hydroxythioquinox, quinoxymethionate), spiroxamine, (E)-Nmethyl -2-[2-(2,5-dimethylphenoxymethyl)phenyl]-2-methoxyiminoacetamide (mandestrobin), azoxystrobin, cumoxystrobin, dimoxystrobin, enestroburin, pyriotrobin, phenamistrobin, flufenoxystrobin, fluoxastrobin, kresoxim-methyl, mandestrobin, methaminostrobin, methominostrobin, oris astrobine , picoxystrobin, pyraclostrobin, pyramethostrobin, pyraoxystrobin, trichloropyricarb, trifloxystrobin, amisulbrom, dichlofluanid, tolylfluanid, but-3-ynyl-N[6[[(2)-[(1-methyltetrazol-5-yl)phenylmethylene]amino]oxymethyl] -2-pyridyl]carbamate, dazomet, isothianil, thiadinil, tifluzamide, benthiazole (TCMTV), silthiophame, zoxamide, anilazine, tricyclazole, (+-)-cis-1-(4-chlorophenyl)-2-(1H-1, 2,4-triazol-1-yl)cycloheptanol (Huanjunzuo), 1-(5-bromo-2pyridyl)-2-(2,4-difluorophenyl)-1,1-difluoro-3-(1,2,4- triazol-1-yl)propan-2-ol, 2-(1-tert-butyl)-1-(2chlorophenyl)-3-(1,2,4-triazol-1-yl)propan-2-ol (TCDP ), N-[5-bromo-2-methyl-6-(1-methyl-2propoxyethoxy)-3-pyridyl]-N-ethyl-N-methylformamidine, azaconazole, bitertanol (biloxazole), bromuconazole, climbazole, cyproconazole, difenoconazole , dimethconazole, diniconazole, diniconazole-M, epoxiconazole, etaconazole, fenbuconazole, fluquinconazole, flusilazole, flutriafol, hexaconazole, imibenconazole, ipconazole, metconazole, myclobutanil, penconazole, propiconazole, prothioconazole, mefent rifluconazole, simeconazole, tebuconazole, tetraconazole, triadimefon, triadimenol, triazoxide , triticonazole, 2-[[(^^)-5-[(4-fluorophenyl)methyl]-1-hydroxy-2,2dimethylcyclopentyl]methyl]-4H-1,2,4-triazol-3-thione, 2- [[3-(2-chlorophenyl)-2-(2,4difluorophenyl)oxiran-2-yl]methyl]-4H-1,2,4-triazol-3-thione, amethoctradine (imidium), iprovalicarb, valifenalate , 2-benzyl-4-chlorophenol (chlorophen), allyl alcohol, azaphenidine, benzalkonium chloride, chloropicrin, cresol, daracid, dichlorophen (dichlorophen), diphenzoquat, dipyrithione, N-(2-nchlorobenzoylethyl)hexaminium chloride, NNF-0721, octylinone , oxasulfuron; Timorex Gold™ (a plant extract containing tea tree oil), propamidine and propionic acid, or an insecticide selected from abamectin, acephate, acetamiprid, amidoflumet (S-1955), avermectin, azadirachtin, azinphosmethyl, bifenthrin, biphenazate, buprofezin, carbofuran, cartap, chlorantraniliprole (DPX-E2Y45), chlorfenapyr, chlorfluazuron, chlorpyrifos, chlorpyrifos-methyl, cromafenozide, clothianidin, cyflumetofen, cyfluthrin, beta-cyfluthrin, cyhalothrin, lambdacyhalothrin, cypermethrin, cyromazine, deltamethrin, diafenthiuron, dia zinone, dieldrin, diflubenzuron, dimefluthrin , dimethoate, dinotefuran, diophenolan, emamectin, endosulfan, esfenvalerate, ethiprole, phenothiocarb, fenoxycarb, fenpropathrin, fenvalerate, fipronil, flonicamid, flubendiamide, flucitrinate, tau-fluvalinate, flufenerim (UR-50701), flufenoxuron, fonofos, halo fenozide, hexaflumuron, hydramethylnon, imidacloprid, indoxacarb, isofenphos, lufenuron, malathion, metaflumizone, metaldehyde, methamidophos, methidathione, methomyl, methoprene, methoxychlor, metofluthrin, monocrotophos, methoxyfenozide, nitenpyram, nithiazine, novaluron, noviflumuron (XDE-00 7), oxamyl, parathion, parathionmethyl , permethrin, phorate, fosalone, phosmet, phosphamidon, pirimicarb, profenofos, profluthrin, pymetrozine, pyrafluprol, pyrethrin, pyridalyl, pyrifluquinazone, pyriprole, pyriproxyfen, rotenone, ryanodine, spinetoram, spinosad, spirodiclofen, spiromesifen (BSN 2060), spirotetramat, sulprofos , tebufenozide, teflubenzuron, tefluthrin, terbufos, tetrachlorvinphos, thiacloprid, thiamethoxam, thiodicarb, thiosultapodium, tralomethrine, triazamate, trichlorfon and triflumuron, or a bactericide selected from streptomycin, or an acaricide selected from amitraz, quinomethionate, chlorobenzilate, cyenopyrafen, cyhexatin, dicofol , dienochlor, etoxazole, phenazaquin, fenbutatin oxide, fenpropatrin, fenpyroximate, hexythiazox, propargite, pyridabene and tebufenpyrad, or a biological agent selected from Bacillus thuringiensis, Bacillus thuringiensis delta-endotoxin, baculovirus and entomopathogenic bacteria, virus and fungi. 13. A fungicidal composition according to any one of claims 1 to 12, wherein the composition further comprises an agriculturally acceptable carrier and optionally a surfactant and/or formulation auxiliaries. 14. A method for controlling or preventing phytopathogenic diseases of useful plants or their propagation material, especially those caused by phytopathogenic fungi, which includes the use of a fungicidal composition according to any one of claims 1 to 12 in relation to useful plants, their place of growth or their propagation material. 15. The method according to claim 14, wherein components (A) and (B) of the composition are applied in a sequential manner.